<SEC-DOCUMENT>0000914475-21-000020.txt : 20210205
<SEC-HEADER>0000914475-21-000020.hdr.sgml : 20210205
<ACCEPTANCE-DATETIME>20210205161949
ACCESSION NUMBER:		0000914475-21-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210205
DATE AS OF CHANGE:		20210205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		21595641

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nbix-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9,d:0d67836123014e4c9534b0a3600493e4--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nbix="http://www.neurocrine.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV8zLTEtMS0xLTA_fcd14014-5941-43e4-8bba-b24551550198">false</ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV80LTEtMS0xLTA_a961bbfc-7ce0-482e-ad72-6d00604ff53a">2020</ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV81LTEtMS0xLTA_e7a19f1f-50c0-4e6f-b92c-3d2f35248c1d">FY</ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV82LTEtMS0xLTA_614237d8-3b01-43a2-a3bf-a6c63a868a7a">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTAtMS0xLTQ5NQ_87ff2093-6207-4e9e-bccb-3338262ddc44">us-gaap:AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric contextRef="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">P3Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8yMDAzL2ZyYWc6NzRiMmUyZDY4NTJmNDg1MTkzNGUyMWQzOTM0OTAxYjMvdGV4dHJlZ2lvbjo3NGIyZTJkNjg1MmY0ODUxOTM0ZTIxZDM5MzQ5MDFiM18yMTk5MDIzMjU1NjAw_a9f0933f-aa9b-4f9c-a00e-956f55394347">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8yMDAzL2ZyYWc6NzRiMmUyZDY4NTJmNDg1MTkzNGUyMWQzOTM0OTAxYjMvdGV4dHJlZ2lvbjo3NGIyZTJkNjg1MmY0ODUxOTM0ZTIxZDM5MzQ5MDFiM18yMTk5MDIzMjU1NjAw_f9c97543-fe59-4627-97cb-4bec93c55031">one</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="8" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjMvZnJhZzpkZTY3NjU5ZDNkZGE0MGE1OTFkNDhmYjA1ZWQ4ZTY1Yi90YWJsZTo5YWNlYjRjMTY0M2Q0ZGViYmZlMTBhM2E2ZWQ4NjgwMS90YWJsZXJhbmdlOjlhY2ViNGMxNjQzZDRkZWJiZmUxMGEzYTZlZDg2ODAxXzItMS0xLTEtMA_2dbdce13-f7df-463d-9a7f-dc622740dbed">0.00131711</ix:nonFraction><ix:nonNumeric contextRef="i4f37b110bd3e4061a2c3b66a2947d1aa_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if533ce7e9cb447bb8d5ac9d5e64f6a4b_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9ab4380ab9854e7eaa17e28665d4819b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2f40778fc1cd4b3bae1f28a62fea9b66_I20210129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b7ec05369244eebe79a6452649afd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce3e91b366c406685df930cadf32f38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic171b18673194daf9f8214c17b03fc19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc94b76d27134137be897aa51352595d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d47500148149558693bfbec9f730ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifde16a61b7164f458e48b488706d2e70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i967cc502a0d34a008a828c23d2766568_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida87bfcd952941a7af0f7edcab6e9736_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6046fae3eb4b1b840345751855f969_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc18a34429ee4de3ac9357a5328d1977_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f12acbe2b4d455e85cd438766a8ae80_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib635f30312fc4487a25e573ac6e23201_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1dd9d305d94a28b04bb4bc72f357f3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7e6c1d8b5f4e399e1a026be3379b6c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84e64d4ffbf45999357185cd064c9c1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546d8a0a389e47b89727b48a294423df_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029fc56043664f6d9138de8bc16cb3a0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901799886d9a47b29af6431c66c323e3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327a62de7e27488aacd2d461382ad7b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c2af3510294013a84c123a7e4a817a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7765093653d345399a3f53be76391bc0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266de6ffaffd40a9b1545e43688677b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387e248869994066a40d45b968990a24_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i582361eac54a42edb73a091279308584_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49725d32ce2049aeb743abf42b318417_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a3756b3d9842d6b225a73c90aac6c2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27cce8f31fe240f8a17ee911b0e4b878_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dafe132b53e4050b679396ebb6651ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892c766e0f01406790fc8dcd6fe62fbe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d52ca7c1114b7eae229221755ea0be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc15f2ad264b40a4b8477d62bdd3190d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f532ba86dde41ecbd34ea42061d72e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6972c593f49849929a2f6c7717b087de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33b6ecbd7b84a9f94efd720de382191_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4870f57f40f442cda8ea71a0a17dff09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be7a20d35464718b1b57ce65463f4f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7376630f4274498bb13206aa06d9a70c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>nbix:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i20120095d85448189e0c6c75de356c1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestTwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4318f5084d84959b68665678538a7f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestTwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59194d217fcd4be386582a21776d0491_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728ae8d7437841b58f476b7ef0e6ca39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide871789006342f69f8274002bb357ed_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e7588a0725435ebb6068dce53086b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nbix:segment</xbrli:measure></xbrli:unit><xbrli:context id="i257e90a486974747899becd428e20bbc_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97b8d53a265445fa5504b3150879227_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eba589932364662a4c8ccf58b4e239a_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25235904363543e6876b158eafdeffc9_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6545254203aa4df0a400884ff9991e40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:NBI827104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i219730df66154f82827f5448bfe38e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:DevelopmentProductCandidatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14cd484bece46d3a4291e95561a7587_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bbda008026b473097f608802a52aaf9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d131b3f0874d9b980c9f62f4f8df61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a872472e6c44cd7a82a479cbe5b4431_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88977083558b4753b92390c316833a48_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ad4fc332a9473c95e11ea8f94d1479_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50203e6e9ee241d8a1943a131e844922_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib352054c7bad403c94fe2bccf88d5af3_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbecc51b3aae463ca7e62f0c5c3d2253_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20f0364533a47b6992606e2b86457b0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieedd883af091454ab63052c4d4fec48a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf156fd88444c6791467b25bc69b11e_D20150301-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15e32a0a32b49538add4aef55c528e4_D20170701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2360393b7d4d879ba50fd30091a78b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63b4e7a9e71401dacbac7489e2a7e2a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i240d0d89861f4e0da2e8453b512420bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4787a5e20042c296dec4c2db37c273_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60f3795c3904b598b633d9146da597a_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc73fd418b1a4436b3cfc5a71dbfbee0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85b50b61a514151b47324285918ddb5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0ef1a100194cad8dd122747923492d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3004961ef404e91bf6918eb4f99d34d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbe52017cfa402a8a7a3857aaac0220_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f8e4dda08ce4ee7afe7a741837ed4d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1aded41cc7466989f52504c10da860_D20100601-20100630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-06-01</xbrli:startDate><xbrli:endDate>2010-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b38c628e5624d3489f366d90fb7a1a7_D20100701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcef2297f1d4d3fbdc7d17250594d47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48c720d2df545228f70c2015456a974_D20100601-20100630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-06-01</xbrli:startDate><xbrli:endDate>2010-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9725185c63fb43198fdcd110bf77992c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cb602311ab414c9e533241bb5a447f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id67360380b454fd497a4b58684fbdc84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f28a934c47a48cead9ae9993ebfd81b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac17430272d48979e4f4dd6e73b14bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ca2abb9a7a42359562e7a6c260be20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370dab92abd446d99199617601b5e1ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37972e19ce3448d8addd2bec549432ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="i268709911d264865a1eb304bcc13bad5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d9c5acf8fc4d5c8413f75febd4b55b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145664990f9240a9903f63786ecc19a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0984f70ef6410e966e87e2240cf547_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1746b27d72a42a09e8f4c180db8ba1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e6fd039d624ebda3866e81a58d407f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64146f545c644c5b8abab68d5fbcc802_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f22921e8cd3411fb15048449bf9ca63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5471a1995347728c20899dc1dc1145_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64ee97397f44bb5b2b4a59df28591f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95f976d494c4656844d9c9bc46fb639_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9fc3c50a75463e948ac570c94115d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b76b7e0dc64aecb1ffcbcca5554a3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b841b3697ee4d779975c918a2c7c8a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51010a40dd914cfdb8196a4a02176e64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f914a7af504e9a8c1e308372dd4e59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbcd3bf7584b40e6b743d5e037097802_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb535936a4640ccb740f99e14c3566a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id858ede7f298497092b20558ba3f94aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa4a6439abb45a0bbe5a547556b6c0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd8a4041c334ec5b874010f6d65ecb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if137413b5ed641218199d2f07b0be9d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbabb6a8263c48d08803b3cdf08455fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b7dd5052a1419d9b5eca1001915ffc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d8e3f0ed354c24ab54716af189bb5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c602f03adc4410bf05dba9e4ccab5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i586a6d13c402494cb6770d478521529f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i512ab3e7ad974af9ac04248f25184c1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if231ddf6746a46a4aea8216c8a79d9ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595f5dfa2dd643d79953bbb4a3402602_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4097b8463354e23a855ad993b3e185e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5b4944e27842f1ac75b788b5072eb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84af1872e05c4870864980dc019daa4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8026f07e7861492f8e98644add623101_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic655a96eac1d40e58299205ab8797a96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e1d84b48f1403d90c17750f958db4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e03e5b9e1ad419bbb0aefdda65dd330_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb969448f744b4699e0fe3b2054bc9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e685b74d3a440ae9b69cf3a21f6e94b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia200b6eb75094ebba0fdffab64b4098a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8253ad6971bf419497de5085c582cf91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7d8c26c43040ac8423eb140604d3d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e092d8925da40a99bc1aefd6f132f68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14e6ee1921748129105cf214378dd1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695b22218e09442dbb693682b472e4b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf5e27ca5cc4d77bd90dd61ac8a47e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ac9be8342447318a432723c6b78797_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fb3b785aa449358571ef423f2219c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib65158ac540b41cd91166a0e53ba58cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac4ccb925d645399a328c6018222c6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268c052b4cd04cce8ecbc0e2996aa476_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a6b5151cf4490f9a51234227581adc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i408a528ab8eb45e9877acf825e1bf345_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0856066d5f14514abbb08941b50a267_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d887e6eb804e2ba40e5f883f36d75c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c033102d7b6458faa551c243d0e7289_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd0cc61423040c2915457ec8d6e5d02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd111c56381a4d8f9292b85ac7e19496_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f436445a324740ab5c8efd7b56e438_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4b1d571718416faec2b0ce71d8aab5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5986576aabe849f49f87cd5cdae9d04d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a5389b2dd24efab23db9d2c4a3b7b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0517d273790643c98a976440f62fd851_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67d343eecc4941ff98e247350e2ab153_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff8100d45dd4625af5245d8a8c006fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc657f8675ea40f5bf7d4393012f3446_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a1423af80c04b629c1cf1dad548b611_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8a7b9a9e1c4e19906b367cff71df1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7509d8ee40ad447cb623f9963e19a98e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide958d8a47be4cea92940a48e4246ae2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646522578c0b4f8fbe22f01e7929bead_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f95bc7850c4e96acea39610b13ee2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd64f71c0cc942f2b913d01db69e0a56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22be6b7ba979497ca9ece88797ec5f9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d05cd22a7c40f6872ae176348b44ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30e7a2d8e794c59af388b27d36d27fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62749c0209e440f7b96473ce6fd4b8a3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0e119c44184cc685474e43e33f71bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd60d8e7dce40b0aca76907070d868d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida05ac1eb4ff4313a9d1f27643667abb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8645b15c1c462293674465d9ffd0b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida219830132544daa2c45cd2d963ac68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fac764203a4713af1443597ffa888a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee56e84363a64281a0bb67ffa597df58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30674d569f74deb8350b47ed380e2d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2575bd668b4015b8ad679f19bd5a1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8a5dc0856b4cdba6c86a366b76c812_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ce58ee37ae4b92b5d958c540e8289a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad81ae5e7644259a48165fae6c46349_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca67d557d334f00a0544aa5f24f6b34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad56dc439b641358459b58e8079887a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c117b96dea48f4ac63a4022bae19d6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec42070cca3e4dbb8475c09e274ad678_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c603ce0ef14a36b7c219ff93558f30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830e7abc03c443829d9692cb82e8dada_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia219d51ea1f4489893af819d696712f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4275d4edccb744bf87c8dce992b293b1_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id222ff8c62cd4111a8f3c7d582b27ee4_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89667253f1654865bbfb0ea260237daa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1e2b0fdafc40cea056719ee341bf3f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d919d3678346498deb137a73366cf9_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ced8a0a7764272b813ab553a8bc5ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06934d96e69448b9a6a7de8228e9ae5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa184a589454ef3b217797ac3f37c85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c737c06e3a64363abae7512867edfb9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a92c0d75562403aaeb7e6195396a9c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4132f626519c4dd6915f68702956d54a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2114f7c7620e47ed9b7c7252ab48432d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76651c30b164c06b76804edbd718ae7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c9dfd023f94ae6b49d6219f49911a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ff256dae7c4d7da1e1f691ad48ee76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic403135dcdce433cb75127f4ba52569f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545e098699484f749aa1893bd9f4d9ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie580a98b5f904017acbc0be2a81b1401_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb93957d4a2347d0893965c4a30cbdd0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad0a98345c14590bf7d5f5fd862c9fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613490d34e8a4611aab2ffd9a16f8ef0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e784185d98a4b9cb1bb7bcad7598aea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fcb21b072c4b679ca34c108cfa6ef4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8581e780a80c4442b21f27be29b95775_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bea0f817d424b9faef8c2af8c43a23d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16180db6d54a49ce83ee4500d72b9962_I20110531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21f4f7020f68499385d6f2a13567d7f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60fca317ddb748798d4cb98a5fbf2aea_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5803489bd44c3cb9e6f31d1e0a6681_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bbd2bddcdc44dca0395f6d99c449aa_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035747211e4f44e193c5d551cf4d62ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:A2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965516f5121d4176b5ae292b90be804a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc67e37cd02430da9f8da535e6d7526_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521c723b6c49422a84b72328e24a5c55_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1faa6db7b38d43dd97845deb75c32b0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e87b16f9684b559824bed5cc3bfaad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a82057bae22484ab39cbc0b26398dd5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b54e325551b473da0598c96d708c5da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7638d60a91cb4ff787321cee24ae9f48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie680af40b96e455aaaaf75ab295c9ac4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdaaf1063b5640c096eab926298a36b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f37b110bd3e4061a2c3b66a2947d1aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5add3ec602347a4872184c665490f93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9010f4078c43eb99d30b01f597843b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if533ce7e9cb447bb8d5ac9d5e64f6a4b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8da843469b46af91bfcfc456693d02_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c587d6dc8c6451fba9c6dbe18ec82bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaad045d0ff0b4b949b001aa2efd85687_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i478244770d8e4c27a0658c7c1918fbe0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>nbix:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="i6da45b8c6e074d14bdc079a1f2265f01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib123ada82f724fe49861cecabdde52c1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2db4ddee19489eaad07271d5031b33_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0d67836123014e4c9534b0a3600493e4_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIx_6a572cb7-cdf7-4f11-8546-8debf546d000">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MTJiYWYyOTAxYzQ1NGMyOTk2Y2E0Y2ZiN2FhMDdkNGMvdGFibGVyYW5nZToxMmJhZjI5MDFjNDU0YzI5OTZjYTRjZmI3YWEwN2Q0Y18wLTAtMS0xLTA_ec6c9f06-8471-44e2-9c9d-48768dbb2620">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE3_bae0edc3-9aee-40ba-8a31-5d15ab587e62"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE3_8d3e5022-76d5-491e-bc00-b2253648fea0">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6OWZjNTYyNTZiMjU5NGFiNGI4OWI4YTAxYTZkYzU1Y2YvdGFibGVyYW5nZTo5ZmM1NjI1NmIyNTk0YWI0Yjg5YjhhMDFhNmRjNTVjZl8wLTAtMS0xLTA_dfa6afec-bad1-4d8c-9173-c6186222a1e1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from __________to__________</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIy_3ca58c23-ee47-4fa3-896f-8d98537773b0">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE4_00edbf6c-9871-425b-9a50-55f723e2f247">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8wLTAtMS0xLTA_ecf9783d-3176-4d13-9b6d-65770d53a944">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8wLTYtMS0xLTA_323274c3-0d85-4e21-83f6-f2c882683a81">33-0525145</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTAtMS0xLTA_ff181019-3a2b-489e-a9f7-4a34c2609109">12780 El Camino Real,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTItMS0xLTA_b34522a6-c7e1-4232-8a6d-69ef01d6a684">San&#160;Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTQtMS0xLTA_a1fb615c-0d68-4211-ae66-d8a6fa56bad8">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTYtMS0xLTA_b6913220-4ca8-4990-8d6d-d59ad2e96976">92130</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIz_38e79d89-423e-4d95-99bf-51250b7b86dc">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE5_7e86f018-2f0f-47f0-ae37-546bd9114ac4">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.087%"><tr><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.770%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTAtMS0xLTA_5fed48c5-3029-493e-88e8-8b107a74f603">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTItMS0xLTA_33d950a6-eeb9-4d98-860d-3c2121504311">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTQtMS0xLTA_e3da681b-a019-4106-9c7d-a97c9ed83e9a">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Title of each class)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Trading Symbol)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Name of each exchange on which registered)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">class</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIw_10421f79-6755-4d85-aa44-f3af61af9919">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTEz_508aeeb6-ea7b-4a7d-a567-dc26e78916f9">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE0_15f9d391-c9ff-4fef-a963-5018343a931f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE1_2bc7ff90-dd52-4f28-87a7-cd04cf49944d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.863%"><tr><td style="width:1.0%"></td><td style="width:15.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTAtMS0xLTA_764ba5b0-d6c9-44b3-aa24-cf550f0a165e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9745;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTEwLTEtMS0w_aef3b110-2975-4f98-83d9-7d9f3fea4d51">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTEzLTEtMS0w_8c5f59ca-f31b-4330-be20-db23c4be67bd">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yMTk5MDIzMjU4ODc1_8c6b97c5-8e1d-4e1d-ab6f-20a8efb35bbc">&#9745;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTI0_3edb264d-e3b7-430a-9534-bd9d2508c5d8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2020, was approximately $<ix:nonFraction unitRef="usd" contextRef="i9ab4380ab9854e7eaa17e28665d4819b_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yNDk2_e4d348bb-517b-4105-97e6-21a61bae4701">11,231,617,436</ix:nonFraction>.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of January&#160;29, 2021, <ix:nonFraction unitRef="shares" contextRef="i2f40778fc1cd4b3bae1f28a62fea9b66_I20210129" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yNTEw_d4f9ce3e-d6da-4f9e-a5d0-818a12e7a92a">93,943,645</ix:nonFraction> shares of the registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE2_fefb1076-820f-4188-9942-53d73230f1cf" escape="true">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K.</ix:nonNumeric></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_64">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_64">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_70">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_70">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_73">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_73">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_76">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_76">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_79">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_79">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_82">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_85">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_85">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Selected Financial Data</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_97">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_97">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_118">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_118">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_121">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_121">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_196">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_196">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_199">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_199">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_208">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_208">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_211">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_214">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_214">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_217">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_217">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_220">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_220">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_223">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_223">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_226">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_226">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_229">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_232">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d67836123014e4c9534b0a3600493e4_232">72</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are registered trademarks of Neurocrine Biosciences, Inc. Any other brand names or trademarks appearing in this Annual Report that are not the property of Neurocrine Biosciences, Inc. are the property of their respective holders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i0d67836123014e4c9534b0a3600493e4_13"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K and the information incorporated herein by reference contain forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part I titled &#8220;Item&#160;1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_16"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div id="i0d67836123014e4c9534b0a3600493e4_19"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div id="i0d67836123014e4c9534b0a3600493e4_22"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Pipeline</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exclusive and Partnered Commercial Products</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our exclusive and partnered commercial products and is followed by detailed descriptions of each product:<br/></span></div><div><img src="nbix-20201231_g1.jpg" alt="nbix-20201231_g1.jpg" style="height:252px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA (valbenazine)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA in the U.S. in May 2017, after receiving FDA approval for INGREZZA as the first FDA-approved drug for the treatment of tardive dyskinesia in April 2017. INGREZZA provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 mg and 80 mg capsules), with 40 mg taken for the first seven days of treatment and an option to take 40 mg or 80 mg thereafter, depending on the patient&#8217;s dosing needs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Mitsubishi Tanabe Pharmaceutical Company, or MTPC, reported positive top-line results from the J-KINECT Phase III study, designed to evaluate the efficacy and safety of valbenazine in tardive dyskinesia. Detailed results from this trial will be presented at a future medical conference. With positive data in hand, a marketing authorization with the Ministry of Health and Welfare is planned for 2021 in Japan. In addition, MTPC submitted filings for marketing authorizations in South Korea, Thailand, Singapore, Indonesia, and Malaysia in 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tardive dyskinesia is defined by hyperkinetic involuntary movements which arise after months or years of treatment with dopamine receptor blocking agents, such as antipsychotics used for treating schizophrenia, bipolar disorder and depression, and certain treatments for nausea, vomiting and gastric emptying in patients with gastroparesis. While the prevalence rates of tardive dyskinesia can vary greatly in accordance with the population being studied, it is estimated that over 500 thousand individuals are affected by tardive dyskinesia in the U.S. alone (Kantar Health).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA net product sales totaled $993.1 million, $752.9 million and $409.6 million for 2020, 2019 and 2018, respectively, and represented the significant majority of our total net product sales for 2020 and all of our net product sales for 2019 and 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ONGENTYS (opicapone)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. We acquired the U.S. and Canada rights to ONGENTYS from BIAL &#8211; Portela &amp; Ca, S.A., or BIAL, in the first quarter of 2017. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONGENTYS is a novel, once-daily, peripherally acting, highly selective Catechol-O-methyltransferase, or COMT, inhibitor utilized as an adjunct therapy to levodopa/carbidopa in patients with Parkinson&#8217;s disease experiencing motor fluctuations. COMT inhibitors are utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson&#8217;s disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen, also referred to as &#8220;off-time.&#8221; Parkinson&#8217;s disease is a chronic and progressive movement disorder that affects approximately 1 million individuals in the U.S. alone.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORILISSA (elagolix)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Inc., or AbbVie, launched ORILISSA in the U.S. and Canada in August and November 2018, respectively, after receiving FDA and Health Canada approval for ORILISSA for the management of moderate to severe endometriosis pain in women in July and October 2018, respectively. Discovered and developed through Phase II clinical studies by us, we out-licensed the global rights to elagolix to AbbVie in 2010. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The World Endometriosis Research Foundation estimates that there are over 170&#160;million women worldwide who suffer from endometriosis, including approximately 7.5&#160;million women in the U.S. alone.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie launched ORIAHNN in the U.S. in June 2020, after receiving FDA approval for ORIAHNN as the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women in May 2020. We out-licensed the global rights to elagolix to AbbVie in 2010.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uterine fibroids are benign hormonally responsive tumors that form in the wall of the uterus with a prevalence rate of at least 25% (American College of Obstetricians and Gynecologists) and are a leading indication for hysterectomy in the U.S., with approximately 250,000 hysterectomies performed each year related to uterine fibroids (Whiteman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> et al AJOG </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2008,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 198, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e1).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Clinical Development Pipeline</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our clinical development pipeline and is followed by detailed descriptions of each program:<br/></span></div><div><img src="nbix-20201231_g2.jpg" alt="nbix-20201231_g2.jpg" style="height:311px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Neurology</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">valbenazine &#8211; VMAT2 Inhibitor</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VMAT2 is a protein concentrated in the human brain that is essential for the transmission of nerve impulses between neurons. VMAT2 is primarily responsible for packaging and transporting monoamines (dopamine, norepinephrine, serotonin and histamine) in neurons. Specifically, dopamine enables neurotransmission among nerve cells that are involved in voluntary and involuntary motor control. Disease states such as tardive dyskinesia, Tourette syndrome, Huntington&#8217;s chorea, schizophrenia, and tardive dystonia are characterized in part by a hyperdopaminergic state in the brain, and modulation of neuronal dopamine levels may provide symptomatic benefits for patients with these conditions, among others.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting the KINECT-HD study, a Phase III, randomized, placebo-controlled, double-blind, multi-center Phase III clinical study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of chorea in 120 patients with Huntington&#8217;s disease, or HD, with Phase III top-line data expected in the fourth quarter of 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HD is a hereditary progressive neurodegenerative disorder, in which neurons within the brain break down, resulting in motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 to 50 and worsen over a 10 to 25-year period. Many patients with HD experience chorea, a troublesome involuntary movement disorder, in which patients develop abnormal, abrupt or irregular movements. Chorea can affect various body parts, and interfere with speech, swallowing, posture and gait. HD is estimated to affect approximately 30,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease (NORD).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-921352 (XEN901) &#8211; Nav1.6 Sodium Channel Inhibitor</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety, tolerability and pharmacokinetics of NBI-921352 have been evaluated in a randomized, double-blind, placebo-controlled Phase I study using a powder-in-capsule formulation of NBI-921352 in healthy adult subjects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xenon has developed a pediatric-specific, granule formulation of NBI-921352, and completed juvenile toxicology studies to support pediatric development activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA requested additional non-clinical data to support the IND we submitted in August 2020 in support of a Phase II clinical study for NBI-921352 in patients with SCN8A-DEE. Based on feedback received in January 2021, we plan to initiate a Phase II clinical study in adolescent patients (aged 12 years and older) with SCN8A-DEE in the third quarter of 2021, and the study protocol will be amended to include younger pediatric patients (aged 2-11 years) with SCN8A-DEE as soon as the FDA has reviewed and approved additional non-clinical information. We are also advancing clinical plans to initiate a Phase II clinical study of NBI-921352 for the treatment of adult focal epilepsy in 2021. In addition, in October 2020, we announced the FDA granted us Rare Pediatric Disease Designation for NBI-921352 for the treatment of SCN8A-DEE.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCN8A-DEE is a rare, extremely severe, single-gene epilepsy caused by mutations in the SCN8A gene that activates Nav1.6, the most highly expressed sodium channel in the excitatory pathways of the central nervous system, or CNS. Children born with SCN8A-DEE typically start experiencing seizures between birth and 18 months of age, and most have multiple seizures per day. Other symptoms include learning difficulties, muscle spasms, low or high muscle tone, poor coordination, developmental delay, and features similar to autism. An estimated 10% of people with SCN8A are reported to have experienced sudden unexpected death in epilepsy. The prevalence of SCN8A-DEE is estimated to be 1% of all developmental and epileptic encephalopathies (Larsen et al, Neurology 2015, 84, 480). As SCN8A mutations were discovered only recently (i.e., in 2012), the number of SCN8A-DEE cases is expected to increase as awareness of and access to genetic surveillance increases. SCN8A-DEE is generally refractory to anti-epilepsy treatments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing NBI-921352 with Xenon Pharmaceuticals Inc., or Xenon, as part of a strategic collaboration announced in December 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-827104 (ACT-709478) &#8211; T-type Calcium Channel Blocker</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the global rights to NBI-827104 from Idorsia Pharmaceuticals Ltd., or Idorsia, in May 2020. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker, being developed for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we initiated a Phase II clinical study for NBI-827104 in a rare pediatric epileptic encephalopathy known as Continuous Spike and Wave During Sleep, or CSWS. CSWS typically impacts children initially between the ages of two and four years old and manifests itself via a variety of seizure types, including atypical absence seizures, generalized tonic-clonic seizures and focal seizures that usually occur during sleep. In addition, children with CSWS often present with cognitive, behavioral and developmental regression or delay. Due to the differentiated mechanism of action of this molecule, when compared to non-selective calcium channel inhibitors, treatment with NBI-827104 could lead to an enhanced benefit risk profile for patients with this rare pediatric form of epilepsy. In parallel we are advancing clinical plans to initiate a Proof of Concept clinical study of NBI-827104 for the treatment of essential tremor in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Endocrinology</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">crinecerfont (NBI-74788) &#8211; CRF1 Antagonist</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crinecerfont&#160;is a potent, selective, orally active, corticotropin-releasing factor1, or CRF1, receptor antagonist as demonstrated in a range of in vitro and in vivo assays. CRF1, is a hypothalamic hormone released directly into the hypophyseal portal vasculature which acts on the CRF1 receptor, a G protein-coupled receptor, or GPCR, in the anterior pituitary to stimulate the release of adrenocorticotropin hormone, or ACTH. The primary role of ACTH is the stimulation of the synthesis and release of adrenal steroids, including cortisol. Cortisol from the adrenals have a negative feedback role at the level of the hypothalamus that decreases CRF1 release as well as at the level of the pituitary to inhibit the release of ACTH. This tight control loop is known as the hypothalamic-pituitary-adrenal axis. Blockade of CRF1 receptors at the pituitary has been shown to decrease the release of ACTH, which in turn decreases the production of adrenal steroids including androgens, and potentially the symptoms associated with classic CAH. Lower ACTH levels would also reduce the amount of exogenous corticosteroid necessary for classic CAH patients to thrive avoiding the side-effects currently associated with excessive steroid therapy. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classic CAH is a group of autosomal recessive genetic disorders that affects approximately 30 thousand people in the U.S. and approximately 50 thousand people in the EU, and results in an enzyme deficiency altering the production of adrenal steroids. Because of this deficiency, the adrenal glands have little to no cortisol biosynthesis resulting in a potentially life-threatening condition. If left untreated, classic CAH can result in salt wasting, dehydration, and eventually death. Even with cortisol replacement, persistent elevation of ACTH from the pituitary gland results in excessive androgen levels leading to virilization of females including precocious puberty, menstrual irregularity, short stature, hirsutism, acne and fertility problems.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corticosteroids are the current standard of care for classic CAH and are used chronically to both correct the endogenous cortisol deficiency and to reduce the excessive ACTH levels and androgen excess. However, the dose and duration of steroid use required to suppress ACTH is well above the normal physiological level of cortisol; resulting in metabolic syndrome, bone loss, growth impairment, and Cushing&#8217;s syndrome as common and serious side effects. We have been granted orphan drug designation for crinecerfont in the treatment of classic CAH in the U.S. and the EU.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, positive data from a completed Phase II, open-label, pharmacokinetic/pharmacodynamic clinical study of crinecerfont in adult patients with classic CAH, which assessed key pharmacodynamic biomarkers including ACTH, 17-hydroxyprogesterone (17-OHP), androgen and cortisol levels collected the morning following bedtime dosing on Day 1 and Day 14, demonstrated meaningful reductions in elevated ACTH and 17-hydroxyprogesterone (17-OHP) levels (by 54% to 75%) at all doses studied, together with a dose-related decrease in androstenedione (A4) levels, ranging from 21% to 64%. At the highest dose of crinecerfont (100 mg twice daily), 75% of patients showed a response of at least 50% reduction from baseline for each of the three hormone markers at day 14. Treatment with crinecerfont was well tolerated with a favorable safety profile with no related serious adverse events reported. Adverse events reported in two or more participants included headache, upper respiratory tract infection, fatigue, contusion, insomnia and nausea.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we initiated the CAHtalyst study, a global registrational Phase III, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of crinecerfont in 165 adult patients with classic CAH, followed by an open-label treatment period. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we initiated a Phase IIa proof-of-concept, pharmacokinetic/pharmacodynamic clinical study to evaluate the safety and tolerability of crinecerfont in pediatric patients with classic CAH. We plan to initiate a single global registrational Phase III clinical study for crinecerfont in pediatric patients with CAH in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">elagolix &#8211; GnRH Antagonist</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gonadotropin-releasing hormone, or GnRH, is the endogenous peptide that binds to the GnRH receptor and stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function. Researchers have found that chronic administration of GnRH agonists, after initial stimulation, reversibly shuts down this transmitter pathway and is clinically useful in treating hormone-dependent diseases such as Polycystic Ovary Syndrome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCOS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie initiated a Phase II clinical study of elagolix in patients with PCOS in mid-2019. The study is designed to evaluate whether there is a potential impact on disordered hormonal dynamics in women with PCOS. We out-licensed the global rights to elagolix to AbbVie in 2010.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCOS is one of the most common hormonal disorders among women of reproductive age, affecting approximately 3.5 million women in the U.S. PCOS occurs when the ovaries or adrenal glands produce more male hormones (androgens) than normal. Women with PCOS experience irregular menstrual periods, infertility, pelvic pain, weight gain, acne and excess hair growth on the face, chest, stomach and thighs. There is no cure for PCOS, and treatment options are limited. If left untreated, PCOS can lead to certain cancers, diabetes and coronary artery disease. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Psychiatry</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the global rights to develop and commercialize NBI-1065844 (TAK-831), NBI-1065845 (TAK-653) and NBI-1065846 (TAK-041) from Takeda Pharmaceutical Company Limited, or Takeda, in June 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-1065844 (TAK-831) &#8211; DAAO Inhibitor</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is a potential first-in-class D-Amino Acid Oxidase, or DAAO, inhibitor that has completed multiple Phase I clinical studies and is currently in on-going Phase II clinical studies, including the Phase II INTERACT proof-of-concept clinical study in negative symptoms of schizophrenia, with Phase II top-line data expected in the first quarter of 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the World Health Organization, or WHO, 20 million people across the globe are affected by schizophrenia. In the U.S., the prevalence of schizophrenia is estimated to be approximately 0.6% of the population. The negative symptoms associated with schizophrenia describe a lessening or absence of behaviors and functions related to motivation and interest, or verbal and emotional expression. There are currently no approved treatment options in the U.S. for patients with predominant negative symptoms of schizophrenia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is currently designated as a royalty-bearing product for Takeda. Takeda retains a one-time opt-in right for a 50:50 profit share arrangement upon achievement of a certain development event.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-1065845 (TAK-653) &#8211; AMPA Potentiator</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065845 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid, or AMPA, potentiator with the potential to be developed for treatment-resistant depression. NBI-1065845 has completed multiple Phase I clinical studies. We plan to initiate a Phase II clinical study of NBI-1065845 in treatment-resistant depression in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">According to the WHO, major depressive disorder, or MDD, is one of the leading causes of disability. While there are a number of marketed treatments for MDD, approximately 1/3 of patients do not benefit from them. There is a significant need to develop new therapies with improved, faster onset of efficacy that are well tolerated. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065845 is currently designated as a 50:50 profit share product with Takeda. Takeda retains a one-time opt-out right to convert the designation to a royalty-bearing product dependent on a certain development event.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBI-1065846 (TAK-041) &#8211; G Protein-Coupled Receptor 139 Agonist</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065846 is a potential first-in-class G Protein-Coupled Receptor 139, or GPR139, agonist with the potential to be developed for the treatment of anhedonia in depression. NBI-1065846 has completed multiple Phase I clinical studies. We plan to initiate a Phase II clinical study of NBI-1065846 in anhedonia in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anhedonia is a psychological condition characterized by the inability to experience pleasure. In patients with depression, anhedonia often does not improve with current treatments and predicts lack of functional improvement. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065846 is currently designated as a 50:50 profit share product with Takeda. Takeda retains a one-time opt-out right to convert the designation to a royalty-bearing product dependent on a certain development event.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Research Programs</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in research and development in order to address diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal disorders to stress-related disorders and neurological/neuropsychiatric diseases. CNS and endocrinology drug therapies are among the largest therapeutic categories, accounting for over $110&#160;billion in drug sales in the U.S. alone according to IQVIA (2018).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to improve the lives of patients living with serious and under-addressed neurological, neuro-endocrinology and psychiatry related diseases and disorders. The following are the key elements of our business strategy:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercializing Our Product Portfolio. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, we received approval from the FDA for INGREZZA for the treatment of tardive dyskinesia. In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients. We market INGREZZA and ONGENTYS in the U.S. The commercial launch of INGREZZA occurred in May 2017 and ONGENTYS occurred in September 2020. We have built a specialty sales force in the U.S. of approximately 250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experienced sales professionals. This specialty sales force focuses on promotion to physicians, primarily psychiatrists and neurologists.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial team is comprised of experienced professionals in marketing, access and reimbursement, managed markets, market research, commercial operations, and sales force planning and management. In addition, our commercial infrastructure includes capabilities in manufacturing, medical affairs, quality control and compliance. We intend to retain commercial rights to certain products, including INGREZZA, that we can effectively and efficiently develop, secure regulatory approval and commercialize, which includes products with a concentrated prescriber base and well-defined patient population that can be accessed with an efficient patient and prescriber outreach program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advancing Life-Changing Discoveries in Neurology, Neuro-Endocrinology and Psychiatry. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that by continuing to advance and extend our product pipeline, we can mitigate some of the clinical development risks associated with drug development. We currently have multiple programs in various stages of research and development, including symptomatic disease modifying and curative treatments. We take a portfolio approach to managing our pipeline that balances the size of the market opportunities with clear and defined clinical and regulatory paths to approval. By doing so, we focus our internal development resources on innovative therapies with improved probabilities of technical and commercial success.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discovering Novel Medicines to Address Unmet Patient Needs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to identify and validate new medicines on novel targets for internal development or collaboration. We believe the creativity and productivity of our discovery research group will continue to be a critical component for our ongoing success.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquiring Rights to Commercial Products, Drug Development Candidates and Technologies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We plan to continue to selectively acquire rights to programs at all stages of development and commercial products to take advantage of our drug development and commercial capabilities.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_28"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Collaborations and Strategic Alliances</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our business strategies is to utilize strategic alliances to enhance our development and commercialization capabilities. The following is a summary of our significant collaborations/alliances:</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2020, we entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the license agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the royalty term has expired in such country; and (ii) for any Profit-Share Product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the United States, Japan, the European Union, and the United Kingdom, or the Major Markets, on 6 months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class(es) for which first commercial sale occurs. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class(es) for which first commercial sale. Takeda may terminate the license agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the license agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the global rights to NBI-827104 from Idorsia in May 2020. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker, being developed for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. The agreement also included a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. Under the terms of the agreement, we are responsible for all manufacturing, development and commercialization costs of any collaboration product. We may terminate the collaboration and licensing agreement, in its entirety or with respect to a particular compound or development candidate, by providing 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#8217;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the license and collaboration agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular product and country, the exclusive license granted by Xenon to us with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to such product and country will become fully paid, royalty free, perpetual, and irrevocable. We may terminate the license and collaboration agreement by providing at least 90 days&#8217; written notice, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a collaboration and license agreement with Voyager, a clinical-stage gene therapy company, which became effective in March 2019. The agreement is focused on the development and commercialization of four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the following: NBIb-1817 for Parkinson&#8217;s disease, the Friedreich&#8217;s ataxia program and two undisclosed programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commercialization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activities of such program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect. With respect to the other programs, we may terminate the collaboration and license agreement with Voyager upon 180 days written notice to Voyager prior to the first commercial sale of any collaboration product or upon 1 year after the date of notice if such notice is provided after the first commercial sale of any collaboration product. Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the U.S. and Canada rights to ONGENTYS from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-product and country-by-country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency. BIAL may terminate the agreement if we fail to use commercially reasonable efforts to submit a new drug application, or NDA, for a licensed product by a specified date, in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. We may terminate the agreement at any time for any reason upon nine months&#8217; written notice to BIAL.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MTPC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with MTPC for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, MTPC is responsible for all development, marketing and commercialization costs in Japan and other select Asian markets, with the exception of a single Huntington&#8217;s chorea study to be performed by us. We will </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. MTPC may terminate the agreement at its discretion upon 180 days&#8217; written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation GnRH antagonists, or collectively the GnRH Compounds, for women&#8217;s and men&#8217;s health.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval of ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received approval from the FDA for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days&#8217; written notice to us.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_31"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect our products and product candidates and related inventions and improvements that we consider important to our business. We own a portfolio of U.S and non-U.S. patents and patent applications and have licensed rights to a number of U.S. and non-U.S. patents and patent applications. Our owned and licensed patents and patent applications cover or relate to our products and product candidates, including certain formulations, used to treat particular conditions and methods of administration, drug delivery technologies and delivery profiles and methods of manufacturing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have licensed rights to the following U.S. patents relating to INGREZZA and our other products and product candidates in our pipeline (in addition to non-U.S. patents and certain patents covering our early-stage product candidates):</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA, our highly selective VMAT2 inhibitor for the treatment of tardive dyskinesia, is covered by eight issued U.S. patents that are listed in the FDA&#8217;s Orange Book and are set to expire between 2027 and 2037. There is also a potential patent term extension of up to an additional two years for U.S. Patent No. 8,039,627, which is currently set to expire in 2029 and is the earliest patent covering valbenazine, the active pharmaceutical ingredient contained in INGREZZA. In Japan and certain other East Asian markets, we are actively pursuing most of the patents corresponding to those listed in the FDA&#8217;s Orange Book entry for INGREZZA.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ONGENTYS, a highly selective COMT inhibitor for Parkinson&#8217;s disease, is covered by nine issued U.S. patents that are listed in the FDA&#8217;s Orange Book and set to expire between 2026 to 2035 (not including a potential patent term extension of up to an additional four years for one of these patents).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA, our small molecule GnRH antagonist for the treatment of endometriosis pain, is covered by eight issued U.S. patents that are listed in the FDA&#8217;s Orange Book and are set to expire between 2021 to 2036 (not including a potential patent term extension of up to an additional five years for one of the patents currently set to expire either in 2021 or 2024). </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORIAHNN, containing our small molecule GnRH antagonist for the treatment of menstrual bleeding associated with uterine fibroids, is covered by six issued U.S. patents that are listed in the FDA&#8217;s Orange Book and are set to expire between 2021 to 2024 (not including a potential patent term extension of up to an additional five years for one of the patents).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Valbenazine, our highly selective VMAT2 inhibitor under further clinical development for the treatment of chorea in Huntington&#8217;s disease, is covered by at least six of the issued U.S. patents that are listed in the FDA&#8217;s Orange Book entry for INGREZZA and are set to expire between 2027 and 2036 . There is also a potential patent term extension of up to an additional two years for U.S. Patent No. 8,039,627, which is currently set to expire in 2029. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Crinecerfont, our CRF1 antagonist for the treatment of CAH, is covered by U.S. Patent No. 10,905,690, which expires in 2035 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-1065844, a DAAO inhibitor for the treatment of negative symptoms of schizophrenia, is covered by U.S. Patent No. 9,290,456, among others, which expires in 2032 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-827104, an inhibitor of T-type calcium channels for the treatment of CSWS epilepsy, is covered by U.S. Patent No. US 9,932,314, among others, which expires in 2035 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-921352, an inhibitor of the Nav1.6 voltage-gated sodium channel for the treatment of SCN8A-DEE epilepsy, is covered by U.S. Patent No. US 10,246,453, among others, which expires in 2037 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Elagolix, our small molecule GnRH antagonist under further development for the treatment of polycystic ovary syndrome, is covered by six of the issued U.S. patents that are listed in the FDA&#8217;s Orange Book entry for ORILISSA and are set to expire between 2021 to 2024 (not including a potential patent term extension of up to an additional five years for one of the patents).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-1065845, a positive allosteric modulator of AMPA for the treatment of treatment-resistant depression is covered by U.S. Patent No. 8,778,934, among others, which expires in 2031 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-1065846, a GPR139 agonist for the treatment of anhedonia in depression, is covered by U.S. Patent No. 9,556,130, among others, which expires in 2035 (not including a potential patent term extension of up to an additional five years).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential patent term extensions referenced above, the products and product candidates in our pipeline may be subject to additional terms of exclusivity that we might obtain by future patent issuances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the U.S., the European Union, or EU, and Japan all provide data and marketing exclusivity for new medicinal compounds. If this protection is available, no competitor may use the original applicant&#8217;s data as the basis of a generic marketing application during the period of data and marketing exclusivity, which is measured from the date of marketing approval by the FDA or corresponding foreign regulatory authority. This period of exclusivity is generally five years in the U.S., six years in Japan and ten years in the EU, except that for biologics, this period of exclusivity in the U.S. is twelve years under the Biologics Price Competition and Innovation Act. In addition, if granted orphan drug designation, certain of our product candidates, including crinecerfont, may also be eligible for market exclusivity in the U.S. and EU for seven years and ten years, respectively.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_34"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on, and intend to continue to rely on, third-party manufacturers for the production of INGREZZA and our product candidates. Raw materials, active pharmaceutical ingredients, or API, and other supplies required for the production of INGREZZA and our product candidates are procured from various third-party manufacturers and suppliers in quantities adequate to meet our needs. Continuing adequate supply of such raw materials and API is assured through our long-term commercial supply and manufacturing agreements with multiple manufacturers and our continued focus on the expansion and diversification of our third-party manufacturing relationships. In addition, under the terms of our agreement with BIAL, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our outsource manufacturing strategy enables us to direct our financial resources to the maximization of our opportunities with INGREZZA and ONGENTYS, investment in our internal R&amp;D programs and expansion of our clinical pipeline through business development opportunities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers, suppliers and service providers may be subject to routine current Good Manufacturing Practice, or cGMP, inspections by the FDA or comparable agencies in other jurisdictions. We depend on our third-party partners for continued compliance with cGMP requirements and applicable foreign standards.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing, Sales and Distribution</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales force in the U.S. consists of approximately 250 experienced sales professionals focused on educating health care professionals, including psychiatrists and neurologists, who treat patients with tardive dyskinesia and Parkinson&#8217;s disease.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For INGREZZA, our customers in the U.S. consist of a limited network of specialty pharmacy providers that deliver INGREZZA to patients by mail and a specialty distributor that distributes INGREZZA primarily to closed-door pharmacies and government facilities. For ONGENTYS, our customers in the U.S. consist primarily of wholesale distributors. We rely on third-party service providers to perform a variety of functions related to the packaging, storage and distribution of INGREZZA and ONGENTYS.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_40"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities are subject to extensive regulation by the U.S. and other countries. Regulation by government authorities in the U.S. and foreign countries is a significant factor in the development, manufacture, distribution, tracking, marketing and sale of our proposed products and in our ongoing research and product development activities. All of our products in development will require regulatory approval by government agencies prior to commercialization. The process of obtaining these approvals and the subsequent compliance with appropriate federal and state statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal and state healthcare laws restrict business practices in the pharmaceutical industry. These laws include, without limitation, federal and state fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. We have a comprehensive compliance program designed to ensure our business practices remain compliant.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute makes it illegal for any person or entity to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal civil and criminal false claims laws and the federal civil monetary penalties law, which prohibit among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed and knowingly making, or causing to be made, a false record or to avoid or decrease an obligation to pay money to the federal government.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to HIPPA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their privacy and security regulations, which impose certain obligations, including the adoption of administrative, physical and technical safeguards to protect individually identifiable health information on covered entities subject to HIPPA (i.e., health plans, healthcare clearinghouses and certain healthcare providers) and their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information as we as their covered subcontractors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;and Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable entities to report ownership and investment interests held by the physicians and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse-midwives.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar healthcare statutes or regulations that may be broader in scope and may apply regardless of payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these laws, where applicable, can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, and additional reporting requirements and regulatory oversight, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Marketing Approval for Products</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies generally are conducted in laboratory animals to evaluate the potential safety and efficacy of a product. Drug developers submit the results of preclinical studies to the FDA as a part of an investigational new drug, or IND, application before clinical trials can begin in humans. Typically, clinical evaluation involves a time consuming and costly three-phase process.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with a small number of subjects to determine the early safety profile, maximum tolerated dose and pharmacokinetic properties of the product in human volunteers and for certain products, such as gene therapies, in patients with the target disease.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Larger, multi-center, comparative clinical trials are conducted with patients afflicted with a specific disease in order to determine safety and efficacy as primary support for regulatory approval by the FDA to market a product candidate for a specific disease.</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the U.S. and may, at its discretion, re-evaluate, alter, suspend or terminate the testing based upon the data accumulated to that point and the FDA&#8217;s assessment of the risk/benefit ratio to the patient. Institutional Review Boards, Institutional Ethics Committees, and Data Safety Monitoring Boards also closely monitor the conduct of our trials and may also place holds on our clinical trials or recommend that we voluntarily do so. Clinical trials conducted in foreign countries are also subject to oversight by regulatory authorities in those countries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once Phase&#160;III trials are completed, drug developers submit the results of preclinical studies and clinical trials to the FDA in the form of an NDA or a biologics license application, or BLA, for approval to commence commercial sales. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, the FDA has a goal of ten months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission. The FDA generally has a six-month review goal of priority NDAs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain applications or supplements to an application must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy to ensure that the benefits of the drug outweigh its risks. The risk evaluation and mitigation strategy could include medication guides, physician communication plans, assessment plans, and/or additional elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs and BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA or BLA to determine, among other things, whether the drug is safe and effective for its intended use and whether the facility in which it is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with current Good Manufacturing Practice requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with Good Clinical Practice requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the application and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a risk evaluation and mitigation strategy, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have to complete an approval process similar to that in the U.S. in order to commercialize our product candidates in each foreign country. The approval procedure and the time required for approval vary from country to country and may involve additional testing. Foreign approvals may not be granted on a timely basis, or at all. In addition, regulatory approval of prices is required in most countries other than the U.S. The resulting prices may not be sufficient to generate an acceptable return to us or our corporate collaborators.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, there are currently two potential tracks for seeking marketing approval for a product not authorized in any EU member state: a decentralized procedure and a centralized procedure. In the decentralized procedure, identical applications for marketing authorization are submitted simultaneously to the national regulatory agencies. Regulatory review is led by one member state (the reference-member state), and its assessment&#8212;based on safety, quality and efficacy&#8212;is reviewed and approved (assuming there are no concerns that the product poses a serious risk to public health) by the other member states from which the applicant is seeking approval (the concerned-member states). The decentralized procedure leads to a series of single national approvals in all relevant countries. In the centralized procedure, which is required of all products derived from biotechnology, a company submits a single marketing authorization application to the European Medicines Agency, or EMA, which conducts an evaluation of the dossier, drawing upon its scientific resources across Europe. If the drug product is proven to fulfill the requirements for quality, safety and efficacy, the EMA&#8217;s Committee for Medicinal Products of Human Use, or CHMP, adopts a positive opinion, which is transmitted to the European Commission for final decision on grant of the marketing authorization. While the EC generally follows the CHMP&#8217;s opinion, it is not bound to do so. Subsequent commercialization is enabled by country-by-country reimbursement approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the U.S. will be sufficient to offset the costs of developing and making the drug available in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a sponsor&#8217;s marketing application for a designated orphan drug for use in the rare disease or condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during which the FDA may not approve another sponsor&#8217;s marketing application for a drug with the same active moiety and intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsor&#8217;s orphan drug exclusivity period, competitors, however, may receive approval for drugs with different active moieties for the same indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of the orphan drug exclusivity exist, or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation similar to the Orphan Drug Act has been enacted in other countries outside of the United States, including the EU. The orphan legislation in the EU is available for therapies addressing conditions that affect five or fewer out of 10,000 persons, are life&#8209;threatening or chronically debilitating conditions and for which no satisfactory treatment is authorized. The market exclusivity period is for ten years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that the product does not justify maintenance of market exclusivity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase IV clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with current Good Manufacturing Practices, or cGMP, requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new safety risks; or imposition of distribution or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_43"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Regulation for Gene Therapy Products</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of standards that apply to gene therapy. FDA has issued various guidance documents regarding gene therapies, which outline factors that FDA will consider at each of the stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the chemistry, manufacturing and controls information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum five-year period, followed by 10 years of annual queries, either in person or by questionnaire. FDA does not require the long-term tracking to be complete prior to its review of the BLA.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA oversight and oversight by institutional review boards, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_46"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reimbursement</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such drug products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication.&#160;We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our products or product candidates, including INGREZZA, may not be considered medically necessary or cost-effective.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product or product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_49"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, was signed into law, which intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private third-party payor.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain legal and political challenges to certain aspects of the ACA. Since January 2017, the Trump administration signed several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the ACA.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include, among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through May 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several Congressional hearings and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Both the U.S. House of Representatives and the Senate Finance Committee passed legislation in 2019 to reform pharmaceutical pricing in a variety of meaningful ways, and we expect legislative efforts to reform drug pricing to continue in 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to drug pricing that sought to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. This rule is undergoing legal challenge.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. This rule has been stayed until 2023 while pending litigation is heard in the courts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. Two additional lawsuits in other jurisdictions are challenging the legality of this rule. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_52"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things, new drug development technologies, new or improved treatment options for preventing or reducing the incidence of disease in diseases our products treat and new small </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">molecule or other classes of therapeutic agents. Such developments by competitors could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about the competition that our marketed products face is set forth below.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tardive Dyskinesia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INGREZZA competes with AUSTEDO (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parkinson&#8217;s Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Endometriosis and Uterine Fibroids. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Congenital Adrenal Hyperplasia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several clinical development-stage programs targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epilepsy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications, or ASMs, and development-stage programs being pursued by several other companies. Commonly used ASMs, among others, include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different ASMs are currently used in these patient populations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schizophrenia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investigational treatment NBI-1065844 for the negative symptoms of schizophrenia may in the future compete with off-label antipsychotic and antidepressant medicines, including cariprazine, clozapine, fluoxetine, citalopram, sertraline, and amisulpride. In addition, there are several development-stage programs being pursued by other companies, including pimavanserin, roluperidone, RO6889450 and sodium benzoate. Currently, there are no-FDA approved treatments specifically indicated for the negative symptoms of schizophrenia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our investigational treatments for potential use in endocrinology, neurology, and psychiatry, as well as our investigational gene therapies, may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_55"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Employees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown to a team of over 845 employees as of December 31, 2020, all of whom were employed in the U.S. Our highly qualified and experienced team which includes scientists, physicians and professionals across sales, marketing, manufacturing, regulatory, finance and other important functions are critical to our success. We also leverage temporary workers to provide flexibility for our business needs. During 2020, we added 191 new employees to our team. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to add additional employees in 2021 with a focus on expanding our expertise and bandwidth in clinical and preclinical research and development. We continually evaluate our business needs and opportunities </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and balance in house expertise and capacity with external expertise and capacity. Currently, we rely on third-party contract manufacturers. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Culture. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our human capital management investments is evidenced by our low employee turnover, a number which is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy. In recognition of our efforts, in 2020, we were named to the Fortune Best Small and Medium Workplaces 2020 list ranking Number 8 across the country. We were also named a Great Place to Work Certified company and were recognized on Great Place to Work&#8217;s Best Workplace for Parents 2020 list.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement, Talent Development &amp; Benefits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing leadership development through programs as well as offer tuition reimbursement. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of focus.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity &amp; Inclusion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_61"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated in California in January 1992 and reincorporated in Delaware in May 1996. Our principal executive offices are located at 12780 El Camino Real, San Diego, California 92130. Our telephone number is (858) 617-7600.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to reports filed pursuant to Sections&#160;13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.neurocrine.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after such reports are available on the Securities and Exchange Commission, or SEC, website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, copies of our Annual Report will be made available, free of charge, upon written request. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_64"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form&#160;10-K and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_67"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical studies may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval. For example, the FDA has placed a clinical hold on the RESTORE-1 study, a Phase II, randomized, placebo-surgery controlled, double-blind, multi-center clinical study of NBIb-1817 in Parkinson&#8217;s disease patients, following our submission of an IND safety report related to the observation of MRI abnormalities in some study participants. The clinical implications of this observation are currently unknown and are being evaluated. On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of the termination will be August 2, 2021.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including our sales force expansion in late 2018. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully commercialize INGREZZA, or to successfully commercialize ONGENTYS or any product candidate approved by the FDA in the future. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. Most hospitals, community mental health facilities, and other healthcare facilities have implemented policies that limit access of our sales representatives, medical affairs personnel, and patients to such facilities. Due to these closures and our work from home decisions, our field force is currently functioning utilizing digital and telephonic engagement tools and tactics, which may be less effective than our ordinary sales and marketing and medical education programs. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA or ONGENTYS could be affected by a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for indications;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community and patients do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or to commercialize ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the price of prescription drugs through various means may reduce our potential revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, face additional uncertainty related to pricing and reimbursement. As an example, there are a limited number of gene therapy products currently approved for coverage and reimbursement by the Centers for Medicare &amp; Medicaid Services, or CMS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, the COVID-19 pandemic has resulted in increased travel restrictions and the shutdown or delay of business activities in various regions, including San Diego, California, where our headquarters are located. In response to state and local restrictions, we implemented work-from-home policies for all employees except certain key essential members involved in business-critical activities.&#160;The effects of the stay at home order and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, we may face several challenges or disruptions upon a return back to the workplace if and when the COVID-19 pandemic subsides, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure to COVID-19) may be hindered, which would adversely impact our clinical trial operations. For example, due to the impact of the COVID-19 pandemic, we initially paused enrollment of new patients in several of our clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since then, we have begun enrolling patients again in the Phase III study of valbenazine for chorea in HD and the Phase IIa pediatric study of crinecerfont in CAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, increases in COVID-19 cases or hospitalizations in the future could cause us to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are currently in research or clinical development with the exceptions of INGREZZA, which has been approved by the FDA for tardive dyskinesia, ONGENTYS, which has been approved by the FDA for Parkinson&#8217;s disease, ORILISSA (partnered with AbbVie), which has been approved by the FDA for the management of moderate to severe endometriosis pain in women, and ORIAHNN (partnered with AbbVie), which has been approved by the FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Only a small number of research and development programs ultimately result in commercially successful drugs. In addition, to date the FDA has granted regulatory approval for only a very limited number of gene therapy products and the clinical development of a gene therapy product may result in unforeseen adverse events. For example, the FDA has placed a clinical hold on the RESTORE-1 study, a Phase II, randomized, placebo-surgery controlled, double-blind, multi-center clinical study of NBIb-1817 in Parkinson&#8217;s disease patients, following our submission of an IND safety report related to the observation of MRI abnormalities in some study participants. The clinical implications of this observation are currently unknown and are being evaluated. On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of the termination will be August 2, 2021. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may be delayed or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND application or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not replicate the results of earlier, smaller trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the US;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. For example, due to the impact of the COVID-19 pandemic, we paused enrollment of new patients in several of our clinical trials, and increases in COVID-19 cases or hospitalizations in the future could cause us to further limit or suspend our patient enrollment and screening activities. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we collaborate with AbbVie for the manufacture and commercialization of two of our commercial products, ORILISSA and ORIAHNN, and for the continued development of elagolix. We collaborate with MTPC for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. We also rely on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BIAL for the commercial supply of ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we collaborate with Xenon for the development of NBI-921352, Idorsia for the development of NBI-827104 and Takeda for the development of NBI-1065844.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing INGREZZA infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may adversely affect our ability to initiate or continue clinical development or obtain regulatory approvals for gene therapy product candidates or the commercialization of gene therapy products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy remains a novel technology, with few gene therapy products approved to date in the US. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. Even if we are able to successfully complete clinical development of a gene therapy product and obtain commercial approval, the success of our collaboration with Voyager will depend upon physicians who specialize in the treatment of genetic diseases targeted by gene therapy product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations, negative public opinion related to gene therapy products, or safety issues identified in our clinical trials may delay or impair the development and commercialization of our gene therapy product candidates or demand for any gene therapy products we develop.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has limited experience in the review and approval of gene therapy products. The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. As a result, the regulatory review process may take longer or cost more than we anticipate, including requirements for additional preclinical studies or clinical trials, and delay or prevent approval and commercialization of our gene therapy product candidates we are developing through our collaboration with Voyager. While the FDA has issued draft guidance for the development of gene therapies and proposed rules that would streamline certain requirements to which gene therapies are currently subject, it remains to be seen as to whether such initiatives will ultimately increase the speed of drug development in gene therapies such as the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. If our gene therapy products are approved but fail to achieve market acceptance among physicians, patients, hospitals, third-party payors or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease, Friedreich&#8217;s ataxia, and other neurological and endocrine-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful, the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to INGREZZA for tardive dyskinesia, we compete with Teva Pharmaceutical Industries, which received FDA approval for AUSTEDO to treat tardive dyskinesia in August 2017, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as Xenazine (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In endometriosis, ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to ONGENTYS for Parkinson&#8217;s disease, there are currently two other FDA-approved COMT inhibitors. ONGENTYS competes directly with these two drugs and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As for CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products. Additionally, there are several clinical development-stage programs targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications, or ASMs, and development-stage programs being pursued by several other companies. Commonly used ASMs, among others, include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different ASMs are currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The investigational treatment NBI-1065844 for the negative symptoms of schizophrenia may in the future compete with off-label antipsychotic and antidepressant medicines, including ciraprazine, clozapine, fluoxetine, citalopram, sertraline, and amisulpride. In addition, there are several development-stage programs being pursued by other companies, including pimavanserin, roluperidone, RO6889450 and sodium benzoate. Currently, there are no-FDA approved treatments specifically indicated for the negative symptoms of schizophrenia.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in endocrinology, neurology, and psychiatry, as well as our investigational gene therapies, may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. In addition, the manufacture of gene therapy products, which will be necessary under our collaboration and license agreement with Voyager, is technically complex and necessitates substantial expertise and capital investment. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, and the finished product in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced U.S., state, and non-U.S. regulations, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. We depend on a limited number of suppliers for the production of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and contract research organizations, or CROs, to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our FDA applications and our introduction of new drugs. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. In November 2020, we entered into separate, privately negotiated transactions with certain </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. At December 31, 2020, we had an accumulated deficit of $0.7 billion as a result of historical operating losses.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson&#8217;s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations, in-licensing or acquisition opportunities, and capital expenditures. While we were profitable for the year ended December 31, 2020, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we had approximately 845 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially now that we have a commercial sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. A high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus, small declines in revenue could disproportionately affect financial results in a quarter. While we were profitable for the year ended December 31, 2020, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the US tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future US tax expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years ending on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable US tax law. Under the Tax Cut and Jobs Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cut and Jobs Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2020, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California passed legislation imposing limits on the usability of California state NOLs and certain tax credits in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we expect to commence recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which would result in a significant reduction in our net income and net income per share.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $72 per share to approximately $136 per share. The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and ORILISSA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the commercial launch of ONGENTYS and ORIAHNN;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA and ONGENTYS;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, or ORIAHNN;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and a specialty distributor, and all of our product sales are to these customers. Two of these customers </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented approximately 86% of our product revenue for the year ended December 31, 2020 and a significant majority of our accounts receivable balance at December 31, 2020. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources, together with investment income, and future payments due under our strategic alliances, will be sufficient to satisfy our current and projected funding requirements for at least the next twelve months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to curtail significantly our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the 2024 Notes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of additional strategic alliances;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of product in-licensing and any possible acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed, and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the U.S., comprehensive health care reform legislation was enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the U.S. will continue to put pressure on the rate of adoption and pricing of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers are required to provide certain information regarding the drug product provided to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding distribution of the drug product. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, notification and purchaser license verification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2010, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our potential drug candidates are:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain legal and political challenges to certain aspects of the ACA. Since January 2017, several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA have been put into place. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a U.S. District Court Judge in Texas ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the ACA and our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through May 31, 2021 due to the COVID-19 pandemic, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration&#8217;s budget proposal for the 2021 fiscal year includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. In particular, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements, such as our contributions to patient assistance programs, have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects, and reputation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the U.S. and internationally.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. To prevent infringement or unauthorized use, we may need to file infringement claims, which are expensive and time-consuming. In addition, in an infringement proceeding a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Interference proceedings declared by the U.S. Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the U.S. and the EU for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such orphan drug designations may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal, and administrative penalties, fines, and imprisonment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0&#160;million per occurrence and $45.0&#160;million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber security breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect and store confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personally identifiable information of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal information. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors. A security breach or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or other protected information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with evolving U.S. and global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the EU&#8217;s General Data Protection Regulation, or GDPR, imposes strict obligations on the processing of personal data, including personal health data, and the free movement of such data. The GDPR applies to any company established in the EU as well as any company outside the EU that processes personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the EU, including the U.S. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million euros, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, created new individual privacy rights for California consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. For example, the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCPA requires covered companies to provide additional disclosures to California consumers, and provides such consumers with new rights, such as the ability to opt out of certain disclosures of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_70"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 1B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Unresolved Staff Comments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_73"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Properties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease our corporate headquarters, which are located in San Diego, California, and consist of 141 thousand square feet of laboratory and office space located at 12780 El Camino Real, 88 thousand square feet of office space located at 12790 El Camino Real, 46 thousand square feet of laboratory space located at 10420 Wateridge Circle, and 45 thousand square feet of office space located at 12777 High Bluff Drive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our property and equipment are generally well maintained, in good operating condition, and suitable for the conduct of our business.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_76"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Legal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Proceedings</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the normal course of business, we may be subject to various legal matters such as threatened or pending claims or proceedings. We are not currently a party to any material legal proceedings or claims, nor are we aware of any pending or threatened litigation or claims that could have a material adverse effect on our business, operating results, cash flows or financial condition should such litigation or claim be resolved unfavorably.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_79"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i0d67836123014e4c9534b0a3600493e4_85"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;NBIX&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At January 29, 2021, there were approximately 47 stockholders of record of our common stock. We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item&#160;12 of Part&#160;III of this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of our equity securities during 2020. In addition, we did not repurchase any of our equity securities during 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph and Cumulative Total Return*</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the cumulative total stockholder return assuming the investment of $100 on December&#160;31, 2015 (and the reinvestment of dividends thereafter) in each of (i)&#160;Neurocrine Biosciences, Inc.&#8217;s common stock, (ii)&#160;the Nasdaq Composite Index and (iii)&#160;the Nasdaq Biotechnology Index. The comparisons in the graph below are based upon historical data and are not indicative of, or intended to forecast, future performance of our common stock or Indexes.</span></div><div><img src="nbix-20201231_g3.jpg" alt="nbix-20201231_g3.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The material in this section is not &#8220;soliciting material&#8221;, is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, and is not to be incorporated by reference into any of our SEC filings whether made before or after the date hereof and irrespective of any general incorporation language in any such SEC filing except to the extent we specifically incorporate this section by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_1956"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Selected Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following selected financial data have been derived from our audited financial statements. The information set forth below is not necessarily indicative of our results of future operations and should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and notes thereto appearing elsewhere in this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="30" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on restricted equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before (benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.63)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Balance Sheets Data</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and debt securities available-for-sale</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working capital </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,734.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,306.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">817.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(725.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,132.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,177.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,198.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,056.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,126.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements pertaining to, among other things, the commercialization of our product and product candidates, the expected continuation of our collaborative agreements, the receipt of research and development payments thereunder, the future achievement of various milestones in product development and the receipt of payments related thereto, the potential receipt of royalty payments, preclinical testing and clinical trials of potential products, the period of time that our existing capital resources will meet our funding requirements, and our financial results of operations. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various risks and uncertainties, including those set forth in this Annual Report on Form&#160;10-K under the heading &#8220;Item&#160;1A. Risk&#160;Factors.&#8221; See &#8220;Forward-Looking Statements&#8221; in Part&#160;I of this Annual Report on Form&#160;10-K.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_94"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes United States Food and Drug Administration, or FDA,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we have specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the U.S. with our specialty sales force in May 2017, after receiving FDA approval for INGREZZA as the first FDA-approved drug for the treatment of tardive dyskinesia in April 2017. In September 2020, we launched ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the U.S. leveraging our existing INGREZZA commercial infrastructure after receiving FDA approval for ONGENTYS for Parkinson's disease in April 2020. INGREZZA net product sales represent the significant majority of our total net product sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie Inc., or AbbVie, launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix) in the U.S. and Canada in August and November 2018, respectively, after receiving FDA and Health Canada approval for ORILISSA for endometriosis in July and October 2018, respectively. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix, estradiol, and norethindrone acetate; elagolix) in the U.S. after receiving FDA approval for ORIAHNN for uterine fibroids in May 2020. We receive royalties at tiered percentage rates on any net sales of ORILISSA and ORIAHNN.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have a rapidly expanding pipeline of potential treatments and gene therapies for diseases such as Huntington&#8217;s disease, or HD, Parkinson&#8217;s disease, epilepsy, congenital adrenal hyperplasia, or CAH, schizophrenia and depression. Refer to Part I, Item 1, &#8220;Business&#8221; for more information about our exclusive and partnered commercial products, clinical development pipeline and research programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Highlights:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA net product sales for 2020 increased $240.2 million, or 31.9%, to $993.1 million, primarily reflecting strong refill and persistency rates for existing INGREZZA patients.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AbbVie launched ORIAHNN in the U.S. in June 2020, after receiving FDA approval for ORIAHNN as the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women in May 2020. We recognized a $30.0 million event-based milestone as revenue in the second quarter of 2020. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed strategic partnerships with Idorsia Pharmaceuticals Ltd, or Idorsia, and Takeda Pharmaceutical Company Limited, or Takeda, to expand clinical pipeline for epilepsy and psychiatry disorders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognized </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in-process research and development, or IPR&amp;D, expense for 2020 of $164.5 million, related to upfront payments.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total debt outstanding decreased by $136.2 million to $381.3 million after repurchase of approximately 26% of our debt outstanding in December 2020. The total aggregate repurchase price of $186.9 million was paid in cash and resulted in an $18.4 million loss.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined that there is sufficient positive evidence to conclude that it is more likely than not that deferred tax assets of $319.4 million are realizable. We therefore reduced the valuation allowance accordingly.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Highlights:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Crinecerfont (NBI-74788): In July 2020, we initiated the CAHtalyst study, a global registrational Phase III, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of crinecerfont in 165 adult patients with classic CAH, followed by an open-label treatment period.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBI-827104 (ACT-709478): In November 2020, we initiated a Phase II clinical study for NBI-827104 in a rare pediatric epileptic encephalopathy known as Continuous Spike and Wave During Sleep.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA: In February 2021, Mitsubishi Tanabe Pharmaceutical Company, or MTPC, reported positive top-line results from the J-KINECT Phase III study, designed to evaluate the efficacy and safety of valbenazine in tardive dyskinesia. Detailed results from this trial will be presented at a future medical conference. With positive data in hand, a marketing authorization with the Ministry of Health and Welfare is planned for 2021 in Japan. In addition, MTPC submitted filings for marketing authorizations in South Korea, Thailand, Singapore, Indonesia, and Malaysia in 2020.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NBIb-1817 (VY-AADC): On February 2, 2021, we notified Voyager Therapeutics, Inc., or Voyager, of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has dramatically changed the ways in which we live and interact with one another. While we adapt to this new shared reality, our mission remains unchanged: to discover and develop life-changing treatments for people with serious, challenging and under-addressed disorders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unable to reliably estimate the duration or extent of any potential business disruption or financial impact during this time, including any impacts on INGREZZA product sales or R&amp;D expense, we remain committed to (1) prioritizing the safety, health and well-being of patients, their caregivers, healthcare providers and our employees; (2) ensuring patients with tardive dyskinesia are well supported and have continued uninterrupted access to INGREZZA, for which we currently do not expect any supply disruption; and (3) advancing ongoing clinical studies. As part of this commitment, we implemented a &#8220;Work from Home Policy&#8221; in early March 2020 for employees not involved in business-critical activities. For employees involved in business-critical activities, we implemented safety measures designed to comply with federal, state and local guidelines.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the impact of COVID-19, we initially paused enrollment of new patients in several of our clinical trials. Beginning in the third quarter of 2020, we began enrolling patients in our HD and CAH studies. To date, we have not experienced any interruption of our supply of drug products needed to support our ongoing clinical studies, but we expect that completion and data readouts for several of our ongoing and planned studies will be delayed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that existing funds, cash generated from operations, and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures, debt service requirements and other business development initiatives that we plan to strategically pursue. However, should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing new medicines.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by category.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INGREZZA product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONGENTYS product sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales were $994.1 million for 2020, $752.9 million for 2019 and $409.6 million for 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues reflect the achievement of certain event-based milestones, royalties earned at tiered percentage rates on any net sales of ORILISSA and ORIAHNN and license fees earned under our collaboration agreements with AbbVie and MTPC.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we recognized a $30.0 million event-based milestone as revenue upon FDA-approval of AbbVie&#8217;s ORIAHNN for uterine fibroids. In the third quarter of 2019, we recognized a $20.0 million event-based milestone as revenue upon the FDA&#8217;s acceptance of AbbVie&#8217;s new drug application, or NDA, submission of elagolix for uterine fibroids. In the third quarter of 2018, we recognized a $40.0 million event-based milestone as revenue upon FDA-approval of AbbVie&#8217;s ORILISSA for the treatment of moderate to severe pain associated with endometriosis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For ORILISSA and ORIAHNN, we recognized royalty revenue of $19.2 million for 2020, $14.3 million for 2019 and $1.6 million for 2018. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $10.1 million for 2020, $7.4 million for 2019 and $4.9 million for 2018, primarily reflecting a higher annual volume of INGREZZA product sales since commercial launch in April 2017.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, R&amp;D programs and business development opportunities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the R&amp;D activities are part of our collaborative and other relationships.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Late stage consists of costs incurred related to product candidates in Phase II registrational studies and onwards. Early stage consists of costs incurred related to product candidates in post-investigational new drug application, or IND, through Phase II non-registrational studies. Research and discovery consists of pre-IND costs. Milestone expenses reflect payments made in connection with our collaborative and other relationships. Payroll and benefits consists of costs incurred for salaries and wages, payroll taxes, benefits and share-based compensation associated with employees involved in ongoing R&amp;D activities. Share-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Facilities and other consists of indirect costs incurred in support of overall R&amp;D activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are not allocated to a specific program or stage.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents R&amp;D expense by category:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late stage</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early stage</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.8&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense was $275.0 million for 2020, $200.0 million for 2019 and $155.8 million for 2018. The increase in R&amp;D expense was primarily the result of increased investment to support advancing our expanded clinical portfolio and increased personnel expenses on higher headcount.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D expense was $164.5 million for 2020, $154.3 million for 2019 and $4.8 million for 2018. For 2020, we recorded IPR&amp;D expense of $46.0 million and $118.5 million in connection with the payments of the upfront fees pursuant to our collaborations with Idorsia and Takeda, respectively. For 2019, we recorded IPR&amp;D expense of $118.1 million and $36.2 million in connection with the payments of the upfront fees pursuant to our collaborations with Voyager and Xenon Pharmaceuticals, Inc., or Xenon. For 2018, we recorded IPR&amp;D expense of $4.8 million in connection with payment of the upfront fee to Jnana to obtain access to Jnana&#8217;s proprietary drug discovery platform.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative, or SG&amp;A, expense was $433.3 million for 2020, $354.1 million for 2019 and $248.9 million for 2018. The increase in SG&amp;A expense from 2019 to 2020 was primarily due to increased personnel expenses on higher headcount and continued investment in INGREZZA marketing. The increase in SG&amp;A expense from 2018 to 2019 was primarily due to the sales force expansion completed in the third quarter of 2018, the national launch of a patient-focused disease state awareness campaign, Talk About TD, and an increase in the Branded Pharmaceutical Drug Fee expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, was $56.3 million for 2020, $25.8 million for 2019 and $15.0 million for 2018. Periodic fluctuations in other expense, net, primarily reflect unrealized losses recognized to adjust our equity investments in Voyager and Xenon Pharmaceuticals Inc. to fair value. For 2020, other expense, net, also reflects an $18.4 million loss on debt extinguishment recognized for the partial repurchase of the 2024 Notes in November 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Benefit from) Provision for Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our benefit from income taxes was $300.6 million for 2020, compared to a provision for income taxes of $9.5 million for 2019 and $0.7 million for 2018. The benefit from income taxes for 2020 included a $296.3 million benefit related to the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020. The decision to release the valuation allowance was made after we determined that it was more likely than not the deferred tax assets, including net operating losses and tax credits, would be realized, and was based on the evaluation and weighting of both positive and negative evidence, such as our achievement of a cumulative three-year income position at December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. The provision for income taxes for 2019 and 2018 reflected estimated current state income taxes for both periods. At December 31, 2019 and 2018, we had full valuation allowances against our net deferred tax assets as realization was uncertain. Our tax expense for 2020, 2019 and 2018 varied from the statutory tax rate primarily due to changes in our valuation allowances, net of other permanent book/tax differences, tax credits generated and impacts of changes in tax laws.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was $407.3 million, or $4.16 diluted earnings per share, for 2020, $37.0 million, or $0.39 diluted earnings per share, for 2019 and $21.1 million, or $0.22 diluted earnings per share, for 2018. The change from 2019 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to 2020 was primarily the result of increased INGREZZA net product sales and a non-cash tax benefit of $296.3 million related to the release of substantially all of our valuation allowance against our deferred tax assets on December 31, 2020, offset by $164.5 million of IPR&amp;D in connection with our collaborations with Idorsia and Takeda, ongoing support for the commercial launch of INGREZZA for tardive dyskinesia and progression of our clinical pipeline. The change from 2018 to 2019 was primarily the result of increased INGREZZA net product sales, offset by $154.3 million of IPR&amp;D in connection with our collaborations with Voyager and Xenon, ongoing support for the commercial launch of INGREZZA for tardive dyskinesia and progression of our clinical pipeline.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_100"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and debt securities available-for-sale totaled $1.0 billion and $970.2 million at December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $228.5 million for 2020, $147.0 million for 2019 and $101.4 million for 2018. The increase in positive cash flow from 2019 to 2020 was primarily due to increased INGREZZA net product sales partially offset by incremental INGREZZA investment and progression of our clinical pipeline. The increase in positive cash flow from 2018 to 2019 was primarily due to increased INGREZZA net product sales, partially offset by incremental INGREZZA investment and upfront payments of $154.3 million in connection with our collaborations with Voyager and Xenon.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $4.1 million for 2020, compared with net cash used in investing activities of $211.1 million for 2019 and $242.9 million for 2018. Periodic fluctuations in cash flows from investing activities primarily reflect timing differences in purchases, sales and maturities of debt securities available-for-sale and changes in our portfolio-mix. Net cash used in investing activities for 2019 also reflects equity investments of $54.7 million in Voyager and $14.2 million in Xenon.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $157.8 million for 2020, primarily reflecting our repurchase of $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash in November 2020, compared to net cash provided by financing activities of $32.4 million for 2019 and $29.5 million in 2018. For 2019 and 2018, periodic fluctuations in cash flows from financing activities reflect proceeds from issuances of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf Registration Statement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we filed an automatic shelf registration statement which immediately became effective by rule of the Securities and Exchange Commission, or SEC. We sold no securities under this shelf registration statement in 2020, 2019 or 2018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes scheduled to mature on May 15, 2024, unless earlier converted, redeemed, or repurchased. We may not redeem the 2024 Notes prior to May 15, 2021. On or after this date, at our election, we may redeem all, or any portion, of the 2024 Notes under certain circumstances. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable. Amounts for the 2024 Notes and related interest in the table above assume that the 2024 Notes will be held until maturity. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_106"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon financial statements that we have prepared in accordance with accounting principles generally accepted in the United&#160;States of America, or GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an on-going basis, we evaluate these estimates, including those related to revenue recognition and share-based compensation. Estimates are based on historical experience, information received from third parties and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Historically, revisions to our estimates have not resulted in a material change to the financial statements. The items in our financial statements requiring significant estimates and judgments are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period, which are primarily based on actual historical rebates, estimated payor mix, state and federal regulations and related contractual terms. Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of calculating share-based compensation, we estimate the fair value of share-based compensation awards using a Black-Scholes option-pricing model. The determination of the fair value of share-based compensation awards utilizing the Black-Scholes model is affected by our stock price and a number of assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. Our stock options have characteristics significantly different from those of traded options, and changes in the assumptions can materially affect the fair value estimates. For example, an increase in the underlying stock price results in a significant increase in the Black-Scholes option-pricing. The fair value of performance-based restricted stock units, or PRSUs, is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition for PRSUs commences when attainment of the associated performance-based criteria is determined to be probable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If factors change and we employ different assumptions, share-based compensation expense may differ significantly from what we have recorded in the past. If there is a difference between the assumptions used in determining share-based compensation expense and the actual factors which become known over time, we may change the input factors used in determining share-based compensation expense for future grants. These changes, if any, may materially impact our results of operations in the period such changes are made. For actual forfeitures, we recognize the adjustment to compensation expense in the period the forfeitures occur.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a corresponding income tax benefit. We continue to maintain a valuation allowance against our California state deferred tax assets.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_109"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the consolidated financial statements for information on accounting pronouncements that have impacted or are expected to materially impact our consolidated financial condition, results of operations, or cash flows.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_112"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors That May Affect Future Financial Condition and Liquidity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funding necessary to execute our business strategies is subject to numerous uncertainties, which may adversely affect our liquidity and capital resources. Marketing of approved pharmaceuticals and completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate. It is also important to note that if a clinical candidate is identified, the further development of that candidate can be halted or abandoned at any time due to a number of factors. These factors include, but are not limited to, funding constraints, safety or a change in market demand.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature and efforts required to develop our product candidates into commercially viable products include research to identify a clinical candidate, preclinical development, clinical testing, FDA approval and commercialization. In the pharmaceutical industry, total R&amp;D spend for a drug candidate that successfully completes all stages of R&amp;D and is commercialized may exceed $2&#160;billion. Further, it can take in excess of ten years to complete all stages of R&amp;D for a drug candidate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our potential product candidates in numerous preclinical studies to identify disease indications for which our product candidates may show efficacy. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain product candidates or for certain indications in order to focus our resources on more promising product candidates or indications. The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient recruitment and enrollment may be slower or more difficult than expected; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of our programs, we periodically assess the scientific progress and merits of the programs to determine if continued R&amp;D is economically viable. Certain of our programs have been terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization. Because of the uncertainties associated with R&amp;D of these programs, we may not be successful in achieving commercialization. As such, the ultimate timeline and costs to commercialize a product cannot be accurately estimated.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our in-license, research and clinical development agreements are generally cancellable with written notice within 180 days or less. We may be required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-8" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMTIvZnJhZzphODUyNGZhNjFlOTI0NWYwODZiMjkyNjhhZGQyYmU0Mi90ZXh0cmVnaW9uOmE4NTI0ZmE2MWU5MjQ1ZjA4NmIyOTI2OGFkZDJiZTQyXzEwOTk1MTE2NDA2OTA_62b87349-9048-4c6d-9c7c-ff53e2f5e4f2">8.5</ix:nonFraction> billion in milestone payments, plus sales royalties, in the event that all scientific research, development and commercialization milestones under these agreements are achieved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than INGREZZA, which has been FDA-approved for the treatment of tardive dyskinesia; ONGENTYS, which has been FDA-approved as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients; ORILISSA (partnered with AbbVie), which has been FDA-approved for the management of moderate to severe endometriosis pain in women; and ORIAHNN (partnered with AbbVie), which has been FDA-approved for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, our product candidates have not yet achieved FDA regulatory approval, which is required before we can market them as therapeutic products in the U.S. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, the FDA must conclude that our clinical data establish safety and efficacy. We must satisfy the requirements of similar regulatory authorities in foreign countries in order to market products in those countries. The results from preclinical testing and early clinical trials may not be predictive of results in later </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials. It is possible for a candidate to show promising results in clinical trials, but subsequently fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the uncertainties discussed above, among others, the duration and completion costs of our R&amp;D projects, clinical trials, and post-marketing studies are difficult to estimate and are subject to considerable variation. Our inability to complete our R&amp;D projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited experience in marketing and selling pharmaceutical products. If we fail to maintain successful marketing, sales, and reimbursement capabilities, or fail to enter into successful arrangements with third parties, our product revenues may suffer. We also may be required to make further substantial expenditures if unforeseen difficulties arise in other areas of our business. In particular, our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the 2024 Notes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of additional strategic alliances;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of product in-licensing and any possible acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, funds generated by anticipated INGREZZA net product sales and investment income will be sufficient to satisfy our current and projected funding requirements for at least the next twelve&#160;months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and product development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, the cost of product in-licensing and any possible acquisitions, and we may require additional funding to establish manufacturing and marketing capabilities in the future. We may seek to access the public or private </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity markets whenever conditions are favorable. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue an unlimited number of shares of our securities from time to time. In addition, we issued $517.5&#160;million of convertible debt in May 2017 and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding. We may also seek additional funding through strategic alliances or other financing mechanisms. We cannot assure you that adequate funding will be available on terms acceptable to us, if at all. In addition, COVID-19 pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. Any additional equity financings will be dilutive to our stockholders and any additional debt may involve operating covenants that may restrict our business. If adequate funds are not available through these means, we may be required to curtail significantly one or more of our research or development programs or obtain funds through arrangements with collaborators or others. This may require us to relinquish rights to certain of our technologies, products or product candidates. To the extent that we are unable to obtain third-party funding for such expenses, we expect that increased expenses will result in increased cash flow losses from operations. We cannot assure you that we will successfully develop our products under development or that our approved products will generate revenues sufficient to enable us to earn a profit.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_1969"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our contractual obligations at December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025 and<br/>Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes and related interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401.6&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.9&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In May 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% convertible senior notes scheduled to mature on May 15, 2024, unless earlier converted, redeemed, or repurchased. We may not redeem the 2024 Notes prior to May 15, 2021. On or after this date, at our election, we may redeem all, or any portion, of the 2024 Notes under certain circumstances. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable. Amounts for the 2024 Notes and related interest in the table above assume that the 2024 Notes will be held until maturity. In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. At December 31, 2020, $381.3 million aggregate principal amount of the 2024 Notes remained outstanding.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) We lease our corporate headquarters, which consist of laboratory and office space located San Diego, California, under various operating lease agreements. In addition to minimum rental commitments, these operating leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. The non-cancelable lease terms for these operating leases expire at various dates between 2025 and 2031 and do not include renewal options. Amounts for operating leases presented in the table above reflect future minimum rental commitments under non-cancelable operating leases as of December 31 for each of the periods presented.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_118"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 7A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceed twelve months. If a 1% change in interest rates were to have occurred on December 31, 2020, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements and Supplementary Data</span></div><div id="i0d67836123014e4c9534b0a3600493e4_124"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_127">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_127">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_130">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_130">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_136">Consolidated Statements of Income and Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_136">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_139">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_139">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_142">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_142">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_145">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d67836123014e4c9534b0a3600493e4_145">69</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Shareholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related consolidated statements of income and comprehensive income, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;5, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standard</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2016-02</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for leases effective January 1, 2019, due to the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and the related amendments.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Reserves for government rebates related to product sales</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:63pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company sells drugs to specialty pharmacies and specialty distributors in the U.S. (collectively, &#8220;customers&#8221;). As described in Note 1 to the consolidated financial statements, the Company recognizes revenues for sales of INGREZZA to its customers after deducting management&#8217;s estimates of reserves, including drug coverage gap rebates, it will provide under government rebate programs (&#8220;government rebates&#8221;). Estimated government rebates are presented within accounts payable and accrued liabilities on the consolidated balance sheets.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:74pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the estimates of government rebates was complex and judgmental due to the level of uncertainty involved in management&#8217;s assumptions used in the measurement process. In particular, management was required to estimate, for product that remains in the distribution channel at December 31, 2020, the portion of product that is expected to be subject to a government rebate and the applicable contractual government rebate percentage by forecasting the revenue, the payor type underlying the revenue and the applicable rebate amount for the payor type.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We tested the Company&#8217;s internal controls over management&#8217;s process for estimating the portion of product that is expected to be subject to a government rebate for product that remains in the distribution channel at December 31, 2020, including controls over management&#8217;s forecast of revenue and the accuracy of data used in the calculation.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:104pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test management&#8217;s estimate of government rebate reserves our audit procedures included, among others, evaluating the methodologies used, testing the significant assumptions discussed above and testing the completeness and accuracy of the underlying data used by the Company in its analyses. Specifically, we compared the significant assumptions to third-party reports used by the Company to estimate product remaining in the distribution channel at December 31, 2020. In addition, we compared the underlying government rebate percentages used in the Company&#8217;s analyses to those published by the applicable government entity. We assessed the historical accuracy of management&#8217;s rebate estimates, tested payments of rebates and performed a sensitivity analysis of significant assumptions to evaluate the changes in the rebate allowance that would result from changes in the assumptions.</span></div></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1992.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;5, 2021</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzQtMS0xLTEtMA_ebbeda42-b480-437e-99a0-bf4ef62815e2">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzQtMy0xLTEtMA_fd67b778-82ce-4b6b-b902-34a1f04fe1c6">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale (amortized cost $<ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMC0xLTEtMzc1L3RleHRyZWdpb246ZGM5NTA1ZWI2OGQ2NGJjZmJkOTBkNWFkMWFkODNkZGVfMTY0OTI2NzQ0MTgwOQ_816ea726-1eab-4b55-85fe-05ee4b2b0628">612.4</ix:nonFraction> million at December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMC0xLTEtMzc1L3RleHRyZWdpb246ZGM5NTA1ZWI2OGQ2NGJjZmJkOTBkNWFkMWFkODNkZGVfMTY0OTI2NzQ0MTgyNw_a798131f-999c-45d7-950e-a25a9226e3b4">557.3</ix:nonFraction> million at December&#160;31, 2019)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMS0xLTEtMA_d2d4f445-fd07-4702-a83e-df51d525547a">613.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMy0xLTEtMA_c79e09fd-488c-42fb-bfcd-2e191251b9f9">558.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzYtMS0xLTEtMA_5b58fe31-62bd-4c3b-92d3-be49d6058885">157.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzYtMy0xLTEtMA_dd4e8bfb-5c06-4b88-a4b5-4ca5b3084228">126.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzctMS0xLTEtMA_be3296fa-34d6-410c-8ec5-65d106b2494b">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzctMy0xLTEtMA_62d35719-4970-4996-a2c6-fe6e4bb1fe74">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzgtMS0xLTEtMA_0e6f19e5-5599-460c-b2a0-4b5b6df01a05">30.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzgtMy0xLTEtMA_01ca6520-8902-40eb-abac-8d5ff1312fb4">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzktMS0xLTEtMA_3d23a27d-d63e-4f2a-bdf5-0ec18868ff11">1,016.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzktMy0xLTEtMA_0a1f6b92-b134-4eac-94d7-15e1252e7476">831.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale (amortized cost $<ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTAtMS0xLTM4Ny90ZXh0cmVnaW9uOjZjZGZjNmU4NjhkODRiMzI4NDAzODQzMTgyZWQ3NzkzXzE2NDkyNjc0NDE4MDk_58e33223-f08c-4fca-be5a-c52afec3c467">226.7</ix:nonFraction> million at December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="ic2d47500148149558693bfbec9f730ae_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTAtMS0xLTM4Ny90ZXh0cmVnaW9uOjZjZGZjNmU4NjhkODRiMzI4NDAzODQzMTgyZWQ3NzkzXzE2NDkyNjc0NDE4Mjc_09c97882-8b5d-4acf-9e88-b10fe79dc848">299.3</ix:nonFraction> million at December&#160;31, 2019)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTEtMS0xLTA_399007bf-bba0-4b9a-97a8-137d82df795e">227.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTMtMS0xLTA_c71bd958-e7f9-4473-8739-ab64b015e03f">299.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzExLTEtMS0xLTA_3ee70df4-f2f0-400b-bf0d-9863e381069c">82.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzExLTMtMS0xLTA_13eac9ab-8324-43be-a628-9c53c582ed53">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEyLTEtMS0xLTA_a07a7abd-ef01-42bf-8bba-b9dc823aa22f">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEyLTMtMS0xLTA_34aea0e1-639c-4796-b94a-ad3cd3cc1827">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEzLTEtMS0xLTA_baf6d9d1-20e0-4a2f-96ff-814eb086e0a5">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEzLTMtMS0xLTA_c3566852-1e1c-48e5-95b8-8e54bc906259">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTEtMS0xLTk3MTM_43044372-f81f-46da-876c-781c33384167">319.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTMtMS0xLTk3MTY_91de990a-44b4-4e22-a81e-71268399444d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTEtMS0xLTA_e0e0e1b8-e908-4844-83da-5ba2839a6a0c">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTMtMS0xLTA_996a28dc-1f7f-4f8f-b49a-dc2c4b5c86a2">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE1LTEtMS0xLTA_2cf3a1c4-fdb2-4c22-a830-3676f65661bb">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE1LTMtMS0xLTA_99dcb5a2-420e-4467-bc22-bd082d68f9c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE2LTEtMS0xLTA_f0d6ac1e-02e4-4b59-9378-304010c5c2ef">1,734.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE2LTMtMS0xLTA_966a07ef-8c34-4e80-a8a7-e0ee18bc8b20">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIwLTEtMS0xLTA_b086d65a-e6c2-4478-82dc-5e63d3cba638">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIwLTMtMS0xLTA_4f7787fa-f2b2-4a40-a52b-33e2569b46e7">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIxLTEtMS0xLTA_3ebaa20f-e838-416e-92c0-310b4869cb02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIxLTMtMS0xLTA_dcb79257-c9a3-4304-8e02-4cab38026c9d">408.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIyLTEtMS0xLTA_bc585008-aeec-4d08-a4d8-7cc821a3e2b4">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIyLTMtMS0xLTA_b6719457-6bec-4261-a477-305aeba1010d">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIzLTEtMS0xLTA_aab4eee2-3a5d-4450-80dd-8bfdbb2aec0c">186.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIzLTMtMS0xLTA_045d4020-9c58-4824-bfe0-7ad9e4763b15">565.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI0LTEtMS0xLTA_933b5f44-658b-47c1-ac39-76547a545b92">317.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI0LTMtMS0xLTA_b3ce6938-e5a6-421b-a629-2764f2d0f87f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI1LTEtMS0xLTA_d8602645-fa76-47a3-8742-e0e275dacebc">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI1LTMtMS0xLTA_4377d2b0-1a2b-42ef-be22-dac454026648">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI2LTEtMS0xLTA_b49b781c-ab1a-4512-8e79-4b53432ca994">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI2LTMtMS0xLTA_0662f3fa-e947-42c4-b55c-084f8f6089ab">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI3LTEtMS0xLTA_20cf9b4b-90fc-4711-b052-4e5578cba099">608.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI3LTMtMS0xLTA_d239d38e-416d-4806-ba68-5e7fda525233">669.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODg4_4a84b852-c12e-4dd2-917e-a58ba64fdf27"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODg4_6c88fd98-bdb3-46c8-a538-8ddecafd42ee">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk0_305d712c-66af-4492-9c09-9943be90c928"><ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk0_a27c611c-7ae9-4eee-becd-fcd3c2352f85">5.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_5284ae1c-95eb-41a7-8ec0-0a14e7935d83"><ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_7197b3f8-a23f-4205-97f4-c74987f6dca7"><ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_954be599-0fcd-4a8c-9e7e-feb128f0d46e"><ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_9b01d412-920a-4b3d-93b4-5eacf770fe53">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2020 and 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTEtMS0xLTA_ecfc046b-b39c-4cc6-bf33-ec0f71ffca62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTMtMS0xLTA_69dcac56-ce1b-43c1-adc1-79f3edcbff81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTQw_3a38b74f-7d36-4aed-be87-a5132c9013c1"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTQw_66292566-0d74-4f4f-b637-62eecff20d45">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTEz_4c9769c1-4e58-459a-9f5d-7be37ba6cf1f"><ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTEz_dede4854-4d8c-45c2-a2be-d5752a49a014">220.0</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding shares were <ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl85Ng_0564775b-fec3-45b0-ab90-91357a4c0b73"><ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl85Ng_f54b7b20-c96f-457e-8123-e9507c4df4df">93.5</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDM_29892bc0-2a04-4b9c-b496-d91a2f670f5c"><ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDM_84a65dc1-faaf-471d-85e0-d4d3761b5c8c">92.3</ix:nonFraction></ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTEtMS0xLTA_99fe7fb8-a166-4b5c-b175-bb72ceee4f96">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTMtMS0xLTA_1cae0df0-58c9-49e9-afc1-c46e80459779">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMyLTEtMS0xLTA_278baebf-f566-4ac0-b260-f1196e046f61">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMyLTMtMS0xLTA_c44b0451-88d5-4592-9e3c-9bbecf7d85bd">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMzLTEtMS0xLTA_ce8704a7-0812-43bd-81a6-12656e1d75c6">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMzLTMtMS0xLTA_df1ddc50-7c1e-4726-b908-00a83565d778">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM0LTEtMS0xLTA_5c027211-0eaa-4d6d-bd89-d5c88a16078a">725.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM0LTMtMS0xLTA_cb7a35a3-363b-4010-b5b4-0d6a9f67e5c2">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM1LTEtMS0xLTA_fc17012f-1e20-404d-a88f-13f9b11a603c">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM1LTMtMS0xLTA_f79101a2-3432-4fc9-83e9-05fc705e7733">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM2LTEtMS0xLTA_7801f5be-5f5e-483a-83e3-fee4816e2c47">1,734.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM2LTMtMS0xLTA_7ce4fa98-d4a7-4a49-b19c-f2ffa46337e9">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE INCOME</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde16a61b7164f458e48b488706d2e70_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtMS0xLTEtMA_f8531db7-d204-49ac-9a2b-7e2163ee43e3">994.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967cc502a0d34a008a828c23d2766568_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtMy0xLTEtMA_40ba7f20-a5c6-4ef2-be77-1d1572961bc8">752.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida87bfcd952941a7af0f7edcab6e9736_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtNS0xLTEtMA_80dfc09a-7961-4295-9aec-e5994666fcff">409.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6046fae3eb4b1b840345751855f969_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtMS0xLTEtMA_62b83ae2-a332-466d-9275-90c521302659">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc18a34429ee4de3ac9357a5328d1977_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtMy0xLTEtMA_eeedd4e4-696d-437f-912c-edfe0348ed5d">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f12acbe2b4d455e85cd438766a8ae80_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtNS0xLTEtMA_60f7349e-2a12-4912-bf6f-7869af2844c1">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtMS0xLTEtMA_2d988d67-930b-42ba-b07e-73ca9cfec98a">1,045.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtMy0xLTEtMA_46a955bd-c091-461d-b9e6-2398d0e07d8f">788.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtNS0xLTEtMA_3ca98a6c-0eff-40cc-85fb-a43a2cb4a4f5">451.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:CostOfSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctMS0xLTEtMA_ed8ab8e4-f8b1-4990-bde8-e9f23bd24477">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:CostOfSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctMy0xLTEtMA_942e2a7a-ecea-486f-ab6d-2ce8ebbd2543">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="nbix:CostOfSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctNS0xLTEtMA_e982f06c-22c7-44a3-8403-4998e1503d45">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtMS0xLTEtMA_32de1d56-f0be-4a51-9572-a510d7e80213">275.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtMy0xLTEtMA_27e0ad1a-7ddf-416c-bd06-08b68ca1b2ef">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtNS0xLTEtMA_426b8550-bf04-430d-9af9-b6aaa4f1e54a">155.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktMS0xLTEtMA_50976b10-9d5f-4291-ab6f-f6297888039e">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktMy0xLTEtMA_4bff62bf-3140-464a-bb94-c1d095596f20">154.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktNS0xLTEtMA_d3dcf6f4-1ca3-4f7a-8d20-9189ef52f993">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTEtMS0xLTA_4bf04dba-f8b4-40b4-a39d-63cbc9fa42e9">433.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTMtMS0xLTA_10f1699b-ce2f-4721-a45e-014f71f7dec4">354.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTUtMS0xLTA_9d2004c1-de6c-4c2e-aac7-ec339ec6ead1">248.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTEtMS0xLTA_27b4d25c-342b-4986-9100-9c2f669d2458">882.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTMtMS0xLTA_8b4224db-8ce0-45d2-8e0a-008dfaf63829">715.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTUtMS0xLTA_4e636c27-7203-4486-87d7-20544f9eaf85">414.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTEtMS0xLTA_9e947545-a361-4445-ac2a-fb780bc50815">163.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTMtMS0xLTA_769bcf94-f5cb-464c-845e-a9f9179cb80f">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTUtMS0xLTA_d0cb2e7a-d785-4b2f-9553-9dd0f2bf59c8">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTEtMS0xLTA_a705b1ac-ebbc-4f9a-9a15-67c50ee4e33b">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTMtMS0xLTA_eed5515e-8184-40a7-b52c-14e6c102d120">32.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTUtMS0xLTA_8fe502ce-a6a5-4bc3-9898-a3e0a1805708">30.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on restricted equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTEtMS0xLTA_5869e4c6-db88-4c4f-81e3-e31244c5ed1f">17.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTMtMS0xLTA_d07e45fe-c4e8-452e-8f0f-7a00162eef11">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTUtMS0xLTA_15410f14-f52a-4bbb-81cf-8337ab2acaef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTEtMS0xLTQ1NjA_b15dba46-2242-4ae7-811e-f00fd5216462">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTMtMS0xLTQ1NjA_9637da15-9ff7-47ff-9945-498bce96f3b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTUtMS0xLTQ1NjA_656d49b1-77b9-42ca-acea-762f7c2cdc5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTEtMS0xLTA_9d1ad0e6-7cdf-4ac0-b7af-637c14c862e7">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTMtMS0xLTA_e40bdff5-c4dc-4c0e-8158-688c52b68993">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTUtMS0xLTA_ab8b2c71-23f2-4833-b904-b2c2da9c7233">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTEtMS0xLTA_0d673b0f-c820-4abb-b9ba-41109c170f1e">56.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTMtMS0xLTA_87905780-2140-43b7-a432-ee2862ff69d9">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTUtMS0xLTA_54c83bea-df37-4e38-ba62-b2e779388d63">15.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before (benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTEtMS0xLTA_a7c7af73-eb0d-4c71-82ac-82d32537f051">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTMtMS0xLTA_cd344fd5-6c10-4746-b183-b82f7e67df28">46.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTUtMS0xLTA_201213fe-c946-48dc-b8ff-f1eaf860d2c1">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTEtMS0xLTA_708be55c-04db-4fa4-9a6b-35bd1fd39221">300.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTMtMS0xLTA_a4759595-672e-4579-9f0d-7a2dd30245c1">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTUtMS0xLTA_030e34ab-2585-46a4-9645-36bcdd91a536">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTEtMS0xLTA_b5a3c4b6-d7bc-40ee-b9f3-1f2d368da685">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTMtMS0xLTA_61451c5a-1b82-4f9e-83a9-271f7c05f998">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTUtMS0xLTA_81c6f734-56c3-42b3-9514-5046f2edf92a">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTEtMS0xLTA_8eb15934-efc6-44c0-870f-661c9ef59fff">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTMtMS0xLTA_1a7de1de-b6b6-4b9f-92c8-8d9ea19a2338">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTUtMS0xLTA_e8063e2a-71e4-4a42-94c2-edf3f73a6c84">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTEtMS0xLTA_34bc17fd-9728-43f7-beb7-42db3c75a433">407.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTMtMS0xLTA_5d8fa052-a892-468b-9eac-57adee2d418e">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTUtMS0xLTA_ce86dce7-91d9-4e5f-ace4-e05961becf27">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTEtMS0xLTA_be317350-bfb0-4ce9-920b-a153e051a999">4.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTMtMS0xLTA_12206885-2ab7-4697-b966-4897a7521f24">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTUtMS0xLTA_b5939c51-0574-4366-8bc6-e397dc4e2a61">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTEtMS0xLTA_de2e5df1-8e9a-4b47-9b73-399babd4e772">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTMtMS0xLTA_e9345df5-203b-47fe-8aa7-18184b7f46b7">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTUtMS0xLTA_2e3cbe1e-dbbc-46b3-aa81-3527d932ce61">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTEtMS0xLTA_6257beaf-c55c-4741-a573-250bd6922cfe">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTMtMS0xLTA_cce729c7-6164-49ea-a394-43de6bdfd7f4">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTUtMS0xLTA_98cdb3ec-d4bd-446f-abe3-4f5be20c7a1c">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTEtMS0xLTA_19702b59-f357-449d-b55a-51dcbf02816b">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTMtMS0xLTA_0c26d173-b752-4163-b6af-2c29f4eaf19d">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTUtMS0xLTA_e507bb09-801b-48ca-9707-bb6cad5451b9">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMS0xLTEtMA_8515497d-9be1-48a3-a708-2c8c3d42795e">88.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMy0xLTEtMA_eafc3af9-fe4b-4636-804e-5c661eb04b49">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib635f30312fc4487a25e573ac6e23201_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItNS0xLTEtMA_2cd1136f-73e6-47aa-b61e-e3404ca5435e">1,572.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb1dd9d305d94a28b04bb4bc72f357f3_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItNy0xLTEtMA_7559d931-d633-4412-9b0e-ae233bfd4611">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b7e6c1d8b5f4e399e1a026be3379b6c_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItOS0xLTEtMA_255eb5ac-a460-49b6-8fdb-84ed61167211">1,198.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMTEtMS0xLTA_4a0b1c84-4ba4-4a2e-be0e-f291da479281">372.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d8a0a389e47b89727b48a294423df_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzMtOS0xLTEtMA_071d3fda-9e1e-4198-9a91-9b302cce1483">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzMtMTEtMS0xLTA_3a197bf8-6155-483d-a7c2-c268d9a2506a">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i029fc56043664f6d9138de8bc16cb3a0_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzQtNy0xLTEtMA_7315ac51-6153-4e83-a9e3-032f539838da">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzQtMTEtMS0xLTA_861c6f7f-d2f1-4557-b97e-f59544ecc631">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzUtNS0xLTEtMA_d65848ac-a598-4579-9ae5-f9c9fde520ce">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzUtMTEtMS0xLTA_fdfeec65-4a7f-4289-a392-29ba53de04b9">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i901799886d9a47b29af6431c66c323e3_D20180101-20181231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzctMS0xLTEtMA_f8983ce9-e07c-4327-ac63-7bd249547f76">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i901799886d9a47b29af6431c66c323e3_D20180101-20181231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtMS0xLTEtMA_60625812-776a-44f9-a991-d9c14f1c82cb">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtNS0xLTEtMA_dd3ab515-7889-43d5-be87-d1acbdee81d7">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtMTEtMS0xLTA_606181f0-de6c-4b81-ae4d-554a8ace66e2">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTEtMS0xLTA_c8f90998-c37a-480d-a18f-c89286462dfa">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTMtMS0xLTA_91b08ac7-c5e2-4cfe-b1ce-6542be1afee7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i327a62de7e27488aacd2d461382ad7b8_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTUtMS0xLTA_219e6afc-0af9-4981-98d6-4fde10fd0058">1,660.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c2af3510294013a84c123a7e4a817a_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTctMS0xLTA_16c6e0a3-a477-49ca-af63-3c3b6dde32f6">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7765093653d345399a3f53be76391bc0_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTktMS0xLTA_13c93a9a-f3cd-43b5-b7cd-42a4465dccad">1,177.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTExLTEtMS0w_14a7beef-cc8c-4a72-9fb5-7676123adbd1">480.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266de6ffaffd40a9b1545e43688677b6_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzExLTktMS0xLTA_9f3276be-e68f-4e10-b3f2-fcdea9efe498">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzExLTExLTEtMS0w_d752134f-725a-42db-a263-7d7f0f78f4bf">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387e248869994066a40d45b968990a24_D20190101-20191231" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEyLTctMS0xLTA_0b93e714-bfdc-488d-8fd4-6128d5046036">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEyLTExLTEtMS0w_04a09e4b-5fd7-4ee8-a48c-a6a187dc133e">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEzLTUtMS0xLTA_e6c7394b-65ca-4ae9-accc-99d6a849bea0">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEzLTExLTEtMS0w_98097d04-4e3c-4eeb-b262-f0d333ee868d">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTAtMS0xLTQ5NQ_87ff2093-6207-4e9e-bccb-3338262ddc44">Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49725d32ce2049aeb743abf42b318417_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTktMS0xLTA_6b8eb40a-1780-4334-aa44-fada1672fed5">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a3756b3d9842d6b225a73c90aac6c2_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTExLTEtMS0w_2ea6123e-34cb-45ec-a48b-25732d2384ca">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE1LTEtMS0xLTA_f05f56d6-d9ca-4044-b07d-0a91a5401002">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTEtMS0xLTA_307f1b93-9c10-4adc-ac58-a108ccc888ad">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTUtMS0xLTA_c1e87432-ab85-4de0-b879-dc1265945369">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTExLTEtMS0w_a3586a43-d0c8-4ede-8f4b-64c7d2162342">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTEtMS0xLTA_38b4f586-5cfb-4e6d-9162-79ed3db22880">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTUtMS0xLTA_50dbdb84-b3f0-44a1-98ea-9c2c4f3fa897">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTExLTEtMS0w_b5f21dc4-5436-4455-829f-6f7fcfc50676">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27cce8f31fe240f8a17ee911b0e4b878_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTEtMS0xLTA_4b4c6922-6185-4e15-b265-639ce15e0dfe">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27cce8f31fe240f8a17ee911b0e4b878_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTMtMS0xLTA_f66e53a8-844e-4088-bb83-6c34b7fac19c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dafe132b53e4050b679396ebb6651ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTUtMS0xLTA_44ff9c31-c1e0-49bf-9daf-d4955b358079">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892c766e0f01406790fc8dcd6fe62fbe_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTctMS0xLTA_df364685-ef42-4187-990d-16d23a3c838a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5d52ca7c1114b7eae229221755ea0be_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTktMS0xLTA_3aa7a64b-ca6b-4f93-8a63-b70b943061c5">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTExLTEtMS0w_0b6f62e8-ebb7-4a02-bcb9-60a5114c68b7">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc15f2ad264b40a4b8477d62bdd3190d_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE5LTktMS0xLTA_8db6240e-49e2-4c6d-a027-3f2a7735d4c1">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE5LTExLTEtMS0w_7831f2e3-05a5-490b-b5df-7151c4053fe0">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f532ba86dde41ecbd34ea42061d72e5_D20200101-20201231" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIwLTctMS0xLTA_69a9a90b-39ed-4bd1-8000-29acbe0e677b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIwLTExLTEtMS0w_56589b8c-3dc9-4605-83c7-5338321ae3ef">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIxLTUtMS0xLTA_eab83edb-ee94-40fe-b5c5-298b0eb16ac8">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIxLTExLTEtMS0w_c1543e34-c662-40e3-8ab6-4758d16f6d77">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity component of repurchased convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIyLTUtMS0xLTQ1MTE_ef9bbe25-d8d1-4733-93f1-be099c08e18c">47.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIyLTExLTEtMS00NTEx_a2354bc3-0160-4d91-9e5a-c13b57c12c86">47.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIzLTEtMS0xLTA_24d03ea8-bfce-4e36-b663-7f49f1b54e70">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTEtMS0xLTA_a97d3ea3-549f-40b4-9c72-f20e773eff85">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTUtMS0xLTA_6363e27b-f17b-4e96-b672-67460de35fa5">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTExLTEtMS0w_840fcfaa-23a3-466a-a714-dbc9d3ece1a8">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTEtMS0xLTA_7dae2e3c-2270-4255-bc9f-b67c85c59643">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTUtMS0xLTA_5c8bcee1-74e3-4888-8b24-f21feccfdb8a">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTExLTEtMS0w_231ca7ed-eda4-406a-910a-e8271128783d">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33b6ecbd7b84a9f94efd720de382191_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTEtMS0xLTA_fd894136-c0e4-4af2-9f40-7733ab6f1c46">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33b6ecbd7b84a9f94efd720de382191_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTMtMS0xLTA_12c44e30-a35a-430e-90e8-493f0c52bfef">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4870f57f40f442cda8ea71a0a17dff09_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTUtMS0xLTA_bb686966-c09e-453a-84ae-285625c2f1d2">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be7a20d35464718b1b57ce65463f4f0_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTctMS0xLTA_c43a6544-6b6a-4cce-aa31-ee2a45bda5d3">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7376630f4274498bb13206aa06d9a70c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTktMS0xLTA_1b42b56c-bb45-4ec0-8272-0aa8bae68d7c">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTExLTEtMS0w_150ca80f-8046-4eb0-9424-f3796e613ccf">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtMS0xLTEtMA_cf82f209-8663-4ab5-8b35-a800f3eff2a4">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtMy0xLTEtMA_cd6a6258-9b6a-4fc6-b6bd-18c424c2a9fe">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtNS0xLTEtMA_b1a9341f-49cc-4259-b112-be49d9e3f963">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtMS0xLTEtMA_43e14ace-7c5e-409e-8140-c4d01183f8e8">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtMy0xLTEtMA_58e537f8-37df-4077-a712-3c7e7cfe16c9">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtNS0xLTEtMA_f290bae8-c107-4bab-8b47-db96df0c98f6">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtMS0xLTEtMA_4b688748-9a3e-4ec0-9436-11c16a46bfe6">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtMy0xLTEtMA_66c4c38a-1c20-40c9-ae9b-e4f50ab1dcdf">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtNS0xLTEtMA_f3d710c9-2d14-46e2-904e-e9f0d3750883">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctMS0xLTEtMA_4f25e8f5-527d-4f5a-877f-527e0698a6ce">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctMy0xLTEtMA_1e5aa9e9-00ab-4b41-93ce-c6ee05db1feb">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctNS0xLTEtMA_d24176ff-e559-47f4-9d0f-c53cd07c5169">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtMS0xLTEtMA_56737841-8558-4c14-a8af-40e9869853ba">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtMy0xLTEtMA_d09cf5f9-6ecb-40f2-80ed-5e6cc8a7d243">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtNS0xLTEtMA_9682548b-df6c-4577-be71-866ee043c4e0">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktMS0xLTEtMA_0a10267a-446d-4d07-b408-6a87504e679b">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktMy0xLTEtMA_e181aa1b-c44c-4511-9a3a-0ee2f4bd38dc">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktNS0xLTEtMA_d5a78fd9-cfe2-45f5-a19c-49b41d2b45c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes (including benefit from valuation allowance release)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTU4OTc_0a0586b4-872e-41f1-a9a3-2c9197e59881">310.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTU4OTc_5b64de6d-30be-40d6-8ed1-925dd84f6faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTU4OTc_67c07b40-bcb7-41f3-bca2-64a64222ca95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTQ1NzE_8e73f2a1-4d96-4a7e-9ff7-5b19298d8834">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTQ1NzE_6a072f4b-16f3-4826-965a-badf8f249329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTQ1NzE_25b7ae6f-1b41-4df9-9535-8b69f3ad8946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTA_f391edcf-0467-4176-befa-ccbcf3c52b56">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTA_45427ce3-6f79-45aa-a61b-f54d3424315a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTA_202f9a22-6fde-4f18-83f2-e9cbeeeb4643">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTEtMS0xLTA_b400feed-2d45-4ffa-bdc9-22830b33b732">30.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTMtMS0xLTA_22bade06-d536-495f-8f63-4b161e7615db">69.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTUtMS0xLTA_be33603d-2dd5-46fc-aa50-2ecf11564591">25.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTEtMS0xLTA_04837c69-1196-4ab7-961f-6f044cf959fe">10.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTMtMS0xLTA_09faa1d8-135e-4e0e-9110-5a4a956e3380">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTUtMS0xLTA_680602a7-bf3e-44a9-b327-607b16d9cad2">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTEtMS0xLTA_39d08040-3629-45f0-9c7d-5c6672815c65">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTMtMS0xLTA_ca8db2b6-18cb-4418-844f-ed7aee1b8823">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTUtMS0xLTA_89c76d89-7d5f-4fc2-a310-fedef477b04c">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTEtMS0xLTA_583211f3-cc57-497a-8fbe-7e8c915b65b3">23.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTMtMS0xLTA_f54a4045-e903-43d8-9fe0-93b90e99594c">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTUtMS0xLTA_fa6f4f2a-9d0e-438a-9a79-962523c8ae8b">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTEtMS0xLTA_3fb7b4d1-1cbc-44b1-97b0-358bda130b03">228.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTMtMS0xLTA_76a33bb2-b04b-4441-93da-015013d600e1">147.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTUtMS0xLTA_4143d5de-2bc2-463d-ae16-881c34a57af9">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTEtMS0xLTA_3f4775fd-a4c9-427f-81b4-ca284b23a775">735.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTMtMS0xLTA_75223e5b-c213-4da3-a29f-9c1a7aa987a6">797.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTUtMS0xLTA_db439fd3-6ecd-403c-87d7-312f0e1fa6b3">545.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTEtMS0xLTA_3051d466-2b30-455a-854b-6cb4542b351b">750.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTMtMS0xLTA_f01460bc-3955-4ac0-aea5-f2767be74c4f">669.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTUtMS0xLTA_8f33c243-5d3d-44fb-8d83-bae22a95bc96">327.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTEtMS0xLTA_01933e71-1b4c-4c1b-861b-3b25b5644104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTMtMS0xLTA_adc7b6cc-86ae-4bb5-9bfa-327d82d916e4">68.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTUtMS0xLTA_9dd4ba2d-a67c-47ba-9a7b-48d2252b978d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTEtMS0xLTA_1769fbea-9130-4b23-89f6-98e27b2f988b">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTMtMS0xLTA_ce7fe787-c2cc-449f-a8f5-1127afb3c93c">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTUtMS0xLTA_7630f0be-468d-4c0a-a76f-282c85b3675d">24.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTEtMS0xLTA_4b4127e4-84d0-4516-880e-8bbb51d3f9a1">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTMtMS0xLTA_d6898b7c-bab8-466a-a51b-e19efee88aed">211.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTUtMS0xLTA_87aefe26-14b2-4325-807f-8629b1bfa085">242.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTEtMS0xLTA_b1035828-847c-4978-9585-89f589b3a0ec">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTMtMS0xLTA_fc3ea225-abbb-4a93-be39-ffa5471304bb">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTUtMS0xLTA_00154a9f-e082-46e3-80a1-7cbb07e98eb9">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partial repurchase of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTEtMS0xLTQ1Njk_469b0b17-a73f-4f7b-86d0-f4faf236ddc8">186.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTMtMS0xLTQ1Njk_62c38c88-b7b9-43ee-a2a1-6166150d649b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTUtMS0xLTQ1Njk_5e8c481d-b3c7-421a-bbe6-0800cfae4364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTEtMS0xLTA_26c07b28-41ec-40e5-8b38-8e6c69d615ea">157.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTMtMS0xLTA_c73b53b8-5c00-494f-958e-b82fd028abec">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTUtMS0xLTA_52e9cfe8-4075-41d7-ba34-cf169513f2db">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTEtMS0xLTA_0ef8f030-aa7c-4ca3-a81c-17c523ba4721">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTMtMS0xLTA_8d8382cf-4165-4099-88ae-5af68731e341">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTUtMS0xLTA_d79eed58-7524-4aef-b0f7-28c23248a12a">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTEtMS0xLTA_30bf4fb6-07d4-4277-b34d-9ae6bb30b3ec">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTMtMS0xLTA_fcbdd557-b0c3-4c8e-a765-4d2e88705c1b">147.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTUtMS0xLTA_56ba99cf-a9d4-4f58-b104-1e4a1c64134f">259.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTEtMS0xLTA_35571e8f-9fa5-40b0-8c1a-256407ce20ba">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTMtMS0xLTA_4fa8ea55-dfe8-4923-82e3-e483aa42a342">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTUtMS0xLTA_6f332eb7-06cc-483e-ab4f-3b59c3cb81ae">147.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTEtMS0xLTA_525595d9-278c-42a2-af6f-e9e7923921e1">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTMtMS0xLTA_164e2579-3d57-4750-8ebb-5f4f1ed10244">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTUtMS0xLTA_d1710974-7636-4f06-96dc-3acd3bdc68e7">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets acquired through operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTEtMS0xLTExMzY2_81efe66c-ea9f-4511-8290-3cb4a54a4d00">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTMtMS0xLTExMzY5_27ace454-a0f2-4c7a-9970-d9397f9a07ec">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTUtMS0xLTExMzcy_7b6ef329-2ee8-4775-acdf-e706769bc8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTEtMS0xLTA_03065afb-c0c4-4cb5-a7ec-6feb3ec2748c">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTMtMS0xLTA_5c232575-a7ec-4280-8d23-998329193325">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTUtMS0xLTA_bfb7213e-e168-4cc6-bf64-71ff12836d91">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTEtMS0xLTA_8da51fa6-e848-4207-a008-b4b13301ee31">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTMtMS0xLTA_9012319c-e755-45e6-a5d4-3c76a393905d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTUtMS0xLTA_6469a07c-58c7-4261-b417-d4c93bc5a1c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i0d67836123014e4c9534b0a3600493e4_148"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY2_97956fa9-d0e0-47b3-8100-c95d2501d7ed" continuedAt="ia5d9cc1b34b4405abdd9755e48024a23" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia5d9cc1b34b4405abdd9755e48024a23" continuedAt="i90a2e944c8e347da9142c75d8c9f511b"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="nbix:BusinessDescriptionPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU5_2274e0ee-5cf6-41be-85b0-213ff88748d0" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have <ix:nonFraction unitRef="subsidiary" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nbix:NumberOfIrishSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzM4NDgyOTA3MjYwNTc_825f6a35-55e5-48b7-8729-eda10beda790">two</ix:nonFraction> wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY3_9baf74cf-d302-4ed3-b4ab-c22b500ca474" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYx_2382372d-ae78-4919-b3ef-ccb8d6e9567d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU0_28d4e437-9d65-45f1-8898-db3152bd38fc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Segment and Geographic Information. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single industry segment&#160;&#8211; the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIxOTkwMjMzMjU5NDk_bee4ef62-de4a-40e8-8e10-770587d57cbc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU1_c795a2c2-c66f-408a-94c4-4e2d6ad77074" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYw_f6611742-4177-4da5-8957-37980341923d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYy_152558e0-93a1-4b9c-93b2-11b6a188c09e" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become <ix:nonNumeric contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" format="ixt-sec:durday" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzQ4_0bb47b87-702d-4301-9ff6-4efb7bdea639">90</ix:nonNumeric> days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYz_166bf73e-0d44-4f64-8d72-4366807f0e19" continuedAt="i1f279879a5e74a2c98a31abbd49a2658" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i90a2e944c8e347da9142c75d8c9f511b" continuedAt="i312689bbad3e43e09927b6d494a1ac31"><ix:continuation id="i1f279879a5e74a2c98a31abbd49a2658"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU1MTE_1ab5b325-9b83-4479-9274-b69a9093497a">3.7</ix:nonFraction> million at December&#160;31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_50e012e6-f5da-48ce-8bec-7d0dc7cfa77e"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_55049ed4-e9af-41b2-8f12-03a465458de0"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_ae9877e2-b252-48f1-b74c-963205942e5f">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during 2020, 2019 or 2018.</span></div></ix:continuation><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzQ5_160df67b-ea30-4f18-95fe-3a5ba7a74b73" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during 2020 or 2019.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUx_08bf5ef3-ae69-4b0a-9f4d-9361118f37a6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY0_f858edf6-1fee-47a6-9646-7b76b7962875" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">three</span> to <ix:nonNumeric contextRef="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MjU_a6ca8357-21c8-46a3-bf29-24df42364440">seven years</ix:nonNumeric>. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2NzE_285aea54-5cb2-4d5b-b994-9613b6d091c7">8.6</ix:nonFraction> million for 2020, $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2ODI_36397d35-92c2-4b71-8275-1b30375e6df2">7.4</ix:nonFraction> million for 2019 and $<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2OTY_a42f7ea3-6ace-4200-b000-9958dbc3e7d9">4.0</ix:nonFraction> million for 2018.</span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i312689bbad3e43e09927b6d494a1ac31" continuedAt="id4ab16942c274d04b5c65f6b50bea897"><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUy_5f20e332-ec51-43e0-8752-2e73a79f27ae" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If&#160;the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4Nzcx_8c8b0cfd-9d3b-4228-8711-e2f915379a7a" continuedAt="i30713e44e2ae470e8ed58b9114a6ba61" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4ab16942c274d04b5c65f6b50bea897" continuedAt="i30479e8a3d2d4ab5ba18ae3c05f177de"><ix:continuation id="i30713e44e2ae470e8ed58b9114a6ba61"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div></ix:continuation><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4Nzcy_67f78d63-570e-4060-b659-d0206b88de4b" continuedAt="i4d97e17b6eb94a5f8cf35ade493542b5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i30479e8a3d2d4ab5ba18ae3c05f177de" continuedAt="i072ad5fa79b7498ba9260dc2c0bb9cf0"><ix:continuation id="i4d97e17b6eb94a5f8cf35ade493542b5"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately <ix:nonFraction unitRef="number" contextRef="i20120095d85448189e0c6c75de356c1a_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTQ_0f67832a-9a2d-4185-a6e5-2a8ac07161a8"><ix:nonFraction unitRef="number" contextRef="ie4318f5084d84959b68665678538a7f5_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTQ_6dec9dd7-0ced-4d2e-8b3f-00aeaf6e87ba">86</ix:nonFraction></ix:nonFraction>% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December&#160;31, 2020 and 2019. For 2018, our three largest customers represented approximately <ix:nonFraction unitRef="number" contextRef="i59194d217fcd4be386582a21776d0491_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTg_880e365f-32f1-41c9-8bfa-1a7334fc3f4d">93</ix:nonFraction>% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.</span></div></ix:continuation><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY1_72e7dcb0-7ef5-4072-9b66-28f8b47793f3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY4_2112744d-145e-4261-8233-5bc80ee77ccd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;D expense as incurred. These expenses result from our independent R&amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY5_1809aea1-cf70-472a-8c59-37e95bc3feaa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;D expense as they are incurred.</span></ix:nonNumeric></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUz_16c81ade-8ca0-4b5a-bc95-e99b48adb8a0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODA2_db4f2a1a-0fb5-453a-b320-72fce605d98e">64.8</ix:nonFraction> million for 2020, $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODE3_3ef12255-ba97-490b-9f20-f4d73cce5cee">40.6</ix:nonFraction> million for 2019 and $<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODMx_e657d933-8ea8-4797-b222-a8b9bdc5e232">20.5</ix:nonFraction> million for 2018.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU2_4827fdeb-e352-45eb-9a5f-c8a488386cb3" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">three</span> to <ix:nonNumeric contextRef="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNjA1_be63ed97-02c0-4795-a075-1e08c7145e64">four years</ix:nonNumeric>; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally <ix:nonNumeric contextRef="i728ae8d7437841b58f476b7ef0e6ca39_D20200101-20201231" format="ixt-sec:durwordsen" name="nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzODg3_ae4869c0-0296-45d0-8b0b-e33bd436cd13">six months</ix:nonNumeric>. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIxOTkwMjMzMTY2Mzk_8c6bd3ac-63bd-4f8a-b8cc-b75af22efbab" continuedAt="i390a71ba20f44c7dbed52f85d25b388a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by </span></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i072ad5fa79b7498ba9260dc2c0bb9cf0" continuedAt="i971dd656fe6a41b996bf7c9e8dafa4fa"><ix:continuation id="i390a71ba20f44c7dbed52f85d25b388a"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:continuation><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU4_8c430682-13cc-4690-b1d8-45e8b0747c73" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately <ix:nonFraction unitRef="shares" contextRef="ide871789006342f69f8274002bb357ed_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI1MzAw_156f7b95-b6ee-4091-9a51-60f934befe1f">5.0</ix:nonFraction> million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately <ix:nonFraction unitRef="shares" contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI1NDkz_c5009509-b72d-493f-825d-68cbc8718e55">0.2</ix:nonFraction> million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU3_ab20b2a3-a6c2-41d1-a1cf-ca3c0ae763a3" continuedAt="i166937127713466ab4e73b88089d9a16" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="i971dd656fe6a41b996bf7c9e8dafa4fa"><ix:continuation id="i166937127713466ab4e73b88089d9a16"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.</span></ix:continuation></ix:continuation></div><div id="i0d67836123014e4c9534b0a3600493e4_151"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NTU3NzI_33a4adaf-f890-4ccd-83b4-98519bca1aa1" continuedAt="iaf249f90e0584f55b4e912c183625ace" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NTU3NzE_2f3d96c2-aa41-4235-afe5-85a0f0cff000" escape="true">Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-8" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjMxMzg_62b87349-9048-4c6d-9c7c-ff53e2f5e4f2">8.5</ix:nonFraction> billion and pay royalties on future sales, if any, of commercial products resulting from these agreements.</ix:nonNumeric></span></div><ix:continuation id="iaf249f90e0584f55b4e912c183625ace" continuedAt="iefb103049fb54e3781eb740c420fec08"><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $<ix:nonFraction unitRef="usd" contextRef="i257e90a486974747899becd428e20bbc_I20200731" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU0OTc_58c9da8d-7162-4fbf-bb02-1bbf4a314ddb">120.0</ix:nonFraction>&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&amp;D, in the third quarter of 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="ia97b8d53a265445fa5504b3150879227_I20201231" decimals="-8" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1MjY_23f3056b-4d23-4fca-a219-74f2a00b74d9">1.9</ix:nonFraction>&#160;billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iefb103049fb54e3781eb740c420fec08" continuedAt="ie1537e34d93a44c59a546fb39c9a515a"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the exercise of the option, we paid Idorsia $<ix:nonFraction unitRef="usd" contextRef="i0eba589932364662a4c8ccf58b4e239a_I20200531" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1NTQ_3d8be251-437d-47fd-855d-57b5e5e125b4">45.0</ix:nonFraction>&#160;million upfront, which we expensed as IPR&amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $<ix:nonFraction unitRef="usd" contextRef="i0eba589932364662a4c8ccf58b4e239a_I20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1ODI_f0ffb411-4193-41d4-bef8-9e665de849c1">7.2</ix:nonFraction>&#160;million in funding, which we recorded as a prepaid asset and is being expensed over the <ix:nonNumeric contextRef="i25235904363543e6876b158eafdeffc9_D20200501-20200531" format="ixt-sec:durwordsen" name="nbix:ResearchCollaborationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzIxOTkwMjMzMjE5NzY_753a79c0-8a16-4d31-93cf-64f483e6dbee">two-year</ix:nonNumeric> research collaboration term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i6545254203aa4df0a400884ff9991e40_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2MTY_8c20f78a-5014-46a7-93e0-ea53b2cf14b0">365.0</ix:nonFraction>&#160;million with respect to NBI-827104 and $<ix:nonFraction unitRef="usd" contextRef="i219730df66154f82827f5448bfe38e9d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2NDc_e02ec671-9ff6-43d5-a90b-a7e8ba7e94cd">620.0</ix:nonFraction>&#160;million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="id14cd484bece46d3a4291e95561a7587_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialCommercialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2Nzg_47bc35be-2564-467c-baad-99f032fa4934">750.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#8217;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $<ix:nonFraction unitRef="usd" contextRef="i3bbda008026b473097f608802a52aaf9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTcyODc_a9fef469-19ac-44e0-a6e1-c43f22815f1c">30.0</ix:nonFraction>&#160;million upfront and purchased $<ix:nonFraction unitRef="usd" contextRef="i3bbda008026b473097f608802a52aaf9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMDI_4f8a47e8-bc8c-4f16-ae46-7b32d0fa5fea">20.0</ix:nonFraction>&#160;million of Xenon&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i3bbda008026b473097f608802a52aaf9_I20191231" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNDQ_7d3b0a97-d6dd-4f08-a705-eaea6eea0366">14.196</ix:nonFraction> per share, representing approximately <ix:nonFraction unitRef="shares" contextRef="i42d131b3f0874d9b980c9f62f4f8df61_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMTc_a4e2872f-522a-45eb-8d15-c29b5311a119">1.4</ix:nonFraction>&#160;million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i2a872472e6c44cd7a82a479cbe5b4431_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMzA_1e43b4f6-be02-4df5-ae2a-b5e6830dbcdf">1.7</ix:nonFraction>&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i3bbda008026b473097f608802a52aaf9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNjg_7136c81d-3956-46e8-abea-5be1c4b9a9f7">14.1</ix:nonFraction>&#160;million after considering Xenon&#8217;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNTM_8397f46e-0235-4cde-adc7-6274f7a68a7c">36.2</ix:nonFraction>&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&amp;D in the fourth quarter of 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson&#8217;s disease, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="i88977083558b4753b92390c316833a48_I20190331" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Mzc_84923bd1-e6cc-4403-8954-e3cd843789fb">115.0</ix:nonFraction>&#160;million upfront and purchased $<ix:nonFraction unitRef="usd" contextRef="i88977083558b4753b92390c316833a48_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4NTM_bc2e9de6-c5c2-4cfc-b6fa-ac8e64a522f7">50.0</ix:nonFraction>&#160;million of Voyager&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i88977083558b4753b92390c316833a48_I20190331" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Njg_900928be-1dcf-4f75-ae16-d51d375e15b4">11.9625</ix:nonFraction> per share, representing approximately <ix:nonFraction unitRef="shares" contextRef="i81ad4fc332a9473c95e11ea8f94d1479_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Nzg_6e3673f9-f3bd-4109-8cfd-aae7f08336d5">4.2</ix:nonFraction>&#160;million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i50203e6e9ee241d8a1943a131e844922_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4OTE_93d385a2-7f3f-4769-a0a1-c8f6f8963a65">1.7</ix:nonFraction>&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies of such program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i88977083558b4753b92390c316833a48_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MDU_c88fc7fd-597b-4df6-b0b7-782bb4b3d6fb">54.7</ix:nonFraction>&#160;million after considering Voyager&#8217;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MjA_ca3f5a35-2c46-45c7-ae22-694721cd3f66">113.1</ix:nonFraction>&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&amp;D, in the first quarter of 2019.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1537e34d93a44c59a546fb39c9a515a" continuedAt="i93fa23da58bf4040943203f0209afe3d">In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MzY_ce797761-ec52-4bf7-9c8a-f39a89e4370a">5.0</ix:nonFraction>&#160;million upfront to obtain rights outside the U.S. to the Friedreich&#8217;s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager&#8217;s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&amp;D in the second quarter of 2019.</ix:continuation></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3NDE4ODI_1b21bad8-24d3-4d5c-b041-9fb6ff28f6fa" escape="true">On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.</ix:nonNumeric></span></div><ix:continuation id="i93fa23da58bf4040943203f0209afe3d" continuedAt="i7c83fe60dde1484a80087ae51b894f9c"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the U.S. and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson&#8217;s disease resulted in a $<ix:nonFraction unitRef="usd" contextRef="ib352054c7bad403c94fe2bccf88d5af3_I20200430" decimals="-5" format="ixt:numdotdecimal" name="nbix:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU3NTU_965554db-0e08-48d8-8710-48e436ce39fb">20.0</ix:nonFraction>&#160;million event-based payment to BIAL, which we expensed as R&amp;D in the second quarter of 2020. We further recognized R&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="ibbecc51b3aae463ca7e62f0c5c3d2253_I20191231" decimals="-5" format="ixt:numdotdecimal" name="nbix:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MDg4OTY_7c521c1c-967d-41dd-80fc-6f4eb6564c5c"><ix:nonFraction unitRef="usd" contextRef="ie20f0364533a47b6992606e2b86457b0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="nbix:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MDg4OTY_bd5e2f3c-8ca6-40de-9ba6-7abd47d3560e">10.0</ix:nonFraction></ix:nonFraction>&#160;million in each 2019 and 2018 in connection with BIAL&#8217;s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="ieedd883af091454ab63052c4d4fec48a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU3ODQ_e27feb85-9546-4932-b564-e33369c74899">75.0</ix:nonFraction>&#160;million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="iedf156fd88444c6791467b25bc69b11e_D20150301-20170630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3MTU2_364cc9d7-d407-4bfb-a7ec-2a511de8b55a">19.8</ix:nonFraction>&#160;million associated with the delivery of a technology license and existing know-how and $<ix:nonFraction unitRef="usd" contextRef="ib15e32a0a32b49538add4aef55c528e4_D20170701-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3MjM2_ec873e61-98a2-4b0c-bf13-92dbdd060da3">15.0</ix:nonFraction>&#160;million associated with the achievement of a certain event-based milestone. We further recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8d2360393b7d4d879ba50fd30091a78b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ5MTU5_bbef1a0d-ea66-47bd-9c2b-deb7dc9b6c66">2.7</ix:nonFraction>&#160;million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="ia63b4e7a9e71401dacbac7489e2a7e2a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ5MTY3_513c5dd5-944e-4104-aa09-8c6725841a30">0.9</ix:nonFraction>&#160;million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#8217;s disease patients with chorea. In accordance with our continuing performance obligations, $<ix:nonFraction unitRef="usd" contextRef="i240d0d89861f4e0da2e8453b512420bc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjcyNzE_930d2fed-473d-4f14-ac1a-3cec2471f654">6.7</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i5e4787a5e20042c296dec4c2db37c273_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjcyODI_d3c76a22-c66b-4cc9-a136-8f4e4f6a2e4c">30.0</ix:nonFraction>&#160;million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i240d0d89861f4e0da2e8453b512420bc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3NDg1_9bec9e11-85a5-4acb-93be-d4bd132f1abb">70.0</ix:nonFraction>&#160;million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of <ix:nonNumeric contextRef="ib60f3795c3904b598b633d9146da597a_D20150301-20150331" format="ixt-sec:durwordsen" name="nbix:PatentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NDI2Mzg_3de9af2d-7e13-417c-ab18-068ceb7837ea">ten years</ix:nonNumeric> or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7c83fe60dde1484a80087ae51b894f9c"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women&#8217;s and men&#8217;s health.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $<ix:nonFraction unitRef="usd" contextRef="icc73fd418b1a4436b3cfc5a71dbfbee0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3MjA_07caea5e-4129-4d3e-8768-926379adc330">19.2</ix:nonFraction>&#160;million in 2020, $<ix:nonFraction unitRef="usd" contextRef="id85b50b61a514151b47324285918ddb5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3MzQ_012d3675-56e2-4e48-99b3-07395e581879">14.3</ix:nonFraction>&#160;million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="iac0ef1a100194cad8dd122747923492d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3NTE_9e88412c-22d5-4498-916e-9bed0599cd6d">1.6</ix:nonFraction>&#160;million in 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="ie3004961ef404e91bf6918eb4f99d34d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyMDg_afb48528-1c83-496c-8bff-a361dd7c2629">30.0</ix:nonFraction>&#160;million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="i5cbe52017cfa402a8a7a3857aaac0220_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzI3NDg3NzkxODQzNTI_ff35da7e-7e50-48cb-aed0-0abd394575e3">20.0</ix:nonFraction>&#160;million in connection with the FDA&#8217;s acceptance of AbbVie&#8217;s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="i6f8e4dda08ce4ee7afe7a741837ed4d0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzI3NDg3NzkxODQzNjc_52330be0-8827-4d4d-961d-8ad945ac3b96">40.0</ix:nonFraction>&#160;million in connection with the FDA&#8217;s approval for ORILISSA for endometriosis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i7f1aded41cc7466989f52504c10da860_D20100601-20100630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyMzc_8dfe134d-ccb4-4b1d-8d55-17993b6ae5dd">75.0</ix:nonFraction>&#160;million associated with the delivery of a technology license and existing know-how and $<ix:nonFraction unitRef="usd" contextRef="i9b38c628e5624d3489f366d90fb7a1a7_D20100701-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyNjc_d8ff3f90-f077-4e00-8006-1a3d95bd3392">165.0</ix:nonFraction>&#160;million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i0bcef2297f1d4d3fbdc7d17250594d47_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyOTg_290f6801-bdcf-47a9-bf63-512422948e99">366.0</ix:nonFraction>&#160;million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of <ix:nonNumeric contextRef="ie48c720d2df545228f70c2015456a974_D20100601-20100630" format="ixt-sec:durwordsen" name="nbix:PatentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYzMjg_405d48d6-8e9e-4329-be18-bd844447c0d8">ten years</ix:nonNumeric> or the life of the related patent rights.</span></div></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_154"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzE2MTE_bc4e0492-9b2a-4885-a885-15c54b9a60d0" continuedAt="i5cfde43f0641422292f5b5f6e5dee08d" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="i5cfde43f0641422292f5b5f6e5dee08d" continuedAt="i1e0f5292cc7d430381f18768fca9126c"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzM4NDgyOTA2OTg4NDQ_eaf27391-849d-4fb4-92d9-41b8ea2aeafc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December&#160;31, 2020, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtMy0xLTEtMA_708e5d99-0769-475b-9738-f622a5e904a5">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtNS0xLTEtMA_cc9a40b9-09ba-4e98-aa63-a5039b888089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtNy0xLTEtMA_9bd49237-9fbf-4de5-b4f0-bc4fd262bf13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtOS0xLTEtMA_e69ee772-1bab-4691-be87-83b3db67b487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtMTEtMS0xLTA_927ebee3-b1bb-4e1d-841c-5da5f5c74042">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItMy0xLTEtMA_0529fc23-aeb6-4497-a018-259afd2733d3">299.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItNS0xLTEtMA_f1ca5e91-1e10-4e05-89e5-4502fdd77367">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItNy0xLTEtMA_c2cc2f08-afa9-4c0f-be50-d075bd0d8eaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItOS0xLTEtMA_4a377d00-1ff1-40e3-86af-d729c076c9b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItMTEtMS0xLTA_ea4b3f9b-b5f3-4d65-9852-4dfc7cf84f18">300.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtMy0xLTEtMA_38c44620-e872-42bd-a1a4-20381c1906e8">230.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtNS0xLTEtMA_dce147dd-5724-4351-970c-dcb879620116">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtNy0xLTEtMA_f7e1435b-9155-45bd-9ce2-391b57dd24f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtOS0xLTEtMA_9060e98a-e33d-450f-88e2-1ffce9fcf30e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtMTEtMS0xLTA_051ad149-68c1-4587-a37d-3442387cad43">231.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtMy0xLTEtMA_816ea726-1eab-4b55-85fe-05ee4b2b0628">612.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtNS0xLTEtMA_3eef2987-9171-4d79-b760-5576ddef66bc">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtNy0xLTEtMA_3bde62e6-5b96-452b-84b8-40847f74f26f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtOS0xLTEtMA_4e7020a1-d231-4410-ba7c-1ec7b708d587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce3e91b366c406685df930cadf32f38_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtMTEtMS0xLTA_561a4e40-0721-46fb-90f2-7b74d123971d">613.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67360380b454fd497a4b58684fbdc84_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtMy0xLTEtMA_a650b408-f13a-46b8-8745-d6342abd6971">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67360380b454fd497a4b58684fbdc84_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtNS0xLTEtMA_61abf499-a5fb-4813-bdc9-36b2c6b838ad">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67360380b454fd497a4b58684fbdc84_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtNy0xLTEtMA_157cdd1c-0d07-4dfb-80fd-fbe83f586624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67360380b454fd497a4b58684fbdc84_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtOS0xLTEtMA_6e327629-bd77-474c-9741-86e1578de7aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67360380b454fd497a4b58684fbdc84_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtMTEtMS0xLTA_86b82ca0-1c4a-49f8-b0e2-31eb5fa052d1">145.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctMy0xLTEtMA_0e35d8b0-c7d4-4bc4-845d-abe75cf9c167">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctNS0xLTEtMA_8fbddf82-58dc-466a-b3bc-8167938ff66a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctNy0xLTEtMA_f870e37d-e186-4aac-b66a-7d99aeba626d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctOS0xLTEtMA_3ac783fb-2f93-4608-a77a-dd7d3a542f38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctMTEtMS0xLTA_18d7f696-67de-46fa-9aae-18f2666ab99d">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtMy0xLTEtMA_58e33223-f08c-4fca-be5a-c52afec3c467">226.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtNS0xLTEtMA_0fc42dda-afd1-4a35-8460-e88e13dfe99d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtNy0xLTEtMA_b0a5ba9b-14e8-4cc9-a824-3c4044753fb8">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtOS0xLTEtMA_b0ddfb61-29e7-4660-92a6-3f96ae86d6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc94b76d27134137be897aa51352595d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtMTEtMS0xLTA_4848dcd5-c8ef-4651-88ae-dbb241da3df1">227.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtMy0xLTEtMA_ce2db987-8360-4f2c-b1df-d3c7def1609b">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtNS0xLTEtMA_d3ba9bbc-a8a1-46e1-9276-ba79f9ec480e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtNy0xLTEtMA_93d635f5-2f86-429e-bd25-91409c92bc33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtOS0xLTEtMA_be9a4501-80ca-42f7-90b0-3e3654945132">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItMy0xLTEtMA_9b718ab9-b69f-44f4-845f-b009fd415bcf">270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItNS0xLTEtMA_9a188fe0-0d71-4571-9338-6257bc935930">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItNy0xLTEtMA_471ff010-a4b5-4667-b95c-e90ca63fca1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItOS0xLTEtMA_5115d82b-9251-4a07-b780-6e0591398bf5">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtMy0xLTEtMA_1a57657d-4352-4f0e-a8c2-fd5eafccc8a4">142.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtNS0xLTEtMA_83414efe-8068-4dc4-88bb-4e59e7abe3dc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtNy0xLTEtMA_2adfdf5f-2ef0-4f4d-b95a-c31ff7b05b62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtOS0xLTEtMA_dcf78682-4366-45ae-a2d3-f76c1ea7765f">142.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtMy0xLTEtMA_a798131f-999c-45d7-950e-a25a9226e3b4">557.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtNS0xLTEtMA_51d2001c-cb1c-4141-88a4-ec4dafd9dbf1">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtNy0xLTEtMA_328ae486-11ba-4568-8a5e-b6e9715b7de0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtOS0xLTEtMA_6844c75e-f88c-493c-80bb-c6688b3d45b8">558.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtMy0xLTEtMA_e9237793-1e86-4247-bf50-b34d3a26791d">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtNS0xLTEtMA_4866123d-6e11-49f6-af99-075dbbf49662">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtNy0xLTEtMA_95334d0d-42cc-4cc3-9b9c-97cf4e1782cb">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtOS0xLTEtMA_fcc9ce37-3437-4f03-9c23-c2595b4ece02">250.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370dab92abd446d99199617601b5e1ce_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctMy0xLTEtMA_2e941439-ba68-4666-a1f9-1b98ba030b1f">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370dab92abd446d99199617601b5e1ce_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctNS0xLTEtMA_d869bb9b-633a-4707-9580-1a039aa8996d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370dab92abd446d99199617601b5e1ce_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctNy0xLTEtMA_1916e74e-e1fa-4093-88b0-938d9107e6f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370dab92abd446d99199617601b5e1ce_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctOS0xLTEtMA_3aca9d48-93af-492d-b9d2-a03b67bfcf8e">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d47500148149558693bfbec9f730ae_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtMy0xLTEtMA_09c97882-8b5d-4acf-9e88-b10fe79dc848">299.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d47500148149558693bfbec9f730ae_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtNS0xLTEtMA_69cb1bf9-9a8f-41b4-b3e1-4e838c3131e4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d47500148149558693bfbec9f730ae_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtNy0xLTEtMA_723a9e45-6ff1-4942-8927-46f1f516aefe">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d47500148149558693bfbec9f730ae_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtOS0xLTEtMA_872aa6a3-70f5-4827-a357-e738443d7dc4">299.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e0f5292cc7d430381f18768fca9126c"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzM4NDgyOTA2OTg4NDU_68ec367c-7670-4905-8a56-1a14fe19b277" continuedAt="i33e4a773397646b1ad30ed30348e096c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December&#160;31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMS0xLTEtMA_44673f64-378e-4f91-a292-87ee4908fafc">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMy0xLTEtMA_20d283b9-42f6-47bd-92c0-9dc5cbdac57d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtNS0xLTEtMA_da172cd1-1eb1-46fc-b4a9-c6a4a7b7de8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtNy0xLTEtMA_45866a62-7b94-4d4f-b56c-ce73e28b44f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtOS0xLTEtMA_72b7851c-a266-4391-9bad-25c58aba8f55">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMTEtMS0xLTA_99b24bec-13fa-4458-9587-a6a6058b12f6">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3Xzg3NA_abbab9cb-6a49-408e-88b7-5b7b6595d8f5">148</ix:nonFraction> securities related to investments in debt securities available-for-sale, of which <ix:nonFraction unitRef="security" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3Xzk1OQ_8d422202-2e9f-464c-a51e-251415b5886a">30</ix:nonFraction> securities were in an unrealized loss position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position at December&#160;31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.</span></div><ix:continuation id="i33e4a773397646b1ad30ed30348e096c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMS0xLTEtMA_bbfc32ab-ac9f-4f9b-9e60-8f32c2cf87a3">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMy0xLTEtMA_08541d43-2faf-4a39-a403-d2b62afc5bb5">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItNS0xLTEtMA_81b7bd47-f4e7-4a9a-ad08-8d79e23a7e7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItNy0xLTEtMA_5c81436f-ab50-487f-9816-c1a0ac2ad2e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItOS0xLTEtMA_deecfd25-04fe-434c-8bdf-ae3317588a60">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i268709911d264865a1eb304bcc13bad5_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMTEtMS0xLTA_e34dd202-f216-4902-999b-1bb9f97e2059">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_157"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzkyNA_8600e1e2-814e-44f7-9732-1d8609ef0424" continuedAt="ifc85d4634ce24e5b9644e551b6f8aabf" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ifc85d4634ce24e5b9644e551b6f8aabf" continuedAt="ic8efc0f4907d4c79a88d6aaffa7c1c16"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzM4NDgyOTA2OTgxNDQ_08ef10f1-4242-43c2-b2c9-fc0cfd162f00" continuedAt="i3fa569bbe4474bf4bc09c87db2070c84" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d9c5acf8fc4d5c8413f75febd4b55b_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtMS0xLTEtMA_58dc73f3-675b-4437-b2ba-1d645ccc4b0d">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i145664990f9240a9903f63786ecc19a7_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtMy0xLTEtMA_4c8dbd03-c95c-45bf-b199-5ec2d5ba2a27">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0984f70ef6410e966e87e2240cf547_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtNS0xLTEtMA_7beee25b-6b9b-4fe0-adce-5a586de312bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1746b27d72a42a09e8f4c180db8ba1c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtNy0xLTEtMA_8a3ab007-d502-46c8-a28e-a1ca30f84eb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e6fd039d624ebda3866e81a58d407f_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtMS0xLTEtMA_aaeddc34-5098-4bd0-b395-58b914224aa8">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64146f545c644c5b8abab68d5fbcc802_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtMy0xLTEtMA_e97ffd66-a680-4fb7-81f2-089456d1bcf9">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f22921e8cd3411fb15048449bf9ca63_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtNS0xLTEtMA_4439bd2e-b94b-4fe7-9f8c-74bde9975956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5471a1995347728c20899dc1dc1145_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtNy0xLTEtMA_e7a62fc1-4d72-4b92-be6b-0af3c6742b23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64ee97397f44bb5b2b4a59df28591f9_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtMS0xLTEtMA_1b626b13-18ef-4aab-9377-23717a05a438">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95f976d494c4656844d9c9bc46fb639_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtMy0xLTEtMA_7b737c50-c0b7-4f1d-b61c-226357f6611b">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9fc3c50a75463e948ac570c94115d2_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtNS0xLTEtMA_9ecda6dd-2873-42f9-a7a2-bffb438d2263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b76b7e0dc64aecb1ffcbcca5554a3b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtNy0xLTEtMA_7553539b-8f76-4377-af6d-2d95478aca41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b841b3697ee4d779975c918a2c7c8a2_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctMS0xLTEtMA_68d83821-0ed7-44d2-ab64-c4014a10e94d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51010a40dd914cfdb8196a4a02176e64_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctMy0xLTEtMA_a9b3c2ef-4b42-44e6-b300-08de3ce0a28e">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f914a7af504e9a8c1e308372dd4e59_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctNS0xLTEtMA_2e150024-fa84-4506-9390-be46a49b7589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbcd3bf7584b40e6b743d5e037097802_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctNy0xLTEtMA_52208d2d-58c4-49ea-b7bc-00f0b5b7f35f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb535936a4640ccb740f99e14c3566a_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktMS0xLTEtMA_902396ae-f289-44f9-b335-37ecc8693610">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id858ede7f298497092b20558ba3f94aa_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktMy0xLTEtMA_e97ff7b9-7b51-4949-ab8d-6cb7c0248904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa4a6439abb45a0bbe5a547556b6c0c_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktNS0xLTEtMA_bb79aea5-16cf-4b6f-ab3b-e0ff28030a3e">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd8a4041c334ec5b874010f6d65ecb9_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktNy0xLTEtMA_74da6437-8c7d-4a83-82f6-9b27c5221da0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if137413b5ed641218199d2f07b0be9d2_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTEtMS0xLTA_7d3efc4e-cc7e-4a7e-90ae-a5b9d7abc959">445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbabb6a8263c48d08803b3cdf08455fd_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTMtMS0xLTA_c9eaf390-c5b3-4836-b999-3e3a3d510e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97b7dd5052a1419d9b5eca1001915ffc_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTUtMS0xLTA_28036e33-9d83-4b6b-aaa9-5e3d00b1d77d">445.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d8e3f0ed354c24ab54716af189bb5b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTctMS0xLTA_cf3ed8db-4511-464f-8ed1-fb01de3462dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c602f03adc4410bf05dba9e4ccab5b_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTEtMS0xLTA_ff9abeab-12cc-4889-abe9-14259784df2b">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586a6d13c402494cb6770d478521529f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTMtMS0xLTA_ef074bf9-829a-4525-bcd0-31fedf689b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512ab3e7ad974af9ac04248f25184c1d_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTUtMS0xLTA_68470e8d-e8bb-4647-a256-593d12a9024b">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if231ddf6746a46a4aea8216c8a79d9ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTctMS0xLTA_720ae128-b378-430b-943b-824bf425dd3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595f5dfa2dd643d79953bbb4a3402602_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTEtMS0xLTA_de792dd4-9094-476f-bfc7-cce737beadc2">841.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4097b8463354e23a855ad993b3e185e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTMtMS0xLTA_26d63f81-51f4-4a48-b43f-205aff3e4d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5b4944e27842f1ac75b788b5072eb5_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTUtMS0xLTA_09748743-ce1d-4ffd-8c1e-22eb944a062a">841.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84af1872e05c4870864980dc019daa4a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTctMS0xLTA_14bacc32-1070-4cb1-841f-bd345271d37a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8026f07e7861492f8e98644add623101_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTEtMS0xLTA_3541feff-0f89-438d-af07-c3d2a0a1d53c">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic655a96eac1d40e58299205ab8797a96_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTMtMS0xLTA_c6caf6d2-a894-4087-bdfc-36110801f377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e1d84b48f1403d90c17750f958db4e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTUtMS0xLTA_eff5021e-0b1d-40b6-bfd3-5297c7a567cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e03e5b9e1ad419bbb0aefdda65dd330_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTctMS0xLTA_58da4eac-2ac9-492b-b52e-f251923ab141">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb969448f744b4699e0fe3b2054bc9e_I20201231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTEtMS0xLTA_8e4820b9-377b-482c-9c33-051a5c02d0e9">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e685b74d3a440ae9b69cf3a21f6e94b_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTMtMS0xLTA_4656b074-adcc-4752-8e08-c12cedd25b8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia200b6eb75094ebba0fdffab64b4098a_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTUtMS0xLTA_8e0b7687-2578-403a-bc32-6e46053bec59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8253ad6971bf419497de5085c582cf91_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTctMS0xLTA_a054d3f9-7512-4a4d-935c-0fbba0afc4aa">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7d8c26c43040ac8423eb140604d3d1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTEtMS0xLTA_d0639cfb-5d52-4119-b817-0f3196588bed">1,069.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e092d8925da40a99bc1aefd6f132f68_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTMtMS0xLTA_af3d8800-487a-485d-a3f5-3e906317e731">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14e6ee1921748129105cf214378dd1d_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTUtMS0xLTA_f4ac522b-db70-48f9-9808-6a6344707b2d">841.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695b22218e09442dbb693682b472e4b5_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTctMS0xLTA_e6772c29-8435-4322-a41b-f6d52d39eab8">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic8efc0f4907d4c79a88d6aaffa7c1c16"><ix:continuation id="i3fa569bbe4474bf4bc09c87db2070c84"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf5e27ca5cc4d77bd90dd61ac8a47e4_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtMS0xLTEtMA_7a035dda-6cbf-4789-83e7-85919c38a4d9">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ac9be8342447318a432723c6b78797_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtMy0xLTEtMA_d4de67b7-e3d2-4e99-aa57-41cc9d80e0cb">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fb3b785aa449358571ef423f2219c9_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtNS0xLTEtMA_5baefb29-c312-439e-9f53-6c904a1f8053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65158ac540b41cd91166a0e53ba58cf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtNy0xLTEtMA_112bb4ff-d9c1-4057-a251-3870801fa93e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac4ccb925d645399a328c6018222c6f_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtMS0xLTEtMA_5292d8d3-7584-4610-99ee-49635e064d8c">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268c052b4cd04cce8ecbc0e2996aa476_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtMy0xLTEtMA_978e080f-313f-45ed-8775-820fd5be0376">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a6b5151cf4490f9a51234227581adc_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtNS0xLTEtMA_db81c38f-481f-4a1b-abbb-f1f28969f2c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408a528ab8eb45e9877acf825e1bf345_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtNy0xLTEtMA_290083d1-cdf5-4d66-a8b7-82415768f76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0856066d5f14514abbb08941b50a267_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtMS0xLTEtMA_0ef0480e-1643-477b-8d0d-885f15d6ac51">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d887e6eb804e2ba40e5f883f36d75c_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtMy0xLTEtMA_a04c399b-23fa-455b-b70a-6903a0448cf1">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c033102d7b6458faa551c243d0e7289_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtNS0xLTEtMA_dc333783-44a4-4b65-bcda-79a5ee3b19f7">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd0cc61423040c2915457ec8d6e5d02_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtNy0xLTEtMA_49927dc4-b3f0-4bee-8757-367fb4bb6cdc">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd111c56381a4d8f9292b85ac7e19496_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctMS0xLTEtMA_3a8297d0-de9f-4207-82bb-5b8bb8324fd3">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f436445a324740ab5c8efd7b56e438_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctMy0xLTEtMA_cf09a73e-9e3b-4786-8157-d600419eee80">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4b1d571718416faec2b0ce71d8aab5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctNS0xLTEtMA_b095a3db-895b-4c49-a32b-063513dcf062">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5986576aabe849f49f87cd5cdae9d04d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctNy0xLTEtMA_0777c510-53d4-4d47-a7a8-e4a39ce3277c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a5389b2dd24efab23db9d2c4a3b7b6_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktMS0xLTEtMA_7278da56-29fb-4ce3-a2f6-f5242aade826">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0517d273790643c98a976440f62fd851_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktMy0xLTEtMA_df55ba80-28d8-474c-a731-895d5efd7770">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d343eecc4941ff98e247350e2ab153_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktNS0xLTEtMA_18d9d4a4-bbce-4872-b033-e6e337a142de">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff8100d45dd4625af5245d8a8c006fa_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktNy0xLTEtMA_bd923120-a153-4715-9295-18652da54d70">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc657f8675ea40f5bf7d4393012f3446_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTEtMS0xLTA_55d1809e-ab17-4a48-8bb0-ad7ff2324f41">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1423af80c04b629c1cf1dad548b611_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTMtMS0xLTA_2d965ba3-0db2-4f2f-ab63-8e6f6d2b0125">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8a7b9a9e1c4e19906b367cff71df1d_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTUtMS0xLTA_d2cd1099-cb3b-45e1-8188-b2a35f80769e">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7509d8ee40ad447cb623f9963e19a98e_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTctMS0xLTA_a2d03bda-5785-4291-9c94-a219d9e05553">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide958d8a47be4cea92940a48e4246ae2_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTEtMS0xLTA_3e491c9d-3aad-4528-8589-8a215af3dec6">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646522578c0b4f8fbe22f01e7929bead_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTMtMS0xLTA_780d7ed7-de10-4da5-a462-95547a468eb1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f95bc7850c4e96acea39610b13ee2c_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTUtMS0xLTA_cab9e1f1-f554-4c9a-a4d8-774a77a856cb">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd64f71c0cc942f2b913d01db69e0a56_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTctMS0xLTA_a5448284-420f-4dbb-bd0e-6dda2f76fb2f">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22be6b7ba979497ca9ece88797ec5f9a_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTEtMS0xLTA_f00983e5-9867-4753-9558-69d4a6c8d82b">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d05cd22a7c40f6872ae176348b44ed_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTMtMS0xLTA_dc7ad3ed-d964-4402-b535-8dff89b1f21e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30e7a2d8e794c59af388b27d36d27fd_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTUtMS0xLTA_36eb21cd-56eb-47a7-8184-24ec21e8237f">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62749c0209e440f7b96473ce6fd4b8a3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTctMS0xLTA_52250eb0-3aea-4bf9-bcbf-ee9f0e2cc0fa">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e119c44184cc685474e43e33f71bf_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTEtMS0xLTA_9ae4f4fd-61ec-4f96-a59f-d815f2309a09">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd60d8e7dce40b0aca76907070d868d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTMtMS0xLTA_21c423c9-7aad-468e-83cb-bf893f051948">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida05ac1eb4ff4313a9d1f27643667abb_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTUtMS0xLTA_a1724cf4-cf88-45f4-a4ee-b0937aa7a42d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8645b15c1c462293674465d9ffd0b6_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTctMS0xLTA_c4c484ca-fdf8-442c-af6a-bbe0e0caf733">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida219830132544daa2c45cd2d963ac68_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTEtMS0xLTA_85471a6e-4fcd-46c7-b2ed-d3ab4a1b01e8">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fac764203a4713af1443597ffa888a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTMtMS0xLTA_10741611-83db-40e0-8b68-3685d97eac28">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee56e84363a64281a0bb67ffa597df58_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTUtMS0xLTA_c85ae30e-8f0c-4dbb-839c-a682e5faad44">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30674d569f74deb8350b47ed380e2d4_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTctMS0xLTA_04bb4f51-49dc-4e6e-9ab9-a517b0b10817">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2575bd668b4015b8ad679f19bd5a1b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTEtMS0xLTA_19b1c77d-ffd8-4938-b611-6a1e1fdd4958">1,029.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8a5dc0856b4cdba6c86a366b76c812_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTMtMS0xLTA_53ceffe7-e396-43b8-a3fd-81dc8bbf96af">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ce58ee37ae4b92b5d958c540e8289a_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTUtMS0xLTA_76c53e63-4a47-4dd2-a034-2126de60a325">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad81ae5e7644259a48165fae6c46349_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTctMS0xLTA_433fe1b9-2ed5-411f-aed3-63a5c61ce7b8">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzM4NDgyOTA2OTgxNDY_2048f789-4a9e-4f68-9221-9657389e8b71" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca67d557d334f00a0544aa5f24f6b34_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItMS0xLTEtMA_d7ddc504-50d1-4a08-a5c9-d15e97a10059">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad56dc439b641358459b58e8079887a_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItMy0xLTEtMA_2c77c296-e671-4c89-afc1-ae1f1bc335c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05c117b96dea48f4ac63a4022bae19d6_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItNS0xLTEtMA_0ea94be4-502b-4aac-99ed-c6df4406a140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtMS0xLTEtMA_a7e8bf5a-39f8-4736-b78a-8310485f16b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtMy0xLTEtMA_e0a97d5e-fac4-49fe-8e70-f677941b2ea2">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtNS0xLTEtMA_30bc7006-f25e-4c6e-9e9a-5410d3630c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtMS0xLTEtMA_f726210b-d4f5-474e-aa1c-75f0af29bf5f">17.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtMy0xLTEtMA_ad0b055c-8447-4afa-aa95-6a255cd47150">13.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtNS0xLTEtMA_f300cf1e-04c1-4458-a1ea-f27d8fd78455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec42070cca3e4dbb8475c09e274ad678_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtMS0xLTEtMA_024933c0-760b-4d1f-86d3-c5f3a1e8c2fd">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ca67d557d334f00a0544aa5f24f6b34_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtMy0xLTEtMA_68e14344-abff-4d91-af79-9d18097641ca">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad56dc439b641358459b58e8079887a_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtNS0xLTEtMA_448a7f02-ca6f-4dbf-9481-e1b929de8829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from <ix:nonFraction unitRef="number" contextRef="i83c603ce0ef14a36b7c219ff93558f30_I20201231" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzUzOA_bc456567-33b8-49b2-805e-75fc25135cf6">15.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i830e7abc03c443829d9692cb82e8dada_I20201231" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzU0NA_c840a27e-e763-4e31-9aac-fb067856556d">34.0</ix:nonFraction>% (weighted average of <ix:nonFraction unitRef="number" contextRef="ia219d51ea1f4489893af819d696712f3_I20201231" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzU2OA_07ee834c-690c-4814-8cb3-a10921b48c4c">24.8</ix:nonFraction>%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.</span></div></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_160"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NjA_414927f5-36b5-428d-8b90-48bbb8831a0f" continuedAt="i529ea81ba74d4ae988e3f09f4c4babe0" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="i529ea81ba74d4ae988e3f09f4c4babe0" continuedAt="ife3201aea17d4cdd8788cd3b69988f63"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzg1_2ac9fae1-4214-42ec-8e01-812b2bd0311b">517.5</ix:nonFraction> million&#160;in aggregate principal amount of&#160;<ix:nonFraction unitRef="number" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEyMQ_90377839-7843-420f-8fd8-f94a0affe6c4">2.25</ix:nonFraction>%&#160;convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;<ix:nonFraction unitRef="number" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzMyNA_92454b76-3385-40ba-be2d-193e02c16c33">2.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $<ix:nonFraction unitRef="usd" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU0Mg_e3789ec7-6790-4424-b510-c85a7406e4c2">502.8</ix:nonFraction> million, after deducting commissions and the offering expenses payable by us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0Mg_938f3569-a462-4a7a-bf45-3a3b518fcf86">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwMDY_734fe4d2-0bfe-4dc7-8dbe-1c2b5f74ef17">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzExMjc_b7c04d93-b2ef-4fb2-a196-f2a7b58f7704">130</ix:nonFraction>%&#160;of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<ix:nonFraction unitRef="d" contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzExOTc_aedf9838-273d-4f1e-8dfd-2a8091dc4f81">5</ix:nonFraction>&#160;business-day period immediately after any&#160;<ix:nonFraction unitRef="d" contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5NjE_add5d0c8-f1fd-472e-9815-38a78aef1690">5</ix:nonFraction>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="id222ff8c62cd4111a8f3c7d582b27ee4_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEzNjY_49639824-a1a5-4f12-a404-5fcf28ba1865">1,000</ix:nonFraction>&#160;principal amount of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ife3201aea17d4cdd8788cd3b69988f63" continuedAt="ic61706adc1ca4748af2706bb18afac27"><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzE0NjU_57933658-96e8-4168-92a4-edaf5a33ebc9">98</ix:nonFraction>%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;<ix:nonNumeric contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" format="ixt-sec:durday" name="nbix:TradingDaysDuringObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzI3NjU_37b8bb10-586a-41f5-ba45-96b38d4a5dcf">30</ix:nonNumeric>&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Nzg_a92b6cb4-7a76-45e1-a5ee-925f4165be26"><ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Nzg_feac82fb-d18b-4455-bf87-340db100f7df">1,000</ix:nonFraction></ix:nonFraction> in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Njg_bb852bd1-7b23-46f8-bdf4-26bdba744ec6">1,000</ix:nonFraction>, and the conversion value during the <ix:nonNumeric contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" format="ixt-sec:durwordsen" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMTU_e1e8274f-6bc2-4968-b891-a1f062797989">25-day</ix:nonNumeric> observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by <ix:nonNumeric contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" format="ixt-sec:durday" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5ODg_7be02aba-3620-4eea-948e-728a9570b3d3">25</ix:nonNumeric> days and the daily volume-weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMDI_f36c386a-601e-4c3e-bdad-f4d5cce8cd46">1,000</ix:nonFraction>. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQwNzg_f87474f3-d375-4d23-a0c8-d3006583deea">1,000</ix:nonFraction>&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQxNjc_f33a8057-4e9d-40c5-9f01-ed8eeb3ff363">75.92</ix:nonFraction>&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate <ix:nonFraction unitRef="shares" contextRef="ide871789006342f69f8274002bb357ed_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDYxNTM_156f7b95-b6ee-4091-9a51-60f934befe1f">5.0</ix:nonFraction> million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;<ix:nonFraction unitRef="number" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQ1MzU_6cd7b436-225b-44aa-b120-ea0487c58f64">42.5</ix:nonFraction>%&#160;to the closing sale price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQ1Njc_f4089132-d9fd-45b9-a784-bee08b94816b">53.28</ix:nonFraction>&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU0NjY_4e4571cd-74ba-47e2-86ce-7fb2c3878117">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="d" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU1MjE_7f313987-700b-4ac5-ac29-3cfa70db54cc">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU1Nzc_96490504-baf7-4a84-b841-70cd9ad5bde7">30</ix:nonFraction> consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU3Njc_d48b9b59-987f-4909-a8d4-25f0e50ca560">100</ix:nonFraction>%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMTA_8c4a25a5-aee9-43d3-8c93-cdf78888c905">100</ix:nonFraction>%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic61706adc1ca4748af2706bb18afac27"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="-5" format="ixt:numdotdecimal" name="nbix:CarryingAmountOfLiabilityComponentUponIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzczNjA_e0247963-88f4-468f-b13a-db61a9e63b00">368.3</ix:nonFraction> million&#160;was calculated using a&#160;<ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzczODY_3078a858-2e6a-418d-8c47-4e8e8c47ada9">7.5</ix:nonFraction>%&#160;assumed borrowing rate. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzc0Mzc_27d0d022-9e67-4582-96aa-f458e3e6be06">149.2</ix:nonFraction> million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the <ix:nonNumeric contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTc_8b4e0d67-6494-4a4a-a04e-c0cfdf5b454d">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December&#160;31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately <ix:nonNumeric contextRef="i89667253f1654865bbfb0ea260237daa_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzgxMTA_20beed40-b794-4255-a932-3083f0aa6228">3.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzgxNzI_8c3fbae0-b991-4714-820d-fe68fefff131">14.7</ix:nonFraction> million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;<ix:nonFraction unitRef="number" contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" decimals="INF" name="nbix:EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzg5MDA_d4e8765d-b31e-4a4e-8807-ffe6dad94f33">100</ix:nonFraction>%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="i3f1e2b0fdafc40cea056719ee341bf3f_I20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyNjE_a825e985-7818-482c-9182-f542f90549bf">136.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyNzc_1f67204b-6065-4e3e-862a-327bd9f04345">186.9</ix:nonFraction>&#160;million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $<ix:nonFraction unitRef="usd" contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyOTM_10380982-e293-4118-83a9-cd3ab553f236">130.7</ix:nonFraction>&#160;million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of <ix:nonFraction unitRef="number" contextRef="if4d919d3678346498deb137a73366cf9_I20201130" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMDk_b085cb0a-fd04-4949-a5c3-8432ab8bc61c">3.37</ix:nonFraction>%, which was the market rate for similar notes that have no conversion rights. The difference of $<ix:nonFraction unitRef="usd" contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMTY_2f6385c8-c5e1-4978-be17-ad36613179e8">56.3</ix:nonFraction>&#160;million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $<ix:nonFraction unitRef="usd" contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="nbix:CarryingAmountOfLiabilityComponentAtSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMzE_aa7bd59d-8527-493c-8704-c63e88011761">112.4</ix:nonFraction>&#160;million at settlement was recognized as a reduction to convertible senior notes and resulted in an $<ix:nonFraction unitRef="usd" contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzNDc_d4e9fd7b-c657-4fe6-b30f-940489bb08cb">18.4</ix:nonFraction>&#160;million loss on extinguishment.</span></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTg_788f441d-9635-4831-8431-715adc60f046" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzItMS0xLTEtMA_fac26b05-3a82-4204-975a-36c4179c1921">381.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzItMy0xLTEtMA_db650990-722e-414b-9cf5-6c24e74f0538">517.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzMtMS0xLTEtMA_a98f2fd3-7de8-4c9d-afd6-d82c4ba18afc">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzMtMy0xLTEtMA_fd02a5ec-1d4f-429f-a5f4-a379c28e805a">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzQtMS0xLTEtMA_43af3821-1554-49de-92d5-e39490d5378a">59.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzQtMy0xLTEtMA_ce2b7dc7-72db-4a45-98ef-ec56e6f594f8">101.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:ConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzUtMS0xLTEtMA_223e9c30-1ddc-4472-9411-7e9821234e21">317.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:ConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzUtMy0xLTEtMA_51fe5ec4-d7ea-4914-9a49-9c14237d51d4">408.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their <ix:nonNumeric contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTk_28579dfc-cff8-4901-9a54-6a4f4344686d">seven-year</ix:nonNumeric> term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $<ix:nonFraction unitRef="usd" contextRef="i60ced8a0a7764272b813ab553a8bc5ed_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0MzM_2d58162b-2734-4178-af94-552e71700cb4">514.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i06934d96e69448b9a6a7de8228e9ae5b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NDY_8617ae40-2843-41c2-8d9c-a240c89ce855">596.8</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1MA_39db0c74-0ae5-4924-a277-0f13055e517a" continuedAt="i3815b2b328de4f3d80537c660be0574e" escape="true">Other Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i3815b2b328de4f3d80537c660be0574e"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1MQ_296af8dc-6c15-4a0d-99ba-095c43776796" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzItMS0xLTEtMA_6b79f96c-4b47-45de-b7c3-1e05903b100e">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzItMy0xLTEtMA_f72578c5-5fc3-4746-a14c-2db55fad3842">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzMtMS0xLTEtMA_f1388aab-2cc2-4b92-9cdb-3c2492a3c7fa">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzMtMy0xLTEtMA_1571f855-c3a5-440f-8876-10ef9d034163">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzQtMS0xLTEtMA_af12669d-878d-49b1-a4f9-9bb97fa47c00">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzQtMy0xLTEtMA_1b565bbe-e674-40c5-993f-20ab5cfdfee5">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzUtMS0xLTEtMA_564f4b98-5beb-4ff1-ada0-b038b7ae2c49">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzUtMy0xLTEtMA_3646c63b-5439-4d90-9472-784e205bc3bf">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1Mg_4e6ac4ea-418d-4237-9bd8-f0f417c77f9d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa184a589454ef3b217797ac3f37c85_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzItMS0xLTEtMA_2eb721ff-db90-4469-b65e-d79c7cb90421">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c737c06e3a64363abae7512867edfb9_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzItMy0xLTEtMA_c9ec886c-b1f1-425f-b52c-93c6f1ee57c5">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a92c0d75562403aaeb7e6195396a9c0_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzMtMS0xLTEtMA_30a87f0d-82fc-41b0-b1dd-4ad1cb689975">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4132f626519c4dd6915f68702956d54a_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzMtMy0xLTEtMA_1ffe3730-6988-45c1-a55b-34cd2260ac8f">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2114f7c7620e47ed9b7c7252ab48432d_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzQtMS0xLTEtMA_0dc0eed2-f9f9-4349-9987-4e71d403ee1c">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76651c30b164c06b76804edbd718ae7_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzQtMy0xLTEtMA_5c6ae998-05a2-4f7a-82c7-f150f14f2723">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c9dfd023f94ae6b49d6219f49911a0_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzUtMS0xLTEtMA_9352742a-f7cb-49c4-8b7b-c2fadb84f8a8">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ff256dae7c4d7da1e1f691ad48ee76_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzUtMy0xLTEtMA_4c97b1d4-d916-42f3-a472-e222e131f490">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzYtMS0xLTEtMA_b44697a9-54c6-44a5-b6d1-446dd742b2ae">86.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzYtMy0xLTEtMA_dc348144-38ae-47a4-ac9c-f555c2c7b1dd">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzctMS0xLTEtMA_4d6f69d1-d8df-4bda-b39d-73104b4db162">41.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzctMy0xLTEtMA_c087d8fd-22a5-4669-83ec-77f3ea0de50d">33.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzgtMS0xLTEtMA_1e48ca8a-ef7a-4076-a78b-53d9979d39f0">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzgtMy0xLTEtMA_e9d28cac-d610-4ecc-8e8f-0235a836792e">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ0OA_adb06be1-ed51-4aec-b9c0-c178a05a9d6c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzItMS0xLTEtMA_c6d6b404-7782-4686-9092-9d675b8c678f">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzItMy0xLTEtMA_a1e7eb54-9379-430c-822b-d17a21cce8c6">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:RevenueRelatedReservesForDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzMtMS0xLTEtMA_0bf3672a-c93a-4d30-a1ef-c8f317cdf666">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:RevenueRelatedReservesForDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzMtMy0xLTEtMA_adeda392-8225-4f02-877e-a7468dee01d1">30.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzQtMS0xLTEtMA_e2517ee1-04c2-4621-af82-d5b491a836c1">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzQtMy0xLTEtMA_ca036201-58e2-420d-a04a-9553884bba93">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Branded Prescription Drug Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMS0xLTEtOTQ1Ng_ef066d87-e0ef-4e66-8af7-fea2e61316fc">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:AccruedBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMy0xLTEtOTQ1OQ_41995817-1499-4c54-ac6c-76811127bed2">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMS0xLTEtMA_d4da9db8-e160-4228-be3c-a2ab51178d9d">39.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMy0xLTEtMA_4e310828-34e4-49bf-a454-7cabe6bd6a63">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzYtMS0xLTEtMA_93e76827-103c-47c7-af52-e230ffba0835">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzYtMy0xLTEtMA_40e672e3-828d-4997-b87c-13b42c1a86ca">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ0OQ_f239a1b8-37d2-4cd9-a450-cb46fbe9ae57" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzItMS0xLTEtMA_f0b8fafe-0b45-466a-aeb6-e20c5744f20e">187.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzItMy0xLTEtMA_a5af6e86-7dd8-4a71-b2d1-806d405c6a60">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzMtMS0xLTEtMA_433e3c17-917e-4ac1-b7b7-db74de14c974">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzMtMy0xLTEtMA_99748033-5928-45e4-ad7c-63bd4a470ba1">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzQtMS0xLTEtMA_c04d9ef9-c2d4-4fd1-8ef3-997297249edf">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzQtMy0xLTEtMA_808c7114-2288-4c49-8f23-735476ce6396">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzI0NQ_5ea8536b-1646-44df-b35c-4d28b661c4b7" continuedAt="i1ce70e22f62a407f8e193a56a5b07193" escape="true">Net Income Per Share</ix:nonNumeric></span></div><ix:continuation id="i1ce70e22f62a407f8e193a56a5b07193"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzI0Ng_4801de3d-a856-4646-86d0-c494b2e6d829" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItMS0xLTEtMA_cda2b763-bb8c-4752-9181-403a5f22e291">407.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItMy0xLTEtMA_deb105d5-6ea4-4149-943a-073d9e595f81">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItNS0xLTEtMA_6bd5ec37-a48d-4959-a9c7-1ae4e6608c1a">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtMS0xLTEtMA_11692b4c-4057-4d5b-92ca-48eafb1d25d0">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtMy0xLTEtMA_ddf4173d-4140-4a69-acb0-b9aa3942394f">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtNS0xLTEtMA_12bc10c9-a0fa-4735-9fdb-38b55a16e319">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic403135dcdce433cb75127f4ba52569f_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctMS0xLTEtMA_aa38425e-d104-478c-983d-f286a138885e">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i545e098699484f749aa1893bd9f4d9ac_D20190101-20191231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctMy0xLTEtMA_5690d1c7-5b7b-4c18-aae1-86988423894f">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie580a98b5f904017acbc0be2a81b1401_D20180101-20181231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctNS0xLTEtMA_d79dac03-cd11-4808-9d3a-1fe0509ea7f8">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb93957d4a2347d0893965c4a30cbdd0_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtMS0xLTEtMA_393764f6-fb20-489f-a8c4-a64b5eb1400a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ad0a98345c14590bf7d5f5fd862c9fe_D20190101-20191231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtMy0xLTEtMA_5fa36392-cdcb-47c6-85f1-96d02404114b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i613490d34e8a4611aab2ffd9a16f8ef0_D20180101-20181231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtNS0xLTEtMA_ff4a8e3e-8e0e-402c-ace0-fddf9e593cc2">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktMS0xLTEtMA_8899db99-d820-4a66-a401-4b2c2b888975">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e784185d98a4b9cb1bb7bcad7598aea_D20190101-20191231" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktMy0xLTEtMA_883709a1-4a07-46ec-9b09-624b8a27cfc6">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81fcb21b072c4b679ca34c108cfa6ef4_D20180101-20181231" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktNS0xLTEtMA_17f7e981-06a3-4736-8ee3-cf8fc520876c">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTEtMS0xLTA_2d72ea94-6917-4604-9653-b56eb31582ba">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTMtMS0xLTA_f88ccdb8-8f7d-428b-91a0-c1787d2fc2d5">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTUtMS0xLTA_1cedd44a-c576-4a8f-8263-93da0bb0cf25">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTEtMS0xLTA_b6103048-5363-497d-8d63-17f1cfa949e5">4.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTMtMS0xLTA_9049503b-4c70-4b93-932c-2cc4c32b7331">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTUtMS0xLTA_9867378a-0101-4241-946d-3a8bd8cd7277">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTEtMS0xLTA_d660e07d-cb9d-4638-adf5-d8b41fc4fa5d">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTMtMS0xLTA_072d6267-5f5d-4482-b8d2-8a6695caefa4">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTUtMS0xLTA_7dbfd563-657f-4cc5-9522-0ce34e6a3cd4">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzE5OQ_8548933a-d751-4435-a218-1520d36bb6e4">2.5</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i8581e780a80c4442b21f27be29b95775_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzIwMw_224bf1c3-ed86-4f21-8f5b-2ccf821b4277">2.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i5bea0f817d424b9faef8c2af8c43a23d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzIxMA_3d421ab8-16ab-4f2f-8818-275414f0e296">0.9</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_172"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjI_7ac896d2-ea84-4ab4-a4a9-81cfeb3f6118" continuedAt="i440ccf69c0ff47ff985e728f92d79a21" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i440ccf69c0ff47ff985e728f92d79a21" continuedAt="ib0cbacecd5a3460c998ac467668940ca"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized <ix:nonFraction unitRef="shares" contextRef="i16180db6d54a49ce83ee4500d72b9962_I20110531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE0OQ_59529dd5-bb33-43c5-af1e-ba0d6dfd4308">21</ix:nonFraction> million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were <ix:nonFraction unitRef="shares" contextRef="i21f4f7020f68499385d6f2a13567d7f0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjM_ec3d794f-c857-4838-82ae-7bb6973915bf">no</ix:nonFraction> shares of common stock remaining available for future grant under the 2011 Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which <ix:nonFraction unitRef="shares" contextRef="i60fca317ddb748798d4cb98a5fbf2aea_I20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzY5OQ_eea4a1a1-e362-47bc-939b-91ae3510cb4e">0.3</ix:nonFraction> million shares of common stock are authorized for issuance. At December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="idd5803489bd44c3cb9e6f31d1e0a6681_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzc3Ng_f16822f0-8001-4084-932c-97ef63b8d137">0.2</ix:nonFraction>&#160;million shares of common stock remain available for future grant under the 2018 ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized <ix:nonFraction unitRef="shares" contextRef="i48bbd2bddcdc44dca0395f6d99c449aa_I20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzk1Ng_78f24588-c8f3-432f-a5c9-cb9c4e0cebe0">3.3</ix:nonFraction>&#160;million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="i035747211e4f44e193c5d551cf4d62ed_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEzMTM_93694252-c582-4daa-8657-71e56924edf9">8.2</ix:nonFraction>&#160;million shares of common stock remain available for future grant under the 2020 Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNTg_5f7cdb41-80d4-4193-8427-fde30a91c93e" continuedAt="i02559ed9d1b4479688fcc59a20d32869" escape="true">The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</ix:nonNumeric></span></div><ix:continuation id="i02559ed9d1b4479688fcc59a20d32869" continuedAt="i4ea4c5c18d484d018fa38f7de1bcdd49"><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965516f5121d4176b5ae292b90be804a_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItMS0xLTEtMA_ab374693-a825-4a31-a3c4-1255a69941bd">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc67e37cd02430da9f8da535e6d7526_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItMy0xLTEtMA_a1bc121d-1d13-4e5f-a2c9-154d111ab034">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521c723b6c49422a84b72328e24a5c55_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItNS0xLTEtMA_7d68efdf-0347-469d-a6dc-b6ed48be7545">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1faa6db7b38d43dd97845deb75c32b0a_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtMS0xLTEtMA_1be35483-36e2-46d6-9bac-bcf334b87292">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e87b16f9684b559824bed5cc3bfaad_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtMy0xLTEtMA_7da05c77-eea0-497d-aa2f-4adb8e60a368">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a82057bae22484ab39cbc0b26398dd5_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtNS0xLTEtMA_4b702de0-9607-4b90-bb1f-89fc1a82177d">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtMS0xLTEtMA_fc29a5ff-bc0c-4bf9-85a9-b8b6d793dfd7">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtMy0xLTEtMA_bb6eceb0-1b6a-4ded-83f5-23a981dc2257">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtNS0xLTEtMA_c2a8967f-b250-4f10-8ac4-24382e603a05">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItMS0xLTEtOTk1_c8887e7b-43ad-464c-8c1c-25614e48099e">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItMy0xLTEtOTk1_5ae4bd17-688b-4e28-8bcb-e8c728ec6161">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItNS0xLTEtOTk1_9861380e-64d4-4cd6-b603-c88ea27dc384">35.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMS0xLTEtMTA4Mg_3af7739a-e502-496d-b70d-d8ec63f4317c">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMy0xLTEtMTA3Nw_effb2101-b2e3-4bec-89d1-1acde4318751">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtNS0xLTEtMTA3NA_a31450a7-8e1b-4113-a0fa-6b4f09212beb">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMS0xLTEtOTk1_918f6f66-57c2-410d-a375-df4e2b840aa0">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMy0xLTEtOTk1_23b2015c-c615-4867-aa6f-b979e41ca08b">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtNS0xLTEtOTk1_2ec08710-b5b0-47e4-af95-f22dc3302bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b54e325551b473da0598c96d708c5da_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtMS0xLTEtMTA4Mg_1175c554-45bc-460c-85a9-9ed0482f78a4">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7638d60a91cb4ff787321cee24ae9f48_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtMy0xLTEtMTA3Nw_23482f93-60e4-4480-80d4-f1cd5120baa8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie680af40b96e455aaaaf75ab295c9ac4_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtNS0xLTEtMTA3NA_b48f2df0-f177-4fbc-9af5-febc1e1170eb">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtMS0xLTEtOTk1_13fe7774-3175-4243-96ad-3b8716149be2">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtMy0xLTEtOTk1_252579ef-a1cc-40c0-81da-68374b7beed1">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtNS0xLTEtOTk1_fbaa5372-5041-4c8d-aee0-87018a3c61d5">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib0cbacecd5a3460c998ac467668940ca" continuedAt="i82ae7e7f878d4686bbb501c0530863b6"><ix:continuation id="i4ea4c5c18d484d018fa38f7de1bcdd49"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdaaf1063b5640c096eab926298a36b4_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzItMS0xLTEtMTE3NA_c4e1a619-4f35-4974-9d46-13f75f2ae177">86.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzItMy0xLTEtMTE3NA_e0017f02-701d-402e-99ce-21f99c4027ce">2.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzMtMS0xLTEtMTE3NA_1630a8d4-f188-4ed9-9588-ce2be32db184">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzMtMy0xLTEtMTE3NA_3e770ae8-86c9-4d10-9cec-b2a96ca63290">2.3</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a <ix:nonNumeric contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzQ5MjY_01fc2bb0-a7ae-4f5e-a146-45857adc7899">ten-year</ix:nonNumeric> term and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa">three</span> to <ix:nonNumeric contextRef="ib5add3ec602347a4872184c665490f93_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzQ5MTM_795cbf2b-32ca-4b1f-abcb-d8a9192ae4bd">four-year</ix:nonNumeric> period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $<ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NjA_9a04606d-ac17-4ecf-8483-0f22c2b48891">45.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NjU_ca1ec67b-c67b-49b9-b4d2-925fec537d83">41.74</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NzM_22686d2f-d30e-4c24-a2b4-d272d6963a81">43.42</ix:nonFraction> for 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNTk_a265b29b-0755-43ea-8cc8-8960ac0c2231" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItMS0xLTEtMA_818db87a-9a12-4d0c-9da0-45110fd65dcf">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItMy0xLTEtMA_0812dc2f-0811-41e6-ad7f-0ecd3e0c501c">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItNS0xLTEtMA_14bf8274-20ff-4e3b-8c34-c74cf2c609f6">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtMS0xLTEtMA_83355fc5-4cad-4ce8-bd9e-93f5cdc7297b">48.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtMy0xLTEtMA_c6578e37-dbf7-4cab-8a91-29c19e31599a">54.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtNS0xLTEtMA_429721a3-4e72-4c15-b092-1de5de681f52">59.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtMS0xLTEtMA_ed25ffb7-d7c6-4841-ac80-ce7982041b39">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtMy0xLTEtMA_0cdf0548-0d8f-4188-b989-8032b8bae0f7">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtNS0xLTEtMA_0b088acf-e9f1-4859-af88-2035ef1cf52b">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtMS0xLTEtMA_51e7b540-9c91-40ee-8424-9dafa472f4c0">5.3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtMy0xLTEtMA_5a057cce-9934-4153-b523-aa92797df326">5.4</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtNS0xLTEtMA_9b0197cf-bce6-47d4-b27f-0984952efe34">4.7</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjA_9f8cec54-1651-40b7-a5ea-e93cc887b482" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to stock options follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzMtMS0xLTEtMA_8d1abcea-90c3-4a2a-933a-de5a528ad09d">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzMtMy0xLTEtMA_86998461-d065-4a4b-9e68-ce23c36eea4e">52.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzQtMS0xLTEtMA_f0a7a256-e828-476f-a5c4-0dc1c42451e8">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzQtMy0xLTEtMA_4d6b7597-dc40-4161-9288-3d765655ff0b">103.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzUtMS0xLTEtMA_eb2030fa-6df7-4238-982b-3e07916b35fe">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzUtMy0xLTEtMA_9f1625a3-10c2-4f8d-b1b3-006536481422">43.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzYtMS0xLTEtMA_414a3efd-4ca1-4f58-be1c-154c17564591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzYtMy0xLTEtMA_bf4de1c8-52d5-4fdd-a914-562cae20558b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMS0xLTEtMA_19f03c5d-3625-4d5f-b0ae-99428d85ab01">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMy0xLTEtMA_b3b10b61-fd0c-476d-821d-3a71a06f9c67">62.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNS0xLTEtMA_bf81e26b-4922-4c6b-8211-2bb9f47f60f7">6.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNy0xLTEtMA_8505ac97-fcf8-4e50-8fec-e2f2bba1bff0">235.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMS0xLTEtMTMyOA_4f48ab47-afc6-4545-b2a2-5f4efc961f99">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMy0xLTEtMTMzMQ_43bae52e-73f9-455d-af42-658a7e854a86">49.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNS0xLTEtMTMzNg_7bd4869f-d99d-4037-af04-134078bfa02a">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNy0xLTEtMTMzOQ_04182bbb-2e65-429d-92b1-cd1327cafd83">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MDE_c2e8863d-3c6a-4421-bcc3-e8108b2498bf">40.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MDU_b8d76a6f-2d78-44ce-b09e-f8592e592210">64.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MTI_25da2c8c-74fd-4f5e-9f4e-399f415a764c">117.0</ix:nonFraction> million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MDE_57f80bc6-1926-4ef3-a70d-13288fdb9c37">23.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MDU_ee3e706a-0d17-4319-a072-62c6d2101d27">27.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MTM_b5ffafab-0e53-419c-a634-88b3f212b222">29.5</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, RSUs vest over a <ix:nonNumeric contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzU2NDM_c0b97396-8530-4d85-9f6a-fa1b3ac55f28">four-year</ix:nonNumeric> period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i82ae7e7f878d4686bbb501c0530863b6"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjE_88cd43da-b089-40b6-944a-3f43e4b07651" continuedAt="ida4827825cd0463cab04a1c7c2b69444" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to RSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b9010f4078c43eb99d30b01f597843b_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzEtMS0xLTEtMTQ0Mw_49144743-2626-4bd0-99dc-e5ba87da050a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b9010f4078c43eb99d30b01f597843b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzEtMy0xLTEtMTQ0Mw_b87af189-d4e9-42b9-844e-3f8c04a41546">74.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzItMS0xLTEtMTQ0Mw_e85ef5d4-a9b5-4abf-adbb-7cfe1a1a30aa">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzItMy0xLTEtMTQ0Mw_8e708789-6b19-4f90-b7b2-7aba3d63b943">102.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzMtMS0xLTEtMTQ0Mw_0da44525-720c-4cb3-b250-3ae9db7d66aa">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzMtMy0xLTEtMTQ0Mw_1b712158-5449-4b44-be95-52e8c9e21666">67.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzQtMS0xLTEtMTQ0Mw_3350e92a-88ee-4b29-b4c3-5e7461d7dc4b">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzQtMy0xLTEtMTQ0Mw_6678926d-f97d-4227-bac0-4702682290bb">84.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtMS0xLTEtMTQ0Mw_9f934935-0703-4da4-97a6-20039c603653">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtMy0xLTEtMTQ0Mw_48119b3f-5888-44d3-83b0-48f9b87859c3">89.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtNS0xLTEtMTQ0Mw_551a1753-81f0-4872-aab1-34f1f3d110d0">1.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtNy0xLTEtMTQ0Mw_41d2520a-0ab9-494b-b88c-0914f7bc9086">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs that vested during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM2ODk_e4966ab4-29f2-4bbb-a954-88d682aa3438">49.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM2OTQ_0390b30b-82ce-4110-b2fe-e67eb9d8c2bb">36.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM3MDM_221d712a-02bc-493a-b29c-4d11435a8693">35.5</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9">four</span> to <ix:nonNumeric contextRef="ice8da843469b46af91bfcfc456693d02_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3OTQ_233b7470-6410-4b61-a9e6-01d64ea92bc5">five years</ix:nonNumeric> from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant.&#160;Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable. </span></div><ix:continuation id="ida4827825cd0463cab04a1c7c2b69444"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to PRSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzEtMS0xLTEtNjMxOA_abb306b7-49f3-4d8a-8838-0a7e6ed94206">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzEtMy0xLTEtNjMxOA_aa181035-60fb-450b-a29b-82bdfcb7ab31">59.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzItMS0xLTEtNjMxOA_c7f25dcd-3428-4f98-86db-62af8682164a">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzItMy0xLTEtNjMxOA_feda5102-8f25-4efb-947b-96e90b014532">102.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzMtMS0xLTEtNjMxOA_c605b36e-1052-40b3-9e46-a6a5fafc90f3">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzMtMy0xLTEtNjMxOA_defa3e0e-a350-4e1f-96a1-ca035071c6a4">82.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzQtMS0xLTEtNjMxOA_f14aac9c-9516-469f-a934-d130155e0b4d">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzQtMy0xLTEtNjMxOA_69cc08ff-02ca-454b-b0a4-b95ca5104ce9">45.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtMS0xLTEtNjMxOA_435339df-d672-4004-858b-ee14ff44f1ad">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtMy0xLTEtNjMxOA_96ee7990-2018-4a18-82c2-e11c5f1fe852">102.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtNS0xLTEtNjMxOA_1e5417fd-703e-456a-9882-afbef3dca72b">2.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtNy0xLTEtNjMxOA_23914e1e-7927-4bf6-8353-dbb1ceb2bd6e">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized share-based compensation expense for PRSUs was $<ix:nonFraction unitRef="usd" contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDgwMzQ_13477837-65e4-40fd-8d4f-e301abecaed2">17.0</ix:nonFraction> million. The total fair value of PRSUs that vested during 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDc4NTM_3348e31b-8902-428c-977b-7654462f5f9c">13.5</ix:nonFraction>&#160;million. <ix:nonFraction unitRef="shares" contextRef="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE2NDkyNjc0NjE3MjE_34f6fa57-674c-4857-aec0-2be7b2d3e45b"><ix:nonFraction unitRef="shares" contextRef="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE2NDkyNjc0NjE3MjE_ca840c1a-8659-43ec-aa4d-89b770c29d4d">No</ix:nonFraction></ix:nonFraction> PRSUs vested during 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of <ix:nonFraction unitRef="number" contextRef="i3c587d6dc8c6451fba9c6dbe18ec82bf_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzc4MDA_96077c8e-e0f7-4fca-8174-ec06235b60c1">85</ix:nonFraction>% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_175"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTY_b8027867-0be0-4935-ba9d-4b86f021abe5" continuedAt="iee2349aa4a1c4521a2aaf3eed4329dc0" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iee2349aa4a1c4521a2aaf3eed4329dc0" continuedAt="i83fc0f2465814be683efa0f7b8e2a656"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTc_3d755f1d-0749-4327-94dc-29a8a19efbea" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense for continuing operations were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtMS0xLTEtMA_f7bffe75-7e7a-44f6-92e2-f1da48c1bd25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtMy0xLTEtMA_36bbd02a-3418-4dda-bcd8-191b43751ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtNS0xLTEtMA_9e4a29cb-afea-4176-88ba-5b4101eb2062">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtMS0xLTEtMA_6d7b357a-8870-4a8e-9f09-66fd828758f6">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtMy0xLTEtMA_0b9656ed-aee3-43a9-aadc-a3750b63e961">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtNS0xLTEtMA_93117d7f-4b8a-4783-9aaa-0c91443a57b2">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtMS0xLTEtMA_02ee7312-46a6-41ad-8180-080ec8f99275">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtMy0xLTEtMA_05627f39-54c2-45db-8ead-8b6afb3e154f">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtNS0xLTEtMA_eeda28bf-af22-4382-b8ca-34b09c1ef863">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctMS0xLTEtMTA0MjI_924655d2-3d73-40c9-86bc-a51941d18c37">287.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctMy0xLTEtMTA0MjI_3102e637-1ee9-499b-83a9-e252c17ae29b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctNS0xLTEtMTA0MjI_354b7c5f-9a3a-49e0-9864-ffb587e997bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtMS0xLTEtMTA0MjI_bf4e2b71-b710-4b8d-9155-a030cf6090c5">23.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtMy0xLTEtMTA0MjI_d1c3048a-613c-4a42-9f96-2a5bbf7482c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtNS0xLTEtMTA0MjI_089338b1-d766-4386-83cd-49c6c05ab02f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktMS0xLTEtMTA0MjI_5582e22e-61c4-401f-9454-2e1b83f1bb26">310.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktMy0xLTEtMTA0MjI_cc2acea0-ebc3-478e-87bc-abecf530345e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktNS0xLTEtMTA0MjI_933a219d-6791-4e96-afd1-47c9bfe32747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTEtMS0xLTEwNDIy_7baf89c4-d40d-43c1-8f81-f1c19cee412f">300.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTMtMS0xLTEwNDIy_34bef9eb-e1b4-4044-a1ff-f81a771c6a62">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTUtMS0xLTEwNDIy_0049c50b-313d-4710-9b3c-14a1c8f81e7e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i83fc0f2465814be683efa0f7b8e2a656" continuedAt="i7e323c9bdb384aa2abbd5236f397fb50"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTg_14b4c41c-5400-4c03-9a7d-006366bf8a4d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at <ix:nonFraction unitRef="number" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_76f6e3f9-4a07-4540-94c4-e9f7deda16d8"><ix:nonFraction unitRef="number" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_8c6a69d2-7f66-4b08-89d7-bf2872a59a97"><ix:nonFraction unitRef="number" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_9ed365e8-8dd3-451e-a5b8-b971e438471b">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for 2020, 2019, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMS0xLTEtMA_827e3b0b-9da1-4a88-9648-a89f615659f6">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMy0xLTEtMA_7f4bb2f4-c676-4ccd-ab52-f3a6a1a24675">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItNS0xLTEtMA_6c60751f-dbfa-4da2-acb0-b0969fd3d407">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtMS0xLTEtMA_ac5889b8-161a-4a27-bae4-64648108694a">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtMy0xLTEtMA_a2715398-3467-4417-b0c9-4942d93d8fb0">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtNS0xLTEtMA_893b137c-522c-404e-9cd3-e5a727522086">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtMS0xLTEtMA_a2bd8c00-2d22-479d-bf43-ad6f46b45825">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtMy0xLTEtMA_752dcd77-25cf-4e23-a001-93750059633e">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtNS0xLTEtMA_c7c2faf0-f78d-48ec-8c5b-a748d3311358">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtMS0xLTEtMA_50343b8f-1023-491d-b439-36d83098261d">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtMy0xLTEtMA_6eddfa12-0b4a-4d42-96fe-6785a12ca0d3">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtNS0xLTEtMA_a02cb758-7e51-41d6-b45f-a747d339caa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtMS0xLTEtMA_40bbdc5d-44e3-4c48-ae39-bc74d33688c9">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtMy0xLTEtMA_a45a5492-ce01-439b-a723-d7e3cec021ee">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtNS0xLTEtMA_bdc789df-bf60-4571-96fd-9c89b6580c4c">9.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctMS0xLTEtMA_9a181445-57fa-49f3-969c-a5c0cfeae8e2">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctMy0xLTEtMA_1293a2ac-5f35-4713-97e2-d8fdea83a456">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctNS0xLTEtMA_5b348e4c-b16c-448f-bed0-40423525af51">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtMS0xLTEtMA_5886ec70-1ea5-4d6e-a9b3-c0e3b087ac2d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtMy0xLTEtMA_6e766741-ed19-4c67-8002-92807773751b">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtNS0xLTEtMA_c547641d-4b3c-4e10-becb-e804ae1aadab">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktMS0xLTEtMA_a944304d-5aa2-41ca-a3d0-24b006592986">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktMy0xLTEtMA_ebfe540d-9894-4305-84e0-fa018a7cb89e">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="nbix:IncomeTaxReconciliationExpirationOfTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktNS0xLTEtMA_19c06344-f1c0-4618-be60-ff7441704a23">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTEtMS0xLTA_c0c66ab8-12ae-4ec0-9efe-36d6a29ca210">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTMtMS0xLTA_f6bbfb44-e1bc-47d8-9d97-e448c1e353b2">10.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTUtMS0xLTA_bd204da1-e9af-417b-b2b1-78a616cfa55b">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTEtMS0xLTA_2644deb1-d034-4297-92e2-63f163435acb">296.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTMtMS0xLTA_af936aaf-c3a7-450d-b2d9-b3634afae750">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTUtMS0xLTA_56124c11-c3db-44d9-9350-6fe29793737e">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTEtMS0xLTA_57ef03d7-426a-4bb9-bb1a-a567b98945a2">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTMtMS0xLTA_223f422d-506e-4328-8cdc-206037375a80">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTUtMS0xLTA_52f00ac2-3ef9-47a9-9aa6-d2300f965b38">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTEtMS0xLTA_4af68ecc-3ab6-41b3-a223-0d3a3e5da4ff">300.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTMtMS0xLTA_86d575d8-7893-47cc-924c-a63cf27e7d22">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTUtMS0xLTA_54adbea0-94c3-4f16-be37-000b9f0fb2b8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTk_169d40e9-55e5-4424-9f6c-f92ca17dac11" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzMtMS0xLTEtMA_a03e643d-c509-4776-b8a1-6a8d6e8467b9">111.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzMtMy0xLTEtMA_d8fda1dc-e3c7-4c5e-8cab-e9cc2d1f9104">181.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzQtMS0xLTEtMA_d1dcc055-5286-413c-92c5-54eddae2800b">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzQtMy0xLTEtMA_c59f692f-8985-45bf-9da1-474a55ca2b5d">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzUtMS0xLTEtMA_cb2b5589-06f8-49b3-bd21-840f128bdd3e">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzUtMy0xLTEtMA_78601701-5afd-487e-9b37-0ce453fec67f">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzYtMS0xLTEtMA_e77ccb24-c440-4b82-befc-956776b3eae9">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzYtMy0xLTEtMA_a7911d46-2f92-45b8-a0c0-23829e5cfa28">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzctMS0xLTEtMA_c17140ab-43f7-40e6-8871-e217e6ad43fd">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:DeferredTaxAssetsOperatingLeasesAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzctMy0xLTEtMA_5368f955-3b18-4aad-a698-727c84fc8f80">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzgtMS0xLTEtMA_737c93fd-a3a8-4aac-be13-9f805045c747">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzgtMy0xLTEtMA_315a30d5-1f75-404b-bd2f-32283eaaaf13">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzktMS0xLTEtMA_66296ce7-51ec-47aa-ac78-e22d4a958c82">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzktMy0xLTEtMA_6749bb46-f31f-4bf2-945a-bbec108185fc">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEwLTEtMS0xLTA_f45475a4-358d-40fb-bbb0-81dc130fce05">411.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEwLTMtMS0xLTA_7a9f9932-5ab2-47f0-b84f-fceda4705d57">395.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEyLTEtMS0xLTA_684509fb-2b45-4e7d-831c-219cc4f4d94e">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEyLTMtMS0xLTA_40fa3f8a-7cca-4879-92aa-4573380f5a12">24.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEzLTEtMS0xLTA_f64395be-5099-4982-b175-a883dcf4e4ec">19.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEzLTMtMS0xLTA_d428f057-7b7a-4343-89a2-8c3682b73d63">18.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE0LTEtMS0xLTA_ef6247ca-15c8-4cdf-b02c-c42dd93579c6">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE0LTMtMS0xLTA_16f601a9-09fb-4ecb-a4b2-aeff82bbaf71">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE1LTEtMS0xLTA_42710c0e-d729-425a-9733-2edd662e1632">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE1LTMtMS0xLTA_0479fef9-3673-4cb9-ac52-f3c7fbb72984">49.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE2LTEtMS0xLTA_f17fa7a8-32d1-475a-be49-1edf607e9192">369.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="nbix:DeferredTaxAssetsLiabilitiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE2LTMtMS0xLTA_ac89601a-6264-4ef6-a608-85986bc9a947">346.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE3LTEtMS0xLTA_66bdbc91-9a91-4abd-a5a9-32c447b47c22">49.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE3LTMtMS0xLTA_58c160e7-a534-49f0-8a4f-df4d03e19e52">346.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE4LTEtMS0xLTA_a97d4cf6-935f-44f5-bd03-0456c846178c">319.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE4LTMtMS0xLTA_5b22a87e-832b-4173-9632-a49fdc5254f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzExMDM_66bdbc91-9a91-4abd-a5a9-32c447b47c22">49.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzExMDk_58c160e7-a534-49f0-8a4f-df4d03e19e52">346.0</ix:nonFraction> million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzIxOTkwMjMyOTg4NjI_bdc6be5a-996e-43f4-962c-8d41e9b2176f">319.4</ix:nonFraction>&#160;million are realizable. Accordingly, we recorded a net valuation release of $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzM2NzI_6097cfe1-d07f-4ea5-9b64-da021ebe7bf0">296.3</ix:nonFraction> million on the basis of management&#8217;s assessment. The remaining valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzI1OTE_66bdbc91-9a91-4abd-a5a9-32c447b47c22">49.8</ix:nonFraction> million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7e323c9bdb384aa2abbd5236f397fb50"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had federal and state income tax net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="iaad045d0ff0b4b949b001aa2efd85687_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEzOTY_1f18f9f6-d7a9-45d5-ad05-749b97aee453">518.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i478244770d8e4c27a0658c7c1918fbe0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE0MDM_e42ccda2-5c9b-4d75-bbd7-79505294eb42">340.8</ix:nonFraction> million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have federal and California R&amp;D tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="iaad045d0ff0b4b949b001aa2efd85687_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE4MTg_2c895d0e-3ae6-49bf-a54a-5e725a3d2a36">92.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i478244770d8e4c27a0658c7c1918fbe0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE4MjU_380d73db-df0c-4b32-ac4a-2ce8147aaf71">56.4</ix:nonFraction> million, respectively. A portion of the federal R&amp;D tax credit carryforwards expired in 2020. The remaining federal R&amp;D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&amp;D tax credits carry forward indefinitely.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NjA_5c8ef811-dba2-4db1-bb0c-bc9d93fe840e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to unrecognized tax benefits follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItMS0xLTEtMA_32c0aa4b-14e0-4d43-b7e1-3556140cf181">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItMy0xLTEtMA_0d4a41f8-cc54-4449-8eff-e4108cf35026">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItNS0xLTEtMA_075ff4fc-6131-4329-9174-f7f2e3ccdae6">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtMS0xLTEtMA_e3f85e58-b17d-4ed8-b4b3-0c128ed9dea4">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtMy0xLTEtMA_3538bc30-b742-4eaf-add2-6507afaec7f5">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtNS0xLTEtMA_13f9575c-8948-432c-8080-7309ddc948db">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtMS0xLTEtMA_0b52feeb-2a06-45ca-a43c-d8b1ecc26eea">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtMy0xLTEtMA_78b0cca9-b48b-4124-9872-bb6846796838">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtNS0xLTEtMA_c6cee376-14de-40d1-b0d8-1fc78f752ab5">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMS0xLTEtMTAxMTQ_29bee1f6-04de-40ae-904f-69cbd417c3bb">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMy0xLTEtMTAxMTc_d7909242-a794-4e01-8345-be0514155d11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtNS0xLTEtMTAxMjA_315cd701-8e06-4c58-ac65-8e073d29c6c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMS0xLTEtMA_5ff759e3-e5a1-4612-900c-81a956bf2f80">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMy0xLTEtMA_da7ebe13-3456-4bd5-83ee-33b946460955">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtNS0xLTEtMA_306b95a0-235b-4b73-8310-d934113a7c0c">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtMS0xLTEtMA_307edb2f-3aea-4df5-987b-700141e334aa">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtMy0xLTEtMA_7f619099-4b7c-4c68-85df-84fb27f9fd8e">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtNS0xLTEtMA_21badfbf-d0c3-413a-9f91-e420411491cf">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM0Mzg_f7060e0b-3f36-4965-937a-f61f1e500d47">3.9</ix:nonFraction> million for current year tax positions, as reflected in the table above.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM1MjA_d8b4ec76-2b41-40c5-a53a-0dbe0fb7b7f7">53.9</ix:nonFraction> million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.</span></div></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_181"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzQxMjM_9eedfbdb-43b0-49e0-89b1-80438175c884" continuedAt="i9f3fbe32842145fba60ce0832ea1fea9" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i9f3fbe32842145fba60ce0832ea1fea9" continuedAt="i39423c71b54d4bd69fe97ed71b0d9c77"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have <ix:nonFraction unitRef="renewaloption" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="nbix:NumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzIxOTkwMjMyNjYxODc_2e5c676f-39da-42a4-b632-3cc70ca5a6ad">two</ix:nonFraction> options to extend the term of the operating lease for our corporate headquarters for a period of <ix:nonNumeric contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzIxOTkwMjMyNjYxODg_f810eace-1c32-4491-ade4-cf0115e286d4">ten years</ix:nonNumeric> each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $<ix:nonFraction unitRef="usd" contextRef="i6da45b8c6e074d14bdc079a1f2265f01_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzE2NDkyNjc0NTIxMDc_dd981b41-6ebe-46cc-9950-2b9010d61e27">3.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MDM_2304650b-a270-4156-9c1a-2b8cd7a9c84b">10.1</ix:nonFraction> million for 2020 and $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MTA_d8399174-7b3a-4965-88d7-13f99019c1a4">8.1</ix:nonFraction> million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MTY_3724a067-37d4-4c3c-9762-ccf09e9a2abf">8.6</ix:nonFraction> million for 2020 and $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MjI_97cf0822-837e-42dc-8d03-426307e80c72">7.7</ix:nonFraction> million for 2019.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i39423c71b54d4bd69fe97ed71b0d9c77"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases had a weighted-average remaining lease term of approximately <ix:nonNumeric contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1Mjc_676bff7d-b46b-4a39-b927-d0f3b501bd4d">10.3</ix:nonNumeric> years and <ix:nonNumeric contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MzI_a82a6373-c26c-4573-b859-147f916750fb">11.2</ix:nonNumeric> years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1NDQ_fe5fcc31-7b17-437b-843f-5304d59b4483">5.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1Mzg_7edae265-9f80-472c-8870-1638e81efe34">5.8</ix:nonFraction>% at December 31, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzQxMjQ_1f2258cb-f129-47f8-a80c-28871141e76c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzItMS0xLTEtMA_8ceb558f-f3e2-4d82-9443-d75d7eb49d20">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzMtMS0xLTEtMA_a265c4d8-206f-4746-aacf-3f8f6e4ef6f0">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzQtMS0xLTEtMA_eeb785d2-485c-4803-9464-a546c924e8b7">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzUtMS0xLTEtMA_085e673a-14eb-4ab1-9bd3-5e6f9fa970fb">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzYtMS0xLTEtMA_675d0883-ed3d-4752-961d-2ec9e3a9299f">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzctMS0xLTEtMA_3191a454-f853-4755-8cde-245fc4c0d8b7">77.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzgtMS0xLTEtMA_489b261e-8c65-42eb-8f06-c668b1bd5f08">139.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzktMS0xLTEtMA_279b3faf-3a6a-4ba1-8350-67ef596a57af">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzEwLTEtMS0xLTA_496c9d06-d570-412b-a9a4-6360f1dcf68d">104.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">Less current operating lease liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTEtMS0xLTA_8b988c23-7f8b-410a-889b-d755943cf69b">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzEyLTEtMS0xLTA_897576b5-51d2-4181-8a68-edfee6a484ec">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzgxMzU_a78448d1-3cba-46da-80e2-2b99f8256deb">19.7</ix:nonFraction> million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div id="i0d67836123014e4c9534b0a3600493e4_187"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzM0OQ_e6d56cfb-de21-48e6-9208-010487a86bd5" continuedAt="i4f1db8a1d42448e4abbb35200006248f" escape="true">Retirement Plan</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f1db8a1d42448e4abbb35200006248f">We have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to <ix:nonFraction unitRef="number" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzIyMA_5fce0afb-f117-433c-bbe6-67dca97f764f">60</ix:nonFraction>% of base salary limited by the IRS-imposed maximum. Employer contributions were $<ix:nonFraction unitRef="usd" contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMwMg_9589f26a-ff4f-4563-ae72-40a8caac5763">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMwNg_3e30597c-ede2-41a5-9956-a4b450d5602d">4.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMxNA_450c4cd4-40ab-40c0-a736-04c225fdfa9a">1.8</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div id="i0d67836123014e4c9534b0a3600493e4_1963"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTM4_1a192c06-571a-4d6e-98d3-eba2007ad6b9" continuedAt="i4423b61673c94bba84ae7dbb30677b46" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="i4423b61673c94bba84ae7dbb30677b46"><ix:nonNumeric contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTM5_8ad4709c-97e2-4443-98ac-8581a55bd0c1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our quarterly results follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTEtMS0xLTQyMDM_67e33c26-a279-45ce-a6ea-06ffeaf45efe">237.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTMtMS0xLTQyMDM_adde9ec3-d9be-499c-8f36-b54ab87d63c6">302.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTUtMS0xLTQyMDM_01266ca7-2082-4009-9860-591e5531b53e">258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTctMS0xLTQyMDM_9cf6d050-3544-48d6-b00b-911d3b853208">247.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTEtMS0xLTQyMDM_0dd65d69-007f-45fa-bb2f-ea53fa980fd0">178.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTMtMS0xLTQyMDM_d6afe626-a859-43e4-b840-32eb25f3cb90">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTUtMS0xLTQyMDM_99d7565e-49a7-4c52-8d90-02f1ea079227">302.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTctMS0xLTQyMDM_7724d3b1-a5da-4b2b-8d29-ca0bb2447421">176.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTEtMS0xLTQyMDM_674e2e86-f3fb-47fb-ac9d-3d0b5177c5f1">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTMtMS0xLTQyMDM_cb1f2be2-6a1c-45f0-99cb-ce0597a0690e">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTUtMS0xLTQyMDM_8370d6fd-9613-4a07-825e-261feae56448">57.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTctMS0xLTQyMDM_71c6e80a-2f5c-44ac-90eb-f2c578bcbd1e">347.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTEtMS0xLTQyMDM_920e27c8-32e1-49ba-8de4-05834515ce0e">0.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTMtMS0xLTQyMDM_b57f1a8f-3b18-4297-8e1e-a1207f95a3f0">0.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTUtMS0xLTQyMDM_0ec9963c-2a23-478c-b782-c6dc277775b5">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTctMS0xLTQyMDM_fa3da188-02a9-4e68-81f5-c06e3560e0ed">3.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTEtMS0xLTQyMDM_7cbeac96-21e3-40ea-9ed5-518cb4d0119d">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTMtMS0xLTQyMDM_6c4aa32d-f93c-4c8f-a2f6-ec00389f52da">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTUtMS0xLTQyMDM_55a52e20-0865-423f-91ad-17f403620e6a">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTctMS0xLTQyMDM_69ce4aa0-9c15-4a17-80e3-6d87d63d2a98">3.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTEtMS0xLTQyMDM_43258673-e8b2-4e8f-b3af-d8d77af3778f">92.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTMtMS0xLTQyMDM_1975686a-0ddf-4a66-88fb-6d3e5caafca8">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTUtMS0xLTQyMDM_69c788b6-899c-49a3-98ca-98209853f898">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTctMS0xLTQyMDM_313e21a7-d872-4138-9090-b7efccb3b5ff">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTEtMS0xLTQyMDM_84944d59-698d-4769-a7f1-b5596bb560fc">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTMtMS0xLTQyMDM_51ad58d5-5449-4d91-8cef-9a3fdb15d7ea">98.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTUtMS0xLTQyMDM_6b801b12-aa4e-4e37-9172-f5abe2bd28f7">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTctMS0xLTQyMDM_1010995d-d255-467d-836c-e022869a2415">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS0xLTEtMS00MjAz_f5117385-eaa7-480c-a368-a8f187021a0d">138.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS0zLTEtMS00MjAz_6dd0e748-e3b4-4832-903d-85075ad1756e">183.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS01LTEtMS00MjAz_dbccd33f-bad0-4de6-a539-4314ca998a9e">222.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS03LTEtMS00MjAz_17eb7da0-918a-479e-9086-557918ec5cfc">244.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi0xLTEtMS00MjAz_0fd940e1-f9c1-4220-91ea-929437413798">239.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi0zLTEtMS00MjAz_3786aa55-2069-4df7-ae2f-213ed5a41f50">149.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi01LTEtMS00MjAz_8797f181-3280-467f-9a10-abc27c0b076d">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi03LTEtMS00MjAz_dff28f64-f908-48ed-a7be-e85c41f3ed02">195.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy0xLTEtMS00MjAz_b0cf41d0-ed9d-4903-8b7f-ad707dba5009">102.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy0zLTEtMS00MjAz_2b54ab86-6561-4eb8-809b-2659d2373d2e">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy01LTEtMS00MjAz_def31df6-9337-4ea1-b94c-f71fffe96e22">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy03LTEtMS00MjAz_66c5bc66-4380-4c7e-9d62-7c51a034aa33">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC0xLTEtMS00MjAz_58e68ddc-138a-4114-ac10-22811c653668">1.12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC0zLTEtMS00MjAz_ec1fbc57-9733-4cf0-a415-f744f7ff0173">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC01LTEtMS00MjAz_35302713-4e6a-4571-b8c0-e72d7ac74a41">0.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC03LTEtMS00MjAz_aec11b7b-9f1f-41e9-b37c-acb774e8cd05">0.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS0xLTEtMS00MjAz_b09d4fea-b22d-4b9f-b802-0da58d9699a4">1.12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS0zLTEtMS00MjAz_6f197d71-7f7c-4228-bcd8-db81b11a1a41">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS01LTEtMS00MjAz_901dd5e9-fdc2-46bf-b424-46226c941ee8">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS03LTEtMS00MjAz_a294bc3d-1f57-4855-996f-57238cdde560">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi0xLTEtMS00MjAz_2cef4720-a313-4b53-9e96-140e15e8f3ff">91.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi0zLTEtMS00MjAz_3683d772-7dde-4193-9da9-f4e42468422d">91.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi01LTEtMS00MjAz_bc6bb5cc-f808-44a2-901b-ed8e55c93530">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi03LTEtMS00MjAz_150ecb71-73d8-44ee-8956-4e0319e1ce4e">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy0xLTEtMS00MjAz_bb4e3ee8-76c8-499e-afad-e38c9faa5355">91.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy0zLTEtMS00MjAz_e82425f5-a09b-4dd1-b2d0-7e1c2de2c2d3">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy01LTEtMS00MjAz_7dc78c40-433f-46e6-889e-77bb14162e66">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy03LTEtMS00MjAz_2db9e2e3-43eb-4493-851e-958698f2414a">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="ib123ada82f724fe49861cecabdde52c1_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTQx_2fc7e9a5-7869-4db2-aee8-e030bcccb7a0">46.0</ix:nonFraction>&#160;million, accounted for as IPR&amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i8d2db4ddee19489eaad07271d5031b33_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTU2_21bc42b2-dce4-4a5e-ac20-c79dbc7254d6">118.5</ix:nonFraction>&#160;million, accounted for as IPR&amp;D, in the third quarter of 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTcy_9d75f6ce-aed2-4cb8-8bcb-299857827122">113.1</ix:nonFraction>&#160;million, accounted for as IPR&amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTg4_3a674afe-246d-45b1-a3af-60becf8fba3c">5.0</ix:nonFraction>&#160;million upfront, accounted for as IPR&amp;D, to obtain outside the U.S. rights to the Friedreich&#8217;s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MjM4_27dc7071-4069-4bea-ab06-aa51e3b5a1bd">36.2</ix:nonFraction>&#160;million, accounted for as IPR&amp;D, in the fourth quarter of 2019.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Changes and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_199"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule&#160;13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_202"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">&#160;&#160;&#160;&#160;Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorization of our management and directors;&#160;and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:33.34pt">&#160;&#160;&#160;&#160;Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has used the framework set forth in the report entitled Internal Control-Integrated Framework (2013&#160;framework)&#160;published by the Committee of Sponsoring Organizations of the Treadway Commission (2013&#160;framework), known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2020. Ernst&#160;&amp; Young, LLP, our independent registered public accounting firm, has issued an attestation report on our internal control over financial reporting as of December&#160;31, 2020, which is included herein.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_205"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Neurocrine Biosciences, Inc.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Neurocrine Biosciences, Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Neurocrine Biosciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of income and comprehensive income, stockholders&#8216; equity, and cash flows, for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February&#160;5, 2021 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:32.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;5, 2021</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_208"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i0d67836123014e4c9534b0a3600493e4_214"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the Securities and Exchange Commission within 120&#160;days of December&#160;31, 2020. Such information is incorporated herein by reference.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to our Chief Executive Officer, Chief Financial Officer, and to all of our other officers, directors, employees and agents. The code of ethics is available at the Corporate Governance section of the Investors page on our website at www.neurocrine.com. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within four business days following the date of such amendment or waiver. Information found on, or accessible through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_217"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;11. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the Securities and Exchange Commission within 120&#160;days of December&#160;31, 2020. Such information is incorporated herein by reference.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_220"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the Securities and Exchange Commission within 120&#160;days of December&#160;31, 2020. Such information is incorporated herein by reference.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_223"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the Securities and Exchange Commission within 120&#160;days of December&#160;31, 2020. Such information is incorporated herein by reference.</span></div><div id="i0d67836123014e4c9534b0a3600493e4_226"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;14. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Principal Accounting Fees and Services</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our Definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, to be filed pursuant to Regulation&#160;14A with the Securities and Exchange Commission within 120&#160;days of December&#160;31, 2020. Such information is incorporated herein by reference.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_229"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i0d67836123014e4c9534b0a3600493e4_232"></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 15. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exhibits, Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;Documents filed as part of this report.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. List of Financial Statements. The following are included in Item&#160;8 of this report:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income and Comprehensive Income for the years ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements (includes unaudited Selected Quarterly Financial Data)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. List of all Financial Statement schedules. All schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. List of Exhibits required by Item&#160;601 of Regulation&#160;S-K. See part (b)&#160;below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Exhibits. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex32_89.htm">Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003267/nbix-ex31_19.htm">First Amendment of Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on February 4, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000025/nbix-20200828exhibit31.htm">Second Amendment of Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on August 28, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003773/nbix-ex44_74.htm">Description of Common Stock of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.4 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20201231exhibit211.htm">Subsidiaries of the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20201231exhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20201231exhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20201231exhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20201231exhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Collaboration and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312510170734/dex102.htm">Collaboration Agreement dated June 15, 2010, by and between Abbott International Luxembourg S.a.r.l. and the Company as amended on August&#160;31, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2010</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312511288728/d235273dex102.htm">First Amendment to Collaboration and License Agreement Dated August 31, 2011 between the Company and Abbott International Luxemburg S.a.r.l.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on October 31, 2011</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515161293/d899476dex101.htm">Collaboration and License Agreement dated March&#160;31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on April 30, 2015</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517136695/d376977dex994.htm">License Agreement dated February&#160;9, 2017 between BIAL&#8211; Portela&#160;&amp; CA, S.A. and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.4 of the Company&#8217;s Current Report on Form 8-K filed on April 25, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex105_822.htm">Collaboration and License Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.5 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex106_401.htm">Stock Purchase Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019002328/nbix-ex107_400.htm">Investor Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex101_71.htm">Amendment No. 1 to Collaboration and License Agreement dated June 14, 2019 between Voyager Therapeutics, Inc. and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000018/nbix-20200630exhibit103.htm">Exclusive License Agreement dated June 12, 2020 between Takeda Pharmaceutical Company Limited and the Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Equity Plans and Related Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517181670/d363882dex991.htm">Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515209053/d934906dex991.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on June 1, 2015</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1017.htm">Neurocrine Biosciences, Inc. Inducement Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.17 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312515268390/d938011dex101.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for use under the Neurocrine Biosciences, Inc. Inducement Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2015</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518178679/d592659dex992.htm">Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan dated May 30, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on May 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000018/nbix-20200630exhibit101.htm">Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000018/nbix-20200630exhibit102.htm">Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements with Officers and Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000093639207000628/a32155exv10w3.htm">Amended and Restated Employment Agreement effective August&#160;1, 2007 between the Company and Kevin C. Gorman,&#160;Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2007</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312511030707/dex1032.htm">Form of Amendment to Employment Agreement for executive officers, effective as of December 15, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.32 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2008</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003773/nbix-ex1016_75.htm">Employment Agreement dated November 3, 2014 between the Company and Kyle Gano</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.16 of the Company&#8217;s Annual Report on Form 10-K filed on February 6, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517043838/d324435dex103.htm">Employment Agreement dated May 26, 2015 between the Company and Eric Benevich</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 14, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312518042794/d520757dex1026.htm">Employment Agreement effective November&#160;29, 2017 between the Company and Matthew C. Abernethy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.26 of the Company&#8217;s Annual Report on Form 10-K filed on February 13, 2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex101.htm">Form of Indemnity Agreement entered into between the Company and its officers and directors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019026602/nbix-ex102_72.htm">Employment Agreement dated January 8, 2018 between the Company and Eiry W. Roberts, M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on July 29, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Agreements Related to Real Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312512015472/d284170dex992.htm">Amended and Restated Lease dated November 1, 2011 between the Company and Kilroy Realty, L.P.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on January 18, 2012</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517247437/d253292dex101.htm">First Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated June&#160;5, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517329460/d466738dex103.htm">Second Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P., dated October&#160;12, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 1, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000093639207000926/a36358exv10w3.htm">Letter of Credit dated December 3, 2007, issued by Wells Fargo Bank, N.A. for the benefit of Kilroy Realty, L.P., as amended on November&#160;20, 2014 and June 19, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed on December 10, 2007; Exhibit 10.5 of the Company&#8217;s Annual Report on Form 10-K filed on February 9, 2015; and Exhibit 10.2 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 3, 2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459019039803/nbix-ex101_32.htm">Third Amendment to Amended and Restated Lease between the Company and Kilroy Realty, L.P. dated August 7, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain portions of the exhibit.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of the exhibit have been omitted because the omitted information is not material and would likely cause competitive harm if publicly disclosed.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this annual report pursuant to 18&#160;U.S.C. Section&#160;1350 and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;Financial Statement Schedules. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;15(a)(2) above.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_235"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 5, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 5, 2021</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i0d67836123014e4c9534b0a3600493e4_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power of authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities indicated as of February&#160;5, 2021:</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kevin C. Gorman, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">/ Matthew C. Abernethy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">William H. Rastetter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William H. Rastetter, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gary A. Lyons</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gary A. Lyons</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">George J. Morrow</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">George J. Morrow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Leslie V. Norwalk</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leslie V. Norwalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Richard F. Pops</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard F. Pops</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Stephen A. Sherwin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stephen A. Sherwin, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Shalini Sharp</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shalini Sharp</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>nbix-20201231exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ife234c468dea40c2a124852d52332e7d_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:57.692%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Continental, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, USA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Europe, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurocrine Therapeutics, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>nbix-20201231exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id259dc80a84e4fe1a0b8bf7df4bc7276_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Registration Statements (Form S-8 Nos. 333-175889, 333-190178, 333-197916, and 333-212871) pertaining to the 2011 Equity Incentive Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Registration Statements (Form S-8 Nos. 333-199837, and 333-216067) pertaining to the Inducement Plan of Neurocrine Biosciences, Inc.,  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Registration Statements (Form S-8 Nos. 333-205933 and 333-223020) pertaining to the 2011 Equity Incentive Plan and Inducement Plan of Neurocrine Biosciences, Inc.,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statements (Form S-8 No. 333-226971) pertaining to the 2011 Equity Incentive Plan and 2018 Employee Stock Purchase Plan of Neurocrine Biosciences, Inc., and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statements (Form S-8 No. 333-234501) pertaining to the 2011 Equity Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statements (Form S-8 No. 333-240301) pertaining to the 2020 Equity Incentive Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;5, 2021 with respect to the consolidated financial statements of Neurocrine Biosciences, Inc., and the effectiveness of internal control over financial reporting of Neurocrine Biosciences, Inc., included in this Annual Report (Form 10-K) of Neurocrine Biosciences, Inc. for the year ended December 31, 2020.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:32.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Ernst &#38; Young LLP</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;5, 2021</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nbix-20201231exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i600113f46ec14505a067699617d92acc_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this annual report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;5, 2021</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nbix-20201231exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2fb7abc600c645318c721aa8e74b00d8_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;5, 2021</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:147.75pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>nbix-20201231exhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic2ac609cba1c41969feaea9da550b42c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;5, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Kevin C. Gorman</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;5, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Matthew C. Abernethy</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nbix-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsIncomeandComprehensiveIncome" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome">
        <link:definition>1003004 - Statement - Consolidated Statements Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreements">
        <link:definition>2104102 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>2106103 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails">
        <link:definition>2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails">
        <link:definition>2410405 - Disclosure - Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>2111104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>2312302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>2116105 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2317303 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails">
        <link:definition>2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails">
        <link:definition>2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails">
        <link:definition>2120106 - Disclosure - Other Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsTables" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables">
        <link:definition>2321304 - Disclosure - Other Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsInventoriesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails">
        <link:definition>2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsPropertyandEquipmentDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails">
        <link:definition>2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.neurocrine.com/role/NetIncomePerShare">
        <link:definition>2126107 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.neurocrine.com/role/NetIncomePerShareTables">
        <link:definition>2327305 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails">
        <link:definition>2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails">
        <link:definition>2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.neurocrine.com/role/ShareBasedCompensation">
        <link:definition>2130108 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables">
        <link:definition>2331306 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>2432417 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails">
        <link:definition>2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails">
        <link:definition>2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails">
        <link:definition>2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails">
        <link:definition>2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails">
        <link:definition>2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.neurocrine.com/role/IncomeTaxes">
        <link:definition>2139109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.neurocrine.com/role/IncomeTaxesTables">
        <link:definition>2340307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails">
        <link:definition>2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails">
        <link:definition>2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails">
        <link:definition>2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2444427 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>2146110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTable" roleURI="http://www.neurocrine.com/role/LeasesTable">
        <link:definition>2347308 - Disclosure - Leases (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2448429 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails">
        <link:definition>2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.neurocrine.com/role/RetirementPlan">
        <link:definition>2150111 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails">
        <link:definition>2451431 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofQuarterlyResultsofOperationsDetails" roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails">
        <link:definition>2454432 - Disclosure - Summary of Quarterly Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails">
        <link:definition>2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LargestThreeCustomersMember" abstract="true" name="LargestThreeCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_RevenueRelatedReservesForDiscountsAndAllowances" abstract="false" name="RevenueRelatedReservesForDiscountsAndAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PotentialCommercialMilestonePayments" abstract="false" name="PotentialCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_UpfrontPaymentsReceived" abstract="false" name="UpfrontPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtConversionObservationPeriod" abstract="false" name="DebtConversionObservationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_NBI827104Member" abstract="true" name="NBI827104Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A225ConvertibleSeniorNotesMember" abstract="true" name="A225ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" abstract="false" name="EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_LargestTwoCustomersMember" abstract="true" name="LargestTwoCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_PerformanceBasedRestrictedStockUnitMember" abstract="true" name="PerformanceBasedRestrictedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CostOfSales" abstract="false" name="CostOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_TotalEquitySecuritiesMember" abstract="true" name="TotalEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentAtSettlement" abstract="false" name="CarryingAmountOfLiabilityComponentAtSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_TwoThousandAndElevenPlanMember" abstract="true" name="TwoThousandAndElevenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsOperatingLeasesAssets" abstract="false" name="DeferredTaxAssetsOperatingLeasesAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_BusinessDescriptionPolicyPolicyTextBlock" abstract="false" name="BusinessDescriptionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbix_NumberOfRenewalOptions" abstract="false" name="NumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationExpirationOfTaxCredits" abstract="false" name="IncomeTaxReconciliationExpirationOfTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" abstract="true" name="SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" abstract="false" name="DeferredTaxLiabilitiesConvertibleSeniorNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" abstract="false" name="DeferredTaxLiabilitiesOperatingLeasesLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_BIALMember" abstract="true" name="BIALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_TradingDaysDuringObservationPeriod" abstract="false" name="TradingDaysDuringObservationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" abstract="false" name="FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbvieIncMember" abstract="true" name="AbbvieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentUponIssuance" abstract="false" name="CarryingAmountOfLiabilityComponentUponIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" abstract="false" name="ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A2020EquityIncentivePlanMember" abstract="true" name="A2020EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" abstract="true" name="StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NumberOfIrishSubsidiaries" abstract="false" name="NumberOfIrishSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_AccruedBrandedPrescriptionDrugFee" abstract="false" name="AccruedBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DevelopmentProductCandidatesMember" abstract="true" name="DevelopmentProductCandidatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbix_ResearchCollaborationTerm" abstract="false" name="ResearchCollaborationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_ScientificEquipmentMember" abstract="true" name="ScientificEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nbix-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3257cc5d-d703-4422-8bd4-dd46fb0a6f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:to="loc_us-gaap_PreferredStockValue_3257cc5d-d703-4422-8bd4-dd46fb0a6f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a72b7115-6417-4f87-882a-a31992ec2381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:to="loc_us-gaap_CommonStockValue_a72b7115-6417-4f87-882a-a31992ec2381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_37a38276-0a90-44b9-8802-d3187d063ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_37a38276-0a90-44b9-8802-d3187d063ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8d68178-4430-48fa-81f6-0a144a06364a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c8d68178-4430-48fa-81f6-0a144a06364a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dd52af-d59b-4ca1-8ce7-374bb2d17250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ce82e97c-71b6-4aac-9a1b-2c76d0e49252" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45dd52af-d59b-4ca1-8ce7-374bb2d17250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3729ca4b-7658-4ec8-a6ab-d8f4a54f0b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_Liabilities_3729ca4b-7658-4ec8-a6ab-d8f4a54f0b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f191b1fa-20fd-4e0f-815b-c0ed801b9f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_PreferredStockValue_f191b1fa-20fd-4e0f-815b-c0ed801b9f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_15d1694f-94e3-4962-953f-8c5fbc33bab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_CommonStockValue_15d1694f-94e3-4962-953f-8c5fbc33bab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fab4b536-174e-4f4d-8def-967da8057d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fab4b536-174e-4f4d-8def-967da8057d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd7285b0-7a3b-454a-bf30-cc7744f6e0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd7285b0-7a3b-454a-bf30-cc7744f6e0e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b19eac3-a997-484f-9383-147ab02df256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6250bf15-f142-4bb9-92a3-0a807a118f47" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b19eac3-a997-484f-9383-147ab02df256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3da70534-7bed-44c9-b5f9-80ce068287f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4ac7c7b-7316-4169-84d1-d24c576b3790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3da70534-7bed-44c9-b5f9-80ce068287f3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4ac7c7b-7316-4169-84d1-d24c576b3790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_9d42f8a1-3802-4722-b27e-46378ddf3cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3da70534-7bed-44c9-b5f9-80ce068287f3" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_9d42f8a1-3802-4722-b27e-46378ddf3cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_05abb952-1140-411a-a3d7-ed18fc07e27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3da70534-7bed-44c9-b5f9-80ce068287f3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_05abb952-1140-411a-a3d7-ed18fc07e27b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bda754b4-bc95-41b5-9d47-3fad80d47464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_AssetsCurrent_bda754b4-bc95-41b5-9d47-3fad80d47464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7e013508-618e-429c-9865-1d6bda0663d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7e013508-618e-429c-9865-1d6bda0663d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95775d77-0bb0-44ee-bf43-33976ed6557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95775d77-0bb0-44ee-bf43-33976ed6557e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_2d639771-326b-43bd-860d-daa2d18f6853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_2d639771-326b-43bd-860d-daa2d18f6853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8103d603-de09-4aa5-8cee-d96b1a3e1723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8103d603-de09-4aa5-8cee-d96b1a3e1723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f45da97f-e7e9-4cdd-8b1e-dd175cea1c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f45da97f-e7e9-4cdd-8b1e-dd175cea1c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64335b8e-fa5e-4916-bc09-9544191c43c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64335b8e-fa5e-4916-bc09-9544191c43c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36fe0f18-c2e1-435f-89ce-f1ae81dbf72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_803e3221-c6bf-4411-8cc6-ed5162a49cdc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_36fe0f18-c2e1-435f-89ce-f1ae81dbf72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cd6af2fe-c4af-4e5f-8b4c-c93acaea4b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1d8bc908-715b-4856-a9bf-6431085e4466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cd6af2fe-c4af-4e5f-8b4c-c93acaea4b7f" xlink:to="loc_us-gaap_LiabilitiesCurrent_1d8bc908-715b-4856-a9bf-6431085e4466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_574ef962-b5b3-47aa-abfd-9e9b6c761b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cd6af2fe-c4af-4e5f-8b4c-c93acaea4b7f" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_574ef962-b5b3-47aa-abfd-9e9b6c761b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07bc28c1-cdbd-4585-9de3-6255338f7940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cd6af2fe-c4af-4e5f-8b4c-c93acaea4b7f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07bc28c1-cdbd-4585-9de3-6255338f7940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_152f3e04-0823-4f8a-8c33-407ab01ff977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cd6af2fe-c4af-4e5f-8b4c-c93acaea4b7f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_152f3e04-0823-4f8a-8c33-407ab01ff977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66f6ff55-8b90-427a-9496-b1dd41313377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66f6ff55-8b90-427a-9496-b1dd41313377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_32f45f91-59c6-4e55-9852-dec20a1197a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_32f45f91-59c6-4e55-9852-dec20a1197a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4477e337-6bff-4648-bd32-95f9bfb6ecc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4477e337-6bff-4648-bd32-95f9bfb6ecc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_70e27422-1afa-432b-ac4d-67b82e4d7638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:to="loc_us-gaap_InventoryNet_70e27422-1afa-432b-ac4d-67b82e4d7638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4fe713c1-6b7e-45bf-8525-c6ed49131cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_779f73e6-56db-4fea-8477-0c6f2ae62357" xlink:to="loc_us-gaap_OtherAssetsCurrent_4fe713c1-6b7e-45bf-8525-c6ed49131cec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_20863105-1f1d-4ff3-aaa5-3ae2343b235e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CostOfSales_979b41d7-3b6b-45f4-b570-e881b63f1936" xlink:href="nbix-20201231.xsd#nbix_CostOfSales"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_20863105-1f1d-4ff3-aaa5-3ae2343b235e" xlink:to="loc_nbix_CostOfSales_979b41d7-3b6b-45f4-b570-e881b63f1936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_aa34a9fb-4bde-4b59-8ffc-55c388d40d6b" xlink:href="nbix-20201231.xsd#nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_20863105-1f1d-4ff3-aaa5-3ae2343b235e" xlink:to="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_aa34a9fb-4bde-4b59-8ffc-55c388d40d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_704e3e98-32c2-483c-b7d5-0af99232ee02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_20863105-1f1d-4ff3-aaa5-3ae2343b235e" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_704e3e98-32c2-483c-b7d5-0af99232ee02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_da7d3d45-d112-4afe-91f4-39e6a3c41775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_20863105-1f1d-4ff3-aaa5-3ae2343b235e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_da7d3d45-d112-4afe-91f4-39e6a3c41775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7477196-a43a-4e7b-82f8-797a28043fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_181e670b-cae8-4e62-a5cc-c87b64efee3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7477196-a43a-4e7b-82f8-797a28043fcd" xlink:to="loc_us-gaap_NetIncomeLoss_181e670b-cae8-4e62-a5cc-c87b64efee3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_011cc459-e3dc-41c7-b43d-c533a9885bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f7477196-a43a-4e7b-82f8-797a28043fcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_011cc459-e3dc-41c7-b43d-c533a9885bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ed15d63-237b-4d56-be3e-304bfe0e5016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c86adc16-e225-4835-8871-3c2e9bf73f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9ed15d63-237b-4d56-be3e-304bfe0e5016" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c86adc16-e225-4835-8871-3c2e9bf73f1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_571383d3-3429-47b9-ad51-d92f8086a105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9ed15d63-237b-4d56-be3e-304bfe0e5016" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_571383d3-3429-47b9-ad51-d92f8086a105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b490e399-b0a2-4e37-a67b-aa02405ed467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a163802c-a580-4225-9509-7b05f7caec8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b490e399-b0a2-4e37-a67b-aa02405ed467" xlink:to="loc_us-gaap_InterestExpense_a163802c-a580-4225-9509-7b05f7caec8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_50fa5de9-3d30-4873-8763-a616d7f8e897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b490e399-b0a2-4e37-a67b-aa02405ed467" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_50fa5de9-3d30-4873-8763-a616d7f8e897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d452767b-9799-49e1-896e-2df98965cc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b490e399-b0a2-4e37-a67b-aa02405ed467" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d452767b-9799-49e1-896e-2df98965cc99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_b1045e4b-5d2b-47be-8d75-99da314e98df" xlink:href="nbix-20201231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b490e399-b0a2-4e37-a67b-aa02405ed467" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_b1045e4b-5d2b-47be-8d75-99da314e98df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f07a5d6c-63cb-4558-9fcc-7ba5d4c37941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d62f983a-681c-4f2f-a776-c6ec86abf976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f07a5d6c-63cb-4558-9fcc-7ba5d4c37941" xlink:to="loc_us-gaap_OperatingIncomeLoss_d62f983a-681c-4f2f-a776-c6ec86abf976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_265e1200-1156-432d-9ba3-aaa574f7ced0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f07a5d6c-63cb-4558-9fcc-7ba5d4c37941" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_265e1200-1156-432d-9ba3-aaa574f7ced0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_25cf65ba-794c-40a8-b4a0-b6c2f412d1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c401f1f-9368-440f-b4fb-40b8edcfde93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25cf65ba-794c-40a8-b4a0-b6c2f412d1eb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c401f1f-9368-440f-b4fb-40b8edcfde93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41c091a2-fa1a-44d4-a693-30a4a51fe86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_25cf65ba-794c-40a8-b4a0-b6c2f412d1eb" xlink:to="loc_us-gaap_OperatingExpenses_41c091a2-fa1a-44d4-a693-30a4a51fe86f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f47909ed-8a0f-470c-9a27-b7e2dada380f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_NetIncomeLoss_f47909ed-8a0f-470c-9a27-b7e2dada380f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e3fd2bd8-358a-4130-aa2d-f5bc74702e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_ShareBasedCompensation_e3fd2bd8-358a-4130-aa2d-f5bc74702e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_43d119e3-34cc-4f90-9236-fb0dbe63eb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_Depreciation_43d119e3-34cc-4f90-9236-fb0dbe63eb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_170f5260-60c3-42b4-b242-c2583d321c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_170f5260-60c3-42b4-b242-c2583d321c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a012fbea-18e5-47db-bfae-42b48affe979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a012fbea-18e5-47db-bfae-42b48affe979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e59e49c0-6383-4043-829e-aef51d6bb2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e59e49c0-6383-4043-829e-aef51d6bb2ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ed13f40f-5bc0-469a-98f3-6ada653be881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ed13f40f-5bc0-469a-98f3-6ada653be881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5058b953-6dd4-4788-8115-bef6d5cc3ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5058b953-6dd4-4788-8115-bef6d5cc3ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_203b7258-2115-4a10-a4d3-f654dcc235fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_203b7258-2115-4a10-a4d3-f654dcc235fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_325075b2-aa61-4f76-a404-d8efba966aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_325075b2-aa61-4f76-a404-d8efba966aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fc539c05-4ca4-4cea-8ca5-25a520d32b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fc539c05-4ca4-4cea-8ca5-25a520d32b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d572c4f0-af14-4d0a-8829-c63eb0fb7419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d572c4f0-af14-4d0a-8829-c63eb0fb7419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_628a4c8d-6ca9-489b-963f-e2a3f3e80bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b804ec1e-fb00-4363-93a2-d37cb6c06a0a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_628a4c8d-6ca9-489b-963f-e2a3f3e80bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0c44c51a-4943-4477-8666-87fe4973e14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8e277339-3e47-4e62-8a21-25947051a1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0c44c51a-4943-4477-8666-87fe4973e14c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8e277339-3e47-4e62-8a21-25947051a1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_42f03385-bdbf-4aa2-8626-5bbeb3e2fd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0c44c51a-4943-4477-8666-87fe4973e14c" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_42f03385-bdbf-4aa2-8626-5bbeb3e2fd19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_543c9d22-91e4-476c-a11c-a3a95e6a6910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2cdc5d3a-756f-49d0-8681-bd9cb714054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_543c9d22-91e4-476c-a11c-a3a95e6a6910" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2cdc5d3a-756f-49d0-8681-bd9cb714054a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5abb8aba-a673-4b8e-b78b-49186a0808a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_543c9d22-91e4-476c-a11c-a3a95e6a6910" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5abb8aba-a673-4b8e-b78b-49186a0808a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6dc60ae6-c54b-4ad5-8fdf-a09cc679b9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_543c9d22-91e4-476c-a11c-a3a95e6a6910" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6dc60ae6-c54b-4ad5-8fdf-a09cc679b9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca47d93-4d59-425e-ad78-5f62fad0d8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_543c9d22-91e4-476c-a11c-a3a95e6a6910" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca47d93-4d59-425e-ad78-5f62fad0d8c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f0c078-8e81-4876-89a1-d1958272c18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bcc33bd-3178-4856-a4fd-bf502bceb011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f0c078-8e81-4876-89a1-d1958272c18e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bcc33bd-3178-4856-a4fd-bf502bceb011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ac31194-ac55-40f1-bff7-25ecb6a08023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f0c078-8e81-4876-89a1-d1958272c18e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ac31194-ac55-40f1-bff7-25ecb6a08023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7b89d19-7460-40c9-8e66-9881ca196908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45f0c078-8e81-4876-89a1-d1958272c18e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7b89d19-7460-40c9-8e66-9881ca196908" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecurities"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f55ca3ac-3221-49af-827f-eca1f779fe28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9ffd4cfd-2216-4772-aaf3-e986b00ff674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f55ca3ac-3221-49af-827f-eca1f779fe28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_9ffd4cfd-2216-4772-aaf3-e986b00ff674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fb5f1c06-6f3d-4c4f-9cbe-2abe2647c4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f55ca3ac-3221-49af-827f-eca1f779fe28" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fb5f1c06-6f3d-4c4f-9cbe-2abe2647c4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b77c2455-49dc-436a-bb7b-e330ba314c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5d5c2b54-8f5a-4d64-9300-e27818bf573c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b77c2455-49dc-436a-bb7b-e330ba314c72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5d5c2b54-8f5a-4d64-9300-e27818bf573c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d4b55190-d8ad-466a-9f0b-e7fd6943ebb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b77c2455-49dc-436a-bb7b-e330ba314c72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d4b55190-d8ad-466a-9f0b-e7fd6943ebb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_8c310a3c-5b39-47fb-9be4-36aaf835507f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ac2fd3df-faab-4022-9240-0af4b352b1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_8c310a3c-5b39-47fb-9be4-36aaf835507f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ac2fd3df-faab-4022-9240-0af4b352b1a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1ca0f488-ff47-4de7-8ccb-eae1ec9dd6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_8c310a3c-5b39-47fb-9be4-36aaf835507f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1ca0f488-ff47-4de7-8ccb-eae1ec9dd6b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f1b3e65f-4d47-4867-9234-7d9049afc1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_8c310a3c-5b39-47fb-9be4-36aaf835507f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f1b3e65f-4d47-4867-9234-7d9049afc1de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8810214a-1778-4152-a607-9060a5d8e010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_43a80e19-0828-40fe-b692-e7ecc50e1a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8810214a-1778-4152-a607-9060a5d8e010" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_43a80e19-0828-40fe-b692-e7ecc50e1a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f2743495-2d21-4926-a050-8b9ff1b22dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8810214a-1778-4152-a607-9060a5d8e010" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f2743495-2d21-4926-a050-8b9ff1b22dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_30ac2de1-b822-4803-adc4-fd761181bdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8810214a-1778-4152-a607-9060a5d8e010" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_30ac2de1-b822-4803-adc4-fd761181bdc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8818a78c-627b-4efe-aaa1-d08fa8d1cdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d668bd5f-4f1d-420c-9d32-fb45f7db596a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8818a78c-627b-4efe-aaa1-d08fa8d1cdfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d668bd5f-4f1d-420c-9d32-fb45f7db596a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7505a99c-29ae-40b5-8246-d19dc324562d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8818a78c-627b-4efe-aaa1-d08fa8d1cdfa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7505a99c-29ae-40b5-8246-d19dc324562d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_900631ec-47af-44e8-8e2e-3c93dd29be80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_900631ec-47af-44e8-8e2e-3c93dd29be80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_2f12a910-ceae-43a8-a429-55e4b2c5bafd" xlink:href="nbix-20201231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:to="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_2f12a910-ceae-43a8-a429-55e4b2c5bafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_1465b865-168e-4ca1-8f67-5ecfde82ac8c" xlink:href="nbix-20201231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_1465b865-168e-4ca1-8f67-5ecfde82ac8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_b873e439-eaa2-4058-a40c-52d4b80145c0" xlink:href="nbix-20201231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_b873e439-eaa2-4058-a40c-52d4b80145c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_85a603dc-5834-44d7-9204-25056d81351b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b5b80ad3-5fe2-463c-a553-ba5e57212e51" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_85a603dc-5834-44d7-9204-25056d81351b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9f1b76be-6a06-4fce-af41-8fd6c663ce0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_244267de-c2f0-4e71-9f6b-f93c8392fdd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_9f1b76be-6a06-4fce-af41-8fd6c663ce0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_244267de-c2f0-4e71-9f6b-f93c8392fdd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5e5d928d-a5e9-4817-8220-e2fa3ed4c82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_9f1b76be-6a06-4fce-af41-8fd6c663ce0c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5e5d928d-a5e9-4817-8220-e2fa3ed4c82f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShare"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18f27ed0-464d-4039-aae2-2ebd326e7117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e40cc8f5-19af-460d-aa6a-34ac1416bbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18f27ed0-464d-4039-aae2-2ebd326e7117" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e40cc8f5-19af-460d-aa6a-34ac1416bbf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_833a2642-03c3-45a4-8fd0-dfacd7485972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18f27ed0-464d-4039-aae2-2ebd326e7117" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_833a2642-03c3-45a4-8fd0-dfacd7485972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_86f4a5da-6e6a-41b2-a9ac-4b250b4c5347" xlink:href="nbix-20201231.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18f27ed0-464d-4039-aae2-2ebd326e7117" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_86f4a5da-6e6a-41b2-a9ac-4b250b4c5347" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5f6539bf-219a-47fd-8bc4-f86b81b157af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_989962dc-d0ba-4049-9182-96e331a2b2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5f6539bf-219a-47fd-8bc4-f86b81b157af" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_989962dc-d0ba-4049-9182-96e331a2b2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_659e9f6c-8439-40ac-840d-236ba648b960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5f6539bf-219a-47fd-8bc4-f86b81b157af" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_659e9f6c-8439-40ac-840d-236ba648b960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ce8ffa14-0592-4506-9459-7b4d30dd6458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_342f27d8-910c-4902-9aab-977d57a600cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ce8ffa14-0592-4506-9459-7b4d30dd6458" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_342f27d8-910c-4902-9aab-977d57a600cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_646b3591-72b5-49e4-8ab8-6c589b4ebc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ce8ffa14-0592-4506-9459-7b4d30dd6458" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_646b3591-72b5-49e4-8ab8-6c589b4ebc8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b79a2e76-a6a9-4924-96e0-41625d606a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_73708609-fb2d-4ae9-88ba-594cbd35ddf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b79a2e76-a6a9-4924-96e0-41625d606a16" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_73708609-fb2d-4ae9-88ba-594cbd35ddf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3967c424-5723-436b-a514-4088ad625a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b79a2e76-a6a9-4924-96e0-41625d606a16" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3967c424-5723-436b-a514-4088ad625a97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_da3ed1b6-e163-40b4-a1e8-60258e27d654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_da3ed1b6-e163-40b4-a1e8-60258e27d654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9cc8387f-94b7-4e94-8efa-032eaeafa70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9cc8387f-94b7-4e94-8efa-032eaeafa70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1a1f76d4-e536-4a38-8de3-3189dae05d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1a1f76d4-e536-4a38-8de3-3189dae05d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_eeb58c8e-d9db-4c40-9cc8-319727fae933" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_eeb58c8e-d9db-4c40-9cc8-319727fae933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_62511e38-6e2b-4714-8cae-4367470f4e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_62511e38-6e2b-4714-8cae-4367470f4e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_5b5e56e8-aabe-4dbc-ad9d-b8755bafc850" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_5b5e56e8-aabe-4dbc-ad9d-b8755bafc850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_7240e094-271d-4fb3-91be-b474f21ff38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_7240e094-271d-4fb3-91be-b474f21ff38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_3979f374-bc11-492a-a0b5-1add4eaf3bb2" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_3979f374-bc11-492a-a0b5-1add4eaf3bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_bf73f084-bbf5-4ddb-b261-ef7ae11a6081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_bf73f084-bbf5-4ddb-b261-ef7ae11a6081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_09000134-9bc8-483e-8337-3e947b3f4d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_09000134-9bc8-483e-8337-3e947b3f4d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ce297023-1e61-4518-bc90-89820f2e3b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98c54ec4-2fda-46d6-9736-6dad9af5a1c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ce297023-1e61-4518-bc90-89820f2e3b6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_51abd08f-2b77-4c6c-adeb-132afab5db65" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d015aa69-bd81-458e-85df-945a057b3688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_51abd08f-2b77-4c6c-adeb-132afab5db65" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d015aa69-bd81-458e-85df-945a057b3688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ecd60943-a1fc-4cbe-ab0f-2b23429a7061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross_51abd08f-2b77-4c6c-adeb-132afab5db65" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ecd60943-a1fc-4cbe-ab0f-2b23429a7061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_fac4c10c-d3d1-40f6-b7de-a9de6649479d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_fac4c10c-d3d1-40f6-b7de-a9de6649479d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_46c472d0-e6a3-4dcd-94df-a2bdbdd68a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_46c472d0-e6a3-4dcd-94df-a2bdbdd68a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7242faf7-3d90-4b26-93da-fc02ef8e2637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7242faf7-3d90-4b26-93da-fc02ef8e2637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_57aaa319-d4bb-4fe1-9466-4d2885c1e96e" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_57aaa319-d4bb-4fe1-9466-4d2885c1e96e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_798e7042-d463-4f9f-9a9e-0501f194416e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_798e7042-d463-4f9f-9a9e-0501f194416e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0e73d0b7-ea76-4ba2-aadc-9a8135db5b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0e73d0b7-ea76-4ba2-aadc-9a8135db5b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_ed42cd16-cf8e-4181-b34e-f39901d8c57e" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6cafad6f-1d82-41b7-8cca-ddbcc19b0de5" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_ed42cd16-cf8e-4181-b34e-f39901d8c57e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c073850-6631-4933-a7d8-29519cc74e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_05f53a37-9421-4fe1-bae4-689a6f149064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c073850-6631-4933-a7d8-29519cc74e2e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_05f53a37-9421-4fe1-bae4-689a6f149064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_ab10f2c2-e218-4d8f-9219-98c56ec78d55" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c073850-6631-4933-a7d8-29519cc74e2e" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_ab10f2c2-e218-4d8f-9219-98c56ec78d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a16fd957-e6f9-4124-8393-304dcfe50310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_46fedcd2-2d39-4b28-903c-336a8e6b64eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a16fd957-e6f9-4124-8393-304dcfe50310" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_46fedcd2-2d39-4b28-903c-336a8e6b64eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_221e7fce-bb2f-4cea-b8bc-b93f13e4ea54" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a16fd957-e6f9-4124-8393-304dcfe50310" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_221e7fce-bb2f-4cea-b8bc-b93f13e4ea54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_aaa91871-d29b-49cc-b29c-750fb3398645" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a16fd957-e6f9-4124-8393-304dcfe50310" xlink:to="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_aaa91871-d29b-49cc-b29c-750fb3398645" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTable" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesTable"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesTable" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c4ce7d9e-3bfb-4256-8c91-8f0e3770abf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bdfd7890-2de0-463c-aa4f-26290de62c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c4ce7d9e-3bfb-4256-8c91-8f0e3770abf5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bdfd7890-2de0-463c-aa4f-26290de62c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87223abc-03b8-4ce6-9d95-7b46b1ed3b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c4ce7d9e-3bfb-4256-8c91-8f0e3770abf5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87223abc-03b8-4ce6-9d95-7b46b1ed3b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4d36113-f10b-48d4-b17c-df9ce4b7432e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4d36113-f10b-48d4-b17c-df9ce4b7432e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ab1daa9-ec80-4059-a84a-d80b205b9bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ab1daa9-ec80-4059-a84a-d80b205b9bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_058c752d-f26c-4b54-816b-faa65d570a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_058c752d-f26c-4b54-816b-faa65d570a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e982a3f-d462-47f2-8908-044b654948fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e982a3f-d462-47f2-8908-044b654948fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_67024ea4-e60d-4de0-b7c6-58e645ef6ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_67024ea4-e60d-4de0-b7c6-58e645ef6ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9c7fffe7-ae13-4c00-b3b1-a1882957680a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_528179f0-f97e-49a7-b830-8ec92533286f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9c7fffe7-ae13-4c00-b3b1-a1882957680a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57f32f9e-ecdf-48b2-8a71-69ebd85f2e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_442c5ed1-2c40-495d-8302-d127b6720344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57f32f9e-ecdf-48b2-8a71-69ebd85f2e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_442c5ed1-2c40-495d-8302-d127b6720344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_21664f8c-2e32-4a1e-8026-a2e04ccb64ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_57f32f9e-ecdf-48b2-8a71-69ebd85f2e07" xlink:to="loc_us-gaap_OperatingLeaseLiability_21664f8c-2e32-4a1e-8026-a2e04ccb64ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlan" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlan"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/RetirementPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlanAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nbix-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended" id="i8681922d76ca4f77a922ccae2d60b2d0_CoverPage"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ibd2215e58a4249e38aaff75a0030d925_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ib5ac0a23e15c42c498b8ebb6474c8402_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea1ec4ac-1981-48fc-b277-881de80a116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea1ec4ac-1981-48fc-b277-881de80a116c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44db815f-d58c-47a4-b960-3249c89497df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44db815f-d58c-47a4-b960-3249c89497df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3d1bdd93-c416-46f3-aa03-b25a13470d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3d1bdd93-c416-46f3-aa03-b25a13470d76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b11def44-348b-47f6-add7-201b84f2387c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b11def44-348b-47f6-add7-201b84f2387c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a43980a4-1507-4039-aa0a-94cbcf1eb934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a43980a4-1507-4039-aa0a-94cbcf1eb934" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5018998-86eb-4d6d-be92-1c2401d753f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5018998-86eb-4d6d-be92-1c2401d753f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_00418944-018a-4579-9e1a-ee0f2aa3d0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesIssued_00418944-018a-4579-9e1a-ee0f2aa3d0a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b25d9725-c115-4917-84a1-0f74592116d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b25d9725-c115-4917-84a1-0f74592116d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_78920adf-93f1-4a66-a888-f12ae898f839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_78920adf-93f1-4a66-a888-f12ae898f839" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:to="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_45b69698-d3bb-453b-8787-ea12bccfc9b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_45b69698-d3bb-453b-8787-ea12bccfc9b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7526523d-d52c-42d6-981d-6b767f682bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7526523d-d52c-42d6-981d-6b767f682bb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_f4f31521-43c5-422e-bf41-98b90caad9db" xlink:href="nbix-20201231.xsd#nbix_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:to="loc_nbix_LongTermInvestmentsMember_f4f31521-43c5-422e-bf41-98b90caad9db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended" id="i17deb9ceb52e47009b0f1c5aa6262e6a_ConsolidatedStatementsIncomeandComprehensiveIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8140d088-be1e-4508-9644-1ee33ffad907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8140d088-be1e-4508-9644-1ee33ffad907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CostOfSales_5dc4826d-6026-483a-8f9b-a9f830ce00a3" xlink:href="nbix-20201231.xsd#nbix_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_nbix_CostOfSales_5dc4826d-6026-483a-8f9b-a9f830ce00a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_123f4552-f8a1-4f77-9bf7-61e884752476" xlink:href="nbix-20201231.xsd#nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_123f4552-f8a1-4f77-9bf7-61e884752476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b0abf0f1-a00e-46b1-8bd5-7c36ee8b300d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b0abf0f1-a00e-46b1-8bd5-7c36ee8b300d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e25f46cc-e9de-4a85-81bc-ecb3b5771185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e25f46cc-e9de-4a85-81bc-ecb3b5771185" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8ff1eb1c-6fcd-4504-b908-4c9a446515aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_OperatingExpenses_8ff1eb1c-6fcd-4504-b908-4c9a446515aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f82ae848-104f-470c-a546-76ef675ec2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_f82ae848-104f-470c-a546-76ef675ec2f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_87105e35-2115-4803-a633-37e6750684d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_InterestExpense_87105e35-2115-4803-a633-37e6750684d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d96f4f34-bcfa-4200-9658-8572cbf1d552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d96f4f34-bcfa-4200-9658-8572cbf1d552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31f8a020-ca9d-4df5-b12d-9afa10c95539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31f8a020-ca9d-4df5-b12d-9afa10c95539" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_f109386c-1219-4c90-8a87-f0a4112bcb33" xlink:href="nbix-20201231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_f109386c-1219-4c90-8a87-f0a4112bcb33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aae1fef1-f0b4-4880-878e-632149df28ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aae1fef1-f0b4-4880-878e-632149df28ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38daaf18-44ef-4372-af5d-e1116b325da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38daaf18-44ef-4372-af5d-e1116b325da4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_071323b3-cb4b-4e17-b4fe-ba692cfc6a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_071323b3-cb4b-4e17-b4fe-ba692cfc6a59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_805c5daa-a901-485c-a378-5780676445b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_NetIncomeLoss_805c5daa-a901-485c-a378-5780676445b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_abc8e3dd-4ace-46d4-8baf-776dd9dbfc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_abc8e3dd-4ace-46d4-8baf-776dd9dbfc42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6551ce12-0296-413d-b83f-df62a095140b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6551ce12-0296-413d-b83f-df62a095140b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2b964396-3307-4902-b527-120b45de63e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_EarningsPerShareBasic_2b964396-3307-4902-b527-120b45de63e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_80893eec-702f-4540-ba22-fdafad449240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_EarningsPerShareDiluted_80893eec-702f-4540-ba22-fdafad449240" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0766e56b-fcb3-4610-b384-4328cd8d3865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0766e56b-fcb3-4610-b384-4328cd8d3865" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52af4543-c4e1-45a1-958f-433b1f74d21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52af4543-c4e1-45a1-958f-433b1f74d21a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:to="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cfd7e98-5792-487e-9085-29e94fa68f90_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:to="loc_srt_ProductsAndServicesDomain_2cfd7e98-5792-487e-9085-29e94fa68f90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:to="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_346e5cad-3cbf-4f80-a38f-9a13fd4f1f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:to="loc_us-gaap_ProductMember_346e5cad-3cbf-4f80-a38f-9a13fd4f1f38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_7d81d62d-b47d-44cb-a0aa-90eb80b414fb" xlink:href="nbix-20201231.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:to="loc_nbix_CollaborationRevenueMember_7d81d62d-b47d-44cb-a0aa-90eb80b414fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i06d5cddf294e409da47bea63f2ecf9fe_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9bb9de37-6cfb-463f-b3b1-4406a0a6b9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_SharesOutstanding_9bb9de37-6cfb-463f-b3b1-4406a0a6b9b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56dce236-3241-4ce6-b55e-217f97bb5758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockholdersEquity_56dce236-3241-4ce6-b55e-217f97bb5758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bc93ad5-fa6f-4741-974f-1dd8d1dd80ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_NetIncomeLoss_3bc93ad5-fa6f-4741-974f-1dd8d1dd80ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6f027862-ebfc-434d-88e8-d09052e42c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6f027862-ebfc-434d-88e8-d09052e42c94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb58e3e8-651e-4e1b-8c2e-8edee675805f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb58e3e8-651e-4e1b-8c2e-8edee675805f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_cf7c67b8-ff2a-4411-bf55-50fa2c7bdb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_cf7c67b8-ff2a-4411-bf55-50fa2c7bdb55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_16ccdc99-579b-4296-a4ee-9553f60991b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_16ccdc99-579b-4296-a4ee-9553f60991b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13a30e07-c490-458b-b3c9-5ae95de8ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13a30e07-c490-458b-b3c9-5ae95de8ef14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29e72ea4-68d5-4ff0-a0f3-567bee8a6131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29e72ea4-68d5-4ff0-a0f3-567bee8a6131" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16bf893b-460c-4ed9-9711-98fbfc664bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16bf893b-460c-4ed9-9711-98fbfc664bc1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cf657889-eb99-408e-a415-75f5106ad8cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cf657889-eb99-408e-a415-75f5106ad8cf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_224d22f9-65d1-4382-a98e-ed94944c66b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_224d22f9-65d1-4382-a98e-ed94944c66b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31d5f60e-40fa-4d55-b35b-1820e174bd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5f5e1c1-8874-43d9-a801-9cba54bf7a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_48e37593-336d-4417-8788-7b46ccd8a18a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:to="loc_us-gaap_EquityComponentDomain_48e37593-336d-4417-8788-7b46ccd8a18a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:to="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5b5f6a55-efd2-41b6-a802-71ea4532348a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_CommonStockMember_5b5f6a55-efd2-41b6-a802-71ea4532348a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df3e42c2-eae0-4b4e-9105-9dd7ec557753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df3e42c2-eae0-4b4e-9105-9dd7ec557753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_de39c9a0-a1b4-4d22-bb83-6cd04bbfb78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_de39c9a0-a1b4-4d22-bb83-6cd04bbfb78e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c01636cf-321d-45ed-8a84-ade7fa2872ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_RetainedEarningsMember_c01636cf-321d-45ed-8a84-ade7fa2872ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f5ddb50-638c-4833-93eb-6216db8fbff9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f5ddb50-638c-4833-93eb-6216db8fbff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_75a62ddb-f976-410f-bd99-c462058b8cc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_75a62ddb-f976-410f-bd99-c462058b8cc0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i67c45b13d0d24d199c55c2b923958070_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i468c29173a9d4683a4eb5744c444dfa6_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i0fcd9c97346b4368a233a9bffa919d67_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i8e5ddfc721384e079eb85457714beef5_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries_931690d9-06c0-442a-b69a-37bc384ffc1a" xlink:href="nbix-20201231.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_nbix_NumberOfIrishSubsidiaries_931690d9-06c0-442a-b69a-37bc384ffc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8067964b-1284-4197-a8ce-e28235083b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8067964b-1284-4197-a8ce-e28235083b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b5decca6-ed15-4edf-ac57-a4df6748db68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_NumberOfReportableSegments_b5decca6-ed15-4edf-ac57-a4df6748db68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_04db0a04-a1ab-4481-9e70-d8883511be24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_04db0a04-a1ab-4481-9e70-d8883511be24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_35e65e58-9ff4-4e46-ae4a-4ae545d3c702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_InterestReceivableCurrent_35e65e58-9ff4-4e46-ae4a-4ae545d3c702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_42d7fe3d-79a3-46cd-b539-bc15a8e2fd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_42d7fe3d-79a3-46cd-b539-bc15a8e2fd5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_675371ec-b0a1-4f97-a488-db2f79b517d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_675371ec-b0a1-4f97-a488-db2f79b517d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e4e132ee-763e-4c05-9260-b8b7270ce121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_Depreciation_e4e132ee-763e-4c05-9260-b8b7270ce121" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_57fe84cb-06d8-4540-96ac-abd2ad949cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_57fe84cb-06d8-4540-96ac-abd2ad949cb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_9a11226f-e833-460c-939e-b124ac2555d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_AdvertisingExpense_9a11226f-e833-460c-939e-b124ac2555d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_22e02ba4-780b-4813-bf06-2e291ac81b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_22e02ba4-780b-4813-bf06-2e291ac81b24" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_e3867b51-7c38-408c-ba79-fdf7b61d108d" xlink:href="nbix-20201231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_e3867b51-7c38-408c-ba79-fdf7b61d108d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_28e0c4fb-af3e-4ef9-a528-36b8ec61aa4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_28e0c4fb-af3e-4ef9-a528-36b8ec61aa4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6039f3fe-7622-4970-a5a8-028b3c2996c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6039f3fe-7622-4970-a5a8-028b3c2996c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f4091bbc-baac-4b0c-b30a-43a1b6d7c396_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:to="loc_srt_RangeMember_f4091bbc-baac-4b0c-b30a-43a1b6d7c396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:to="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22da5723-cc10-47a5-b6e5-c82b5cd95c0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:to="loc_srt_MinimumMember_22da5723-cc10-47a5-b6e5-c82b5cd95c0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63a469c8-a549-4229-919c-98d87f8d10f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:to="loc_srt_MaximumMember_63a469c8-a549-4229-919c-98d87f8d10f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9a450e0-9200-4117-b83f-a359f4cbb8fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9a450e0-9200-4117-b83f-a359f4cbb8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_75e17869-38a1-4ffa-af64-084511171440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_75e17869-38a1-4ffa-af64-084511171440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7449bd78-80b8-4727-91e0-6e32164f5db0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7449bd78-80b8-4727-91e0-6e32164f5db0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7f4f84c4-3474-4ae9-9987-c3a851f32332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7f4f84c4-3474-4ae9-9987-c3a851f32332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c8362cdd-6b0f-4867-8074-481e0da7f372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:to="loc_us-gaap_EmployeeStockMember_c8362cdd-6b0f-4867-8074-481e0da7f372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_77e519a2-9d11-44f6-983d-dd1afbba2abc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_77e519a2-9d11-44f6-983d-dd1afbba2abc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_2453bc2e-2ca5-433c-9654-523661868b73" xlink:href="nbix-20201231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_2453bc2e-2ca5-433c-9654-523661868b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_b684b092-78f9-45d0-8bad-4c3530a19868" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_b684b092-78f9-45d0-8bad-4c3530a19868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_948e76af-c04b-477f-8625-710c58b268a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_948e76af-c04b-477f-8625-710c58b268a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestTwoCustomersMember_8602b972-df80-4b29-afc1-7afed41a1986" xlink:href="nbix-20201231.xsd#nbix_LargestTwoCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:to="loc_nbix_LargestTwoCustomersMember_8602b972-df80-4b29-afc1-7afed41a1986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestThreeCustomersMember_34ab52f1-86b6-457a-81da-98fe808f1940" xlink:href="nbix-20201231.xsd#nbix_LargestThreeCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:to="loc_nbix_LargestThreeCustomersMember_34ab52f1-86b6-457a-81da-98fe808f1940" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i362f648421b446538b1ab3410de544f8_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="i9412a03c098d46a9aef758dcce6bc902_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_d2f4d8a0-19e7-4532-aa16-3f495d75344d" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialMilestonePayments_d2f4d8a0-19e7-4532-aa16-3f495d75344d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_02d8f7e0-182e-4102-b013-99825e5751f1" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_UpfrontPaymentsMade_02d8f7e0-182e-4102-b013-99825e5751f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fadf5cae-be60-485e-8a1b-7fa3fabad002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fadf5cae-be60-485e-8a1b-7fa3fabad002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm_006c7271-18fc-4313-a6ca-b66a5bafb275" xlink:href="nbix-20201231.xsd#nbix_ResearchCollaborationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_ResearchCollaborationTerm_006c7271-18fc-4313-a6ca-b66a5bafb275" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments_e11df3a4-963c-4074-b192-3e3182e2c6a3" xlink:href="nbix-20201231.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialCommercialMilestonePayments_e11df3a4-963c-4074-b192-3e3182e2c6a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9112e00f-4ea7-469f-9c70-f2ad78a6b492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9112e00f-4ea7-469f-9c70-f2ad78a6b492" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_588a37bc-bbf8-4b0a-9699-fd26c6eedfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_SharePrice_588a37bc-bbf8-4b0a-9699-fd26c6eedfec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_98d7d816-813c-406f-88cb-b7d040d71bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_98d7d816-813c-406f-88cb-b7d040d71bd6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_0470c39b-7e03-42c9-812c-4ccf48bf17c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_0470c39b-7e03-42c9-812c-4ccf48bf17c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f047e3b7-a039-4fb9-bf4f-5c5e45faf08a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f047e3b7-a039-4fb9-bf4f-5c5e45faf08a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_ba9b0db4-da6d-4595-a314-791bc7e40d90" xlink:href="nbix-20201231.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_MilestonePayment_ba9b0db4-da6d-4595-a314-791bc7e40d90" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c2f8c13-28a7-47d2-9305-0f5c612d9f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c2f8c13-28a7-47d2-9305-0f5c612d9f30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_523c8fce-3715-4aa7-b54f-ec2509672af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_523c8fce-3715-4aa7-b54f-ec2509672af0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ffd7b5db-2cf5-459f-b134-795e0a211df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ffd7b5db-2cf5-459f-b134-795e0a211df8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived_ab923d7c-75c0-4904-b494-206632ab8a6e" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_UpfrontPaymentsReceived_ab923d7c-75c0-4904-b494-206632ab8a6e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_a0904855-3220-496f-9669-18a04db22867" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_a0904855-3220-496f-9669-18a04db22867" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_75438c48-3463-44a5-a892-920332a944fa" xlink:href="nbix-20201231.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PatentTerm_75438c48-3463-44a5-a892-920332a944fa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a680b70a-590b-4b2c-b47d-05f70b4186ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:to="loc_us-gaap_RelatedPartyDomain_a680b70a-590b-4b2c-b47d-05f70b4186ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:to="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_e80f9cb9-97b3-43f9-b598-a494591451d7" xlink:href="nbix-20201231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_e80f9cb9-97b3-43f9-b598-a494591451d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_3fb20503-689a-47a5-8467-3d754242fee1" xlink:href="nbix-20201231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_3fb20503-689a-47a5-8467-3d754242fee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_c9ac73bf-8bd8-4039-ab34-efded19fc43c" xlink:href="nbix-20201231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_c9ac73bf-8bd8-4039-ab34-efded19fc43c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_227a1a8c-01da-45e2-ada6-cd88f38615a4" xlink:href="nbix-20201231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_VoyagerTherapeuticsMember_227a1a8c-01da-45e2-ada6-cd88f38615a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember_296a88ae-4a56-4a06-8c82-5e421771d940" xlink:href="nbix-20201231.xsd#nbix_BIALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_BIALMember_296a88ae-4a56-4a06-8c82-5e421771d940" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_82b2b712-e167-42d9-ba5e-c51bfd10e7c0" xlink:href="nbix-20201231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_82b2b712-e167-42d9-ba5e-c51bfd10e7c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember_635f800f-5bc4-474a-aefc-babab080d22c" xlink:href="nbix-20201231.xsd#nbix_AbbvieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_AbbvieIncMember_635f800f-5bc4-474a-aefc-babab080d22c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fad5ffde-4c75-41d3-ba01-0b162f70fb7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fad5ffde-4c75-41d3-ba01-0b162f70fb7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_a33130c3-ceca-4d49-af91-2a11c687222b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:to="loc_us-gaap_CollaborativeArrangementMember_a33130c3-ceca-4d49-af91-2a11c687222b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95db3b20-7c3c-475d-b76c-1a5997a19989_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:to="loc_us-gaap_EquityComponentDomain_95db3b20-7c3c-475d-b76c-1a5997a19989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:to="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2cdd27b8-723e-480f-81c0-f7d085888629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:to="loc_us-gaap_CommonStockMember_2cdd27b8-723e-480f-81c0-f7d085888629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_843fdf8b-2849-408d-a6bb-19ed64f6af45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_843fdf8b-2849-408d-a6bb-19ed64f6af45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_d8243aca-12f4-4cc1-a11a-324bfadbae28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:to="loc_us-gaap_PatentsMember_d8243aca-12f4-4cc1-a11a-324bfadbae28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c288f1c-5ab3-4812-b11c-9727f4217765_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:to="loc_srt_ProductsAndServicesDomain_4c288f1c-5ab3-4812-b11c-9727f4217765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:to="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member_800b82c7-6943-43df-94ea-121c4848cd96" xlink:href="nbix-20201231.xsd#nbix_NBI827104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_nbix_NBI827104Member_800b82c7-6943-43df-94ea-121c4848cd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember_72b25388-dce6-4866-9ed3-f2ab21daafdf" xlink:href="nbix-20201231.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_nbix_DevelopmentProductCandidatesMember_72b25388-dce6-4866-9ed3-f2ab21daafdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_65d39bc8-a1db-4dbe-938f-ef5d8f6dcbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_us-gaap_RoyaltyMember_65d39bc8-a1db-4dbe-938f-ef5d8f6dcbcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18b1d752-6adf-4869-9f7b-e214baa799ec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:to="loc_srt_RangeMember_18b1d752-6adf-4869-9f7b-e214baa799ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:to="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_67f04aab-9dba-4d0a-a2e3-1dbdf99e44f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:to="loc_srt_MinimumMember_67f04aab-9dba-4d0a-a2e3-1dbdf99e44f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecurities"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended" id="i90eac149dbb34ceea901e3321b6a1b8e_DebtSecurities"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended" id="i666cfaac7a0a432ca90094454dce41b0_DebtSecuritiesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" id="i4bff0fa4b01c4dfda74edff51423256c_DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8602d62-ede5-46b7-b0ab-ff18eeaab9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8602d62-ede5-46b7-b0ab-ff18eeaab9de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0669a01-d4d2-49ba-be7e-b3267a781158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0669a01-d4d2-49ba-be7e-b3267a781158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7aaedef9-7d3f-47a8-8d96-36745167f522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7aaedef9-7d3f-47a8-8d96-36745167f522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5ad2eaea-85ba-4d75-a014-3b366eee2f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5ad2eaea-85ba-4d75-a014-3b366eee2f5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1297c06d-3986-49dc-8000-20135f32b1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1297c06d-3986-49dc-8000-20135f32b1a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0502444d-c282-4253-954e-8406d0b28041_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0502444d-c282-4253-954e-8406d0b28041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1206cbc5-1e2e-4b9f-b4df-d3ea6899a741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1206cbc5-1e2e-4b9f-b4df-d3ea6899a741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_36e1e21b-2c70-4166-8b5b-36e0b0be7d9e" xlink:href="nbix-20201231.xsd#nbix_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:to="loc_nbix_LongTermInvestmentsMember_36e1e21b-2c70-4166-8b5b-36e0b0be7d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d2962d03-9c1c-41cd-8c47-5c95ab85af33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d2962d03-9c1c-41cd-8c47-5c95ab85af33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_28c81374-2df0-4078-95d0-14cbf9f44386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:to="loc_us-gaap_CommercialPaperMember_28c81374-2df0-4078-95d0-14cbf9f44386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4fe9acbe-1927-4a26-aefe-0d068841ecff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4fe9acbe-1927-4a26-aefe-0d068841ecff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dc19b7ec-cfa3-4373-8778-452480f202ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dc19b7ec-cfa3-4373-8778-452480f202ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0006306e-259c-4229-9e2c-41e8aeeaa9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0006306e-259c-4229-9e2c-41e8aeeaa9d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended" id="ic13b7f5fe3a24577aad57eb8b6a65b31_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33b80c7d-4e4e-430b-bbe0-d76a63b3b57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33b80c7d-4e4e-430b-bbe0-d76a63b3b57a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_29805842-4304-498c-89de-87ff79bc9030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_29805842-4304-498c-89de-87ff79bc9030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b79714f2-0622-4e61-98c6-333f86469740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b79714f2-0622-4e61-98c6-333f86469740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f54320f-b5a0-40bd-9c37-923cf0fe0ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f54320f-b5a0-40bd-9c37-923cf0fe0ab0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dbb1f25c-9ab9-4d3d-be5a-b22c0c220efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dbb1f25c-9ab9-4d3d-be5a-b22c0c220efe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f23dc5e7-f5e0-4e7e-b91d-e5998635ce66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f23dc5e7-f5e0-4e7e-b91d-e5998635ce66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f6b0788-dede-4ea3-8fac-ad7fee2f902c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6f6b0788-dede-4ea3-8fac-ad7fee2f902c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_77f069f2-b5bb-4cf9-bf1a-80e0b673c6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_77f069f2-b5bb-4cf9-bf1a-80e0b673c6bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9737b5d8-56de-4681-9dec-f6db4a5487d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9737b5d8-56de-4681-9dec-f6db4a5487d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended" id="i8267d93563a641caa32294f772de70da_DebtSecuritiesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended" id="i963e021e0f2f46c8aaa960a411944a02_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i9bd4c5b623c447a6b715284174789b48_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i803968cadab24a2d88e583915c18d820_FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_79c90c3c-18c4-4fec-9c41-f55f64546d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:to="loc_us-gaap_Investments_79c90c3c-18c4-4fec-9c41-f55f64546d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_72f5a2b7-9977-4184-b541-ffdefd6448d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_72f5a2b7-9977-4184-b541-ffdefd6448d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6ada664-c94c-4aeb-a1db-54b6da1976c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6ada664-c94c-4aeb-a1db-54b6da1976c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d0180c48-5f78-40aa-8cba-9c5f0b54cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d0180c48-5f78-40aa-8cba-9c5f0b54cdb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ae70426c-7519-4c9c-b21d-60a0d97d1768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ae70426c-7519-4c9c-b21d-60a0d97d1768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82b5710a-b1c7-41ed-8f52-32287aac12d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82b5710a-b1c7-41ed-8f52-32287aac12d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b561a735-e2dd-4140-a17f-ab16d82fc1bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b561a735-e2dd-4140-a17f-ab16d82fc1bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_373ce3aa-bba2-4c71-9d01-8b4f3f9a7e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_373ce3aa-bba2-4c71-9d01-8b4f3f9a7e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_99d1a0da-4f2c-4830-b58d-50d3ab802fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_99d1a0da-4f2c-4830-b58d-50d3ab802fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_f05bec7c-7f89-4f4c-b203-057c2ef9636f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_f05bec7c-7f89-4f4c-b203-057c2ef9636f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_129e73fe-0982-4dba-b7a7-6fecd49e539c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_EquitySecuritiesMember_129e73fe-0982-4dba-b7a7-6fecd49e539c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember_460b106d-1608-405c-8cdf-95ecafb2c3f6" xlink:href="nbix-20201231.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_nbix_TotalEquitySecuritiesMember_460b106d-1608-405c-8cdf-95ecafb2c3f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3e1f2a8d-70e7-4b75-bf82-2abaf3565795_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3e1f2a8d-70e7-4b75-bf82-2abaf3565795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_3ba29005-6598-43da-9f86-54230c66bde0" xlink:href="nbix-20201231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_3ba29005-6598-43da-9f86-54230c66bde0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_90d64915-3eb4-4825-95ac-b92f14ffa739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CashEquivalentsMember_90d64915-3eb4-4825-95ac-b92f14ffa739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b317301f-dda0-4ee9-a464-b7e298ea2b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b317301f-dda0-4ee9-a464-b7e298ea2b6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember_cb3f374c-511c-4104-9e6e-b3d682cb09ab" xlink:href="nbix-20201231.xsd#nbix_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_nbix_RestrictedCashMember_cb3f374c-511c-4104-9e6e-b3d682cb09ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d16a15fd-a6e6-49c3-b6b8-7df2ca3f7e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CommercialPaperMember_d16a15fd-a6e6-49c3-b6b8-7df2ca3f7e02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f857592f-0e01-4f0e-b85b-a7cff0e356d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f857592f-0e01-4f0e-b85b-a7cff0e356d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_becd69a5-4f6c-4d2f-bc12-79ef844bcbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_becd69a5-4f6c-4d2f-bc12-79ef844bcbb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i57faa94a4a0a47649cbdbb933b938e1f_FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_527cdbdf-a3dc-4a5a-9f3a-4ea86927e62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_527cdbdf-a3dc-4a5a-9f3a-4ea86927e62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_477ac44e-9c04-4dd8-8c57-113a169ebcfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_477ac44e-9c04-4dd8-8c57-113a169ebcfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8555af3d-84e9-40d2-9acb-da89abcab4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8555af3d-84e9-40d2-9acb-da89abcab4af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_e49c1701-851c-481f-a758-9a5f42c4fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d188b3f-46de-4951-9323-fd12df03a6ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d188b3f-46de-4951-9323-fd12df03a6ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0aa77695-0a25-4631-8c46-bd1d9167c2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0aa77695-0a25-4631-8c46-bd1d9167c2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_61a3d264-0354-43ce-8223-98ce19fd7ff9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:to="loc_us-gaap_CollateralDomain_61a3d264-0354-43ce-8223-98ce19fd7ff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:to="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a09b5977-16cd-4775-a404-30fdde7f6940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:to="loc_us-gaap_EquitySecuritiesMember_a09b5977-16cd-4775-a404-30fdde7f6940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b83c1b3-4fcf-487c-a345-2515178f68c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b83c1b3-4fcf-487c-a345-2515178f68c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b176d013-8b6f-4737-8b22-35d9c17870d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b176d013-8b6f-4737-8b22-35d9c17870d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i0663568f88644710bbfdcad72e474cc0_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_ffdd25f6-5e0f-4c67-846f-fa081ad8ce1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_ffdd25f6-5e0f-4c67-846f-fa081ad8ce1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:to="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e7165a2-655d-456d-9619-0fddaed061ab_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:to="loc_srt_RangeMember_1e7165a2-655d-456d-9619-0fddaed061ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:to="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5fcbafa-3f24-4a0f-a5f1-00ef5db6663c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_MinimumMember_d5fcbafa-3f24-4a0f-a5f1-00ef5db6663c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f53b634-b7e0-4005-a8ad-fb4fa5c500ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_MaximumMember_8f53b634-b7e0-4005-a8ad-fb4fa5c500ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_42dec1d2-705a-40a0-9cca-eaa31dd8b627" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_WeightedAverageMember_42dec1d2-705a-40a0-9cca-eaa31dd8b627" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_dac73bad-4396-4944-9d80-931cd4862e68_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_dac73bad-4396-4944-9d80-931cd4862e68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_e6804e96-d60d-4f58-8844-9716d2ad26c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_e6804e96-d60d-4f58-8844-9716d2ad26c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended" id="iea56d4f0d1ce45debf8602d0fb507c39_ConvertibleSeniorNotes"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" id="ia3b1150e4a504d0aa349accb803a2823_ConvertibleSeniorNotesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended" id="i525f9a9120754b59a03c27ec809d8c2f_ConvertibleSeniorNotesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c729974f-28b8-442f-9e1a-f67eb43143b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c729974f-28b8-442f-9e1a-f67eb43143b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d674c3d6-699e-4c14-a6b8-3d5646018d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d674c3d6-699e-4c14-a6b8-3d5646018d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1168065f-a51a-435b-9ae9-dc234f725dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1168065f-a51a-435b-9ae9-dc234f725dcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6498ccba-76ba-439d-9da3-cd8aca8062d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6498ccba-76ba-439d-9da3-cd8aca8062d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_577f1a07-beaf-4f6e-9b4e-10f96f955dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_577f1a07-beaf-4f6e-9b4e-10f96f955dcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_06c8f8d9-6ec3-4047-917f-a584c094f054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_06c8f8d9-6ec3-4047-917f-a584c094f054" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_8c13a31f-8f98-4913-b557-8cca222deeeb" xlink:href="nbix-20201231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_8c13a31f-8f98-4913-b557-8cca222deeeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_40a0c093-c72b-486b-b594-b7d9a399c22b" xlink:href="nbix-20201231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_40a0c093-c72b-486b-b594-b7d9a399c22b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TradingDaysDuringObservationPeriod_09725275-ad90-4edf-9fb8-30f18ae6b1a5" xlink:href="nbix-20201231.xsd#nbix_TradingDaysDuringObservationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_TradingDaysDuringObservationPeriod_09725275-ad90-4edf-9fb8-30f18ae6b1a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_2641b215-5fcd-4830-b7f9-2c7eca715a31" xlink:href="nbix-20201231.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_DebtConversionObservationPeriod_2641b215-5fcd-4830-b7f9-2c7eca715a31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c06cfe6-f1cb-4f52-9542-67032b0ed5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c06cfe6-f1cb-4f52-9542-67032b0ed5ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_bb413641-5bd7-405f-9461-cc30fe80c738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_bb413641-5bd7-405f-9461-cc30fe80c738" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e89b4299-ad72-4485-961f-1ab53bbaabe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e89b4299-ad72-4485-961f-1ab53bbaabe3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_a1db7a1c-dc7c-46ab-9f65-5412a5af3cd8" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_a1db7a1c-dc7c-46ab-9f65-5412a5af3cd8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ba91d325-f3e5-43e7-9b57-02bb71945c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_SharePrice_ba91d325-f3e5-43e7-9b57-02bb71945c11" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4133fd59-e461-4f39-9852-453d6493f317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4133fd59-e461-4f39-9852-453d6493f317" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_642c33b4-2542-4374-970a-342fa53f0b8a" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_642c33b4-2542-4374-970a-342fa53f0b8a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_326cd99c-c052-4092-abea-ea54298a5661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_326cd99c-c052-4092-abea-ea54298a5661" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5cb94941-70e0-42a4-a3e8-5924335de5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5cb94941-70e0-42a4-a3e8-5924335de5da" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_2882d9d2-0afb-486e-b23d-b6658036f341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentTerm_2882d9d2-0afb-486e-b23d-b6658036f341" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0b5edec3-430f-4804-b644-59e5916c3c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0b5edec3-430f-4804-b644-59e5916c3c24" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_9861a3a4-a910-4712-8f5c-cb65c5a6ea2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_9861a3a4-a910-4712-8f5c-cb65c5a6ea2e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_7589c849-9489-4bee-a450-cd66a1087eea" xlink:href="nbix-20201231.xsd#nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_7589c849-9489-4bee-a450-cd66a1087eea" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_61799f03-871b-4529-9646-d50b5e6433e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_61799f03-871b-4529-9646-d50b5e6433e6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3a94155c-d5ba-4d2c-b12b-162be7d3faf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_RepaymentsOfDebt_3a94155c-d5ba-4d2c-b12b-162be7d3faf7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_5de1b00e-99f3-483e-9440-b0435ae8c19f" xlink:href="nbix-20201231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_5de1b00e-99f3-483e-9440-b0435ae8c19f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_25012df2-14b8-4a6d-9ed4-f71a283b73b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_25012df2-14b8-4a6d-9ed4-f71a283b73b0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_3ca3854d-4d5f-40b4-b802-b7814c1b9b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_3ca3854d-4d5f-40b4-b802-b7814c1b9b17" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_117e9c6f-6439-4fe0-8155-a713caaacd4e" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_117e9c6f-6439-4fe0-8155-a713caaacd4e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b1caefe1-1644-4171-84b9-23c54145a907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b1caefe1-1644-4171-84b9-23c54145a907" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ac85ec45-47a5-4f8e-a97f-145e5a7cbe4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ac85ec45-47a5-4f8e-a97f-145e5a7cbe4e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98e68b2d-1606-4923-b613-2ab7094a93c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98e68b2d-1606-4923-b613-2ab7094a93c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_cb3c7f92-5533-4e28-a829-e2ded55acede" xlink:href="nbix-20201231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_cb3c7f92-5533-4e28-a829-e2ded55acede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4cc33c79-8b52-4c59-89ad-13cb44a893dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4cc33c79-8b52-4c59-89ad-13cb44a893dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9d47174f-40ff-4fe9-b5af-4d85f64e88bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9d47174f-40ff-4fe9-b5af-4d85f64e88bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_6e9bccf1-d351-4dd0-9dff-b7ebad671256_default" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:to="loc_nbix_DebtInstrumentConversionDomain_6e9bccf1-d351-4dd0-9dff-b7ebad671256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:to="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_01f666fb-40f0-412f-8991-c7f026aca6d6" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:to="loc_nbix_ConversionPeriodOneMember_01f666fb-40f0-412f-8991-c7f026aca6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_2215b73b-e414-4a2c-b0cc-a6a0fc0aacb2" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:to="loc_nbix_ConversionPeriodTwoMember_2215b73b-e414-4a2c-b0cc-a6a0fc0aacb2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="extended" id="ibbcc7f9afc814de5a54cca415642481d_ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="extended" id="i081d987f62a841ea8d1997a69bd54d69_OtherBalanceSheetDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended" id="iaaab15d9d7814d24838c2ded30903dff_OtherBalanceSheetDetailsTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="extended" id="i77581572b6e141938f8568d4bbce5b0f_OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended" id="ib3d7a5c6d0f34dc595515f6bd8e63efa_OtherBalanceSheetDetailsPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_85d52633-ea72-4ef0-b94f-0fba4e6bc273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_85d52633-ea72-4ef0-b94f-0fba4e6bc273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c718c862-303c-4e6e-bba4-2262e0656d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c718c862-303c-4e6e-bba4-2262e0656d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0cbbdbb-b98b-480f-9396-3746dc354bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0cbbdbb-b98b-480f-9396-3746dc354bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_189675d6-b798-4fe8-8252-e7f4d1e0a286_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_189675d6-b798-4fe8-8252-e7f4d1e0a286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_54943239-9627-4daa-9885-e4fafa41bdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_54943239-9627-4daa-9885-e4fafa41bdb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_36733594-8c1f-468d-be47-679a55312e7c" xlink:href="nbix-20201231.xsd#nbix_ScientificEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_nbix_ScientificEquipmentMember_36733594-8c1f-468d-be47-679a55312e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e35976cc-2ae2-4a71-84ff-3e7fabfc958e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_ComputerEquipmentMember_e35976cc-2ae2-4a71-84ff-3e7fabfc958e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e3bb0857-bb8e-4cd0-8647-21ac5b8d9822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e3bb0857-bb8e-4cd0-8647-21ac5b8d9822" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended" id="ib84b1f7be64342b2943770b794869bea_OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i936f8efc994142deadc49b417de10c12_OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShare"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="extended" id="i926ab4463e22462dad834e21318bab52_NetIncomePerShare"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="extended" id="i0fe681cb34c644578f6b94fc2521d491_NetIncomePerShareTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended" id="i5d664eeab6594a548fa63d306f708296_NetIncomePerShareScheduleofNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d283a107-58f2-4681-b9a7-cc24a7079ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_NetIncomeLoss_d283a107-58f2-4681-b9a7-cc24a7079ff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed4bece8-e876-458d-9bbd-29e50901ddd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed4bece8-e876-458d-9bbd-29e50901ddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0a7e63ca-f776-4715-8a90-8c2301ab5fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0a7e63ca-f776-4715-8a90-8c2301ab5fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_1d899cd1-5b34-422e-9414-557ed64ef359" xlink:href="nbix-20201231.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_1d899cd1-5b34-422e-9414-557ed64ef359" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dc506e7-e910-414d-a021-29adf83e1263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dc506e7-e910-414d-a021-29adf83e1263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d158966d-38aa-4e92-bcc6-0da24cb0a80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:to="loc_us-gaap_EarningsPerShareBasic_d158966d-38aa-4e92-bcc6-0da24cb0a80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_43ff1c08-17a6-4bb7-b0c5-382c82c64065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_43ff1c08-17a6-4bb7-b0c5-382c82c64065" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_47f2ef6c-8e68-484e-ba57-a468190dd4aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_47f2ef6c-8e68-484e-ba57-a468190dd4aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b6d0f6b-1641-489f-8f60-9a9bd9e5c5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b6d0f6b-1641-489f-8f60-9a9bd9e5c5b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0aaa81b1-9322-43e9-a22c-fd10ff1aa347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:to="loc_us-gaap_RestrictedStockMember_0aaa81b1-9322-43e9-a22c-fd10ff1aa347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60234601-e70f-4ab5-842f-68b884159710_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60234601-e70f-4ab5-842f-68b884159710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_c89954b3-7986-416a-ba11-474c84bbe83f" xlink:href="nbix-20201231.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_c89954b3-7986-416a-ba11-474c84bbe83f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended" id="i418e61e280584079aa2b504a6398c68a_NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eac13c38-1eba-4775-b647-85fa777d55bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eac13c38-1eba-4775-b647-85fa777d55bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_57475a54-c1bb-4253-94c7-36f645aa9337_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_57475a54-c1bb-4253-94c7-36f645aa9337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9f329159-d432-4328-8fb8-111b83b1f25e" xlink:href="nbix-20201231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9f329159-d432-4328-8fb8-111b83b1f25e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="extended" id="ib5f73a42d49b49d1b9fa2d665aa22765_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i2f5c7f3dd6ca48938385070e690823cb_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i4cd9aca766fe4142a601ce0391ca8af9_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3112dbbd-64a6-4559-a784-27a8b32bca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3112dbbd-64a6-4559-a784-27a8b32bca7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e52bcfc2-62ae-4149-8c1c-a2b1ae446f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e52bcfc2-62ae-4149-8c1c-a2b1ae446f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c1b3341-4573-4890-a432-9c575a6e3156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c1b3341-4573-4890-a432-9c575a6e3156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90388902-401e-4d61-ace6-4afd33804f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90388902-401e-4d61-ace6-4afd33804f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69705a8-81b9-431e-88b7-dd973fbd1866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69705a8-81b9-431e-88b7-dd973fbd1866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_aeedc0bb-5e40-4edf-883c-6cb9070f7e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_aeedc0bb-5e40-4edf-883c-6cb9070f7e18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_833107ed-3ae2-47b5-99c8-928f549e2976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_833107ed-3ae2-47b5-99c8-928f549e2976" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0da457c-6165-4015-bf67-4507b21191e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0da457c-6165-4015-bf67-4507b21191e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_351b535f-c4e0-428b-a06b-88056ba8743c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_351b535f-c4e0-428b-a06b-88056ba8743c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_03b6b2e5-fd30-4462-be47-46097ed3122e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_03b6b2e5-fd30-4462-be47-46097ed3122e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5a4cb396-dd83-484d-9042-1cd85291e210_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:to="loc_us-gaap_PlanNameDomain_5a4cb396-dd83-484d-9042-1cd85291e210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:to="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenPlanMember_f2c6222e-493c-4af9-8f9c-c0dc979ad130" xlink:href="nbix-20201231.xsd#nbix_TwoThousandAndElevenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:to="loc_nbix_TwoThousandAndElevenPlanMember_f2c6222e-493c-4af9-8f9c-c0dc979ad130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2020EquityIncentivePlanMember_2e6fb1c6-04a9-4c4c-a123-fa21f6a4d947" xlink:href="nbix-20201231.xsd#nbix_A2020EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:to="loc_nbix_A2020EquityIncentivePlanMember_2e6fb1c6-04a9-4c4c-a123-fa21f6a4d947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d402955-e4a7-4708-abaa-0a5743b5cf2f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d402955-e4a7-4708-abaa-0a5743b5cf2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_87121ce0-da74-4cb6-9d5e-313aa8ca35c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_EmployeeStockMember_87121ce0-da74-4cb6-9d5e-313aa8ca35c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a8017204-705c-4e27-942d-c0ec0719999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a8017204-705c-4e27-942d-c0ec0719999f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf6fb97b-e5be-4ce1-8d6f-af7486713f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf6fb97b-e5be-4ce1-8d6f-af7486713f41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_cc2348c9-1867-4701-a1ab-122936c42671" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_cc2348c9-1867-4701-a1ab-122936c42671" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b2655af-8d25-4622-a6bc-e0256ca6c71b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:to="loc_srt_RangeMember_3b2655af-8d25-4622-a6bc-e0256ca6c71b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:to="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcfd9178-b964-4ef3-bade-1601240c3d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:to="loc_srt_MinimumMember_fcfd9178-b964-4ef3-bade-1601240c3d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef308245-b8c5-466f-8c6f-580e0c117b7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:to="loc_srt_MaximumMember_ef308245-b8c5-466f-8c6f-580e0c117b7b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended" id="i832c80ed3a2749ffbee18fc9189cf7c4_ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5d79c4fc-f261-4094-a851-bc5c94e52378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5d79c4fc-f261-4094-a851-bc5c94e52378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62e1f684-c8d0-4462-9344-4151b3ecde72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62e1f684-c8d0-4462-9344-4151b3ecde72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_846ee4c6-58c0-4bdd-bf2b-05ff2e44ba0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_846ee4c6-58c0-4bdd-bf2b-05ff2e44ba0c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended" id="ia58a1a6189a34dfb807612c27af81d9e_ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24a75139-e12a-48f5-b67e-a6f97f2860e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24a75139-e12a-48f5-b67e-a6f97f2860e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:to="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f74115f6-8499-4bbb-96af-ba5859d884e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f74115f6-8499-4bbb-96af-ba5859d884e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e81c3c2f-b277-4cf9-9b0f-c8eeda083399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e81c3c2f-b277-4cf9-9b0f-c8eeda083399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14639ac1-dddd-4d9b-a809-e97545e1d5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14639ac1-dddd-4d9b-a809-e97545e1d5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_ff77ae9b-c1d0-4b77-9594-543c31c885ff" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_ff77ae9b-c1d0-4b77-9594-543c31c885ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0184a847-1dda-4216-badf-0a7f3b4aa2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_EmployeeStockMember_0184a847-1dda-4216-badf-0a7f3b4aa2c3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i2cea425be9b546b4880d728534a7242e_ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3980c620-8088-4447-b8b7-5157db3e9965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3980c620-8088-4447-b8b7-5157db3e9965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a46efe9-4aa0-43b8-b120-4d8a5e2d810a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a46efe9-4aa0-43b8-b120-4d8a5e2d810a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:to="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ec705f-4e83-4523-a056-fe01d58d3d31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9ec705f-4e83-4523-a056-fe01d58d3d31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b870dda-96f6-429d-9cb4-13eea416fb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b870dda-96f6-429d-9cb4-13eea416fb6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_894e7f2c-7b8a-4caf-8b32-3c66efc9be8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_894e7f2c-7b8a-4caf-8b32-3c66efc9be8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended" id="ie76c4a2dcee94ba899e68581dbb574a1_ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57df9366-7b15-4ede-9863-3b894ca01b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57df9366-7b15-4ede-9863-3b894ca01b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1df19fea-6b82-4b4d-b1cc-bc508b1053dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1df19fea-6b82-4b4d-b1cc-bc508b1053dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd483279-117b-4c6c-9bdf-5963f3e64b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd483279-117b-4c6c-9bdf-5963f3e64b93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c43eb59-2e6b-4544-b298-3ed8f5e9d8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c43eb59-2e6b-4544-b298-3ed8f5e9d8de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:to="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c54b638-9d78-454d-b918-32e3ba695d28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c54b638-9d78-454d-b918-32e3ba695d28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7d585fbb-6654-473d-8916-d6aae383d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7d585fbb-6654-473d-8916-d6aae383d39b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="extended" id="i4babaa3a326f41b99b77200ab2659e2e_ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended" id="i7fb5b27228134d41ae1f57e9dbea4199_ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b43b6abb-4408-4be9-bb1d-7323de29a637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b43b6abb-4408-4be9-bb1d-7323de29a637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d08c69b7-08e8-4d7a-ab9b-cbdc7fe30a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d08c69b7-08e8-4d7a-ab9b-cbdc7fe30a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8258c54-a13f-4166-bfe5-fe58c249b9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8258c54-a13f-4166-bfe5-fe58c249b9dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3abce2b-d843-4a84-8b26-5ea09631ac66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3abce2b-d843-4a84-8b26-5ea09631ac66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_312fdce0-82e8-4abd-938e-9c333ca197c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74034621-54e5-4242-95f0-a9da4ccd8a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74034621-54e5-4242-95f0-a9da4ccd8a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b87f7977-d115-4b05-8042-101c85d7c563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b87f7977-d115-4b05-8042-101c85d7c563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_371b76c4-b75a-4d82-a15d-3704f7c9bb03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_371b76c4-b75a-4d82-a15d-3704f7c9bb03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1bfc5234-e222-437e-ad64-76104b08f2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1bfc5234-e222-437e-ad64-76104b08f2a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2511d32c-4968-4094-ab2d-946a7bb45da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b7552a81-3284-41f4-a459-deebe735a045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b7552a81-3284-41f4-a459-deebe735a045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0c9cc286-67ef-40e9-9005-6b7aa7f79d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0c9cc286-67ef-40e9-9005-6b7aa7f79d5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:to="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aaeba017-3f89-4c00-b1d8-852fc0a3cd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aaeba017-3f89-4c00-b1d8-852fc0a3cd82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_d25a178c-de4d-477e-ae6c-9b31239769d8" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_d25a178c-de4d-477e-ae6c-9b31239769d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="extended" id="i29759081ce13439f8bfcbd68a4ad262d_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="extended" id="i751f7946912a48368e5cb755d5bd8721_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="extended" id="if6f5b54ab5bf4e70b3aaa4f1e75c597b_IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended" id="i4bc6b4bc784b45158b707a59b7b8bcd8_IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended" id="i62722550e2d349299ddab4f5530fb87a_IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i31d7e42d0e4349078c2e979bdb398023_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e956742-3c97-42f1-88fe-357eac0b4bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e956742-3c97-42f1-88fe-357eac0b4bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f96eb50e-f910-4ae9-9532-8da76f08db85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f96eb50e-f910-4ae9-9532-8da76f08db85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6bf5a5f8-1f1b-4753-b33b-d28dfe769619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6bf5a5f8-1f1b-4753-b33b-d28dfe769619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c1160e00-61b2-4c3e-8f34-37c180e34080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c1160e00-61b2-4c3e-8f34-37c180e34080" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f7b1e5a8-4509-4ea1-b21d-47fa02fe3ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f7b1e5a8-4509-4ea1-b21d-47fa02fe3ec8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ecb9230c-7832-47df-a39d-985048759f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ecb9230c-7832-47df-a39d-985048759f9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4ed12b9d-8f55-4d0e-951b-11451e63a25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4ed12b9d-8f55-4d0e-951b-11451e63a25c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6dc28915-ae24-4def-a691-111812fa93d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6dc28915-ae24-4def-a691-111812fa93d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6bfb541c-bf3e-43be-a46c-33def032e731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6bfb541c-bf3e-43be-a46c-33def032e731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5bd365fc-4c40-434a-9d14-7cd68a642b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5bd365fc-4c40-434a-9d14-7cd68a642b48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i7895f1c48c6c4178bf0ce2bcc4c83c05_IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended" id="i4bd895f234174e1f97871cef32050f0f_Leases"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTable" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesTable"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesTable" xlink:type="extended" id="i33290549f49843ba938c99324b2a0202_LeasesTable"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i3dc10e56b2244195b4aaad1d79cd439d_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_f972b60a-ef62-4d08-8b5b-e040bf73734b" xlink:href="nbix-20201231.xsd#nbix_NumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_nbix_NumberOfRenewalOptions_f972b60a-ef62-4d08-8b5b-e040bf73734b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33127624-afcd-4c34-8bda-c159ead0d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33127624-afcd-4c34-8bda-c159ead0d057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_edf476a6-756d-4cb3-8aaf-dddb23b07ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_edf476a6-756d-4cb3-8aaf-dddb23b07ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_dec2b61e-aa6c-40c5-84f6-7298bd4d9401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseCost_dec2b61e-aa6c-40c5-84f6-7298bd4d9401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0a58bc26-6e65-4af6-8578-59fcc5a857d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeasePayments_0a58bc26-6e65-4af6-8578-59fcc5a857d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89bc8213-deda-4a8d-a526-4c5abf342ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89bc8213-deda-4a8d-a526-4c5abf342ad1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87ac9cce-5863-43bf-8801-d4cf6c14373e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87ac9cce-5863-43bf-8801-d4cf6c14373e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:to="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c448d6a6-416f-4a25-8f7a-fde049f57082_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:to="loc_us-gaap_CreditFacilityDomain_c448d6a6-416f-4a25-8f7a-fde049f57082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:to="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b500c135-af3b-47b5-a813-dc50d87d7eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:to="loc_us-gaap_LetterOfCreditMember_b500c135-af3b-47b5-a813-dc50d87d7eaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="i5c70f4d3a1894bb98fa6fa8709fa5365_LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlan" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlan"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/RetirementPlan" xlink:type="extended" id="i9719f381c6f04385a17db3a5a21a9763_RetirementPlan"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlanAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="extended" id="i59dc54d367cf4a80b449a622372ab6a6_RetirementPlanAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" id="iad0ca98287f94bf69225765726f353e1_SelectedQuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="if2e0e25147a14ab2b54dbe24b26df23e_SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="extended" id="ica62b8b0f25a4f7ca44d97f8ee5904e6_SummaryofQuarterlyResultsofOperationsDetails"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="extended" id="ie3b2e907b1c242d19332999927dafdfe_SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ea796f1c-5d89-4a3a-ae29-1cc394253094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ea796f1c-5d89-4a3a-ae29-1cc394253094" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_638e0dfe-c2ff-4b01-aa82-6800f309799d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:to="loc_us-gaap_RelatedPartyDomain_638e0dfe-c2ff-4b01-aa82-6800f309799d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:to="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_e9798a54-7769-46e1-9c19-09274c02df1a" xlink:href="nbix-20201231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_e9798a54-7769-46e1-9c19-09274c02df1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d5f0b784-0e3c-449e-a688-384fb1ba7b3e" xlink:href="nbix-20201231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d5f0b784-0e3c-449e-a688-384fb1ba7b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_8b344921-02f6-4045-ba06-fcc18d933c91" xlink:href="nbix-20201231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_VoyagerTherapeuticsMember_8b344921-02f6-4045-ba06-fcc18d933c91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_5606f7aa-6542-440f-b635-deb541a1d04f" xlink:href="nbix-20201231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_5606f7aa-6542-440f-b635-deb541a1d04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358f821e-d25c-497c-b625-3928fad8ec17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_358f821e-d25c-497c-b625-3928fad8ec17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4fd632a1-92f2-4173-900f-01e66ef35ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4fd632a1-92f2-4173-900f-01e66ef35ab5" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nbix-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_307273c3-e74d-4936-bbda-672c6106283e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85297248-3151-4057-9222-3e61987c6b66_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_edd4c04e-c4a7-4755-adbf-30dda99c7cb4_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionDomain" xlink:to="lab_nbix_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NBI827104Member_fc65e0ec-7403-49b2-b19a-64cd357df096_terseLabel_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104</link:label>
    <link:label id="lab_nbix_NBI827104Member_label_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104 [Member]</link:label>
    <link:label id="lab_nbix_NBI827104Member_documentation_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member" xlink:href="nbix-20201231.xsd#nbix_NBI827104Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NBI827104Member" xlink:to="lab_nbix_NBI827104Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c52edc57-0794-4b8a-80d2-2718295ab6ea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c0045135-54ff-4566-bd31-747a0f657859_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_f8262b3a-9590-4233-862a-0d95a0a73734_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20201231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_69eaed0c-b9e5-4755-97a9-4e00b4fb656f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e049ef6e-8a82-438e-b302-bef382f4166c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ab089dec-d509-44a4-8537-0d7a770ee06f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0e4b9faf-8781-4aae-beda-ee90c4f86c49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_95f0b1c5-efcc-409d-bbd1-d291fe1fd587_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e1785a0c-461c-43ca-8436-f20540591371_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9337953b-b277-41eb-8ee8-873c3ec4d4b2_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_361a970a-e1d0-4b7b-8fc2-ddb3d08ceb77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e6e1e62b-c324-476d-8415-a8c666d3831f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_dfdbfb3b-1acb-4eeb-adee-db73f7ddcd2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_dd039ada-a071-42ab-83d8-d53dfe64678a_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20201231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5a9a7e0e-b633-452d-8e37-70ae06035cfd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior note</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_78aa7a27-4ed6-4f49-9b4c-8a44dbec7ee7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_b49fe9b9-af0d-4568-8f5e-db4933465762_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_7e2cc432-3668-41b7-a0ff-206b19a3e6e4_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1eb4ac99-232c-487b-8c9e-046c6f68a80b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_300c9a33-8a71-4cdc-9c51-0b65e8ce68e3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_7e097918-bf2d-4584-a6c7-c7e59b7c1d57_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928ab7d-b016-44ed-aaa2-17024ae0607e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_e33b38f7-c4d5-4109-a28a-967b8e37212d_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20201231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3af19f58-35c3-421f-b02c-93079c2903aa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_d9a07774-89a7-4f84-a861-02b2ebaaf511_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bf78a797-d83f-48a8-b6a6-eeb67e69dd89_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d9c9cc51-b60e-499e-931a-1d48ab7706a8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d9c44b1-55a7-43f0-9a6b-9519ead8637d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98e6111b-fbf3-4e9c-8154-d27991f72a52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_75a20404-de2a-4135-a06b-7d91edff05f4_terseLabel_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes (in shares)</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_label_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_documentation_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:href="nbix-20201231.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:to="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_eaa0b0b4-1736-4f24-9467-e78fc7d18107_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum employee contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0bd3c6fd-c462-4c97-ad42-a7edfe7dd920_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f51c2a10-ddad-417b-b801-78b6b699594b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_36f053af-8e27-46cc-9ebb-73e3a1a20d61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_df1fb4e0-4c8d-45d5-8ce8-74150d86db65_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_be720006-fdd9-4a09-8ce2-0b79d6f07abc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TwoThousandAndElevenPlanMember_c9bd3f9c-9683-4a66-9fc5-9ce67230f673_terseLabel_en-US" xlink:label="lab_nbix_TwoThousandAndElevenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenPlanMember_label_en-US" xlink:label="lab_nbix_TwoThousandAndElevenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eleven Plan [Member]</link:label>
    <link:label id="lab_nbix_TwoThousandAndElevenPlanMember_documentation_en-US" xlink:label="lab_nbix_TwoThousandAndElevenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand and Eleven Plan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenPlanMember" xlink:href="nbix-20201231.xsd#nbix_TwoThousandAndElevenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TwoThousandAndElevenPlanMember" xlink:to="lab_nbix_TwoThousandAndElevenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_dc8e4a44-7dff-470e-93f0-8ee5952878d9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_26acdac4-91c2-456e-83ec-d6dc85c2a141_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c0956d4c-db9f-4838-93dd-ff872104a3bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_15abaa85-a388-4cf9-84f3-0d467b0a7b37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_94537b87-b365-47a6-be78-907785781ac1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes at 21% for 2020, 2019, 2018</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_164ed070-47bd-4a13-b575-8a5963cf375e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b4e58082-7699-432d-9660-7d8fc9a9d284_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e1d4608c-748b-4e8a-935d-2b1bb4ce80a5_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d4e0dee7-fe38-4697-9c90-88d13b042fef_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a4064abc-c8c7-41e2-b2cb-a7e457a59fcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ae9cc5e6-2597-4138-936d-ed216af080e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_87100336-432d-4201-ab20-6749567df533_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_f3e57641-3ea7-4bb7-8394-bf2a32b27cae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_75171299-5d10-4d64-a6bd-bd0ca6e13421_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b362165-232d-4a70-b817-f7430a3fba7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8163ef6-9674-4404-ab7a-632a3a2feb64_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7f6fc533-724f-45e8-9df1-d78a977291e4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f5d7c28-c436-428a-bee4-09c63ee6c303_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_9f777c89-16e7-4995-b766-7d004d4fd0d2_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20201231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2e2ee212-4327-4787-8cd8-1c6c22d4980b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_369b0596-baaa-4be8-8bec-4213e7a16639_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_6099d1b7-f526-4aad-a413-f372ac96220c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6efc6b67-103e-46e8-ad81-d7f1af9b08f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_400f1f7a-a5af-4137-9a74-bc1a14468a0b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December&#160;31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_4281d03a-3b94-4c60-a3f0-c38602c57d91_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI, measurement input</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3d6f7ef2-21ed-48e8-ba9a-e0ebb29a8487_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_322e0eda-070f-4633-8a13-0617df5d11d4_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20201231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_71bac359-78ea-4415-a746-47adeedae1b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_285354c2-aefe-4f0f-a17f-12f231a6827d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c6865a33-822e-4cfa-a5bc-9f16e34b5d93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9fed8398-f0d3-4d43-b658-fa6dff860cc2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_f6810dbf-b8e6-44e6-959d-390eaafc6a01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_624570d4-5f3a-4421-a3e3-cd446a1e686b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale (amortized cost $612.4 million at December&#160;31, 2020 and $557.3 million at December&#160;31, 2019)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_86a802c6-08bc-4e9c-b61c-d2641ddb992c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4536cd3d-7eef-4e55-8704-3e35d52a8301_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfRenewalOptions_54d45e1f-48c7-47d5-8174-6c0d7d262182_terseLabel_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_label_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewal Options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_documentation_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of renewal options under the terms of the lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions" xlink:href="nbix-20201231.xsd#nbix_NumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfRenewalOptions" xlink:to="lab_nbix_NumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c559c420-0f17-49ec-8ce8-558aaa1d12f4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_65d707a6-590a-4435-9d8f-6879f021e2d5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TradingDaysDuringObservationPeriod_bdc3e936-8fbe-411a-964b-bb2a4d8d6a27_terseLabel_en-US" xlink:label="lab_nbix_TradingDaysDuringObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days during observation period</link:label>
    <link:label id="lab_nbix_TradingDaysDuringObservationPeriod_label_en-US" xlink:label="lab_nbix_TradingDaysDuringObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Days During Observation Period</link:label>
    <link:label id="lab_nbix_TradingDaysDuringObservationPeriod_documentation_en-US" xlink:label="lab_nbix_TradingDaysDuringObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days during observation period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TradingDaysDuringObservationPeriod" xlink:href="nbix-20201231.xsd#nbix_TradingDaysDuringObservationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TradingDaysDuringObservationPeriod" xlink:to="lab_nbix_TradingDaysDuringObservationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_919f3eed-a8c7-4a74-a8c7-be2811a24068_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7e6bc25-8d08-4bc4-8279-cef62087f96b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_364f18dc-3a67-405b-933e-bd13f9a91b88_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component upon issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component Upon Issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component upon issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d120ceb4-41ab-485d-8235-cecd8c9a0907_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_5d50a740-6955-4774-a8bb-fa8adc413a1d_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9165f3c0-5e39-47c0-b9d3-6c2fe941908c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_fe0ee57a-269e-4cac-90d0-7fb816da92f6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_93630899-43db-4f3f-a4f3-deb388ab2398_terseLabel_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_nbix_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other balance sheet details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract" xlink:to="lab_nbix_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a60fcbc0-a804-4b04-8a4f-0ceae5e39e13_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_00412f8b-dbcc-48ff-959c-89a993728c4d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_86754ad7-a5d7-4fd6-8718-45f3dcfb33ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4478db16-feb4-4cdc-9ecf-889ae1d0200c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0c096889-3ddc-436a-9263-164c8d50882f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_9abd3aa8-3407-4fab-a50a-48bc864b5ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_a3e2af22-1a76-423f-9088-9f152de86d8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3a448396-9d12-4f37-ac72-abe290cd8bd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8a3f22a1-6519-4cef-9edb-33c04f13fd5e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_2b7263a6-99ac-48d9-8a4b-eb19f87c4051_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b1ef4ad8-9abf-4dda-810a-dd239365637d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_033f6f8f-56aa-485e-a39d-5baa6d7722aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_531207d5-ea46-4187-aa3d-abf912c8e50c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_30d306c0-556e-4cc9-aa5c-154a3f99f0c3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_cb378d1c-8d76-40c3-a343-94ded3e2042c_terseLabel_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development costs</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="nbix-20201231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_nbix_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_7495b13a-8949-40d1-b898-31261b031341_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_c0904e59-9120-4eda-951f-e0fc757bad66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes (including benefit from valuation allowance release)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8ff9ce9a-d311-4130-ad9a-0752925b9832_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_a94ca06c-a6f6-4b0c-9025-0396f6debf7e_terseLabel_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned Irish subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_label_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_documentation_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries" xlink:href="nbix-20201231.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfIrishSubsidiaries" xlink:to="lab_nbix_NumberOfIrishSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_9c46fd89-7550-4160-b6f4-5070e9c0ceaa_terseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:href="nbix-20201231.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:to="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_4d709a51-7741-4b66-a040-9f6126c8187a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_fcddd17a-3b21-43d9-add1-aa36debb2a26_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_02c071b9-932e-4e00-bd72-9fa2a49cda34_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6a325a28-61ba-4fd5-b8d6-504d09e37097_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8393bef3-a169-4923-a619-28bb1970e549_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f7df9d5c-46cb-4cc0-beee-e6508bc70695_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A2020EquityIncentivePlanMember_166ceba1-da4a-4938-8395-48c3513ec253_terseLabel_en-US" xlink:label="lab_nbix_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_nbix_A2020EquityIncentivePlanMember_label_en-US" xlink:label="lab_nbix_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nbix_A2020EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nbix_A2020EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2020EquityIncentivePlanMember" xlink:href="nbix-20201231.xsd#nbix_A2020EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A2020EquityIncentivePlanMember" xlink:to="lab_nbix_A2020EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c27d63f4-62b5-4e06-8c03-7eb784e53a01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cc8ca3e-91c8-433b-ad7a-96d9e4d5c130_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_32d58c86-3708-4a58-85b8-56106b3eccfa_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made for milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20201231.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_489f81b1-e05b-4e0f-ba8a-520a47f1c931_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5c0c7547-ebeb-458d-a0aa-4686a0d1fb58_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ffe26c75-b806-4e4c-96dd-3d833559aaac_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_32f1491c-3433-4cad-92b0-c59d104e447a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cf4cf477-8c2d-4015-b35b-feb04e5a3f30_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b983946a-c662-4810-8c84-d3db4dd7d254_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3ce0deb6-bff3-454d-950c-613f4f53db16_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5b9a63ff-a4ce-4f33-943c-d981452c4052_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4eccc3c1-ae8c-4fad-bc06-217a0e1222b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_40af1a42-a70b-410e-a549-2b56a9038ba3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_c4795f36-4425-4b3e-b8af-52b19d461f7c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_222f5905-b946-4e22-89e3-08d6881f40f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LargestTwoCustomersMember_5c167380-b334-417a-a6b1-a26019aad54d_terseLabel_en-US" xlink:label="lab_nbix_LargestTwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest two customers</link:label>
    <link:label id="lab_nbix_LargestTwoCustomersMember_label_en-US" xlink:label="lab_nbix_LargestTwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Two Customers [Member]</link:label>
    <link:label id="lab_nbix_LargestTwoCustomersMember_documentation_en-US" xlink:label="lab_nbix_LargestTwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Two Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestTwoCustomersMember" xlink:href="nbix-20201231.xsd#nbix_LargestTwoCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LargestTwoCustomersMember" xlink:to="lab_nbix_LargestTwoCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_4cad224f-8815-49fb-9d1e-895a542b554b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_206a351a-4e15-4820-9696-d66f38f4c4c2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_00de7a88-00a6-4a8d-bd75-0d93f54f872e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e8acb918-cb8a-4269-98e0-344a06c545f9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_66a6c190-d8d3-40fe-a444-80caf83c1194_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20201231.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8d9891bc-3b49-4a4e-8fd9-87e986c066b4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7f607200-4b6c-45e0-adca-05fcaed862af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_320214df-85bd-4c34-8ac6-28b7e7ed1381_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_5966cbc9-1e44-4285-ad58-56792f7d8174_negatedTerseLabel_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_label_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Leases Liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_documentation_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities operating leases liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:to="lab_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_42985487-e4e3-4ff3-8329-a7b78f3e714e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a7554147-1c60-44a2-84ff-5ab3ad7d8092_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_47683606-38e4-4333-9bb7-de7d1369e1aa_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7d728f3b-ffb4-4dfb-9596-86d1e40bebd2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_22f13d10-ba61-4e63-94af-e11aa6c2c2f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_2b11dd10-6524-4449-bae4-9a7e3d04fb7a_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component At Settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2d2a62fe-903f-4943-afe2-4016c377b98d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a60093e2-7759-43e2-8275-ebf68b4810e6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_af2f1b19-f4e7-4725-81f9-27739bcc5646_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_407c9ee3-8506-408e-972c-e321fe02702e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_6abd0198-77d2-492a-882e-e71cf7cdf454_terseLabel_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award purchase period</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Purchase Period</link:label>
    <link:label id="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award, purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="nbix-20201231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_3323647f-37f5-47fa-917e-97648bf541c3_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Received</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsReceived" xlink:to="lab_nbix_UpfrontPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9b36b5ea-f531-4d5c-9eac-e46678dc356a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a29459bc-0257-4925-a186-5cd94774604d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_acdc9afc-047e-42f9-abe3-2c0ce8b5a61e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_c7d1929b-2fd4-4c2d-a59f-230103e43ec8_terseLabel_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_AccruedBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:href="nbix-20201231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AccruedBrandedPrescriptionDrugFee" xlink:to="lab_nbix_AccruedBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a0c59b17-94d3-4450-88f8-1b552f437e06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ac910763-72d4-4e1c-8bce-ef4092e7ab6e_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_42d042c6-d9af-4b3b-9e8f-980db694be3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7da048f9-3db1-4185-b3e4-54ca4670b869_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_150b012d-6877-410d-aea5-565a91754bbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d9f8bf99-0319-435f-99a3-664387f1a09c_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4d80effb-46f5-4ed6-b772-fe4e74e45d93_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_25c6ee56-9ac0-47f2-9f4f-3d1f098b60b3_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer compensation</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense officer compensation cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ab9a6413-f423-4965-954a-d8c6c1761aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_e419a163-1477-4849-8f03-73dce317aebd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_617432b1-39ed-4238-a6ed-028ef8bf6c77_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_b8dada3d-fcaf-4925-9c1d-e4a266f003c1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALMember_6b1cb429-c388-4242-9044-a1f6e0d81947_terseLabel_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B I A L</link:label>
    <link:label id="lab_nbix_BIALMember_label_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B I A L [Member]</link:label>
    <link:label id="lab_nbix_BIALMember_documentation_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to BIAL, an entity with which Neurocrine has a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember" xlink:href="nbix-20201231.xsd#nbix_BIALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALMember" xlink:to="lab_nbix_BIALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a29f693f-23c8-4a54-9f0e-91831a228484_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_f03141f2-01b9-45aa-a789-515a906ac9ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b4c83f11-99b0-4116-8cff-ea4ce62b3ce0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7a767d51-02c6-4015-b2d0-baa8df1d632e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e92077f0-b7a8-4f97-97bd-46340a8309ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_2f4b3eb4-c7f1-4e16-9e19-e915880651ec_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale (amortized cost $226.7 million at December&#160;31, 2020 and $299.3 million at December&#160;31, 2019)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9c8cabb2-a51f-43aa-a5a8-b518faeaee3a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b629469f-8217-4101-b509-de1590cee9f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_402da3dc-60d9-448e-b84b-32b7bc0319fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Unvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7f852e15-cd74-421d-a174-9231d3c121dc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54927576-085f-48e7-84f5-e6508e8ce4df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to settle notes at initial conversion rate (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33ae630b-a69c-42a3-9d7d-c8b847d8e8b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair values of stock options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5a00e2c8-783f-4dbd-aa58-ab0769614366_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_554990bb-1f6e-4d12-8e3b-72ba2e6ffc74_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_3392106b-c66d-4d99-a9a8-6c721bef7fb5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, discount for lack of marketability</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2cb6ce3b-da8c-4c8a-af52-3f72a29f857b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7fea0a23-2378-4907-94f6-3d91e263a7a8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_46babf61-a232-4f3a-a28c-61a8da6c63db_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_301c0ce2-41a0-401f-9cd2-64bc1db38666_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_f57e9f72-7f14-4670-864c-98119fc7a442_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0961d7bb-7b47-43ca-89a8-ce4cfb4102fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income tax expense for continuing operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_090c1452-59e0-49de-939b-597780243bfc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on restricted equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1bf13add-0dc4-4aa0-8cb2-776bcc1411f5_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e666342d-ed17-4c4b-9c2e-44e1f4107353_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss included in earnings</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f853b969-d1c1-48db-be61-38c30179ab8a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0127e321-4478-485f-8763-4e3dff2cab85_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_fc29e09f-88f8-4d18-b19e-832e469b7700_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f25d6b58-2a37-4b8a-9140-8234c1a9f0bc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Recognition Period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cf9e21ba-5319-4e7d-a62b-cedfb4fd37d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e872537c-59c9-4155-b20f-682fdd193da2_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b41a22ac-0a58-4e6a-a3df-fc860b8b459a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dd0a6bb2-92f7-43bc-a500-e71c0258ffef_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_686cb7b7-b885-4a45-92ef-bb32bd17ba0a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_555a2259-925b-4680-93ee-a4102fbd2c78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7033d75c-ac10-4d89-8877-a52e9126f322_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b6d5a3c9-d102-49ba-b260-e03aa7465bfe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_efd9da72-454c-45d6-97a9-8ac007b9fe1e_terseLabel_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible senior notes due 2024</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the 2.25% Convertible Senior Notes Due in May 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:href="nbix-20201231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:to="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70518b14-7f8e-4584-b401-368e80142b37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_84b1267b-7b90-4d5c-895c-d95abb45d104_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4de14238-5db0-4ee8-8816-2d5a83a05590_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88c9338b-ac2d-408c-a3f7-7d23abf1b0c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_66e3cb0f-1295-4d68-984a-2f424ae66847_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_725f6345-bf58-4aff-9e27-7ca27a9e3d58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net valuation release</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f27e661e-e3e4-4d1f-8428-e00b2909b4c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_75183a90-9976-4f23-ad2e-a8e4f022f634_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_355e0ac5-e302-42ea-b16f-77f8951ad81f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_0835919a-6f2c-4be6-a6b7-ce79b72bfbdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Quarterly Results of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_51a1181f-7224-434b-9c70-65ba36ead5b1_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20201231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_84abea7e-e987-402b-90bc-e6855fe1c304_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9c1b673f-842d-47eb-8da1-9b77442a6284_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74209b62-30e7-4515-8bdf-a1bce7496b58_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_6ef7c987-99ba-47a3-bb89-2bee5be1c4a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3943da82-f5dc-4c61-bc48-28ed8df5c05b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d1645d82-d021-4e41-bcf3-aafd345619a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a2f71b77-580c-4b12-ace0-8ac3304f5291_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b6cce3b1-37aa-4d5f-b724-6893323d9de4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before (benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_253f132d-e93f-4c3b-a19d-29b4e0337e26_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_94769918-3a16-4ea3-81cf-b01bb788c976_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13382376-07f7-43d2-81d0-3b627ab5aec1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Outstanding (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_54430959-9e5e-497c-ac12-67602cc92533_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6e95887f-1418-4f8b-8258-22e0ecef908d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_732c25b3-e8fc-4c31-a6f1-ded4b9481ade_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4528af3b-0c9c-4dab-8585-3e00f9e80427_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and changes in restricted stock units outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_ff3190b1-3e7d-4775-a801-ddbda0b1401d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_73e3afff-dd38-4573-b5a3-e6c48a93f087_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0136ffc9-8474-44d5-8caf-77a8b1fb6635_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b0ec5721-020b-4c5e-a34c-016b5addf11a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ea2edc00-74a4-4931-bb4c-b0839e4a537d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1683441b-0d2e-4c08-b754-e9153ed035dc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e9ff9933-a78f-4e07-9f86-1d8ee62bc984_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0cf3f7a0-825b-47c0-94a8-746a30134526_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_224931d1-3a05-4e65-ab6c-fa9bbc828d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_07777812-8fb9-4707-9bc6-965e4b3705b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_77ecc41a-6146-48d4-b798-201099655549_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_2c87cb99-720a-4cbf-976c-5ddad5490bfc_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0421c239-28df-4e98-8193-7a795e46dfdf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e140e1c1-11dc-4467-b1d6-a6a7ec1295c7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_37b2f489-ce73-4bda-96da-bfc71329f8a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashMember_23470b3c-758d-41a0-90ce-1f0017c44d99_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_nbix_RestrictedCashMember_label_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label id="lab_nbix_RestrictedCashMember_documentation_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember" xlink:href="nbix-20201231.xsd#nbix_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashMember" xlink:to="lab_nbix_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_13fa76f1-a401-42c2-91f0-5f3bcca1a1fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8fb9929a-a395-4bb8-be67-472911da1d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_70227242-094e-46ea-98bc-1e443dfc4034_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_11356c2a-4248-49bc-b2f1-6477b8a0f17c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_cce7195a-bee1-4657-a8a5-4c5cc6b5a95c_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_a493a282-7f50-4dc6-8523-411f70603d33_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2f891216-36b4-48ed-af86-bfe8b84b99e1_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7fe28568-053a-4cba-9119-35557f46a09d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes on earnings subject to income taxes differs from statutory federal rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_4469279a-6dc8-46fe-b01a-8458b175bf85_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_bf84aee8-4445-4630-bf49-1b762fecef4c_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential later stage milestone payments and royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c74c70d5-d813-405d-8778-bd6e06ea8dba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6b6caeff-b073-4f0d-b56e-9b139746f92c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ee387175-b7a1-4945-8904-b17bc496ec7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_46329932-0a29-44a1-bfdf-62a219f35fe3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c82b91cc-f7a7-4c77-9817-e62f4af7cfa7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6ccf30bc-bc1c-4996-b3a3-f6c9c558a46b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ad7dc963-c13d-4505-9c34-2d816664c64a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5614f82d-a92f-411b-9bbf-17b2b00156fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7636954a-075d-416b-9ef0-f3dde37cf8ff_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CostOfSales_db8f4164-a479-4b32-b142-f462254000a3_terseLabel_en-US" xlink:label="lab_nbix_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_nbix_CostOfSales_label_en-US" xlink:label="lab_nbix_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Sales</link:label>
    <link:label id="lab_nbix_CostOfSales_documentation_en-US" xlink:label="lab_nbix_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CostOfSales" xlink:href="nbix-20201231.xsd#nbix_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CostOfSales" xlink:to="lab_nbix_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_56d9f2ea-2eb8-42f1-91d6-38d68f956caf_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f3cdfccd-d31e-494b-971b-312b54bdfcb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ab2423f7-6d51-4b68-a7e6-2366a0fc6dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_1438b705-e294-4b57-8245-7e1de02f01f0_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_d865a5ec-412a-4ff9-81b7-782d2ef6d70f_terseLabel_en-US" xlink:label="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off</link:label>
    <link:label id="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_documentation_en-US" xlink:label="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding the write-off for research and development assets that were acquired in a transaction other than a business combination during the period. Excludes software research and development, which has a separate concept.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="nbix-20201231.xsd#nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_76ad5a76-caa6-4ba9-8d7e-cfbdf9399e7f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_243769ee-557c-405e-9d00-4f807bf54ad8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_e2c9b75d-e4a9-455f-bc27-f8f7b89c4e6f_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_849b305f-975c-4c00-995a-f85856b9fc11_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments for operating leases that have not yet commenced</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cancelable future minimum lease payments for operating leases not yet commenced.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:href="nbix-20201231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_df908757-8930-4101-a152-76b266934c05_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_4ecdf237-5b6c-4966-aecd-e7e313d9c533_terseLabel_en-US" xlink:label="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events of default percentage of principal and accrued and unpaid interest due and payable upon default</link:label>
    <link:label id="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_label_en-US" xlink:label="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default</link:label>
    <link:label id="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_documentation_en-US" xlink:label="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events of default percentage of principal and accrued and unpaid interest due and payable upon default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:href="nbix-20201231.xsd#nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:to="lab_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_a8674fe0-6217-4156-91c3-2ddfc7ca97ca_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionAxis" xlink:to="lab_nbix_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad41e2c3-0c37-4d39-a2e2-f71017389a33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8da93288-e344-4c89-9489-83699f419b7f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_84cf3f6a-09cf-4922-8910-b48feb02af99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining discount amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f24ca632-c7c3-440b-91c0-99d28aa941fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b7dd4d25-00c2-4d23-9856-6ed62c2117a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9e83dd99-ddd1-49f5-aec5-5d71ca145103_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_0c6b6ad8-f318-437b-8e22-6bef2f42957c_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_37af7dfd-995b-40e3-8d4c-cb951e06072c_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ae0bb34-d11d-46ed-b6fe-f94baf1332a4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d66760b8-6a5a-44d9-a32d-5e04cd580b29_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9cba3516-1ee9-41bd-8c02-ab94292c02bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f9fd97e1-18f6-4271-a70f-7c4430106414_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_27f066f2-38e4-4bf1-b936-33156294eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_1235c514-77eb-4339-add7-dcc5e8740e5f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_dc7686aa-b20b-4d8a-95d7-cb1dfd2e92fb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_2e643e99-2198-4610-85ba-41d532c93fa6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d3c9150-7bd2-4c7b-8762-f2eae44213ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3233b008-4333-4953-b443-eeed4e4f4ce2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c9f31e25-1ca4-4838-be1a-78646b63dedc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4884c364-f693-4c96-9d9b-5f100b2226a7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_13cc0e40-9559-44f2-a285-e15190c42624_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ac4f6fe4-2510-45d3-a200-cad0f244b544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f4efb838-4897-4a1f-a805-edfcc0984beb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions for stock option grants using black-scholes option-pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8dd58f5a-7fed-4baa-8adb-fd0e273f33d7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c7e778fb-2190-4d50-aa84-a5957ab58f92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_786132a7-e52d-4312-a697-fb97af20244d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c08a03ce-5644-478b-adc7-2d61319331a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50ca7301-5cfa-4179-ab1b-a8d556f73c4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6333fc62-f564-460c-88cf-f9685702bb2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary and changes in stock options outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_523904c5-0625-407f-b6f9-126726562233_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses and fair value available-for-sale investments in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7bac58a7-6a67-402b-b592-61000d31bf64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_067b8eeb-c9a4-42bc-b30a-99f748aca5fe_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b6e154d4-abb7-4c34-a325-b437bfef487d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e911fc7f-5ddb-4fce-8bcc-874e945df9a7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a75c3b26-4fbf-4411-a3e7-4f5963c7e3f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1f8b2bb3-0986-403a-ab85-50f7115f9ef5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_98ebabc6-575f-42dd-bb19-9058a177a89c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fb751cb0-7b74-4aeb-a078-a5af0e5964df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6540a1c8-7bd8-40ae-8263-83dcf37d3315_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0bc21b53-2c7a-486d-ada9-0e774a0248ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_5763835c-8d33-4d0d-a0f3-57496701e864_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_096d12ed-343c-4294-baaa-2a6620b85f24_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_7c596b8c-a9a5-4c06-9b4e-ba578e1d0e7e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_582b8de7-22af-4a5b-9f98-bedd96f6dffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_46f5f158-fc08-4789-8efb-126067a251f3_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20201231.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8bea0011-4178-4f54-b667-cf900a64d010_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a71018c2-5b2c-4e10-8284-18e908222f82_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c52d7a58-d139-423a-bc1b-9c6eff7a6ce8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_d106fbd8-5156-4e11-8832-7bfeb3e2a498_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d125db6e-2f62-4818-b5e3-b5270fa15494_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a165db25-e67a-43e0-99d9-dcca1584d17e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b59cbb9f-b207-4676-887b-d12fff4b7cbf_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_306f3379-80d2-4361-8bda-ff59f449a251_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_b6aa2861-6097-457a-a5e0-54f8aaaef493_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_c1ebd943-09f6-4b7a-adae-f7351169cd2d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cff10fcd-7a62-4b11-992d-9ced3dda9108_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b775c61f-a74a-4e1e-a325-22f7816e9bb7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_951aa794-3a62-4db6-bddb-7f2a34c556e0_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_42a4ba99-1c78-4d3e-898d-5eb597aac89d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_3def4db4-8190-4d2a-a0f2-1a6530cf1374_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realizable deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_15e2851d-1d05-4f0a-9035-19f97c1f703b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted purchase price percentage of common stock authorized for issuance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_db03f2d4-7f3f-4962-882c-e56e5c8184b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5118acf4-dbd3-4215-972f-4801e11e8a38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_420f2f53-e28c-4fe7-96a5-85d929750490_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1a5f982a-2052-4f25-8703-305ab6158eaa_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4fd0bd4-4ef1-4c6e-b402-d4d431a6150c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dd37b986-4d93-4675-80b7-fce65363c3b9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ab3c3ef0-59e5-4b81-baae-c5dcc7c275c7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4fdb59cb-a0cc-4a4d-986b-8d85f13264cd_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2ad720e8-fede-4930-adf7-0e823a3acde2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d412de87-ac18-4b40-9dad-a67378f6e564_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c53ac4df-a283-4408-827e-d18f716e491f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2c033460-3d23-4de8-9a3b-07037a8575ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_82b5e663-5833-4f7a-94b0-7e21ac29bb24_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_ff287abc-7f69-438d-aa90-db501253c996_terseLabel_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRSUs</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_label_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</link:label>
    <link:label id="lab_nbix_PerformanceBasedRestrictedStockUnitMember_documentation_en-US" xlink:label="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units which are awarded to employees after certain performance targets are met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:to="lab_nbix_PerformanceBasedRestrictedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e69e4eb6-42f0-4997-8167-9a56fbf474d1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_02e3b054-5bd5-4f67-bcb6-3d8e3537cab2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_6424fe2a-c34e-4a37-a0c9-cbea24fb7efb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_666d23c2-98f2-4141-bffc-6ba0edfd604d_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities fair value amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_d03e3f9a-a45f-4a79-8496-71a606598c60_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, beginning balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_5bd1a0f2-0302-4941-a6a2-a65f958174e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, ending balance</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LargestThreeCustomersMember_1e97f6d9-6714-44d6-b7d8-4e9d5c5efc8c_terseLabel_en-US" xlink:label="lab_nbix_LargestThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest three customers</link:label>
    <link:label id="lab_nbix_LargestThreeCustomersMember_label_en-US" xlink:label="lab_nbix_LargestThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Three Customers [Member]</link:label>
    <link:label id="lab_nbix_LargestThreeCustomersMember_documentation_en-US" xlink:label="lab_nbix_LargestThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Three Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestThreeCustomersMember" xlink:href="nbix-20201231.xsd#nbix_LargestThreeCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LargestThreeCustomersMember" xlink:to="lab_nbix_LargestThreeCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_f3a2c876-17ca-4da1-a6b8-0b841183bed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d39ac4ed-dd64-47b0-8c7d-000fd0a1b115_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_b52d8bee-f60e-4279-9509-de61c535ea16_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_afe2ef0f-6e43-42ad-bb98-e4c01cfdb5f0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e81130f5-1894-43ff-b59f-23791b796533_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_a6d2d975-b926-41c5-8011-5332ba06de12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_56ada8e2-e0a1-46a4-a34f-dfdd1c24efcd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b82d7682-5641-4f33-b8f3-4c8d378856f3_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_d861e956-f9e7-4ac2-bf93-de5ed19830c9_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f88aca70-2fbf-4944-b90e-15c09a744ea9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a001abe4-fafe-47a6-8117-7b5741992a6e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0d15a653-c297-495b-9d6e-288d6a432f71_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_be9975ff-e6dc-44d3-acb9-07a916f59459_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e8e20e62-4436-477b-bc61-e4a088e936d4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_26a9f361-da79-49fa-a1c0-f069df68e457_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_7bf88538-cbed-43ec-b92b-638d346efeba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ba0a6002-ae13-43fb-b60b-7258c296d0df_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cbfbb4af-bdfe-48e5-a8e4-51bb1ffe8638_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a534703f-56e0-460e-9696-9e0b9783d0e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_10834cca-da3c-429c-9c97-fbacd5375241_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_92963855-1683-4c51-9fe9-8296aa7ea795_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c3ea6c0b-4983-4b6d-b56b-e7d4a7b978df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b8d8c30-df9a-4626-aa9f-af2d30a33666_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_92664aa7-76c4-4e08-8885-b4fdf66b9314_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a7b9e4dd-3354-4061-bf9b-bd41c57b49e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9caa7280-8b42-4240-a387-b02d9b5c5c5a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for employee stockpurchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9a48e922-849b-4954-b09f-e7625adb7597_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_67741da4-ef70-450b-96f9-093625b05635_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d64a616a-71ab-4756-97b8-839dac7a9b9c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3ee450ab-60a8-4205-bffe-e566a12eea03_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d99803d4-8516-4950-9c4c-8d50d41c229b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_2a718f3a-f221-477a-a77e-3c69cb2d6612_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a35b876f-6921-4994-bfd7-e093c7583387_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_5935a9db-ab35-494f-b4d5-8ee38a952e11_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_1975a081-e91c-4e5e-98fe-665467e982b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_e519d92c-58a0-46bb-a4d0-6becdcc35982_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired tax attributes</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Expiration Of Tax Credits</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation, expiration of tax credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:to="lab_nbix_IncomeTaxReconciliationExpirationOfTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_47d4fa19-df1a-4e90-9f1f-5c286cc91db2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f528e872-bd25-4b46-bce0-be49e9e8238f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8bed491a-55f1-41dc-9f84-a4499af88aa5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1699e844-2198-41b3-bbd2-246c12aef44c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_82df3b08-7b86-4c71-aea9-8503433d96ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d2b47bb-52bf-4436-9652-ceb92a9882ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_53fd3ac1-cf7d-4f0e-832c-403c8e1d1f10_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6214688d-d02b-4518-8d23-db06a0f822a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0a3ad69b-5619-440a-a245-d47157fbee27_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c455edf4-4746-4808-92da-626942fbcfe8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_98f7e8dd-9552-413f-8213-1ecf3514d144_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Mitsubishi Tanabe Pharma Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20201231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_3c6198b6-befd-45ef-8ced-b2e2424e0a4d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_f6363154-8f6d-47d2-8551-dfc77f853195_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4d85ce6f-a417-43ed-a93c-177a475dc7e4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6ec9cc77-ccd9-4a2b-974d-847e8d780afa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_acf72204-4f1c-417e-8b6f-444eadf7190a_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments to be paid under a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b6614d11-f94b-4e34-9829-56d90f2c2dd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_be359af5-c551-472a-a419-d95afa13b4be_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5ea5e635-1cc6-493c-abf4-ec4d6a64f90f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6378636b-5c9f-4177-aa95-f80771ccb4a2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_83014c4e-d5ee-460f-b7f3-1ba0a4b9633a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_19c00a87-53ef-4b3c-b762-c5afd41ca2ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_dc9388dd-e720-479d-bec2-9530a18863f4_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20201231.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_19da13b6-9124-4438-a0d8-688a028133f8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_933a813b-4e44-424b-aee8-4e55b69cd764_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_89d8f0dc-c64c-4949-afcf-ce505c797e42_terseLabel_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion observation period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_label_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Observation Period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_documentation_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod" xlink:href="nbix-20201231.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtConversionObservationPeriod" xlink:to="lab_nbix_DebtConversionObservationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad5852a9-54bd-46b2-a468-0535eb11e529_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_067fbd98-cc0f-49e7-837b-fc2e956e49f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dc819c37-950c-46fd-b429-d42fc864dfde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d4a1689-0304-4210-8299-1eb05790c7fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f76e8e7f-defa-4ad1-b06e-45fc7fd157c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ea193a4a-3bff-4aea-a5b0-92de43145448_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6ddd3618-a105-4a09-9ecc-2a4d420b5d07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_36887410-1e32-4f86-a1f6-2d387f9ad1b3_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of the statute of limitations for the assessment of taxes</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d7b3f71c-2800-4a20-8059-ad1067ebfdf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c18ae67-ad4e-41b1-9c58-9e9141aa6448_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6a25f00f-2f80-4905-bc43-67fa3153a198_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_b06eac54-87c9-4eb5-ac24-512184a78be6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_9aee97a7-1587-4024-a6bd-cf2c709e1569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fb90a487-d2db-4929-819e-9d5651f6a5d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_154713c9-cb25-486e-bb8c-39a16baa56de_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee</link:label>
    <link:label id="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense branded prescription drug fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:to="lab_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_079fbc57-9d0a-47bf-ad62-d169a705e552_negatedTerseLabel_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_label_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:to="lab_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_22e16828-5275-4106-adae-433b8137c277_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9e9b66d-5ebf-40af-8643-30d9579ad5bb_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares excluded from diluted per share amounts (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_35afb427-a938-4a21-81b6-a992b731e1fd_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_e21da351-80b9-4cd6-a12b-4db3d2988566_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5ba450d9-b564-4ba9-99fe-feadc3c7473c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_199fa23b-d7b4-4735-9803-f381209fe15e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d8a2f64c-f3a6-4756-85ec-fa16640b1678_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c44d8c78-a1be-4b23-9802-2d806c781c70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0b55343d-005e-48c5-8375-75e363ad6888_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fe2240f2-7b72-43ca-928b-9964d1cf7e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6e92c3e6-b188-48fb-b23b-53cfaddce845_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b6c74f2e-4ac3-4ee7-b413-ce1df209347d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_82321ce3-f28c-46b1-90e9-0e1dfef29959_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a87090a9-a8c8-451c-b7df-bdd676039789_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2aaa32c5-fa13-4503-86c9-fcf72f1244e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_af10fc8f-a37a-4962-8473-268d0f975e31_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities available-for sale</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_299a08fa-4f88-4325-b244-7471db0b6dc7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c7feef70-fada-4028-898e-822a2f536103_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_639da134-7e3f-4f94-b29c-fb456d755768_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a33f39cf-738f-42b1-807c-1c1fbd0d66c5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bed43b03-1c41-43b1-ae08-e923b47d300d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2c03e3f0-a847-4483-ab12-de103af17c02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_af9b4df2-90a5-4509-a468-1779aad7c654_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the equity component upon issuance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LongTermInvestmentsMember_be254079-a110-4bf7-9274-98750aa4647b_terseLabel_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_label_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember" xlink:href="nbix-20201231.xsd#nbix_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LongTermInvestmentsMember" xlink:to="lab_nbix_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_ba4c2972-8fbd-4b36-ab31-516d7945258a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_b59cbc96-5eaa-490b-83f7-d13dc75863d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_d80d18ca-e55f-433d-a804-14bdb78a4e26_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5626c598-a642-49d4-8851-91e18c7c13f8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6cafd561-b10e-4047-9b9a-ddc716581a52_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c75edf9f-cfc6-4b93-9836-2aafe9337be6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_960958ff-d49e-4a61-91e2-05496ed39b40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry forward, net</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_468b4fed-21c7-4a06-9b1d-ceccd9d964bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c0c0bd2a-934b-40f0-935a-ddca5bd3d8e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_741abb29-0b8a-4e73-91c0-947b6537375c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ae9768c6-b4d4-413e-b757-77fc0ede91c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2ff6d26f-30c4-4fbc-88ac-55723394e2d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0b2e67a8-759f-40cc-8ffe-471059a13810_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_1acd9a54-d162-4231-9d14-bf0db99ba0d8_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_e78cecc2-b01c-4c26-a438-791e76146276_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_da81f50f-6900-474b-a3f2-c19f2d13d442_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_551e2189-a1d1-4154-80f4-949287984d34_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_48218d14-8d55-4ab9-ab3d-1de751e0a6cc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_73867921-f319-4976-80db-6836893cae38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesTable_faaed203-a6dc-4a80-a360-4aa75de5235f_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_label_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_nbix_IncomeTaxesTable_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesTable" xlink:to="lab_nbix_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2caf97e4-f68e-42d6-b683-0eb800e84a61_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5ddc2a4e-1bfe-4968-9bc3-2bac5b0a95ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost related to share based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3e0b0dd8-2fdb-40b6-bd3a-ec9ccf6c4939_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_fb53d919-1e8a-4a0a-929f-71473f6d52c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cfd444a8-691d-4763-bc67-ad7e84ee1ab9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6fb28d11-7b67-466b-bbb9-caa1303a75c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_49902e10-95d0-4734-a649-3a0f7a769f02_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_7a310930-d714-4096-a57f-8c67272b80fe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7b0e2231-e2af-4d2f-b9a9-1c2eacba6547_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_475fe3a3-9e1c-49db-99ae-d73c7d2fce8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_032748ba-9a85-44a6-8f23-e161c891f958_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_faf85034-d1da-4c50-a78d-b6e55ae8ebc0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_dba6a632-cc01-4ccf-a4ed-e78aeceb5bc6_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5a009795-3b04-4a91-ab9b-343cfc1d22db_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_2c18ce6b-32a2-4526-9859-8b0e47280a0f_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20201231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f1c2bf8a-7df1-4d01-93d1-0a62e396968e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_00b3c89f-bf99-408a-9d31-488c34d752b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b1bbba43-5ddc-4ff7-b9b1-381447df2315_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ba37e242-5fea-4ac3-8077-40e491d473fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9b016eac-cf8e-47de-a31b-48a2fe8eb27b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_2bbc0369-0342-40d5-89b7-ac895206ec5b_terseLabel_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_label_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Related Reserves For Discounts And Allowances</link:label>
    <link:label id="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances_documentation_en-US" xlink:label="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:href="nbix-20201231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:to="lab_nbix_RevenueRelatedReservesForDiscountsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_10ad8023-c3a7-4632-92b0-84a5291288a9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5961f29f-5159-42b0-bb51-bb187eaca4d4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_6a5c268c-8eed-4caf-8fa4-66f037a0b246_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off threshold period</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_047f6752-981f-48c4-b96c-d809d77eaa36_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_9d71b9cc-2805-44a6-88c8-84be21773028_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial repurchase of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodOneMember_9281b3c0-408b-4b6e-8480-4dbcae1abdc9_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodOneMember" xlink:to="lab_nbix_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6d0b28d-fc37-4606-a63a-09e05d592646_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of minimum lease payments for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f3d6294d-4a60-4aad-bd7d-33a7be959285_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_282af068-a591-447c-a25a-b9fad1ce7979_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock_e55130a9-fab8-492b-a958-41ea7cdae3ab_terseLabel_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Activities</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description Policy [Policy Text Block]</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description Policy [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:href="nbix-20201231.xsd#nbix_BusinessDescriptionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:to="lab_nbix_BusinessDescriptionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fcfb5d12-f4b8-4f9f-8db1-8b03ddc0a13f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7fd34bb9-e55d-4783-8456-47b893d66857_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9a749882-7395-49ea-9ebd-fb078545c506_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_970ad004-ae1b-4a48-8de0-62b591951add_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_36b88947-46b2-47f5-8e7e-b1024ab4c6d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available-for-sale in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_ac64d724-952c-4b88-9a27-99568c3e76f0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ScientificEquipmentMember_bfcb1b0c-54db-4d18-aaea-02b7b36809bf_terseLabel_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_label_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Equipment [Member]</link:label>
    <link:label id="lab_nbix_ScientificEquipmentMember_documentation_en-US" xlink:label="lab_nbix_ScientificEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember" xlink:href="nbix-20201231.xsd#nbix_ScientificEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ScientificEquipmentMember" xlink:to="lab_nbix_ScientificEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_84b146b7-5f39-4239-a348-76ccb4cf3023_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_31a8daea-955d-4f4d-a36b-34d91f151d8a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cdaa0330-f864-458b-9e9a-896d30d54137_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3cd207ec-ffdb-484b-b07d-96c0d07084f8_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_916926a7-334f-4e6e-a5da-7b1f8d977792_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_e635bf4d-1dff-462f-bb31-efb5bb666a56_terseLabel_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity securities</link:label>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_label_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Equity Securities [Member]</link:label>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_documentation_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember" xlink:href="nbix-20201231.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TotalEquitySecuritiesMember" xlink:to="lab_nbix_TotalEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dcb35dab-319e-4184-a74c-54324b4be483_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d537480d-55ef-4d8d-8895-caa1b8b032ec_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_32d4eb22-6c92-447f-8cf9-5a7c06a35d22_terseLabel_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d26a864e-5262-44cb-9b19-362758a12104_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_71d0bb64-afad-4268-8811-8c85ea03049c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7c621f6b-bed5-42fe-9757-f09381cf7517_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_89777ea8-82ea-41b4-9fb8-84e567002fcd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncomeTaxesLineItems_dfe541f6-6074-44d5-8765-7d6d1c55ae59_terseLabel_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_label_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_nbix_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_nbix_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncomeTaxesLineItems" xlink:to="lab_nbix_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f9add46-f2cc-439d-b4a7-608fcad167df_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b10a5290-52b6-4b47-84eb-ba592906ffd8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_955ce4c2-640e-4b14-a345-138d655889af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3fc71fb7-c575-438c-9c76-21c5f4426034_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8950ab35-9146-43ba-bb48-420f76c00ba1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1a29b907-59df-4e22-b697-75d5361decfa_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_a6fcec78-585f-47ce-9d35-07d603c842b6_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20201231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4727d6a0-aa40-4249-9eda-4d8142e4388f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_52bd76ab-3f6b-401b-80e5-9ce145bde626_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_28cf684d-6ceb-4687-b5b0-664ce2295005_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_46c6f401-cd49-44e4-bd7b-1945d6113eed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised in period intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_3d2decae-6e16-4cde-b091-0b7499eb3d0b_terseLabel_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates</link:label>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_label_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates [Member]</link:label>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_documentation_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember" xlink:href="nbix-20201231.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DevelopmentProductCandidatesMember" xlink:to="lab_nbix_DevelopmentProductCandidatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_461b27d3-ebe8-42c8-9484-6de67c8783f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes net of discounts and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_405d5f83-c18a-49d8-af14-8a8986285eb9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_66ed2ea7-474f-4e13-97ef-1c4df1610ba0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2bd90032-e1b1-4e25-b0c4-f2030ff289b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b89ed540-acca-4971-a425-563b8e319066_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9ecdd79b-a22b-4863-9a9e-6729720c0838_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e678e23a-b429-47aa-b2cf-012d7e21ea0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_864aee49-e224-487b-b718-2a9ce095a4c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3afd3a9b-6da3-49f0-80b3-abca460ca7c9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_4fa281dd-cf15-4111-83a6-c42d94b95607_terseLabel_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_label_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Liability Component Immediately Before Extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_documentation_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:href="nbix-20201231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:to="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_5c31b79e-5246-419b-ba8b-e5bb5a9d30e5_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ca98cb25-9ec8-471a-8a6b-39c7e1023b0c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f8e9f358-c169-4bc8-a4d4-3dcfc2217044_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_5642fac3-9c40-4204-bd4f-58a88a0a7632_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental funding provided</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_a1ec1ac2-57ac-4775-9b4a-c2b49257ac43_terseLabel_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payments for commercial milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments" xlink:href="nbix-20201231.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialCommercialMilestonePayments" xlink:to="lab_nbix_PotentialCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_5afbd24f-f848-4123-bf32-90b6a7ed9182_totalLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net of deferred tax assets and liabilities</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsLiabilitiesGross_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assts (liabilities) gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_nbix_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_37e8448a-b550-471f-8603-b3004794ed4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of PRSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_43649bea-5ee1-4e2e-82e2-1ce648789120_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_715307bf-67b9-46a7-87f9-53362e3ff97b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_2dc125c9-be09-4a0e-86aa-2dd6bb5aab20_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_08625df4-9e7e-46fa-a2d1-ca37696e30fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_dcacb234-a668-47f8-9886-69f093e974f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a6d04f60-7ad7-40b0-975a-63c1bb15106b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_884704ca-dcd2-4183-b662-85c28fbd2a02_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20201231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_82e4e8cd-59d4-4ef3-b9e5-84b87d0c6cdd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_defac361-44d8-4fc5-a20c-b3fceee59238_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodTwoMember" xlink:to="lab_nbix_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_f98ba622-a9dc-4bfd-8aeb-40fe3c0499fc_terseLabel_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_label_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Leases Assets</link:label>
    <link:label id="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets_documentation_en-US" xlink:label="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets operating leases assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:to="lab_nbix_DeferredTaxAssetsOperatingLeasesAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3815741b-6d3a-4a26-ad70-53d97047a370_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4167339f-9c7b-4dc2-bffb-6b8d239d2a00_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8455e145-eb90-4526-a5e4-9ca7fdaeeb3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddd7f4e-c4ab-4750-bc6b-b5d0d5cb4764_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ResearchCollaborationTerm_bc32c3b0-193b-4002-ad13-9665c5463ea8_terseLabel_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration term</link:label>
    <link:label id="lab_nbix_ResearchCollaborationTerm_label_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration Term</link:label>
    <link:label id="lab_nbix_ResearchCollaborationTerm_documentation_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm" xlink:href="nbix-20201231.xsd#nbix_ResearchCollaborationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ResearchCollaborationTerm" xlink:to="lab_nbix_ResearchCollaborationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ff3d430-e112-4839-99b8-8f4f6ffb64b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5967aa2d-3086-4be0-8bca-f703b144f6a3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_caef5917-d60f-4bfd-915a-57987fdb2b25_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e87c480c-c6e4-4e0d-8dd3-cb0146e08eae_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5904867a-933c-4c3d-9eaa-7278e87a154b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7c5586f4-9243-4d2e-a942-56335b610cb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_400bbc24-bf9a-47fe-b1e7-e60e813c21e3_terseLabel_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options restricted stock and convertible senior notes</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock And Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, restricted stock and convertible senior notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:href="nbix-20201231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:to="lab_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_14f2c6f4-ce11-4a13-a2ae-8daf656fd78c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_be5e2095-3564-47ce-8281-e516fe15f7fd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a0a96204-c09d-44a6-98de-f51e83851626_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_794a86ee-bce9-47d1-bbb3-07012151383d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income taxes, rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0df67b38-6e61-4cf4-ab62-8ac8cb3023bb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3627aa5c-0ac8-45ee-8b41-5b6d58d7cd75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8cfb968c-709e-4691-8a94-eafb7ccec28d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbvieIncMember_8cd5ec29-747f-47b7-a5bb-a4f664cb9a24_terseLabel_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_nbix_AbbvieIncMember_label_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbvie Inc [Member]</link:label>
    <link:label id="lab_nbix_AbbvieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember" xlink:href="nbix-20201231.xsd#nbix_AbbvieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbvieIncMember" xlink:to="lab_nbix_AbbvieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a200d791-fedd-4a71-9b1f-bf2ff6f3e810_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7ac7d923-e05a-4b12-b50b-7069c685009c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_dcb60581-83d5-44fa-88ae-60a210511ae2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_65dfc288-dd2d-43c5-8047-9ba8be4746c2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f6d6d245-9cb5-4ba4-90fe-3523626505c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nbix-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc944f67-c6ac-4677-ab7b-1ffe92aaa8a7,g:c85b9a0b-3b71-4a29-9b10-a3f3428e05d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6484a8c3-e3fe-497a-b50f-7cbf353135b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentType_6484a8c3-e3fe-497a-b50f-7cbf353135b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ea813a17-c91e-46c1-a18b-4727d947f01e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentAnnualReport_ea813a17-c91e-46c1-a18b-4727d947f01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c64a8662-3030-476b-a14e-0fc824b80fea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentPeriodEndDate_c64a8662-3030-476b-a14e-0fc824b80fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bb211c6e-27ce-43cb-9672-d6354bafc3a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_CurrentFiscalYearEndDate_bb211c6e-27ce-43cb-9672-d6354bafc3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ae1f0759-19de-49dd-8dd8-6a9fb5674afb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentTransitionReport_ae1f0759-19de-49dd-8dd8-6a9fb5674afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1be2bab6-5f75-4cc9-b138-dfa9cfb7214f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityFileNumber_1be2bab6-5f75-4cc9-b138-dfa9cfb7214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f0071dc7-7839-4aa0-84af-76e86c0188c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityRegistrantName_f0071dc7-7839-4aa0-84af-76e86c0188c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c58b9dc1-bf9b-4e48-a90b-00cbe38548f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c58b9dc1-bf9b-4e48-a90b-00cbe38548f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3904715d-d620-4eaf-8c52-f8381d3de527" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityTaxIdentificationNumber_3904715d-d620-4eaf-8c52-f8381d3de527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_051f9047-47fc-4e5a-b768-0863133a5f6d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityAddressAddressLine1_051f9047-47fc-4e5a-b768-0863133a5f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_48e159a9-24cf-4ae4-9d77-a82b46206ed5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityAddressCityOrTown_48e159a9-24cf-4ae4-9d77-a82b46206ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_38bae92a-0ab5-438e-b438-829bb86e4ed7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityAddressStateOrProvince_38bae92a-0ab5-438e-b438-829bb86e4ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f1437af7-5aae-4607-8154-2bd7b6e1983d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityAddressPostalZipCode_f1437af7-5aae-4607-8154-2bd7b6e1983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_150d0876-b114-49f7-82ce-33373bb0fa73" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_CityAreaCode_150d0876-b114-49f7-82ce-33373bb0fa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_79d84152-3782-45d7-9380-d0936e5413bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_LocalPhoneNumber_79d84152-3782-45d7-9380-d0936e5413bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f9482fa8-46f7-4979-84da-b8002e057db4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_Security12bTitle_f9482fa8-46f7-4979-84da-b8002e057db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_101b349d-1a9f-45eb-93a1-257851d9529f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_TradingSymbol_101b349d-1a9f-45eb-93a1-257851d9529f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7315bfa3-d1fe-4a6f-aca1-3bfce3797dbb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_SecurityExchangeName_7315bfa3-d1fe-4a6f-aca1-3bfce3797dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_39019993-9ea2-4987-b9bf-4c69f7e20fa4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_39019993-9ea2-4987-b9bf-4c69f7e20fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f8c98171-47f9-46e6-a1d3-1558ce36fade" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityVoluntaryFilers_f8c98171-47f9-46e6-a1d3-1558ce36fade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_74e70730-a98b-440c-ac51-e8d0ed5d2fcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityCurrentReportingStatus_74e70730-a98b-440c-ac51-e8d0ed5d2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e95d855d-679b-4c86-b5be-981ebe8c0b1c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityInteractiveDataCurrent_e95d855d-679b-4c86-b5be-981ebe8c0b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_36827af8-1801-4f87-ba3e-6e035dd35850" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityFilerCategory_36827af8-1801-4f87-ba3e-6e035dd35850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a7235151-6cd0-44fc-a728-aba3b6880b05" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntitySmallBusiness_a7235151-6cd0-44fc-a728-aba3b6880b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7df2afbb-eb75-4e23-bf52-ec6a4f060537" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityEmergingGrowthCompany_7df2afbb-eb75-4e23-bf52-ec6a4f060537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4046b0f7-8f84-44f5-8a41-32d6caa806a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4046b0f7-8f84-44f5-8a41-32d6caa806a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c31b77b0-12c5-45d5-a3a7-2e77e0717c4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityShellCompany_c31b77b0-12c5-45d5-a3a7-2e77e0717c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5e6e0874-477a-4e27-8984-855714f0bac3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityPublicFloat_5e6e0874-477a-4e27-8984-855714f0bac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d3e12c19-9db1-4d68-95ad-b4b10b0eeab9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d3e12c19-9db1-4d68-95ad-b4b10b0eeab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5062edb4-6a97-4593-94e9-e67fc70853ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_5062edb4-6a97-4593-94e9-e67fc70853ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7dd4eada-ecd1-40d1-97eb-e4a9ce3a3928" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_AmendmentFlag_7dd4eada-ecd1-40d1-97eb-e4a9ce3a3928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_70238497-9da3-4b0f-a55a-51f80e9dd437" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentFiscalYearFocus_70238497-9da3-4b0f-a55a-51f80e9dd437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_583959a2-5eb3-4090-923d-876ac4415656" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_583959a2-5eb3-4090-923d-876ac4415656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e0b95ca9-efdb-4aea-919b-c0ddfb279169" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0a5a221-0b81-46c7-9e97-bc4fcff4f4f4" xlink:to="loc_dei_EntityCentralIndexKey_e0b95ca9-efdb-4aea-919b-c0ddfb279169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6b6b806d-82b4-4605-9b23-9775596cc8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b6b806d-82b4-4605-9b23-9775596cc8c1" xlink:to="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d86428ab-d82a-4d5a-8fe7-c69a15e7bd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d86428ab-d82a-4d5a-8fe7-c69a15e7bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_080c682d-4f59-4a87-9198-b826f6efff6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_080c682d-4f59-4a87-9198-b826f6efff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6e2483fb-3d9f-4394-be5c-b2bf3e74d7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6e2483fb-3d9f-4394-be5c-b2bf3e74d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c8f49233-138a-474e-9b0e-98790d496ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_InventoryNet_c8f49233-138a-474e-9b0e-98790d496ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d091a32d-653c-4426-ae32-78f3ad97c14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_OtherAssetsCurrent_d091a32d-653c-4426-ae32-78f3ad97c14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_07b58e51-34f3-4d93-bfa3-fa50a7f63466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_df83f6b6-3d7d-4ae8-b691-744807bc51e0" xlink:to="loc_us-gaap_AssetsCurrent_07b58e51-34f3-4d93-bfa3-fa50a7f63466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5650ad9c-f273-43ff-83db-1ccad6f603f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5650ad9c-f273-43ff-83db-1ccad6f603f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dc6de5f9-636f-4dae-b47f-5fc1e3698a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dc6de5f9-636f-4dae-b47f-5fc1e3698a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_dfdc7e49-0414-429e-b8db-1db8b2d1e683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_dfdc7e49-0414-429e-b8db-1db8b2d1e683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49fcb4b5-15d5-469c-bffa-4127cb781dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49fcb4b5-15d5-469c-bffa-4127cb781dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d794ac6d-23a7-4187-83d2-dce71e863b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d794ac6d-23a7-4187-83d2-dce71e863b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1e848558-41e6-4e7b-b3f3-5305765f4e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1e848558-41e6-4e7b-b3f3-5305765f4e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_edfef85b-1b2b-4fee-bbd9-97a96168ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_edfef85b-1b2b-4fee-bbd9-97a96168ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2dc92cd6-6692-4dd4-9cdd-2da5215feba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70720dd2-a136-43f2-b5b9-e7c2d84212d3" xlink:to="loc_us-gaap_Assets_2dc92cd6-6692-4dd4-9cdd-2da5215feba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6b6b806d-82b4-4605-9b23-9775596cc8c1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0c6ee0f1-eba7-4610-a27d-f208a1ad6f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0c6ee0f1-eba7-4610-a27d-f208a1ad6f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_e84af0d4-bc4e-45ea-8976-588a6b67357e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_e84af0d4-bc4e-45ea-8976-588a6b67357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a6b5e284-7dc1-441c-90e9-e515851dd060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a6b5e284-7dc1-441c-90e9-e515851dd060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_530e2456-a92c-415e-915a-1200189f34cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a728456c-83cb-40e6-80a1-beab89e74083" xlink:to="loc_us-gaap_LiabilitiesCurrent_530e2456-a92c-415e-915a-1200189f34cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_6d7547cd-ffbd-4967-899c-d5be1a10867c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_6d7547cd-ffbd-4967-899c-d5be1a10867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0c027f6-9782-465c-aa2f-416abfc74e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0c027f6-9782-465c-aa2f-416abfc74e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ee1bb4b3-cc78-4155-8062-ca9ace576e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ee1bb4b3-cc78-4155-8062-ca9ace576e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f08c8758-7dc0-44c3-960e-ae40f5bf57fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_Liabilities_f08c8758-7dc0-44c3-960e-ae40f5bf57fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0030a0ac-d518-423f-98c0-8129445d2d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_PreferredStockValue_0030a0ac-d518-423f-98c0-8129445d2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_983d1eb4-4280-4bc3-b834-9aca129ec93e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_CommonStockValue_983d1eb4-4280-4bc3-b834-9aca129ec93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9fe2c142-efa2-43ad-b81d-259aace60cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9fe2c142-efa2-43ad-b81d-259aace60cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1ac12ff6-a6ed-4863-894b-0f9449f489f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1ac12ff6-a6ed-4863-894b-0f9449f489f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36b27417-dc72-4bff-b06b-5fb5c97307d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36b27417-dc72-4bff-b06b-5fb5c97307d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_467109f3-8157-4fc2-ba06-02db877b3167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b2662d5-6b07-4239-be94-13a73d455eb0" xlink:to="loc_us-gaap_StockholdersEquity_467109f3-8157-4fc2-ba06-02db877b3167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f893374-a559-4399-8aee-0e8678041a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_374b6d0a-f87e-468d-9e33-e79243cd28fc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f893374-a559-4399-8aee-0e8678041a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cc1f99c7-49dd-42be-bc17-e1b7a1b05f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc1f99c7-49dd-42be-bc17-e1b7a1b05f30" xlink:to="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:to="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_45b69698-d3bb-453b-8787-ea12bccfc9b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7526523d-d52c-42d6-981d-6b767f682bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7526523d-d52c-42d6-981d-6b767f682bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_f4f31521-43c5-422e-bf41-98b90caad9db" xlink:href="nbix-20201231.xsd#nbix_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70b1dd25-c872-4bb8-ad6e-899260878874" xlink:to="loc_nbix_LongTermInvestmentsMember_f4f31521-43c5-422e-bf41-98b90caad9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_519e84a9-8911-4ba8-a90f-aac5e37c0e46" xlink:to="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea1ec4ac-1981-48fc-b277-881de80a116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea1ec4ac-1981-48fc-b277-881de80a116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44db815f-d58c-47a4-b960-3249c89497df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44db815f-d58c-47a4-b960-3249c89497df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3d1bdd93-c416-46f3-aa03-b25a13470d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3d1bdd93-c416-46f3-aa03-b25a13470d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b11def44-348b-47f6-add7-201b84f2387c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b11def44-348b-47f6-add7-201b84f2387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a43980a4-1507-4039-aa0a-94cbcf1eb934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a43980a4-1507-4039-aa0a-94cbcf1eb934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5018998-86eb-4d6d-be92-1c2401d753f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5018998-86eb-4d6d-be92-1c2401d753f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_00418944-018a-4579-9e1a-ee0f2aa3d0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesIssued_00418944-018a-4579-9e1a-ee0f2aa3d0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b25d9725-c115-4917-84a1-0f74592116d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b25d9725-c115-4917-84a1-0f74592116d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_78920adf-93f1-4a66-a888-f12ae898f839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9566dc8d-29ac-4a39-b4a8-9853e6185464" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_78920adf-93f1-4a66-a888-f12ae898f839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsIncomeandComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1b46f637-4df0-4330-b97f-408026555f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b46f637-4df0-4330-b97f-408026555f9b" xlink:to="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:to="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2cfd7e98-5792-487e-9085-29e94fa68f90" xlink:to="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_346e5cad-3cbf-4f80-a38f-9a13fd4f1f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:to="loc_us-gaap_ProductMember_346e5cad-3cbf-4f80-a38f-9a13fd4f1f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_7d81d62d-b47d-44cb-a0aa-90eb80b414fb" xlink:href="nbix-20201231.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_21049f11-db8a-4246-b569-db0dce48e304" xlink:to="loc_nbix_CollaborationRevenueMember_7d81d62d-b47d-44cb-a0aa-90eb80b414fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6825b71e-c3c2-4d1f-9e0a-c746f443ad0e" xlink:to="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8140d088-be1e-4508-9644-1ee33ffad907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_369e7fc2-8a7d-4daf-8554-2fc7a101ccbd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8140d088-be1e-4508-9644-1ee33ffad907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CostOfSales_5dc4826d-6026-483a-8f9b-a9f830ce00a3" xlink:href="nbix-20201231.xsd#nbix_CostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_nbix_CostOfSales_5dc4826d-6026-483a-8f9b-a9f830ce00a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_123f4552-f8a1-4f77-9bf7-61e884752476" xlink:href="nbix-20201231.xsd#nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_123f4552-f8a1-4f77-9bf7-61e884752476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b0abf0f1-a00e-46b1-8bd5-7c36ee8b300d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_b0abf0f1-a00e-46b1-8bd5-7c36ee8b300d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e25f46cc-e9de-4a85-81bc-ecb3b5771185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e25f46cc-e9de-4a85-81bc-ecb3b5771185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8ff1eb1c-6fcd-4504-b908-4c9a446515aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f228647-0ac8-460b-ab64-d28f4742f05c" xlink:to="loc_us-gaap_OperatingExpenses_8ff1eb1c-6fcd-4504-b908-4c9a446515aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f82ae848-104f-470c-a546-76ef675ec2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_f82ae848-104f-470c-a546-76ef675ec2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_87105e35-2115-4803-a633-37e6750684d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_InterestExpense_87105e35-2115-4803-a633-37e6750684d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d96f4f34-bcfa-4200-9658-8572cbf1d552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d96f4f34-bcfa-4200-9658-8572cbf1d552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31f8a020-ca9d-4df5-b12d-9afa10c95539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31f8a020-ca9d-4df5-b12d-9afa10c95539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_f109386c-1219-4c90-8a87-f0a4112bcb33" xlink:href="nbix-20201231.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_f109386c-1219-4c90-8a87-f0a4112bcb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aae1fef1-f0b4-4880-878e-632149df28ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_db660fad-760d-4b15-a720-7d566e867b80" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aae1fef1-f0b4-4880-878e-632149df28ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38daaf18-44ef-4372-af5d-e1116b325da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38daaf18-44ef-4372-af5d-e1116b325da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_071323b3-cb4b-4e17-b4fe-ba692cfc6a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_071323b3-cb4b-4e17-b4fe-ba692cfc6a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_805c5daa-a901-485c-a378-5780676445b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_NetIncomeLoss_805c5daa-a901-485c-a378-5780676445b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_abc8e3dd-4ace-46d4-8baf-776dd9dbfc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_abc8e3dd-4ace-46d4-8baf-776dd9dbfc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6551ce12-0296-413d-b83f-df62a095140b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6551ce12-0296-413d-b83f-df62a095140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2b964396-3307-4902-b527-120b45de63e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_EarningsPerShareBasic_2b964396-3307-4902-b527-120b45de63e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_80893eec-702f-4540-ba22-fdafad449240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_EarningsPerShareDiluted_80893eec-702f-4540-ba22-fdafad449240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0766e56b-fcb3-4610-b384-4328cd8d3865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0766e56b-fcb3-4610-b384-4328cd8d3865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52af4543-c4e1-45a1-958f-433b1f74d21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b7ef8551-8cb5-4dad-802f-6b9106a179ea" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_52af4543-c4e1-45a1-958f-433b1f74d21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3d44daa-799a-4228-863d-ad4b4059e657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a3d44daa-799a-4228-863d-ad4b4059e657" xlink:to="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_48e37593-336d-4417-8788-7b46ccd8a18a" xlink:to="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5b5f6a55-efd2-41b6-a802-71ea4532348a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_CommonStockMember_5b5f6a55-efd2-41b6-a802-71ea4532348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df3e42c2-eae0-4b4e-9105-9dd7ec557753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df3e42c2-eae0-4b4e-9105-9dd7ec557753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_de39c9a0-a1b4-4d22-bb83-6cd04bbfb78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_de39c9a0-a1b4-4d22-bb83-6cd04bbfb78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c01636cf-321d-45ed-8a84-ade7fa2872ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec846b20-8457-430c-bb0a-541293aaeac7" xlink:to="loc_us-gaap_RetainedEarningsMember_c01636cf-321d-45ed-8a84-ade7fa2872ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3f5ddb50-638c-4833-93eb-6216db8fbff9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_75a62ddb-f976-410f-bd99-c462058b8cc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c9ea03ea-f36a-4b57-ae81-7ac1927e305e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_75a62ddb-f976-410f-bd99-c462058b8cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f47a1ab8-5432-49af-9212-ad6e2733ec73" xlink:to="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9bb9de37-6cfb-463f-b3b1-4406a0a6b9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_SharesOutstanding_9bb9de37-6cfb-463f-b3b1-4406a0a6b9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56dce236-3241-4ce6-b55e-217f97bb5758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockholdersEquity_56dce236-3241-4ce6-b55e-217f97bb5758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bc93ad5-fa6f-4741-974f-1dd8d1dd80ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_NetIncomeLoss_3bc93ad5-fa6f-4741-974f-1dd8d1dd80ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6f027862-ebfc-434d-88e8-d09052e42c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6f027862-ebfc-434d-88e8-d09052e42c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb58e3e8-651e-4e1b-8c2e-8edee675805f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb58e3e8-651e-4e1b-8c2e-8edee675805f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_cf7c67b8-ff2a-4411-bf55-50fa2c7bdb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_cf7c67b8-ff2a-4411-bf55-50fa2c7bdb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_16ccdc99-579b-4296-a4ee-9553f60991b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_16ccdc99-579b-4296-a4ee-9553f60991b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13a30e07-c490-458b-b3c9-5ae95de8ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_13a30e07-c490-458b-b3c9-5ae95de8ef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29e72ea4-68d5-4ff0-a0f3-567bee8a6131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29e72ea4-68d5-4ff0-a0f3-567bee8a6131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16bf893b-460c-4ed9-9711-98fbfc664bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16bf893b-460c-4ed9-9711-98fbfc664bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cf657889-eb99-408e-a415-75f5106ad8cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cf657889-eb99-408e-a415-75f5106ad8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_224d22f9-65d1-4382-a98e-ed94944c66b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_224d22f9-65d1-4382-a98e-ed94944c66b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31d5f60e-40fa-4d55-b35b-1820e174bd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_SharesOutstanding_31d5f60e-40fa-4d55-b35b-1820e174bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5f5e1c1-8874-43d9-a801-9cba54bf7a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05dc8903-dae8-41dc-be20-dc1ca52d9d41" xlink:to="loc_us-gaap_StockholdersEquity_a5f5e1c1-8874-43d9-a801-9cba54bf7a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac79c807-5c37-4626-bbd5-99cca7c0e3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac79c807-5c37-4626-bbd5-99cca7c0e3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8bd3b1f9-e45d-411a-ae50-94d55c9e94de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac79c807-5c37-4626-bbd5-99cca7c0e3af" xlink:to="loc_us-gaap_NetIncomeLoss_8bd3b1f9-e45d-411a-ae50-94d55c9e94de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac79c807-5c37-4626-bbd5-99cca7c0e3af" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_985863d9-150c-47c0-86fe-192501085023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_ShareBasedCompensation_985863d9-150c-47c0-86fe-192501085023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1bc0aa00-28d9-4bab-bbb8-b749bd15467d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_Depreciation_1bc0aa00-28d9-4bab-bbb8-b749bd15467d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e96eabc2-6d0c-46f2-ac65-19b251040c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e96eabc2-6d0c-46f2-ac65-19b251040c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_64589d1f-9a82-44eb-ae07-faaa77a817a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_64589d1f-9a82-44eb-ae07-faaa77a817a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7b455360-37f3-4178-8175-7041d253354e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7b455360-37f3-4178-8175-7041d253354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4c48d06b-9dc1-4fe3-b488-7a949631c4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_4c48d06b-9dc1-4fe3-b488-7a949631c4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cf19137c-f612-4690-a767-396103513f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cf19137c-f612-4690-a767-396103513f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9f76e0b2-3735-4e14-a09c-aaa56dba5b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9f76e0b2-3735-4e14-a09c-aaa56dba5b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724cec1d-ede0-4772-81a1-2be8c98cb5c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16b6a696-4c34-47a9-ac92-fe005f984306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16b6a696-4c34-47a9-ac92-fe005f984306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_43b1d8fd-dd6f-41b5-b4cd-681bfd8822e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_43b1d8fd-dd6f-41b5-b4cd-681bfd8822e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b9e93b75-467e-49b8-b579-ec0acf5abd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b9e93b75-467e-49b8-b579-ec0acf5abd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_38654e89-7a9e-4fff-b3ee-9af0644be4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4de4645d-10aa-4972-b3a1-72e4866aaac4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet_38654e89-7a9e-4fff-b3ee-9af0644be4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8cba7120-7d32-41b2-8d2b-6aaebcc5c00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ac79c807-5c37-4626-bbd5-99cca7c0e3af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8cba7120-7d32-41b2-8d2b-6aaebcc5c00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f666c685-cf44-42c8-9699-d538859cb000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f666c685-cf44-42c8-9699-d538859cb000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11d1cf0a-92ff-4ec6-b4fb-decb5665f474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_11d1cf0a-92ff-4ec6-b4fb-decb5665f474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_03c18a63-3718-4bb3-a285-88cd09358390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_03c18a63-3718-4bb3-a285-88cd09358390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3eaa4450-7e12-49cc-9576-684490b1544c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d25c55a4-827a-442a-a79d-72291571b801" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3eaa4450-7e12-49cc-9576-684490b1544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_593579cd-fe42-4774-9312-132dc1e1d6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_593579cd-fe42-4774-9312-132dc1e1d6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb411040-3fc7-48ed-afa9-f3ed7a936f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb411040-3fc7-48ed-afa9-f3ed7a936f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3594cdff-6d21-4747-9e34-ae054e74a3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb411040-3fc7-48ed-afa9-f3ed7a936f24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3594cdff-6d21-4747-9e34-ae054e74a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_de21fc0a-b44e-4892-9aa5-203015c420f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb411040-3fc7-48ed-afa9-f3ed7a936f24" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_de21fc0a-b44e-4892-9aa5-203015c420f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7d6d4d9-f097-48bf-8919-fbc36dc0944c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb411040-3fc7-48ed-afa9-f3ed7a936f24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7d6d4d9-f097-48bf-8919-fbc36dc0944c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6c0f891-0d14-4b17-a37d-e4046bfed39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6c0f891-0d14-4b17-a37d-e4046bfed39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26569b58-5faa-4e3d-b4fc-ead4cb6c48f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26569b58-5faa-4e3d-b4fc-ead4cb6c48f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dffecc10-9a07-467a-8637-7b403dd780fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dffecc10-9a07-467a-8637-7b403dd780fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b58fdd61-3aed-448e-ab4b-8f6d17605ca6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aaa55086-d96e-40cc-8e1f-8befb114140c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aaa55086-d96e-40cc-8e1f-8befb114140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e15484f2-d431-400c-8af3-85ea074a92c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e15484f2-d431-400c-8af3-85ea074a92c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_79504619-022d-4e1f-a3f8-9fce944f8f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:to="loc_us-gaap_InterestPaidNet_79504619-022d-4e1f-a3f8-9fce944f8f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_1ec8162e-7236-4e96-9bf7-4ce38f39696b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3bc48411-65cb-47aa-aad9-97f88391baff" xlink:to="loc_us-gaap_IncomeTaxesPaid_1ec8162e-7236-4e96-9bf7-4ce38f39696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_714796fc-d425-4a40-b912-e9c0356c322a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_5a701272-7f4e-4727-af88-ac8b038358a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_714796fc-d425-4a40-b912-e9c0356c322a" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_5a701272-7f4e-4727-af88-ac8b038358a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyPolicyTextBlock_47e76db4-38bf-4d14-b58d-1762d2749855" xlink:href="nbix-20201231.xsd#nbix_BusinessDescriptionPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_nbix_BusinessDescriptionPolicyPolicyTextBlock_47e76db4-38bf-4d14-b58d-1762d2749855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_21bef246-c7e9-46f6-8b3d-8b640adae453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_21bef246-c7e9-46f6-8b3d-8b640adae453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_cc12cccc-46a9-4acc-99ab-3d7c1b3a88ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_UseOfEstimates_cc12cccc-46a9-4acc-99ab-3d7c1b3a88ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d0b78329-245a-48d5-ba92-ec0faed4ecad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d0b78329-245a-48d5-ba92-ec0faed4ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_c1037bd0-d7e2-417d-ae18-fe3745c62113" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_c1037bd0-d7e2-417d-ae18-fe3745c62113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_27d498cf-3eea-46d7-bc4b-1be82f3fafe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_27d498cf-3eea-46d7-bc4b-1be82f3fafe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_257298e7-f1e6-4da0-9f60-080f1665c7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_257298e7-f1e6-4da0-9f60-080f1665c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_f8832531-443f-4a7d-b9e4-b5d1ff02680e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_f8832531-443f-4a7d-b9e4-b5d1ff02680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_94922e32-1a1b-4817-9591-fe4a32b93cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_94922e32-1a1b-4817-9591-fe4a32b93cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_13caf819-07af-4521-9869-5cd6e2a69eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_13caf819-07af-4521-9869-5cd6e2a69eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d1709b36-228f-4ec0-a242-7e90bffb72b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d1709b36-228f-4ec0-a242-7e90bffb72b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_889f31cb-23ad-4001-88c3-e89e54230454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_889f31cb-23ad-4001-88c3-e89e54230454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3b3a009b-6bfb-448c-a57e-b4e42402a365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3b3a009b-6bfb-448c-a57e-b4e42402a365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_91b40c96-7ef2-41a4-98f8-9b3cff5c0eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_91b40c96-7ef2-41a4-98f8-9b3cff5c0eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3ac33acb-c0dd-4a42-8c28-47a821624fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3ac33acb-c0dd-4a42-8c28-47a821624fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_4133a0c8-0abf-405a-afcb-2bfbcc98c234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_4133a0c8-0abf-405a-afcb-2bfbcc98c234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cffd110f-6057-4895-919e-a3780f343111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cffd110f-6057-4895-919e-a3780f343111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_27d05dc8-61f1-46ae-8d29-6c6063faabaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_27d05dc8-61f1-46ae-8d29-6c6063faabaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_b5860d5a-458b-4dd8-93a7-94579f58e3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_b5860d5a-458b-4dd8-93a7-94579f58e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ed97d893-1d31-4c8f-87b4-b2dfe42dddd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ed97d893-1d31-4c8f-87b4-b2dfe42dddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_253d8dec-2f5e-47a3-9c24-b57b1c45efcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_253d8dec-2f5e-47a3-9c24-b57b1c45efcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_774cd5c6-b587-4cf8-8255-9ffc5c991d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_774cd5c6-b587-4cf8-8255-9ffc5c991d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b22400ee-6c3a-4e7a-8ca4-b6e5539baad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bba52239-1c78-429f-9ce9-a1f204a2216f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b22400ee-6c3a-4e7a-8ca4-b6e5539baad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_727040ec-7edc-46e9-a414-eaf5967da64b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_727040ec-7edc-46e9-a414-eaf5967da64b" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f4091bbc-baac-4b0c-b30a-43a1b6d7c396" xlink:to="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22da5723-cc10-47a5-b6e5-c82b5cd95c0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:to="loc_srt_MinimumMember_22da5723-cc10-47a5-b6e5-c82b5cd95c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_63a469c8-a549-4229-919c-98d87f8d10f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_06b19405-2435-45f5-b4c2-a4a6e0fb9d8c" xlink:to="loc_srt_MaximumMember_63a469c8-a549-4229-919c-98d87f8d10f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9a450e0-9200-4117-b83f-a359f4cbb8fa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_75e17869-38a1-4ffa-af64-084511171440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1f6e169-00d6-4630-96b6-c50b4a12f676" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_75e17869-38a1-4ffa-af64-084511171440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7449bd78-80b8-4727-91e0-6e32164f5db0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7f4f84c4-3474-4ae9-9987-c3a851f32332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_17c750f3-ec90-4f74-b890-a5086a87d59c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7f4f84c4-3474-4ae9-9987-c3a851f32332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cbaa6c74-bf43-4741-9e69-ccc4a61c9b1b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c8362cdd-6b0f-4867-8074-481e0da7f372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2797f505-47c9-4818-ae37-6b693cb3ab5e" xlink:to="loc_us-gaap_EmployeeStockMember_c8362cdd-6b0f-4867-8074-481e0da7f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_77e519a2-9d11-44f6-983d-dd1afbba2abc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_2453bc2e-2ca5-433c-9654-523661868b73" xlink:href="nbix-20201231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e948cd44-8a77-4bc6-b992-c220fecbef3b" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_2453bc2e-2ca5-433c-9654-523661868b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a1e389f-a2e9-41a9-9075-c5b9805d0a8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_b684b092-78f9-45d0-8bad-4c3530a19868" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5078c99-b653-48ce-92bf-636932d11734" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_b684b092-78f9-45d0-8bad-4c3530a19868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_948e76af-c04b-477f-8625-710c58b268a5" xlink:to="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestTwoCustomersMember_8602b972-df80-4b29-afc1-7afed41a1986" xlink:href="nbix-20201231.xsd#nbix_LargestTwoCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:to="loc_nbix_LargestTwoCustomersMember_8602b972-df80-4b29-afc1-7afed41a1986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LargestThreeCustomersMember_34ab52f1-86b6-457a-81da-98fe808f1940" xlink:href="nbix-20201231.xsd#nbix_LargestThreeCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a5b7bcbd-bc56-4d69-ad01-d86032bbd3bf" xlink:to="loc_nbix_LargestThreeCustomersMember_34ab52f1-86b6-457a-81da-98fe808f1940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:href="nbix-20201231.xsd#nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_c6203236-0a08-4350-b4fd-0209e0b9538e" xlink:to="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries_931690d9-06c0-442a-b69a-37bc384ffc1a" xlink:href="nbix-20201231.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_nbix_NumberOfIrishSubsidiaries_931690d9-06c0-442a-b69a-37bc384ffc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8067964b-1284-4197-a8ce-e28235083b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8067964b-1284-4197-a8ce-e28235083b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b5decca6-ed15-4edf-ac57-a4df6748db68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_NumberOfReportableSegments_b5decca6-ed15-4edf-ac57-a4df6748db68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_04db0a04-a1ab-4481-9e70-d8883511be24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_04db0a04-a1ab-4481-9e70-d8883511be24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_35e65e58-9ff4-4e46-ae4a-4ae545d3c702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_InterestReceivableCurrent_35e65e58-9ff4-4e46-ae4a-4ae545d3c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_42d7fe3d-79a3-46cd-b539-bc15a8e2fd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_42d7fe3d-79a3-46cd-b539-bc15a8e2fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_675371ec-b0a1-4f97-a488-db2f79b517d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_675371ec-b0a1-4f97-a488-db2f79b517d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e4e132ee-763e-4c05-9260-b8b7270ce121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_Depreciation_e4e132ee-763e-4c05-9260-b8b7270ce121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_57fe84cb-06d8-4540-96ac-abd2ad949cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_57fe84cb-06d8-4540-96ac-abd2ad949cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_9a11226f-e833-460c-939e-b124ac2555d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_AdvertisingExpense_9a11226f-e833-460c-939e-b124ac2555d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_22e02ba4-780b-4813-bf06-2e291ac81b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_22e02ba4-780b-4813-bf06-2e291ac81b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_e3867b51-7c38-408c-ba79-fdf7b61d108d" xlink:href="nbix-20201231.xsd#nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_e3867b51-7c38-408c-ba79-fdf7b61d108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_28e0c4fb-af3e-4ef9-a528-36b8ec61aa4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_28e0c4fb-af3e-4ef9-a528-36b8ec61aa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6039f3fe-7622-4970-a5a8-028b3c2996c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e4cea4e4-a4e1-4f56-800e-63385e5ef952" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6039f3fe-7622-4970-a5a8-028b3c2996c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_32975ac7-6ac2-4525-9728-94f412b2ee03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89a47cdf-23d7-4f3e-852a-f5d330e8e3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_32975ac7-6ac2-4525-9728-94f412b2ee03" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_89a47cdf-23d7-4f3e-852a-f5d330e8e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7c7ba688-9c24-48bf-867f-3f360aa1210c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_32975ac7-6ac2-4525-9728-94f412b2ee03" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7c7ba688-9c24-48bf-867f-3f360aa1210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3d44f80c-097e-4b4b-b486-4ffd2a170d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_32975ac7-6ac2-4525-9728-94f412b2ee03" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3d44f80c-097e-4b4b-b486-4ffd2a170d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1055206b-03e4-4a64-8269-7122430c3bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1055206b-03e4-4a64-8269-7122430c3bec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a680b70a-590b-4b2c-b47d-05f70b4186ad" xlink:to="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_e80f9cb9-97b3-43f9-b598-a494591451d7" xlink:href="nbix-20201231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_e80f9cb9-97b3-43f9-b598-a494591451d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_3fb20503-689a-47a5-8467-3d754242fee1" xlink:href="nbix-20201231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_3fb20503-689a-47a5-8467-3d754242fee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_c9ac73bf-8bd8-4039-ab34-efded19fc43c" xlink:href="nbix-20201231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_c9ac73bf-8bd8-4039-ab34-efded19fc43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_227a1a8c-01da-45e2-ada6-cd88f38615a4" xlink:href="nbix-20201231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_VoyagerTherapeuticsMember_227a1a8c-01da-45e2-ada6-cd88f38615a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember_296a88ae-4a56-4a06-8c82-5e421771d940" xlink:href="nbix-20201231.xsd#nbix_BIALMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_BIALMember_296a88ae-4a56-4a06-8c82-5e421771d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_82b2b712-e167-42d9-ba5e-c51bfd10e7c0" xlink:href="nbix-20201231.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_82b2b712-e167-42d9-ba5e-c51bfd10e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember_635f800f-5bc4-474a-aefc-babab080d22c" xlink:href="nbix-20201231.xsd#nbix_AbbvieIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eb81ccf2-d51a-4614-b577-93098655e3c9" xlink:to="loc_nbix_AbbvieIncMember_635f800f-5bc4-474a-aefc-babab080d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fad5ffde-4c75-41d3-ba01-0b162f70fb7f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_a33130c3-ceca-4d49-af91-2a11c687222b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df482c72-9f97-4144-9431-7034e3fdd415" xlink:to="loc_us-gaap_CollaborativeArrangementMember_a33130c3-ceca-4d49-af91-2a11c687222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_95db3b20-7c3c-475d-b76c-1a5997a19989" xlink:to="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2cdd27b8-723e-480f-81c0-f7d085888629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ba07d1fb-7586-42e5-8b7c-601863f03cdd" xlink:to="loc_us-gaap_CommonStockMember_2cdd27b8-723e-480f-81c0-f7d085888629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_843fdf8b-2849-408d-a6bb-19ed64f6af45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_d8243aca-12f4-4cc1-a11a-324bfadbae28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfefd280-bdce-4fbd-9146-2f6c815ecddc" xlink:to="loc_us-gaap_PatentsMember_d8243aca-12f4-4cc1-a11a-324bfadbae28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4c288f1c-5ab3-4812-b11c-9727f4217765" xlink:to="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member_800b82c7-6943-43df-94ea-121c4848cd96" xlink:href="nbix-20201231.xsd#nbix_NBI827104Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_nbix_NBI827104Member_800b82c7-6943-43df-94ea-121c4848cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember_72b25388-dce6-4866-9ed3-f2ab21daafdf" xlink:href="nbix-20201231.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_nbix_DevelopmentProductCandidatesMember_72b25388-dce6-4866-9ed3-f2ab21daafdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_65d39bc8-a1db-4dbe-938f-ef5d8f6dcbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08f779bd-fdfd-4b47-b5e1-9bb681e3fb6d" xlink:to="loc_us-gaap_RoyaltyMember_65d39bc8-a1db-4dbe-938f-ef5d8f6dcbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18b1d752-6adf-4869-9f7b-e214baa799ec" xlink:to="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_67f04aab-9dba-4d0a-a2e3-1dbdf99e44f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_585932fe-fb49-42b2-a4b6-2633fb329d24" xlink:to="loc_srt_MinimumMember_67f04aab-9dba-4d0a-a2e3-1dbdf99e44f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84a6d39a-69d4-4910-8514-df5f7eb1f06a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_d2f4d8a0-19e7-4532-aa16-3f495d75344d" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialMilestonePayments_d2f4d8a0-19e7-4532-aa16-3f495d75344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_02d8f7e0-182e-4102-b013-99825e5751f1" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_UpfrontPaymentsMade_02d8f7e0-182e-4102-b013-99825e5751f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_fadf5cae-be60-485e-8a1b-7fa3fabad002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_fadf5cae-be60-485e-8a1b-7fa3fabad002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm_006c7271-18fc-4313-a6ca-b66a5bafb275" xlink:href="nbix-20201231.xsd#nbix_ResearchCollaborationTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_ResearchCollaborationTerm_006c7271-18fc-4313-a6ca-b66a5bafb275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments_e11df3a4-963c-4074-b192-3e3182e2c6a3" xlink:href="nbix-20201231.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialCommercialMilestonePayments_e11df3a4-963c-4074-b192-3e3182e2c6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9112e00f-4ea7-469f-9c70-f2ad78a6b492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9112e00f-4ea7-469f-9c70-f2ad78a6b492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_588a37bc-bbf8-4b0a-9699-fd26c6eedfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_SharePrice_588a37bc-bbf8-4b0a-9699-fd26c6eedfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_98d7d816-813c-406f-88cb-b7d040d71bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_98d7d816-813c-406f-88cb-b7d040d71bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_0470c39b-7e03-42c9-812c-4ccf48bf17c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_0470c39b-7e03-42c9-812c-4ccf48bf17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f047e3b7-a039-4fb9-bf4f-5c5e45faf08a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f047e3b7-a039-4fb9-bf4f-5c5e45faf08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_ba9b0db4-da6d-4595-a314-791bc7e40d90" xlink:href="nbix-20201231.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_MilestonePayment_ba9b0db4-da6d-4595-a314-791bc7e40d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c2f8c13-28a7-47d2-9305-0f5c612d9f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c2f8c13-28a7-47d2-9305-0f5c612d9f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_523c8fce-3715-4aa7-b54f-ec2509672af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_523c8fce-3715-4aa7-b54f-ec2509672af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ffd7b5db-2cf5-459f-b134-795e0a211df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ffd7b5db-2cf5-459f-b134-795e0a211df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived_ab923d7c-75c0-4904-b494-206632ab8a6e" xlink:href="nbix-20201231.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_UpfrontPaymentsReceived_ab923d7c-75c0-4904-b494-206632ab8a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_a0904855-3220-496f-9669-18a04db22867" xlink:href="nbix-20201231.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_a0904855-3220-496f-9669-18a04db22867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_75438c48-3463-44a5-a892-920332a944fa" xlink:href="nbix-20201231.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7a565e2b-66b2-4fb0-b0a0-bea951a39ef5" xlink:to="loc_nbix_PatentTerm_75438c48-3463-44a5-a892-920332a944fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ba1eaa8-61a2-4a7f-b6a4-5e6a4bd20753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_db08a4a4-39bd-48f8-9fd8-fb1debac20cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ba1eaa8-61a2-4a7f-b6a4-5e6a4bd20753" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_db08a4a4-39bd-48f8-9fd8-fb1debac20cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f331ec6-2f95-416b-a6d6-3813fc02ac1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a8f597b7-237f-4bdb-a510-8a73690c5bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f331ec6-2f95-416b-a6d6-3813fc02ac1a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a8f597b7-237f-4bdb-a510-8a73690c5bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bdf985da-229e-4e57-a9f9-a172d7e50fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f331ec6-2f95-416b-a6d6-3813fc02ac1a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bdf985da-229e-4e57-a9f9-a172d7e50fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546abfe7-36a6-4e33-8c06-5d8ff2325907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_546abfe7-36a6-4e33-8c06-5d8ff2325907" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0502444d-c282-4253-954e-8406d0b28041" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1206cbc5-1e2e-4b9f-b4df-d3ea6899a741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1206cbc5-1e2e-4b9f-b4df-d3ea6899a741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_36e1e21b-2c70-4166-8b5b-36e0b0be7d9e" xlink:href="nbix-20201231.xsd#nbix_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b8d9186e-fe47-4629-b19e-ab945619f797" xlink:to="loc_nbix_LongTermInvestmentsMember_36e1e21b-2c70-4166-8b5b-36e0b0be7d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d2962d03-9c1c-41cd-8c47-5c95ab85af33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_28c81374-2df0-4078-95d0-14cbf9f44386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b39708c5-aec1-4feb-804f-0157e52a2f24" xlink:to="loc_us-gaap_CommercialPaperMember_28c81374-2df0-4078-95d0-14cbf9f44386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4fe9acbe-1927-4a26-aefe-0d068841ecff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dc19b7ec-cfa3-4373-8778-452480f202ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dc19b7ec-cfa3-4373-8778-452480f202ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0006306e-259c-4229-9e2c-41e8aeeaa9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08efa512-88d5-42ae-881c-e4cbfabdf769" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0006306e-259c-4229-9e2c-41e8aeeaa9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c4fad1ab-0dc6-475f-9b02-ee295d3bf8ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8602d62-ede5-46b7-b0ab-ff18eeaab9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8602d62-ede5-46b7-b0ab-ff18eeaab9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0669a01-d4d2-49ba-be7e-b3267a781158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0669a01-d4d2-49ba-be7e-b3267a781158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7aaedef9-7d3f-47a8-8d96-36745167f522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7aaedef9-7d3f-47a8-8d96-36745167f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5ad2eaea-85ba-4d75-a014-3b366eee2f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_5ad2eaea-85ba-4d75-a014-3b366eee2f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1297c06d-3986-49dc-8000-20135f32b1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6daf2098-dbc0-45f1-a684-f5a571a4f498" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1297c06d-3986-49dc-8000-20135f32b1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc2ba435-eede-4393-b161-a42a557a802f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fc2ba435-eede-4393-b161-a42a557a802f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6f6b0788-dede-4ea3-8fac-ad7fee2f902c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_77f069f2-b5bb-4cf9-bf1a-80e0b673c6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_77f069f2-b5bb-4cf9-bf1a-80e0b673c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9737b5d8-56de-4681-9dec-f6db4a5487d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8bf1e6d-46a6-4927-bef8-209ed2b4378e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9737b5d8-56de-4681-9dec-f6db4a5487d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3469760a-137c-4a8b-b298-81c059cfa9dc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33b80c7d-4e4e-430b-bbe0-d76a63b3b57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33b80c7d-4e4e-430b-bbe0-d76a63b3b57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_29805842-4304-498c-89de-87ff79bc9030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_29805842-4304-498c-89de-87ff79bc9030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b79714f2-0622-4e61-98c6-333f86469740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b79714f2-0622-4e61-98c6-333f86469740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f54320f-b5a0-40bd-9c37-923cf0fe0ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1f54320f-b5a0-40bd-9c37-923cf0fe0ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dbb1f25c-9ab9-4d3d-be5a-b22c0c220efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_dbb1f25c-9ab9-4d3d-be5a-b22c0c220efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f23dc5e7-f5e0-4e7e-b91d-e5998635ce66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_803f54e3-ebd0-47ed-a155-59d87278488f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f23dc5e7-f5e0-4e7e-b91d-e5998635ce66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16212f9f-1896-448f-a3b8-8b59ccfb0499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_230b736c-e767-425b-af62-68ff05025f00" xlink:href="nbix-20201231.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16212f9f-1896-448f-a3b8-8b59ccfb0499" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_230b736c-e767-425b-af62-68ff05025f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_95ce41ff-ed12-438c-af5a-654d521643c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16212f9f-1896-448f-a3b8-8b59ccfb0499" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_95ce41ff-ed12-438c-af5a-654d521643c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0e82340b-387d-4339-958c-4dc1b0be8400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_734cac9e-7395-4b13-b78b-8927b89cd8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0e82340b-387d-4339-958c-4dc1b0be8400" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_734cac9e-7395-4b13-b78b-8927b89cd8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c7190ae7-e00f-44ec-b7d8-68c55514e502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_39b10d49-1ed4-42c0-bc58-364b921e7fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7190ae7-e00f-44ec-b7d8-68c55514e502" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_39b10d49-1ed4-42c0-bc58-364b921e7fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7a374249-01ae-4486-888e-e34ee7cf9011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7190ae7-e00f-44ec-b7d8-68c55514e502" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7a374249-01ae-4486-888e-e34ee7cf9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_613eb1c1-cc89-458d-8947-879095717e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_613eb1c1-cc89-458d-8947-879095717e81" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6ada664-c94c-4aeb-a1db-54b6da1976c6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d0180c48-5f78-40aa-8cba-9c5f0b54cdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d0180c48-5f78-40aa-8cba-9c5f0b54cdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ae70426c-7519-4c9c-b21d-60a0d97d1768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ae70426c-7519-4c9c-b21d-60a0d97d1768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_82b5710a-b1c7-41ed-8f52-32287aac12d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_181fa451-627a-4bb3-b5d2-9ebce2660aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_82b5710a-b1c7-41ed-8f52-32287aac12d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b561a735-e2dd-4140-a17f-ab16d82fc1bc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_373ce3aa-bba2-4c71-9d01-8b4f3f9a7e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_373ce3aa-bba2-4c71-9d01-8b4f3f9a7e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_99d1a0da-4f2c-4830-b58d-50d3ab802fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_99d1a0da-4f2c-4830-b58d-50d3ab802fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_f05bec7c-7f89-4f4c-b203-057c2ef9636f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_f05bec7c-7f89-4f4c-b203-057c2ef9636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_129e73fe-0982-4dba-b7a7-6fecd49e539c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_us-gaap_EquitySecuritiesMember_129e73fe-0982-4dba-b7a7-6fecd49e539c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember_460b106d-1608-405c-8cdf-95ecafb2c3f6" xlink:href="nbix-20201231.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_02ef678f-2780-4030-b7fb-147edcf74aad" xlink:to="loc_nbix_TotalEquitySecuritiesMember_460b106d-1608-405c-8cdf-95ecafb2c3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3e1f2a8d-70e7-4b75-bf82-2abaf3565795" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_3ba29005-6598-43da-9f86-54230c66bde0" xlink:href="nbix-20201231.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_3ba29005-6598-43da-9f86-54230c66bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_90d64915-3eb4-4825-95ac-b92f14ffa739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CashEquivalentsMember_90d64915-3eb4-4825-95ac-b92f14ffa739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b317301f-dda0-4ee9-a464-b7e298ea2b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b317301f-dda0-4ee9-a464-b7e298ea2b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember_cb3f374c-511c-4104-9e6e-b3d682cb09ab" xlink:href="nbix-20201231.xsd#nbix_RestrictedCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_nbix_RestrictedCashMember_cb3f374c-511c-4104-9e6e-b3d682cb09ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d16a15fd-a6e6-49c3-b6b8-7df2ca3f7e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be963226-0190-4c24-89ac-9173cb74b874" xlink:to="loc_us-gaap_CommercialPaperMember_d16a15fd-a6e6-49c3-b6b8-7df2ca3f7e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f857592f-0e01-4f0e-b85b-a7cff0e356d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_becd69a5-4f6c-4d2f-bc12-79ef844bcbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dafcf205-b3de-46d5-896b-4be443e0b058" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_becd69a5-4f6c-4d2f-bc12-79ef844bcbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15bfbc5d-0f14-42ce-96e7-4f764d84b5a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_79c90c3c-18c4-4fec-9c41-f55f64546d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:to="loc_us-gaap_Investments_79c90c3c-18c4-4fec-9c41-f55f64546d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_72f5a2b7-9977-4184-b541-ffdefd6448d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5249ab99-ca5c-42c3-82e0-4177b26a9328" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_72f5a2b7-9977-4184-b541-ffdefd6448d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d150734a-8305-4fea-9626-ee7afa175a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d150734a-8305-4fea-9626-ee7afa175a87" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d188b3f-46de-4951-9323-fd12df03a6ca" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0aa77695-0a25-4631-8c46-bd1d9167c2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_93de4d30-07b9-4cfb-8fac-84fcdbc9d6a5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0aa77695-0a25-4631-8c46-bd1d9167c2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_61a3d264-0354-43ce-8223-98ce19fd7ff9" xlink:to="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a09b5977-16cd-4775-a404-30fdde7f6940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_07260234-9473-42de-bbb8-41e7802eefe1" xlink:to="loc_us-gaap_EquitySecuritiesMember_a09b5977-16cd-4775-a404-30fdde7f6940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b83c1b3-4fcf-487c-a345-2515178f68c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b176d013-8b6f-4737-8b22-35d9c17870d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5994a6e7-456b-49fb-9b4f-3856d0421ce4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b176d013-8b6f-4737-8b22-35d9c17870d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9d68998-0d91-43c9-95f5-5902b73e7586" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_527cdbdf-a3dc-4a5a-9f3a-4ea86927e62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_527cdbdf-a3dc-4a5a-9f3a-4ea86927e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_477ac44e-9c04-4dd8-8c57-113a169ebcfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_477ac44e-9c04-4dd8-8c57-113a169ebcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8555af3d-84e9-40d2-9acb-da89abcab4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8555af3d-84e9-40d2-9acb-da89abcab4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_e49c1701-851c-481f-a758-9a5f42c4fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a2704b-d64f-4d32-a1b5-c5669526a8de" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_e49c1701-851c-481f-a758-9a5f42c4fdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c0e24d9-d54e-4241-9873-96c73cfd8c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c0e24d9-d54e-4241-9873-96c73cfd8c17" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:to="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1e7165a2-655d-456d-9619-0fddaed061ab" xlink:to="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d5fcbafa-3f24-4a0f-a5f1-00ef5db6663c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_MinimumMember_d5fcbafa-3f24-4a0f-a5f1-00ef5db6663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f53b634-b7e0-4005-a8ad-fb4fa5c500ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_MaximumMember_8f53b634-b7e0-4005-a8ad-fb4fa5c500ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_42dec1d2-705a-40a0-9cca-eaa31dd8b627" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94683a42-e7ff-446b-be46-d73149b94802" xlink:to="loc_srt_WeightedAverageMember_42dec1d2-705a-40a0-9cca-eaa31dd8b627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_dac73bad-4396-4944-9d80-931cd4862e68" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_e6804e96-d60d-4f58-8844-9716d2ad26c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_36116a70-61d7-4ecc-8b47-08d7b4f2aa0d" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_e6804e96-d60d-4f58-8844-9716d2ad26c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_43a585fb-bbb1-4511-b614-40eec4022be2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_ffdd25f6-5e0f-4c67-846f-fa081ad8ce1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_72949520-c6dd-4b54-8549-2b2fd4f8ea13" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_ffdd25f6-5e0f-4c67-846f-fa081ad8ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9d250b9-f446-4983-a272-4fa2cd528ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ae1a510f-f6d9-465b-9c38-78e28e908fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9d250b9-f446-4983-a272-4fa2cd528ca1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ae1a510f-f6d9-465b-9c38-78e28e908fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7b860093-f106-429a-bf33-c0e313d00677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e8f5a640-96b5-47ff-b4a8-8e98cbed79cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7b860093-f106-429a-bf33-c0e313d00677" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e8f5a640-96b5-47ff-b4a8-8e98cbed79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f356a66-591d-4f28-a340-d1b2079b2468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f356a66-591d-4f28-a340-d1b2079b2468" xlink:to="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_98e68b2d-1606-4923-b613-2ab7094a93c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_cb3c7f92-5533-4e28-a829-e2ded55acede" xlink:href="nbix-20201231.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2899157c-27d4-42de-b71e-29e8b8270ae5" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_cb3c7f92-5533-4e28-a829-e2ded55acede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4cc33c79-8b52-4c59-89ad-13cb44a893dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9d47174f-40ff-4fe9-b5af-4d85f64e88bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bf9326ce-d6ce-4606-bd57-7f8e776d86b8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9d47174f-40ff-4fe9-b5af-4d85f64e88bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionAxis_6e9bccf1-d351-4dd0-9dff-b7ebad671256" xlink:to="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_01f666fb-40f0-412f-8991-c7f026aca6d6" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:to="loc_nbix_ConversionPeriodOneMember_01f666fb-40f0-412f-8991-c7f026aca6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_2215b73b-e414-4a2c-b0cc-a6a0fc0aacb2" xlink:href="nbix-20201231.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_d01778fb-f6eb-426a-8f52-d0e812bd3dbb" xlink:to="loc_nbix_ConversionPeriodTwoMember_2215b73b-e414-4a2c-b0cc-a6a0fc0aacb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ba431f7-ea04-42e4-93b6-adb0d8a50652" xlink:to="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c729974f-28b8-442f-9e1a-f67eb43143b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c729974f-28b8-442f-9e1a-f67eb43143b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d674c3d6-699e-4c14-a6b8-3d5646018d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d674c3d6-699e-4c14-a6b8-3d5646018d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1168065f-a51a-435b-9ae9-dc234f725dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1168065f-a51a-435b-9ae9-dc234f725dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6498ccba-76ba-439d-9da3-cd8aca8062d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6498ccba-76ba-439d-9da3-cd8aca8062d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_577f1a07-beaf-4f6e-9b4e-10f96f955dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_577f1a07-beaf-4f6e-9b4e-10f96f955dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_06c8f8d9-6ec3-4047-917f-a584c094f054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_06c8f8d9-6ec3-4047-917f-a584c094f054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_8c13a31f-8f98-4913-b557-8cca222deeeb" xlink:href="nbix-20201231.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_8c13a31f-8f98-4913-b557-8cca222deeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_40a0c093-c72b-486b-b594-b7d9a399c22b" xlink:href="nbix-20201231.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_40a0c093-c72b-486b-b594-b7d9a399c22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TradingDaysDuringObservationPeriod_09725275-ad90-4edf-9fb8-30f18ae6b1a5" xlink:href="nbix-20201231.xsd#nbix_TradingDaysDuringObservationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_TradingDaysDuringObservationPeriod_09725275-ad90-4edf-9fb8-30f18ae6b1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_2641b215-5fcd-4830-b7f9-2c7eca715a31" xlink:href="nbix-20201231.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_DebtConversionObservationPeriod_2641b215-5fcd-4830-b7f9-2c7eca715a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c06cfe6-f1cb-4f52-9542-67032b0ed5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c06cfe6-f1cb-4f52-9542-67032b0ed5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_bb413641-5bd7-405f-9461-cc30fe80c738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_bb413641-5bd7-405f-9461-cc30fe80c738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e89b4299-ad72-4485-961f-1ab53bbaabe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_e89b4299-ad72-4485-961f-1ab53bbaabe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_a1db7a1c-dc7c-46ab-9f65-5412a5af3cd8" xlink:href="nbix-20201231.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_a1db7a1c-dc7c-46ab-9f65-5412a5af3cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ba91d325-f3e5-43e7-9b57-02bb71945c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_SharePrice_ba91d325-f3e5-43e7-9b57-02bb71945c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4133fd59-e461-4f39-9852-453d6493f317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_4133fd59-e461-4f39-9852-453d6493f317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_642c33b4-2542-4374-970a-342fa53f0b8a" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_642c33b4-2542-4374-970a-342fa53f0b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_326cd99c-c052-4092-abea-ea54298a5661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_326cd99c-c052-4092-abea-ea54298a5661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5cb94941-70e0-42a4-a3e8-5924335de5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5cb94941-70e0-42a4-a3e8-5924335de5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_2882d9d2-0afb-486e-b23d-b6658036f341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentTerm_2882d9d2-0afb-486e-b23d-b6658036f341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0b5edec3-430f-4804-b644-59e5916c3c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0b5edec3-430f-4804-b644-59e5916c3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_9861a3a4-a910-4712-8f5c-cb65c5a6ea2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_9861a3a4-a910-4712-8f5c-cb65c5a6ea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_7589c849-9489-4bee-a450-cd66a1087eea" xlink:href="nbix-20201231.xsd#nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_7589c849-9489-4bee-a450-cd66a1087eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_61799f03-871b-4529-9646-d50b5e6433e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_61799f03-871b-4529-9646-d50b5e6433e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3a94155c-d5ba-4d2c-b12b-162be7d3faf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_RepaymentsOfDebt_3a94155c-d5ba-4d2c-b12b-162be7d3faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_5de1b00e-99f3-483e-9440-b0435ae8c19f" xlink:href="nbix-20201231.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_5de1b00e-99f3-483e-9440-b0435ae8c19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_25012df2-14b8-4a6d-9ed4-f71a283b73b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_25012df2-14b8-4a6d-9ed4-f71a283b73b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_3ca3854d-4d5f-40b4-b802-b7814c1b9b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_3ca3854d-4d5f-40b4-b802-b7814c1b9b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_117e9c6f-6439-4fe0-8155-a713caaacd4e" xlink:href="nbix-20201231.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_117e9c6f-6439-4fe0-8155-a713caaacd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b1caefe1-1644-4171-84b9-23c54145a907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b1caefe1-1644-4171-84b9-23c54145a907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ac85ec45-47a5-4f8e-a97f-145e5a7cbe4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af7edd46-983e-4e97-840b-fac2ae6d317a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ac85ec45-47a5-4f8e-a97f-145e5a7cbe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6716e7ba-6097-4a3e-9a31-755670b729c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_93647690-46fa-47fd-bb95-1b950a38a801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6716e7ba-6097-4a3e-9a31-755670b729c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_93647690-46fa-47fd-bb95-1b950a38a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_f2cb8b70-c8cb-4858-8682-c987fde10d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6716e7ba-6097-4a3e-9a31-755670b729c3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_f2cb8b70-c8cb-4858-8682-c987fde10d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f45dc3a7-d4cb-4196-8758-3d52e0987006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6716e7ba-6097-4a3e-9a31-755670b729c3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f45dc3a7-d4cb-4196-8758-3d52e0987006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_b05f4e9e-b3b0-49cc-8f45-3a414e1bcde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6716e7ba-6097-4a3e-9a31-755670b729c3" xlink:to="loc_us-gaap_ConvertibleDebt_b05f4e9e-b3b0-49cc-8f45-3a414e1bcde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_89ed3c96-65ae-46b9-85d8-a94f71626c72" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_07e24eb5-5788-4a0b-afbb-cab606a410cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_89ed3c96-65ae-46b9-85d8-a94f71626c72" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_07e24eb5-5788-4a0b-afbb-cab606a410cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_8368d10c-cba1-4f5f-b0fa-77c6715d3aaf" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_36f6450b-95c8-448d-b257-35848fa85340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8368d10c-cba1-4f5f-b0fa-77c6715d3aaf" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_36f6450b-95c8-448d-b257-35848fa85340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5af4bdfe-4231-457c-8017-83bba6f4b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8368d10c-cba1-4f5f-b0fa-77c6715d3aaf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5af4bdfe-4231-457c-8017-83bba6f4b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6621d459-52c9-4b67-a70d-aec37f809969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8368d10c-cba1-4f5f-b0fa-77c6715d3aaf" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6621d459-52c9-4b67-a70d-aec37f809969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_4501cdb3-17c9-455b-b18e-6642e81cfdbd" xlink:href="nbix-20201231.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_8368d10c-cba1-4f5f-b0fa-77c6715d3aaf" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_4501cdb3-17c9-455b-b18e-6642e81cfdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_d84bc6eb-951f-4726-b547-f7d849ded0b9" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2554ed2e-0e66-4881-a334-7cc0ace91519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d84bc6eb-951f-4726-b547-f7d849ded0b9" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2554ed2e-0e66-4881-a334-7cc0ace91519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2ff5ef36-8a37-4e42-944a-cb2e667df319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d84bc6eb-951f-4726-b547-f7d849ded0b9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2ff5ef36-8a37-4e42-944a-cb2e667df319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f3f6d324-a755-4aba-aa9d-02092c693efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d84bc6eb-951f-4726-b547-f7d849ded0b9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f3f6d324-a755-4aba-aa9d-02092c693efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fe871d3d-3105-4841-bccf-c6ea98981992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_d84bc6eb-951f-4726-b547-f7d849ded0b9" xlink:to="loc_us-gaap_InventoryNet_fe871d3d-3105-4841-bccf-c6ea98981992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1ffdc8ac-901b-4983-8b17-16a651464012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1ffdc8ac-901b-4983-8b17-16a651464012" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189675d6-b798-4fe8-8252-e7f4d1e0a286" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_54943239-9627-4daa-9885-e4fafa41bdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_54943239-9627-4daa-9885-e4fafa41bdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ScientificEquipmentMember_36733594-8c1f-468d-be47-679a55312e7c" xlink:href="nbix-20201231.xsd#nbix_ScientificEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_nbix_ScientificEquipmentMember_36733594-8c1f-468d-be47-679a55312e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e35976cc-2ae2-4a71-84ff-3e7fabfc958e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_ComputerEquipmentMember_e35976cc-2ae2-4a71-84ff-3e7fabfc958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e3bb0857-bb8e-4cd0-8647-21ac5b8d9822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_71eeee0c-df18-4d07-aa0b-d2a320b1d4af" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e3bb0857-bb8e-4cd0-8647-21ac5b8d9822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59d5820f-2ea4-423c-8e10-235aecb085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_85d52633-ea72-4ef0-b94f-0fba4e6bc273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_85d52633-ea72-4ef0-b94f-0fba4e6bc273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c718c862-303c-4e6e-bba4-2262e0656d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c718c862-303c-4e6e-bba4-2262e0656d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0cbbdbb-b98b-480f-9396-3746dc354bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abb36bd3-a222-4dbf-99f5-95c5a9e5b140" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0cbbdbb-b98b-480f-9396-3746dc354bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f195e8c4-ca18-44df-bf9d-274c355ff403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f195e8c4-ca18-44df-bf9d-274c355ff403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_380f4116-aac7-46de-9385-ba04557bbc73" xlink:href="nbix-20201231.xsd#nbix_RevenueRelatedReservesForDiscountsAndAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_nbix_RevenueRelatedReservesForDiscountsAndAllowances_380f4116-aac7-46de-9385-ba04557bbc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_d3a20005-f1ce-4f03-810d-0b4b01b92835" xlink:href="nbix-20201231.xsd#nbix_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_nbix_AccruedResearchAndDevelopmentExpenseCurrent_d3a20005-f1ce-4f03-810d-0b4b01b92835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AccruedBrandedPrescriptionDrugFee_0897572b-d130-4dcf-a1f5-8bdb3d889bd0" xlink:href="nbix-20201231.xsd#nbix_AccruedBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_nbix_AccruedBrandedPrescriptionDrugFee_0897572b-d130-4dcf-a1f5-8bdb3d889bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_09b0ea6b-1883-46a8-afe9-40dca236fb2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_09b0ea6b-1883-46a8-afe9-40dca236fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c240546b-da5f-4028-867a-29d31574ddec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_9e0cc52c-6841-4197-ba03-69408ea7ac84" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c240546b-da5f-4028-867a-29d31574ddec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbix_OtherBalanceSheetDetailsAbstract_fd6d0d41-e375-4afa-9086-48483e879a73" xlink:href="nbix-20201231.xsd#nbix_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9a605e2-a920-4b51-a78b-5e139d09ee02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_fd6d0d41-e375-4afa-9086-48483e879a73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9a605e2-a920-4b51-a78b-5e139d09ee02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_109c33cf-83cb-44b6-8ea5-3796be96d598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_fd6d0d41-e375-4afa-9086-48483e879a73" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_109c33cf-83cb-44b6-8ea5-3796be96d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_58dd47ba-c3f1-40d2-b462-71feb6c2c7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_OtherBalanceSheetDetailsAbstract_fd6d0d41-e375-4afa-9086-48483e879a73" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_58dd47ba-c3f1-40d2-b462-71feb6c2c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f126cdda-561e-4ad1-a56b-3b30edec9d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cc31ce57-e4f4-4180-9bd0-e68ef2bad0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f126cdda-561e-4ad1-a56b-3b30edec9d43" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cc31ce57-e4f4-4180-9bd0-e68ef2bad0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2660d78c-19ce-49ac-ae8d-4781bb13fdbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c38a6b20-e8d0-4732-9b26-01f141fddcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2660d78c-19ce-49ac-ae8d-4781bb13fdbe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c38a6b20-e8d0-4732-9b26-01f141fddcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6e3ce4a9-611c-4da7-87ef-6f34032ef809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e3ce4a9-611c-4da7-87ef-6f34032ef809" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_47f2ef6c-8e68-484e-ba57-a468190dd4aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b6d0f6b-1641-489f-8f60-9a9bd9e5c5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b6d0f6b-1641-489f-8f60-9a9bd9e5c5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0aaa81b1-9322-43e9-a22c-fd10ff1aa347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0966141b-dca6-47ac-8d1f-7dbd94085f18" xlink:to="loc_us-gaap_RestrictedStockMember_0aaa81b1-9322-43e9-a22c-fd10ff1aa347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_60234601-e70f-4ab5-842f-68b884159710" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_c89954b3-7986-416a-ba11-474c84bbe83f" xlink:href="nbix-20201231.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80444489-f81e-4d32-a4fa-6679419e7aa2" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_c89954b3-7986-416a-ba11-474c84bbe83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_186d656e-9d8a-4c2a-853f-64932e3cf3d8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d283a107-58f2-4681-b9a7-cc24a7079ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_NetIncomeLoss_d283a107-58f2-4681-b9a7-cc24a7079ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed4bece8-e876-458d-9bbd-29e50901ddd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_10b6de3c-e78a-4cbf-bb5a-70384d3b95ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed4bece8-e876-458d-9bbd-29e50901ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0a7e63ca-f776-4715-8a90-8c2301ab5fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0a7e63ca-f776-4715-8a90-8c2301ab5fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_1d899cd1-5b34-422e-9414-557ed64ef359" xlink:href="nbix-20201231.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_1d899cd1-5b34-422e-9414-557ed64ef359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dc506e7-e910-414d-a021-29adf83e1263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8e4479af-e800-4b79-8a34-6f990f0540ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dc506e7-e910-414d-a021-29adf83e1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_13c0015b-ecb5-462e-8bab-4d2528d4ed48" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d158966d-38aa-4e92-bcc6-0da24cb0a80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:to="loc_us-gaap_EarningsPerShareBasic_d158966d-38aa-4e92-bcc6-0da24cb0a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_43ff1c08-17a6-4bb7-b0c5-382c82c64065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ff7899e4-a377-419f-b091-613f0ebf47a1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_43ff1c08-17a6-4bb7-b0c5-382c82c64065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97d47f23-2368-446f-af14-9600a479c337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97d47f23-2368-446f-af14-9600a479c337" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57475a54-c1bb-4253-94c7-36f645aa9337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9f329159-d432-4328-8fb8-111b83b1f25e" xlink:href="nbix-20201231.xsd#nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f6921c6b-9cd9-4b70-8b91-d1267dc8ad7c" xlink:to="loc_nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember_9f329159-d432-4328-8fb8-111b83b1f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_343d1e45-c085-4336-8202-4ca439df8d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eac13c38-1eba-4775-b647-85fa777d55bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba84a142-8679-4ee4-bd71-458700cdb9f0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eac13c38-1eba-4775-b647-85fa777d55bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_faf3c96b-050e-489c-875b-9382148c0c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9333742e-632d-4e7c-b473-a1c8a27f60b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_faf3c96b-050e-489c-875b-9382148c0c6a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9333742e-632d-4e7c-b473-a1c8a27f60b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37961d83-d96b-4f2a-a7ac-4eb3c587b241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3ffe7c27-cb0e-4ed8-a5e9-63fe397df68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37961d83-d96b-4f2a-a7ac-4eb3c587b241" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3ffe7c27-cb0e-4ed8-a5e9-63fe397df68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ebd14c05-7ee0-428f-9bd6-f862f9b6d919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37961d83-d96b-4f2a-a7ac-4eb3c587b241" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ebd14c05-7ee0-428f-9bd6-f862f9b6d919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a4a75796-b42d-4701-bfb5-a61cc7adf2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37961d83-d96b-4f2a-a7ac-4eb3c587b241" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a4a75796-b42d-4701-bfb5-a61cc7adf2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_40d0e076-6bac-4b40-9181-93c937d0bd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37961d83-d96b-4f2a-a7ac-4eb3c587b241" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_40d0e076-6bac-4b40-9181-93c937d0bd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d0809aa-ec9e-4b81-be16-cc96eb8ecab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d0809aa-ec9e-4b81-be16-cc96eb8ecab9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5a4cb396-dd83-484d-9042-1cd85291e210" xlink:to="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoThousandAndElevenPlanMember_f2c6222e-493c-4af9-8f9c-c0dc979ad130" xlink:href="nbix-20201231.xsd#nbix_TwoThousandAndElevenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:to="loc_nbix_TwoThousandAndElevenPlanMember_f2c6222e-493c-4af9-8f9c-c0dc979ad130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A2020EquityIncentivePlanMember_2e6fb1c6-04a9-4c4c-a123-fa21f6a4d947" xlink:href="nbix-20201231.xsd#nbix_A2020EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_26adcc96-7f54-46d7-b884-497fa43bad38" xlink:to="loc_nbix_A2020EquityIncentivePlanMember_2e6fb1c6-04a9-4c4c-a123-fa21f6a4d947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8d402955-e4a7-4708-abaa-0a5743b5cf2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_87121ce0-da74-4cb6-9d5e-313aa8ca35c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_EmployeeStockMember_87121ce0-da74-4cb6-9d5e-313aa8ca35c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a8017204-705c-4e27-942d-c0ec0719999f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a8017204-705c-4e27-942d-c0ec0719999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cf6fb97b-e5be-4ce1-8d6f-af7486713f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cf6fb97b-e5be-4ce1-8d6f-af7486713f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_cc2348c9-1867-4701-a1ab-122936c42671" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef201d4f-1cd1-404d-94cc-0ac109a99b10" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_cc2348c9-1867-4701-a1ab-122936c42671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3b2655af-8d25-4622-a6bc-e0256ca6c71b" xlink:to="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fcfd9178-b964-4ef3-bade-1601240c3d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:to="loc_srt_MinimumMember_fcfd9178-b964-4ef3-bade-1601240c3d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ef308245-b8c5-466f-8c6f-580e0c117b7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42490632-f3d7-415a-9d22-e643ec9672f4" xlink:to="loc_srt_MaximumMember_ef308245-b8c5-466f-8c6f-580e0c117b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_359d80cb-5189-4f3f-a169-8616ae6ef9c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3112dbbd-64a6-4559-a784-27a8b32bca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3112dbbd-64a6-4559-a784-27a8b32bca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e52bcfc2-62ae-4149-8c1c-a2b1ae446f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e52bcfc2-62ae-4149-8c1c-a2b1ae446f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c1b3341-4573-4890-a432-9c575a6e3156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2c1b3341-4573-4890-a432-9c575a6e3156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90388902-401e-4d61-ace6-4afd33804f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90388902-401e-4d61-ace6-4afd33804f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69705a8-81b9-431e-88b7-dd973fbd1866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a69705a8-81b9-431e-88b7-dd973fbd1866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_aeedc0bb-5e40-4edf-883c-6cb9070f7e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_aeedc0bb-5e40-4edf-883c-6cb9070f7e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_833107ed-3ae2-47b5-99c8-928f549e2976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_833107ed-3ae2-47b5-99c8-928f549e2976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0da457c-6165-4015-bf67-4507b21191e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0da457c-6165-4015-bf67-4507b21191e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_351b535f-c4e0-428b-a06b-88056ba8743c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_351b535f-c4e0-428b-a06b-88056ba8743c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_03b6b2e5-fd30-4462-be47-46097ed3122e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_062b3531-2acd-42ac-aaa8-36644c699f8d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_03b6b2e5-fd30-4462-be47-46097ed3122e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27144987-808f-4243-a041-a9a3351b3c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27144987-808f-4243-a041-a9a3351b3c59" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ba3f8d6f-58ee-4dd2-9613-9c41a3be00ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62e1f684-c8d0-4462-9344-4151b3ecde72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62e1f684-c8d0-4462-9344-4151b3ecde72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_846ee4c6-58c0-4bdd-bf2b-05ff2e44ba0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3bf9ec09-7a89-409d-a628-616778daf7a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_846ee4c6-58c0-4bdd-bf2b-05ff2e44ba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_183d2198-eeb2-4c82-9149-36cc2991be08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5d79c4fc-f261-4094-a851-bc5c94e52378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6df98a25-740c-4fce-b86c-0429929312cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5d79c4fc-f261-4094-a851-bc5c94e52378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c62b1653-ed9c-4d78-b528-9b17ac0e570b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c62b1653-ed9c-4d78-b528-9b17ac0e570b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:to="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f74115f6-8499-4bbb-96af-ba5859d884e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e81c3c2f-b277-4cf9-9b0f-c8eeda083399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e81c3c2f-b277-4cf9-9b0f-c8eeda083399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14639ac1-dddd-4d9b-a809-e97545e1d5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14639ac1-dddd-4d9b-a809-e97545e1d5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_ff77ae9b-c1d0-4b77-9594-543c31c885ff" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_ff77ae9b-c1d0-4b77-9594-543c31c885ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0184a847-1dda-4216-badf-0a7f3b4aa2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f7e02a8-d497-48c4-8feb-1593714ca257" xlink:to="loc_us-gaap_EmployeeStockMember_0184a847-1dda-4216-badf-0a7f3b4aa2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fabe23b6-03ba-4a5e-a0c0-19c4066eb7ed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24a75139-e12a-48f5-b67e-a6f97f2860e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d8a12204-0415-40a0-8ef8-4bdab6a69748" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24a75139-e12a-48f5-b67e-a6f97f2860e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2327520-45f4-4b92-a610-2ac31e61fffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2327520-45f4-4b92-a610-2ac31e61fffa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:to="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a9ec705f-4e83-4523-a056-fe01d58d3d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b870dda-96f6-429d-9cb4-13eea416fb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b870dda-96f6-429d-9cb4-13eea416fb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_894e7f2c-7b8a-4caf-8b32-3c66efc9be8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58af6670-3bdb-4b16-9cbd-9ecc59d38897" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_894e7f2c-7b8a-4caf-8b32-3c66efc9be8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79d8e469-b4de-40df-b80d-853431c4b357" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3980c620-8088-4447-b8b7-5157db3e9965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3980c620-8088-4447-b8b7-5157db3e9965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a46efe9-4aa0-43b8-b120-4d8a5e2d810a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_89ea7475-01e5-49d3-a9ae-8e57fa40c6d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7a46efe9-4aa0-43b8-b120-4d8a5e2d810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aac7ada9-6047-4553-a26e-74ee170d4316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aac7ada9-6047-4553-a26e-74ee170d4316" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:to="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c54b638-9d78-454d-b918-32e3ba695d28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7d585fbb-6654-473d-8916-d6aae383d39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f044d45-e61d-44e6-91a3-d79e3db1dbbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7d585fbb-6654-473d-8916-d6aae383d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d57438f-cf0e-446a-b698-449a40db9eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57df9366-7b15-4ede-9863-3b894ca01b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57df9366-7b15-4ede-9863-3b894ca01b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1df19fea-6b82-4b4d-b1cc-bc508b1053dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1df19fea-6b82-4b4d-b1cc-bc508b1053dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd483279-117b-4c6c-9bdf-5963f3e64b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cd483279-117b-4c6c-9bdf-5963f3e64b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c43eb59-2e6b-4544-b298-3ed8f5e9d8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a74d5f1-a5a2-4cf1-a492-613cd25c1cf3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c43eb59-2e6b-4544-b298-3ed8f5e9d8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4eb438b3-79a2-4d02-b42c-c79b9168966c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4eb438b3-79a2-4d02-b42c-c79b9168966c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f09236d3-fd23-4c49-a042-0e88205562a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f09236d3-fd23-4c49-a042-0e88205562a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b20bd767-1757-4220-a9fa-b71ac6963945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b20bd767-1757-4220-a9fa-b71ac6963945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6897e847-338b-4f60-85a5-4fb16e71bc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6897e847-338b-4f60-85a5-4fb16e71bc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db062025-10d5-4a6f-8606-95171cc8216f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_382f708c-d39f-4011-a86e-1541389871cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db062025-10d5-4a6f-8606-95171cc8216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_42702286-a543-43a6-9381-85ee59e1b4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_42702286-a543-43a6-9381-85ee59e1b4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5190a6b-28cd-4809-872f-c44ba5868e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5190a6b-28cd-4809-872f-c44ba5868e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5a19666b-22e4-43c8-9864-46bc7aade193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5a19666b-22e4-43c8-9864-46bc7aade193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b5718185-9c69-4eec-8d55-fbec94726059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b5718185-9c69-4eec-8d55-fbec94726059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aba1a1ed-18e1-45d7-afd3-42d02ef79388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aba1a1ed-18e1-45d7-afd3-42d02ef79388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6fe90783-0a6d-4520-8f07-67fc4cb4b3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0d61cd2-d482-4d4f-a8be-fca2b270dcee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6fe90783-0a6d-4520-8f07-67fc4cb4b3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_db8f41ef-530a-4fbb-93ec-5cf33c7e2f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_db8f41ef-530a-4fbb-93ec-5cf33c7e2f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7782f8f9-2e88-42ba-a7df-757255fab78f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c92854a2-76d2-43dc-9723-319e00151fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c92854a2-76d2-43dc-9723-319e00151fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90dd2872-3def-40ef-a5ac-7a2fbeeea1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90dd2872-3def-40ef-a5ac-7a2fbeeea1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63d8a576-5e74-4275-b286-271e18e54e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63d8a576-5e74-4275-b286-271e18e54e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0c5ee0e5-44d6-47c4-b127-533c7a999ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e533384-f4da-49ec-b748-015d4f8dd7be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0c5ee0e5-44d6-47c4-b127-533c7a999ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d12c2150-3557-4e1b-bf88-8dc6b30bef03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d12c2150-3557-4e1b-bf88-8dc6b30bef03" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:to="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_20b9c984-1bb3-4cbf-9349-4f09e2b4cd1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aaeba017-3f89-4c00-b1d8-852fc0a3cd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aaeba017-3f89-4c00-b1d8-852fc0a3cd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PerformanceBasedRestrictedStockUnitMember_d25a178c-de4d-477e-ae6c-9b31239769d8" xlink:href="nbix-20201231.xsd#nbix_PerformanceBasedRestrictedStockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e69f9cd-ecbd-416d-a10b-c91cc1954e77" xlink:to="loc_nbix_PerformanceBasedRestrictedStockUnitMember_d25a178c-de4d-477e-ae6c-9b31239769d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab87d7ec-248b-4904-bc54-c9f8d3a937b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b43b6abb-4408-4be9-bb1d-7323de29a637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b43b6abb-4408-4be9-bb1d-7323de29a637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d08c69b7-08e8-4d7a-ab9b-cbdc7fe30a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d08c69b7-08e8-4d7a-ab9b-cbdc7fe30a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8258c54-a13f-4166-bfe5-fe58c249b9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8258c54-a13f-4166-bfe5-fe58c249b9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3abce2b-d843-4a84-8b26-5ea09631ac66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3abce2b-d843-4a84-8b26-5ea09631ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_312fdce0-82e8-4abd-938e-9c333ca197c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_134a646a-5021-4eae-b263-fb6d673129ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_312fdce0-82e8-4abd-938e-9c333ca197c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74034621-54e5-4242-95f0-a9da4ccd8a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74034621-54e5-4242-95f0-a9da4ccd8a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b87f7977-d115-4b05-8042-101c85d7c563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b87f7977-d115-4b05-8042-101c85d7c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_371b76c4-b75a-4d82-a15d-3704f7c9bb03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_371b76c4-b75a-4d82-a15d-3704f7c9bb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1bfc5234-e222-437e-ad64-76104b08f2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1bfc5234-e222-437e-ad64-76104b08f2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2511d32c-4968-4094-ab2d-946a7bb45da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_23335edf-f676-4801-844c-0c0ec9d6caad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2511d32c-4968-4094-ab2d-946a7bb45da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffc77ca9-888c-4d95-8a4e-b3680330894e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b7552a81-3284-41f4-a459-deebe735a045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b7552a81-3284-41f4-a459-deebe735a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0c9cc286-67ef-40e9-9005-6b7aa7f79d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_92776bc2-bbb2-419e-b9c4-7778dbb9fcac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0c9cc286-67ef-40e9-9005-6b7aa7f79d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_44ae7d8f-ee08-4d14-9faf-65893ed1a07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5b86c7f7-38ba-4912-b746-73c32ba21cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_44ae7d8f-ee08-4d14-9faf-65893ed1a07f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5b86c7f7-38ba-4912-b746-73c32ba21cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7e7bfa4-3789-4aeb-b69c-f5c9bf384699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3d4dff9b-35ea-440b-ad95-f7ee45ec92d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7e7bfa4-3789-4aeb-b69c-f5c9bf384699" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3d4dff9b-35ea-440b-ad95-f7ee45ec92d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5647e38f-4fcd-4d00-9eb0-9b21f314189b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7e7bfa4-3789-4aeb-b69c-f5c9bf384699" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5647e38f-4fcd-4d00-9eb0-9b21f314189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c4e2eaa1-6a10-41c1-8e04-cfd865f73342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7e7bfa4-3789-4aeb-b69c-f5c9bf384699" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c4e2eaa1-6a10-41c1-8e04-cfd865f73342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_81e8bc93-4bd5-4c56-a685-586a4a5bc098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7e7bfa4-3789-4aeb-b69c-f5c9bf384699" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_81e8bc93-4bd5-4c56-a685-586a4a5bc098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e3ae740e-3759-4121-a749-fb1f93f5d590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4302de28-04a0-4ad9-9347-81d0580e85aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e3ae740e-3759-4121-a749-fb1f93f5d590" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4302de28-04a0-4ad9-9347-81d0580e85aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_45ac466a-912e-4e93-bbb3-fdef9c29b7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4302de28-04a0-4ad9-9347-81d0580e85aa" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_45ac466a-912e-4e93-bbb3-fdef9c29b7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d4b5b0dd-c8bf-4014-89e7-96560a4fafd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4302de28-04a0-4ad9-9347-81d0580e85aa" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d4b5b0dd-c8bf-4014-89e7-96560a4fafd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00d1ac42-b192-436b-b637-86bb390d3e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4302de28-04a0-4ad9-9347-81d0580e85aa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_00d1ac42-b192-436b-b637-86bb390d3e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b47c2897-d442-417c-bfaf-158a7c47d34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e3ae740e-3759-4121-a749-fb1f93f5d590" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b47c2897-d442-417c-bfaf-158a7c47d34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_011bbd91-34a8-415b-a070-3da6496df14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b47c2897-d442-417c-bfaf-158a7c47d34b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_011bbd91-34a8-415b-a070-3da6496df14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_af9f0999-e76f-4bb4-b959-685ddc3bf1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b47c2897-d442-417c-bfaf-158a7c47d34b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_af9f0999-e76f-4bb4-b959-685ddc3bf1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9cf04cfb-3934-42c4-bc62-3b5ac391fc78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_b47c2897-d442-417c-bfaf-158a7c47d34b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9cf04cfb-3934-42c4-bc62-3b5ac391fc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b66b7b76-782f-476c-b00b-1d006240db88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e3ae740e-3759-4121-a749-fb1f93f5d590" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b66b7b76-782f-476c-b00b-1d006240db88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11001891-ca2f-4e2d-a2e8-fffbc71fc6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11001891-ca2f-4e2d-a2e8-fffbc71fc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_80916126-4acd-4322-a056-8cda3cbf1521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_80916126-4acd-4322-a056-8cda3cbf1521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0239d2c5-daf4-408f-b6b9-3a52c3e0f2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0239d2c5-daf4-408f-b6b9-3a52c3e0f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_29eae816-9d4f-4eec-87b0-806a590972cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_29eae816-9d4f-4eec-87b0-806a590972cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_1c1a1fbb-cf25-4fd8-88d4-d79e9038d764" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee_1c1a1fbb-cf25-4fd8-88d4-d79e9038d764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e730e22d-236e-43d8-961c-72ba138355ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e730e22d-236e-43d8-961c-72ba138355ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_fdc6425f-7b55-4d7f-aa73-0c48a0482401" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost_fdc6425f-7b55-4d7f-aa73-0c48a0482401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73e4cbf9-e2f3-4e99-8fa9-09d2db3e096e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_73e4cbf9-e2f3-4e99-8fa9-09d2db3e096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_fad5c5e7-5724-490a-9dc2-b724383866f0" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxReconciliationExpirationOfTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_nbix_IncomeTaxReconciliationExpirationOfTaxCredits_fad5c5e7-5724-490a-9dc2-b724383866f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8691d09d-6803-4ee2-b609-407991e05f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8691d09d-6803-4ee2-b609-407991e05f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_46493ebd-20d7-40e7-8118-ba40842a961c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_46493ebd-20d7-40e7-8118-ba40842a961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b9a84ec3-5094-46d3-ab0c-5daf62a71e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b9a84ec3-5094-46d3-ab0c-5daf62a71e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29e5d8de-08d4-45ac-af17-d86f3f375d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_711a6895-7107-42db-a8a8-59369da48973" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29e5d8de-08d4-45ac-af17-d86f3f375d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_98c39ae4-a5a2-4e7c-930d-fdab64c28f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_98c39ae4-a5a2-4e7c-930d-fdab64c28f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_96f17447-2a08-4d81-b03c-158e2558b08a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_96f17447-2a08-4d81-b03c-158e2558b08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_920e8590-2d9e-4de9-84f4-18af1fa8246e" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment_920e8590-2d9e-4de9-84f4-18af1fa8246e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_aa990c3a-15a2-40dc-bba6-6d74bcdff271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_aa990c3a-15a2-40dc-bba6-6d74bcdff271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_aeca6b9f-2f28-41d8-9306-f22b3e05f909" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsOperatingLeasesAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_nbix_DeferredTaxAssetsOperatingLeasesAssets_aeca6b9f-2f28-41d8-9306-f22b3e05f909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4fbd942b-ec0b-4ec4-8332-11803c173ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4fbd942b-ec0b-4ec4-8332-11803c173ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_81ee25b2-e559-45fc-bdce-bb5ca3adc840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_81ee25b2-e559-45fc-bdce-bb5ca3adc840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e9b61106-b776-4635-b869-088fd8e8586c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_b98b1b11-58e0-404a-8ad6-97ebcab6ef84" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e9b61106-b776-4635-b869-088fd8e8586c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_6744f971-f157-4bd3-9e76-71df8e31aae7" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:to="loc_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes_6744f971-f157-4bd3-9e76-71df8e31aae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_dca21e04-b7fc-4163-980a-6b71d248d2e5" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:to="loc_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities_dca21e04-b7fc-4163-980a-6b71d248d2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_c85cde78-be15-4cd8-ac2a-3fb077145b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_c85cde78-be15-4cd8-ac2a-3fb077145b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0cb0df9b-a711-4196-9e90-733247e16641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a320cd46-4098-4644-a49a-d5f3376faa47" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0cb0df9b-a711-4196-9e90-733247e16641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DeferredTaxAssetsLiabilitiesGross_3080efe9-a521-47dc-8b0b-d660096a4b07" xlink:href="nbix-20201231.xsd#nbix_DeferredTaxAssetsLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:to="loc_nbix_DeferredTaxAssetsLiabilitiesGross_3080efe9-a521-47dc-8b0b-d660096a4b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4412961-f790-468c-9fa6-06cf8736c780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f4412961-f790-468c-9fa6-06cf8736c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9bcad01-c879-475f-b96f-c993837ef2c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9decc96-e3bc-40a8-854f-385db60a6c7c" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9bcad01-c879-475f-b96f-c993837ef2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f84413bf-280f-42ba-8dd4-11085c245872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f84413bf-280f-42ba-8dd4-11085c245872" xlink:to="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6dc28915-ae24-4def-a691-111812fa93d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6bfb541c-bf3e-43be-a46c-33def032e731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6bfb541c-bf3e-43be-a46c-33def032e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5bd365fc-4c40-434a-9d14-7cd68a642b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e1e8a1e7-f0f3-4e7f-a531-48eed9a7c844" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5bd365fc-4c40-434a-9d14-7cd68a642b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:href="nbix-20201231.xsd#nbix_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesTable_c0fb3eac-12e5-4ea8-9513-d99eb705106b" xlink:to="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e956742-3c97-42f1-88fe-357eac0b4bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e956742-3c97-42f1-88fe-357eac0b4bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f96eb50e-f910-4ae9-9532-8da76f08db85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f96eb50e-f910-4ae9-9532-8da76f08db85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6bf5a5f8-1f1b-4753-b33b-d28dfe769619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6bf5a5f8-1f1b-4753-b33b-d28dfe769619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c1160e00-61b2-4c3e-8f34-37c180e34080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c1160e00-61b2-4c3e-8f34-37c180e34080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f7b1e5a8-4509-4ea1-b21d-47fa02fe3ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f7b1e5a8-4509-4ea1-b21d-47fa02fe3ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ecb9230c-7832-47df-a39d-985048759f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ecb9230c-7832-47df-a39d-985048759f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4ed12b9d-8f55-4d0e-951b-11451e63a25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_IncomeTaxesLineItems_0c3762f0-8b8d-4e6d-9570-de3888169fc6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_4ed12b9d-8f55-4d0e-951b-11451e63a25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0d0b677f-5e5d-45fc-a3ec-eac425e0ace1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0d0b677f-5e5d-45fc-a3ec-eac425e0ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b0cb8ef6-425a-4e2d-9d6a-4a9a343dd1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b0cb8ef6-425a-4e2d-9d6a-4a9a343dd1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6526cb3d-6723-43ed-86f1-b9fabfd310ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6526cb3d-6723-43ed-86f1-b9fabfd310ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f95a9507-045b-4c9b-b6ff-079ddcc6bd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f95a9507-045b-4c9b-b6ff-079ddcc6bd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c61c1e99-027b-4412-b230-a2520e4ccc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_c61c1e99-027b-4412-b230-a2520e4ccc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_ee700a99-bd2c-4f45-a4f3-1b7f0d03f092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_ee700a99-bd2c-4f45-a4f3-1b7f0d03f092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a6a54246-0b67-4f45-adff-c8dd6d0d7a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22b00324-f8f1-4ba9-81d7-fd5ce5e2524c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a6a54246-0b67-4f45-adff-c8dd6d0d7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b67cc4a-f11f-47b7-b6ba-acba9c83b83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_107b61aa-f592-4a63-8268-000f5322ee6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b67cc4a-f11f-47b7-b6ba-acba9c83b83f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_107b61aa-f592-4a63-8268-000f5322ee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTable" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesTable"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b973a9b6-19a0-459a-adc4-c6e8e4aa3b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b6210084-a95d-42bd-b861-8be170cca4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b973a9b6-19a0-459a-adc4-c6e8e4aa3b98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b6210084-a95d-42bd-b861-8be170cca4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_64ba8445-46fb-43cc-91f1-598f4cd50e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_64ba8445-46fb-43cc-91f1-598f4cd50e6e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:to="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c448d6a6-416f-4a25-8f7a-fde049f57082" xlink:to="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b500c135-af3b-47b5-a813-dc50d87d7eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_888ee24a-b61a-479f-bec1-1281540b2519" xlink:to="loc_us-gaap_LetterOfCreditMember_b500c135-af3b-47b5-a813-dc50d87d7eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_172319b0-cfa9-4bd8-be9b-8ec8726e2c40" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_f972b60a-ef62-4d08-8b5b-e040bf73734b" xlink:href="nbix-20201231.xsd#nbix_NumberOfRenewalOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_nbix_NumberOfRenewalOptions_f972b60a-ef62-4d08-8b5b-e040bf73734b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33127624-afcd-4c34-8bda-c159ead0d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33127624-afcd-4c34-8bda-c159ead0d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_edf476a6-756d-4cb3-8aaf-dddb23b07ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_edf476a6-756d-4cb3-8aaf-dddb23b07ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_dec2b61e-aa6c-40c5-84f6-7298bd4d9401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseCost_dec2b61e-aa6c-40c5-84f6-7298bd4d9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0a58bc26-6e65-4af6-8578-59fcc5a857d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeasePayments_0a58bc26-6e65-4af6-8578-59fcc5a857d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89bc8213-deda-4a8d-a526-4c5abf342ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89bc8213-deda-4a8d-a526-4c5abf342ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87ac9cce-5863-43bf-8801-d4cf6c14373e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c155e02e-a96f-4a96-986a-996625a558c9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87ac9cce-5863-43bf-8801-d4cf6c14373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1b00d2a7-5bef-4257-a31c-8e634d9f90aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1b00d2a7-5bef-4257-a31c-8e634d9f90aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a69dc24f-d1e8-4ded-8c03-e572affd7c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a69dc24f-d1e8-4ded-8c03-e572affd7c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc69bb67-d845-4c9c-bf97-fe32aeb2a5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fc69bb67-d845-4c9c-bf97-fe32aeb2a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6f15fb8a-f902-40c8-9550-76f1db158aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6f15fb8a-f902-40c8-9550-76f1db158aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_36404a8e-86e1-44e4-9927-4dbb25d59902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_36404a8e-86e1-44e4-9927-4dbb25d59902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_45f56f6c-fca3-4ccf-8b97-50b171875797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_45f56f6c-fca3-4ccf-8b97-50b171875797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e6e3b71-a5c3-4eff-9b80-df5b1447ce3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e6e3b71-a5c3-4eff-9b80-df5b1447ce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_78b51662-b93d-4b2d-a654-24f7fe2a60ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_78b51662-b93d-4b2d-a654-24f7fe2a60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d8c5be68-3fdf-40ba-8d36-59a3c348a8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_OperatingLeaseLiability_d8c5be68-3fdf-40ba-8d36-59a3c348a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49e6cdcd-213f-4096-84c9-8c2deaaa5d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49e6cdcd-213f-4096-84c9-8c2deaaa5d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_803d089b-afa5-4e0d-8328-b8ca9cb8dd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_803d089b-afa5-4e0d-8328-b8ca9cb8dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_486a191c-0be8-4109-96c4-3a91054af850" xlink:href="nbix-20201231.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_486a191c-0be8-4109-96c4-3a91054af850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_36ab05e2-8f80-443e-8c78-1833488e4bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669e2710-33c7-4528-b6bc-dba049e25f17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_36ab05e2-8f80-443e-8c78-1833488e4bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nbix-20201231.xsd#LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlan" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlan"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_213ac5f2-f27c-4b62-ad42-3a8edb83533f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fbb8ac6e-9032-4436-8df0-faf657eb033c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_213ac5f2-f27c-4b62-ad42-3a8edb83533f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fbb8ac6e-9032-4436-8df0-faf657eb033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#RetirementPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_585ccd9c-d488-426f-8835-ccf1f1d8e729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_750e08c8-2173-448f-893c-456157de8e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_585ccd9c-d488-426f-8835-ccf1f1d8e729" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_750e08c8-2173-448f-893c-456157de8e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_702b5537-75ea-42b3-aed9-3de7eda5c431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_585ccd9c-d488-426f-8835-ccf1f1d8e729" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_702b5537-75ea-42b3-aed9-3de7eda5c431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4d3961ef-4be7-4055-b5d1-abc4b60ef88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_598c605b-0ed9-43c4-90ba-736c1a7e2a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4d3961ef-4be7-4055-b5d1-abc4b60ef88b" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_598c605b-0ed9-43c4-90ba-736c1a7e2a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="nbix-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2875ba28-1a85-46c8-88ad-98d3b31fea97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a5d6d38f-ba7c-432d-91ad-5a209cffa1da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2875ba28-1a85-46c8-88ad-98d3b31fea97" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a5d6d38f-ba7c-432d-91ad-5a209cffa1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178e50ee-0c8f-48d4-9de9-b04fd0c26bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178e50ee-0c8f-48d4-9de9-b04fd0c26bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ff17834f-1995-45f0-a649-da2731fa7e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_OperatingExpenses_ff17834f-1995-45f0-a649-da2731fa7e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_768ef5ca-7883-43a7-bf77-2893975b314f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_NetIncomeLoss_768ef5ca-7883-43a7-bf77-2893975b314f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_71cb79a7-4bfd-4d04-932d-f1b166644a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_EarningsPerShareBasic_71cb79a7-4bfd-4d04-932d-f1b166644a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a30016e3-c69a-4457-89f4-142e6cd07cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a30016e3-c69a-4457-89f4-142e6cd07cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cff140ac-4105-43f1-9261-bc2e30b01d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cff140ac-4105-43f1-9261-bc2e30b01d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a9874be-21d4-4bc5-b8a6-09bf1c4ff51a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7acf7c23-7d22-4527-941d-9b1c3bc2aa45" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4a9874be-21d4-4bc5-b8a6-09bf1c4ff51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20201231.xsd#SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_81401b2d-4d32-42c4-af22-f2b79fb84bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_81401b2d-4d32-42c4-af22-f2b79fb84bc8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638e0dfe-c2ff-4b01-aa82-6800f309799d" xlink:to="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_e9798a54-7769-46e1-9c19-09274c02df1a" xlink:href="nbix-20201231.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_e9798a54-7769-46e1-9c19-09274c02df1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d5f0b784-0e3c-449e-a688-384fb1ba7b3e" xlink:href="nbix-20201231.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_d5f0b784-0e3c-449e-a688-384fb1ba7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_8b344921-02f6-4045-ba06-fcc18d933c91" xlink:href="nbix-20201231.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_VoyagerTherapeuticsMember_8b344921-02f6-4045-ba06-fcc18d933c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_5606f7aa-6542-440f-b635-deb541a1d04f" xlink:href="nbix-20201231.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_525fa07d-305d-460e-bdf8-fa8a299c3b9d" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_5606f7aa-6542-440f-b635-deb541a1d04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_358f821e-d25c-497c-b625-3928fad8ec17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4fd632a1-92f2-4173-900f-01e66ef35ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_342aff5d-fa8f-4d6f-acbf-0ecb7b3e2b71" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4fd632a1-92f2-4173-900f-01e66ef35ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be935a8b-7da0-46c2-98c6-f19fdeb3bd00" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ea796f1c-5d89-4a3a-ae29-1cc394253094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_914843b6-9fe5-4d46-b9c6-7ab8e3326ea2" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ea796f1c-5d89-4a3a-ae29-1cc394253094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nbix-20201231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +#!M,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJWL_4^ESCA9Y;@E4B[SCK+LT^WI_F>[4445J?G04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MG_\ 9#_YK5_V4S6O_:-?0%?/_P"R'_S6K_LIFM?^T: /H"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *S->\-Z;XGLC:ZG9QW<)Z;QRON#U!K3K
MB?BI\1(O .A[XP)=3N,K;1=?JY]A0=>$I5ZU>%/#WYV]+'B7Q?\ AOH/@A6?
M3]58WC\II\@W,!ZEAT'UKYXUGPO>ZM<&26VMAZ>5@?GZUZ!JFHWFLWTUW>2R
M3W$K%F=^22:99Z==7\RQ6\$DTC':%123FH/Z'RV5?+Z*56ISRZM_UMZZGFL/
MPWDD;]YLB'^_FO4O@]^SU;^,-;C\R%GL8"&N+AQ\H']T>I->F^!?V?=4UJ2.
MYUL-IEEU,;?ZYO;';\?RKZ)T/0K'PYIL5CI]NMO;1C 5>I]R>Y]ZK4^<SWC.
M=*FZ&$J7F^JV7SZL^7OVL/ NI;]!;1K1I=!L+;[*+>U7*V[ YY4=,C'/M73?
ML=^%==T'1==N]2AFM;"\>+[-%,""S*&W. >V"HSWQ[5Z?X,^%<?A#Q=X@UP:
MK=7W]K-G[/.<K'EMQ'OST]!6G\3/&,?P_P# >KZXP4M:0_N4/1I&(5!]-Q'X
M5\UA\KOCGF-1N,M?=W\KW]-;'R=?/:F)R^&0X9*IS<JYK--MM2M9]>;2]]3S
MOXY?M!Q?#^1M$T1$O?$+C!XW);YZ9'=O:O-M#^ _CWXLE=6\7:S-I\$V'6*X
M):3'J$Z+Q]*F_99^'I\9:UJ/CK7LWSQW!6W\[YM\Y^9Y#],C'N?:OJ^OI-S?
M&YA2X8?U#+(IUE\=1J[OVC?9+^M=3YSD_8QTGRCY?B2]$N.&:%<9_.N*UKX>
M_$GX G^U-$U.34=(AY?R<LBK_MQGH/<?G7V#39(UFC9'4.C#:RL,@@]C3L>7
M0XNS)2Y<8U6IO>,DK/\ #0\S^"OQNL/BMIK1.JV>MVZYGM<\,/[Z>W\J].KX
MS^+WAV?X _%S3?$>@J8M.NG^T1PJ<*,'$L/T(/Y,/2OL'2=2@UG2[._MFWVU
MU"D\;>JLH8'\C0CGS_+</A_98[ _P*RNE_*UO'Y?Y]BW17S)JW[5FI^&_&7B
M#3+W3[>XM[.26&UCA5@[R!L)N.>F,YXJHWQ(^.%Y;_VU#H1CT_'F" 6?5?7!
M.XC'>BYK'A/'V4JLH032LY22O=7LO,^HY8UFC>-QE&!4CV->9_#SX Z%\.?%
ME[KMA<7$TTRLD4,F-L*L<D>_IS6[\)_&&J>.O!=IJVK:4VDW4I($9Z2K@8D4
M'D \\'TKBO@_\9-8\?>/?$6BW\%K';:?O\MH5(8XDVC.3SQ0<5##9EAZ6,I4
M96C!)5$FM5>WSU['5_'7_DD/BK_KR?\ I7%?L>_\DED_["4W_H,==K\=?^20
M^*O^O)_Z5Q7['O\ R263_L)3?^@QT=3T*'_),UO^OL?_ $DZ_P"+/P7TGXMQ
MV!O[B:SN+,L$FA .5.,J0?I79Z!HMMX;T2QTJS#+:V<*P1!CD[5&!D^M>9?M
M"_%K5?A1INC7&EP6\SWLTD;_ &A2V J@C&"/6O3=!OI-2T33[R4*)+BWCE8+
MT!903C\Z#Q\3''K+:$JT[T6Y<BOLT]="_17C_P 9OV@+;X;7<>CZ;:?VKK\J
M@^3D[(L]-V.23Z"O/O\ A+OCSK2F[M](-E"W*Q?957CZ,<T7.O"\.8O$T8XB
MI*%*$MG.2C?T6Y]0T5\O:?\ M+>,? ^HPVGCOPY(D+<&58C#)C/W@#PWZ5]%
M^%O%&F^,M#MM6TFX%S93C*L."".H([$>E%SCS')<9E<8U*T4X2VE%WB_FC6H
MKR+XT_M 6?PPN(M)L;;^U-?F4,+?.$B!^Z6QSD]@*\[7QA\>->7[7:Z0;*%N
M5C-JJ<>P8YHN=F$X=Q>)H1Q,Y1IPELYR4;^G4^H:*^7+/]I+QKX#U"&U\=>&
MW$#<&58C#)C/49^5OTKZ+\)^+-,\;:%;:OI-P+FRG'RMC!!'52.Q'I0<F8Y)
MC,KC&I62<);2B[Q?S7ZFQ17EOQ?^/6E_"N6.P^RRZCK,R"2.V7Y5"DD LWN0
M>!DUY?#\2/C9XTC%UI&A?V?9L-R'[-@,#TP7/-%SIP?#N,Q5%8F3C3IO:4Y*
M*?IU/J*BOE1_CY\3/AO=1#QCH/G6;-@N\)B+?[KC(KZ"\,_$;2/%O@MO$NG2
M-+91Q/))'C]Y&47+(1ZT7,LPR'&9="-6:4H2=E*+YE?M<ZFODG]KGXK_ !3\
M*^+O!.GZ#X+O+?0U\9:4EEK-GXDBMO[?=HV8Z=)" &BCD<NA:0E/W0)&"*]0
MM_'?B:^\7&PAN+8WI*LEBIR@4VPGRPQD+\RQE\_>8<8K%_:0L=1\?:/\$-1T
M32K[485\?:'JUPMK;O*;:U"RLTLFT'8BAAEC@#(R:3//Q6 JX-1=1IW2>GGM
M]YZ_\/\ 6M?\1>$;#4/$_AO_ (1'7)O,^T:-]NCO?L^)&5?WT8"MN0*_ XW8
MZBNAHHJCS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\33-&NIR)I[2>846/_2!^[$>T3;LA=@"XV] .<\UW<$$=K#'#$BQQ1J$1%&
MJ@8 %2451^;5L56Q"2JRO8****#E"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[*9K7_M&@#Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU_\ CE3_ !@^%^F_&#X?ZKX8U-0$NDW038R8)EY20?0]?4$CO7X[^-/!^I>
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\+[\=_\ 0=_\DX/_ (W1]7D'^L>$_EE]R_S/L"BOC_\ X7WX[_Z#O_DG!_\
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M_#TC]H?_ *&Z#_P"2@#]]:*_ K_AZ1^T/_T-T'_@$E'_  ](_:'_ .AN@_\
M )* /WUHKY1_X)M_''Q?\?O@%-XD\:ZBNI:LNIS6XF6(1_(N,# JO_P4T^.W
MC']GG]G_ $GQ+X(U%=,U>?Q%;V$DSQ"0&%K>Y=EP?]J-.?:@#ZVHK\"O^'I'
M[0__ $-T'_@$E'_#TC]H?_H;H/\ P"2@#]]:*_ K_AZ1^T/_ -#=!_X!)0/^
M"I'[0Y(_XJZ#_P  DH _?6BN-^#'B"^\6?"#P1K>IRB?4=2T2RO+F0+@/+)
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MCNK>9>CQNH93^1%:%?#--.S/H-]4%%5[Z_MM,M9+F\N(;2VC&7FG<(BCU)/
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M4+R. $#J1O(]#^5-1<G9(3:6K-FBN*L/C=\.M4G$-EX^\+WDQP!';ZS;.W/
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M'M;26<?54+?TKX29B[%F)9B<DGJ:ZJ$;MR9\=Q%BI4Z<*$7\6K^0E%%%=Q\
M%%%% !1110 4444 =Y\&_ >G_$3Q/=:;J4US!!%9M<*UJRJVX.BX.Y2,88]O
M2O3-0^"'PVTF[DM;WQ9-9W4>-\-QJ5LCKD C*E,C@@_C7+_LO_\ (_:A_P!@
MR3_T;%7H'C[]GW_A./%E]K?]O_8OM7E_N/L?F;=L:I][S!G.W/3O7).5IV;L
MC[' X15,"JM.BJD[O=VT^\X_Q%\+?AMI_A_4[JQ\7_:;Z"UEE@A_M.V?S)%0
ME5VA<G) &!SS7A]>P>/OV??^$'\)WVM_V_\ ;?LOE_N/L?E[MTBI][S#C&[/
M3M72? /P3HOBSX<ZNFI:=;3SRWDUNMVT"-/$IACY1V4E2"Q(]#S5J:C'FO<X
MZN!JXG$QP_LE2E:^CO<^>Z*^B/ OBCX?ZYXQC\+:;X,LWL6\P6NHW,23/*54
MN2PD4N%(#X)8G[HP.B\7XX^$,5C\6-/\-:-*ZVVJ*MP@DPQMHRS[QDL-X58V
M89()&!R>3:J:V:L<53+9*DJM&:FK\NE]_GN>5U[)X;^#>BZQ\(9O%4UU?KJ"
M6=U<"*.1!%NB,@48*9Q\@SSZ]*ZSQUJ'@;X.6FF:,GA.SUV_,7F'[7$F_P O
M+#S'E9&RS,#A0,#!^Z H/46O]C'X$ZHWA_SAI$FF7TD"7&=\>X2ED.?[K%EZ
MG[O5NIRE4;2:5CU\)EE*G5J0JR4W&+NM='I]_P"A\CT5[)\%?A)I?B71[SQ%
MXE#II4+$0HTIAC=54^8[M@?("1@JPY1@>E;'AOQOX!\?^(E\/7/@BPTNTO&*
M6]XOEQ2,P.4#%%4H6QC"N>2%Y!S6KJ:M)7L>32RURA"52:BY_"G?7[EH>!T5
M[A8?"JU\'_'31-*FM_[1T*\BEE@^W()0^('W*^5"EE<9P!P"AZFMSXD7'@3X
M5Z]YH\*VVL:M?J)39R*L=M;PX" JNPH"6C)X4MDOE@" 5[1722N6LJG&G.I6
MFH*,N5WOY;6WW/G.BOJCQ/X,^'=UX5M?&%]HGV/3TM8[GR;-3"94=?DC9(R%
MW%I%Y!'(&6V@UG^ ?^$.^,^B:U:'PA9Z'-!L1I+2.,.H?)5TD5%(8%&R",=,
MY!(J?;:7L;O)9*HJ/M8\TE>*UU7W:'S/17MGPI^"-EK?B+7VUDO>:5I-Y)I\
M:J?+%S*I(8MM;<H4;3@=2PY^4@[GACQ+X"^(WBJZ\,'P=IMI:R^9]EOK=/+>
MXV-N&-D:M'E%9N6[;3G-4ZBZ*]CGI97.48NI-0<G:*=]6O3;7^MCPOPQX;O?
M%VO6>D:>J-=W3%5\QMJJ "S,3Z  GC)XX!/%=!\5?A_%\-]<LM+CO'OWDLUN
M))F0("QDD7"KDX&%7J3SD]\#TSX=Z/:_#7XT7?AAM.^W_;,26&J72!9((Q#(
MY*?+\V<F,LI4$H>.PD_:2\4:?:S'0Y-"MKC4+FSBECU=MOFP*)F.Q?DSCY&Z
M,/OGCUGVC<TEL=*R^E3P%2K5=JBE;KI;I\^^WXGSW6QX1M=&O/$5I#X@NYK'
M2&W^?<6X)=<(Q7 "MU;:.AZ_C7TA:^#_  =;_#'P_KNKZ39I'86-OJ$S10QH
M]RX@X1R0-^YF'RD_,VT'/(/!Z+K'A/Q]\9?#<>D^'+:STL03)/;SVD:"9Q%*
MPW1JS(0,*0<9SG.<+A^TYD[(AY6Z$Z?-.+<G&RUUNUOY'F_CRQ\,Z?K$,?A7
M4;G4].,"M)-=*582[FRHRB<;0IZ=SS7-U[)\;/!,5U\4M$T/0-.MK)[VSB C
MM8!'&&,LH+L$7H ,DXX"^U=)XNM? WP-M+*S7PY#XEU*\R[_ -HR([K&I.&.
M5(7);:-J -M.3E>6JFB2U;(J9?*56K*;4(0=F];>B6K/G>BOH#6OA[X;^)_P
M_E\5>&--_LS5UB9FT^U<%#(FW=&8U!^;:I*!0I;>I8<\9_[/OPNT;Q5I]UKN
MKQ?;O(NOL\-F^1&&4(Y=L'Y\[@-IXQG(.1@]HK-OH9K*:TJ\*,&FI*Z?2W]=
M#P^ND\!V/AG4-8FC\5:C<Z9IP@9HYK52S&7<N%.$?C:6/3L.:]8;QW\/;S4[
MW1?$G@1/#<6X!)C:".4+RP,@C59(R0$X7=G=R<<G#^!6BZ!K7Q*U:W2T_M/2
M%L9)+=-6MHV<?O(L%ERR[ADC<.O7 S@#G[KNK%4\#&->G&G4C.[M;7?S6CL>
M;^+K71K/Q%=P^'[N:^TA=GD7%P"';**6R"J]&W#H.GXUCUZYXF\"Z?X@_:"F
M\-PJFE:?*T9*V<2H%5;59&"J. 3@\XX+9P>A[SQU<>$?A-)IEE_PK^'4--DY
MEU"2W5Q'N9OD$DBL9'P'.UF& %YQT/:6LEJV/^S95'5JSDH0C)KKO?HM78^9
MZ*[SXI77@?4;BTO/"4=S:SS+YEU:F'; A8DD#+95U/!504P1M(P<\'6J=U<\
MFM3]C-P4E+S6P4444S **** "BBB@ K>\$^,K_P+X@M]3L7(*G;+#G"S1Y^9
M&^OZ'![5@T4FKZ,N$Y4Y*<'9H^]-'U:VU[2K34;-_,MKJ-98V(P<$9Y]Z*^4
M_"/QGU/PIX>M-*MY,0V^_:-N?O.S?^S45P.C*^A^C4\_PSA%SO>VOJ?7%9OB
M3P[8>+=!U#1M4MUNM/OH6@GB8<,K#'Y]P>Q K2HKG/J8RE3DIQ=FMC\8OCS\
M(;_X)_$G4_#EVK/;*WFV=P1Q- Q.UOKV/N*\^K]6OVSO@"/C1\-9+W3;?S/%
M&B*US9;1\TZ8S)#_ ," R/\ : K\IF4HQ5@0P."#VK?FYD?VAP?Q#'B'+8U)
MO][#W9KSZ/TEOZW70OQZ+J$NFOJ"65P]BAVM<+&3&IXX+8P.H_.JRU]%?L=_
M%FPT;6-1^''BUA/X*\7+]FDCE/R6]RPVI(,]-W"YQU"'M7F?QN^$^H?!GXBZ
MGX<O0SQ1MYEK<8P)X6/R./PX^H-8R/=P^9N68U<NKPY9)*4'?2<=F_)Q>C7H
MSZ$^#U];?M0_ F[^&&K3)_PF/AN,W/A^ZE(WR1*,>5GK@#Y3CMM]*^2]0T^X
MTF_N;*\A:WN[:1H9H9!AD=3AE/N""*UOA]XXU/X;^+],\1:1,8;ZQF$J^C =
M58=P1QBOH?\ :P\$Z;X^\-:)\;O",(_LK7$6'6+:/G[+=@;=S#MD@J>G(4_Q
MUA+5'C4?^$'-/J[TP^);<>T:N[CY*?Q+^\FNIQ/[*?QHB^%/CS[%K!$WA'7%
M^PZI;R\QA&X$A'3Y<\^JDBF_M%?!F3X,?$>ZL+<-)H%Y_I>EW&=P:!CD+GN5
M^[[X![UXM'UK[+^%5]!^U!\";GX?:I*I\:^&(_/T6YD/S30@8\O..P 4X'0(
M<]:XJT?:1Y.O06;1>2XV.<T_X4[0K+R^S4_[=>DO[K\CYI\,ZU>>'=9LM4T^
M9K>]LY5GAE7JK*00:^J/C=I-E\;OAEIOQ7T*%5U.V1;;7K6/JC#CS,>W'/\
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M;K_T6:_FITK_ )"EG_UV3_T(5_2M^TA_R0/X@?\ 8%NO_19K^:G2O^0I9_\
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M.UK_ ,&LO^->Z?\ #8GP3_Z*9X?_ / H4?\ #8GP3_Z*9X?_ / H4 :O[/\
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MK9/_  "@#YM^+7PMUWX+_$'5O!OB2!;?6=,9%G13E<M&KC![\,*_<C_@F?\
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M[C4M/M[B/9)]CSM@D93R"Z -@],U[+110 4444 %%%% !1110 4444 %%%%
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M_@IM_P D&T'_ +&6W_\ 26ZKSS_@E[XTG^U>-O"4LK-;%(=4MXL\(P)BE/\
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MOV@/#\GB;3$TK4(()K=88XF1618Y_F&YFW DL-P.#CBLO]J#_D?M/_[!D?\
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MXHU!+,Q/0 "OP#_;P_;$U']K#XHR36;S6O@;2':#1;%\J67.#<2+_??K_LC
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MOA7K/P9\?:GX7UN%DGM7)@GVX2YA).R5/56 _ @@\@U]Q?L9_MI:1J7AW3_
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MND:K;7\N.JH1)#G\YA^&37T.+:CG--OR/-HIO RMYGS%_P $T_\ DO\ J?\
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M_P!!#1_^_P!+_P#&J/\ AE[Q5_T$-'_[_2__ !JOJ"BCV\P_L#!=G]Y\O_\
M#+WBK_H(:/\ ]_I?_C5'_#+WBK_H(:/_ -_I?_C5?4%%'MYA_8&"[/[SY?\
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MU7U!11[>8?V!@NS^\^7_ /AE[Q5_T$-'_P"_TO\ \:H_X9>\5?\ 00T?_O\
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M7Y^A\3X@9\L+AUEE!^_4^+RCV_[>_+U+5%%%?M)_/ 5\2_\ !7S_ ),_O/\
ML,67_H1K[:KP']MS]G/5OVH_@A/X(T75+/2+V2^@NQ<WP<Q[8R21\H)R<^E
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M]#_X7_[YN?\ XW1_PY)^(O\ T/\ X7_[YN?_ (W0![=_P^P^'7_0B>(/^_\
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MY@5+9B&$9#J#D,7/T;VH ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1L/P(S5C1/#>K^);D6^D:5>ZK<$X$5C;O,^3TX4$U^[E%?1_ZRNW\+7U_P"
M>7_92O\ '^'_  3\\OV1/V'_ !%'XOTKQKX_L3HUAILJW5GH]P ;BXF4Y1I%
M_P"6:JV&PWS$C! '7]#:**^9QF-JXZI[2K\EV/6H4(8>/+ ****X#H"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?_P!D/_FM7_93-:_]HU]
M5\__ +(?_-:O^RF:U_[1H ^@**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXT>$_@G\!];B\,W<]S\3?$"_9YKC[.R+8PG(PCGJ0.>/XB#VK.1^K9I/$8+
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MO^Z0>W/2G*,'!5(JVIIB<-@:F CF%&DX)3Y7'FO=6ON<[_P\N^'/_0N^*/\
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M4(/"6L#3=^//9XA+M]=F[&?;=7FF@^%])\8?\%$]7TS6]/M]4T^34+QWM;I
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M3&X[%XF+E&FU[J=KM^9[U\'?V[/!_P 4O%4'AN]TZ^\-:K<OY=O]LVM#(_\
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M>M:7BKQYHO@NYTB#6+O[(^JW(M+4E&*M(<8!(&%'(Y/%?+_Q7\,Z=\'?VBO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'S]^V5\?E^"OPUEM=-N GBG6
ME:VL0I^:!2,//C_9!P/]HK[U^4C,9&+,2S,<DGO7ZP?%S]CGPO\ &KQA-XA\
M0ZUK37+(L4<$,J+%"@Z*H*GW-<5_P[>^''_05UW_ +_1_P#Q%:)I(_?^$.*.
M'>',O5*<I.K/6;Y>O1+R7YW?4_-6I%K])_\ AV_\./\ H*:Y_P!_H_\ XBG?
M\.XOAR/^8IKG_?Z/_P"(J):GW7_$2N'_ .:?_@/_  3\^? '@G4_B+XNTSP[
MI$)FOK^98D'9<]6)[ #))]J_8CX5_#G3/A/X#TGPQI2#[/918>7&&FD/+R-[
MDY^@P.U<'\%/V4/!GP-UVZUG1FO+W49HO)6:^=6,*G[VS"C!/&?I7M%2D?C?
M'/%T.(:M/#X.ZH0UUTYI=[>2T7S"BBBF?E04444 %%%% !1110 4444 %?&/
M_!3/P^UQ\/\ PGK2KN%IJ36S$9R!)&S9^F8Q^E?9U>5?M0?#=OBE\#_%&BP1
M&6_6W^UV:J,L9HB)%5?=MI7_ (%6U&7+43/8R?$K"8^C6ELGKZ/1_F;/P'\0
M+XH^#?@W4P_F-<:7 7.[)#! &!/J"#7RC^TW:M\+?VS/A]XW@CVP:MY"3.W0
MR*Q@?\HVCKKO^"<_Q(77/AQJ7@^YDQ?:'.98XV)+&&0YS^#9%=!^WM\*]6^(
MOPUT>]\/Z9=:IKFD7^Z*&SC+R^5(N'( YX*1UO%>SK.+V9[N&@LOSJIAJKM"
M7-%^DEI^AY=\$(XOBY^W=XM\4JWVC3]#6XDMW)W)D 6Z@?\ ?;,/I5__ (*#
M?$[Q';>(?#'@'0M0GT^VU*(371MI#&TS,Y148CG;QG'O78_\$_\ X2ZU\/?!
MOB35/$>F76EZMJEXL8AOH3'*(XU)S@C.&+GZ[:QOV]/@;XH\97GA[QMX2L)M
M5O-*C\B>TM$+S8#ETD51RV"2,#FK4H^W2>RT/0C7PSSV%.4DX4XJ,6]KJ.GX
MG)>(/^"<>G>'O!FJ:O=^-+VYOK'3YKN18[91&\B1ER!DYP2/KBIO^"8HVKX\
M'O:_^U*L)\>_V@OB_P"')_"^F?#!].NKJV>TO=4OK:2"(AD*R$>8%56//&3C
M/2MW_@GQ\-O%/P\D\;Q^)-"OM&,SP+$UY T:R[3)DH2.1R.1ZU4Y3]E)5'J;
MXNMB_P"R\33Q]6,I^[9)Q;M?R/-/V9O^3[O%'_7SJO\ Z&U:'[:'_)Y7PT_Z
M]=,_]+YJU_V??A?XNT']LWQ%KVH^&]3LM%FGU)H]0GMG6%P[-M(<C'.1CUIG
M[<7@#QQ>?'KPIXR\->%=2\06>F:=:X>QMGG'G174TFQE0%NC+V[U7,O;+7H=
M*K4I9O3:FK>RMNM[/0^S_B%_R(?B/_L'7'_HMJ^&_P#@G'&_V7XE/M.PV<:A
ML<9Q)Q4WC3]I3XZ_%CP[>>%=(^%^I:/+J$36ES<QV-P6"N,, SJJQY&1DGO7
MOO['O[/=[\#OAU=P>(/*;7M7E\Z[AB8.L";<+%N'#'&22.,D@$CFL+>RI24M
MV>%[%Y3EE>CB)+GJ.-DFF]'>^A\4_LL_LZZ+^T)XI\66.L:M?:4VFJDL0LMF
MY]SN&SN4],#\Z^C_ /AV;X-R"?%FO'_OS_\ $5YYKWPO^*G[)OQKU?Q9X%\/
MS^*/#FI&0A+2!IQY3OO,4D:?,I0@8;&,=^H'70_M4_'_ ,:SVUMX<^$MQ8,S
MX>:[LYC&0",C?($13]36\Y5)/FIRT/>QN(S'$U%7R_$15)I?:BK::IWU+7_!
M22U6Q^&O@>V5BRPWKQAFZD"-17TU\"_^2,^"?^P1:_\ HM:\(_X*!^!?$?CW
MP/X5A\/:'?:S<07LDDT-E 96C!0#)"Y[U[_\'-/NM)^%/A&RO8)+6[M]+MXI
M895*NC", J1V(-<LG^YBO-GR6*J1EDV'C?7FEH?%?[*/_)YWC'_M]_\ 0ZJ_
MM!:CXH_:'_:L?X8VNN3Z5X?M95M!$C'RUQ&&ED9 0';=D#/;%=A^S5\,_%GA
MW]K'Q5K6I^'=2L-(G^U^5?7%LR1/N;*X8C!S6/\ M(_#'X@_"G]I!/BMX*T*
MXUZQNI$N3'9P/<>7((PDJ2HGS -@MNQCYNN175=>UTWMIZGU2K4I9HW&4>?V
M24&[6YK?F<M^T)^PYI?P8^%FJ>*[;Q1>ZE-9O"@MYH456WR*G4>F<U]'?\$_
M2%_9OT\G@"_NO_0A7B7Q0\;?'G]I;X?:EI4/PUET#P^B+/<B>&19[@HP95B#
MA6;G'"J>G6N^^$OAOQQX(_8?UO3+/1-2L?%C&[2&R:W=;D!V W*O7."2#4SY
MI4^6;UN<V.EB,1EBP^-K1=5U%U3LFNMCS+XC:A<_MD?M76?A?3I6D\&^'W:)
MIH^4,:,//E]"78;1ZJ%K]!=-T^VTC3[:QLX5M[2VC6&&)!A411@ ?0"OS,^!
M<_QO^ %OJ:^'_A9>7%SJ+J9KJ\TN9I-JCY4!!&%!)/U-?4G[._QB^,GCKQ[)
MIWCSP2WA[1%LY)5NS82PYE#*%7<Q(Y!;CVJ*T':T6K(X\\P4W3C&A./L:4=/
M>5WW=N[9XCX-_P"4CFJ?]?UU_P"B6K0_X*-_\E#^'?\ UR;_ -&BM;PK\,_%
MEK^WIJ/B6;P[J4?A][RY==2:V80%3$P!WXQR:O?MY?#?Q3XW\<^!;GP_X?U#
M6;>UC83R65NTBQGS0?F(''%:*2]K!WZ'H4ZU+^U,)+F5E22W\F?6\'_(EQ_]
M@\?^BZ^(/^":W_(Y>/?^N$?_ *,-?<<-O*OA-(#&PF^PA/+QSN\O&/KFOD#]
M@'X;>*O OBOQI/XA\/:CHL-S#&L+WUNT0D(D).W(YXKF@U[.?R/G,#4A'+<;
M%O5\MO/5GA_@GX*:;\>?VM/B/X;U74+O3;:/4-5NQ-9[=Y9;LJ!\P(Q\Y_*O
M?O\ AV;X-/7Q9KQ_[\__ !%<A\9_@Q\2O@9\?+SXH?#729M=T_4)I+F6WM8C
M.Z/)S-')$OS,K-E@5Z9'I6LW[6_QY\41K::!\(;NSO&.PW$]C</&&]RRJJ]^
MIKIE*I*SIRTL?48C$9ABHTJN75TJ?*K^]%6?6]S[(\&^&8?!GA/2-!MY9)X-
M-M8[2.67&]E10H)QQGBO@[PVS?$?_@HYJ%_;A9K;3;US)U(5;>W$!_\ 'P/Q
MS7V=XI^($W@7X.W7BKQ%;BQOK33?M%Q:EURL^S_5@@D$[N.":^5?^"<W@F[U
MK5_&?Q+U0%Y[R9K*"9A@N[,)9V^A)CY]0?2N>G[L9S?H?.99?#X7&8VH]6N1
M>;D];?F?<U?GS^W5_P G+> _^N%M_P"CVK]!J^1OVZ/V=_$GQ(DT7QEX0MVU
M#5M(C\F>QB($KQABZR1Y^\P)/R]<=,]*G#R4:FIR<.UZ=#'Q=67*FFKO:[1]
M<U\8_P#!1OXJ:_X2T7PSX9T:^GTZ#5_.FNYK60I)(J;5$>1SM)?)'?&.E<WI
M?[6O[0+Z9%I*_"R\N=;A4))>2:3<@$X #,F  >I/S <]JZ_]M[X*^*OB]X"\
M)>)]&TR>\UG2H#]LTN%?WH6159RJ\EBK*!M'.#WK2G3]G4CSV/1R[+_[-S&C
M+&N/*V[:IZVT;[:VM<YF+_@FM91:";S4_&UX^H+;F:<06Z^7OVY(!)R1GN:R
M_P#@F7#]G\5_$.('(2"U7/T>45L^'_VCOVA?'>CQ>&M,^&,T.L-%]FGU:_M9
M8(@<89F\P*JMCG&[\*T?V _A;XN^''B[Q^/$^AWNEB58(HKBXA9(YV227<48
MCYAR#D=B*UDY^SDJC/7Q5;&?V=BJ>858RD^7E2<;_%V1QWP]_P"4E&J?]?M_
M_P"DDE?1G[;G_)N7B7ZQ?^ABOC3QGXL\4>"?VW/%&L>#M';7M?M[^Z,-@D#S
M&13"PDPB?,2$+'CTKI?B=\4OCO\ M(:.G@H?#F_TNVEG5KC;830Y93P'DD 5
M%!SG/6JE3;G"?1)&V(R^I6Q>#Q?-%0A"%[M+;78^B?V%=.M=8_9CM+&]MX[J
MSN;FZBF@E7<DB,0"I'<$5Q'Q6_X)P^'=8-YJ'@C5Y]!NVW2)IUW^^ML]0JM]
M]![DMBO5O!'@3Q+^SY^R_P#V3H-HFL>,;&U:X%O&ID22Y=\E0,C(4''!YVUX
M7>?M?_'<:8^EGX1W\.NR(52Z&F71 /\ >$6SG_OK%8QYW.4J;ZGC4)8ZMC:^
M)RVJE%S>[2NN]GNBW_P3_P#BQXEU*\\3> O$5]-?1:7#YEH+IB\D!5BKQ[CR
M5'&!VY[=./\ V%?^3LO'O_8.O_\ TM@KUO\ 8;_9Y\1_#>WUWQ7XR@:RUC6E
M$<5G*P:6./)9G<CHS$_=ZC'.#P/ ?[!^*_[+G[0GB'7=!\'7VMP7\D\,4L5E
M+<P7-O-*)% >,</E$XZ\'CFM?=E*<8]3V'+#XK$8[#X:4;SC&VJ2;6]OF>U_
M\%-/^27^%/\ L+G_ -$O7=^(?^3"[3_L2K+_ -)XJ^9_CII?[0_Q\\(V>H^(
M/!<MIHUM=;K;2K.V(N-Q4C>T>3)@ XR0.O2OJW7/"NL3?L7VWA^/3;E];7PE
M:6IT]8SYPF6",,FWKN!!&/:LVE&$(M]3RZU..%PF#H2G%RC4ULT[:GE/[!*E
MOV;?&ZJ"S&[N@ !DG_1EKYS_ &5?V<])_:$\2>)K+5]4OM+73XEE1K+9EB7P
M0=RFOKO]@;P/KO@KX3:S8>(]&O-'N9M4>1;>^A:-F0Q(,X(Z9!KPNZ^&GQ:_
M9!^+>K:]X)\/S^*?#=^67-M UP)(2VX)(J?.C*?XL8^M:*7O347J]CU*>+_V
MO'T</54:DVG%W5G;?78]0M/^":O@ZSO(+@>*M=9HG5P&\G'!S_<KZ!^)_P "
M_"7Q@\)6N@^)K%KJ*T4"UO(VV7$#!0NY&'J!R""#QD<"OFG3?VHOCUXZU73[
M71?A3<Z5;23H)[BYLYBNS=\V'D"*O'KFO6OVD_BO\3_AK?>')O W@R;Q-I\T
M<IU*.*TDN'1\IY:@QY(_CR<$5A)57)*4M?4^?Q4,VJ8BE"O67M->7WEI\UM?
MIW/D[X__ +)>L_LQV,7CKP?XLNY+"WN%CWY,%W;%CA3O0@."< \#Z&ON?]G3
MXB7?Q6^"OA7Q1J&W[?>V[+<,H #R12/$[X' W&,G X&:^+_BA\0?C=^U9I]G
MX0M?AS?:%ICSK).SV\L<;LO3?+*%50.N.M?<?P9^':?"?X7^'?":RK.^FVVR
M66,85Y68O(1[%V;'M55F_9I3?O?H=&=U*CP%*&-E&6(4GM9OEMUMY_UN=I11
M17"?"A1110 4444 %%%% !1110 4444 %%%% !1110 4444 07EC;ZC;M!=0
M1W$+=4D4,*X36O@[I]V6DTZX>Q<\^6_SQ_XC\S7H5%;4ZU2E\#L<E?"4,2K5
M8W_/[SP35OAMKVDEC]C-W&/^6EJ=^?P^]^E<U+"\$A21&C=>JL,$?A7U!5:]
MTVTU)-MW:PW*^DT8;^=>E#,9+XXW/GJW#].6M&=O74^9:*]VU#X6^'[[)6U>
MT8_Q6\A'Z'(_2N?O?@G$V3::HZ>BS1!OU!'\J[8X^C+?0\>IDF+A\*4O1_YV
M/*:T+7Q!JECC[/J-U"/1)F _+-=5=?!W6X<F*6UN!VVN5/ZC^M9-U\.?$5KG
M=IDCCUB=7_D:W]M1G]I'"\'C*+OR27I?]!UM\2/$=KP-2:0>DD:-^I&:TH/C
M!KL/WUM)O]^(C^3"N8N/#>K6N?.TR\C'JT# ?GBJ,D3PMMD1D;T88-'L:$_L
MH?UO&4='.2];_J>AQ_&J_'^LTZV;G^%F'^-64^-SA?GT=6/^S<X_]DKS"BH>
M#H/[/YFJS;&QVJ?@O\CU9?C;#M&=)D![XG!_]EKTQ6W*#ZC-?+M?4$7^K3Z"
MO*QM"G1Y>16O<^GR?&5\7[3VTKVMT7GV/EGPO_R>]KOF9W>4^W_P&CQ^E/\
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M=E:V^ZW/G#XN_"/1OA)\4O MIH\][<+>7$4TTE]*LCEA.HSE57^5>C?MT?\
M(J>&/^OV3_T77GGQ@^*6F_%KXJ>#=0T.UO!IFGWD-H;RXBV++(9E;Y?3@=#@
M^U>A_MT?\BIX8_Z_9/\ T77K0]M]:P/UCX[2O?<\R7LOJV,]A\'NVML?2.D?
M\@FR_P"N"?\ H(K.\=,B>"?$+2_ZL:=<%OIY39KS7PA^U-\.]2TNUCN=7DT>
M[C18WM]0MW5E( 'WE#+C/O\ E7&?'C]I;P[K'@^^\,>$;F76]5U9/LADMXG"
M1HQPP&0"[,/E 4'[W7L?E*.6XN6)C!TVM=[.R\[['TM;,<+'#N:J)Z;7U]+&
M7^S)%<-^SC\0?+.-SWJQ?[_V-.?U6NF_8?8?\*KU<?Q?VU*3]/(@_P#KUW/P
M(^&;> _A)9Z'J46+R\62XOHL_=>48*?4*%4^X->#?!_QP/V9?'7B+PAXQCN+
M?2[F598+Y(RZC;D++M')1UQR,D%0,=<>W5DLP6,IT-9.2DEW2T=OS/(IQ^HO
M"5*VBY6F^S>JN?8]?*>I*TG[=5B(3AEC!<^WV!L_I7J^J_M0?#;2]/>Z'B)+
MU@I*6]K!(TCGT *@ _[Q KRO]G/2]2^)WQB\0_%&^M)+73R9([/S.=SL @4'
MN$C&TGU(]ZX,!0JX2EB*]>+BN1Q5U:[>VYVXVO3Q56A1HR4GSJ3MK9(9\2/^
M3S?"7^Y;?RDKZLKY3^)'_)YOA+_<MOY25]65AFG\+#?X%^;-\M_B8C_&_P D
M?+'[47_);?AC_P!=X?\ TI2JG[9ZWB^-_ 3VSQQR'S! TH^19!+'R?;E:M_M
M1?\ );?AC_UWA_\ 2E*Z_P#:[^'%]XR\#V6KZ5#)<:AH<KS&.(9<PN!YA7'4
M@HC?0&O:PM6-&6!<W9-27WMH\C%4Y58XQ05VG%_<DRE_8O[1G_0?\._]^T_^
M,U@^-OA?\=?B%H$NC:WJ^@7.GR.KM&A$9RIR.5B!ZUUOPQ_:P\(>(/#=FOB+
M4ET77(T6.X2X1C'*P',BNJXP>N#@CISU.WK_ .U1\-]"MV==<;5)1T@T^!W9
MOH2 OYM7)S9A1K<L<+'F3W4/Q3_4Z>7 UJ7-+$OE:V<_P:.P^%7AF]\&_#O0
M=$U%HVO;&V$,IA8LF03T) R,>U> _L68_P"$C^(OEY\KS;?'_?<^*^G=0U*/
M3](N=0<[888&G;=V55+'/X"OFO\ 89L9/[#\7:F^3]INX(=_JR*['_T:/SKC
MP\W/ XRK/>3C]_-<ZJ\%#&82G':*E]W+8T_V@MR_'KX0-)S ;U0O^]Y\?^*U
M]&UX3^UIX/O]4\*Z1XHT>%I=4\-W8NAL&2(C@LV!UVLD9]@&-:'A7]K+X?:Y
MH\%QJ&JG1;XH/.L[B"1MC8YVLJD,,YQSGU I5:%7%X*A.A%RY;Q=M;.]U]Z9
M5.M3PN+K0K24>:S5]+Z6?W-'L-U<QV=M+<2MMBB0N[>B@9)KY:\'6GC3]J*^
MU76[KQ3>^%_"$%RUM;6.FL4:4##;6P0"0K+EFW<G   X]J\)_%+PO\98=?TK
MP]=S7<=O;B.:X>!HD(E#J-N[#'[IZ@5X=^S[\7='^#%EK'@;QL\FBWUGJ$C)
M.T+O&V0H(^4$CE<AL8(8<UK@J%:C2K<E/]]'ELFKM)[M)]=NFAEC*U&M4H\\
M_P!T^;5.R;6R;7S*'QZ_9TT+X<_#.[URWU;6M3U".>%0;^X1X_F?!.T(#G!]
M:[7XS_\ )H.E?]@[2_\ VE7+?M&?'[PU\1/!%UX;\+K>:S*SI<S7D=LZ10QQ
ML"2=P#>G. !ZUU/QG_Y-!TK_ +!VE_\ M*O5B\2XX5XN_-[3KO;3H>;)8=2Q
M*PMN7V?3:^IZ]\(_^24>"_\ L"67_HA*X3]KQE'P1U/<.3<VX7Z^8/Z9K%^$
MO[37@2Q\"Z!H^K:A-HNH:=I]O:R1W=LY60I$J[U9 PVG&1G!YZ5QOQE^)5K^
MT1KGA_P#X*\^_LY+Q;F]OQ$T:A0"N0& .U59F)(&3M S7FX; XBGF*JU(.,8
MRYFVM+)WWV._$8RA/ >SIS3E*/*DGK=Z;'M%O\.].^)GP-\-Z#KJN5?2K-Q-
M$0)(95A7#J3GGDCW!([UYS%\#?B[X)C$7A3XD+=V<(Q#;:D& "CHH5A(H].P
M^E>P^-OB!X>^#N@Z7+J[36NF/*EA"T,1D$>$8KD#G&$/0&N7O/VJ/AE:V9N%
M\1_:#C*PPV<Y=O;!08/UQ7-AZN/Y6Z%-RA)MV<>97^[0Z*]/!72K5%&<4E=2
MY7;[]2G\!?C!K7C34=<\+>+K..R\5:*W[WREVK*F=I) )&0<<C@A@17*?LI_
M\E"^,'_84C_]&W5)^S<MWX\^*7C?XE&SDL=+U ?8[19>"XW(3[$@1)DCC+$#
MH:P/!/C;3O@'\=_B#IOBDR:=IVM7'VNVNQ$TB!3)(\>=H)((E89&<%2#[>G4
MH)O%8>A'WG&#Y5T::<DO0\ZG6=L-7K2]U2DN9]FFHM^I[]\9O^21^,_^P1=?
M^BFKS?X#_P#)J?\ VY:E_P"C)JA^*W[1G@OQ!X+UGP[X?N[KQ%K&K6<UG!;:
M?:2,0SH5!)8#(&>BY/'2KW[.UC)J?[,=M9Q#,MQ;W\2#W:64#^=<*HU</E_[
MZ+C>I%ZZ=&=KK4Z^._=24OW;VUZHH?LOK(W[.EXL1Q*7O0GUQQ7EO[/6G_%J
M[\"3/X'U32+/1Q>R!X[Q5,GG;4W'F-N,;>]>G?L:^)-.N_AW=>'3+C5K&ZED
MN+1T((C<C#<C&,Y&.O%<A\,_'EK^S/X[\3^"_%,=Q9Z#<79N["^6-I%53PK$
M*"6#($!(R0R$8ZX]:7M%6QE*$%*?,I)-7NKO9?-,\R/LW2PE2<W&-G%M.UGI
MN_E8WO$7@7X_^*M#O=(U'6O#\UC>1&&:-0JEE/49$617I?@#X4_8_@C9>!O%
M,<-U^XEAN5MW++\TKNI5B!R,J0<<$5GZM^U5\--+M6E37VOY ,K!:6LK.WL"
M5"C\2*ZWQ!\3M'\+^ [;Q=J*W$6E31P2X2,-(@EV[<@'MN&<$_C7BXBICI0A
M2='DO*ZM'E;D>O0IX.,YU%5Y[1L[RYK(\;C_ &=?B-X%S#X&^(TD6G*28;+4
M=P2//; #J?J%&?2MOX/_ !<\6CXA7GP^^(-O -<CA,]K>VZA1.H&XYV_*05R
MP( ^Z01FM]?VI_A@UNTW_"3#"]4-E<;L^F/+Y_E7G'PUUI_C=^TG)XWTVSFM
M_#VAV1M8YYUVF1BCJ 0.Y\QVQV"C."0*[;8G$4:KQ]*R46U)QY7S=-;*]SCO
MAZ%6DL%5NW)+E4N96ZZ:VL?3]%%%?(GU(4444 %%%% !1110 5\__LA_\UJ_
M[*9K7_M&OH"OG_\ 9#_YK5_V4S6O_:- 'T!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!\F^#_P!E[Q7\-_VK+KQ=X6FM;/P1>%YKF.63DK)R\"QCGAN58\#
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MQO\ SZ8?ZP95_P _XGU%17R[_P /#_AQ_P! 7Q1_X"6W_P D4?\ #P_X<?\
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M?+O_  \/^''_ $!?%'_@);?_ "11_P /#_AQ_P! 7Q1_X"6W_P D4?V7C?\
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M9>-_Y],/]8,J_P"?\3ZBHKY=_P"'A_PX_P"@+XH_\!+;_P"2*/\ AX?\./\
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M'_0%\4?^ EM_\D4?V7C?^?3#_6#*O^?\3ZBHKY=_X>'_  X_Z OBC_P$MO\
MY(H_X>'_  X_Z OBC_P$MO\ Y(H_LO&_\^F'^L&5?\_XGU%17R\O_!0[X<,P
M!T;Q0H]3:6^!_P"1Z[#PI^VA\*?%4R0'7I-&G8@*NK6[0KUQRXR@_%A42R[%
MP5W2?W&M//,MJRY85XW];?F>XT57L-0M=5LXKNRN8;RUF7='/;R!T<>H8<$?
M2K%>=L>TFFKH****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\./^@+XH_P# 2V_^2*/^'A_PX_Z OBC_ ,!+;_Y(H_LO&_\ /IA_K!E7_/\
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MP:VJ\^47%VDK,]N,XU(J4'=,****DL**** "BBB@ HHHH **** "OG_]D/\
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ME>WE^1VRP6(CAEC'']VWRWNM^UM^G8XFBBBNDX@HHHH **** "BBB@ HHHH
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M_L[^'/CW_P )7_PD%[JEG_9/V3R/[-EC3=YOG;MV^-\_ZM<8QU/6OJ_3=/\
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MVNM:AHNH6^IW>FSZA;7K3017$)8J8 ICP-W)5@S,@RG6J7_!2;_FG7_<1_\
M;6OFK]G?6KW0?CKX#N;";R)Y-8MK5FVJV8II!#*N"#UCD=<]1G(P0#7TK_P4
MF_YIU_W$?_;6DZ56CF="-2?/I*U]]F4L1A\5D&+G1HJF[QNDVU\4;/7;S^\X
M_P !_LJ^$_%'[+]S\1[K4-9CUR+2]2OA;PSPBVWV[3A 5,1;!\I<_-GDX([4
MOV4/V;_ WQX\+ZW/K6KZS;:YIMXJ/;:=)''&MNZ Q.2\+9)=9APW 09 R"?<
M_A!_RC_O_P#L7]<_]&7=?+O['?Q$_P"%>_'71=\'G6NN?\22;:FYT\Z1/+9?
MF &)5BW$Y^3?@$XIQJXFM2Q7)-WA)V]%T(EA\#A:^7NK23C4@N;U:6OWGD&N
M:+>^&]:U#2-1A^SZA87$EK<P[E;9*C%77*D@X((R"17TW\:/V5?"?P?^ MGX
MGU'4-9MO&=Q'9P?V?-/#+;?;7"M/$/+BZ*BSD'?CY!\QR >P^)G[/O\ ;'[;
M6@;+#=X>UKR]=N]NE[[0>0/W\4G.Q_,>./>QQS=KD,2-W$_\% /B)_PDGQ2L
M?"L<&R#PU;_/(R89Y[A(Y&P=QR@C$.. =V_J,5TK%SQE:A"C*R:YI6_+[]#A
MEEM++,+C*N)AS-2]G"_??F_\!LT0? 7]C:3QYX7_ .$R\<ZK+X5\+>6UQ%&H
M2.>>W",3<&23Y88Q\K!F5MRACA5*N>]O/V(_AQXXT6]_X5K\1?[2U>TPS^=?
M6U_;C<K[$D\A5:+<RCY_FP%;"-V]R_:4T?X?Q_"JPT?QIKE_X.\)_;(+>)=#
M0JKE(W,=N42*0>6 FX+MP#&G(P*\&^%.I?LW_!WQE;>)=!^)GB1KR&.2%[>Y
MMYS!.CJ05D5+12P!VL!G&Y%/:O)CC,7B8RKPE)/HE&\?1L^CJ97EV J0P=6%
M-QLN:4JBC/7JE?1+IW_$^0O%'A?5?!?B"^T/7+&73=5LI/*GMIA\RG&001P0
M000P)# @@D$&LNO<OVQ/B!X1^)GQ5M=<\'745]9R:7#%=W,=I);M)<+)*,N'
M168B/RANP> HSQ@>&U]AAZDZM&,ZD;-K5'YCCJ-/#XFI2HSYHIZ/>ZZ;:'Z'
M?\%#_P#DBNB_]C!!_P"DUS7P9X/\;:]\/]:BU?PYJUUH^H1X'G6LA7>H96V.
M.CH2JDHP*G R#7WG_P %#_\ DBNB_P#8P0?^DUS7YXUXN1Q4L#RR5U=GU?%L
MY4\V<X.S2CJC] /VT]%L_BC^SOX>^(&GP^5]A^S:C$UVS)*MI=JBF/8I*ER[
M6Y.3P$;#=F\GL_V5?"?BC]E]OB/H&H:S'KD6ER7TEOJ4\(MM]NQ%T%5(BV#Y
M4WEY;/*;B.<>O_'V\C\+_L+Z+I.K++I^I76EZ-I\=K/"ZR?:$$,CQL,?(0D,
MI.['*XZD \3_ ,$^/&UMJEEXM^'&HV$5W9W$;ZJHDA#QRHPC@N(Y=S8((,.%
MVX(,F3T%>50J5J. =2DW:G-_..GZL^BQE'"XK.(T<3%-UJ2U[3UL_N7Y'S)\
M%?AW_P +7^*7AWPJT_V>"_N#]HD#[6$"(TDNP[6^?RT?;D$;L9XS7J_QY_9I
MT7P;\5?!WP_\#2ZSJ&N:U&)IGU5DEAC1Y"B,#%&& 3RYGD)4@* 1T->H_L9_
M NY\&_&CQ_>:I!+(OAF1]'LKB[T\QB=Y&)^T1,Q.P^2BG"Y)2Z'S8(W>)WW[
M0$=I^UE<?$V*.*]TV+5&1/(A<&6P$9M@ZH[*1(8/F&X@;SR /EKUWB*M?%R6
M'=XPA>W1R>Q\U' X;!Y;3>-C:=2I:_6,(NTK?-?B>YW7[$?PG\"Z;8)XW^(M
MU8:A<>9MGEOK33HI]K<^7'*KGY0R _.W)SQD"N)^/'[%VF^#/A_-XV\":]=:
M[I%M;Q7,MK<*MP\L#$EKB*:%0K(%9&P5P$#OOX KV7Q%XJ_9V_:<LDO->UBP
MLM5MK,0I<:C=-IEW:^:"0H9RJ3&-@QQ^]16)[/\ -YY^T%^Q]JOA'X937'A/
MQAK.K>&M#C:^E\-ZS=;HX@OF-+/"1MC!"L3LV D&0AB2$/DX?%UXU8*O6E&3
M>JE'1^G](^DQV7826'JRP>&A4IJ/NRA/WEIN^_736]B?_@FS_P U%_[AW_MU
M7FGA_P"!-S\>/VI/B#IKSRV&AV.N7]SJ5['&2RI]K<+$C8*B1^=N[@!7;#;=
MI]+_ .";/_-1?^X=_P"W5?5%CI.BV=EXLT#P?J-AHVOR23WEY);;+B>TO;H,
MZW,\1.222&57P"J!1A0 ,\9C)83'8CDWDHJ_;1:F^6973S+*<$JS]V+FVNLO
M>EHMOGK_ )K\Y/VD/ GPU^&/B >&_!>IZSK>LVLA&IW-Y<PR6UN0"/(4)$I:
M0'[QSA,;>6+!/0_'G[*OA/PO^R_;?$>UU#69-<ETO3;XV\T\)MM]PT <!1$&
MP/-;'S9X&2>_S)KFBWOAO6M0TC48?L^H6%Q):W,.Y6V2HQ5URI(."",@D5^@
M/Q?_ .4?]A_V+^A_^C+2O9Q4ZN&^K0C4;O))ON?+9?2H8[Z]5J45'EA)Q7\K
M2?X_J?/'[(_[._ASX]_\)7_PD%[JEG_9/V3R/[-EC3=YOG;MV^-\_P"K7&,=
M3UKTKPO^Q+X!T&&QTCXB^/XK3QG?29@TW2]2MX%='?9$L:3QF24LRGY@H!)V
M@';EI_\ @FS_ ,U%_P"X=_[=5\U?&[7-23X^>-M174+I=0M?$%U]GNQ,WFP^
M5.RQ;'SE=@1 N#\H4 8P*RD\3B,=6H0JN,4D_P %_3.B$<!@<IPN,JX=5)R<
MD[NWVGJ^[25D=?\ M-_LR7/P#O=/O+/4)=9\.:E)*D-Q) 4DM74Y6&5A\A)0
M@AAM+%)/D4+S>_9O_9*U7XW0G7-4NI=!\)QR!$N5BW37Q#@2)""<  !@92"
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M=!U7PEJ]Y\)OB'JFE6NM>9NA@U(7.EWD0$JBW8Q89D#,4W,TI4;P58DUR_\
MP3[\%_V%XU^)7]JV?D>(=%\C2G_>[O)W23>?'\K%6^>WC^;G[G!P3F*.8.EA
MZU15>=QM9-6:OIKWU-,5DL<1C<+0=!4E.]W&5XR25].SLM/7K8+/]B/X<>!]
M%LO^%E?$7^S=7N\LGDWUM86YVJF](_/5FEVLQ^?Y<AERB]^/^,W[$4GA?PO=
M^,/ GB"+Q!X:M[,Z@\-W(GG_ &<(C&2*5!Y<P*^9)T3Y0 N\GGR']I#Q1JOB
MKXX>,I-6OI;UK+5+K3[82'Y8;>*9TCC0#@  =NI+,<EB3]1?\$Y_%&JZEX?\
M8Z'=7TMQI6ER6DME;2'*VYF,YE"'J QC4[<XSN( +,3=9XW"8=8QU>;9M6TL
M^QGAHY7F6,EE<<-R)W49)OFO%/5][V??]3YX_95^#.B_'+XA:AH.O75_:6=O
MI<E\CZ=(B2%UFA0 ET88Q(W;.0.:]LA_8E\ ^"[W4V^(OC^+1+.ZO)1H<2:E
M;VTCVJ'[TKSQ@/)AT#*BA5/.3N 6#]D31;/PW^US\2M(TZ'[/I]A;ZE:VT.Y
MFV1)?PJBY8DG  &22:\G_;8OKF[_ &D/$\4]Q+-%:QV<,"2.66)#:Q.50'[H
MWN[8'&68]2:TE4KXG'.A3J.,>5/\O\S"G1P> RF.+KT%4J*HX[NW7?OMH=%^
MTY^R%_PI714\3>']3NM7\/-<+;SP74.;BSW*-KO(@",C.&7)5-I>-?F+9KG?
MV3/'6G_#?QEJGB76?%LNB:-I=FUS/H<!D,FM.5:*.)4!".4:7<-YR#R %#NG
MU%\;KZYU3]@V"\O+B6[O+C0]%FFN)W+R2NTMJ69F/)))))/))K\ZZUP$JF/P
MDZ6(E>S<;^6G]?\ !.?.(4<GS*EB,'"R<5-+6R;OYWMI>U[=-M#MFM-2^.7Q
MBNDTBR\C4/%&L33Q6Y9I5M_.E9R795R4C#$LP7A5)QQ7U?=?L1_"?P+IM@GC
M?XBW5AJ%QYFV>6^M-.BGVMSY<<JN?E#(#\[<G/&0*^4/@K\1/^%4?%+P[XJ:
M#[1!87!^T1A-S&!T:.78-R_/Y;OMR0-V,\9K[>\1>*OV=OVG+)+S7M8L++5;
M:S$*7&HW3:9=VOF@D*&<JDQC8,<?O45B>S_-GF53$4:D(T^94DM7%7=_ZL;Y
M%1P6*HU:E;DE7;T4WRJV[:MUWZ:>2N>-?'C]B[3?!GP_F\;>!->NM=TBVMXK
MF6UN%6X>6!B2UQ%-"H5D"LC8*X"!WW\ 5\H5]H_M!?L?:KX1^&4UQX3\8:SJ
MWAK0XVOI?#>LW6Z.(+YC2SPD;8P0K$[-@)!D(8DA#\75W976]M1;]ISV?:S7
MJ>1Q!A?JN*450]E=;7NF^K7^7X(^V/\ @FS_ ,U%_P"X=_[=5\N_'#_DM7C_
M /[&#4/_ $IDKZB_X)L_\U%_[AW_ +=5\N_'#_DM7C__ +&#4/\ TIDKEPW_
M "-,1Z1_)'H8_P#Y)_!?XI_^E2/JC_@GW\6-5UJ]U_P7J^IW^I16]G%>Z8EP
M_F1VL49$4D:LQW*/G@VH/E 1L;23N^?_ !E\(;/0OVHF^'\O^C:1<^(+>UC6
MRE9FAM+F2-HU5Y 3O6*502P;Y@?O=3Z5_P $[;&YD^+GB"\6WE:SAT.2&2X5
M"8T=[B HI;H"PC<@'DA&QT-9?Q(UJSU[]O2TN;";SX(_%.E6K-M9<2PM;PRK
M@@=)(W7/0XR,@@UE']SF%=4]$X7?KT.F=L3DN#E7UDJG*K[\KO?Y;+[D4OVN
M/V=_#GP$_P"$4_X1^]U2\_M;[7Y_]I2QOM\KR=NW9&F/]8V<YZ#I74? ?]B[
M3?&?P_A\;>.]>NM"TBYMY;F*UMU6W>*!2"MQ+-,I54*J[8"X*%'W\D5U/_!2
M;_FG7_<1_P#;6M3X+?M-?#/QG\']*^'?Q%:*QEBLX-(ECO+9Q9W**2D3+*I;
MRRJ)$S2.8PKG<I &5Y_K&,GEU*I3;;;?,TKNUV=OU'+*>>8BA748QC%<J;M'
MFY8O5D%K^Q'\)_'6FWZ>"/B+=7^H6_E[IXKZTU&*#<W'F1Q*A^8*X'SKR,\X
M(KY)OOA/XGM/B;<> 8M,EO?$L5XUDEM C 2D9(D4N%Q&4_>!V &P[C@<U]OZ
M?^R?X#US^T]?^$GQ"U3PS=2XM%NO#NK"[M(,>6TD3%&$C;@ Q4S<%E/0!:\N
M_8Y^&M[\/?VHO$OAWQ%:6LFKZ+H\S)(A6549I+<++$V,C=%*>>&VR$$#)%/#
M8]TZ=:?M7/E5^62LU_P/Z]8Q^3QK5L-2>'5-3E9SA*\6O)=';:_X]-NS_8C^
M''@?1;+_ (65\1?[-U>[RR>3?6UA;G:J;TC\]6:7:S'Y_ER&7*+WX+X]?L;2
M> _"_P#PF7@;59?%7A;RUN)8V"23P6Y12+@21_+-&?F8LJKM4J<,H9QZC^T5
MX=^!'B#XL:K+X^^('B33?$<,<$,FGVT<DD%JGE*R+'_HL@ (;>0&(W2,>"2*
MV_A?\:O@#\+/ MQX0M?'5_KFASR2L;?7-/N;A5210'A"BV51&?F8KC!+N3UK
MGABL;&,*\7.;>ZY'RV?9_J=U;+\KG.IA*BITXJZC+VBYDU_,F^O5/;UU/COX
M(_!'7OCGXM72-(7[-90[9-0U21"T5G$2>3TW.V"%0$%B#R%#,OU39_L;? S4
M/$#:#:_$*_N=<622$Z9#K5B]R'0$NIB$.[*[6R,9&TYZ5X+^RKX/^*7BCQ!J
M]Q\-?$$7AYK".-[V:\N"MM(6#K$CQ;'$AP92NY"%P3E25SZ_X5_9^^'7@/XN
M:/JGB7XRQ>)?$8UR%(=/LHU-W)J?V@,HN,23. 75E<L%^9AEU/![\?6G[:45
M6Y;+113;OYZ?=J>/DV$I/#0J2PJGS2UE.2C&U[>[K=];Z/7[EX+^T-^SUJO[
M/_B"QM;J^BU?2M1C9[+4(T\II"@7S4>+<Q0J77N00RD'.Y5]S^'W[#7ARS^'
M\'B;XF^*KK0?M%O#</!&\=BFG[SPD\DZG+G=&I&U-K[E^;@U>_X*3?\ -.O^
MXC_[:UVVA_M'?!W]H;P5I_ASXA26MCJ$OEM<V>J(]K;BXCC#O+#<*Y$29\Q5
M+2*Y&5(^;#<T\7C*N"HU8WUOS.*ULGV_K[COI9;E>'S7%8:I;W4O9J<FHW:O
MJ_*]EN[>9Q]]^PKX!\:>%[B\^''CV74+R&1D%Q/=V]]:,X0GR6:!%,9):,EO
MF*J?N'(KY0\!_"?Q/\1?'2>$=)TR5=961DN8[I&B6R"-MD>?(R@0\'(SG"@%
MB ?M&^_8YT'5?"6KWGPF^(>J:5:ZUYFZ&#4A<Z7>1 2J+=C%AF0,Q3<S2E1O
M!5B37._\$^?"\GA_Q1\3[75+&*'7-*DM=/E9@CR0$/<"6,.,\%XESM."44\X
M%.EF$J6&K5(U>=QM9-6:N[:]]2,1DL,1CL+0E0]DIWNXRO&5E?3MHOQZV"X_
M8Q^#W@F&VT_QI\39;+7&C,S>9J-GIZR(78*R0RJ[ <;<[B"5;IT'D/[2'[)6
MJ_!&$:YI=U+KWA.20H]RT6V:Q)<B-)@#@@@J!*  6R"J90-Z5\4O"O[.>N?$
MCQ->>*/B5XHC\0OJ$RWT(BDD6"57*F)";-OD3;L4;B J@ D"NIU[XY?!;3?V
M=]:^'^F>,;KQ)Y>CW5KIZZS8W,LKR[7:W4N8%4;'V!#@! B=-N:FEB,93E3F
MG.=_B3@TK/JGY&N(P665H5J4E3I<J?(U43E==)*^M^O^>I\&4445]B?EX444
M4 %%%% !1110!]\_\$ZO$<E[X!\4Z(\A==/U".Y13GY5FCQ@>V82<>I/K7UO
M7QE_P3>T^6/2?'EZ0?)FGLX5/;<BS$_I(M?9M?EF;I1QU1+R_)']#<,RE+**
M#EV?X2=OP"BBBO'/IPHHHH **** "BBB@ KY_P#V0_\ FM7_ &4S6O\ VC7T
M!7S_ /LA_P#-:O\ LIFM?^T: /H"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\:_:W^&TOQ,^"6L6MG$T^IZ:RZI:1KU9HP=Z@8Y)C
M:0 =V*U[+16U&K*A4C5CNG<Y<5AX8NA/#U-I)K[S\3Z*^I?VP/V7[OP-K5[X
MT\,V9F\,7DAFN[>!23I\K'+' Z1,>01PI.W@;<_+5?K>&Q-/%4E5IO1_AY'\
MV8_ ULNQ$L/75FON:[KR"BBBNH\\**** "BBB@ HHHH ]>_9)US3?#?[0?A3
M4=7U"UTO3X?M?FW=[,L,29M)E&YV( R2 ,GJ0*Z_]N[Q5HOB_P"+FD7F@ZQ8
M:W9QZ'#"]QIUTEQ&KBXN"5+(2 <,IQUP1ZU\Y45P2PD98I8J^J5K'KPS*<,O
MEE_+I*7-?KLE;\#O/@3\1K;X2_%CP_XKO+.6_L["20300,%D*21/$S+G@E1(
M6"D@$KC*YR/M+XT:+\ ?CI]@\5Z[\0[6QGL]/P&TW5H4N)(.951K=U=]ZEGP
MBH'RY4@D #\\:*QQ. 6(JQKQFXR2M==CJP&<2P>&GA)THU*<G>TNC[Z>B_JY
M^BFF_&7X:^*?@1XY\+>%+[1O#-C:V=]HFBV&HZC#9R7H-J-LX69E*B265QN<
MY8@LY#%@/*/^"?WCCPYX,_X3S_A(/$&EZ%]I^P>1_:5[';^;M^T[MN]ANQN7
M..F1ZU\A45S_ -DTU1J4%)VFT_/3_,[7Q)6EBJ&+E37-2322T3336W2USK_C
M%?6VJ?%SQQ>6=Q%=V=QKE]-#<0.'CE1KARK*PX(((((X(-?3?[,?[3WAJZ^'
M[_##XE3_ &;3VMVT^UU*XEE,<]O*2AMYG!S%M#D*^501C!*; 6^-:*[<1@J>
M)HJC/I:SZIKJ>5@\UKX'%2Q-)+WKW3U33Z,^[/#/A?\ 9Y_9OUB/QQ9>.Y?$
M>I6<<L5I9P:G!?2>8\; E8[=%P2F] TA$8+\D':1R'_!0'QQX<\9_P#"!_\
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MES'91?:%\R.67HNPHYY)(C*%F))->B?\% ?''ASQG_P@?_"/^(-+UW[-]O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&+_ (R?]"=_Y4[/_P"/5^HE%'^L6*_EC]S_ ,P_U)R[_GY/[X__ ")^7?\
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M3L__ (]7ZB44?ZQ8K^6/W/\ S#_4G+O^?D_OC_\ (GY=_P##%_QD_P"A._\
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MK%BOY8_<_P#,/]2<N_Y^3^^/_P B?EW_ ,,7_&3_ *$[_P J=G_\>H_X8O\
MC)_T)W_E3L__ (]7ZB44?ZQ8K^6/W/\ S#_4G+O^?D_OC_\ (GY=_P##%_QD
M_P"A._\ *G9__'J/^&+_ (R?]"=_Y4[/_P"/5^HE%'^L6*_EC]S_ ,P_U)R[
M_GY/[X__ ")^7?\ PQ?\9/\ H3O_ "IV?_QZC_AB_P",G_0G?^5.S_\ CU?J
M)11_K%BOY8_<_P#,/]2<N_Y^3^^/_P B?EW_ ,,7_&3_ *$[_P J=G_\>H_X
M8O\ C)_T)W_E3L__ (]7ZB44?ZQ8K^6/W/\ S#_4G+O^?D_OC_\ (GY=_P##
M%_QD_P"A._\ *G9__'J/^&+_ (R?]"=_Y4[/_P"/5^HE%'^L6*_EC]S_ ,P_
MU)R[_GY/[X__ ")^7?\ PQ?\9/\ H3O_ "IV?_QZC_AB_P",G_0G?^5.S_\
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M=G_\>H_X8O\ C)_T)W_E3L__ (]7ZB44?ZQ8K^6/W/\ S#_4G+O^?D_OC_\
M(GY=_P##%_QD_P"A._\ *G9__'J/^&+_ (R?]"=_Y4[/_P"/5^HE%'^L6*_E
MC]S_ ,P_U)R[_GY/[X__ ")^7?\ PQ?\9/\ H3O_ "IV?_QZC_AB_P",G_0G
M?^5.S_\ CU?J)11_K%BOY8_<_P#,/]2<N_Y^3^^/_P B?EW_ ,,7_&3_ *$[
M_P J=G_\>H_X8O\ C)_T)W_E3L__ (]7ZB44?ZQ8K^6/W/\ S#_4G+O^?D_O
MC_\ (GY>+^Q?\8V.#X0Q[G4[/_X]76^$_P!@'XAZS<)_;5SIGAZV_C9YOM$H
M^BQ_*3_P(5^BU%1+B#%R5DHKY?YMFM/@O+(2O)SEY-K]$F>)_!;]DWP9\&YX
M]1CC?7M?7E=2OU'[H_\ 3)!PGUY;WKVRBBO!K5ZF(GSU979]CA<)0P=-4L/!
M1CY?UJ%%%%8'6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XK\
M:?V3_!GQDDEU"6)M"\0/R=4L$7,IP!^^0\2=.O#>]>U45O1K5,//GI2LSDQ.
M%H8RFZ6(@I1??^M#\Z?%G[ /Q$T65VT:ZTOQ#;_P>7.;>4_59 %'X.>E<B?V
M+_C)G_D3\_\ <3L__CU?J)17O1X@Q<59J+^7^31\=4X+RV<KQ<X^2:_5-GY=
M_P##%_QD_P"A._\ *G9__'J/^&+_ (R?]"=_Y4[/_P"/5^HE%7_K%BOY8_<_
M\S+_ %)R[_GY/[X__(GY=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L_
M_CU?J)11_K%BOY8_<_\ ,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#Q
MZC_AB_XR?]"=_P"5.S_^/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_
M  Q?\9/^A._\J=G_ /'J/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_
M %)R[_GY/[X__(GY=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?
MJ)11_K%BOY8_<_\ ,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#QZC_A
MB_XR?]"=_P"5.S_^/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_  Q?
M\9/^A._\J=G_ /'J/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_ %)R
M[_GY/[X__(GY=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?J)11
M_K%BOY8_<_\ ,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#QZC_AB_XR
M?]"=_P"5.S_^/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_  Q?\9/^
MA._\J=G_ /'J/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_ %)R[_GY
M/[X__(GY=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?J)11_K%B
MOY8_<_\ ,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#QZC_AB_XR?]"=
M_P"5.S_^/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_  Q?\9/^A._\
MJ=G_ /'J/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_ %)R[_GY/[X_
M_(GY=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?J)11_K%BOY8_
M<_\ ,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#QZC_AB_XR?]"=_P"5
M.S_^/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_  Q?\9/^A._\J=G_
M /'J/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_ %)R[_GY/[X__(GY
M=_\ #%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?J)11_K%BOY8_<_\
M,/\ 4G+O^?D_OC_\B?EW_P ,7_&3_H3O_*G9_P#QZC_AB_XR?]"=_P"5.S_^
M/5^HE%'^L6*_EC]S_P P_P!2<N_Y^3^^/_R)^7?_  Q?\9/^A._\J=G_ /'J
M/^&+_C)_T)W_ )4[/_X]7ZB44?ZQ8K^6/W/_ ##_ %)R[_GY/[X__(GY=_\
M#%_QD_Z$[_RIV?\ \>H_X8O^,G_0G?\ E3L__CU?J)11_K%BOY8_<_\ ,/\
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MWM;(_H+*$_JJ<NH4445Q'MA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^?_P!D/_FM7_93-:_]HU] 5\__ +(?_-:O
M^RF:U_[1H ^@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD2$L3+URIK.2<9<K6IT0G&I!5(.Z>J9[91112+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M000>017=45Y#;D^9GVD(QIQ4(*R04444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&78I4<LBX:TFN;;3W;?U8]@HHHKPS[\^4_@;_P G4>/OI<_^C4KZLKQ_X?\
MP-O?!OQ>\1^,9M5M[FVU3S=EJD3*\>]PW))P<8KV"O1QU2%6I%P=U9'S'#^%
MK8/"SA7CRMSF_DWH%%%%><?3A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEUN&%+5$(EB"3;0V[.#G'(Q70WOQ \16J^*-3$=B=(T2YEMQ$0WFSD8"\]
M2,GO1RA<]2HKS";QEXD\-W#0:K+97INM*FOX'MXBGE21J#L(S\PYZU%9^//$
M>G7&@WFK_8I;#5K.:?[-;H0\+)'O^\3SD>U'*.YZI17FGAWQEXA>^\.7&IO9
MRZ?KX?RH((RKVQ"[ERQ/S<=>E.\7>*O%&DG6]2@2VL]+TID$<%S$2]ZO&YE;
M/ YP.#THY0N>DT5YG?>+_$^J7>N3Z(MJMMHYC4V<D1DENF*AF (/R\' ZU7U
M3Q_XA:/7-6LQ:VVF:)*D4UG/&6EF.%+_ #9^7&[C@]*.4+GJ2R*S,H8%EZ@'
MD4I(4$DX%>.Z;?\ B.S\:>,=1M!;7Q2"&7[''&V^3,>8U7T(SSZUH7>O>*(Y
M+[1;ZZL)[BZTB2\CE2%D\@CAD89.>,X-'**YZBK+(H92&4]"#D4ZO'/".M^)
M+3PWX2T6UN;%;C4H3)#<M$S""%%!P5S\S$FNAM_B%J%KX!UK5+R"&;4]*FDM
M7$>5CD<.%#>P.0<46'<]"HKS>;Q!XUT5+B*6TAUN6:T2>VFM8&1(Y&<*489.
M0 =WT%9NL_$+Q'X5CUNTN9+'4KVTM[>Y@FCC,:GS)-A1AD_G1RA<]:HKRG5/
M'OB;PG<ZE#J2V5^_]F?VA;_9HV41?/M*MS\P&<Y]JGNO&'BC0;2TEO&L=0M;
MN[M4@O[=-J.DI.]=N3R.QHY0N>CWNH6VFVYGN[F&U@!"F29PBY)P!D^IJ?.>
M1R*\E^*GB"YNAKVCNL8M;0V$T; ?-EYAG/Y5<U[QKX@6Y\13:4]G#8>'E3S8
M;B,L]R=@9@"#\HQTZT<H7/3Z*\R@\:>)->UB_.D)9^3820;M,F4^=/$ZJ6D#
MYP,9...U>F*<@'&*5@%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN:CY:X/"[>.M%W=1:;XQFOKEO)M(/%),LS#Y4!@P"3V&:]Q6SMT92L$:E6+
MA!P3U(]Z;+I]K/')');0R)(=SJT8(8^I&.:?,'*>=> =0@U;Q1X\N[5O,MY)
M8_+DQPX$>,CU%<WIJD_#?P(,'_D,1]O]MZ]LAM8;<$10QQ@@ [% R!P!2"SM
MUC2,01A$.Y5V#"GU [4KA8\,M=4MF\ Z?X?\P?VTFN(C6./WHQ<;B<>F.<U;
MNK:2Y^&/CI4C>3&K3.RH#NVB52Q'X U[*--M%NS="UA%T1CSO+&__OK&:ECM
MXHE=4B1 Y)8*H&2>I-/F"QY+<Z;X5E\*:]=:%>MJ.I-I+JVZZ:9UC(SC!)QR
M*7P_J%MJ7C+P++:S)<1KI$R,T9R PV@@^]>IVNEV5EYGV>S@@\S[_E1*N[ZX
M'-+;Z;:6NTP6L,.W.WRXPN,]<8%*X6/%]&4_VMH?!_Y&#4^W^R:ET\'_ (5O
MX'X/_(8B[?[;U[,MG;J01!&"K%@0@X)ZGZF@6< C2,01A$.Y5V#"GU [4<PN
M4\#76[-?A_I^C^;G4TU]?,M0#OC N"<L.PY'/O6[J%K-=>!_B9'#&TDG]IS,
M%49) 92<?@#7KG]FV?G22_9(/-D(+OY:[FQTR<<U*D,<>_9&J[SN;:H&X^I]
M:?,.QXOXHUJR\37UK+IEPM[':^';LSM%R(]R  -Z'@\5-K=O)<Z?X AB0O(^
MGW*JH'4FW&!7KEOI=G:K*L%I!"LO^L6.)5#_ %P.:E^RPYC/E1YC^Y\H^7Z>
ME+F"QY-\+=.\)36?AZ47SRZ]!%Q:RW3L8I ,./+)^7\JP?B!>6-['X[&M2L^
MK6\J1:=;.S?+%A2&11P<\DFO<HM+LH;IKF.SMX[AOO3+$H<_4XS2S:;:7$WG
M2VL,DVW9YCQ@MM],XZ4<VMPMH>4Z+XPL_!-YXPDO&'VMI(;BVM6.U[A3$H&S
MUR:SM/T_PUJ'B#Q5'XHN)-/GGO1*MK)<O$LD;JI7Y0<-S7L\VFV=Q-'++:02
M2Q?<D>-2R?0XXI+C2[*\F2:>T@GE3[LDD2LR_0D47"QY'KVKMH.M>/H[&?R-
M0>QMS:(OWV41X+(.^!FJNDKHC>+%70W^TAO#LQGF5VD+R'GEC_%[5[2]C;27
M G:WB:=5VB1D!8#TSZ4VWTVTL\>1:PP8SCRXPN,]>@HY@L>%6]QI&H6'P]>^
MO&BT^"WEM;BXAF,?DS;00K,/NFNM\2Z3H]O\(]>3PXQO+5V\UG20REF$BESD
M\GH?RKT7^R+#[.\'V*W\EVW-'Y2[6/J1CDU/!:P6L(AAACAA' CC4*OY"GS!
M8\I\;?$A+SP_/8Z%*T\:6D,UU?VCY\B-I K#CHVW)]JXOQ5_8MO<>)6T0J]A
M'I]D6DC9G#L)\D[B3DXKZ%M]+L[6.2."T@ACD^^L<2J&^H YK"\8^#(_$'AN
M;3+%;>Q=VC*N(P  KAL<#VH32!HX>^\7Z5+XX_M:$G5=-M="$=W]F7?L#R]&
M'T.2/2N:U*\MM,AN=.TZ[^V^&+'5+&\AN =RVH=B6CW>@Z^V:]YL],M;*)DB
MMH8O,'[SRXPN\X[X'-+'I5E':O;)9VZ6[\M"L2A&^HQ@T<P6/#O'&L6FL:EX
MPO+.87%I''IV9T!*$+*"Q![@>M6[>U\+:IXL\5G7M0:W@NGBE@Q=-%'<0M&.
M0 <,,U[.NFV<<)B6U@6)EV%!& I7TQCI[4R71M/F\H26-M((AB/="IV#T''%
M',%CRCQ9K6E6NK6M]HSO9>(=(N8; 6K##7UNQ VX_B7!R&[8KV)264$C!QTJ
M!M/M9+E+AK:%KA!A93&"ZCV/458J6QA1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Y'Q6P/C#5SG(_M[3!_Y#I-9476D>/+"./S=0OM>6WLE4X8384JP/;&"<T6
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M:UXJTSP[';-J5RML;C(B4@DN0,D #J:S;/XG>&]0N+.&#4E=[I_+C^5@-_\
M=)QPWL:H>+5#>,/ VY0<33D9'0^4.:XVS55\-@A0"?%F3QU_>FILAW/1G^(G
MA^/5CIS:@HNO.^SA=IVF3^X#C!(J+6M0OYO%,>FV-S]F5+"2X=]@<;B=J$CV
MP:\]A>/_ (1O358KYO\ PEK[0<9_UCYKO-%_T[Q9XIO>JQ".S0_[J;F_\>8T
M6#<=\/\ Q!/?> ;35=6N1)*L;O//MVC"DY.!["D7XK>&&+A=35R$\Q0J,3(O
MJG'S?A6'X3_Y(A<?]>-U_)ZK^&X47Q1X'PBC;H<FWCI]WI3L@N=?<?$+0+6Q
ML;M[]6@O5+P%%+%E'4X X [U#KWBR*;P//JVCW*RB952VF09RS.$!&?<_I7
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M&1@4;.!NX^7)]:PO%*AO!G@E67(_M"QR&'^R:Q_$,:C2/B4P4!FO;?)QR?\
M5U*2'<[_ %3XB>']&U"2SN]02*>/:'^4E5+?=4D# )STKHU8,H8<@C(KQ;7G
MB7PYX]#E QU2WP&QG/[K%>S6_P#Q[Q?[H_E28T24444AA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\_P#[(?\ S6K_
M +*9K7_M&OH"OG_]D/\ YK5_V4S6O_:- 'T!1110 4444 %%%% !1110 444
M4 %%%% &3XB\+Z?XJM8H-0B9Q%()8I(W*/&P[JPY%4+/X=Z#IXA$%EL$5U]L
M7YV/[W;MW<GDXKI:*=P.?U3P'HNLKJ NK3>;YXY)F#D-O081@0>"!Z5)X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ/\ A87BK_H9M8_\#Y?_ (JN?HHY5V#V];^=_>SH/^%A>*O^AFUC_P #Y?\
MXJC_ (6%XJ_Z&;6/_ ^7_P"*KGZ]D^,GP;T7X=^&+74M-NK^>>6\6W9;J1&7
M:4=LC:@.<J._K4/EBTFMSKHQQ5:G.K"3M#?7N>=_\+"\5?\ 0S:Q_P"!\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"OQ%Y@^R1)O\O*CS$E5%PRL1E2,'(^\"P'0:WH=WXC_9YM;"R3S+IM'LY4C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1-8AU'4H;:">*!;=5M595VAF;)W,><L>_I7>?\,O>*O^@AH__?Z7_P"-4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG_\ 9#_Y
MK5_V4S6O_:-?0%?/_P"R'_S6K_LIFM?^T: /H"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFL:-J6IZONUVX66^GMI[%(F5U8&T7-W*Y2S\A6.U2#&H2BX'ME%?/=GXDO\
M5O"^C^'YI?$OB!_[4\00?V5H%XMMJ5U9V&IO:PN]_+<P,L<2FW5\2>?,[1DL
MRB</V/P%NM<CA\;:-K@\I]$UX65M;?VM/JWD0OI]G<;?M=PB339>XD;,@RN_
M8#M1:+@>A0>(+"X\07NAQS[M4L[6"]G@V,-D,SS)$V[&T[FMYA@'(V<@9&=&
MO'-2\$VWC3]H+Q3'?:EK-I9V_A?16-MI.ISZ?YKF[U7:[RV[)*=H#@('"'S"
M65BJ%.>L_$E_JWA?1_#\TOB7Q _]J>((/[*T"\6VU*ZL[#4WM87>_EN8&6.)
M3;J^)//F=HR691.' /H2BOG+0K7QMJ&@>(M#N+?4KJT\/^+5MKS1=$\2SSW\
MNGOI,$ZPP:G<-;S,PN[F.=C))&0BR1!F0+&_J?PCO+271=3L;?\ M^VFTV_-
MM<Z7XDO!>W>G2-#%*(3<"27S59)4F!,TI'G[-RA!'& =U17FFN6;>/\ XHZM
MX7U&^U*ST71]&T_4HXM'U*XT^6>>YGO8V:6:!TD*HMHNU P7,KEPY$9CS[R:
M[\2>(_"O@F[\43:KIEQ8:O=WVJ:-.;&ZNI+&[M;>.%YK=P8V4W+>=Y)B+2P8
M CC+PD$>MT5\]ZI=:MJ?B+2/!/\ PD.LVFF:=X[;1/MEK>NE[<V!\.2WWD33
M_>?#R^6).)=L<;[_ #E\XYWB73+W1?!_QJU.V\3>)0_@+[0WAR&36[ETM732
M+:^WS$OOO,SS$E+MID"J$554LK%QGTK17SEX[CU'^S?C[XK'B/7XK[PG++<:
M':P:I-#:64L6AV5R&,*,JS*TK!FBF\R+@X0>9+YFCX^U34?@?J&J7ND:MJ6L
MS?\ "$Z_K]RNOW\UY%<WMD;(PR>66"0*3<3[H[80H0X&T!(PI<#WRBO"_"=Y
MXA\/^._#,2Z%XRTRWUBZEMM7NO&>O6%U%=$6L\RO;PQWLABG\R(?N[:-(O+>
M8F/$<9BQO!,>H^'?V?? _C%?$>OZEXJ\0V'A[3[G4M4U2:Y6);^XLX'ECMG8
MVPEC2;Y)#$6+(#)YI>3>7 ^A-1OH]+T^ZO9EF>&WB:9UMX'GE*J"2$C0%W;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nbix-20201231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,4!BD# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<^TK_\)[''O;R_[,9MF>,^
M:O./6N@KG6_Y*%'_ -@MO_1RT =%1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6!!,_P#PG5W'O;R_[/B;9GC/F/SB
MM^N=@_Y'^\_[!L7_ *,>@#HJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M>J$9*A5P&W,<<4W0J)7L'M8-VN>LT5D>+?$4/A/PSJFL3[&2RMWF$<D@C$C
M?*FX]"S84<'DC@UQWPH^,/\ PLJ\U*TN-(_L.[M8H9XX);GS))HY 3O"E%.T
M#8<\@^8OJ,PH2<7-+1%.2347N>D45YO\8?C#_P *G_LC_B4?VK_:'G?\O/D^
M7LV?[#9SO]NE=)X=\=:?KW@.W\5,WV:P:T:ZGX9O)V ^:OW06VE6&0.=N1U%
M'LY<JG;1ASQYG&^J.DHKR;X2_'G_ (6CXCN=*_L/^S/)M&NO.^U^;G#HNW&Q
M?[^<Y[5ZS2G"5-\LEJ.,E-7B%%%%04%%%% !7.^._P#D!Q_]?=O_ .C5KHJY
MWQW_ ,@./_K[M_\ T:M '14444 %%>;^"_C#_P )A\.=>\5?V1]D_LOS_P#1
M/M._S?*A63[^P8SNQT.,9YJ]\)_BQ8_%32KJ>"U>POK1PMS:.V\(&SL97P P
M(4]@00>,8)U=*<4VUL9JI%V2>YW5%<3I7Q)_M/XJ:SX,_L[R_P"SK1;K[=Y^
M?,R(CMV;>/\ 6]=Q^[[\<5>_M":O_P )'K>E:5X"OM;_ ++NY+62:SG=_NNR
MAF"PG;NVDX)['KBFJ,Y;('4BMV>UT5Y=X.^.EOK6O0:%XAT.^\(ZQ=<VL-^#
MY<P. H#,JD,Q#  K@[<!B2!6WJOQ)_LSXJ:-X,_L[S/[1M&NOMWGX\O E.W9
MMY_U77</O>W*=*:=FO,%4BU>YVU%>;_$CXW:7X"U*+1[:SGUWQ!-M":?:'&T
ML5"J[8)#,#E5"L3QD ,"><M_VDGTO4K:'Q9X-U3PQ:7&1'=3;WY!4$[6C0E0
M&R2NXCCY3FJC1J25TA.K!.S9[7145U=0V5O+<7$J06\*&2265@JHH&2Q)X
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M'^5\AOO;U0C)4*N VYCCBMW0J)7L9>U@W:YZS17$Z5\2?[3^*FL^#/[.\O\
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M5<Z;J5LEY8W*;)89!PPZ_4$'!!'((!&"*^1(=:OH?V:9K5;ES;S>(_LC1O\
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MHHHKB.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"[CRK(A(4G.['<.#WK-\(^)?C%;^$]%BTOPIH]SIJ64"VLTLJAI(A&H1C_I
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M =%1110 4444 %?-FL^+=2\&_M'>*[W2_#UUXEN)+**%K2TW;D4Q6Y+G:C'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KG6_Y*%'_V"V_]'+715SK?\E"C_P"P6W_H
MY: .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KG8/^1_O/\ L&Q?^C'KHJYV#_D?[S_L&Q?^C'H Z*BBB@ HHHH
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M_@A]8QO_ $#K_P #7^1[E17AO_#)ND_]#_\ $'_P?G_XBC_ADW2?^A_^(/\
MX/S_ /$4>RPW_/W_ ,E_X(?6,;_T#K_P-?Y'N5%>&_\ #)ND_P#0_P#Q!_\
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M_@A]8QO_ $#K_P #7^1[E17AO_#)ND_]#_\ $'_P?G_XBC_ADW2?^A_^(/\
MX/S_ /$4>RPW_/W_ ,E_X(?6,;_T#K_P-?Y'N5%>&_\ #)ND_P#0_P#Q!_\
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M!_\ !^?_ (BC_ADW2?\ H?\ X@_^#\__ !%'LL-_S]_\E_X(?6,;_P! Z_\
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M_P#Q!_\ !^?_ (BC_ADW2?\ H?\ X@_^#\__ !%'LL-_S]_\E_X(?6,;_P!
MZ_\  U_D>Y45X;_PR;I/_0__ !!_\'Y_^(H_X9-TG_H?_B#_ .#\_P#Q%'LL
M-_S]_P#)?^"'UC&_] Z_\#7^1[E17AO_  R;I/\ T/\ \0?_  ?G_P"(H_X9
M-TG_ *'_ .(/_@_/_P 11[+#?\_?_)?^"'UC&_\ 0.O_  -?Y'N5%>&_\,FZ
M3_T/_P 0?_!^?_B*/^&3=)_Z'_X@_P#@_/\ \11[+#?\_?\ R7_@A]8QO_0.
MO_ U_D>Y45X;_P ,FZ3_ -#_ /$'_P 'Y_\ B*/^&3=)_P"A_P#B#_X/S_\
M$4>RPW_/W_R7_@A]8QO_ $#K_P #7^1[E17AO_#)ND_]#_\ $'_P?G_XBC_A
MDW2?^A_^(/\ X/S_ /$4>RPW_/W_ ,E_X(?6,;_T#K_P-?Y'N5%>&_\ #)ND
M_P#0_P#Q!_\ !^?_ (BC_ADW2?\ H?\ X@_^#\__ !%'LL-_S]_\E_X(?6,;
M_P! Z_\  U_D>Y45X;_PR;I/_0__ !!_\'Y_^(H_X9-TG_H?_B#_ .#\_P#Q
M%'LL-_S]_P#)?^"'UC&_] Z_\#7^1[E17AO_  R;I/\ T/\ \0?_  ?G_P"(
MH_X9-TG_ *'_ .(/_@_/_P 11[+#?\_?_)?^"'UC&_\ 0.O_  -?Y'N5%>&_
M\,FZ3_T/_P 0?_!^?_B*/^&3=)_Z'_X@_P#@_/\ \11[+#?\_?\ R7_@A]8Q
MO_0.O_ U_D>Y45X;_P ,FZ3_ -#_ /$'_P 'Y_\ B*/^&3=)_P"A_P#B#_X/
MS_\ $4>RPW_/W_R7_@A]8QO_ $#K_P #7^1[E17AO_#)ND_]#_\ $'_P?G_X
MBC_ADW2?^A_^(/\ X/S_ /$4>RPW_/W_ ,E_X(?6,;_T#K_P-?Y'N5%>&_\
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M5X;_ ,,FZ3_T/_Q!_P#!^?\ XBC_ (9-TG_H?_B#_P"#\_\ Q%'LL-_S]_\
M)?\ @A]8QO\ T#K_ ,#7^1[E17AO_#)ND_\ 0_\ Q!_\'Y_^(H_X9-TG_H?_
M (@_^#\__$4>RPW_ #]_\E_X(?6,;_T#K_P-?Y'N5%>&_P##)ND_]#_\0?\
MP?G_ .(H_P"&3=)_Z'_X@_\ @_/_ ,11[+#?\_?_ "7_ ((?6,;_ - Z_P#
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M_$'_ ,'Y_P#B*/98;_G[_P"2_P#!#ZQC?^@=?^!K_(]RHKPW_ADW2?\ H?\
MX@_^#\__ !%'_#)ND_\ 0_\ Q!_\'Y_^(H]EAO\ G[_Y+_P0^L8W_H'7_@:_
MR/<J*\-_X9-TG_H?_B#_ .#\_P#Q%'_#)ND_]#_\0?\ P?G_ .(H]EAO^?O_
M )+_ ,$/K&-_Z!U_X&O\CW*BO#?^&3=)_P"A_P#B#_X/S_\ $4?\,FZ3_P!#
M_P#$'_P?G_XBCV6&_P"?O_DO_!#ZQC?^@=?^!K_(]RHKPW_ADW2?^A_^(/\
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MW_H'7_@:_P CW*BO#?\ ADW2?^A_^(/_ (/S_P#$4?\ #)ND_P#0_P#Q!_\
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MK_(]RHKPW_ADW2?^A_\ B#_X/S_\11_PR;I/_0__ !!_\'Y_^(H]EAO^?O\
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M?]4Z_P#*Y_\ <]'_  \F_P"J=?\ E<_^YZ^)Z*V_L7 ?\^_QE_F<O^M6<?\
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MBBB@ HHHH **** "N=\=_P#(#C_Z^[?_ -&K715SOCO_ ) <?_7W;_\ HU:
M.BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *YUO^2A1_]@MO_1RUT5<ZW_)0H_\
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M1Q_S)W_E4_\ M-?-;5"W>J_LW"?R?B_\S-Y]F/\ S]_"/^1]+-^VMC_F3?\
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M;'_-/O\ RM?_ '/3&_X*-;?^:>_^5K_[GKXU:H7JO[&P/_/O\7_F9OBC-_\
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M_P P_P!:LX_Y_P#_ )+'_P"1/MG_ (>4?]4Z_P#*Y_\ <]'_  \H_P"J=?\
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MY1_U3K_RN?\ W/1_P\H_ZIU_Y7/_ +GKXFHH_L7 ?\^_QE_F'^M6<?\ /_\
M\EC_ /(GW#9_\%)+6291=> )H8L_,T.K"1@/8&%<_G7M?PM_:W^'GQ4NH+"U
MU&71M7F.V/3]601/(WHC@E&)[#=D^E?EG17/6R'!U(VIIQ?JW^9V8;C#,Z,T
MZS4UV:2_%)?J?MG17QO^Q7^T[=^)+B'X?^++QKF^$9_LG4)FR\JJ,F!V/5@
M2I/4 @\XS]D5\%B\+4P=5TJG_#H_9,MS&CFF'6(H;/==4^S"BBBN(]0****
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M]_RY^@GZZ?\ "V/!'_""?\)M_P )EX?_ .$,_P"AC_M2#^SO];Y/_'QO\O\
MUO[O[WWOEZ\4>!?BQX(^*'V[_A#?&7A_Q;]AV?:_["U2"]^S[]VSS/*=MN[8
M^,XSM;'0U\@?&[P[\*/V3/@W\!_A=J?@/_A<'BE+W^S/"GA6\NI+;3M5U*8K
M'>7ERDSR6RYDNV9!,LOEM<@1[%WNGBOPWT3Q?\._^"I?PGLM8\'^#_A7_;_A
MF\G;PO\ #\&&W6Q:#49(X+\HJ1W%RDL"!W0>6Q@A9?NC !J_\/0/BG_PQ?\
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MVU"#Q!8_VOYNH27A-QJ?]H7*W#_;YP!+>^45V1?:'DV@[FWR*LB^UT %%%%
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M%!8ZO]F6Y^Q3M'=+'/Y3G;)L8AMC<-MP>#7*_M"? G]HG1_@%\2[_6_VHO\
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M^RW\4YX-/E7PA=!;['E!IX59<QF3]XI?,7"D?O N&POWB ?>M2U[3-4_:$^
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M*<_B*^,XDC'EI2ZZGZGP+4G[2O3^S9/YZG64445\*?KH4444 %%%% !1110
M4444 %<[H/\ R-7B;_KI;_\ HE:Z*N=T'_D:O$W_ %TM_P#T2M '14444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SO
MA;_D)>(_^O\ _P#:25T5<[X6_P"0EXC_ .O_ /\ :24 =%1110 5\3_\%)O^
M:=?]Q'_VUK[8KXG_ ."DW_-.O^XC_P"VM>WDO^_T_G_Z2SY3BK_D3U_^W?\
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MVVY@D;<1.&=V,C;C(7D\S>)'#5/@K^R?X8^"_BJZ\6?\)%XP\=^,[BR?2_\
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M:GG*J-YMH@KC#QQR*!( K1H% 150?55% !1110 4444 %%%% !1110 4444
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M'CS59)([,-@\1C)JGAX.3\E_5C$_9J^$-S\8OBEIFG&$MH]G(MWJ<I'RK K
M[,^KD;1]2>QK]754*H51@#@ 5Q'PA^#^@?!?PK'HFA0D[B'NKR4#SKF3'WW(
M_0= *[BOS/-,?]>K7C\*V_S/WOA[)_['PKC/6I+67Z+Y?F%%%%>*?4A1110
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M6'_?;_X4 :E%9>[6O[EA_P!]O_A1NUK^Y8?]]O\ X4 :E%9>[6O[EA_WV_\
MA1NUK^Y8?]]O_A0!J45E[M:_N6'_ 'V_^%&[6O[EA_WV_P#A0!J45E[M:_N6
M'_?;_P"%&[6O[EA_WV_^% &I167NUK^Y8?\ ?;_X4;M:_N6'_?;_ .% &I16
M7NUK^Y8?]]O_ (4;M:_N6'_?;_X4 :E%9>[6O[EA_P!]O_A1NUK^Y8?]]O\
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M<L/^^W_PHW:U_<L/^^W_ ,* -2N=\+?\A+Q'_P!?_P#[22KV[6O[EA_WV_\
MA6;X.\[[;XA\\()?M_S>625_U:=,T =-1110 5\3_P#!2;_FG7_<1_\ ;6OM
MBOB?_@I-_P TZ_[B/_MK7MY+_O\ 3^?_ *2SY3BK_D3U_P#MW_TJ)\3T445^
MH'\^GMG[.WB#PI=:#X[^'_B_5_\ A&]/\6V]FMOK1RRP7,$^Z)77:1L)DW,S
M,@"QD;AN#+Z'#X9^&/[.?A+QQ=0_$ZU\<:]XB\/W>B6%EHL,;*GFA0S2%))
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M\JWO_!0?0_\ A*O%>B:)\'/C!XQ_X1K6KO0;[4?#/A=+ZS^U6\FR15D2X^C
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M/?BS\/\ P_HMU>OJ$UML:YW3M''&S[IM-=AE8HQ@''R],DY_3^B@#X*^#/[
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M1\3^*+K6;S4I59@[1^:J( K2 R,<;G8@NS;$"_H3X3_MS_A%=&_X2?\ L_\
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M0 4444 %%%% !1110 5SN@_\C5XF_P"NEO\ ^B5KHJYW0?\ D:O$W_72W_\
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M_P )%:_W+G_P'?\ PKY<_034HK+_ .$BM?[ES_X#O_A1_P )%:_W+G_P'?\
MPH U**R_^$BM?[ES_P" [_X4?\)%:_W+G_P'?_"@#4HK+_X2*U_N7/\ X#O_
M (4?\)%:_P!RY_\  =_\* -2BLO_ (2*U_N7/_@._P#A1_PD5K_<N?\ P'?_
M  H U**R_P#A(K7^Y<_^ [_X4?\ "16O]RY_\!W_ ,* -2BLO_A(K7^Y<_\
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M\*/^$BM?[ES_ . [_P"% &I167_PD5K_ '+G_P !W_PH_P"$BM?[ES_X#O\
MX4 :E%9?_"16O]RY_P# =_\ "C_A(K7^Y<_^ [_X4 :E%9?_  D5K_<N?_ =
M_P#"C_A(K7^Y<_\ @._^% &I167_ ,)%:_W+G_P'?_"C_A(K7^Y<_P#@._\
MA0!J45E_\)%:_P!RY_\  =_\*/\ A(K7^Y<_^ [_ .% &I167_PD5K_<N?\
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M (#O_A0!J45E_P#"16O]RY_\!W_PH_X2*U_N7/\ X#O_ (4 :E%9?_"16O\
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M3IZ_-?D>'R?LF>9_S-6/^X=_]MJK)^Q_YG_,VX_[AO\ ]NKWK_A(K7^Y<_\
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MM?[ES_X#O_A0!J45E_\ "16O]RY_\!W_ ,*/^$BM?[ES_P" [_X4 :E%9?\
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M/_@PE_\ BJJS?$CQ:"<>*=:'_<0F_P#BJO\ LF?\Z,WQ)27_ "[?WH^\J*^
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M -&/7Y2?\+Q^(_\ T4#Q3_X.KG_XNHQ\:/B$+@SCQWXF$[*$,O\ ;%QN*@Y
MSOSC)/'O1_JW5_Y^+[F'^O6&_P"?,OO1^P-%?D%_PO'XC_\ 10/%/_@ZN?\
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M7B;_ *Z6_P#Z)6@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YWPM_R$O$?_7__ .TDKHJYWPM_R$O$?_7_ /\
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M>R^'GQ0^%^H?"3QGJEE<:EH\5QK%IJ5AJ<$)C$D<-U$R[KE=[NT"H2L:>82
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M&>J?#GP[<?$3Q9\2H9)_#'AB/4+>R,RP1":]%Q=LS0P-;IN5TW,WFC8 <,R
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MUKKVDV6IV,HGLKV!+F"5>CQNH96_$$5<KQ[]D/4I]6_9R\%SW#;I%@F@!/\
M=CN)8T'_ 'R@KV&OQRO3]C5G3_E;7W,_J#!U_K6&IU[?%%/[U<****P.L***
M* "BBB@ HHHH **** "BBB@ KG=)_P"1T\0?]<;7^4E=%7.Z3_R.GB#_ *XV
MO\I* .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<1&SW0RBXWCR_+^T7!W;NF,<YZ8KK/+/TQHKS[_AH;X6&7RQ\2?")DW;=O\
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M?%?_  4DMY&M_A].%)B1[]&;T+"W('_CI_*O:R;_ '^G\_R9\IQ3_P B>O\
M]N_^E1/B.BBBOU$_GT**** "BBB@#VS]B_\ Y.6\'?\ ;Y_Z1SU^HE?E[^Q;
M$\G[2GA)E4D1B\9CZ#[),,_F1^=?J%7YYQ%_O<?\*_-G[9P3_P BZ?\ C?\
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M1110 4444 %%%% !7.^._P#D!Q_]?=O_ .C5KHJYWQW_ ,@./_K[M_\ T:M
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MU!KCQ'!%"9$ODMKL'RK8_:6\IU=C*"Q=8RH6OJJB@#Y5_P""H_\ R8G\3?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M #VC_P"^A0',NY-14/VN#_GM'_WT*/M<'_/:/_OH4!S+N345#]K@_P">T?\
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M^!F_YBOB'_P)@_\ C->_?:X/^>T?_?0H^UP?\]H_^^A5?VABO^?C)_L?+?\
MGU$^?&_8;\"-UU;Q%_X$P?\ QBHV_83\!-UU?Q'_ .!-O_\ &*^A_M<'_/:/
M_OH4?:X/^>T?_?0I_P!HXO\ Y^,7]BY9_P ^8GSFW[!G@!NNL>)/_ FW_P#C
M%1M^P+\/F_YC'B;_ ,"K?_XQ7TA]K@_Y[1_]]"C[7!_SVC_[Z%/^TL9_S\9/
M]AY7_P ^8GS4W_!/SX>-_P QGQ/_ .!5O_\ &*C;_@GK\.F_YC7BC_P*MO\
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M7H5%3S2[E_V7@/\ H'A_X#'_ "//?^&?_ /_ $+Z_P#@5/\ _%T?\,_^ ?\
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M"I__ (NO0J*.:7</[+P'_0/#_P !C_D>>_\ #/\ X!_Z%]?_  *G_P#BZ/\
MAG_P#_T+Z_\ @5/_ /%UZ%11S2[A_9> _P"@>'_@,?\ (\]_X9_\ _\ 0OK_
M .!4_P#\71_PS_X!_P"A?7_P*G_^+KT*BCFEW#^R\!_T#P_\!C_D>>_\,_\
M@'_H7U_\"I__ (NC_AG_ , _]"^O_@5/_P#%UZ%11S2[A_9> _Z!X?\ @,?\
MCSW_ (9_\ _]"^O_ (%3_P#Q=8OBSX'^"=-TI)K;0UBD-S#&6^TS'Y6D4$<O
MZ$UZY7.^._\ D!Q_]?=O_P"C5HYI=P_LO ?] \/_  &/^1S_ /PS_P" ?^A?
M7_P*G_\ BZ/^&?\ P#_T+Z_^!4__ ,77H5%'-+N']EX#_H'A_P" Q_R//?\
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M . ?^A?7_P "I_\ XNO0J*.:7</[+P'_ $#P_P# 8_Y'GO\ PS_X!_Z%]?\
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M#_T+Z_\ @5/_ /%T?\,_^ ?^A?7_ ,"I_P#XNO0J*.:7</[+P'_0/#_P&/\
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MO ?] \/_  &/^1Y[_P ,_P#@'_H7U_\  J?_ .+H_P"&?_ /_0OK_P"!4_\
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M  %?Y%?_ (9_\ _]"^O_ (%3_P#Q='_#/_@'_H7U_P# J?\ ^+J;_A<FB_\
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M_AG_ , _]"^O_@5/_P#%T?\ #/\ X!_Z%]?_  *G_P#BZH']HCPX/^7+5/\
MOU'_ /'*;_PT5X;_ .?+5?\ OU%_\<HY:@N3)?Y*?_@*_P C1_X9_P# /_0O
MK_X%3_\ Q='_  S_ . ?^A?7_P "I_\ XNLW_AHSPW_SXZK_ -^HO_CE)_PT
M=X:_Y\=5_P"_,7_QRCEJ"Y<D_DI_^ K_ "-/_AG_ , _]"^O_@5/_P#%T?\
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M'+4\POD?\E/_ ,!7^1O?\,_^ ?\ H7U_\"I__BZ/^&?_  #_ -"^O_@5/_\
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M;MO$&J7[6.JF&ZCA1%$46X% V<_O/]H4<M3S"^1_R4__  %?Y'9_\,_^ ?\
MH7U_\"I__BZ/^&?_  #_ -"^O_@5/_\ %U@_\-0^%?\ H'ZQ_P!^8O\ X[1_
MPU#X5_Z!^L?]^8O_ ([1RU/,+Y'_ "4__ 5_D;W_  S_ . ?^A?7_P "I_\
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MW_#/_@'_ *%]?_ J?_XNC_AG_P  _P#0OK_X%3__ !=8/_#4/A7_ *!^L?\
M?F+_ ..T?\-0^%?^@?K'_?F+_P".T<M3S"^1_P E/_P%?Y&]_P ,_P#@'_H7
MU_\  J?_ .+H_P"&?_ /_0OK_P"!4_\ \76#_P -0^%?^@?K'_?F+_X[6CI?
M[1?@[4IECEGN]/W' :Z@^7\T+8_&ERU/,J*R.3LH4_\ P&/^1=_X9_\  /\
MT+Z_^!4__P 71_PS_P" ?^A?7_P*G_\ BZ[JPU"UU2UCNK.XBN[:092:%PZM
M]"*L5GS2[GI++,O:NJ$/_ 8_Y'GO_#/_ (!_Z%]?_ J?_P"+H_X9_P# /_0O
MK_X%3_\ Q=>A44<TNX_[+P'_ $#P_P# 8_Y'GO\ PS_X!_Z%]?\ P*G_ /BZ
M/^&?_ /_ $+Z_P#@5/\ _%UZ%11S2[A_9> _Z!X?^ Q_R//?^&?_  #_ -"^
MO_@5/_\ %T?\,_\ @'_H7U_\"I__ (NO0J*.:7</[+P'_0/#_P !C_D>>_\
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M_(\]_P"&?_ /_0OK_P"!4_\ \71_PS_X!_Z%]?\ P*G_ /BZ]"HHYI=P_LO
M?] \/_ 8_P"1Y[_PS_X!_P"A?7_P*G_^+H_X9_\  /\ T+Z_^!4__P 77H5%
M'-+N']EX#_H'A_X#'_(\]_X9_P# /_0OK_X%3_\ Q='_  S_ . ?^A?7_P "
MI_\ XNO0J*.:7</[+P'_ $#P_P# 8_Y'GO\ PS_X!_Z%]?\ P*G_ /BZ/^&?
M_ /_ $+Z_P#@5/\ _%UZ%11S2[A_9> _Z!X?^ Q_R//?^&?_  #_ -"^O_@5
M/_\ %T?\,_\ @'_H7U_\"I__ (NO0J*.:7</[+P'_0/#_P !C_D>>_\ #/\
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M_AOK_A7']I_\49_PK/\ X2'^S/L\7_'_ /VKY'G>;M\S_5?+MW;>^,\U] 4
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MW_ Q6[U&U;>@^#==\26*W-EITDT14'S"RHC=1\I8@-R#TSBH%\+ZK)KB:/\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOA;_ )"7B/\
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MJXKXW>";[XE?!?Q]X1TR6W@U+Q!X?U#2K66[9EA26>VDB1G*JQ"AG&2 3C.
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M\FTT&+^S7C$B2R,;B9;GRMVZ8 *\,JID X^G]&_8S^#OA_X-Z[\*;#P?]G\
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MXXU>_P#">GZM=^-OL/\ PD,>J*;RWU#[&NVUWP2EHAY8QC:HR0"<D T ?/\
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M]_'9>'X/'7BOQ1#>W5^T\MM-]FGT^!9FMW\BUV821(PT@(?<IW5]%:E^S?\
M#;5O@DGPAG\+6Z?#I88;<:';330+MCF6929(W60L94#LY;<[%BQ8LV>?^-7[
M&?P=_:)\56OB3XA>#_\ A(-:M;)-/AN?[3O+;; LDDBIMAF13AI9#DC/S=<
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M%% !1110 4444 %%%% !7.^%O^0EXC_Z_P#_ -I)715SOA;_ )"7B/\ Z_\
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MSR;YM#Z6A3A'#KGBMGS7B^:^MN5V].JZWT/#Z***Z#YH] ^ G_)6-"_[;_\
MHB2OL"OC_P" G_)6-"_[;_\ HB2OL"N#$?$?HW#G^Z2_Q/\ )!1117,?5!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOCO_D!Q
M_P#7W;_^C5KHJYWQW_R X_\ K[M__1JT =%1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P" S_X4QO"^L_\ 0(OO_ 9_\*^B**/:/L+^R8?S,^<CX5UK_H#W_P#X#/\
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M (FF?\*^\4_]"UK'_@!+_P#$U]MT4?6'V%_JW2_Y^/[D?$!^'OBK_H6=8_\
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MO[%JO_03B_\  4?_ !5'V+5?^@G%_P" H_\ BJU** ,O[%JO_03B_P# 4?\
MQ5'V+5?^@G%_X"C_ .*K4HH R_L6J_\ 03B_\!1_\51]BU7_ *"<7_@*/_BJ
MU** ,O[%JO\ T$XO_ 4?_%4?8M5_Z"<7_@*/_BJU** ,O[%JO_03B_\  4?_
M !5'V+5?^@G%_P" H_\ BJU** ,O[%JO_03B_P# 4?\ Q5'V+5?^@G%_X"C_
M .*K4HH R_L6J_\ 03B_\!1_\51]BU7_ *"<7_@*/_BJU** ,O[%JO\ T$XO
M_ 4?_%4?8M5_Z"<7_@*/_BJU** ,O[%JO_03B_\  4?_ !5'V+5?^@G%_P"
MH_\ BJU** ,O[%JO_03B_P# 4?\ Q5'V+5?^@G%_X"C_ .*K4HH R_L6J_\
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M+5?^@G%_X"C_ .*K4HH R_L6J_\ 03B_\!1_\51]BU7_ *"<7_@*/_BJU**
M,O[%JO\ T$XO_ 4?_%4?8M5_Z"<7_@*/_BJU** ,O[%JO_03B_\  4?_ !5'
MV+5?^@G%_P" H_\ BJU** ,O[%JO_03B_P# 4?\ Q5'V+5?^@G%_X"C_ .*K
M4HH R_L6J_\ 03B_\!1_\51]BU7_ *"<7_@*/_BJU** ,O[%JO\ T$XO_ 4?
M_%4?8M5_Z"<7_@*/_BJU** ,O[%JO_03B_\  4?_ !5'V+5?^@G%_P" H_\
MBJU** ,O[%JO_03B_P# 4?\ Q58C6]]_PFJ1_;4^T_V>S";R.-GF#Y=N?7G.
M:Z^N=;_DH4?_ &"V_P#1RT 7OL6J_P#03B_\!1_\51]BU7_H)Q?^ H_^*K4H
MH R_L6J_]!.+_P !1_\ %4?8M5_Z"<7_ ("C_P"*K39@JDL0 .236-=>,M%L
MVVR:A$3_ -,\O_Z"#3U(E.,-9.Q-]BU7_H)Q?^ H_P#BJ/L6J_\ 03B_\!1_
M\55 _$+P^O74/_(,G_Q--_X6-X='_,0_\@2?_$T^5]C+ZQ1_G7WHT?L6J_\
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M]Z.F^Q:K_P!!.+_P%'_Q5'V+5?\ H)Q?^ H_^*KE_P#A>G@<?\QO_P E)_\
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MP?7L)_S]C_X$O\SK/L6J_P#03B_\!1_\51]BU7_H)Q?^ H_^*KD_^%]^!/\
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MC_XJC[%JO_03B_\  4?_ !5:E% &7]BU7_H)Q?\ @*/_ (JC[%JO_03B_P#
M4?\ Q5:E% &7]BU7_H)Q?^ H_P#BJQ--M[YO%6M(EZB3K%;F24P9#@A]H"YX
MQS]<UU]<[I/_ ".GB#_KC:_RDH O?8M5_P"@G%_X"C_XJC[%JO\ T$XO_ 4?
M_%5J44 9?V+5?^@G%_X"C_XJC[%JO_03B_\  4?_ !5:E% &7]BU7_H)Q?\
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M\A+Q'_U__P#M)* .BHHHH *^?_VKO^96_P"WK_VC7T!7S_\ M7?\RM_V]?\
MM&MJ/QH\/._^1?4^7_I2/G^BBBO2/RL]$^$Z^'M.L?$GB#7+)-6ETF")K;3I
M&4K*9',98HW4 E!G!"[\X)VUH:S\7O#6I:/?6<'PZTJQGN()(H[J,Q;H692
MXQ"#D$YZCIUK4^$ND^(O!^K>)],/@R'7KX10P7<4M[!'Y,;JS;,MN#*X(R <
M?*,UTGBJQOU\,:PS_"'2M,06<Q:]CN[1FMQL/[P!4R2O7CGBN9M<VOYGU=&E
M6CA$H/EM>Z]FWK=]>5^F^ECYSHHHKI/E#T#X"?\ )6-"_P"V_P#Z(DK[ KX_
M^ G_ "5C0O\ MO\ ^B)*^P*X,1\1^C<.?[I+_$_R04445S'U0445X_XF^-?B
MK0_VE_"?PTM/ACK&J>$]9TQ[Z\\?0F7[#ILJK<D6\@$!3<3;QCF53_I"\=-P
M![!1110 4444 %%%% !117R5\1?VW/%MC^TOXB^"WPR^#-Q\2?$/A[3(=2U&
M:;Q+;:0JJZPN?+\U&#JJW-N,EE8LS )A=Q /K6BBB@ HHKQ_2_VF/#VO_M1Z
MK\#],MKBZUW1?#[:YJ]\P,<-JQDM1#;*",R,T=T)&8$*HV %F9Q& >P4444
M%%%% !1110 5SOCO_D!Q_P#7W;_^C5KHJYWQW_R X_\ K[M__1JT =%1110
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M?$TTS00HDBP6ME;A&O+N>94<1JBR1H@/^LFG@CRH9I(P#M:*^5?&'[6_Q/\
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M[32E6%HO*O(TV2K(HB55NP @C( B !&>+7C+]E+_ (2[]LGP)\>O^$I^R?\
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M (4%\2_^$8_M#_A)/^$9U/\ LO\ LGS/MGVK[+)Y/D>7\_F[]NW;\V[&.:]
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MWGPSU5]/\/ZCXUC\1Q:;J4<$Q*V1$FZ&*=9YI9%9&S)&#Y@!"5] >(/V(?\
MA)OA7\'/L?B7_A _C/\ #C1M-TW3_'6A0?:=OD0)%/;R1OY?VFV?][A)-N-[
M<;7ECDU=$_8YO)/"OQ-F\9?$;4/'?Q)\>>&9O"UWXMU'2[>&+3K5HYT1+*TB
MV^1%^^1Y(A+MEDB#G:Q- 'R!X^_9O\,?!']@WP3^T3X/U#Q!IGQGT;1O#VLP
M>*GU:6>63[0+:W-H\4A,)MDAN/)6,(/W<,:,77>'[_XG^%M+\8>-/^"B]AJ]
MK]KM(?#/A_4$C\QTQ/;:--<P/E2#\LT,;8Z';@@@D'Z5^)?[*7_"Q/V-K/X"
M_P#"4_V?]GT;2=(_X2#^S_-W?8GMV\S[/YHQO^SXV^9\N_JV.;:_LK6-YXX_
M:"UG4_$%Q/IOQ>TRQTJZL;2V6&;38H+"2S=DF9G$C.LI8$Q@*0 0U 'S4/AW
MX*^$?_!.OX9QZ?=:QX>T+Q=-X=U3Q-X>\.J][J?C.6]M[>.ZTRV$ES$\;7("
MEA X(CBE 0J74\K\ HX?A/\ MC?"+3_AS\'?%'P,^'WCN'6H+RW\3ZK)+=^(
MUM+(RH9]/FEE:R:VG#;'W;I$G)!VNRGZ*A_8P\3W7[..@?#C6_BO_;'B3PCK
M6G:OX-\6_P#".10?V%]A6%+:/[(DVRYVHDZ[IF;/GY8,46CP[^QSX[_X6QX#
M^)WC7XY:AX\\9^$KV9;5;SP_!9Z7_9L\#PW$"6D$B[+E_,)^U;V^Y$K1.$%
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M_P +'_XG?]M_\)AXSU+Q=_QZ?9_LGVOR_P#1_OMOV>7]_P"7.?NC%'_"B_\
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M=M#XGD^T>/O$E[/XG\67.U5\W5KPB2<;8W:(>6-D/[K"-Y.\*-QH ]KHHHH
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MG]878C_5NM_S\7W,^'Z*^X/^%>^%?^A9T?\ \ (O_B:/^%>^%?\ H6='_P#
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M/^2L:%_VW_\ 1$E?8%<&(^(_1N'/]TE_B?Y(R_[8G_Z!5Y_XY_\ %4?VQ/\
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M_P#%4?VQ/_T"KS_QS_XJM2B@#+_MB?\ Z!5Y_P".?_%4?VQ/_P! J\_\<_\
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M_P".?_%5J44 9?\ ;$__ $"KS_QS_P"*H_MB?_H%7G_CG_Q5:E% &7_;$_\
MT"KS_P <_P#BJ/[8G_Z!5Y_XY_\ %5J44 9?]L3_ /0*O/\ QS_XJC^V)_\
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M=^/,!W=<8[=:Z^N=;_DH4?\ V"V_]'+0!>_MB?\ Z!5Y_P".?_%4?VQ/_P!
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M_P#0*O/_ !S_ .*K4HH R_[8G_Z!5Y_XY_\ %4?VQ/\ ] J\_P#'/_BJU**
M,O\ MB?_ *!5Y_XY_P#%4?VQ/_T"KS_QS_XJM2B@#+_MB?\ Z!5Y_P".?_%5
MB0ZA*/&5S/\ 8;@NUC&AA^7> )'.[KC'..O:NOKG8/\ D?[S_L&Q?^C'H O?
MVQ/_ - J\_\ '/\ XJC^V)_^@5>?^.?_ !5:E% &7_;$_P#T"KS_ ,<_^*H_
MMB?_ *!5Y_XY_P#%5J44 9?]L3_] J\_\<_^*H_MB?\ Z!5Y_P".?_%5J44
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M_P".?_%4?VQ/_P! J\_\<_\ BJU** ,O^V)_^@5>?^.?_%4?VQ/_ - J\_\
M'/\ XJM2B@#+_MB?_H%7G_CG_P 51_;$_P#T"KS_ ,<_^*K4HH R_P"V)_\
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M_P#'/_BJU** ,O\ MB?_ *!5Y_XY_P#%4?VQ/_T"KS_QS_XJM2B@#+_MB?\
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MDZM8Z]I5GJ>F7EOJ.FWL*7-K>6DJRPSQ.H9)$=20RLI!# X(((H MT45D_\
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M_P 144GQ:\5KTU7_ ,EXO_B*Y:2H9*:C'L9/%8C_ )^/[V=2WQ>\6C_F+?\
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M+#RH)(&-F.I-<111R1[!]>Q?_/V7_@3_ ,ST#_A??CO_ *#O_DG!_P#&Z/\
MA??CO_H._P#DG!_\;KS^BCDCV#Z]B_\ G[+_ ,"?^9Z!_P +[\=_]!W_ ,DX
M/_C='_"^_'?_ $'?_).#_P"-UY_11R1[!]>Q?_/V7_@3_P ST#_A??CO_H._
M^2<'_P ;H_X7WX[_ .@[_P"2<'_QNO/Z*.2/8/KV+_Y^R_\  G_F>@?\+[\=
M_P#0=_\ ).#_ .-T?\+\\=_]!S_R3@_^(KS^BCDCV#Z_B_\ G[+_ ,"?^9ZW
MHG[2WBC3YE_M"*TU2'^)6C\I_P &7@?D:]S^'_Q4T7XAPL+*1K:^C&9+*? D
M _O#LR^X_$"OC&K6EZI=Z+J%O?6,[VUW X>.6,X*G_#V[BLY48R6FAZF#SO$
MX>2]K+GCY[_)GWM17*_#/QO%X^\)VNI@*ER/W-U$O1)5 SCV.0P]B*ZJO/::
M=F?I-.I&M!5(.Z>H4444C4**** "BBB@ HHHH **** "BBB@ KG=)_Y'3Q!_
MUQM?Y25T5<[I/_(Z>(/^N-K_ "DH Z*BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N=T'_ )&KQ-_UTM__ $2M=%7.
MZ#_R-7B;_KI;_P#HE: .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KG?"W_(2\1_]?\ _P"TDKHJYWPM_P A+Q'_
M -?_ /[22@#HJ*** "OG_P#:N_YE;_MZ_P#:-?0%?/\ ^U=_S*W_ &]?^T:V
MH_&CP\[_ .1?4^7_ *4CY_HHHKTC\K/KC7/".K7GQR\/>((;3?I%I8M#-<>8
M@VN5G &TG<?OKT'?ZUS]CX1U;P[I_P 8+W4;3[/:ZG%<S6DGF(WF)BX.<*21
MPZ]<=:\'_P"%A>*O^AFUC_P/E_\ BJCN/'7B6\MY8)_$.JSP2J4DCDO965U(
MP006Y!':N;V<NY]7+-<,Y.:A*]V]UNX\O;:QAT445TGRAZ!\!/\ DK&A?]M_
M_1$E?8%?'_P$_P"2L:%_VW_]$25]@5P8CXC]&X<_W27^)_DC)\6>*=+\#^%=
M9\2:W=?8M%T>RFU"^N?+>3R8(HVDD?:@+-A5)PH).. 37P!_P\ ^/?\ PIO_
M (:%_P"%5^#_ /A27VW[+_8O]LS?V[Y>?LWVG[1CRO*^V?)CR/,QQLV_OJ^Z
MOBQX%_X6A\*_&7@W[;_9G_"1:->:1]M\KS?L_P!H@>+S-FY=VW?G;N&<8R.M
M?D#X6_97U#P_\.+7X?7_ .Q]X@\3?'>&]:-_$>J:K>)X:GM2#<"5[JWO(K<2
MK&1 (ED5=RAC(9,PGF/JCZ4\<>*=+\<?\%:/V</$FB77VW1=8^'[:A8W/EO'
MYT$MMK$D;[7 9<JP.& (SR :] ^/'Q__ &EOA?X5\0>/YM-^#_P^\&6_VAM-
MT+QQJ=S+KMQY4<C)!NMI?LLES.L+R)#%(V X0LQ5FKE=6^!_B3PC_P %(OV<
MI],\,:A<>#/"OP_71)]<T[3+D:7;/%:ZI$L9E=I?+^]$%229W_>("S$Y/A6D
M_!'QJ(_C-X=^)7P"\4?%W]H[Q1-J%CIOCZXMT;PXEK+:PB*XBO9W6W@:+9))
M%MB1UQ';@Q$E$ /I_P <?\%&,_L^_"3Q;X&\&?VGX^^*=[+I&@>&-4O/*2&Z
MCD:VDD>8+LDB2Z,"!6>%I$F#9CPP7G_'_P"UC^TC\#?C1\&/ 7Q#\,?#>6W\
M=^((;!]<\-O>RPO;O<VT,D4<<LB/%/$)2YD</&XGB"C,<F?"M$_9]^)<G[)_
M[,OB_1/ ?B#4?%_P;\3:CJ&K>"-0T^73+RY@:_\ M^^(W 5I/E@@11#'*7:X
M(4%HF2M;]JKXW:I\;OVIOV2KR7X9^,/A[HMCXSBAMI?&MFMA>7L[7VG&94M0
MS,(HU\@B4G#M*Z@ Q-D ^BK_ /:I^,/QJ^/7C_X>? +P_P"!SIOP_F%IK?B7
MQQ<WAAGNFP@@B@@5)(V26*\0MB1'$.X,F4#^*_'[]JF^_:._X)__ !^T;Q3X
M?M_"?Q%\#:GI>C>(='M+EKF$2C4K5#.C[=BJ\T-THC624J(02[!E)ZKP/:^-
M?V'?VH_CGK6H_"KQQ\2/!/Q*U,:SIFM^!],2_FAE622=X);99"8U#7\D8DD9
M"QM\JC!CY?E5]^S7\4;K]D7]JGQMJW@;6-,\6?%CQ!INL:=X'MH/MU]!:C4T
MNPQ$67+8NY5:-XHW3[,S,HW84 ZOX3>)M.M?VNOV--%E\)Z/>:E<_!_3I8O$
M<TMZ+ZU4:9J!\N-$N%MRIV,,O"[?O&^;A=O5:Q_P4TU;X)^'OBUX1^,^GZ/I
M?QP\,3&+0M,\.V-Q/I6J+-;QO:2>89F(4,XED$CPMY3H%4RAD'/_  \^$_CB
MQ_;._9 UNX\&^(+?1=#^$UCINJZC+I<ZV^GW2Z=J*-;SR%-L4H:1%*.0P+J,
M9(KBOBO\"?C;^UQXR\;_ +2FGV>L?#?5_ <UNO@7P9XBT"3^U;J*P NM^PQ
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M6/@M\/?"]KI\NM>.M:N/M4^KQR-;PZ590>??;&C<,MR5:,195D)W;]HP:RO
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MS%9)5CS)^BM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5SK?\ )0H_^P6W_HY:Z*N=;_DH4?\ V"V_]'+0!T5>7_$2Z:;7FB)^
M6&-5 ^HS_6O4*\M^(5N8?$,KGI-&KC\MO_LM:0W/-S"_L=.YRC5!)4[5!)70
M?,L@EJ!ONU/+4#?=IF+*[5 W>IVJ!N],Q9"_>J[58?O5=JHQD025#)4TE0R4
MT8LKOWJNU6'[U7:F8,@DJO)5B2J\E4C%D#U"W>IGJ%N],QD5GJ)OO&I7J)OO
M&FC"1!)3*?)3*HR84444""BBB@ HHHH **** "BBB@ HHHH **** /<OV6=6
MDCUK6]+R3%+;K<@9X!1@IQ]=X_(5]'5\U_LLZ>\GB;6+\*?+ALQ 6[9=PP'_
M )#-?2E>=6^-GZAD3E]1C?N_S"BBBL#Z **** "BBB@ HHHH **** "BBB@
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ME.Z-F<H&)56<N%#A67Z@HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:KF1C*C5_E?W',O43?>-=&W@'Q/_ -"YJW_@#+_\343?#_Q1D_\ %-ZO_P"
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MHHH **** "BBB@ HHHH *YW2?^1T\0?]<;7^4E=%7.Z3_P CIX@_ZXVO\I*
M.BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"&BOA3_P!%.\&_^#^T_P#CE'_#17PI_P"BG>#?_!_:?_'*_#&BMO[ I?\
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M3?\ 13?"/_@[MO\ XNC_ (:2^$W_ $4WPC_X.[;_ .+J3_AG3X4?]$Q\'?\
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M_P#!!:?_ !NC_AG3X4?]$Q\'?^""T_\ C='^R_WOP#_:O[OXD?\ PTE\)O\
MHIOA'_P=VW_Q='_#27PF_P"BF^$?_!W;?_%U)_PSI\*/^B8^#O\ P06G_P ;
MH_X9T^%'_1,?!W_@@M/_ (W1_LO][\ _VK^[^)'_ ,-)?";_ **;X1_\'=M_
M\71_PTE\)O\ HIOA'_P=VW_Q=2?\,Z?"C_HF/@[_ ,$%I_\ &Z/^&=/A1_T3
M'P=_X(+3_P"-T?[+_>_ /]J_N_B1_P##27PF_P"BF^$?_!W;?_%T?\-)?";_
M **;X1_\'=M_\74G_#.GPH_Z)CX._P#!!:?_ !NC_AG3X4?]$Q\'?^""T_\
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M?Q(_^&DOA-_T4WPC_P"#NV_^+H_X:2^$W_13?"/_ (.[;_XNI/\ AG3X4?\
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M$%I_\;H_V7^]^ ?[5_=_$C_X:2^$W_13?"/_ (.[;_XNC_AI+X3?]%-\(_\
M@[MO_BZD_P"&=/A1_P!$Q\'?^""T_P#C='_#.GPH_P"B8^#O_!!:?_&Z/]E_
MO?@'^U?W?Q(_^&DOA-_T4WPC_P"#NV_^+H_X:2^$W_13?"/_ (.[;_XNI/\
MAG3X4?\ 1,?!W_@@M/\ XW1_PSI\*/\ HF/@[_P06G_QNC_9?[WX!_M7]W\2
M/_AI+X3?]%-\(_\ @[MO_BZ/^&DOA-_T4WPC_P"#NV_^+J3_ (9T^%'_ $3'
MP=_X(+3_ .-T?\,Z?"C_ *)CX._\$%I_\;H_V7^]^ ?[5_=_$C_X:2^$W_13
M?"/_ (.[;_XNC_AI+X3?]%-\(_\ @[MO_BZD_P"&=/A1_P!$Q\'?^""T_P#C
M='_#.GPH_P"B8^#O_!!:?_&Z/]E_O?@'^U?W?Q(_^&DOA-_T4WPC_P"#NV_^
M+H_X:2^$W_13?"/_ (.[;_XNI/\ AG3X4?\ 1,?!W_@@M/\ XW1_PSI\*/\
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M?]%-\(_^#NV_^+J3_AG3X4?]$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\
MQNC_ &7^]^ ?[5_=_$C_ .&DOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_
M^+J3_AG3X4?]$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\ QNC_ &7^]^ ?
M[5_=_$C_ .&DOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_^+J3_AG3X4?]
M$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\ QNC_ &7^]^ ?[5_=_$C_ .&D
MOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_^+J3_AG3X4?]$Q\'?^""T_\
MC='_  SI\*/^B8^#O_!!:?\ QNC_ &7^]^ ?[5_=_$C_ .&DOA-_T4WPC_X.
M[;_XNC_AI+X3?]%-\(_^#NV_^+J3_AG3X4?]$Q\'?^""T_\ C='_  SI\*/^
MB8^#O_!!:?\ QNC_ &7^]^ ?[5_=_$C_ .&DOA-_T4WPC_X.[;_XNC_AI+X3
M?]%-\(_^#NV_^+J3_AG3X4?]$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\
MQNC_ &7^]^ ?[5_=_$C_ .&DOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_
M^+J3_AG3X4?]$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\ QNC_ &7^]^ ?
M[5_=_$C_ .&DOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_^+J3_AG3X4?]
M$Q\'?^""T_\ C='_  SI\*/^B8^#O_!!:?\ QNC_ &7^]^ ?[5_=_$C_ .&D
MOA-_T4WPC_X.[;_XNC_AI+X3?]%-\(_^#NV_^+J3_AG3X4?]$Q\'?^""T_\
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MU]R,WB\1_P _)?>SU^;]M+XRKT\8X_[A=E_\9JI-^VU\:5SCQGC_ +A=E_\
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MW_\ 'O\ Z'S_ ,H]A_\ &*^>J*?U/#?\^H_<@^O8K_G[+_P)_P"9]"_\-_\
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M*N=TG_D=/$'_ %QM?Y24 =%1110 4444 %%%% !1110 4444 %%%% !1110
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M&WC"R\V\\2Z2@MKR\NDFE<V<%ZY'ERGR+:-1$0VZ]&]95=(R?L:?$3XAZ/\
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M1-8\):S_ ,(I'>^)M/TS6O%?]CG5/[!TV4OYMYY&"K898DPP.[S=JX=D8'[
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MV_@)].A\;W%\?$%S':+9K<QM) )F=@(V99XAL<A@S[& ;*CVO2?&WA7]G?\
MX*&?%[4_B=%;^$;?XB:9I4GA+Q?JRQ1V,T5G9I'?6WVMFQ"QD6(F-RH;R8RV
M"T'F 'M7P_\ VR? 7Q&^$?COQWI\.L6;^!H;V7Q'X7U*U2WUK36MDD=HY;<O
MA6=87V'?M)#*65DD5?/_  __ ,%,/A=K5QX7NKOP_P"./#O@WQ%-%:6?CO7-
M#^RZ MT\;,8'NS(0&21)(78*45XI&W>6IDKPKQ_X@T/XV?&3]J'XG?#W3?MW
M@72?@SK'A+4_%MM D=GJ>L@&8^3(#FYVVZ1H90" L4?.QH6?J_VEO^4-ND?]
MB9X3_P#1VG4 >U>!?V^_AYXV^(^@^$KC1/&'A"/Q-YG_  C'B'Q7HIT[2_$.
MTIY?V*5WW/YJR(\>]$W;T7AW1&M^/_VW/#WA'QEJWAWP_P##WXD?%%]'F-EJ
M>I> /#IU.QLKU0#)9R3>8H\^-60NBYV[PI(8,J\_^WU_S;E_V6;PY_[<5XI\
M6M-\(?"OQW\5/%/PD_:F_P"%)>*5O=2O/$?@GQ9&+BSNM2>*&<S6UC=+YH\X
MJK?:(8KGS%E"P?*/+8 ^]? 'C_P]\4O!ND^+/">K6^N>'M5A$]G?6Q.V1<D$
M$$ JRL"K(P#*RLK $$#Q_P",7[:7A#X2_$>/P!9^&_&'Q)\9I9'4+[1/ .DC
M4[C3(,H$>Y7S%V;_ #%( R0&4L%$D9?H/V1?BIXJ^-_[.O@SQUXTTBWT/Q#K
M<,US+9VEM+;PB+[1*MO(B2LS[9(5BD#%B&#AAP17SK^S'\3/!'[./QP_:$\&
M_$Z?3_ASXOU[QG?^+;#5?$+P6=OK&C7$O^B^5>,VV38QF/E%@5,T@ ++.$ /
M0/B?^VYH>K?L=ZO\6?A?;>(/$<EY975E;/HNF)=W'AZ_%I+()=1A9BL,4#(A
MD9MZX>-@'1U8U/\ @F_;7VK?!?\ X2[4]>^+&K:EK,-C'=1?$Z\::'S4MEE>
MYTL-S]DE:Y.V0DEQ$N?NY/BO@>YL?B!X%_;P^+7A/0;C2_AKXS\/RQZ#J,UF
MMFNJ2VFF7L=]<QQ<,5>=R_F,H+-(V[$BR*OV5^R=_P FL_!O_L3-&_\ 2&&@
M#YJ^)_B[5/BU^V3XP^$'C;XS^(/@OX6TVRTJX\(Z=X9G71;SQ)/.@625=0D5
MC-MFE> 6Z'$C!2J[K>0GU7X2_"GXK_L^_%BRT.W\7^(/B]\)_$7VB:[O_&-_
M'+JGA:>*"/RF%PSA[N*X<.GE)$HBPC9'[PR\5XJ^*GPN\>?%#XA_"7]J'2/
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M&VC_  UUV>%)?%7Q \17T=A#H-FZ(_EV9E=#-=R1R(08S\@<;65M\MN >O\
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MVO/#WQ4\91^$]0\'>./AGXAO(9)]*L?B!HATMM86(9G%H2["5HE*,Z9#!7#
M$*Y7W6OS+\*W>DW'_!0#]G<K^T#<?'KQ9+#K\^L75K/;_P!D:>ITV6.W%I;V
MVZ&V9TB;S461F9HED8+O7/Z:4 %%%% !1110 4444 %%%% !7.M_R4*/_L%M
M_P"CEKHJYUO^2A1_]@MO_1RT =%7R[^TAK#WWCH6>X^58VZ(%[;F&\G\BOY5
M]15\I?M"V;VOQ(O96!"W,,,J^X"!/YH:[\';VNO8\['7]EIW/*9*H3U?DJA/
M7T"/FV9\U4IJNS52FK9&,C.FZFJ4G0U=FZFJ4G0UHC%F?-WJC-UJ]-WJC-UK
M9;&,C/N.]49OZ5>N.]49OZ5JC%E";[M9\U:$WW:SYJU1BRA<50N.]7[BJ%QW
MK9;&+*,W>LZ;O6C-WK.F[UJC%E&;O5";O5^;O5";O6J,9%*;[U1U)-]ZHZT,
MF%%%% @HHHH **** "BBB@ HHHH **** "BBB@#[T_X)2^,YH?%?CCPF\C-;
MW-E%JD<9!PK1R")R/3(FCSZ[1Z5^C]?F/_P2IT&>X^+GC#6E!^SV>ABS<]MT
MUQ&Z_I;M7Z<5^>9PDL9*WE^1^FY&Y/!1OW?YA1117BGO!1110 4444 %%%%
M!1110 4444 %<[I/_(Z>(/\ KC:_RDKHJYW2?^1T\0?]<;7^4E '14444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SN
M@_\ (U>)O^NEO_Z)6NBKG=!_Y&KQ-_UTM_\ T2M '14444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOA;_ )"7B/\
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M&U7X?^(/"UU916.H> ?B5H37.ES2+,TWV[SXLRM*"L"+"R^6-K/G<%KZ HH
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M\31_8LO_ $%+W_OI/_B: -2N=\=_\@./_K[M_P#T:M7O[%E_Z"E[_P!])_\
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MW_OI/_B:/[%E_P"@I>_]])_\30!J45E_V++_ -!2]_[Z3_XFC^Q9?^@I>_\
M?2?_ !- &I167_8LO_04O?\ OI/_ (FC^Q9?^@I>_P#?2?\ Q- &I167_8LO
M_04O?^^D_P#B:/[%E_Z"E[_WTG_Q- &I167_ &++_P!!2]_[Z3_XFC^Q9?\
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M^)H_L67_ *"E[_WTG_Q- &I167_8LO\ T%+W_OI/_B:/[%E_Z"E[_P!])_\
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MWOD/P>,<8X^IH Z^BLO^Q9?^@I>_]])_\31_8LO_ $%+W_OI/_B: -2BLO\
ML67_ *"E[_WTG_Q-']BR_P#04O?^^D_^)H U**R_[%E_Z"E[_P!])_\ $T?V
M++_T%+W_ +Z3_P")H U**R_[%E_Z"E[_ -])_P#$T?V++_T%+W_OI/\ XF@#
M4HK+_L67_H*7O_?2?_$T?V++_P!!2]_[Z3_XF@#4HK+_ +%E_P"@I>_]])_\
M31_8LO\ T%+W_OI/_B: -2BLO^Q9?^@I>_\ ?2?_ !-']BR_]!2]_P"^D_\
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MBBB@ HHHH **** "N=\=_P#(#C_Z^[?_ -&K715SOCO_ ) <?_7W;_\ HU:
M.BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *YUO^2A1_]@MO_1RUT5<ZW_)0H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC>"Z9BQ=E:Y+,A<F&;[4I:3?N7TK]F7]H[QQ^S]^PG\"O^$-^"_B#XO?VO\
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MNIALME&FO^7E>/,W_P!N_P -7[-2?]XPH_A+XAN3OU+XG^)KAS]Y;-+:UC_
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MDD4]"".HJU7L[ZH_-)1<6XR5F@HHHIDA1110 4444 %<[X6_Y"7B/_K_ /\
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M:>*/$VNC4;PV9BDC?3F$L1B^S,)IB=L:RAI&*RKQCZ5HH \_^$/P5T/X+_\
M":_V)=:A=?\ "6>)KWQ7??VA(C^7=76SS$BV(N(AY8VAMS#)RQKQ^;_@GOX"
MC^%_PY\':9XI\<>'KCP!-?RZ'XGT36$M-7A6]=WNHS*D00JY<#(C#;4 #8+A
M_J"B@ KQ3]H3]E;0_P!HG7O!NMW_ (N\8>#-:\)_;/[-U'P=J26%POVI8TES
M(8G896(+\I7AW!R#Q[710!\O^%_^"??@K3?'WA[Q=XJ\<_$CXHZEX<F6[T6+
MQQXF>]ATZZ66*43Q!$C.[="F58E&'WE;"D>E_M!?LU^$/VD-!TFS\2'4-+U7
M1;U-0T;Q)H5P+75-*G5E8O;S[6V[MB@@@@[5; =$9?5:* /E_P 3_LLZ-\(O
MV;?CG!X7D\4>-/&WBOPE?VVH:UKVHSZKJ^M2QV=REI&W9F19O*18T4E0@.XC
M-<5^SW^P)X8_X57\-+GQ/K?Q _LK^QM,O]4^%VK:U+_PCOV_R(YIEGT^1-W_
M !][IVA9MOFY!79\E?:M% 'G_P#PI70_^%^_\+=^U:A_PDG_  C/_"*?9?,3
M[']E^U?:M^W9O\W?QG?MV_PYYKE/CY^R9X0_: U[P]XDO-2\0>#?&>@[X['Q
M9X.OQI^J) ZNKVYFV-F(^8QP1E=S[2HDD#^UT4 >/^$_V3_AMX6^$?B#X<2Z
M/<>(O#WB29[W7W\07TU[<ZM>R)&LMY-*[96=VACDWQ[-LB[T"'!KBO O[!OA
M#PO\1]!\:^)/&WQ ^*NJ^'_,DT:'X@ZZ-4M].G<H3<0IY2XE'EK@DD A6QO1
M&7Z5HH ^:OBK^P;X0^)VO>([^S\;?$#X?V'B7S)-<T#P7KHL=+U2>1=D]Q/;
M-$Z-+*@59",!]H+ L69NUL_V5? 6B^)OA)JVA6=QX>M_AA#J-OH.DZ:Z+:,M
M[ (9S.&1GD; +[]X9G9F<N2:]@HH ^?_ (Q?L6^$/BW\1X_']GXD\8?#;QF]
MD=/OM;\ ZL-,N-3@RA1+EO+;?L\M0",$A5#%A'&$)OV(/AHO[+]Y\"--@U#1
M/"%]Y$E[?:?+$-1NYXYHIC<2RO&RM*[0(&)3 4!$"*J!?H"B@#S_ .+WP5T/
MXT?\(5_;=UJ%K_PB?B:R\5V/]GR(GF75KO\ +27>C9B/F'<%VL<##"O0***
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M[HKQRBBOH*=.-*"A'9'S]2I*M-U)[L^A/V ?^3M_ G_;_P#^D%Q7[&5^.?[
M/_)V_@3_ +?_ /T@N*_82\EN8HU-M L[9Y5I-F!Z]#7P^??[S'_"OS9]SD'^
MZR_Q/\D6**R_MFJ_] Z'_P "?_L:/MFJ_P#0.A_\"?\ [&OFSZ4U**R_MFJ_
M] Z'_P "?_L:/MFJ_P#0.A_\"?\ [&@#4HK+^V:K_P! Z'_P)_\ L:/MFJ_]
M Z'_ ,"?_L: -2BLO[9JO_0.A_\  G_[&C[9JO\ T#H?_ G_ .QH U**R_MF
MJ_\ 0.A_\"?_ +&C[9JO_0.A_P# G_[&@#4HK+^V:K_T#H?_  )_^QH^V:K_
M - Z'_P)_P#L: -2BLO[9JO_ $#H?_ G_P"QH^V:K_T#H?\ P)_^QH U**R_
MMFJ_] Z'_P "?_L:/MFJ_P#0.A_\"?\ [&@#4HK+^V:K_P! Z'_P)_\ L:/M
MFJ_] Z'_ ,"?_L: -2BLO[9JO_0.A_\  G_[&C[9JO\ T#H?_ G_ .QH U**
MR_MFJ_\ 0.A_\"?_ +&C[9JO_0.A_P# G_[&@#4KG?'?_(#C_P"ONW_]&K5[
M[9JO_0.A_P# G_[&L3QA<7TFDH+BSC@C^TP$,LV\[O,7 Q@=3@9H Z^BLO[9
MJO\ T#H?_ G_ .QH^V:K_P! Z'_P)_\ L: -2BLO[9JO_0.A_P# G_[&C[9J
MO_0.A_\  G_[&@#4HK+^V:K_ - Z'_P)_P#L:/MFJ_\ 0.A_\"?_ +&@#4HK
M+^V:K_T#H?\ P)_^QH^V:K_T#H?_  )_^QH U**R_MFJ_P#0.A_\"?\ [&C[
M9JO_ $#H?_ G_P"QH U**R_MFJ_] Z'_ ,"?_L:/MFJ_] Z'_P "?_L: -2B
MLO[9JO\ T#H?_ G_ .QH^V:K_P! Z'_P)_\ L: -2BLO[9JO_0.A_P# G_[&
MC[9JO_0.A_\  G_[&@#4HK+^V:K_ - Z'_P)_P#L:/MFJ_\ 0.A_\"?_ +&@
M#4HK+^V:K_T#H?\ P)_^QH^V:K_T#H?_  )_^QH U**R_MFJ_P#0.A_\"?\
M[&C[9JO_ $#H?_ G_P"QH U**R_MFJ_] Z'_ ,"?_L:/MFJ_] Z'_P "?_L:
M -2BLO[9JO\ T#H?_ G_ .QH^V:K_P! Z'_P)_\ L: -2BLO[9JO_0.A_P#
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M_0.A_P# G_[&C[9JO_0.A_\  G_[&@#4HK+^V:K_ - Z'_P)_P#L:/MFJ_\
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MA_\ C-5I/V*_!$G75?$'X7$'_P 9KVO[9JO_ $#H?_ G_P"QH^V:K_T#H?\
MP)_^QK?ZW7_F9A]3P_\ (CPN3]ASP))UU;Q%_P"!,'_QFJTG[!O@"3KJ_B3_
M ,";?_XQ7OOVS5?^@=#_ .!/_P!C1]LU7_H'0_\ @3_]C3^N8C^=D_4<-_(C
MYYD_X)__  \DZZSXF_"ZM_\ XQ5>3_@GA\.9.NM>*/PN[;_Y'KZ.^V:K_P!
MZ'_P)_\ L:/MFJ_] Z'_ ,"?_L:KZ]B?YV3_ &?A?^?:/FB3_@G#\-9.NN>*
M_P +NV_^1ZK2?\$TOAC)UUWQ;^%Y:_\ R-7U!]LU7_H'0_\ @3_]C1]LU7_H
M'0_^!/\ ]C3^OXK_ )^,7]G83_GVCY6D_P""8?PMDZZ_XO\ PO+7_P"1JKO_
M ,$M?A3)U\0>,?\ P-M/_D:OK'[9JO\ T#H?_ G_ .QH^V:K_P! Z'_P)_\
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M_P!C1]LU7_H'0_\ @3_]C0!J45E_;-5_Z!T/_@3_ /8T?;-5_P"@=#_X$_\
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M  )_^QH^V:K_ - Z'_P)_P#L: -2BLO[9JO_ $#H?_ G_P"QH^V:K_T#H?\
MP)_^QH U**R_MFJ_] Z'_P "?_L:/MFJ_P#0.A_\"?\ [&@#4HK+^V:K_P!
MZ'_P)_\ L:/MFJ_] Z'_ ,"?_L: -2BLO[9JO_0.A_\  G_[&C[9JO\ T#H?
M_ G_ .QH U*YW0?^1J\3?]=+?_T2M7OMFJ_] Z'_ ,"?_L:SO#32/XB\1-*@
MBF,D&^-6W!3Y0QSWXP?QH Z6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N=\+?\A+Q'_U_P#_ +22NBKG?"W_ "$O
M$?\ U_\ _M)* .BHHHH *_/?_@K/_P TK_[BO_MG7Z$5^>__  5G_P":5_\
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M!;?^CEH Z*BBB@ HKSKXD_&_1/AVS6A5M3U4#/V2!@ G&1O;^'.?0GVKY_\
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MUQ^WE\=(\[?'./\ N$6/_P 8K.F_;\^/*MQX[Q_W![#_ .,5:R/$O[4?O?\
MD0^(,*OLR^Y?YG[%45^./_#?_P >_P#H?/\ RCV'_P 8H_X;_P#CW_T/G_E'
ML/\ XQ3_ +"Q/\T?O?\ D3_K%A?Y9?<O\S]CJ*_''_AO_P"/?_0^?^4>P_\
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M0?\ @D#=ZGIEY<:=J5EX2\4W-K>6DK1302I/J#)(CJ0596 (8'((!% 'NO\
MPWY^SS_PG?\ PB/_  MCP_\ VK_S\>:_]G?ZKS?^/_;]E^[Q_K?O?)]_Y:]
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M_P!&/7Y>?K9T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ0?FH4444 %%%% 'T)^P#_R=OX$_[?\ _P!(+BOV,K\<_P!@'_D[?P)_V_\
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MR9B(+A\""=)'W[F;!"+UV-%/]044 ?)7PQ^&/Q<^-G[16B?&'XPZ);_#73?
M\-U9^$O ]A?V^HS/+=6XBN[NZNXP0RLIVJB[3E%X38S7%3X'_ 7QWX/_ .":
M.I?"G5]"^R>/IO#/B'3TTG[7 ^9[F2]:!/.60Q?,)H^=^!NY(P<?8%% 'G_[
M/?A;5/ _P"^&GAO6[7[%K6C^&=,T^^MO,63R9XK6..1-R$JV&4C*D@XX)%>@
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5SK?\E"C_ .P6W_HY:Z*N=;_DH4?_ &"V_P#1RT =%7RG^T5ISV7Q&N9V
M'RWD$4RGZ+L_FE?5E>6?'WX?R^+O#::A8Q&74M-W.(U&6EB/WE'J1@$?B!R:
MZ\+45.JK]3BQE-U*32W6I\C772L>Z[UL772L>Z[U]-$^5D9%W61==#6O=UD7
M70UTQ.61CW/>LBZ[UKW/>LBZ[UO$Y9&/=UD77>M>[K(NN]=,3FD8]UWK'NZV
M+KO6/=UT1.:1D7?0UDW'WJUKOH:R;C[U=$3ED0T4459F%%%% !1110 4444
M%;/@OP[/XP\8:'H5M&TMQJ=]!9QHHR2TDBH/YUC5]N?\$V_V=KSQ)XU7XFZQ
M:O%HFC%DTSS%(%U=%2I=?58P3S_>(_NG'+BL1'#495)=/S.W!X>6*KQI1Z[^
MG4_3>N=@_P"1_O/^P;%_Z,>NBKG8/^1_O/\ L&Q?^C'K\L/UXZ*BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=TG_
M )'3Q!_UQM?Y25T5<[I/_(Z>(/\ KC:_RDH Z*BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=T'_D:O$W_72W_P#1
M*UT5<[H/_(U>)O\ KI;_ /HE: .BHHHH **** "BBB@ HHHH **** "BBB@
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M_"6:'_T&=/\ _ J/_&C_ (2S0_\ H,Z?_P"!4?\ C0!K45D_\)9H?_09T_\
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M_"6:'_T&=/\ _ J/_&@#6HK)_P"$LT/_ *#.G_\ @5'_ (T?\)9H?_09T_\
M\"H_\: -:BLG_A+-#_Z#.G_^!4?^-'_"6:'_ -!G3_\ P*C_ ,: -:BLG_A+
M-#_Z#.G_ /@5'_C1_P )9H?_ $&=/_\  J/_ !H UJ*R?^$LT/\ Z#.G_P#@
M5'_C1_PEFA_]!G3_ /P*C_QH UJ*R?\ A+-#_P"@SI__ (%1_P"-'_"6:'_T
M&=/_ / J/_&@#6HK)_X2S0_^@SI__@5'_C1_PEFA_P#09T__ ,"H_P#&@#6H
MK)_X2S0_^@SI_P#X%1_XT?\ "6:'_P!!G3__  *C_P : -:BLG_A+-#_ .@S
MI_\ X%1_XT?\)9H?_09T_P#\"H_\: -:BLG_ (2S0_\ H,Z?_P"!4?\ C1_P
MEFA_]!G3_P#P*C_QH UJ*R?^$LT/_H,Z?_X%1_XT?\)9H?\ T&=/_P# J/\
MQH UJ*R?^$LT/_H,Z?\ ^!4?^-'_  EFA_\ 09T__P "H_\ &@#6HK)_X2S0
M_P#H,Z?_ .!4?^-'_"6:'_T&=/\ _ J/_&@#6HK)_P"$LT/_ *#.G_\ @5'_
M (T?\)9H?_09T_\ \"H_\: -:BLG_A+-#_Z#.G_^!4?^-'_"6:'_ -!G3_\
MP*C_ ,: -:BLG_A+-#_Z#.G_ /@5'_C1_P )9H?_ $&=/_\  J/_ !H UJ*R
M?^$LT/\ Z#.G_P#@5'_C1_PEFA_]!G3_ /P*C_QH UJ*R?\ A+-#_P"@SI__
M (%1_P"-'_"6:'_T&=/_ / J/_&@#6HK)_X2S0_^@SI__@5'_C1_PEFA_P#0
M9T__ ,"H_P#&@#6HK)_X2S0_^@SI_P#X%1_XT?\ "6:'_P!!G3__  *C_P :
M -:BLG_A+-#_ .@SI_\ X%1_XT?\)9H?_09T_P#\"H_\: -:BLG_ (2S0_\
MH,Z?_P"!4?\ C1_PEFA_]!G3_P#P*C_QH UJ*R?^$LT/_H,Z?_X%1_XT?\)9
MH?\ T&=/_P# J/\ QH UJYUO^2A1_P#8+;_T<M7/^$LT/_H,Z?\ ^!4?^-83
M>)-)_P"$Z2X_M2R\C^S6C\W[0FW=YJG;G.,X[4 =G163_P )9H?_ $&=/_\
M J/_ !H_X2S0_P#H,Z?_ .!4?^- 'E_Q2_9WL_%L\^IZ%+'IFIR$O+#(/W$S
M>O'*$GJ1D'TSS7SUXB^"/CC19G23P[>72J>)+)/M"M[C9D_I7VK_ ,)9H?\
MT&=/_P# J/\ QH_X2S0_^@SI_P#X%1_XUWTL94IJVZ/.K8&E5?-LSX!NOA;X
MS;IX1UX_33)O_B:R[GX3^-V!QX-\0'Z:7/\ _$5^B7_"6:'_ -!G3_\ P*C_
M ,:/^$LT/_H,Z?\ ^!4?^-=2S.:^RCD>50?VF?FS<?"'QVV<>"O$1_[A4_\
M\165<?!OQ^W3P-XD/_<(N/\ XBOT[_X2S0_^@SI__@5'_C1_PEFA_P#09T__
M ,"H_P#&M%FTU]E&3R>F_ML_*^Z^"OQ#;IX#\3'Z:/<?_$5EW/P/^([9QX \
M4'Z:-<__ !%?K)_PEFA_]!G3_P#P*C_QH_X2S0_^@SI__@5'_C5K.*B^PC-Y
M'3?VV?D-<_ GXE-T^'GBL_31+G_XBLJZ^ ?Q.;I\./%I^FAW7_QNOV._X2S0
M_P#H,Z?_ .!4?^-'_"6:'_T&=/\ _ J/_&M%G=1?81F\AI?SL_%VZ_9]^*3
MX^&OB\_30;K_ .-UF3_L[_%9FX^&7C$_]P"[_P#C=?MK_P )9H?_ $&=/_\
M J/_ !H_X2S0_P#H,Z?_ .!4?^-6L^J+[",WP[2?_+QGXB?\,Z_%?_HF/C+_
M ,$%W_\ &Z/^&=?BO_T3'QE_X(+O_P"-U^W?_"6:'_T&=/\ _ J/_&C_ (2S
M0_\ H,Z?_P"!4?\ C5?V]5_D1/\ JY2_Y^/[D?B)_P ,Z_%?_HF/C+_P07?_
M ,;H_P"&=?BO_P!$Q\9?^""[_P#C=?MW_P )9H?_ $&=/_\  J/_ !H_X2S0
M_P#H,Z?_ .!4?^-']O5?Y$'^KE+_ )^/[D?B)_PSK\5_^B8^,O\ P07?_P ;
MH_X9U^*__1,?&7_@@N__ (W7[=_\)9H?_09T_P#\"H_\:/\ A+-#_P"@SI__
M (%1_P"-']O5?Y$'^KE+_GX_N1^(G_#.OQ7_ .B8^,O_  07?_QNM#1_V6?B
M_KETEO;?#7Q-'(YP&O--EM4_%Y0JC\37[5_\)9H?_09T_P#\"H_\:/\ A+-#
M_P"@SI__ (%1_P"-)Y]5Z07XC7#E'K4?X'Y]_ /_ ()D:C<7UOJWQ4O([2R7
M;(-!TV??-(>I6:4?*H[$(23G[P[_ *&:)HFG^&](M-+TJSAT_3K2,0P6MN@2
M.- ,  #I5?\ X2S0_P#H,Z?_ .!4?^-'_"6:'_T&=/\ _ J/_&O$Q.,K8N5Z
MK^70]_"8&A@H\M)?/JS6KG8/^1_O/^P;%_Z,>KG_  EFA_\ 09T__P "H_\
M&L*'Q)I(\;W4YU2R$#6$:"7[0FTL)')&<XS@CCWKB.\[.BLG_A+-#_Z#.G_^
M!4?^-'_"6:'_ -!G3_\ P*C_ ,: -:BLG_A+-#_Z#.G_ /@5'_C1_P )9H?_
M $&=/_\  J/_ !H UJ*R?^$LT/\ Z#.G_P#@5'_C1_PEFA_]!G3_ /P*C_QH
M UJ*R?\ A+-#_P"@SI__ (%1_P"-'_"6:'_T&=/_ / J/_&@#6HK)_X2S0_^
M@SI__@5'_C1_PEFA_P#09T__ ,"H_P#&@#6HK)_X2S0_^@SI_P#X%1_XT?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_5OV9?@]KVJWFIZG\)_ ^HZE>S/<W5Y=^'+.6:>5V+/([M&2S,Q)+$Y)))H
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MPKJFG^!]%T_1]'T;PGX:U.ZOF\.6VEQ"QNXKC3[^SEMS"NU%5CJ#R-\K!MK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%S^U(/[1_P!5YW_'OO\ ,_U7[S[OW?FZ<U\J^'_A5XO\->%_#6CW_AS4%O\
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MB!KJV>*.W:=W,T]O;$,L<5Q(RA"%CA9RV VVU_PMCP1_P@G_  FW_"9>'_\
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M&7A_6]:6RCU)M.T[5(+BX%K(L;QW!C1RWE,LT3*^-I$J$'##/@'@.'4+S7O
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M?\5_'&T\-^/?B-XZ\-G^TX[CPSX,TR!FL+B=[>:YUW6+%C)9H!</+;R2MOM
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ML6QHP9PPF ![717S_P#$KXLZY\);RUU7Q)H'A_6=:T;X?^*_$$]SIZR1//\
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M_H^N0:]J=UI#P:#X8U."TTJXAL[JZD1=:E=K6_:)K.2V>...&0N78K$89(:
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M+F5Y/M7F?;447 AM\>2S&$^8%CY7]H;QU\4_ OPX^(/AZ_\ %/A^?6KSX?\
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MC(L@\MV&V15$B@G<%==RHVY1X_<_M&ZU9^*M.\-R_!/X@)K6H65SJ%M;?:M
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M7^F^"IF?PUH5S<VZV.F0FRGLA;A8X$>=5AG"K)</+,OE+B4;YA+[!10!Y_\
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M &7J'D?;?-_=>5]L^Q;/-^7SO(Q\^RO:Z* /E7QE_P *@_X0[P)_8'_"/_\
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M\T^X>XCM[N%[>1[2YDMIE5E*DI+&RO&V#PZ,&4X(((!H ^"_C!_PJ#_BO/\
MA3__  C_ /97_"F?''V[_A#MO]C^=_Q*\;?(_P!%^T[<>9L_?;/LWF_)Y%=5
M^U1\*O"'@?0?&FCZ)X<T^RL-6^$WC'4]57R1(^J7UFVEO:7EY(^7NKF)Y9G2
M>8O('ED8-N=B?I7P=\)'\.^*D\2:UXQ\0>.-:M[*;3[&YUU+&+[%!-)%)<)&
MMG:VZMYC6UL29 Y'DKL*!GW>@4 ?&OQ.L_@5:R>'-6TF_P#@OJ/A-=,,6D>&
M?&BVMOX<G475QYTFD7P1X+>?S7<W8BAN&?R;176#*2-]/^ ?$6EW?A7PC;QK
MJ&CW>H:-%?6FB>(YW.L1P)'"'%PLKO*TL1FA25F9R'<;F)8$]710!Y5^T=X%
M?QYX)LH8=!U#7YK.]:81:/-8B]B26VGM96AAU!&L[C?%<R0O%<X3RII74F5(
MU;5^ OA;5/!GPGT+2=8M?L%_'Y\K6"R*R6:23R2QVT:(62&*)'2-+='E2!$6
M)9IUC$K^@44 >5>'/^3IOB'_ -B9X9_]+M>KYJ^)>K>&%^+5GJNA#P?X>\9P
M?$#2=/NK2;29;WQO+"^MV]O/=37PG\RPL9XI&BB62-X7M);>-7074<$?W510
M!\E?"R2^ANM+E\76]O-X D^(WBBSTV*WG8QQ:I_;U_+:7>HAT5"IF1X($WE4
MN3:OB:6>$V/%?LG^'=+D\1?"Z^E\<?#]?B);V0G\4:+X:\,-%XKN9VTZ5+J#
M7;M;V23Y+EUDF>YA0/=PP@[)61:^ZJ* /A7X0?\ "O/[<_9A_LO^S_\ A;'V
MT?\ ";_V;G[9_:'_  C6I_:?[:\OC[=]H\W'VO\ ?[OM>S_EXH^&^K>&&^/?
MPGU'P>/!^A7>L:U>6VLZ'H^DRR>)[2/^Q]1E%OXAU7SV+7+S0)-):W,8D-Q"
MY$DYM'F;[JHH \*^+'@#P]\2/VDOAOI?BC2;?7M(3PEXDN'TV^!DM+AA>:&%
M$\).R906W!)%90ZQN 'C1E\?U2X\(?\ "KO#VA>+8?!]EI4/B;Q=8Z9JWQ(A
M%QX8T>"TUNXAM[9;1YHH9+GR5CAM8M\9BMXKLQN$C>&;[5HH ^%='7PQJOP$
M\"ZAXXUSP?'::9K7BBSLM'^)&BRV/AB\CBUB>.&V6&Z8C3+F.&!(;59#+);6
M[7:+;S!'V?57P%U'2]5^$^A7&BZ1_86E'STMK&*Y>YM419Y%#64K ;[%MN^V
M951#;M!LCC3:B^@44 ?*O[*O_"H/['^'7D?\(_\ \+S_ +&M_P#A)O[)V_V_
M]O\ L?\ I_\ ;'D?OO\ 7;_-^V_+]I\K=^_\JN*^#LGA6&U^!<G@:W\+WGQP
M6'=X]M[2>*#6991H-[]I37)(D>Y13J?V03-.CD7!B+*TH4'[?HH ^=?C1?7U
M]H?P_D^,&C>%]#\'CQ:Z^(K=M6;4M#;3_P"R;[[.]_)<VMO&%^W&U"K(A42B
MV(8N5 Y_QE_PJ#_A#O G]@?\(_\ \*0_X3.3_A(?N_\ ")^3_8][L^__ *']
MF^W?8O\ 5_N?MO7_ $G?7U510!\5:?X6\(>-/$'AC1=(M=/OOA/=?%F4:%::
M)(%T:XL1X,N&GBMA 1$]LUXMZLT:9CD<W*2*VZ52>.OA5X0T7X;?M1ZI8^'-
M/M+OP+]L/A 10A8O#+IX<L;T2Z9%]RQE-U-).TENL;O)M9F8HA7[5HH ^-?B
MMX \/7WAS]KSQO=:3;W?BSP]-<W6B:M<@RS:/<0^%=,FBN+(L2+6<2;&,T(2
M1C%#N8^5'MU?C5X A^%NJZ]I_P +M)N-$UW6?A9XPNG?0!)_:6K:G VEK9W$
MTJ$S75VKW,^R:1GEW7$A#;I&)^M:* /@#5?#OA"S^%?QKO\ P5XX^%^L6D?P
MS\107VD?"3PP--LY'>!&AGU"6&]N8C+&(YE@238Y6>Z*9"RX]?\ BAX ^$WP
MY\?>"-/\9:3X7TOX7SZ9K=U?OXL$+:;>:ZTNEK;W%U+=$K/J#P)?;9I6:=U%
MP=Q'F&OJ"B@#X_FU'P)I6J?$RXT72/[=^'X\&>%TMK%KF>VTY[9M:UQ0TDK
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M(],M;.WNR9;9H$:5;>UW&2!2R+C#5;^$_P#PJS_A%?AE_P +L_X0_P#X1O\
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MO[/_ .$.A^S^;]I_=?8?MGV/[-G]QG['Y'R^175>!_[#_P"$^\'?\(=_9_\
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MM+DL+:WTJUEG\27EM>W;1%1$C26L8AEE(!:) C$J,5:^)W_"H/#?BZ35[?\
MX5_XPCELK%]&\-76VR\16]J+2$6Q\)W2?-+$5C7[-;VJHK7DTY2[C<-&OVK1
M0!XI^T9J.J> ]2\#?$'0=(_M?4]+O;G19K;[2L'VN"_MVCM[+<X*I]HU6+18
M_-"DQ_>8K%YV?-?#GPS\1> ?''@CX2:CJ%QXLT*ZU.Q\87>IW#B(W2V%@$NW
M\LNSHPUJ'2-0D8/NFEU67(D5+EW^M:* /S+L=)^'6F_!SQ'<:G9>%[7QW?\
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M/)^;/D>9_!7H'_%<?\,"_P#,P?\ "R?^%9_]-_[8_M7^RO\ O]]I\[_@>_\
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MQIXH\4V>A327.BZ3K<UK)#ITK02VXD$R6Z7,[+;SS1;KF:8L)"[[Y L@]+H
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M "OA_J]]-X@^%:11Z7*\,2RP#4;"-I([:Y27:UHSS7#M]GO)(V@^>-N_N/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nbix-20201231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20201231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M^ 3* P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\
MUJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA
M%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_
MX:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_
M -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;
MX1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ
M/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[
M_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:
MV^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]
M:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[
M^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^
M&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^_
M_6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?
M^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#
M_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_
MO_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R
M'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\
MP_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\
MO[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0
M<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^B
MO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_
M +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_
MT'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/
MHKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A
M_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1
M?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /
M3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'
M(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^
M$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@
M#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]
M!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7_0<A_P"_O_UJ/^&M
MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_AK;X1?]!R'_O[_P#6
MH ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\ UJ /3Z*\P_X:V^$7
M_0<A_P"_O_UJ/^&MOA%_T'(?^_O_ -:@#T^BO,/^&MOA%_T'(?\ O[_]:C_A
MK;X1?]!R'_O[_P#6H ]/HKS#_AK;X1?]!R'_ +^__6H_X:V^$7_0<A_[^_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KZ2_X)[?\ ,W_]P_\ ]N:^;:^DO^">W_,W_P#</_\ ;F@#Z2HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X+_;!_Y/5U_P#[%;3_
M /V:N/KL/VP?^3U=?_[%;3__ &:N/H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^DO^">W_ #-__</_ /;FOFVOI+_@GM_S-_\
MW#__ &YH ^DJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M"_VP?^3U=?\ ^Q6T_P#]FKCZ[#]L'_D]77_^Q6T__P!FKCZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OI+_@GM_P S?_W#_P#V
MYKYMKZ2_X)[?\S?_ -P__P!N: /I*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /@O]L'_D]77_ /L5M/\ _9JX^NP_;!_Y/5U__L5M/_\
M9JX^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ
M2_X)[?\ ,W_]P_\ ]N:^;:^DO^">W_,W_P#</_\ ;F@#Z2HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#X+_;!_Y/5U_P#[%;3_ /V:N/KL
M/VP?^3U=?_[%;3__ &:N/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^DO^">W_ #-__</_ /;FOFVOI+_@GM_S-_\ W#__ &YH
M ^DJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"_VP?^3U
M=?\ ^Q6T_P#]FKCZ[#]L'_D]77_^Q6T__P!FKCZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKK__ &*VG_\ LU<?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN-0D'P2L9B%7(B@1YKQW6&-20D>["[F;EG=F] N_V?\ ]J73_P!GA/ WA?\
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MN/HH [#^VO@I_P!"7K'_ (,5_P */[:^"G_0EZQ_X,5_PKCZ* .P_MKX*?\
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M_P!"7K'_ (,5_P */[:^"G_0EZQ_X,5_PKCZ* .P_MKX*?\ 0EZQ_P"#%?\
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M_MKX*?\ 0EZQ_P"#%?\ "C^VO@I_T)>L?^#%?\*X^B@#L/[:^"G_ $)>L?\
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MN/HH [#^VO@I_P!"7K'_ (,5_P */[:^"G_0EZQ_X,5_PKCZ* .P_MKX*?\
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M_P"9O_[A_P#[<T ?25%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?!?[8/_ ">KK_\ V*VG_P#LU<?78?M@_P#)ZNO_ /8K:?\ ^S5Q] !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .X?_P"W- 'TE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'P7^V#_R>KK_ /V*VG_^S5Q]=A^V#_R>KK__ &*VG_\ LU<?0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,: -C_A4'Q,_P"A-O/^^1_C1_PJ#XF?]";>?]\C_&L?_A(=?_Z#EY_X$O\
MXT?\)#K_ /T'+S_P)?\ QH V/^%0?$S_ *$V\_[Y'^-'_"H/B9_T)MY_WR/\
M:Q_^$AU__H.7G_@2_P#C1_PD.O\ _0<O/_ E_P#&@#8_X5!\3/\ H3;S_OD?
MXT?\*@^)G_0FWG_?(_QK'_X2'7_^@Y>?^!+_ .-'_"0Z_P#]!R\_\"7_ ,:
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M^1_C1_PJ#XF?]";>?]\C_&L?_A(=?_Z#EY_X$O\ XT?\)#K_ /T'+S_P)?\
MQH V/^%0?$S_ *$V\_[Y'^-'_"H/B9_T)MY_WR/\:Q_^$AU__H.7G_@2_P#C
M1_PD.O\ _0<O/_ E_P#&@#8_X5!\3/\ H3;S_OD?XT?\*@^)G_0FWG_?(_QK
M'_X2'7_^@Y>?^!+_ .-'_"0Z_P#]!R\_\"7_ ,: -C_A4'Q,_P"A-O/^^1_C
M1_PJ#XF?]";>?]\C_&L?_A(=?_Z#EY_X$O\ XT?\)#K_ /T'+S_P)?\ QH V
M/^%0?$S_ *$V\_[Y'^-'_"H/B9_T)MY_WR/\:Q_^$AU__H.7G_@2_P#C1_PD
M.O\ _0<O/_ E_P#&@#8_X5!\3/\ H3;S_OD?XT?\*@^)G_0FWG_?(_QK'_X2
M'7_^@Y>?^!+_ .-'_"0Z_P#]!R\_\"7_ ,: -C_A4'Q,_P"A-O/^^1_C1_PJ
M#XF?]";>?]\C_&L?_A(=?_Z#EY_X$O\ XT?\)#K_ /T'+S_P)?\ QH V/^%0
M?$S_ *$V\_[Y'^-'_"H/B9_T)MY_WR/\:Q_^$AU__H.7G_@2_P#C1_PD.O\
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M)MY_WR/\:Q_^$AU__H.7G_@2_P#C1_PD.O\ _0<O/_ E_P#&@#8_X5!\3/\
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M ,: -C_A4'Q,_P"A-O/^^1_C1_PJ#XF?]";>?]\C_&L?_A(=?_Z#EY_X$O\
MXT?\)#K_ /T'+S_P)?\ QH V/^%0?$S_ *$V\_[Y'^-'_"H/B9_T)MY_WR/\
M:Q_^$AU__H.7G_@2_P#C1_PD.O\ _0<O/_ E_P#&@#8_X5!\3/\ H3;S_OD?
MXT?\*@^)G_0FWG_?(_QK'_X2'7_^@Y>?^!+_ .-'_"0Z_P#]!R\_\"7_ ,:
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MD?XT?\*@^)G_ $)MY_WR/\:Q_P#A(=?_ .@Y>?\ @2_^-'_"0Z__ -!R\_\
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M7S+EX(%0S/\ WF('S'W/-+J.F:;K%E)INKZ?!=6\HQ+;W,0=''7!5@0:GHH
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M_@GM_P S?_W#_P#VYKYMKZ2_X)[?\S?_ -P__P!N: /I*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /@O]L'_D]77_ /L5M/\ _9JX^NP_
M;!_Y/5U__L5M/_\ 9JX^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M50?%FS^$XU>^,;2[[B-=0=7?EBR1OY@DY.6'/)YY->D^'O\ @I)?:+>?V/\
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M ?!?[8/_ ">KK_\ V*VG_P#LU<?78?M@_P#)ZNO_ /8K:?\ ^S5Q] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<S\5OB[X%^#'A:3Q7XZU=;>$96WMTPTUU)C[D:9^8_H.I('-<I^T;^
MU/X'_9_THVMPRZCK\\6ZRT>*3! /224_\LT_5NPZD>'_  I_9W^*7[6/BI/C
M1^T3J5S!HTF&L=/&8WN(LY5(D_Y8P_[7WFZC).^OI,LR.$\/]>S"7LZ"_P#
MIOM!?KM^-OAL^XMJTL;_ &3DU-5\8]U]BDOYJCZ6_EW?S2=#/QS_ ."@/C#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVG_^S5Q]=A^V#_R>KK__ &*VG_\ LU<?0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'C/XM>/_ -F+XKBR_P"$T^'ES:R/?Z? 8;?6M,NHA+;7B1,S&-P#Y<J!F57
M*G#A5]GKXW^%L-[>_P#!</XF7]ADV5E\%;&VU$KT6YDN+.2(-[^6KD>U?9%
M!117B6J?L$?!K5]3N=6N?%7C=9+J=YI%B\7W*J&9BQ  / R>!VH ^>/VP?\
MD]77_P#L5M/_ /9JX^MWXA^%--_9P_:XU_P]X%GNKR#_ (1>S._Q!<-?2?.V
MX_-)SU48]!GUK3_X7;XL_P"@;H__ (*HZ ./HKL/^%V^+/\ H&Z/_P""J.C_
M (7;XL_Z!NC_ /@JCH X^BNP_P"%V^+/^@;H_P#X*HZ/^%V^+/\ H&Z/_P""
MJ.@#CZ*[#_A=OBS_ *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZ ./HKL/\ A=OB
MS_H&Z/\ ^"J.C_A=OBS_ *!NC_\ @JCH X^BNP_X7;XL_P"@;H__ (*HZ/\
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M#_A=OBS_ *!NC_\ @JCH_P"%V^+/^@;H_P#X*HZ ./HKL/\ A=OBS_H&Z/\
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MC_A=OBS_ *!NC_\ @JCH X^BNP_X7;XL_P"@;H__ (*HZ/\ A=OBS_H&Z/\
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M1_PNWQ9_T#='_P#!5'0!Q]%=A_PNWQ9_T#='_P#!5'1_PNWQ9_T#='_\%4=
M''T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\ P51T <?178?\+M\6?] W1_\
MP51T?\+M\6?] W1__!5'0!Q]%=A_PNWQ9_T#='_\%4='_"[?%G_0-T?_ ,%4
M= ''T5V'_"[?%G_0-T?_ ,%4='_"[?%G_0-T?_P51T <?178?\+M\6?] W1_
M_!5'1_PNWQ9_T#='_P#!5'0!Q]%=A_PNWQ9_T#='_P#!5'1_PNWQ9_T#='_\
M%4= ''T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\ P51T <?178?\+M\6?] W
M1_\ P51T?\+M\6?] W1__!5'0!Q]%=A_PNWQ9_T#='_\%4='_"[?%G_0-T?_
M ,%4= ''T5V'_"[?%G_0-T?_ ,%4='_"[?%G_0-T?_P51T <?178?\+M\6?]
M W1__!5'1_PNWQ9_T#='_P#!5'0!Q]%=A_PNWQ9_T#='_P#!5'1_PNWQ9_T#
M='_\%4= ''T5V'_"[?%G_0-T?_P51T?\+M\6?] W1_\ P51T <?178?\+M\6
M?] W1_\ P51T?\+M\6?] W1__!5'0!Q]%=A_PNWQ9_T#='_\%4='_"[?%G_0
M-T?_ ,%4= ''T5V'_"[?%G_0-T?_ ,%4='_"[?%G_0-T?_P51T <?7TE_P $
M]O\ F;_^X?\ ^W->._\ "[?%G_0-T?\ \%4=>\_L1^,]5\92>)I-5MK2,VJV
M8C^R6JQ [_/SG'7[HQZ<^M 'O=%%% !1110 4444 %%%% 'D7QF^#/QIU3XC
M77Q8^#'Q+TRS:]\'_P!AZSX5UW16GMM16.2>6&9)HYHVMYD-Q*H)#H0YRO0C
MGOV;OV4/%WA[Q3X4^./Q[\16E[XH\-?#^V\-^'M#TRR\JTT* QQ_:"SF60W-
MR[(%:4%4"KM5.2Q]^HH \/\ VG_V4?'O[0?Q3^''Q$T7XOZ3H,'PX\2C6K'3
M[GPC)>M>3;54I)*M["%3 ;HF1N')QSV?Q_\  OQO\>_#--#^!_QLA\$>*(;R
MWN$UPZ!%>P3JAS) \$I.(Y/4-N7 Y/.>]HH \L\%?!3XGZ]XBT/QY^TQ\1-&
M\1ZGX;D>?0M+\,Z!)IVFVEV\31&[=)KB>2><1R2(K%U1!*Y$>XAA#\4/V<-3
MU3XZZ1^U!\(?$=CHWC33M"FT+4UU2Q>>RUK2W<2BWF6-T='CF DCE4G'S*RL
M"-OK-% 'F?P _9SM?@_XB\7_ !0\3>($UWQMX_U.*]\5:Y%9?9HF6&(0VUK!
M$7<QP0QC:H9W8DLS,<@#TRBB@ HHHH ^"_VP?^3U=?\ ^Q6T_P#]FKCZ[#]L
M'_D]77_^Q6T__P!FKCZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_/3]N3_DZ7Q1_VY?\
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M\]CNVX)4]U]^_9D_8KT[X>W,?Q(^+KIJ_BB5_/2&5_-BLI"<[B3GS9<\ESD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7TE_P $]O\ F;_^X?\ ^W-?-M?27_!/;_F;_P#N'_\
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M'LN\0<WPN,X#I8QT\5B(NK3S*K0G4Y:LU[24'3Y5*=N9Q3LFVD[%JQ_X*;>
MI,?VE\,M7B]?(NHI/Y[:V++_ (*2? JXXN_#OB:W/<M8P,/_ !V8G]*\YU;]
M@#]H?2/F\-?%+2[^-/NPW-W/&6_X R.A_$UA7O[/7[7?A4'[3\'O#6LP+U9=
M%TJ9F_$*LII+)N%<1_ KP^=1Q?\ Y,CX-^+O@G?_ (4>"LRP_G1Q"KI?.5CW
MNR_X* ?LW7>//U[4K;/_ #WTF0X_[XW5L6/[:W[,5_@1?%*%">T^FW4>/Q:(
M"OE6]N_%GAK*_$?]B?36B7[TT6CZA9;O^!I(4_(57L_B9^R->2>3XF_9EU33
M'!Q(VE^*IY3G_=E*X^F:4N$,/-<U*G.2[PG3DOQ:95/Q2^A_B9<F*>;82;Z2
MA1:7K>/ZGV39?M/_ +/6H8\CXP:$N?\ GO?+%_Z'BMBR^,?PBU+']G?%3PW<
M9Z>3KENW\GKXYT^+_@GAXA(^U7WC;0L]?/ <+_WPLM;FG?L\?L->)P#X=_:8
MNK?=]T:I>00G\I88Z\ROPYAZ/QQK1]:;:^]:'OX3,/HJYO\ [IQ)B*;?2I2I
MR?W1DG^!]A6/B+P_J>/[-UVSN,]/(ND?/Y&KE?)=K_P3H^'WB6(S>#OC^MRA
M&0\5C%<C\TF%+_P[C\?:1_R+?QY"8^[_ *!+!_Z#*V.U>9++LGO;ZW9]G3DC
MWX<"^"N-CS87B^U]E/!5_P#TI2:/K.BODS_AC+]KG2?^1=_:,VXZ?\5!?P_^
M@JWO1_PHO_@H3HO-C\8C=XZ?\5#))G_O\@J?[)P4O@Q</G=%?\0EX-Q'^Z<6
M8-_]?%4I?FF?6=%?)O\ 9'_!3G1.;35#=JIY_?Z9)D?]M #V^O-'_"QO^"D>
MB_\ '_X$-WCK_P 2NVDS_P!^6%']A2E\&(I/_M__ ( ?\0+KUO\ =.(<KJ^2
MQ:3^YP7YGUE17R9_PU%^W5HW&J_L^>>H^\Y\*WQ_5),"C_AO7X^:3SXC_9\"
M8^]_HUU!_P"A*U'^KN8/X'&7I)!_Q+QX@5?]TGAJ_P#U[Q-)W^^43ZSHKY0@
M_P""F]Q:R>1K?P0>-A]XQZZ0?^^6@^O>M2Q_X*;> I,?VE\,M7B]?(NHI/Y[
M:F7#N<Q_Y=?<XO\ 4YL1]'7QEPZN\J<EWC5HR_\ 2:C/INN3^.7Q1_X4Q\+=
M4^)?]A_VE_9OD?Z%]I\GS/,GCB^_M;&-^>ASC'?->467_!23X%7'%WX=\36Y
M[EK&!A_X[,3^E<O^TQ^V)\%?BQ\"-=\#^%=1U#^TK[[+]FANM/9 VRZBD;YA
MD#Y48]:>%R/,/KE.-:C+D<E?TNKZKR-N%_!#C_\ UNR^AG.3UOJLJ]&-;W9<
MOLG4BJEY0=XKDO>2::6MU:Y!_P /0_\ JAW_ )<W_P!S4?\ #T/_ *H=_P"7
M-_\ <U?)M%?=_P"K62?\^O\ R:7^9_=?_$M7@I_T*O\ ROB?_EQ]H_#'_@HO
MH'CCQO9^&?%'@&#P]83I,]SK%SX@$B6XCA>094P+N+% H&0<L,9/!R/B=^W'
MXS^(NMGX;_LN>%KNYN9R475GM=\SCH6BB(Q&O??)T!Y5<9KYX_9\^&6G_&/X
MP:-\.-6U*:SMM1>8SW%NH+JL<$DI"YX!.S&3G&<X.,5]PZA/\ /V,?AXUW!8
M0:=$XVI'$!)>ZE*!TR3N<\]20JY_A%>'F&!RG+L="G0H.I5DERPU<=WJ[W;]
M-M-;;G\Y>,F6^!'@9G<,4LN=6O[%3A0J5)O#0]^HO;595)2E-MKE5)-Q:AJD
MY*3\F\!_L6Z-X?M[CXQ_M<>-A=2(/M-[:37S&-3_ --YL[I6Z#8G!. "V<5S
M?CCXR?$3]J/61\!?V9?#1TCPK OEW$D,7V='@SC?*5&(8>N(QRW<$G:&6FG?
M'/\ X* >,!J&IN^@^"+"Y.P+DQ(1V0''GSX/+'Y5S_#D*WU=\,/A5X(^#_A:
M+PEX%T=+6V3F60\RW#XYDD;JS'\AT   %;8S&4\E:J8MJKBE\,/^7=+M=+1R
M7;\=F_X2XV\2O$/Z0&.4\=B)4<KAI%17LU..W+1IK2G3MHY-.4EI)RU2Y;]G
M?]F#P+^S]H^[3HUO];N(]M_K4T8#MZI&.?+CSV')QR3@8]+HHKX?%XO$X[$2
MKUY.4GNW_6WD>AEV6X'*,'#"X.FH4X[)?UJWU;U?4****YCN"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *?;P374Z6MM$7DD<+&BCEF)P *+>VN;R9;:TMWED<
MX2.-"S,?8#K7IWP7^$VNVOB"/Q/XITI[:&V7=:Q3X#/(> 2O4 <GG'.*^ \1
MO$7A_P -^&L1F>85H*I"$G3I.24ZL_LQC&_,[RLFTGRJ\GHF=6#PE7&5E""T
MOJ^QSGQ/^&4_@"+3KA',D=S;!;A^H6X RP'L>WT-<C7TM\0/"</C3PI=:&X'
MFLN^V<_PRKRI_H?8FOFN>":VF>VN(RDD;%71ARI!P0:_+OHT>+6*\3N#JE/,
MZG-CL+-JH]N:$VY4YV^^'K"[W.[.<!'!8A."]V6WRW_S^8VBBBOZ0/'"BBB@
M HHHH **** "OI+_ ()[?\S?_P!P_P#]N:^;:^DO^">W_,W_ /</_P#;F@#Z
M2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X+_ &P?^3U=
M?_[%;3__ &:N/KL/VP?^3U=?_P"Q6T__ -FKCZ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKC_B3\?/A%\)8F_X3GQQ9
MVMPHR+"-_-N&]/W2989]2 />M*5*K7GR4XN3[)7/0RS*<TSK&1PF7T)UJLMH
MPBYR?HHIL["H[JZM;&V>\O;F.&&)2TDLKA50#J23P!7RSXN_X*#^+/&.I'PO
M^SW\++J\NI.(KF^@::4]LK!"3CZEB/45G6O[+'[5_P"T'<)JOQZ^(LFE6+,'
M%C/*)67OE;>(B)#[DAAW%>S'(YT8\^-J1I+L]9?**/V7#>!V-RBA'%\9YA1R
MNDU?EG+VF(DO[M"FVW\VFNJ/5_B=^W/\"/AYYEGIFMOXAODR!;Z, \8/^U,2
M$Q_NEC[5Y--^T5^V)^T=*UC\%O LFAZ7(Q4WUM&.!WW74P" C_8"M]:]B^&/
M[%'P&^&WEW;^&O[<ODP?MFN$3 '_ &8L",<]/E)'K7K,444$2PP1JB(H"(@P
M% Z #M5?7<HP7^[4?:2_FGM\HK]=3?\ UR\(>"O=X;REX_$+_E_CG>"?>.'A
M:+75.;4D?+O@K_@G?J.O:C_PD_Q\^)MWJ5Y*0T]M83,[.?1[B4%F]" H]FKW
MOX=_!7X5_"BW$/@+P38V#[=K72Q[YW'^U*^7(]LXKIKJZMK*VDO;VXCAAA0O
M++*X544#)8D\  <YKY,^/'[3OC;]H#Q2?@)^S3;W$UM=,8K_ %6#*-=+T;:W
M_+* ?Q.<%NG .&WPL<YXCK.#J6IQUD]H17G:R]%O\KL_)/%#QZXNS'!J.<XV
M<XS]VGAJ7N0D]E&-*"2:6BYI*37=MI/:_:7_ &PM6U/6C\$?V<O-U#6;N7[-
M=:K8#>48\&*W(ZMUS)T7G!S\R]3^RO\ L>Z3\'HX_'7CWRM2\5S@OYA.^.PW
M=50G[TG/S2?@O&2V]^S1^RQX2_9^T87C^7J'B*YBQ?ZJ4X0'K%"#RJ>_5L9/
M8#U6KS'-\-A<*\ORO2G]J?VJC\^T>R_X)^.Y)PUC\?CXYUQ!:5=?PZ2UA17E
MT<^\N^VR:Q_%O@#P5X\^Q?\ "8^&;34?[.NUNK+[5$&\J4=&']0>#@9!Q6Q1
M17S+J5)046W9;+HK[V/O8T:,*DJD8I2E:[MJ[;7?6W2^P4445!H%%%% !6?K
M?A/PMXE3R_$?AK3]07&-M[9I*,?\"!K0HJHSE"5XNS(J4Z=6/+-)KL]3SW7?
MV4/V<_$>XZA\(=(CW=?L,36O_HDIBN+UW_@G9^SSJVXZ<FMZ83]W['J0<#_O
M\KU[M17IT,]SG#?P\1-?]O-K[GH>!B^$>%\=_'P5)OOR13^])/\ $^5]9_X)
MCZ6DOVGPA\8+RU=#F,7FF+(<_P"^DB8^N*I']D7]LKP5\_@3X^^=$GW8!KMW
M#G_MFRE/S-?6M%>G'C#/&N6K*-1=I0B_T3/!GX8\)*7/AJ<Z,N].I./YR:_
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M%6:**_.92<FVW=L_.(QC"*C%62V04444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKH?#
MGPL\=>*-LFGZ%+'"W2XN?W:8]06Y8?0&O'SOB'(>&L$\7FV*IX>DOM5)Q@O1
M.35WY+5FE.E5K2Y:<6WY'/4J(\CB.-2S,<!0,DFO5=/^ 7ASP_;#4OB#XMC1
M!UCB<1)GTWMRWX &IG^*/PC\ J8/ WAL74ZC'GHFT'ZR/ES^1%?BM?Q_P&=U
MI8;@C*\1FU1.W/"#I8=/M*O522_\!:?1GHK*I4ES8F:IKSU?W(XWPY\&?'_B
M/;(FCFTA;_EM?'RQ_P!\_>/Y5V%M\%/A_P"#X%OOB#XL5SC/D^8(4;V Y=OP
MQ7,>(_COX\UW=%:7B:="?X+-<-CW<Y.?IBN/N;JYO)VN;RX>61SEI)'+,3[D
MUC_JMX\<;ZYYFU/*L._^7."CSUK=I8B?P2_O4[KR'[?*\-_"IN;[RT7W+]3U
MK_A<?@/PP5TCX;>#_/ED81HZQB(2$G Y(+N<^N/K7ING?;_L$)U0Q_:3&#/Y
M((0/CD#)/&:^7=)U6^T/48=6TR41W$#[HG:-7VMZX8$?I72?\+Q^*/\ T-'_
M ))0?_$5^1>*/T3<?GDL-#A6I237-*O7Q=>O/$59O2*;5*<5&*N_=Y>:4M5[
MJ9WX+/8TK^W3\E%))+[T?0E>(?M!>#?[$\2+XELXL6^I9,F!PLP^]^8Y^NZL
MK_A>/Q1_Z&C_ ,DH/_B*H^(?B;XV\5Z<=)U_61<6Y</L-K$N&'0@JH(_/O1X
M*?1W\6/"CCJEF\\7A)X>2=.M"-2MS2IRU]U.@DY1DHRC=J]K72;8\RS; X["
MNFHRONM%O]Y@T445_<I\R%%%% !1110 4444 %?27_!/;_F;_P#N'_\ MS7S
M;7TE_P $]O\ F;_^X?\ ^W- 'TE1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'P7^V#_P GJZ__ -BMI_\ [-7'UV'[8/\ R>KK_P#V*VG_
M /LU<?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!( R30 4
M5YG\3OVN_@3\+#):ZKXQCU"^CR#IVC 7$N?0D'8A]F8&O%-4_;._:(^-=_)X
M?_9V^%\MK'NV&^$'VJ:/T+.P$,/_  ('ZUZN%R7,,5'GY>6'\TO=7X_H?JG#
M/@QQ_P 38;ZZL,L-A5JZ^(DJ-)+^:\]9+SA&2/JGQ#XF\.^$M,?6O%&NV>G6
MD?W[F]N%B0>V6(&?:O"_B;_P41^$GA3S+#P#IUWXDNUR%EC!M[8'_?<;F_!"
M#ZUR'AW]A#XL_$_4D\4?M&?%6X,C<FT@N#=3J#_#YC_NXOHH<5[I\,?V9?@I
M\)1'<>%/!-NU['@C4[\>?<9]0[YV'_<"CVKJ]CD>!_BS=:7:.D?OW?R/J/['
M\#^"-<RQ=3.,2O\ EWA[T<.GVE6?OS7:5/[CY]_MS]N_]I[Y='M)/"FAS])4
M#6$10]]YS/(".NS*GT%=C\-O^"<OP_T>1=5^*?B6[\07;-NDMH&-O;DGDY()
MD?GON7/I7T=16=7/<5R>SPT52CVBK/YO?\C@S/QUXIC@Y8#ANC2RK#/[.&BH
MS?G.L_?E+^]%Q;,KPCX&\&^ M-&C^"_#%CI=L,9BLK98PQ]6(&6/N<FM6BBO
M&E*4Y.4G=L_&<3B<3C*\J^(FYSD[N4FVV^[;NV_4*I^(/$&B>%=%N?$7B/5(
M;*QLXC)<W5PX5(U'<G],=23@52\?_$#PE\,/"]SXQ\;:Q'96-LOS2.<L[=D1
M>K,>P'-?)&IZQ\8_^"@7CTZ+H4<NB>"-,N 9'D!*1CL\F.)9R.B X7/898^U
ME&2SS%2KUI>SH0^*;_)=Y/M_P$_B^)>*J62.&$PT/;8NK_#I+=_WI?RP75OL
M^S:L?$OXP?%/]M?QLWP@^"EG-9^&(G!OKN;*"9 ?]=<,/NQ\?+%U8C)!. OT
M=\!_V?\ P/\  +PN-$\,V_G7LZJ=2U69!YMTX_\ 04'.$' ]SDG5^%7PG\%?
M!OPG#X/\#Z6(+=/FGF?F6YDQS)(W\3'\AT  &*Z6MLVSJ%>BL%@8^SP\>G63
M_FF^K\ME]UN;ASA6K@\4\US:?ML;-:R^S37\E-=$MF]WKW=RBBBOG3[8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7Q/\ #CP!
MXUMI;3Q;X+TO44F0K(;NQ1VY[AB,@^A!!'45M45=.I4I2YH-I]UH95J%'$4W
M"K%2B^C2:^YGY]?M6_LI:U\!=:.O:"DUYX7O)L6EV1N>T8](93Z_W6Z,/?(K
MR?0]#UCQ-K%MX?\ #^FS7E[>3"*VMH$W/(YZ "OU1\0>']%\5:+<^'/$>F0W
MEC>0F*ZM9TW+(I['_'J#R*\Z^!7[)OPU^ ^M:AXCT$37M]=S.+2ZO0"]G;GI
M"GOZOU88''.?TW+?$!4LKE'%1<JT5:/:7KV:Z]^FI^!Y[X,O$9_">7S4,--W
MFGO3[J*ZI_9[==#)_9._9.T?X$:.OB3Q)'#>>*;R'%Q<#YDLD/6&(^O]Y^_0
M<=?9Z**_.\?C\5F6*EB,1*\G^'DNR1^W9/D^7Y%E\,%@H<L(_>WU;?5OJPHH
MHKC/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHK1T'PCXF\3R>7H.B7%SS@ND?R#ZL>!^)KBS#,LNRG"2
MQ6.K0I4H[SG)1BO64FDOFRH0G4ERQ5WY&=17I>@?LXZF\8O/%VNPV42C<\4'
MSL![L<*OZUI?VA\!/AQ_QY0+JMXG\:@7#9]=QQ&/PYK\1S#Z0G"5?%RP'"V'
MKYMB5IRX6FY4XO\ OUI)0C'^]'G1Z4,IKJ/-7:IK^\]?NW/._#OP_P#&'BH@
MZ)H,\D;?\MW79'_WTV ?PKN-'_9V@L8/[1\=>*8K:)>9$MV  ^LC\#\OQJEX
MC_:,\3WX:#PYI\&GQ]%D;][)^HVC\C7#ZQX@USQ!<?:M;U:XNG[&:4MM^@Z#
M\*XOJ7TA>./]ZKT,CP\OLTTL3B;=G-VI1\I0M)/H5S93AOA3JOS]V/W;GJ/_
M  F7P/\ AU\GAG2%U"[3I-&F\Y]?,?I_P'-<]XC_ &A/&NK[H=(2'38CT\I=
M\F/]YN/R K@Z*]G)/H_>'V QBS#-H5,SQ?6KC)NN_E"7[M*^UX-KN9U,UQ<H
M\E.T(]HJW_!)]0U/4=6N#=ZI?S7,IZR3REV_,U!117[50H4,-1C2HQ4815DD
MDDEV26B1YS;D[L****U$%%%% !1110 4444 %%%% !1110 4444 %?27_!/;
M_F;_ /N'_P#MS7S;7TE_P3V_YF__ +A__MS0!])4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\%_M@_P#)ZNO_ /8K:?\ ^S5Q]=A^V#_R
M>KK_ /V*VG_^S5Q] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+%=$NROLK%%%%>(?5A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 445/I^FZCJUR+/2[":XE;I'!&78_@
M*RKUZ.&HRJUI*,8J[;:22[MO1(:3D[(@HKO/#G[/GC75]LVK-#IL1Z^<V^3'
MLJ_U(KH1X+^"'P[^?Q/K*ZA=IUAD?><_]<TZ?\"R*_%<\^D#X>Y?C'E^53J9
MEB^E+!P==_.<?W:5]_?;78]&EE6+G'FJ6A'O)V_X)Y;H^@:WK]Q]ET32I[I^
MXAB+8^I[?C7<^'?V<_%%^!/XBOX-/CZLBGS9/T.T?F?I5[5_VB;:PM_[.\"^
M%HK>)>$>X4*!](TX'Y_A7#>(_B#XQ\5EEUK7IY(V_P"6"'9'_P!\K@'\:\?Z
M]](7CC_=</0R/#R^U5:Q.)MW4%:E'SC.S7<TY<IPWQ-U7Y>['[]ST3^S/@)\
M..;^X75;Q.J,1.V?3:,(/^!<UG:]^T=J+1_8O"&@PV<2C"23_,P'LHPJ_K7F
M=%=F7_1[X3KXN..XIQ-?-\0M>;$U&Z<7_<HQ:A&/]V7.B9YM74>6@E37]U:_
M?N:6O>+_ !/XGD\S7M;N+D9R$=\(/HHX'X"LVBBOV[+\MR[*<)'"X&C"E2CM
M"$5"*](Q22^2/-G.=27-)W?F%%%%=I(4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5])?\$]O^9O\ ^X?_ .W-?-M?27_!/;_F;_\ N'_^
MW- 'TE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P7^V#_
M ,GJZ_\ ]BMI_P#[-7'UV'[8/_)ZNO\ _8K:?_[-7'T %%%% !1110 4444
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M%/B9INN?"W2&OM>B\Y-/MDM&G+%X9$8A!UPC,WH,9/ -<M7K/[#?_)TOA?\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMX3_ .BN:/\ ]^Y/\* ./HKL/^%;>$_^BN:/_P!^Y/\ "C_A6WA/_HKFC_\
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M/J\^^E5XA<19'BLJQ.%PJIXBG.E)QA54E&I%P;BW7:32;M=-7W3V./HKL/\
MA6WA/_HKFC_]^Y/\*/\ A6WA/_HKFC_]^Y/\*^9/YG./HKL/^%;>$_\ HKFC
M_P#?N3_"C_A6WA/_ **YH_\ W[D_PH X^BNP_P"%;>$_^BN:/_W[D_PH_P"%
M;>$_^BN:/_W[D_PH X^BNP_X5MX3_P"BN:/_ -^Y/\*9=> /!-E;27M[\9-#
MAAA0O++*'544#)8D\  <YH2;=D)M)79R5?,?[2_[86K:GK1^"/[.7FZAK-W+
M]FNM5L!O*,>#%;D=6ZYDZ+S@Y^9:7[0_[17BCX]?$ _LX_LJZB^H65U*8+[Q
M#"I@6[7HY5FP8K<?Q2-@MT'!^;Z#_9E_80^%/[/^AK>S_%K0K_Q)=0@:CJGE
M2$)GDQ0Y *H#WP"V,G'"C[##9?A,@H1Q>91YJKUA2_*4^R\NOWV_,\=G.9<9
M8N>6Y%/DP\7:KB%^,*7>7>6RW71OS+]E?]CW2?@]''XZ\>^5J7BN<%_,)WQV
M&[JJ$_>DY^:3\%XR6]SKL/\ A6WA/_HKFC_]^Y/\*/\ A6WA/_HKFC_]^Y/\
M*^<S#,,7F>)=?$2O)_<EV2Z)'W&39+EV08".#P4.6"^]OJY/JWU?RVLCCZ*[
M#_A6WA/_ **YH_\ W[D_PH_X5MX3_P"BN:/_ -^Y/\*XCU3CZ*[#_A6WA/\
MZ*YH_P#W[D_PH_X5MX3_ .BN:/\ ]^Y/\* ./HKL/^%;>$_^BN:/_P!^Y/\
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M5S1_^_<G^% ''T5V'_"MO"?_ $5S1_\ OW)_A1_PK;PG_P!%<T?_ +]R?X4
M<?178?\ "MO"?_17-'_[]R?X4?\ "MO"?_17-'_[]R?X4 <?178?\*V\)_\
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MD_PH_P"%;>$_^BN:/_W[D_PH X^BNP_X5MX3_P"BN:/_ -^Y/\*/^%;>$_\
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MLDJA'(_ZYJ^.F:],\!>(?V/_ -H0+_PI3XU:;-=RKF/3HKX"X ]3;3[9@/P
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M'_6JW2&&A.NY>CA%P_\ )SOIY1CYJ[ARKNVE^>IY-4]CIFI:I+Y&F:?/</\
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M<1_$FW\_T"BBBOKSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MZ2_X)[?\S?\ ]P__ -N:^;:^DO\ @GM_S-__ '#_ /VYH ^DJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^"_VP?\ D]77_P#L5M/_ /9J
MX^NP_;!_Y/5U_P#[%;3_ /V:N/H **** "BBB@ HHHH **** "BBB@ HHHH
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M+:XM)FM[J!XI%.&212I'U!IE?K<)PJ04X.Z>J:V9P--!1115 %%%% !1110
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M3@IU*=W'57=.4)-)ZV;M=)VNE;3#XBMA:GM*3L_1/\SUC_AJ#_J1_P#RI_\
MVJC_ (:@_P"I'_\ *G_]JKR>BOR?_B5OP)_Z%'_EQBO_ )>=W]MYG_S\_"/^
M1:UR^L]3U>YU'3]/^R0SS%TMO,WB//. <#(STXJK117[QA<-2P6%IX>E?EA%
M15VY.R5E>4FY2=EJY-M[MMGER;E)MA11170(*5'=&#HQ!'0@X(I**32:LP-&
MS\7>*]/Q]A\2W\..T=XX'Z&M2S^,/Q)L<"'Q7.P'_/9$D_\ 0E-<U17S.8\$
M\&9O?Z_EN'K7_GHTY_\ I46;PQ.(I_#-KT;.ZM/VAOB%;8\YK&X_Z[6V,_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5])?\ !/;_ )F__N'_ /MS7S;7TE_P
M3V_YF_\ [A__ +<T ?25%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?!?[8/_)ZNO\ _8K:?_[-7'UV'[8/_)ZNO_\ 8K:?_P"S5Q] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5])?\ !/;_ )F_
M_N'_ /MS7S;7TE_P3V_YF_\ [A__ +<T ?25%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?!?[8/_)ZNO\ _8K:?_[-7'UV'[8/_)ZNO_\
M8K:?_P"S5Q] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!C^$O '@KP']M_X0[PS::=_
M:-VUU>_98@OFRGJQ_H!P,G &:V***NI4J59N4VV^[U9G1HT</35.E%1BMDE9
M?<@HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKRQ^U'3;0RK%;VL$195:XE=@Q:3*I&,[7+#: >YT5XQ^SA^T9X@\9_%KQ_\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
M,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$
M'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^
M$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/
M^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;
MW_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO
M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17RI_P $H=<\9ZOX-^,UAXX\?:UXEN=&_:!\0:5;:GK]^UQ<-;V\%E'&I8\
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MXM/[%TZ+S[GS(XT0GS)7M(!DX_?MQZ 'W'1110 4444 %%%% !1110 4444
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ML=.L)&.I7-N&!7[0;J>]@4D$![6%F!";:\'_ &B?V>O&G[!'Q*^%WQR_9O\
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MKUSHT_Q2^*&E>%]0URQF\NXL;":3_2&@DZQS,N(U<<IO9E(8*: /HFBOD/\
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MMQXRUF:,NC!EW(]X5<9 ^5@0>A!% '*6VCR>!O\ @M?;^.=0R=-^(_P+FM-
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M2)#D)'D-/(!&I WO'T7A3P)X=\&W^N:IHEO(+GQ%K!U/5II92[37'D0P \]
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M/"__ *%-7U-KFN:-X9T:[\1^(]5M['3[&W>XO;V[F$<4$2 LSNS$!5 !))X
M%</\:?V6O@I^T)J>B:O\6M U349_#>J1:EH7V;Q3J-DEE>1',=RB6MQ&HE7)
MP^-PR>:M_&?]G7X2_M"?#4?"'XO:)J&K>'O,B>6P7Q%?6QN#']P32P3)), <
M-MD9@656(+*" #C]'T2T^)OQ"M?VK_BVO]C>&_".GW)\!Z=K(^SFUCE3;<:Q
M="3'E221#9%&^&AA9RX5YF2/2:3_ (6/^UO&BJ7TSX;^%_-)(^5M6U,E5^DD
M-G;O_P !U(?AP6B_\$B/^">>@:U9>(-.^ ,GVG3[R*ZM3<^,-8GC$L;AT+1R
M7;(X#*#M8%3T((XKWGPIX$\.^#;_ %S5-$MY!<^(M8.IZM-+*7::X\B& 'GH
M%B@B0 < (* .=^+WQ)UW2[F'X7?"J.WN_&VLVS/8I<(7M])M\E6U&[ Z1(<A
M(\AIY (U(&]X_*/V@_V<?#6C?L"?$#]E#X27KZAKK>"+Z^:&699-0U6\D9YW
MN9@.3+<W"R?-@ LQ"X"X&O\ %3_@F-^Q1\;OB!J7Q3^*?PGU#6->U:0/?:A/
MXWUE"^!A55$NU2-%'"H@"J.  *[+]G3]D3]GC]DVPU;3O@!\/!H,>N3Q3:JS
MZK=WDEP\:E8\O=2R, H9L*" -Q.,DT >$Z1\3O#:?\$.8_&,=Y']F@_9\;2@
MS.,&[CTPV'EY]?M"[,=<\=:];_X)Z_#;7OA'^Q+\,_ 'BBTDM]1L_"EO)?6T
MJX>"68&=HF'9E,FTCU4UH_\ #&?P!_M)Y#X:O3I,FM_VR_A,ZU<_V*=0\SS?
MM!L=_DD^:/,V;?+\S]YLW_-7H^OZ'9>)-(FT749[R.&==KO8:C-:3 9S\LL#
MI(A]U8&@#Y;_ ."*7_*/[P]_V,&M?^G&>N2\=?L^^$O^"I_C[XJ'XA7=SX9O
M?A3XKD\*?#O4=*01WNFW<"13RZC*PPTZ2RL@2,L%6.,E-LCF2OJ+X!?LU_!S
M]F#PB? /P0\.7NCZ+YSRIILVOWU[%$[L6<HMU-)Y>YB2=N,DDFH]=_9L^&VJ
M^/\ 4/BEH\FL>']>UF"*'7;_ ,-ZW/9?VHD0(C^T)&VR1T4E5EV^8J_*' XH
M X#_ ()R_%WXU?$_X*ZWX8_:&>"Z\7_#WQQJ/A#6-9M1B/5GLQ$1=K@ ?,LH
M4G RR,<*20/?JQO 'P]\&_"[PO!X-\!Z%'I^G0/)(L*.SM))(Y>2621R7ED=
MV9WD=F=V8LQ))-;- !1110 4444 %%%% !1110 4444 %?)__!)S_D!_'[_L
MYSQ5_P"@V=?56HV$&J6,NG7,DRQS(4=K>Y>&0 _W7C(93[J017"?!']EWX*_
MLYW&LW'P@T#4]-/B#4YM2UF.Y\4:C>QW=Y+M\RY9+JXD7S6VKEP QP.: '?%
M_P"(GB-;Q?@_\()H9/&FJVGF)<RQ>9!H%HQ*'4;D=" 0PBA.&GD7:,(DLD>'
MY_PT_8U_9RU3PG\/@+Z;P5X=:\32Y+H27NHW<[2&)YCP3-=W>\;CC?([8Z<<
MU\2O^"7?[#_QA\>ZI\3_ (E?"/4-6U[6;CS]1U"?QQK2M*W0 *EX%15&%5%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M99)50"214VAFQR0,G&3VR:?0 4444 %%%% !1110 4444 %%%?@S_P %G_\
ME)7\2?\ N#_^F:QKULGRO^UL4Z//RV5[VOU2[KN?J_@]X8?\18XFK91];^K>
MSHRJ\WL_:7Y9TX<O+ST[7]I>]WM:VMU^\U%?R[T5])_J5_T__P#)?_MC^D?^
M)+?^I]_Y:_\ WP?U$45\N_\ !&#_ )1J?#;_ +C'_IYOJ^HJ^,Q5#ZMBIT;W
MY6U?O9V/XTXHR7_5KB;'91[3VGU:M5I<UN7F]G.4.;EN[7M>UW:]KO<**\H_
M;-\9_&_X6_L_>*OC#\$?$7AVVOO"/AV\UBXL/$FBS74-[%;1--)&&BGB:-BB
M,%.&&[ ( .1@_L$?MK:#^V5\*9=2U+2AH?CCPY/_ &?X[\*3*R2Z=>KE2P1_
MF$3E6*YR00R$ED)K \(]UHKR#X?>-/CGK'[4GC/X7^(O&/AZ7PWX9T/1M0M(
M[7PY+%>3M?->JT;RFY9 $^R9!"9;S.<;?F]?H **** "BOG'_@I1\</CC^S[
M\,O"WC;X.>,-.TQ+_P >Z5H^JI<Z*MS/)!<2E6\N21S''PN#F)CSD,I%?1U
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M"WC;X.>,-.TQ+_Q[I6CZJESHJW,\D%Q*5;RY)',<?"X.8F/.0RD4 ?1U%%%
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M*@FK% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'4/9QPM.F[WO%6?IOL?TKDO#.*RC&>WJ9A7KJS7+4DG'6VNRU5OQ/+/VYO\
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M+LK[+^ _[#WPP_9W^)/Q2\5_#D&QT7XGBRFO- MH_+33[B-;I9VA8'Y8Y/M
M8(!\C!L?*55?&K;_ ()=?&9OV.-<_8@U7]K>*7P:58>%1!X,CCN85^V"[6.\
ME,S>=&'' B$39.2Y4>70!L_MN>(OBIX6\1_#KX\:Y^SW<_%?X86'AV[3QIX/
MTVV2YELKN<6[QZF+-\K=>6B2HH8$1B20Y3<&'G?Q"_:P^$_PS_X)]:_\4?V(
M/B-<"U\>_$>#2M-GFB9+CPE<7J0K<0E)"2C11Q2-$.%02Q;,HBEOI33O@?\
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M<\$_M'_ KQ=9^#O'/@6R;3+)Y]+-QIVIZ2P8'3[F%'C81C<Q1D8%"Q(!.TJ
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M;MN?)U)JI4<DK7Z+9'S-^VG^SQ\2_@=XVTO_ (*1_L?:1YOBO0M,C3XC^$H
M1'XJTA47S"54<SHB@YP20B,,M$%?O?V*/VA?AM^U)\<_'WQK^%6K?:=*U?P)
MX1)B? FM)Q+K(DMYE!^61&R".AX()4@GZ"\%Z9XFT;PQ9Z5XOURRU+4+>!(Y
M[W3]->TBE(4#<(GFE*9QG&\]:\H^ _[#WPP_9W^)/Q2\5_#D&QT7XGBRFO-
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MVUP)+.YOXXHVU.[M]ORD,Z6L#..3+;7')S7TQ0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4UX8961Y(E9HVW1EER5.",CT.
M"1]":=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<?\:/@'\)OVA_#"^"OC+X4.N:.)!(^ES7]Q%;RL"K
M*9(XI%64J5!7>#M/(QDUV%% %+PYX>TSPIH=MX<T;[1]ELX_+@%U>RW$@7L#
M)*S.V.@R3@8'0"KM%% !1110 4444 %<)\7OV:?@M\>=0TO4_BUX1EUB71+I
M+K2!)J]W$EG<(25GC2*55249XD WCUXKNZ* (K&SATZQAT^W>5HX(EC1IYWE
M<A1@%G<EG/'+,22>22:EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ./^-'P#^$W[0_AA?!7QE\*'7-'$
M@D?2YK^XBMY6!5E,D<4BK*5*@KO!VGD8R:Z/PYX>TSPIH=MX<T;[1]ELX_+@
M%U>RW$@7L#)*S.V.@R3@8'0"KM% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>nbix-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20201231.xsd" xlink:type="simple"/>
    <context id="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ab4380ab9854e7eaa17e28665d4819b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2f40778fc1cd4b3bae1f28a62fea9b66_I20210129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="i04b7ec05369244eebe79a6452649afd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idce3e91b366c406685df930cadf32f38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic171b18673194daf9f8214c17b03fc19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc94b76d27134137be897aa51352595d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2d47500148149558693bfbec9f730ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifde16a61b7164f458e48b488706d2e70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i967cc502a0d34a008a828c23d2766568_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida87bfcd952941a7af0f7edcab6e9736_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb6046fae3eb4b1b840345751855f969_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc18a34429ee4de3ac9357a5328d1977_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f12acbe2b4d455e85cd438766a8ae80_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie48225642b5d487980c178811a2c13ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib635f30312fc4487a25e573ac6e23201_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ifb1dd9d305d94a28b04bb4bc72f357f3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5b7e6c1d8b5f4e399e1a026be3379b6c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie84e64d4ffbf45999357185cd064c9c1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i546d8a0a389e47b89727b48a294423df_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i029fc56043664f6d9138de8bc16cb3a0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i901799886d9a47b29af6431c66c323e3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i327a62de7e27488aacd2d461382ad7b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40c2af3510294013a84c123a7e4a817a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7765093653d345399a3f53be76391bc0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0aa89f41ac1a41899038841e6f4faaa1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i266de6ffaffd40a9b1545e43688677b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i387e248869994066a40d45b968990a24_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i582361eac54a42edb73a091279308584_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i49725d32ce2049aeb743abf42b318417_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i68a3756b3d9842d6b225a73c90aac6c2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27cce8f31fe240f8a17ee911b0e4b878_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dafe132b53e4050b679396ebb6651ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i892c766e0f01406790fc8dcd6fe62fbe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5d52ca7c1114b7eae229221755ea0be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc15f2ad264b40a4b8477d62bdd3190d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f532ba86dde41ecbd34ea42061d72e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6972c593f49849929a2f6c7717b087de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic33b6ecbd7b84a9f94efd720de382191_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4870f57f40f442cda8ea71a0a17dff09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4be7a20d35464718b1b57ce65463f4f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7376630f4274498bb13206aa06d9a70c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20120095d85448189e0c6c75de356c1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestTwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie4318f5084d84959b68665678538a7f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestTwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59194d217fcd4be386582a21776d0491_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nbix:LargestThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i728ae8d7437841b58f476b7ef0e6ca39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide871789006342f69f8274002bb357ed_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44e7588a0725435ebb6068dce53086b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i257e90a486974747899becd428e20bbc_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ia97b8d53a265445fa5504b3150879227_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0eba589932364662a4c8ccf58b4e239a_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i25235904363543e6876b158eafdeffc9_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i6545254203aa4df0a400884ff9991e40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:NBI827104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i219730df66154f82827f5448bfe38e9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:DevelopmentProductCandidatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id14cd484bece46d3a4291e95561a7587_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bbda008026b473097f608802a52aaf9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42d131b3f0874d9b980c9f62f4f8df61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a872472e6c44cd7a82a479cbe5b4431_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88977083558b4753b92390c316833a48_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i81ad4fc332a9473c95e11ea8f94d1479_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i50203e6e9ee241d8a1943a131e844922_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib352054c7bad403c94fe2bccf88d5af3_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ibbecc51b3aae463ca7e62f0c5c3d2253_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie20f0364533a47b6992606e2b86457b0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieedd883af091454ab63052c4d4fec48a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedf156fd88444c6791467b25bc69b11e_D20150301-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ib15e32a0a32b49538add4aef55c528e4_D20170701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d2360393b7d4d879ba50fd30091a78b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia63b4e7a9e71401dacbac7489e2a7e2a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i240d0d89861f4e0da2e8453b512420bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e4787a5e20042c296dec4c2db37c273_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ib60f3795c3904b598b633d9146da597a_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="icc73fd418b1a4436b3cfc5a71dbfbee0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id85b50b61a514151b47324285918ddb5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac0ef1a100194cad8dd122747923492d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie3004961ef404e91bf6918eb4f99d34d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5cbe52017cfa402a8a7a3857aaac0220_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f8e4dda08ce4ee7afe7a741837ed4d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7f1aded41cc7466989f52504c10da860_D20100601-20100630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-06-01</startDate>
            <endDate>2010-06-30</endDate>
        </period>
    </context>
    <context id="i9b38c628e5624d3489f366d90fb7a1a7_D20100701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0bcef2297f1d4d3fbdc7d17250594d47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie48c720d2df545228f70c2015456a974_D20100601-20100630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-06-01</startDate>
            <endDate>2010-06-30</endDate>
        </period>
    </context>
    <context id="i9725185c63fb43198fdcd110bf77992c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1cb602311ab414c9e533241bb5a447f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id67360380b454fd497a4b58684fbdc84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f28a934c47a48cead9ae9993ebfd81b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idac17430272d48979e4f4dd6e73b14bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22ca2abb9a7a42359562e7a6c260be20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i370dab92abd446d99199617601b5e1ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37972e19ce3448d8addd2bec549432ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i268709911d264865a1eb304bcc13bad5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11d9c5acf8fc4d5c8413f75febd4b55b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i145664990f9240a9903f63786ecc19a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac0984f70ef6410e966e87e2240cf547_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1746b27d72a42a09e8f4c180db8ba1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25e6fd039d624ebda3866e81a58d407f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64146f545c644c5b8abab68d5fbcc802_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f22921e8cd3411fb15048449bf9ca63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d5471a1995347728c20899dc1dc1145_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id64ee97397f44bb5b2b4a59df28591f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie95f976d494c4656844d9c9bc46fb639_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica9fc3c50a75463e948ac570c94115d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7b76b7e0dc64aecb1ffcbcca5554a3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b841b3697ee4d779975c918a2c7c8a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51010a40dd914cfdb8196a4a02176e64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3f914a7af504e9a8c1e308372dd4e59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbcd3bf7584b40e6b743d5e037097802_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcb535936a4640ccb740f99e14c3566a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id858ede7f298497092b20558ba3f94aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaa4a6439abb45a0bbe5a547556b6c0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fd8a4041c334ec5b874010f6d65ecb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if137413b5ed641218199d2f07b0be9d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbabb6a8263c48d08803b3cdf08455fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97b7dd5052a1419d9b5eca1001915ffc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05d8e3f0ed354c24ab54716af189bb5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76c602f03adc4410bf05dba9e4ccab5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i586a6d13c402494cb6770d478521529f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i512ab3e7ad974af9ac04248f25184c1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if231ddf6746a46a4aea8216c8a79d9ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i595f5dfa2dd643d79953bbb4a3402602_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4097b8463354e23a855ad993b3e185e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc5b4944e27842f1ac75b788b5072eb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84af1872e05c4870864980dc019daa4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8026f07e7861492f8e98644add623101_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic655a96eac1d40e58299205ab8797a96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3e1d84b48f1403d90c17750f958db4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e03e5b9e1ad419bbb0aefdda65dd330_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdb969448f744b4699e0fe3b2054bc9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e685b74d3a440ae9b69cf3a21f6e94b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia200b6eb75094ebba0fdffab64b4098a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8253ad6971bf419497de5085c582cf91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad7d8c26c43040ac8423eb140604d3d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e092d8925da40a99bc1aefd6f132f68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if14e6ee1921748129105cf214378dd1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i695b22218e09442dbb693682b472e4b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaf5e27ca5cc4d77bd90dd61ac8a47e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67ac9be8342447318a432723c6b78797_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88fb3b785aa449358571ef423f2219c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib65158ac540b41cd91166a0e53ba58cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ac4ccb925d645399a328c6018222c6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i268c052b4cd04cce8ecbc0e2996aa476_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73a6b5151cf4490f9a51234227581adc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i408a528ab8eb45e9877acf825e1bf345_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0856066d5f14514abbb08941b50a267_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20d887e6eb804e2ba40e5f883f36d75c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c033102d7b6458faa551c243d0e7289_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcd0cc61423040c2915457ec8d6e5d02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd111c56381a4d8f9292b85ac7e19496_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74f436445a324740ab5c8efd7b56e438_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c4b1d571718416faec2b0ce71d8aab5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5986576aabe849f49f87cd5cdae9d04d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16a5389b2dd24efab23db9d2c4a3b7b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0517d273790643c98a976440f62fd851_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67d343eecc4941ff98e247350e2ab153_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ff8100d45dd4625af5245d8a8c006fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc657f8675ea40f5bf7d4393012f3446_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a1423af80c04b629c1cf1dad548b611_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica8a7b9a9e1c4e19906b367cff71df1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7509d8ee40ad447cb623f9963e19a98e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide958d8a47be4cea92940a48e4246ae2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i646522578c0b4f8fbe22f01e7929bead_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12f95bc7850c4e96acea39610b13ee2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd64f71c0cc942f2b913d01db69e0a56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22be6b7ba979497ca9ece88797ec5f9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1d05cd22a7c40f6872ae176348b44ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic30e7a2d8e794c59af388b27d36d27fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62749c0209e440f7b96473ce6fd4b8a3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf0e119c44184cc685474e43e33f71bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcd60d8e7dce40b0aca76907070d868d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida05ac1eb4ff4313a9d1f27643667abb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c8645b15c1c462293674465d9ffd0b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida219830132544daa2c45cd2d963ac68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54fac764203a4713af1443597ffa888a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee56e84363a64281a0bb67ffa597df58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic30674d569f74deb8350b47ed380e2d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd2575bd668b4015b8ad679f19bd5a1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e8a5dc0856b4cdba6c86a366b76c812_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79ce58ee37ae4b92b5d958c540e8289a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifad81ae5e7644259a48165fae6c46349_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ca67d557d334f00a0544aa5f24f6b34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifad56dc439b641358459b58e8079887a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i05c117b96dea48f4ac63a4022bae19d6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec42070cca3e4dbb8475c09e274ad678_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83c603ce0ef14a36b7c219ff93558f30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i830e7abc03c443829d9692cb82e8dada_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia219d51ea1f4489893af819d696712f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4275d4edccb744bf87c8dce992b293b1_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="id222ff8c62cd4111a8f3c7d582b27ee4_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i89667253f1654865bbfb0ea260237daa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f1e2b0fdafc40cea056719ee341bf3f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="if4d919d3678346498deb137a73366cf9_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i60ced8a0a7764272b813ab553a8bc5ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06934d96e69448b9a6a7de8228e9ae5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifaa184a589454ef3b217797ac3f37c85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c737c06e3a64363abae7512867edfb9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a92c0d75562403aaeb7e6195396a9c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4132f626519c4dd6915f68702956d54a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:ScientificEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2114f7c7620e47ed9b7c7252ab48432d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia76651c30b164c06b76804edbd718ae7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i04c9dfd023f94ae6b49d6219f49911a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33ff256dae7c4d7da1e1f691ad48ee76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic403135dcdce433cb75127f4ba52569f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i545e098699484f749aa1893bd9f4d9ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie580a98b5f904017acbc0be2a81b1401_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb93957d4a2347d0893965c4a30cbdd0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ad0a98345c14590bf7d5f5fd862c9fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i613490d34e8a4611aab2ffd9a16f8ef0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e784185d98a4b9cb1bb7bcad7598aea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81fcb21b072c4b679ca34c108cfa6ef4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8581e780a80c4442b21f27be29b95775_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5bea0f817d424b9faef8c2af8c43a23d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i16180db6d54a49ce83ee4500d72b9962_I20110531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-05-31</instant>
        </period>
    </context>
    <context id="i21f4f7020f68499385d6f2a13567d7f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:TwoThousandAndElevenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60fca317ddb748798d4cb98a5fbf2aea_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="idd5803489bd44c3cb9e6f31d1e0a6681_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48bbd2bddcdc44dca0395f6d99c449aa_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i035747211e4f44e193c5d551cf4d62ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nbix:A2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i965516f5121d4176b5ae292b90be804a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iffc67e37cd02430da9f8da535e6d7526_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i521c723b6c49422a84b72328e24a5c55_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1faa6db7b38d43dd97845deb75c32b0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84e87b16f9684b559824bed5cc3bfaad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a82057bae22484ab39cbc0b26398dd5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8b54e325551b473da0598c96d708c5da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7638d60a91cb4ff787321cee24ae9f48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie680af40b96e455aaaaf75ab295c9ac4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibdaaf1063b5640c096eab926298a36b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f37b110bd3e4061a2c3b66a2947d1aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5add3ec602347a4872184c665490f93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b9010f4078c43eb99d30b01f597843b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if533ce7e9cb447bb8d5ac9d5e64f6a4b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice8da843469b46af91bfcfc456693d02_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nbix:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c587d6dc8c6451fba9c6dbe18ec82bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaad045d0ff0b4b949b001aa2efd85687_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i478244770d8e4c27a0658c7c1918fbe0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6da45b8c6e074d14bdc079a1f2265f01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib123ada82f724fe49861cecabdde52c1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8d2db4ddee19489eaad07271d5031b33_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>nbix:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>nbix:segment</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="renewaloption">
        <measure>nbix:renewalOption</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV8zLTEtMS0xLTA_fcd14014-5941-43e4-8bba-b24551550198">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV80LTEtMS0xLTA_a961bbfc-7ce0-482e-ad72-6d00604ff53a">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV81LTEtMS0xLTA_e7a19f1f-50c0-4e6f-b92c-3d2f35248c1d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF80L2ZyYWc6MzM4MzQ2OGU3OTYyNDQ0NGI1OTVkODgwYjRmZmRhOGEvdGFibGU6MGZjMzg1ZjJlNzgyNGI3OTk2ZThhNzM5NjgxODMxMTkvdGFibGVyYW5nZTowZmMzODVmMmU3ODI0Yjc5OTZlOGE3Mzk2ODE4MzExOV82LTEtMS0xLTA_614237d8-3b01-43a2-a3bf-a6c63a868a7a">0000914475</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTAtMS0xLTQ5NQ_87ff2093-6207-4e9e-bccb-3338262ddc44">us-gaap:AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="idc9690d625df4ff1b735e24d1a12e2f2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8yMDAzL2ZyYWc6NzRiMmUyZDY4NTJmNDg1MTkzNGUyMWQzOTM0OTAxYjMvdGV4dHJlZ2lvbjo3NGIyZTJkNjg1MmY0ODUxOTM0ZTIxZDM5MzQ5MDFiM18yMTk5MDIzMjU1NjAw_a9f0933f-aa9b-4f9c-a00e-956f55394347"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8yMDAzL2ZyYWc6NzRiMmUyZDY4NTJmNDg1MTkzNGUyMWQzOTM0OTAxYjMvdGV4dHJlZ2lvbjo3NGIyZTJkNjg1MmY0ODUxOTM0ZTIxZDM5MzQ5MDFiM18yMTk5MDIzMjU1NjAw_f9c97543-fe59-4627-97cb-4bec93c55031"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjMvZnJhZzpkZTY3NjU5ZDNkZGE0MGE1OTFkNDhmYjA1ZWQ4ZTY1Yi90YWJsZTo5YWNlYjRjMTY0M2Q0ZGViYmZlMTBhM2E2ZWQ4NjgwMS90YWJsZXJhbmdlOjlhY2ViNGMxNjQzZDRkZWJiZmUxMGEzYTZlZDg2ODAxXzItMS0xLTEtMA_2dbdce13-f7df-463d-9a7f-dc622740dbed"
      unitRef="number">0.00131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4f37b110bd3e4061a2c3b66a2947d1aa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if533ce7e9cb447bb8d5ac9d5e64f6a4b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIx_6a572cb7-cdf7-4f11-8546-8debf546d000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MTJiYWYyOTAxYzQ1NGMyOTk2Y2E0Y2ZiN2FhMDdkNGMvdGFibGVyYW5nZToxMmJhZjI5MDFjNDU0YzI5OTZjYTRjZmI3YWEwN2Q0Y18wLTAtMS0xLTA_ec6c9f06-8471-44e2-9c9d-48768dbb2620">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE3_bae0edc3-9aee-40ba-8a31-5d15ab587e62">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE3_8d3e5022-76d5-491e-bc00-b2253648fea0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6OWZjNTYyNTZiMjU5NGFiNGI4OWI4YTAxYTZkYzU1Y2YvdGFibGVyYW5nZTo5ZmM1NjI1NmIyNTk0YWI0Yjg5YjhhMDFhNmRjNTVjZl8wLTAtMS0xLTA_dfa6afec-bad1-4d8c-9173-c6186222a1e1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIy_3ca58c23-ee47-4fa3-896f-8d98537773b0">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE4_00edbf6c-9871-425b-9a50-55f723e2f247">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8wLTAtMS0xLTA_ecf9783d-3176-4d13-9b6d-65770d53a944">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8wLTYtMS0xLTA_323274c3-0d85-4e21-83f6-f2c882683a81">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTAtMS0xLTA_ff181019-3a2b-489e-a9f7-4a34c2609109">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTItMS0xLTA_b34522a6-c7e1-4232-8a6d-69ef01d6a684">San&#160;Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTQtMS0xLTA_a1fb615c-0d68-4211-ae66-d8a6fa56bad8">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6NTAxNzlhYTBkM2ZiNDhkMzllYTE1Y2I0NGJhNGYyNzkvdGFibGVyYW5nZTo1MDE3OWFhMGQzZmI0OGQzOWVhMTVjYjQ0YmE0ZjI3OV8zLTYtMS0xLTA_b6913220-4ca8-4990-8d6d-d59ad2e96976">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIz_38e79d89-423e-4d95-99bf-51250b7b86dc">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE5_7e86f018-2f0f-47f0-ae37-546bd9114ac4">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTAtMS0xLTA_5fed48c5-3029-493e-88e8-8b107a74f603">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTItMS0xLTA_33d950a6-eeb9-4d98-860d-3c2121504311">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MDY4NDZjZDRiYjRkNDJiMmE2Zjg2Y2EyN2RkZDI3MzcvdGFibGVyYW5nZTowNjg0NmNkNGJiNGQ0MmIyYTZmODZjYTI3ZGRkMjczN18wLTQtMS0xLTA_e3da681b-a019-4106-9c7d-a97c9ed83e9a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTIw_10421f79-6755-4d85-aa44-f3af61af9919">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTEz_508aeeb6-ea7b-4a7d-a567-dc26e78916f9">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE0_15f9d391-c9ff-4fef-a963-5018343a931f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE1_2bc7ff90-dd52-4f28-87a7-cd04cf49944d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTAtMS0xLTA_764ba5b0-d6c9-44b3-aa24-cf550f0a165e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTEwLTEtMS0w_aef3b110-2975-4f98-83d9-7d9f3fea4d51">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGFibGU6MmQxMzYzOWNkMDA5NGFjMzgzODkyZjczMDFmODYwZDUvdGFibGVyYW5nZToyZDEzNjM5Y2QwMDk0YWMzODM4OTJmNzMwMWY4NjBkNV8wLTEzLTEtMS0w_8c5f59ca-f31b-4330-be20-db23c4be67bd">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yMTk5MDIzMjU4ODc1_8c6b97c5-8e1d-4e1d-ab6f-20a8efb35bbc">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTI0_3edb264d-e3b7-430a-9534-bd9d2508c5d8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i9ab4380ab9854e7eaa17e28665d4819b_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yNDk2_e4d348bb-517b-4105-97e6-21a61bae4701"
      unitRef="usd">11231617436</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2f40778fc1cd4b3bae1f28a62fea9b66_I20210129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yNTEw_d4f9ce3e-d6da-4f9e-a5d0-818a12e7a92a"
      unitRef="shares">93943645</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xL2ZyYWc6MTcwMTFkMjU1Mjc5NGFjZGFjYWZjZjZjNWYwM2Q3MWUvdGV4dHJlZ2lvbjoxNzAxMWQyNTUyNzk0YWNkYWNhZmNmNmM1ZjAzZDcxZV8yOTE2_fefb1076-820f-4188-9942-53d73230f1cf">Portions of the registrant&#x2019;s definitive proxy statement relating to the registrant&#x2019;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#x2019;s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <nbix:PotentialMilestonePayments
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMTIvZnJhZzphODUyNGZhNjFlOTI0NWYwODZiMjkyNjhhZGQyYmU0Mi90ZXh0cmVnaW9uOmE4NTI0ZmE2MWU5MjQ1ZjA4NmIyOTI2OGFkZDJiZTQyXzEwOTk1MTE2NDA2OTA_62b87349-9048-4c6d-9c7c-ff53e2f5e4f2"
      unitRef="usd">8500000000</nbix:PotentialMilestonePayments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzQtMS0xLTEtMA_ebbeda42-b480-437e-99a0-bf4ef62815e2"
      unitRef="usd">187100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzQtMy0xLTEtMA_fd67b778-82ce-4b6b-b902-34a1f04fe1c6"
      unitRef="usd">112300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMC0xLTEtMzc1L3RleHRyZWdpb246ZGM5NTA1ZWI2OGQ2NGJjZmJkOTBkNWFkMWFkODNkZGVfMTY0OTI2NzQ0MTgwOQ_816ea726-1eab-4b55-85fe-05ee4b2b0628"
      unitRef="usd">612400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMC0xLTEtMzc1L3RleHRyZWdpb246ZGM5NTA1ZWI2OGQ2NGJjZmJkOTBkNWFkMWFkODNkZGVfMTY0OTI2NzQ0MTgyNw_a798131f-999c-45d7-950e-a25a9226e3b4"
      unitRef="usd">557300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMS0xLTEtMA_d2d4f445-fd07-4702-a83e-df51d525547a"
      unitRef="usd">613900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzUtMy0xLTEtMA_c79e09fd-488c-42fb-bfcd-2e191251b9f9"
      unitRef="usd">558200000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzYtMS0xLTEtMA_5b58fe31-62bd-4c3b-92d3-be49d6058885"
      unitRef="usd">157100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzYtMy0xLTEtMA_dd4e8bfb-5c06-4b88-a4b5-4ca5b3084228"
      unitRef="usd">126600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzctMS0xLTEtMA_be3296fa-34d6-410c-8ec5-65d106b2494b"
      unitRef="usd">28000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzctMy0xLTEtMA_62d35719-4970-4996-a2c6-fe6e4bb1fe74"
      unitRef="usd">17300000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzgtMS0xLTEtMA_0e6f19e5-5599-460c-b2a0-4b5b6df01a05"
      unitRef="usd">30100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzgtMy0xLTEtMA_01ca6520-8902-40eb-abac-8d5ff1312fb4"
      unitRef="usd">16600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzktMS0xLTEtMA_3d23a27d-d63e-4f2a-bdf5-0ec18868ff11"
      unitRef="usd">1016200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzktMy0xLTEtMA_0a1f6b92-b134-4eac-94d7-15e1252e7476"
      unitRef="usd">831000000.0</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTAtMS0xLTM4Ny90ZXh0cmVnaW9uOjZjZGZjNmU4NjhkODRiMzI4NDAzODQzMTgyZWQ3NzkzXzE2NDkyNjc0NDE4MDk_58e33223-f08c-4fca-be5a-c52afec3c467"
      unitRef="usd">226700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2d47500148149558693bfbec9f730ae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTAtMS0xLTM4Ny90ZXh0cmVnaW9uOjZjZGZjNmU4NjhkODRiMzI4NDAzODQzMTgyZWQ3NzkzXzE2NDkyNjc0NDE4Mjc_09c97882-8b5d-4acf-9e88-b10fe79dc848"
      unitRef="usd">299300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTEtMS0xLTA_399007bf-bba0-4b9a-97a8-137d82df795e"
      unitRef="usd">227100000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEwLTMtMS0xLTA_c71bd958-e7f9-4473-8739-ab64b015e03f"
      unitRef="usd">299700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzExLTEtMS0xLTA_3ee70df4-f2f0-400b-bf0d-9863e381069c"
      unitRef="usd">82800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzExLTMtMS0xLTA_13eac9ab-8324-43be-a628-9c53c582ed53"
      unitRef="usd">74300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEyLTEtMS0xLTA_a07a7abd-ef01-42bf-8bba-b9dc823aa22f"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEyLTMtMS0xLTA_34aea0e1-639c-4796-b94a-ad3cd3cc1827"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEzLTEtMS0xLTA_baf6d9d1-20e0-4a2f-96ff-814eb086e0a5"
      unitRef="usd">44600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzEzLTMtMS0xLTA_c3566852-1e1c-48e5-95b8-8e54bc906259"
      unitRef="usd">41900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTEtMS0xLTk3MTM_43044372-f81f-46da-876c-781c33384167"
      unitRef="usd">319400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTMtMS0xLTk3MTY_91de990a-44b4-4e22-a81e-71268399444d"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTEtMS0xLTA_e0e0e1b8-e908-4844-83da-5ba2839a6a0c"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE0LTMtMS0xLTA_996a28dc-1f7f-4f8f-b49a-dc2c4b5c86a2"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE1LTEtMS0xLTA_2cf3a1c4-fdb2-4c22-a830-3676f65661bb"
      unitRef="usd">3200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE1LTMtMS0xLTA_99dcb5a2-420e-4467-bc22-bd082d68f9c5"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE2LTEtMS0xLTA_f0d6ac1e-02e4-4b59-9378-304010c5c2ef"
      unitRef="usd">1734700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzE2LTMtMS0xLTA_966a07ef-8c34-4e80-a8a7-e0ee18bc8b20"
      unitRef="usd">1306000000.0</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIwLTEtMS0xLTA_b086d65a-e6c2-4478-82dc-5e63d3cba638"
      unitRef="usd">168700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIwLTMtMS0xLTA_4f7787fa-f2b2-4a40-a52b-33e2569b46e7"
      unitRef="usd">141300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIxLTEtMS0xLTA_3ebaa20f-e838-416e-92c0-310b4869cb02"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIxLTMtMS0xLTA_dcb79257-c9a3-4304-8e02-4cab38026c9d"
      unitRef="usd">408800000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIyLTEtMS0xLTA_bc585008-aeec-4d08-a4d8-7cc821a3e2b4"
      unitRef="usd">17800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIyLTMtMS0xLTA_b6719457-6bec-4261-a477-305aeba1010d"
      unitRef="usd">15200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIzLTEtMS0xLTA_aab4eee2-3a5d-4450-80dd-8bfdbb2aec0c"
      unitRef="usd">186500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzIzLTMtMS0xLTA_045d4020-9c58-4824-bfe0-7ad9e4763b15"
      unitRef="usd">565300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI0LTEtMS0xLTA_933b5f44-658b-47c1-ac39-76547a545b92"
      unitRef="usd">317900000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI0LTMtMS0xLTA_b3ce6938-e5a6-421b-a629-2764f2d0f87f"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI1LTEtMS0xLTA_d8602645-fa76-47a3-8742-e0e275dacebc"
      unitRef="usd">94400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI1LTMtMS0xLTA_4377d2b0-1a2b-42ef-be22-dac454026648"
      unitRef="usd">86700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI2LTEtMS0xLTA_b49b781c-ab1a-4512-8e79-4b53432ca994"
      unitRef="usd">9700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI2LTMtMS0xLTA_0662f3fa-e947-42c4-b55c-084f8f6089ab"
      unitRef="usd">17100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI3LTEtMS0xLTA_20cf9b4b-90fc-4711-b052-4e5578cba099"
      unitRef="usd">608500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzI3LTMtMS0xLTA_d239d38e-416d-4806-ba68-5e7fda525233"
      unitRef="usd">669100000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODg4_4a84b852-c12e-4dd2-917e-a58ba64fdf27"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODg4_6c88fd98-bdb3-46c8-a538-8ddecafd42ee"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk0_305d712c-66af-4492-9c09-9943be90c928"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk0_a27c611c-7ae9-4eee-becd-fcd3c2352f85"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_5284ae1c-95eb-41a7-8ec0-0a14e7935d83"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_7197b3f8-a23f-4205-97f4-c74987f6dca7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_954be599-0fcd-4a8c-9e7e-feb128f0d46e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo4ZWM0OWE0ZDM3YTU0YTIzOTM0YzIwOWNmMDRhMGYzOV8xMDk5NTExNjI3ODk5_9b01d412-920a-4b3d-93b4-5eacf770fe53"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTEtMS0xLTA_ecfc046b-b39c-4cc6-bf33-ec0f71ffca62"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMwLTMtMS0xLTA_69dcac56-ce1b-43c1-adc1-79f3edcbff81"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTQw_3a38b74f-7d36-4aed-be87-a5132c9013c1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTQw_66292566-0d74-4f4f-b637-62eecff20d45"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTEz_4c9769c1-4e58-459a-9f5d-7be37ba6cf1f"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDk5NTExNjI3OTEz_dede4854-4d8c-45c2-a2be-d5752a49a014"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl85Ng_0564775b-fec3-45b0-ab90-91357a4c0b73"
      unitRef="shares">93500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl85Ng_f54b7b20-c96f-457e-8123-e9507c4df4df"
      unitRef="shares">93500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDM_29892bc0-2a04-4b9c-b496-d91a2f670f5c"
      unitRef="shares">92300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjo0NjAxNTdlYzU0Mjc0Zjg3OGI3Njk0YzZlMjBlNzlkMl8xMDM_84a65dc1-faaf-471d-85e0-d4d3761b5c8c"
      unitRef="shares">92300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTEtMS0xLTA_99fe7fb8-a166-4b5c-b175-bb72ceee4f96"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMxLTMtMS0xLTA_1cae0df0-58c9-49e9-afc1-c46e80459779"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMyLTEtMS0xLTA_278baebf-f566-4ac0-b260-f1196e046f61"
      unitRef="usd">1849700000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMyLTMtMS0xLTA_c44b0451-88d5-4592-9e3c-9bbecf7d85bd"
      unitRef="usd">1768100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMzLTEtMS0xLTA_ce8704a7-0812-43bd-81a6-12656e1d75c6"
      unitRef="usd">1800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzMzLTMtMS0xLTA_df1ddc50-7c1e-4726-b908-00a83565d778"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM0LTEtMS0xLTA_5c027211-0eaa-4d6d-bd89-d5c88a16078a"
      unitRef="usd">-725400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM0LTMtMS0xLTA_cb7a35a3-363b-4010-b5b4-0d6a9f67e5c2"
      unitRef="usd">-1132700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM1LTEtMS0xLTA_fc17012f-1e20-404d-a88f-13f9b11a603c"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM1LTMtMS0xLTA_f79101a2-3432-4fc9-83e9-05fc705e7733"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM2LTEtMS0xLTA_7801f5be-5f5e-483a-83e3-fee4816e2c47"
      unitRef="usd">1734700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzAvZnJhZzpiOWU0YjBkMjEyNjU0NzZjODUzZjNiM2ZmZjU5YWIwNi90YWJsZTpkZjM2MGU4MWI4MzE0NjEwODJkMjJkOGU2Zjk5ZTkxOC90YWJsZXJhbmdlOmRmMzYwZTgxYjgzMTQ2MTA4MmQyMmQ4ZTZmOTllOTE4XzM2LTMtMS0xLTA_7ce4fa98-d4a7-4a49-b19c-f2ffa46337e9"
      unitRef="usd">1306000000.0</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifde16a61b7164f458e48b488706d2e70_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtMS0xLTEtMA_f8531db7-d204-49ac-9a2b-7e2163ee43e3"
      unitRef="usd">994100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i967cc502a0d34a008a828c23d2766568_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtMy0xLTEtMA_40ba7f20-a5c6-4ef2-be77-1d1572961bc8"
      unitRef="usd">752900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida87bfcd952941a7af0f7edcab6e9736_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzMtNS0xLTEtMA_80dfc09a-7961-4295-9aec-e5994666fcff"
      unitRef="usd">409600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb6046fae3eb4b1b840345751855f969_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtMS0xLTEtMA_62b83ae2-a332-466d-9275-90c521302659"
      unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc18a34429ee4de3ac9357a5328d1977_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtMy0xLTEtMA_eeedd4e4-696d-437f-912c-edfe0348ed5d"
      unitRef="usd">35200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f12acbe2b4d455e85cd438766a8ae80_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzQtNS0xLTEtMA_60f7349e-2a12-4912-bf6f-7869af2844c1"
      unitRef="usd">41600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtMS0xLTEtMA_2d988d67-930b-42ba-b07e-73ca9cfec98a"
      unitRef="usd">1045900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtMy0xLTEtMA_46a955bd-c091-461d-b9e6-2398d0e07d8f"
      unitRef="usd">788100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzUtNS0xLTEtMA_3ca98a6c-0eff-40cc-85fb-a43a2cb4a4f5"
      unitRef="usd">451200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:CostOfSales
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctMS0xLTEtMA_ed8ab8e4-f8b1-4990-bde8-e9f23bd24477"
      unitRef="usd">10100000</nbix:CostOfSales>
    <nbix:CostOfSales
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctMy0xLTEtMA_942e2a7a-ecea-486f-ab6d-2ce8ebbd2543"
      unitRef="usd">7400000</nbix:CostOfSales>
    <nbix:CostOfSales
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzctNS0xLTEtMA_e982f06c-22c7-44a3-8403-4998e1503d45"
      unitRef="usd">4900000</nbix:CostOfSales>
    <nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtMS0xLTEtMA_32de1d56-f0be-4a51-9572-a510d7e80213"
      unitRef="usd">275000000.0</nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtMy0xLTEtMA_27e0ad1a-7ddf-416c-bd06-08b68ca1b2ef"
      unitRef="usd">200000000.0</nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzgtNS0xLTEtMA_426b8550-bf04-430d-9af9-b6aaa4f1e54a"
      unitRef="usd">155800000</nbix:ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktMS0xLTEtMA_50976b10-9d5f-4291-ab6f-f6297888039e"
      unitRef="usd">164500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktMy0xLTEtMA_4bff62bf-3140-464a-bb94-c1d095596f20"
      unitRef="usd">154300000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzktNS0xLTEtMA_d3dcf6f4-1ca3-4f7a-8d20-9189ef52f993"
      unitRef="usd">4800000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTEtMS0xLTA_4bf04dba-f8b4-40b4-a39d-63cbc9fa42e9"
      unitRef="usd">433300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTMtMS0xLTA_10f1699b-ce2f-4721-a45e-014f71f7dec4"
      unitRef="usd">354100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEwLTUtMS0xLTA_9d2004c1-de6c-4c2e-aac7-ec339ec6ead1"
      unitRef="usd">248900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTEtMS0xLTA_27b4d25c-342b-4986-9100-9c2f669d2458"
      unitRef="usd">882900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTMtMS0xLTA_8b4224db-8ce0-45d2-8e0a-008dfaf63829"
      unitRef="usd">715800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzExLTUtMS0xLTA_4e636c27-7203-4486-87d7-20544f9eaf85"
      unitRef="usd">414400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTEtMS0xLTA_9e947545-a361-4445-ac2a-fb780bc50815"
      unitRef="usd">163000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTMtMS0xLTA_769bcf94-f5cb-464c-845e-a9f9179cb80f"
      unitRef="usd">72300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzEyLTUtMS0xLTA_d0cb2e7a-d785-4b2f-9553-9dd0f2bf59c8"
      unitRef="usd">36800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTEtMS0xLTA_a705b1ac-ebbc-4f9a-9a15-67c50ee4e33b"
      unitRef="usd">32800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTMtMS0xLTA_eed5515e-8184-40a7-b52c-14e6c102d120"
      unitRef="usd">32000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE0LTUtMS0xLTA_8fe502ce-a6a5-4bc3-9898-a3e0a1805708"
      unitRef="usd">30500000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTEtMS0xLTA_5869e4c6-db88-4c4f-81e3-e31244c5ed1f"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTMtMS0xLTA_d07e45fe-c4e8-452e-8f0f-7a00162eef11"
      unitRef="usd">-13000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE1LTUtMS0xLTA_15410f14-f52a-4bbb-81cf-8337ab2acaef"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTEtMS0xLTQ1NjA_b15dba46-2242-4ae7-811e-f00fd5216462"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTMtMS0xLTQ1NjA_9637da15-9ff7-47ff-9945-498bce96f3b4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTUtMS0xLTQ1NjA_656d49b1-77b9-42ca-acea-762f7c2cdc5b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTEtMS0xLTA_9d1ad0e6-7cdf-4ac0-b7af-637c14c862e7"
      unitRef="usd">12600000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTMtMS0xLTA_e40bdff5-c4dc-4c0e-8158-688c52b68993"
      unitRef="usd">19200000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE2LTUtMS0xLTA_ab8b2c71-23f2-4833-b904-b2c2da9c7233"
      unitRef="usd">15500000</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTEtMS0xLTA_0d673b0f-c820-4abb-b9ba-41109c170f1e"
      unitRef="usd">-56300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTMtMS0xLTA_87905780-2140-43b7-a432-ee2862ff69d9"
      unitRef="usd">-25800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE3LTUtMS0xLTA_54c83bea-df37-4e38-ba62-b2e779388d63"
      unitRef="usd">-15000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTEtMS0xLTA_a7c7af73-eb0d-4c71-82ac-82d32537f051"
      unitRef="usd">106700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTMtMS0xLTA_cd344fd5-6c10-4746-b183-b82f7e67df28"
      unitRef="usd">46500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE4LTUtMS0xLTA_201213fe-c946-48dc-b8ff-f1eaf860d2c1"
      unitRef="usd">21800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTEtMS0xLTA_708be55c-04db-4fa4-9a6b-35bd1fd39221"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTMtMS0xLTA_a4759595-672e-4579-9f0d-7a2dd30245c1"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzE5LTUtMS0xLTA_030e34ab-2585-46a4-9645-36bcdd91a536"
      unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTEtMS0xLTA_b5a3c4b6-d7bc-40ee-b9f3-1f2d368da685"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTMtMS0xLTA_61451c5a-1b82-4f9e-83a9-271f7c05f998"
      unitRef="usd">37000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIwLTUtMS0xLTA_81c6f734-56c3-42b3-9514-5046f2edf92a"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTEtMS0xLTA_8eb15934-efc6-44c0-870f-661c9ef59fff"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTMtMS0xLTA_1a7de1de-b6b6-4b9f-92c8-8d9ea19a2338"
      unitRef="usd">3400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIxLTUtMS0xLTA_e8063e2a-71e4-4a42-94c2-edf3f73a6c84"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTEtMS0xLTA_34bc17fd-9728-43f7-beb7-42db3c75a433"
      unitRef="usd">407700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTMtMS0xLTA_5d8fa052-a892-468b-9eac-57adee2d418e"
      unitRef="usd">40400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIyLTUtMS0xLTA_ce86dce7-91d9-4e5f-ace4-e05961becf27"
      unitRef="usd">21000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTEtMS0xLTA_be317350-bfb0-4ce9-920b-a153e051a999"
      unitRef="usdPerShare">4.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTMtMS0xLTA_12206885-2ab7-4697-b966-4897a7521f24"
      unitRef="usdPerShare">0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzIzLTUtMS0xLTA_b5939c51-0574-4366-8bc6-e397dc4e2a61"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTEtMS0xLTA_de2e5df1-8e9a-4b47-9b73-399babd4e772"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTMtMS0xLTA_e9345df5-203b-47fe-8aa7-18184b7f46b7"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI0LTUtMS0xLTA_2e3cbe1e-dbbc-46b3-aa81-3527d932ce61"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTEtMS0xLTA_6257beaf-c55c-4741-a573-250bd6922cfe"
      unitRef="shares">93100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTMtMS0xLTA_cce729c7-6164-49ea-a394-43de6bdfd7f4"
      unitRef="shares">91600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI1LTUtMS0xLTA_98cdb3ec-d4bd-446f-abe3-4f5be20c7a1c"
      unitRef="shares">90200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTEtMS0xLTA_19702b59-f357-449d-b55a-51dcbf02816b"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTMtMS0xLTA_0c26d173-b752-4163-b6af-2c29f4eaf19d"
      unitRef="shares">95700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzYvZnJhZzo2ZDkxZWRlNjQ4M2I0OTFkODYyNmY2OTI2OTJmNjQyZC90YWJsZTo1NDA2YzFkOGQ1ZDE0OWExOTExOWNjM2U1ODBiZjhmMS90YWJsZXJhbmdlOjU0MDZjMWQ4ZDVkMTQ5YTE5MTE5Y2MzZTU4MGJmOGYxXzI2LTUtMS0xLTA_e507bb09-801b-48ca-9707-bb6cad5451b9"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMS0xLTEtMA_8515497d-9be1-48a3-a708-2c8c3d42795e"
      unitRef="shares">88800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a23b0e35de74dc0b44113bd6d8a068e_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMy0xLTEtMA_eafc3af9-fe4b-4636-804e-5c661eb04b49"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib635f30312fc4487a25e573ac6e23201_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItNS0xLTEtMA_2cd1136f-73e6-47aa-b61e-e3404ca5435e"
      unitRef="usd">1572800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb1dd9d305d94a28b04bb4bc72f357f3_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItNy0xLTEtMA_7559d931-d633-4412-9b0e-ae233bfd4611"
      unitRef="usd">-1900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b7e6c1d8b5f4e399e1a026be3379b6c_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItOS0xLTEtMA_255eb5ac-a460-49b6-8fdb-84ed61167211"
      unitRef="usd">-1198800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzItMTEtMS0xLTA_4a0b1c84-4ba4-4a2e-be0e-f291da479281"
      unitRef="usd">372200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i546d8a0a389e47b89727b48a294423df_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzMtOS0xLTEtMA_071d3fda-9e1e-4198-9a91-9b302cce1483"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzMtMTEtMS0xLTA_3a197bf8-6155-483d-a7c2-c268d9a2506a"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i029fc56043664f6d9138de8bc16cb3a0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzQtNy0xLTEtMA_7315ac51-6153-4e83-a9e3-032f539838da"
      unitRef="usd">-100000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzQtMTEtMS0xLTA_861c6f7f-d2f1-4557-b97e-f59544ecc631"
      unitRef="usd">-100000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzUtNS0xLTEtMA_d65848ac-a598-4579-9ae5-f9c9fde520ce"
      unitRef="usd">58100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzUtMTEtMS0xLTA_fdfeec65-4a7f-4289-a392-29ba53de04b9"
      unitRef="usd">58100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i901799886d9a47b29af6431c66c323e3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzctMS0xLTEtMA_f8983ce9-e07c-4327-ac63-7bd249547f76"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i901799886d9a47b29af6431c66c323e3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtMS0xLTEtMA_60625812-776a-44f9-a991-d9c14f1c82cb"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9e76e54807c340fd8db687b0a9609807_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtNS0xLTEtMA_dd3ab515-7889-43d5-be87-d1acbdee81d7"
      unitRef="usd">29500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzgtMTEtMS0xLTA_606181f0-de6c-4b81-ae4d-554a8ace66e2"
      unitRef="usd">29500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesOutstanding
      contextRef="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTEtMS0xLTA_c8f90998-c37a-480d-a18f-c89286462dfa"
      unitRef="shares">90800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1c51b6d6e29344b4a57b180c6ddaa6ba_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTMtMS0xLTA_91b08ac7-c5e2-4cfe-b1ce-6542be1afee7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i327a62de7e27488aacd2d461382ad7b8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTUtMS0xLTA_219e6afc-0af9-4981-98d6-4fde10fd0058"
      unitRef="usd">1660400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40c2af3510294013a84c123a7e4a817a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTctMS0xLTA_16c6e0a3-a477-49ca-af63-3c3b6dde32f6"
      unitRef="usd">-2000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7765093653d345399a3f53be76391bc0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTktMS0xLTA_13c93a9a-f3cd-43b5-b7cd-42a4465dccad"
      unitRef="usd">-1177700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEwLTExLTEtMS0w_14a7beef-cc8c-4a72-9fb5-7676123adbd1"
      unitRef="usd">480800000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i266de6ffaffd40a9b1545e43688677b6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzExLTktMS0xLTA_9f3276be-e68f-4e10-b3f2-fcdea9efe498"
      unitRef="usd">37000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzExLTExLTEtMS0w_d752134f-725a-42db-a263-7d7f0f78f4bf"
      unitRef="usd">37000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i387e248869994066a40d45b968990a24_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEyLTctMS0xLTA_0b93e714-bfdc-488d-8fd4-6128d5046036"
      unitRef="usd">3400000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEyLTExLTEtMS0w_04a09e4b-5fd7-4ee8-a48c-a6a187dc133e"
      unitRef="usd">3400000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEzLTUtMS0xLTA_e6c7394b-65ca-4ae9-accc-99d6a849bea0"
      unitRef="usd">75300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzEzLTExLTEtMS0w_98097d04-4e3c-4eeb-b262-f0d333ee868d"
      unitRef="usd">75300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i49725d32ce2049aeb743abf42b318417_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTktMS0xLTA_6b8eb40a-1780-4334-aa44-fada1672fed5"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68a3756b3d9842d6b225a73c90aac6c2_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE0LTExLTEtMS0w_2ea6123e-34cb-45ec-a48b-25732d2384ca"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE1LTEtMS0xLTA_f05f56d6-d9ca-4044-b07d-0a91a5401002"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTEtMS0xLTA_307f1b93-9c10-4adc-ac58-a108ccc888ad"
      unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTUtMS0xLTA_c1e87432-ab85-4de0-b879-dc1265945369"
      unitRef="usd">27300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE2LTExLTEtMS0w_a3586a43-d0c8-4ede-8f4b-64c7d2162342"
      unitRef="usd">27300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id92d85fcb8af4a4aa266249bc1646bfd_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTEtMS0xLTA_38b4f586-5cfb-4e6d-9162-79ed3db22880"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i582361eac54a42edb73a091279308584_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTUtMS0xLTA_50dbdb84-b3f0-44a1-98ea-9c2c4f3fa897"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE3LTExLTEtMS0w_b5f21dc4-5436-4455-829f-6f7fcfc50676"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesOutstanding
      contextRef="i27cce8f31fe240f8a17ee911b0e4b878_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTEtMS0xLTA_4b4c6922-6185-4e15-b265-639ce15e0dfe"
      unitRef="shares">92300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i27cce8f31fe240f8a17ee911b0e4b878_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTMtMS0xLTA_f66e53a8-844e-4088-bb83-6c34b7fac19c"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dafe132b53e4050b679396ebb6651ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTUtMS0xLTA_44ff9c31-c1e0-49bf-9daf-d4955b358079"
      unitRef="usd">1768100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i892c766e0f01406790fc8dcd6fe62fbe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTctMS0xLTA_df364685-ef42-4187-990d-16d23a3c838a"
      unitRef="usd">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5d52ca7c1114b7eae229221755ea0be_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTktMS0xLTA_3aa7a64b-ca6b-4f93-8a63-b70b943061c5"
      unitRef="usd">-1132700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE4LTExLTEtMS0w_0b6f62e8-ebb7-4a02-bcb9-60a5114c68b7"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibc15f2ad264b40a4b8477d62bdd3190d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE5LTktMS0xLTA_8db6240e-49e2-4c6d-a027-3f2a7735d4c1"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzE5LTExLTEtMS0w_7831f2e3-05a5-490b-b5df-7151c4053fe0"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6f532ba86dde41ecbd34ea42061d72e5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIwLTctMS0xLTA_69a9a90b-39ed-4bd1-8000-29acbe0e677b"
      unitRef="usd">400000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIwLTExLTEtMS0w_56589b8c-3dc9-4605-83c7-5338321ae3ef"
      unitRef="usd">400000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIxLTUtMS0xLTA_eab83edb-ee94-40fe-b5c5-298b0eb16ac8"
      unitRef="usd">100000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIxLTExLTEtMS0w_c1543e34-c662-40e3-8ab6-4758d16f6d77"
      unitRef="usd">100000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIyLTUtMS0xLTQ1MTE_ef9bbe25-d8d1-4733-93f1-be099c08e18c"
      unitRef="usd">47500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIyLTExLTEtMS00NTEx_a2354bc3-0160-4d91-9e5a-c13b57c12c86"
      unitRef="usd">47500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzIzLTEtMS0xLTA_24d03ea8-bfce-4e36-b663-7f49f1b54e70"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTEtMS0xLTA_a97d3ea3-549f-40b4-9c72-f20e773eff85"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTUtMS0xLTA_6363e27b-f17b-4e96-b672-67460de35fa5"
      unitRef="usd">23500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI0LTExLTEtMS0w_840fcfaa-23a3-466a-a714-dbc9d3ece1a8"
      unitRef="usd">23500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i290d82cb0e6f488098389643da6c4f71_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTEtMS0xLTA_7dae2e3c-2270-4255-bc9f-b67c85c59643"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6972c593f49849929a2f6c7717b087de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTUtMS0xLTA_5c8bcee1-74e3-4888-8b24-f21feccfdb8a"
      unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI1LTExLTEtMS0w_231ca7ed-eda4-406a-910a-e8271128783d"
      unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesOutstanding
      contextRef="ic33b6ecbd7b84a9f94efd720de382191_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTEtMS0xLTA_fd894136-c0e4-4af2-9f40-7733ab6f1c46"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic33b6ecbd7b84a9f94efd720de382191_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTMtMS0xLTA_12c44e30-a35a-430e-90e8-493f0c52bfef"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4870f57f40f442cda8ea71a0a17dff09_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTUtMS0xLTA_bb686966-c09e-453a-84ae-285625c2f1d2"
      unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4be7a20d35464718b1b57ce65463f4f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTctMS0xLTA_c43a6544-6b6a-4cce-aa31-ee2a45bda5d3"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7376630f4274498bb13206aa06d9a70c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTktMS0xLTA_1b42b56c-bb45-4ec0-8272-0aa8bae68d7c"
      unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xMzkvZnJhZzo0M2EyMjg2MmVmZjY0NzkzODQyYzY2ZTNiM2E1MWM5MC90YWJsZTpkNDczM2RjZDc2NTA0MTI1Yjc1OGFiNDlkZWJkMTNmNS90YWJsZXJhbmdlOmQ0NzMzZGNkNzY1MDQxMjViNzU4YWI0OWRlYmQxM2Y1XzI2LTExLTEtMS0w_150ca80f-8046-4eb0-9424-f3796e613ccf"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtMS0xLTEtMA_cf82f209-8663-4ab5-8b35-a800f3eff2a4"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtMy0xLTEtMA_cd6a6258-9b6a-4fc6-b6bd-18c424c2a9fe"
      unitRef="usd">37000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMtNS0xLTEtMA_b1a9341f-49cc-4259-b112-be49d9e3f963"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtMS0xLTEtMA_43e14ace-7c5e-409e-8140-c4d01183f8e8"
      unitRef="usd">100000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtMy0xLTEtMA_58e537f8-37df-4077-a712-3c7e7cfe16c9"
      unitRef="usd">75300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzUtNS0xLTEtMA_f290bae8-c107-4bab-8b47-db96df0c98f6"
      unitRef="usd">58100000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtMS0xLTEtMA_4b688748-9a3e-4ec0-9436-11c16a46bfe6"
      unitRef="usd">8600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtMy0xLTEtMA_66c4c38a-1c20-40c9-ae9b-e4f50ab1dcdf"
      unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzYtNS0xLTEtMA_f3d710c9-2d14-46e2-904e-e9f0d3750883"
      unitRef="usd">4000000.0</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctMS0xLTEtMA_4f25e8f5-527d-4f5a-877f-527e0698a6ce"
      unitRef="usd">20000000.0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctMy0xLTEtMA_1e5aa9e9-00ab-4b41-93ce-c6ee05db1feb"
      unitRef="usd">18900000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzctNS0xLTEtMA_d24176ff-e559-47f4-9d0f-c53cd07c5169"
      unitRef="usd">17600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtMS0xLTEtMA_56737841-8558-4c14-a8af-40e9869853ba"
      unitRef="usd">1400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtMy0xLTEtMA_d09cf5f9-6ecb-40f2-80ed-5e6cc8a7d243"
      unitRef="usd">1400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzgtNS0xLTEtMA_9682548b-df6c-4577-be71-866ee043c4e0"
      unitRef="usd">1300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktMS0xLTEtMA_0a10267a-446d-4d07-b408-6a87504e679b"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktMy0xLTEtMA_e181aa1b-c44c-4511-9a3a-0ee2f4bd38dc"
      unitRef="usd">-13000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzktNS0xLTEtMA_d5a78fd9-cfe2-45f5-a19c-49b41d2b45c2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTU4OTc_0a0586b4-872e-41f1-a9a3-2c9197e59881"
      unitRef="usd">-310700000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTU4OTc_5b64de6d-30be-40d6-8ed1-925dd84f6faa"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTU4OTc_67c07b40-bcb7-41f3-bca2-64a64222ca95"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTQ1NzE_8e73f2a1-4d96-4a7e-9ff7-5b19298d8834"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTQ1NzE_6a072f4b-16f3-4826-965a-badf8f249329"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTQ1NzE_25b7ae6f-1b41-4df9-9535-8b69f3ad8946"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTEtMS0xLTA_f391edcf-0467-4176-befa-ccbcf3c52b56"
      unitRef="usd">3700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTMtMS0xLTA_45427ce3-6f79-45aa-a61b-f54d3424315a"
      unitRef="usd">-1200000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEwLTUtMS0xLTA_202f9a22-6fde-4f18-83f2-e9cbeeeb4643"
      unitRef="usd">1000000.0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTEtMS0xLTA_b400feed-2d45-4ffa-bdc9-22830b33b732"
      unitRef="usd">30500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTMtMS0xLTA_22bade06-d536-495f-8f63-4b161e7615db"
      unitRef="usd">69200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEyLTUtMS0xLTA_be33603d-2dd5-46fc-aa50-2ecf11564591"
      unitRef="usd">25100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTEtMS0xLTA_04837c69-1196-4ab7-961f-6f044cf959fe"
      unitRef="usd">10700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTMtMS0xLTA_09faa1d8-135e-4e0e-9110-5a4a956e3380"
      unitRef="usd">6400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzEzLTUtMS0xLTA_680602a7-bf3e-44a9-b327-607b16d9cad2"
      unitRef="usd">3500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTEtMS0xLTA_39d08040-3629-45f0-9c7d-5c6672815c65"
      unitRef="usd">26900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTMtMS0xLTA_ca8db2b6-18cb-4418-844f-ed7aee1b8823"
      unitRef="usd">54000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE0LTUtMS0xLTA_89c76d89-7d5f-4fc2-a310-fedef477b04c"
      unitRef="usd">24200000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTEtMS0xLTA_583211f3-cc57-497a-8fbe-7e8c915b65b3"
      unitRef="usd">23600000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTMtMS0xLTA_f54a4045-e903-43d8-9fe0-93b90e99594c"
      unitRef="usd">-16800000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE1LTUtMS0xLTA_fa6f4f2a-9d0e-438a-9a79-962523c8ae8b"
      unitRef="usd">-2700000</us-gaap:IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTEtMS0xLTA_3fb7b4d1-1cbc-44b1-97b0-358bda130b03"
      unitRef="usd">228500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTMtMS0xLTA_76a33bb2-b04b-4441-93da-015013d600e1"
      unitRef="usd">147000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE2LTUtMS0xLTA_4143d5de-2bc2-463d-ae16-881c34a57af9"
      unitRef="usd">101400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTEtMS0xLTA_3f4775fd-a4c9-427f-81b4-ca284b23a775"
      unitRef="usd">735500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTMtMS0xLTA_75223e5b-c213-4da3-a29f-9c1a7aa987a6"
      unitRef="usd">797200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzE5LTUtMS0xLTA_db439fd3-6ecd-403c-87d7-312f0e1fa6b3"
      unitRef="usd">545900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTEtMS0xLTA_3051d466-2b30-455a-854b-6cb4542b351b"
      unitRef="usd">750500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTMtMS0xLTA_f01460bc-3955-4ac0-aea5-f2767be74c4f"
      unitRef="usd">669700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIwLTUtMS0xLTA_8f33c243-5d3d-44fb-8d83-bae22a95bc96"
      unitRef="usd">327800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTEtMS0xLTA_01933e71-1b4c-4c1b-861b-3b25b5644104"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTMtMS0xLTA_adc7b6cc-86ae-4bb5-9bfa-327d82d916e4"
      unitRef="usd">68900000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIxLTUtMS0xLTA_9dd4ba2d-a67c-47ba-9a7b-48d2252b978d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTEtMS0xLTA_1769fbea-9130-4b23-89f6-98e27b2f988b"
      unitRef="usd">10900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTMtMS0xLTA_ce7fe787-c2cc-449f-a8f5-1127afb3c93c"
      unitRef="usd">14700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIyLTUtMS0xLTA_7630f0be-468d-4c0a-a76f-282c85b3675d"
      unitRef="usd">24800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTEtMS0xLTA_4b4127e4-84d0-4516-880e-8bbb51d3f9a1"
      unitRef="usd">4100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTMtMS0xLTA_d6898b7c-bab8-466a-a51b-e19efee88aed"
      unitRef="usd">-211100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzIzLTUtMS0xLTA_87aefe26-14b2-4325-807f-8629b1bfa085"
      unitRef="usd">-242900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTEtMS0xLTA_b1035828-847c-4978-9585-89f589b3a0ec"
      unitRef="usd">29100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTMtMS0xLTA_fc3ea225-abbb-4a93-be39-ffa5471304bb"
      unitRef="usd">32400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI2LTUtMS0xLTA_00154a9f-e082-46e3-80a1-7cbb07e98eb9"
      unitRef="usd">29500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTEtMS0xLTQ1Njk_469b0b17-a73f-4f7b-86d0-f4faf236ddc8"
      unitRef="usd">186900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTMtMS0xLTQ1Njk_62c38c88-b7b9-43ee-a2a1-6166150d649b"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTUtMS0xLTQ1Njk_5e8c481d-b3c7-421a-bbe6-0800cfae4364"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTEtMS0xLTA_26c07b28-41ec-40e5-8b38-8e6c69d615ea"
      unitRef="usd">-157800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTMtMS0xLTA_c73b53b8-5c00-494f-958e-b82fd028abec"
      unitRef="usd">32400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI3LTUtMS0xLTA_52e9cfe8-4075-41d7-ba34-cf169513f2db"
      unitRef="usd">29500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTEtMS0xLTA_0ef8f030-aa7c-4ca3-a81c-17c523ba4721"
      unitRef="usd">74800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTMtMS0xLTA_8d8382cf-4165-4099-88ae-5af68731e341"
      unitRef="usd">-31700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI4LTUtMS0xLTA_d79eed58-7524-4aef-b0f7-28c23248a12a"
      unitRef="usd">-112000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTEtMS0xLTA_30bf4fb6-07d4-4277-b34d-9ae6bb30b3ec"
      unitRef="usd">115500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTMtMS0xLTA_fcbdd557-b0c3-4c8e-a765-4d2e88705c1b"
      unitRef="usd">147200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzI5LTUtMS0xLTA_56ba99cf-a9d4-4f58-b104-1e4a1c64134f"
      unitRef="usd">259200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTEtMS0xLTA_35571e8f-9fa5-40b0-8c1a-256407ce20ba"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTMtMS0xLTA_4fa8ea55-dfe8-4923-82e3-e483aa42a342"
      unitRef="usd">115500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMwLTUtMS0xLTA_6f332eb7-06cc-483e-ab4f-3b59c3cb81ae"
      unitRef="usd">147200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTEtMS0xLTA_525595d9-278c-42a2-af6f-e9e7923921e1"
      unitRef="usd">1400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTMtMS0xLTA_164e2579-3d57-4750-8ebb-5f4f1ed10244"
      unitRef="usd">1000000.0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzMzLTUtMS0xLTA_d1710974-7636-4f06-96dc-3acd3bdc68e7"
      unitRef="usd">2300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTEtMS0xLTExMzY2_81efe66c-ea9f-4511-8290-3cb4a54a4d00"
      unitRef="usd">12800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTMtMS0xLTExMzY5_27ace454-a0f2-4c7a-9970-d9397f9a07ec"
      unitRef="usd">77100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM3LTUtMS0xLTExMzcy_7b6ef329-2ee8-4775-acdf-e706769bc8e0"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTEtMS0xLTA_03065afb-c0c4-4cb5-a7ec-6feb3ec2748c"
      unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTMtMS0xLTA_5c232575-a7ec-4280-8d23-998329193325"
      unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM0LTUtMS0xLTA_bfb7213e-e168-4cc6-bf64-71ff12836d91"
      unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTEtMS0xLTA_8da51fa6-e848-4207-a008-b4b13301ee31"
      unitRef="usd">15300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTMtMS0xLTA_9012319c-e755-45e6-a5d4-3c76a393905d"
      unitRef="usd">500000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDIvZnJhZzo3MjQwOTg4NTNjMTg0Mjg5YTM5NzgwMjUyZDk4OTc0MS90YWJsZTowODk2ODEwMWJmZDU0ZWU2OWQzNDhlZmFmNjRkMjRmNy90YWJsZXJhbmdlOjA4OTY4MTAxYmZkNTRlZTY5ZDM0OGVmYWY2NGQyNGY3XzM1LTUtMS0xLTA_6469a07c-58c7-4261-b417-d4c93bc5a1c1"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY2_97956fa9-d0e0-47b3-8100-c95d2501d7ed">Organization and Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Activities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#x2019;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(*in collaboration with AbbVie Inc.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Industry Segment and Geographic Information. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single industry segment&#160;&#x2013; the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December&#160;31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels in the fair value hierarchy during 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If&#160;the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December&#160;31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;amp;D expense as incurred. These expenses result from our independent R&amp;amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;amp;D expense as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-13.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#x2019;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2020-06. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.&lt;/span&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <nbix:BusinessDescriptionPolicyPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU5_2274e0ee-5cf6-41be-85b0-213ff88748d0">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Activities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#x2019;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(*in collaboration with AbbVie Inc.)&lt;/span&gt;&lt;/div&gt;</nbix:BusinessDescriptionPolicyPolicyTextBlock>
    <nbix:NumberOfIrishSubsidiaries
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzM4NDgyOTA3MjYwNTc_825f6a35-55e5-48b7-8729-eda10beda790"
      unitRef="subsidiary">2</nbix:NumberOfIrishSubsidiaries>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY3_9baf74cf-d302-4ed3-b4ab-c22b500ca474">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYx_2382372d-ae78-4919-b3ef-ccb8d6e9567d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU0_28d4e437-9d65-45f1-8898-db3152bd38fc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Industry Segment and Geographic Information. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single industry segment&#160;&#x2013; the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIxOTkwMjMzMjU5NDk_bee4ef62-de4a-40e8-8e10-770587d57cbc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.&lt;/span&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU1_c795a2c2-c66f-408a-94c4-4e2d6ad77074">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYw_f6611742-4177-4da5-8957-37980341923d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.&lt;/span&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYy_152558e0-93a1-4b9c-93b2-11b6a188c09e">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzQ4_0bb47b87-702d-4301-9ff6-4efb7bdea639">P90D</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzYz_166bf73e-0d44-4f64-8d72-4366807f0e19">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this &lt;/span&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December&#160;31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts>
    <us-gaap:InterestReceivableCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU1MTE_1ab5b325-9b83-4479-9274-b69a9093497a"
      unitRef="usd">3700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_50e012e6-f5da-48ce-8bec-7d0dc7cfa77e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_55049ed4-e9af-41b2-8f12-03a465458de0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzU5Mjc_ae9877e2-b252-48f1-b74c-963205942e5f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzQ5_160df67b-ea30-4f18-95fe-3a5ba7a74b73">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels in the fair value hierarchy during 2020 or 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUx_08bf5ef3-ae69-4b0a-9f4d-9361118f37a6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.&lt;/span&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY0_f858edf6-1fee-47a6-9646-7b76b7962875">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MjU_a6ca8357-21c8-46a3-bf29-24df42364440">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2NzE_285aea54-5cb2-4d5b-b994-9613b6d091c7"
      unitRef="usd">8600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2ODI_36397d35-92c2-4b71-8275-1b30375e6df2"
      unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk2OTY_a42f7ea3-6ace-4200-b000-9958dbc3e7d9"
      unitRef="usd">4000000.0</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUy_5f20e332-ec51-43e0-8752-2e73a79f27ae">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If&#160;the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4Nzcx_8c8b0cfd-9d3b-4228-8711-e2f915379a7a">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#x2019;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant categories of sales discounts and allowances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Discounts.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management&#x2019;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payor and Pharmacy Rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor and Other Fees.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4Nzcy_67f78d63-570e-4060-b659-d0206b88de4b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial &lt;/span&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December&#160;31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i20120095d85448189e0c6c75de356c1a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTQ_0f67832a-9a2d-4185-a6e5-2a8ac07161a8"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie4318f5084d84959b68665678538a7f5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTQ_6dec9dd7-0ced-4d2e-8b3f-00aeaf6e87ba"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59194d217fcd4be386582a21776d0491_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzE2NDkyNjc1MDI3NTg_880e365f-32f1-41c9-8bfa-1a7334fc3f4d"
      unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY1_72e7dcb0-7ef5-4072-9b66-28f8b47793f3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY4_2112744d-145e-4261-8233-5bc80ee77ccd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;amp;D expense as incurred. These expenses result from our independent R&amp;amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzY5_1809aea1-cf70-472a-8c59-37e95bc3feaa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisitions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;amp;D expense as they are incurred.&lt;/span&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzUz_16c81ade-8ca0-4b5a-bc95-e99b48adb8a0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.&lt;/span&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODA2_db4f2a1a-0fb5-453a-b320-72fce605d98e"
      unitRef="usd">64800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODE3_3ef12255-ba97-490b-9f20-f4d73cce5cee"
      unitRef="usd">40600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIyODMx_e657d933-8ea8-4797-b222-a8b9bdc5e232"
      unitRef="usd">20500000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU2_4827fdeb-e352-45eb-9a5f-c8a488386cb3">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1"&gt;three&lt;/span&gt; to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ic97909a35e354b1eb1404ec11bd95d87_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNjA1_be63ed97-02c0-4795-a075-1e08c7145e64">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i728ae8d7437841b58f476b7ef0e6ca39_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzODg3_ae4869c0-0296-45d0-8b0b-e33bd436cd13">P6M</nbix:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIxOTkwMjMzMTY2Mzk_8c6bd3ac-63bd-4f8a-b8cc-b75af22efbab">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by &lt;/span&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU4_8c430682-13cc-4690-b1d8-45e8b0747c73">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income Per Share.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ide871789006342f69f8274002bb357ed_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI1MzAw_156f7b95-b6ee-4091-9a51-60f934befe1f"
      unitRef="shares">5000000.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI1NDkz_c5009509-b72d-493f-825d-68cbc8718e55"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzI4NzU3_ab20b2a3-a6c2-41d1-a1cf-ca3c0ae763a3">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2016-13.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#x2019;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2019-12.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2020-06. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NTU3NzI_33a4adaf-f890-4ccd-83b4-98519bca1aa1">License and Collaboration Agreements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#x2019;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Takeda $120.0&#160;million upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&amp;amp;D, in the third quarter of 2020&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the agreement, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda may also be entitled to receive additional payments of up to $1.9&#160;billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the exercise of the option, we paid Idorsia $45.0&#160;million upfront, which we expensed as IPR&amp;amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2&#160;million in funding, which we recorded as a prepaid asset and is being expensed over the two-year research collaboration term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $365.0&#160;million with respect to NBI-827104 and $620.0&#160;million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $750.0&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#x2019;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Xenon $30.0&#160;million upfront and purchased $20.0&#160;million of Xenon&#x2019;s common stock at $14.196 per share, representing approximately 1.4&#160;million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $1.7&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $14.1&#160;million after considering Xenon&#x2019;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $36.2&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&amp;amp;D in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#x2019;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson&#x2019;s disease, the Friedreich&#x2019;s ataxia program and the rights to two undisclosed programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Voyager $115.0&#160;million upfront and purchased $50.0&#160;million of Voyager&#x2019;s common stock at $11.9625 per share, representing approximately 4.2&#160;million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $1.7&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies of such program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $54.7&#160;million after considering Voyager&#x2019;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $113.1&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&amp;amp;D, in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $5.0&#160;million upfront to obtain rights outside the U.S. to the Friedreich&#x2019;s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager&#x2019;s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&amp;amp;D in the second quarter of 2019.&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We acquired the U.S. and Canada rights to ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson&#x2019;s disease resulted in a $20.0&#160;million event-based payment to BIAL, which we expensed as R&amp;amp;D in the second quarter of 2020. We further recognized R&amp;amp;D expense of $10.0&#160;million in each 2019 and 2018 in connection with BIAL&#x2019;s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $75.0&#160;million upon the achievement of certain event-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#x2019;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception of the agreement, we have recognized revenue of $19.8&#160;million associated with the delivery of a technology license and existing know-how and $15.0&#160;million associated with the achievement of a certain event-based milestone. We further recognized revenue of $2.7&#160;million in 2020 and $0.9&#160;million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#x2019;s disease patients with chorea. In accordance with our continuing performance obligations, $6.7&#160;million of the $30.0&#160;million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $70.0&#160;million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women&#x2019;s and men&#x2019;s health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $19.2&#160;million in 2020, $14.3&#160;million in 2019 and $1.6&#160;million in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0&#160;million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $20.0&#160;million in connection with the FDA&#x2019;s acceptance of AbbVie&#x2019;s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $40.0&#160;million in connection with the FDA&#x2019;s approval for ORILISSA for endometriosis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception of the agreement, we have recognized revenue of $75.0&#160;million associated with the delivery of a technology license and existing know-how and $165.0&#160;million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0&#160;million upon the achievement of certain event-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NTU3NzE_2f3d96c2-aa41-4235-afe5-85a0f0cff000">Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $8.5 billion and pay royalties on future sales, if any, of commercial products resulting from these agreements.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nbix:PotentialMilestonePayments
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjMxMzg_62b87349-9048-4c6d-9c7c-ff53e2f5e4f2"
      unitRef="usd">8500000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i257e90a486974747899becd428e20bbc_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU0OTc_58c9da8d-7162-4fbf-bb02-1bbf4a314ddb"
      unitRef="usd">120000000.0</nbix:UpfrontPaymentsMade>
    <nbix:PotentialMilestonePayments
      contextRef="ia97b8d53a265445fa5504b3150879227_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1MjY_23f3056b-4d23-4fca-a219-74f2a00b74d9"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i0eba589932364662a4c8ccf58b4e239a_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1NTQ_3d8be251-437d-47fd-855d-57b5e5e125b4"
      unitRef="usd">45000000.0</nbix:UpfrontPaymentsMade>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i0eba589932364662a4c8ccf58b4e239a_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU1ODI_f0ffb411-4193-41d4-bef8-9e665de849c1"
      unitRef="usd">7200000</us-gaap:PrepaidExpenseAndOtherAssets>
    <nbix:ResearchCollaborationTerm
      contextRef="i25235904363543e6876b158eafdeffc9_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzIxOTkwMjMzMjE5NzY_753a79c0-8a16-4d31-93cf-64f483e6dbee">P2Y</nbix:ResearchCollaborationTerm>
    <nbix:PotentialMilestonePayments
      contextRef="i6545254203aa4df0a400884ff9991e40_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2MTY_8c20f78a-5014-46a7-93e0-ea53b2cf14b0"
      unitRef="usd">365000000.0</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i219730df66154f82827f5448bfe38e9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2NDc_e02ec671-9ff6-43d5-a90b-a7e8ba7e94cd"
      unitRef="usd">620000000.0</nbix:PotentialMilestonePayments>
    <nbix:PotentialCommercialMilestonePayments
      contextRef="id14cd484bece46d3a4291e95561a7587_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU2Nzg_47bc35be-2564-467c-baad-99f032fa4934"
      unitRef="usd">750000000.0</nbix:PotentialCommercialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i3bbda008026b473097f608802a52aaf9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTcyODc_a9fef469-19ac-44e0-a6e1-c43f22815f1c"
      unitRef="usd">30000000.0</nbix:UpfrontPaymentsMade>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i3bbda008026b473097f608802a52aaf9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMDI_4f8a47e8-bc8c-4f16-ae46-7b32d0fa5fea"
      unitRef="usd">20000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:SharePrice
      contextRef="i3bbda008026b473097f608802a52aaf9_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNDQ_7d3b0a97-d6dd-4f08-a705-eaea6eea0366"
      unitRef="usdPerShare">14.196</us-gaap:SharePrice>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i42d131b3f0874d9b980c9f62f4f8df61_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMTc_a4e2872f-522a-45eb-8d15-c29b5311a119"
      unitRef="shares">1400000</us-gaap:InvestmentOwnedBalanceShares>
    <nbix:PotentialMilestonePayments
      contextRef="i2a872472e6c44cd7a82a479cbe5b4431_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczMzA_1e43b4f6-be02-4df5-ae2a-b5e6830dbcdf"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i3bbda008026b473097f608802a52aaf9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNjg_7136c81d-3956-46e8-abea-5be1c4b9a9f7"
      unitRef="usd">14100000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTczNTM_8397f46e-0235-4cde-adc7-6274f7a68a7c"
      unitRef="usd">36200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:UpfrontPaymentsMade
      contextRef="i88977083558b4753b92390c316833a48_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Mzc_84923bd1-e6cc-4403-8954-e3cd843789fb"
      unitRef="usd">115000000.0</nbix:UpfrontPaymentsMade>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i88977083558b4753b92390c316833a48_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4NTM_bc2e9de6-c5c2-4cfc-b6fa-ac8e64a522f7"
      unitRef="usd">50000000.0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:SharePrice
      contextRef="i88977083558b4753b92390c316833a48_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Njg_900928be-1dcf-4f75-ae16-d51d375e15b4"
      unitRef="usdPerShare">11.9625</us-gaap:SharePrice>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i81ad4fc332a9473c95e11ea8f94d1479_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4Nzg_6e3673f9-f3bd-4109-8cfd-aae7f08336d5"
      unitRef="shares">4200000</us-gaap:InvestmentOwnedBalanceShares>
    <nbix:PotentialMilestonePayments
      contextRef="i50203e6e9ee241d8a1943a131e844922_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE4OTE_93d385a2-7f3f-4769-a0a1-c8f6f8963a65"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i88977083558b4753b92390c316833a48_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MDU_c88fc7fd-597b-4df6-b0b7-782bb4b3d6fb"
      unitRef="usd">54700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MjA_ca3f5a35-2c46-45c7-ae22-694721cd3f66"
      unitRef="usd">113100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1MDE5MzY_ce797761-ec52-4bf7-9c8a-f39a89e4370a"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3NDE4ODI_1b21bad8-24d3-4d5c-b041-9fb6ff28f6fa">On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#x2019;s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#x2019;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.</us-gaap:SubsequentEventsTextBlock>
    <nbix:MilestonePayment
      contextRef="ib352054c7bad403c94fe2bccf88d5af3_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU3NTU_965554db-0e08-48d8-8710-48e436ce39fb"
      unitRef="usd">20000000.0</nbix:MilestonePayment>
    <nbix:MilestonePayment
      contextRef="ibbecc51b3aae463ca7e62f0c5c3d2253_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MDg4OTY_7c521c1c-967d-41dd-80fc-6f4eb6564c5c"
      unitRef="usd">10000000.0</nbix:MilestonePayment>
    <nbix:MilestonePayment
      contextRef="ie20f0364533a47b6992606e2b86457b0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MDg4OTY_bd5e2f3c-8ca6-40de-9ba6-7abd47d3560e"
      unitRef="usd">10000000.0</nbix:MilestonePayment>
    <nbix:PotentialMilestonePayments
      contextRef="ieedd883af091454ab63052c4d4fec48a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTU3ODQ_e27feb85-9546-4932-b564-e33369c74899"
      unitRef="usd">75000000.0</nbix:PotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf156fd88444c6791467b25bc69b11e_D20150301-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3MTU2_364cc9d7-d407-4bfb-a7ec-2a511de8b55a"
      unitRef="usd">19800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib15e32a0a32b49538add4aef55c528e4_D20170701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3MjM2_ec873e61-98a2-4b0c-bf13-92dbdd060da3"
      unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8d2360393b7d4d879ba50fd30091a78b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ5MTU5_bbef1a0d-ea66-47bd-9c2b-deb7dc9b6c66"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia63b4e7a9e71401dacbac7489e2a7e2a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ5MTY3_513c5dd5-944e-4104-aa09-8c6725841a30"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i240d0d89861f4e0da2e8453b512420bc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjcyNzE_930d2fed-473d-4f14-ac1a-3cec2471f654"
      unitRef="usd">6700000</us-gaap:ContractWithCustomerLiability>
    <nbix:UpfrontPaymentsReceived
      contextRef="i5e4787a5e20042c296dec4c2db37c273_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE3MjcyODI_d3c76a22-c66b-4cc9-a136-8f4e4f6a2e4c"
      unitRef="usd">30000000.0</nbix:UpfrontPaymentsReceived>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i240d0d89861f4e0da2e8453b512420bc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2MzQ3NDg1_9bec9e11-85a5-4acb-93be-d4bd132f1abb"
      unitRef="usd">70000000.0</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="ib60f3795c3904b598b633d9146da597a_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc1NDI2Mzg_3de9af2d-7e13-417c-ab18-068ceb7837ea">P10Y</nbix:PatentTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc73fd418b1a4436b3cfc5a71dbfbee0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3MjA_07caea5e-4129-4d3e-8768-926379adc330"
      unitRef="usd">19200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id85b50b61a514151b47324285918ddb5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3MzQ_012d3675-56e2-4e48-99b3-07395e581879"
      unitRef="usd">14300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac0ef1a100194cad8dd122747923492d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzEwOTk1MTE2OTM3NTE_9e88412c-22d5-4498-916e-9bed0599cd6d"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3004961ef404e91bf6918eb4f99d34d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyMDg_afb48528-1c83-496c-8bff-a361dd7c2629"
      unitRef="usd">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cbe52017cfa402a8a7a3857aaac0220_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzI3NDg3NzkxODQzNTI_ff35da7e-7e50-48cb-aed0-0abd394575e3"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f8e4dda08ce4ee7afe7a741837ed4d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzI3NDg3NzkxODQzNjc_52330be0-8827-4d4d-961d-8ad945ac3b96"
      unitRef="usd">40000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f1aded41cc7466989f52504c10da860_D20100601-20100630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyMzc_8dfe134d-ccb4-4b1d-8d55-17993b6ae5dd"
      unitRef="usd">75000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b38c628e5624d3489f366d90fb7a1a7_D20100701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyNjc_d8ff3f90-f077-4e00-8006-1a3d95bd3392"
      unitRef="usd">165000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i0bcef2297f1d4d3fbdc7d17250594d47_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYyOTg_290f6801-bdcf-47a9-bf63-512422948e99"
      unitRef="usd">366000000.0</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="ie48c720d2df545228f70c2015456a974_D20100601-20100630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTEvZnJhZzo2MGU3ZDBiM2VjMzE0Yjk0OTQ4NzBiYmRlZDEyM2ZhYy90ZXh0cmVnaW9uOjYwZTdkMGIzZWMzMTRiOTQ5NDg3MGJiZGVkMTIzZmFjXzE2NDkyNjc0OTYzMjg_405d48d6-8e9e-4329-be18-bd844447c0d8">P10Y</nbix:PatentTerm>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzE2MTE_bc4e0492-9b2a-4885-a885-15c54b9a60d0">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December&#160;31, 2020, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December&#160;31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, our security portfolio consisted of 148 securities related to investments in debt securities available-for-sale, of which 30 securities were in an unrealized loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in corporate debt securities in an unrealized loss position at December&#160;31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzM4NDgyOTA2OTg4NDQ_eaf27391-849d-4fb4-92d9-41b8ea2aeafc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December&#160;31, 2020, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtMy0xLTEtMA_708e5d99-0769-475b-9738-f622a5e904a5"
      unitRef="usd">82200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtNS0xLTEtMA_cc9a40b9-09ba-4e98-aa63-a5039b888089"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtNy0xLTEtMA_9bd49237-9fbf-4de5-b4f0-bc4fd262bf13"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtOS0xLTEtMA_e69ee772-1bab-4691-be87-83b3db67b487"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9725185c63fb43198fdcd110bf77992c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzEtMTEtMS0xLTA_927ebee3-b1bb-4e1d-841c-5da5f5c74042"
      unitRef="usd">82200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItMy0xLTEtMA_0529fc23-aeb6-4497-a018-259afd2733d3"
      unitRef="usd">299300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItNS0xLTEtMA_f1ca5e91-1e10-4e05-89e5-4502fdd77367"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItNy0xLTEtMA_c2cc2f08-afa9-4c0f-be50-d075bd0d8eaa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItOS0xLTEtMA_4a377d00-1ff1-40e3-86af-d729c076c9b7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1cb602311ab414c9e533241bb5a447f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzItMTEtMS0xLTA_ea4b3f9b-b5f3-4d65-9852-4dfc7cf84f18"
      unitRef="usd">300700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtMy0xLTEtMA_38c44620-e872-42bd-a1a4-20381c1906e8"
      unitRef="usd">230900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtNS0xLTEtMA_dce147dd-5724-4351-970c-dcb879620116"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtNy0xLTEtMA_f7e1435b-9155-45bd-9ce2-391b57dd24f6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtOS0xLTEtMA_9060e98a-e33d-450f-88e2-1ffce9fcf30e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ab9f3b1c92d4b10a269fdd50ad57166_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzMtMTEtMS0xLTA_051ad149-68c1-4587-a37d-3442387cad43"
      unitRef="usd">231000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtMy0xLTEtMA_816ea726-1eab-4b55-85fe-05ee4b2b0628"
      unitRef="usd">612400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtNS0xLTEtMA_3eef2987-9171-4d79-b760-5576ddef66bc"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtNy0xLTEtMA_3bde62e6-5b96-452b-84b8-40847f74f26f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtOS0xLTEtMA_4e7020a1-d231-4410-ba7c-1ec7b708d587"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idce3e91b366c406685df930cadf32f38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzQtMTEtMS0xLTA_561a4e40-0721-46fb-90f2-7b74d123971d"
      unitRef="usd">613900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id67360380b454fd497a4b58684fbdc84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtMy0xLTEtMA_a650b408-f13a-46b8-8745-d6342abd6971"
      unitRef="usd">144800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id67360380b454fd497a4b58684fbdc84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtNS0xLTEtMA_61abf499-a5fb-4813-bdc9-36b2c6b838ad"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id67360380b454fd497a4b58684fbdc84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtNy0xLTEtMA_157cdd1c-0d07-4dfb-80fd-fbe83f586624"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id67360380b454fd497a4b58684fbdc84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtOS0xLTEtMA_6e327629-bd77-474c-9741-86e1578de7aa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id67360380b454fd497a4b58684fbdc84_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzYtMTEtMS0xLTA_86b82ca0-1c4a-49f8-b0e2-31eb5fa052d1"
      unitRef="usd">145200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctMy0xLTEtMA_0e35d8b0-c7d4-4bc4-845d-abe75cf9c167"
      unitRef="usd">81900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctNS0xLTEtMA_8fbddf82-58dc-466a-b3bc-8167938ff66a"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctNy0xLTEtMA_f870e37d-e186-4aac-b66a-7d99aeba626d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctOS0xLTEtMA_3ac783fb-2f93-4608-a77a-dd7d3a542f38"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffb43fca85ef4bf297f418eaedc3d9d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzctMTEtMS0xLTA_18d7f696-67de-46fa-9aae-18f2666ab99d"
      unitRef="usd">81900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtMy0xLTEtMA_58e33223-f08c-4fca-be5a-c52afec3c467"
      unitRef="usd">226700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtNS0xLTEtMA_0fc42dda-afd1-4a35-8460-e88e13dfe99d"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtNy0xLTEtMA_b0a5ba9b-14e8-4cc9-a824-3c4044753fb8"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtOS0xLTEtMA_b0ddfb61-29e7-4660-92a6-3f96ae86d6ba"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc94b76d27134137be897aa51352595d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo3YTNiNDI4OTc1YjY0ODRiYjRkYjdlNTcyNWRjMDY1ZS90YWJsZXJhbmdlOjdhM2I0Mjg5NzViNjQ4NGJiNGRiN2U1NzI1ZGMwNjVlXzgtMTEtMS0xLTA_4848dcd5-c8ef-4651-88ae-dbb241da3df1"
      unitRef="usd">227100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtMy0xLTEtMA_ce2db987-8360-4f2c-b1df-d3c7def1609b"
      unitRef="usd">144500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtNS0xLTEtMA_d3ba9bbc-a8a1-46e1-9276-ba79f9ec480e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtNy0xLTEtMA_93d635f5-2f86-429e-bd25-91409c92bc33"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f28a934c47a48cead9ae9993ebfd81b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzEtOS0xLTEtMA_be9a4501-80ca-42f7-90b0-3e3654945132"
      unitRef="usd">144500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItMy0xLTEtMA_9b718ab9-b69f-44f4-845f-b009fd415bcf"
      unitRef="usd">270500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItNS0xLTEtMA_9a188fe0-0d71-4571-9338-6257bc935930"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItNy0xLTEtMA_471ff010-a4b5-4667-b95c-e90ca63fca1b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idac17430272d48979e4f4dd6e73b14bd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzItOS0xLTEtMA_5115d82b-9251-4a07-b780-6e0591398bf5"
      unitRef="usd">271000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtMy0xLTEtMA_1a57657d-4352-4f0e-a8c2-fd5eafccc8a4"
      unitRef="usd">142300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtNS0xLTEtMA_83414efe-8068-4dc4-88bb-4e59e7abe3dc"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtNy0xLTEtMA_2adfdf5f-2ef0-4f4d-b95a-c31ff7b05b62"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3fb8a636ad64e1ab7ea01c767a225cc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzMtOS0xLTEtMA_dcf78682-4366-45ae-a2d3-f76c1ea7765f"
      unitRef="usd">142700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtMy0xLTEtMA_a798131f-999c-45d7-950e-a25a9226e3b4"
      unitRef="usd">557300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtNS0xLTEtMA_51d2001c-cb1c-4141-88a4-ec4dafd9dbf1"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtNy0xLTEtMA_328ae486-11ba-4568-8a5e-b6e9715b7de0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic171b18673194daf9f8214c17b03fc19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzQtOS0xLTEtMA_6844c75e-f88c-493c-80bb-c6688b3d45b8"
      unitRef="usd">558200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtMy0xLTEtMA_e9237793-1e86-4247-bf50-b34d3a26791d"
      unitRef="usd">250500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtNS0xLTEtMA_4866123d-6e11-49f6-af99-075dbbf49662"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtNy0xLTEtMA_95334d0d-42cc-4cc3-9b9c-97cf4e1782cb"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22ca2abb9a7a42359562e7a6c260be20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzYtOS0xLTEtMA_fcc9ce37-3437-4f03-9c23-c2595b4ece02"
      unitRef="usd">250900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i370dab92abd446d99199617601b5e1ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctMy0xLTEtMA_2e941439-ba68-4666-a1f9-1b98ba030b1f"
      unitRef="usd">48800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i370dab92abd446d99199617601b5e1ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctNS0xLTEtMA_d869bb9b-633a-4707-9580-1a039aa8996d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i370dab92abd446d99199617601b5e1ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctNy0xLTEtMA_1916e74e-e1fa-4093-88b0-938d9107e6f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i370dab92abd446d99199617601b5e1ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzctOS0xLTEtMA_3aca9d48-93af-492d-b9d2-a03b67bfcf8e"
      unitRef="usd">48800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2d47500148149558693bfbec9f730ae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtMy0xLTEtMA_09c97882-8b5d-4acf-9e88-b10fe79dc848"
      unitRef="usd">299300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2d47500148149558693bfbec9f730ae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtNS0xLTEtMA_69cb1bf9-9a8f-41b4-b3e1-4e838c3131e4"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2d47500148149558693bfbec9f730ae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtNy0xLTEtMA_723a9e45-6ff1-4942-8927-46f1f516aefe"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2d47500148149558693bfbec9f730ae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo4ZTdmMzlhNDUyNjU0NWE5YTg1NDM2MDY4MzI5ZGUzMy90YWJsZXJhbmdlOjhlN2YzOWE0NTI2NTQ1YTlhODU0MzYwNjgzMjlkZTMzXzgtOS0xLTEtMA_872aa6a3-70f5-4827-a357-e738443d7dc4"
      unitRef="usd">299700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3XzM4NDgyOTA2OTg4NDU_68ec367c-7670-4905-8a56-1a14fe19b277">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December&#160;31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMS0xLTEtMA_44673f64-378e-4f91-a292-87ee4908fafc"
      unitRef="usd">95000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMy0xLTEtMA_20d283b9-42f6-47bd-92c0-9dc5cbdac57d"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtNS0xLTEtMA_da172cd1-1eb1-46fc-b4a9-c6a4a7b7de8e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtNy0xLTEtMA_45866a62-7b94-4d4f-b56c-ce73e28b44f5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtOS0xLTEtMA_72b7851c-a266-4391-9bad-25c58aba8f55"
      unitRef="usd">95000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i37972e19ce3448d8addd2bec549432ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo5MmVjYjdmYWI5ZGU0ZWZiYjBhYWI5ZjEzYjE0MDBhNi90YWJsZXJhbmdlOjkyZWNiN2ZhYjlkZTRlZmJiMGFhYjlmMTNiMTQwMGE2XzMtMTEtMS0xLTA_99b24bec-13fa-4458-9587-a6a6058b12f6"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3Xzg3NA_abbab9cb-6a49-408e-88b7-5b7b6595d8f5"
      unitRef="security">148</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90ZXh0cmVnaW9uOmQzNzUxM2ExZjgyMzRjZmRiNWUyMjkwOWU0NGEyODQ3Xzk1OQ_8d422202-2e9f-464c-a51e-251415b5886a"
      unitRef="security">30</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMS0xLTEtMA_bbfc32ab-ac9f-4f9b-9e60-8f32c2cf87a3"
      unitRef="usd">186100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMy0xLTEtMA_08541d43-2faf-4a39-a403-d2b62afc5bb5"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItNS0xLTEtMA_81b7bd47-f4e7-4a9a-ad08-8d79e23a7e7f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItNy0xLTEtMA_5c81436f-ab50-487f-9816-c1a0ac2ad2e1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItOS0xLTEtMA_deecfd25-04fe-434c-8bdf-ae3317588a60"
      unitRef="usd">186100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i268709911d264865a1eb304bcc13bad5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTQvZnJhZzpkMzc1MTNhMWY4MjM0Y2ZkYjVlMjI5MDllNDRhMjg0Ny90YWJsZTo1ZDcxYjcxM2Y3M2M0MDdmODZlN2FjNDA2YTdjMDUwNi90YWJsZXJhbmdlOjVkNzFiNzEzZjczYzQwN2Y4NmU3YWM0MDZhN2MwNTA2XzItMTEtMS0xLTA_e34dd202-f216-4902-999b-1bb9f97e2059"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzkyNA_8600e1e2-814e-44f7-9732-1d8609ef0424">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2020, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,029.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 15.0% to 34.0% (weighted average of 24.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzM4NDgyOTA2OTgxNDQ_08ef10f1-4242-43c2-b2c9-fc0cfd162f00">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2020, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;445.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;841.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,029.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="i11d9c5acf8fc4d5c8413f75febd4b55b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtMS0xLTEtMA_58dc73f3-675b-4437-b2ba-1d645ccc4b0d"
      unitRef="usd">187100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i145664990f9240a9903f63786ecc19a7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtMy0xLTEtMA_4c8dbd03-c95c-45bf-b199-5ec2d5ba2a27"
      unitRef="usd">187100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac0984f70ef6410e966e87e2240cf547_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtNS0xLTEtMA_7beee25b-6b9b-4fe0-adce-5a586de312bf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1746b27d72a42a09e8f4c180db8ba1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzMtNy0xLTEtMA_8a3ab007-d502-46c8-a28e-a1ca30f84eb2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i25e6fd039d624ebda3866e81a58d407f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtMS0xLTEtMA_aaeddc34-5098-4bd0-b395-58b914224aa8"
      unitRef="usd">187100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64146f545c644c5b8abab68d5fbcc802_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtMy0xLTEtMA_e97ffd66-a680-4fb7-81f2-089456d1bcf9"
      unitRef="usd">187100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f22921e8cd3411fb15048449bf9ca63_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtNS0xLTEtMA_4439bd2e-b94b-4fe7-9f8c-74bde9975956"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d5471a1995347728c20899dc1dc1145_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzQtNy0xLTEtMA_e7a62fc1-4d72-4b92-be6b-0af3c6742b23"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id64ee97397f44bb5b2b4a59df28591f9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtMS0xLTEtMA_1b626b13-18ef-4aab-9377-23717a05a438"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie95f976d494c4656844d9c9bc46fb639_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtMy0xLTEtMA_7b737c50-c0b7-4f1d-b61c-226357f6611b"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica9fc3c50a75463e948ac570c94115d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtNS0xLTEtMA_9ecda6dd-2873-42f9-a7a2-bffb438d2263"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7b76b7e0dc64aecb1ffcbcca5554a3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzYtNy0xLTEtMA_7553539b-8f76-4377-af6d-2d95478aca41"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i5b841b3697ee4d779975c918a2c7c8a2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctMS0xLTEtMA_68d83821-0ed7-44d2-ab64-c4014a10e94d"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i51010a40dd914cfdb8196a4a02176e64_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctMy0xLTEtMA_a9b3c2ef-4b42-44e6-b300-08de3ce0a28e"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3f914a7af504e9a8c1e308372dd4e59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctNS0xLTEtMA_2e150024-fa84-4506-9390-be46a49b7589"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idbcd3bf7584b40e6b743d5e037097802_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzctNy0xLTEtMA_52208d2d-58c4-49ea-b7bc-00f0b5b7f35f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ibcb535936a4640ccb740f99e14c3566a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktMS0xLTEtMA_902396ae-f289-44f9-b335-37ecc8693610"
      unitRef="usd">82200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id858ede7f298497092b20558ba3f94aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktMy0xLTEtMA_e97ff7b9-7b51-4949-ab8d-6cb7c0248904"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icaa4a6439abb45a0bbe5a547556b6c0c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktNS0xLTEtMA_bb79aea5-16cf-4b6f-ab3b-e0ff28030a3e"
      unitRef="usd">82200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8fd8a4041c334ec5b874010f6d65ecb9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzktNy0xLTEtMA_74da6437-8c7d-4a83-82f6-9b27c5221da0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="if137413b5ed641218199d2f07b0be9d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTEtMS0xLTA_7d3efc4e-cc7e-4a7e-90ae-a5b9d7abc959"
      unitRef="usd">445900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icbabb6a8263c48d08803b3cdf08455fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTMtMS0xLTA_c9eaf390-c5b3-4836-b999-3e3a3d510e66"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i97b7dd5052a1419d9b5eca1001915ffc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTUtMS0xLTA_28036e33-9d83-4b6b-aaa9-5e3d00b1d77d"
      unitRef="usd">445900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i05d8e3f0ed354c24ab54716af189bb5b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEwLTctMS0xLTA_cf3ed8db-4511-464f-8ed1-fb01de3462dd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i76c602f03adc4410bf05dba9e4ccab5b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTEtMS0xLTA_ff9abeab-12cc-4889-abe9-14259784df2b"
      unitRef="usd">312900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i586a6d13c402494cb6770d478521529f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTMtMS0xLTA_ef074bf9-829a-4525-bcd0-31fedf689b74"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i512ab3e7ad974af9ac04248f25184c1d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTUtMS0xLTA_68470e8d-e8bb-4647-a256-593d12a9024b"
      unitRef="usd">312900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if231ddf6746a46a4aea8216c8a79d9ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzExLTctMS0xLTA_720ae128-b378-430b-943b-824bf425dd3e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i595f5dfa2dd643d79953bbb4a3402602_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTEtMS0xLTA_de792dd4-9094-476f-bfc7-cce737beadc2"
      unitRef="usd">841000000.0</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic4097b8463354e23a855ad993b3e185e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTMtMS0xLTA_26d63f81-51f4-4a48-b43f-205aff3e4d37"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc5b4944e27842f1ac75b788b5072eb5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTUtMS0xLTA_09748743-ce1d-4ffd-8c1e-22eb944a062a"
      unitRef="usd">841000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i84af1872e05c4870864980dc019daa4a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzEyLTctMS0xLTA_14bacc32-1070-4cb1-841f-bd345271d37a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i8026f07e7861492f8e98644add623101_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTEtMS0xLTA_3541feff-0f89-438d-af07-c3d2a0a1d53c"
      unitRef="usd">38200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic655a96eac1d40e58299205ab8797a96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTMtMS0xLTA_c6caf6d2-a894-4087-bdfc-36110801f377"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3e1d84b48f1403d90c17750f958db4e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTUtMS0xLTA_eff5021e-0b1d-40b6-bfd3-5297c7a567cd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e03e5b9e1ad419bbb0aefdda65dd330_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE0LTctMS0xLTA_58da4eac-2ac9-492b-b52e-f251923ab141"
      unitRef="usd">38200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ibdb969448f744b4699e0fe3b2054bc9e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTEtMS0xLTA_8e4820b9-377b-482c-9c33-051a5c02d0e9"
      unitRef="usd">38200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e685b74d3a440ae9b69cf3a21f6e94b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTMtMS0xLTA_4656b074-adcc-4752-8e08-c12cedd25b8b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia200b6eb75094ebba0fdffab64b4098a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTUtMS0xLTA_8e0b7687-2578-403a-bc32-6e46053bec59"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8253ad6971bf419497de5085c582cf91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE1LTctMS0xLTA_a054d3f9-7512-4a4d-935c-0fbba0afc4aa"
      unitRef="usd">38200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="iad7d8c26c43040ac8423eb140604d3d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTEtMS0xLTA_d0639cfb-5d52-4119-b817-0f3196588bed"
      unitRef="usd">1069500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e092d8925da40a99bc1aefd6f132f68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTMtMS0xLTA_af3d8800-487a-485d-a3f5-3e906317e731"
      unitRef="usd">190300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if14e6ee1921748129105cf214378dd1d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTUtMS0xLTA_f4ac522b-db70-48f9-9808-6a6344707b2d"
      unitRef="usd">841000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i695b22218e09442dbb693682b472e4b5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTphY2ViYmVhZmQxZGU0NDNlYTg3NjhjM2MzYzQ0MDAxMy90YWJsZXJhbmdlOmFjZWJiZWFmZDFkZTQ0M2VhODc2OGMzYzNjNDQwMDEzXzE2LTctMS0xLTA_e6772c29-8435-4322-a41b-f6d52d39eab8"
      unitRef="usd">38200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="icaf5e27ca5cc4d77bd90dd61ac8a47e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtMS0xLTEtMA_7a035dda-6cbf-4789-83e7-85919c38a4d9"
      unitRef="usd">112300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67ac9be8342447318a432723c6b78797_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtMy0xLTEtMA_d4de67b7-e3d2-4e99-aa57-41cc9d80e0cb"
      unitRef="usd">112300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88fb3b785aa449358571ef423f2219c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtNS0xLTEtMA_5baefb29-c312-439e-9f53-6c904a1f8053"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib65158ac540b41cd91166a0e53ba58cf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzMtNy0xLTEtMA_112bb4ff-d9c1-4057-a251-3870801fa93e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i1ac4ccb925d645399a328c6018222c6f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtMS0xLTEtMA_5292d8d3-7584-4610-99ee-49635e064d8c"
      unitRef="usd">112300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i268c052b4cd04cce8ecbc0e2996aa476_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtMy0xLTEtMA_978e080f-313f-45ed-8775-820fd5be0376"
      unitRef="usd">112300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i73a6b5151cf4490f9a51234227581adc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtNS0xLTEtMA_db81c38f-481f-4a1b-abbb-f1f28969f2c8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i408a528ab8eb45e9877acf825e1bf345_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzQtNy0xLTEtMA_290083d1-cdf5-4d66-a8b7-82415768f76b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia0856066d5f14514abbb08941b50a267_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtMS0xLTEtMA_0ef0480e-1643-477b-8d0d-885f15d6ac51"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20d887e6eb804e2ba40e5f883f36d75c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtMy0xLTEtMA_a04c399b-23fa-455b-b70a-6903a0448cf1"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c033102d7b6458faa551c243d0e7289_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtNS0xLTEtMA_dc333783-44a4-4b65-bcda-79a5ee3b19f7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcd0cc61423040c2915457ec8d6e5d02_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzYtNy0xLTEtMA_49927dc4-b3f0-4bee-8757-367fb4bb6cdc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="icd111c56381a4d8f9292b85ac7e19496_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctMS0xLTEtMA_3a8297d0-de9f-4207-82bb-5b8bb8324fd3"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i74f436445a324740ab5c8efd7b56e438_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctMy0xLTEtMA_cf09a73e-9e3b-4786-8157-d600419eee80"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c4b1d571718416faec2b0ce71d8aab5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctNS0xLTEtMA_b095a3db-895b-4c49-a32b-063513dcf062"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5986576aabe849f49f87cd5cdae9d04d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzctNy0xLTEtMA_0777c510-53d4-4d47-a7a8-e4a39ce3277c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i16a5389b2dd24efab23db9d2c4a3b7b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktMS0xLTEtMA_7278da56-29fb-4ce3-a2f6-f5242aade826"
      unitRef="usd">144500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0517d273790643c98a976440f62fd851_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktMy0xLTEtMA_df55ba80-28d8-474c-a731-895d5efd7770"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67d343eecc4941ff98e247350e2ab153_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktNS0xLTEtMA_18d9d4a4-bbce-4872-b033-e6e337a142de"
      unitRef="usd">144500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0ff8100d45dd4625af5245d8a8c006fa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzktNy0xLTEtMA_bd923120-a153-4715-9295-18652da54d70"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ifc657f8675ea40f5bf7d4393012f3446_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTEtMS0xLTA_55d1809e-ab17-4a48-8bb0-ad7ff2324f41"
      unitRef="usd">521900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a1423af80c04b629c1cf1dad548b611_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTMtMS0xLTA_2d965ba3-0db2-4f2f-ab63-8e6f6d2b0125"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica8a7b9a9e1c4e19906b367cff71df1d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTUtMS0xLTA_d2cd1099-cb3b-45e1-8188-b2a35f80769e"
      unitRef="usd">521900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7509d8ee40ad447cb623f9963e19a98e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEwLTctMS0xLTA_a2d03bda-5785-4291-9c94-a219d9e05553"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ide958d8a47be4cea92940a48e4246ae2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTEtMS0xLTA_3e491c9d-3aad-4528-8589-8a215af3dec6"
      unitRef="usd">191500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i646522578c0b4f8fbe22f01e7929bead_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTMtMS0xLTA_780d7ed7-de10-4da5-a462-95547a468eb1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12f95bc7850c4e96acea39610b13ee2c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTUtMS0xLTA_cab9e1f1-f554-4c9a-a4d8-774a77a856cb"
      unitRef="usd">191500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd64f71c0cc942f2b913d01db69e0a56_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzExLTctMS0xLTA_a5448284-420f-4dbb-bd0e-6dda2f76fb2f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i22be6b7ba979497ca9ece88797ec5f9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTEtMS0xLTA_f00983e5-9867-4753-9558-69d4a6c8d82b"
      unitRef="usd">857900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1d05cd22a7c40f6872ae176348b44ed_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTMtMS0xLTA_dc7ad3ed-d964-4402-b535-8dff89b1f21e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic30e7a2d8e794c59af388b27d36d27fd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTUtMS0xLTA_36eb21cd-56eb-47a7-8184-24ec21e8237f"
      unitRef="usd">857900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62749c0209e440f7b96473ce6fd4b8a3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzEyLTctMS0xLTA_52250eb0-3aea-4bf9-bcbf-ee9f0e2cc0fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="icf0e119c44184cc685474e43e33f71bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTEtMS0xLTA_9ae4f4fd-61ec-4f96-a59f-d815f2309a09"
      unitRef="usd">55900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcd60d8e7dce40b0aca76907070d868d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTMtMS0xLTA_21c423c9-7aad-468e-83cb-bf893f051948"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ida05ac1eb4ff4313a9d1f27643667abb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTUtMS0xLTA_a1724cf4-cf88-45f4-a4ee-b0937aa7a42d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8c8645b15c1c462293674465d9ffd0b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE0LTctMS0xLTA_c4c484ca-fdf8-442c-af6a-bbe0e0caf733"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ida219830132544daa2c45cd2d963ac68_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTEtMS0xLTA_85471a6e-4fcd-46c7-b2ed-d3ab4a1b01e8"
      unitRef="usd">55900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i54fac764203a4713af1443597ffa888a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTMtMS0xLTA_10741611-83db-40e0-8b68-3685d97eac28"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee56e84363a64281a0bb67ffa597df58_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTUtMS0xLTA_c85ae30e-8f0c-4dbb-839c-a682e5faad44"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic30674d569f74deb8350b47ed380e2d4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE1LTctMS0xLTA_04bb4f51-49dc-4e6e-9ab9-a517b0b10817"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="idd2575bd668b4015b8ad679f19bd5a1b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTEtMS0xLTA_19b1c77d-ffd8-4938-b611-6a1e1fdd4958"
      unitRef="usd">1029300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e8a5dc0856b4cdba6c86a366b76c812_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTMtMS0xLTA_53ceffe7-e396-43b8-a3fd-81dc8bbf96af"
      unitRef="usd">115500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79ce58ee37ae4b92b5d958c540e8289a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTUtMS0xLTA_76c53e63-4a47-4dd2-a034-2126de60a325"
      unitRef="usd">857900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifad81ae5e7644259a48165fae6c46349_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo1MzBlZDAxY2ZmMTQ0YTc3OTRmMjYzOTM2MDYxZTMwYS90YWJsZXJhbmdlOjUzMGVkMDFjZmYxNDRhNzc5NGYyNjM5MzYwNjFlMzBhXzE2LTctMS0xLTA_433fe1b9-2ed5-411f-aed3-63a5c61ce7b8"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzM4NDgyOTA2OTgxNDY_2048f789-4a9e-4f68-9221-9657389e8b71">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i6ca67d557d334f00a0544aa5f24f6b34_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItMS0xLTEtMA_d7ddc504-50d1-4a08-a5c9-d15e97a10059"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ifad56dc439b641358459b58e8079887a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItMy0xLTEtMA_2c77c296-e671-4c89-afc1-ae1f1bc335c8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i05c117b96dea48f4ac63a4022bae19d6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzItNS0xLTEtMA_0ea94be4-502b-4aac-99ed-c6df4406a140"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtMS0xLTEtMA_a7e8bf5a-39f8-4736-b78a-8310485f16b4"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtMy0xLTEtMA_e0a97d5e-fac4-49fe-8e70-f677941b2ea2"
      unitRef="usd">68900000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzMtNS0xLTEtMA_30bc7006-f25e-4c6e-9e9a-5410d3630c3c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i48c4b95a6ce24ba1939b0e5563b81a3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtMS0xLTEtMA_f726210b-d4f5-474e-aa1c-75f0af29bf5f"
      unitRef="usd">-17700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id0882762e22f4e74a4649865cf3519d3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtMy0xLTEtMA_ad0b055c-8447-4afa-aa95-6a255cd47150"
      unitRef="usd">-13000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5ec3d86b06db4b7a9e1472ae44326bf6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzQtNS0xLTEtMA_f300cf1e-04c1-4458-a1ea-f27d8fd78455"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="iec42070cca3e4dbb8475c09e274ad678_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtMS0xLTEtMA_024933c0-760b-4d1f-86d3-c5f3a1e8c2fd"
      unitRef="usd">38200000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i6ca67d557d334f00a0544aa5f24f6b34_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtMy0xLTEtMA_68e14344-abff-4d91-af79-9d18097641ca"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ifad56dc439b641358459b58e8079887a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90YWJsZTo0NTlhZjVlNTBjM2I0ZDljOGE2ZTUwM2NmZTllMDVlOS90YWJsZXJhbmdlOjQ1OWFmNWU1MGMzYjRkOWM4YTZlNTAzY2ZlOWUwNWU5XzUtNS0xLTEtMA_448a7f02-ca6f-4dbf-9481-e1b929de8829"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i83c603ce0ef14a36b7c219ff93558f30_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzUzOA_bc456567-33b8-49b2-805e-75fc25135cf6"
      unitRef="number">0.150</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i830e7abc03c443829d9692cb82e8dada_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzU0NA_c840a27e-e763-4e31-9aac-fb067856556d"
      unitRef="number">0.340</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="ia219d51ea1f4489893af819d696712f3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNTcvZnJhZzphMDkwM2U1MTY0MjE0MTU5OGRkODQzZDNhN2NhYzg2NC90ZXh0cmVnaW9uOmEwOTAzZTUxNjQyMTQxNTk4ZGQ4NDNkM2E3Y2FjODY0XzU2OA_07ee834c-690c-4814-8cb3-a10921b48c4c"
      unitRef="number">0.248</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NjA_414927f5-36b5-428d-8b90-48bbb8831a0f">Convertible Senior Notes&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;2.25%&#160;convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;2.25%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;5&#160;business-day period immediately after any&#160;5&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#x201c;principal portion&#x201d; and delivery of the &#x201c;share amount&#x201d; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#x201c;principal portion&#x201d; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume-weighted average price, or VWAP, of our common stock. The &#x201c;share amount&#x201d; is the cumulative &#x201c;daily share amount&#x201d; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;100%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#x2018;&#x2018;make-whole fundamental change&#x2019;&#x2019; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December&#160;31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7&#160;million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3&#160;million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4&#160;million at settlement was recognized as a reduction to convertible senior notes and resulted in an $18.4&#160;million loss on extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $514.3 million and $596.8 million at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzg1_2ac9fae1-4214-42ec-8e01-812b2bd0311b"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEyMQ_90377839-7843-420f-8fd8-f94a0affe6c4"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzMyNA_92454b76-3385-40ba-be2d-193e02c16c33"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU0Mg_e3789ec7-6790-4424-b510-c85a7406e4c2"
      unitRef="usd">502800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0Mg_938f3569-a462-4a7a-bf45-3a3b518fcf86"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwMDY_734fe4d2-0bfe-4dc7-8dbe-1c2b5f74ef17"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ia8a23b6cfe3544c3912763071295aa97_D20170502-20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzExMjc_b7c04d93-b2ef-4fb2-a196-f2a7b58f7704"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzExOTc_aedf9838-273d-4f1e-8dfd-2a8091dc4f81"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5NjE_add5d0c8-f1fd-472e-9815-38a78aef1690"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="id222ff8c62cd4111a8f3c7d582b27ee4_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEzNjY_49639824-a1a5-4f12-a404-5fcf28ba1865"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="ie08eeda246eb4b1cb26accf6dc07a82e_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzE0NjU_57933658-96e8-4168-92a4-edaf5a33ebc9"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <nbix:TradingDaysDuringObservationPeriod
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzI3NjU_37b8bb10-586a-41f5-ba45-96b38d4a5dcf">P30D</nbix:TradingDaysDuringObservationPeriod>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Nzg_a92b6cb4-7a76-45e1-a5ee-925f4165be26"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Nzg_feac82fb-d18b-4455-bf87-340db100f7df"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5Njg_bb852bd1-7b23-46f8-bdf4-26bdba744ec6"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:DebtConversionObservationPeriod
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMTU_e1e8274f-6bc2-4968-b891-a1f062797989">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:DebtConversionObservationPeriod
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzM5ODg_7be02aba-3620-4eea-948e-728a9570b3d3">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMDI_f36c386a-601e-4c3e-bdad-f4d5cce8cd46"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQwNzg_f87474f3-d375-4d23-a0c8-d3006583deea"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQxNjc_f33a8057-4e9d-40c5-9f01-ed8eeb3ff363"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ide871789006342f69f8274002bb357ed_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDYxNTM_156f7b95-b6ee-4091-9a51-60f934befe1f"
      unitRef="shares">5000000.0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQ1MzU_6cd7b436-225b-44aa-b120-ea0487c58f64"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzQ1Njc_f4089132-d9fd-45b9-a784-bee08b94816b"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU0NjY_4e4571cd-74ba-47e2-86ce-7fb2c3878117"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU1MjE_7f313987-700b-4ac5-ac29-3cfa70db54cc"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU1Nzc_96490504-baf7-4a84-b841-70cd9ad5bde7"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzU3Njc_d48b9b59-987f-4909-a8d4-25f0e50ca560"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzIxOTkwMjMyNzQwMTA_8c4a25a5-aee9-43d3-8c93-cdf78888c905"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <nbix:CarryingAmountOfLiabilityComponentUponIssuance
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzczNjA_e0247963-88f4-468f-b13a-db61a9e63b00"
      unitRef="usd">368300000</nbix:CarryingAmountOfLiabilityComponentUponIssuance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzczODY_3078a858-2e6a-418d-8c47-4e8e8c47ada9"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzc0Mzc_27d0d022-9e67-4582-96aa-f458e3e6be06"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTc_8b4e0d67-6494-4a4a-a04e-c0cfdf5b454d">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i89667253f1654865bbfb0ea260237daa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzgxMTA_20beed40-b794-4255-a932-3083f0aa6228">P3Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i4275d4edccb744bf87c8dce992b293b1_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzgxNzI_8c3fbae0-b991-4714-820d-fe68fefff131"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <nbix:EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzg5MDA_d4e8765d-b31e-4a4e-8807-ffe6dad94f33"
      unitRef="number">1</nbix:EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i3f1e2b0fdafc40cea056719ee341bf3f_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyNjE_a825e985-7818-482c-9182-f542f90549bf"
      unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyNzc_1f67204b-6065-4e3e-862a-327bd9f04345"
      unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment
      contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUyOTM_10380982-e293-4118-83a9-cd3ab553f236"
      unitRef="usd">130700000</nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="if4d919d3678346498deb137a73366cf9_I20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMDk_b085cb0a-fd04-4949-a5c3-8432ab8bc61c"
      unitRef="number">0.0337</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMTY_2f6385c8-c5e1-4978-be17-ad36613179e8"
      unitRef="usd">56300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <nbix:CarryingAmountOfLiabilityComponentAtSettlement
      contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzMzE_aa7bd59d-8527-493c-8704-c63e88011761"
      unitRef="usd">112400000</nbix:CarryingAmountOfLiabilityComponentAtSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6e745341b313497da254482b5c4fd6d6_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzEwOTk1MTE2NDUzNDc_d4e9fd7b-c657-4fe6-b30f-940489bb08cb"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTg_788f441d-9635-4831-8431-715adc60f046">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(59.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzItMS0xLTEtMA_fac26b05-3a82-4204-975a-36c4179c1921"
      unitRef="usd">381300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzItMy0xLTEtMA_db650990-722e-414b-9cf5-6c24e74f0538"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzMtMS0xLTEtMA_a98f2fd3-7de8-4c9d-afd6-d82c4ba18afc"
      unitRef="usd">4000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzMtMy0xLTEtMA_fd02a5ec-1d4f-429f-a5f4-a379c28e805a"
      unitRef="usd">6900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzQtMS0xLTEtMA_43af3821-1554-49de-92d5-e39490d5378a"
      unitRef="usd">59400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzQtMy0xLTEtMA_ce2b7dc7-72db-4a45-98ef-ec56e6f594f8"
      unitRef="usd">101800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebt
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzUtMS0xLTEtMA_223e9c30-1ddc-4472-9411-7e9821234e21"
      unitRef="usd">317900000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90YWJsZTowYmNjODQyODQyNzE0MTgyODkzNDE2MWJjOGUyYjNhYy90YWJsZXJhbmdlOjBiY2M4NDI4NDI3MTQxODI4OTM0MTYxYmM4ZTJiM2FjXzUtMy0xLTEtMA_51fe5ec4-d7ea-4914-9a49-9c14237d51d4"
      unitRef="usd">408800000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i7cad05c688f242f5a5c51a41f1311fd8_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NTk_28579dfc-cff8-4901-9a54-6a4f4344686d">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i60ced8a0a7764272b813ab553a8bc5ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0MzM_2d58162b-2734-4178-af94-552e71700cb4"
      unitRef="usd">514300000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i06934d96e69448b9a6a7de8228e9ae5b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjAvZnJhZzo3NmNmMGJhOWFiOGE0ZWMwYjM0MjMzMTRmZjZlZTVhYy90ZXh0cmVnaW9uOjc2Y2YwYmE5YWI4YTRlYzBiMzQyMzMxNGZmNmVlNWFjXzk0NDY_8617ae40-2843-41c2-8d9c-a240c89ce855"
      unitRef="usd">596800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1MA_39db0c74-0ae5-4924-a277-0f13055e517a">Other Balance Sheet Details&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Branded Prescription Drug Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1MQ_296af8dc-6c15-4a0d-99ba-095c43776796">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzItMS0xLTEtMA_6b79f96c-4b47-45de-b7c3-1e05903b100e"
      unitRef="usd">16600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzItMy0xLTEtMA_f72578c5-5fc3-4746-a14c-2db55fad3842"
      unitRef="usd">14100000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzMtMS0xLTEtMA_f1388aab-2cc2-4b92-9cdb-3c2492a3c7fa"
      unitRef="usd">2400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzMtMy0xLTEtMA_1571f855-c3a5-440f-8876-10ef9d034163"
      unitRef="usd">1500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzQtMS0xLTEtMA_af12669d-878d-49b1-a4f9-9bb97fa47c00"
      unitRef="usd">9000000.0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzQtMy0xLTEtMA_1b565bbe-e674-40c5-993f-20ab5cfdfee5"
      unitRef="usd">1700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzUtMS0xLTEtMA_564f4b98-5beb-4ff1-ada0-b038b7ae2c49"
      unitRef="usd">28000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTowOTRmNDMyYzgzNTg0ZTE1ODk4ZTI0ZWM0MGY0ZGNlMS90YWJsZXJhbmdlOjA5NGY0MzJjODM1ODRlMTU4OThlMjRlYzQwZjRkY2UxXzUtMy0xLTEtMA_3646c63b-5439-4d90-9472-784e205bc3bf"
      unitRef="usd">17300000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ1Mg_4e6ac4ea-418d-4237-9bd8-f0f417c77f9d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifaa184a589454ef3b217797ac3f37c85_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzItMS0xLTEtMA_2eb721ff-db90-4469-b65e-d79c7cb90421"
      unitRef="usd">29500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c737c06e3a64363abae7512867edfb9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzItMy0xLTEtMA_c9ec886c-b1f1-425f-b52c-93c6f1ee57c5"
      unitRef="usd">26300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a92c0d75562403aaeb7e6195396a9c0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzMtMS0xLTEtMA_30a87f0d-82fc-41b0-b1dd-4ad1cb689975"
      unitRef="usd">39200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4132f626519c4dd6915f68702956d54a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzMtMy0xLTEtMA_1ffe3730-6988-45c1-a55b-34cd2260ac8f"
      unitRef="usd">33500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2114f7c7620e47ed9b7c7252ab48432d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzQtMS0xLTEtMA_0dc0eed2-f9f9-4349-9987-4e71d403ee1c"
      unitRef="usd">13900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia76651c30b164c06b76804edbd718ae7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzQtMy0xLTEtMA_5c6ae998-05a2-4f7a-82c7-f150f14f2723"
      unitRef="usd">12500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i04c9dfd023f94ae6b49d6219f49911a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzUtMS0xLTEtMA_9352742a-f7cb-49c4-8b7b-c2fadb84f8a8"
      unitRef="usd">3700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33ff256dae7c4d7da1e1f691ad48ee76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzUtMy0xLTEtMA_4c97b1d4-d916-42f3-a472-e222e131f490"
      unitRef="usd">3200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzYtMS0xLTEtMA_b44697a9-54c6-44a5-b6d1-446dd742b2ae"
      unitRef="usd">86300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzYtMy0xLTEtMA_dc348144-38ae-47a4-ac9c-f555c2c7b1dd"
      unitRef="usd">75500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzctMS0xLTEtMA_4d6f69d1-d8df-4bda-b39d-73104b4db162"
      unitRef="usd">41700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzctMy0xLTEtMA_c087d8fd-22a5-4669-83ec-77f3ea0de50d"
      unitRef="usd">33600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzgtMS0xLTEtMA_1e48ca8a-ef7a-4076-a78b-53d9979d39f0"
      unitRef="usd">44600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTplM2QxMmVlODc5OGQ0ZDA3OTVkMWQ4OTZmMzc5ZGI0OC90YWJsZXJhbmdlOmUzZDEyZWU4Nzk4ZDRkMDc5NWQxZDg5NmYzNzlkYjQ4XzgtMy0xLTEtMA_e9d28cac-d610-4ecc-8e8f-0235a836792e"
      unitRef="usd">41900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ0OA_adb06be1-ed51-4aec-b9c0-c178a05a9d6c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee related costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Branded Prescription Drug Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzItMS0xLTEtMA_c6d6b404-7782-4686-9092-9d675b8c678f"
      unitRef="usd">38200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzItMy0xLTEtMA_a1e7eb54-9379-430c-822b-d17a21cce8c6"
      unitRef="usd">38900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nbix:RevenueRelatedReservesForDiscountsAndAllowances
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzMtMS0xLTEtMA_0bf3672a-c93a-4d30-a1ef-c8f317cdf666"
      unitRef="usd">34600000</nbix:RevenueRelatedReservesForDiscountsAndAllowances>
    <nbix:RevenueRelatedReservesForDiscountsAndAllowances
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzMtMy0xLTEtMA_adeda392-8225-4f02-877e-a7468dee01d1"
      unitRef="usd">30600000</nbix:RevenueRelatedReservesForDiscountsAndAllowances>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzQtMS0xLTEtMA_e2517ee1-04c2-4621-af82-d5b491a836c1"
      unitRef="usd">32900000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <nbix:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzQtMy0xLTEtMA_ca036201-58e2-420d-a04a-9553884bba93"
      unitRef="usd">25500000</nbix:AccruedResearchAndDevelopmentExpenseCurrent>
    <nbix:AccruedBrandedPrescriptionDrugFee
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMS0xLTEtOTQ1Ng_ef066d87-e0ef-4e66-8af7-fea2e61316fc"
      unitRef="usd">23600000</nbix:AccruedBrandedPrescriptionDrugFee>
    <nbix:AccruedBrandedPrescriptionDrugFee
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMy0xLTEtOTQ1OQ_41995817-1499-4c54-ac6c-76811127bed2"
      unitRef="usd">4900000</nbix:AccruedBrandedPrescriptionDrugFee>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMS0xLTEtMA_d4da9db8-e160-4228-be3c-a2ab51178d9d"
      unitRef="usd">39400000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzUtMy0xLTEtMA_4e310828-34e4-49bf-a454-7cabe6bd6a63"
      unitRef="usd">41400000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzYtMS0xLTEtMA_93e76827-103c-47c7-af52-e230ffba0835"
      unitRef="usd">168700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTo1OTg1ZmEzZTg2OTU0YjQxYjY1Yzc5NDJjZjYzODM2NC90YWJsZXJhbmdlOjU5ODVmYTNlODY5NTRiNDFiNjVjNzk0MmNmNjM4MzY0XzYtMy0xLTEtMA_40e672e3-828d-4997-b87c-13b42c1a86ca"
      unitRef="usd">141300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90ZXh0cmVnaW9uOjEyZmEzYjQyYTNkODRlYjk5ZTJhNmM5MDFkNzFlYTNhXzQ0OQ_f239a1b8-37d2-4cd9-a450-cb46fbe9ae57">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzItMS0xLTEtMA_f0b8fafe-0b45-466a-aeb6-e20c5744f20e"
      unitRef="usd">187100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzItMy0xLTEtMA_a5af6e86-7dd8-4a71-b2d1-806d405c6a60"
      unitRef="usd">112300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzMtMS0xLTEtMA_433e3c17-917e-4ac1-b7b7-db74de14c974"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzMtMy0xLTEtMA_99748033-5928-45e4-ad7c-63bd4a470ba1"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzQtMS0xLTEtMA_c04d9ef9-c2d4-4fd1-8ef3-997297249edf"
      unitRef="usd">190300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjYvZnJhZzoxMmZhM2I0MmEzZDg0ZWI5OWUyYTZjOTAxZDcxZWEzYS90YWJsZTpkZWM5NmZjMDYwMDU0Y2EzYTc2NDBkYzhlOWE0MTczMy90YWJsZXJhbmdlOmRlYzk2ZmMwNjAwNTRjYTNhNzY0MGRjOGU5YTQxNzMzXzQtMy0xLTEtMA_808c7114-2288-4c49-8f23-735476ce6396"
      unitRef="usd">115500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzI0NQ_5ea8536b-1646-44df-b35c-4d28b661c4b7">Net Income Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.5 million, 2.1 million and 0.9 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzI0Ng_4801de3d-a856-4646-86d0-c494b2e6d829">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItMS0xLTEtMA_cda2b763-bb8c-4752-9181-403a5f22e291"
      unitRef="usd">407300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItMy0xLTEtMA_deb105d5-6ea4-4149-943a-073d9e595f81"
      unitRef="usd">37000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzItNS0xLTEtMA_6bd5ec37-a48d-4959-a9c7-1ae4e6608c1a"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtMS0xLTEtMA_11692b4c-4057-4d5b-92ca-48eafb1d25d0"
      unitRef="shares">93100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtMy0xLTEtMA_ddf4173d-4140-4a69-acb0-b9aa3942394f"
      unitRef="shares">91600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzQtNS0xLTEtMA_12bc10c9-a0fa-4735-9fdb-38b55a16e319"
      unitRef="shares">90200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic403135dcdce433cb75127f4ba52569f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctMS0xLTEtMA_aa38425e-d104-478c-983d-f286a138885e"
      unitRef="shares">2400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i545e098699484f749aa1893bd9f4d9ac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctMy0xLTEtMA_5690d1c7-5b7b-4c18-aae1-86988423894f"
      unitRef="shares">2600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie580a98b5f904017acbc0be2a81b1401_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzctNS0xLTEtMA_d79dac03-cd11-4808-9d3a-1fe0509ea7f8"
      unitRef="shares">3200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibb93957d4a2347d0893965c4a30cbdd0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtMS0xLTEtMA_393764f6-fb20-489f-a8c4-a64b5eb1400a"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0ad0a98345c14590bf7d5f5fd862c9fe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtMy0xLTEtMA_5fa36392-cdcb-47c6-85f1-96d02404114b"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i613490d34e8a4611aab2ffd9a16f8ef0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzgtNS0xLTEtMA_ff4a8e3e-8e0e-402c-ace0-fddf9e593cc2"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktMS0xLTEtMA_8899db99-d820-4a66-a401-4b2c2b888975"
      unitRef="shares">1800000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i5e784185d98a4b9cb1bb7bcad7598aea_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktMy0xLTEtMA_883709a1-4a07-46ec-9b09-624b8a27cfc6"
      unitRef="shares">1100000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i81fcb21b072c4b679ca34c108cfa6ef4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzktNS0xLTEtMA_17f7e981-06a3-4736-8ee3-cf8fc520876c"
      unitRef="shares">1300000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTEtMS0xLTA_2d72ea94-6917-4604-9653-b56eb31582ba"
      unitRef="shares">97800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTMtMS0xLTA_f88ccdb8-8f7d-428b-91a0-c1787d2fc2d5"
      unitRef="shares">95700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEwLTUtMS0xLTA_1cedd44a-c576-4a8f-8263-93da0bb0cf25"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTEtMS0xLTA_b6103048-5363-497d-8d63-17f1cfa949e5"
      unitRef="usdPerShare">4.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTMtMS0xLTA_9049503b-4c70-4b93-932c-2cc4c32b7331"
      unitRef="usdPerShare">0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEyLTUtMS0xLTA_9867378a-0101-4241-946d-3a8bd8cd7277"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTEtMS0xLTA_d660e07d-cb9d-4638-adf5-d8b41fc4fa5d"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTMtMS0xLTA_072d6267-5f5d-4482-b8d2-8a6695caefa4"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90YWJsZTpkZDI1YzI1ZDY1OGE0MzViYjUyZWYwNGNlNGIzZTVjNy90YWJsZXJhbmdlOmRkMjVjMjVkNjU4YTQzNWJiNTJlZjA0Y2U0YjNlNWM3XzEzLTUtMS0xLTA_7dbfd563-657f-4cc5-9522-0ce34e6a3cd4"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzE5OQ_8548933a-d751-4435-a218-1520d36bb6e4"
      unitRef="shares">2500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8581e780a80c4442b21f27be29b95775_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzIwMw_224bf1c3-ed86-4f21-8f5b-2ccf821b4277"
      unitRef="shares">2100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5bea0f817d424b9faef8c2af8c43a23d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNjkvZnJhZzpjZTY0YWZjOThlMmM0ZTRlOWFiZjY5MzNlZTgyOGIwNi90ZXh0cmVnaW9uOmNlNjRhZmM5OGUyYzRlNGU5YWJmNjkzM2VlODI4YjA2XzIxMA_3d421ab8-16ab-4f2f-8818-275414f0e296"
      unitRef="shares">900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjI_7ac896d2-ea84-4ab4-a4a9-81cfeb3f6118">Share-Based Compensation&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May&#160;2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized 21 million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were no shares of common stock remaining available for future grant under the 2011 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which 0.3 million shares of common stock are authorized for issuance. At December 31, 2020, 0.2&#160;million shares of common stock remain available for future grant under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized 3.3&#160;million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, 8.2&#160;million shares of common stock remain available for future grant under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Expense. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by award-type follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, stock options have a ten-year term and vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa"&gt;three&lt;/span&gt; to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.67, $41.74 and $43.42 for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average valuation assumptions were determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to stock options follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $40.2 million, $64.3 million and $117.0 million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $23.5 million, $27.3 million and $29.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, RSUs vest over a four-year period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to RSUs follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs that vested during 2020, 2019 and 2018 was $49.7 million, $36.1 million and $35.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9"&gt;four&lt;/span&gt; to five years from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant.&#160;Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to PRSUs follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, unrecognized share-based compensation expense for PRSUs was $17.0 million. The total fair value of PRSUs that vested during 2020 was $13.5&#160;million. No PRSUs vested during 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i16180db6d54a49ce83ee4500d72b9962_I20110531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE0OQ_59529dd5-bb33-43c5-af1e-ba0d6dfd4308"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i21f4f7020f68499385d6f2a13567d7f0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjM_ec3d794f-c857-4838-82ae-7bb6973915bf"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i60fca317ddb748798d4cb98a5fbf2aea_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzY5OQ_eea4a1a1-e362-47bc-939b-91ae3510cb4e"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idd5803489bd44c3cb9e6f31d1e0a6681_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzc3Ng_f16822f0-8001-4084-932c-97ef63b8d137"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i48bbd2bddcdc44dca0395f6d99c449aa_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzk1Ng_78f24588-c8f3-432f-a5c9-cb9c4e0cebe0"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i035747211e4f44e193c5d551cf4d62ed_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEzMTM_93694252-c582-4daa-8657-71e56924edf9"
      unitRef="shares">8200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNTg_5f7cdb41-80d4-4193-8427-fde30a91c93e">The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by award-type follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Recognition Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i965516f5121d4176b5ae292b90be804a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItMS0xLTEtMA_ab374693-a825-4a31-a3c4-1255a69941bd"
      unitRef="usd">66300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iffc67e37cd02430da9f8da535e6d7526_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItMy0xLTEtMA_a1bc121d-1d13-4e5f-a2c9-154d111ab034"
      unitRef="usd">49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i521c723b6c49422a84b72328e24a5c55_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzItNS0xLTEtMA_7d68efdf-0347-469d-a6dc-b6ed48be7545"
      unitRef="usd">31900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1faa6db7b38d43dd97845deb75c32b0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtMS0xLTEtMA_1be35483-36e2-46d6-9bac-bcf334b87292"
      unitRef="usd">33700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84e87b16f9684b559824bed5cc3bfaad_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtMy0xLTEtMA_7da05c77-eea0-497d-aa2f-4adb8e60a368"
      unitRef="usd">25800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a82057bae22484ab39cbc0b26398dd5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzMtNS0xLTEtMA_4b702de0-9607-4b90-bb1f-89fc1a82177d"
      unitRef="usd">26200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtMS0xLTEtMA_fc29a5ff-bc0c-4bf9-85a9-b8b6d793dfd7"
      unitRef="usd">100000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtMy0xLTEtMA_bb6eceb0-1b6a-4ded-83f5-23a981dc2257"
      unitRef="usd">75300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozYjYzYjBjYTMwNTY0YTI0OGQwM2FhNWVkYjdmMTIyZS90YWJsZXJhbmdlOjNiNjNiMGNhMzA1NjRhMjQ4ZDAzYWE1ZWRiN2YxMjJlXzQtNS0xLTEtMA_c2a8967f-b250-4f10-8ac4-24382e603a05"
      unitRef="usd">58100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItMS0xLTEtOTk1_c8887e7b-43ad-464c-8c1c-25614e48099e"
      unitRef="usd">47500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItMy0xLTEtOTk1_5ae4bd17-688b-4e28-8bcb-e8c728ec6161"
      unitRef="usd">36500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzItNS0xLTEtOTk1_9861380e-64d4-4cd6-b603-c88ea27dc384"
      unitRef="usd">35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMS0xLTEtMTA4Mg_3af7739a-e502-496d-b70d-d8ec63f4317c"
      unitRef="usd">44200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMy0xLTEtMTA3Nw_effb2101-b2e3-4bec-89d1-1acde4318751"
      unitRef="usd">30500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtNS0xLTEtMTA3NA_a31450a7-8e1b-4113-a0fa-6b4f09212beb"
      unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMS0xLTEtOTk1_918f6f66-57c2-410d-a375-df4e2b840aa0"
      unitRef="usd">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtMy0xLTEtOTk1_23b2015c-c615-4867-aa6f-b979e41ca08b"
      unitRef="usd">5600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzMtNS0xLTEtOTk1_2ec08710-b5b0-47e4-af95-f22dc3302bab"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b54e325551b473da0598c96d708c5da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtMS0xLTEtMTA4Mg_1175c554-45bc-460c-85a9-9ed0482f78a4"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7638d60a91cb4ff787321cee24ae9f48_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtMy0xLTEtMTA3Nw_23482f93-60e4-4480-80d4-f1cd5120baa8"
      unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie680af40b96e455aaaaf75ab295c9ac4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzUtNS0xLTEtMTA3NA_b48f2df0-f177-4fbc-9af5-febc1e1170eb"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtMS0xLTEtOTk1_13fe7774-3175-4243-96ad-3b8716149be2"
      unitRef="usd">100000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtMy0xLTEtOTk1_252579ef-a1cc-40c0-81da-68374b7beed1"
      unitRef="usd">75300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTowNDExMmE5Y2Q1NWE0YjIzOTUyMjkwYjg4NGYxMzQzNC90YWJsZXJhbmdlOjA0MTEyYTljZDU1YTRiMjM5NTIyOTBiODg0ZjEzNDM0XzQtNS0xLTEtOTk1_fbaa5372-5041-4c8d-aee0-87018a3c61d5"
      unitRef="usd">58100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibdaaf1063b5640c096eab926298a36b4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzItMS0xLTEtMTE3NA_c4e1a619-4f35-4974-9d46-13f75f2ae177"
      unitRef="usd">86200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzItMy0xLTEtMTE3NA_e0017f02-701d-402e-99ce-21f99c4027ce">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzMtMS0xLTEtMTE3NA_1630a8d4-f188-4ed9-9588-ce2be32db184"
      unitRef="usd">99500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiOWFhMTFiY2NjNjc0MmMyYjMxMTU1OTdmZjFmNzhmNi90YWJsZXJhbmdlOmI5YWExMWJjY2M2NzQyYzJiMzExNTU5N2ZmMWY3OGY2XzMtMy0xLTEtMTE3NA_3e770ae8-86c9-4d10-9cec-b2a96ca63290">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzQ5MjY_01fc2bb0-a7ae-4f5e-a146-45857adc7899">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib5add3ec602347a4872184c665490f93_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzQ5MTM_795cbf2b-32ca-4b1f-abcb-d8a9192ae4bd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NjA_9a04606d-ac17-4ecf-8483-0f22c2b48891"
      unitRef="usdPerShare">45.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NjU_ca1ec67b-c67b-49b9-b4d2-925fec537d83"
      unitRef="usdPerShare">41.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2Mzk0NzM_22686d2f-d30e-4c24-a2b4-d272d6963a81"
      unitRef="usdPerShare">43.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNTk_a265b29b-0755-43ea-8cc8-8960ac0c2231">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected option term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItMS0xLTEtMA_818db87a-9a12-4d0c-9da0-45110fd65dcf"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItMy0xLTEtMA_0812dc2f-0811-41e6-ad7f-0ecd3e0c501c"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzItNS0xLTEtMA_14bf8274-20ff-4e3b-8c34-c74cf2c609f6"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtMS0xLTEtMA_83355fc5-4cad-4ce8-bd9e-93f5cdc7297b"
      unitRef="number">0.485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtMy0xLTEtMA_c6578e37-dbf7-4cab-8a91-29c19e31599a"
      unitRef="number">0.548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzMtNS0xLTEtMA_429721a3-4e72-4c15-b092-1de5de681f52"
      unitRef="number">0.595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtMS0xLTEtMA_ed25ffb7-d7c6-4841-ac80-ce7982041b39"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtMy0xLTEtMA_0cdf0548-0d8f-4188-b989-8032b8bae0f7"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzQtNS0xLTEtMA_0b088acf-e9f1-4859-af88-2035ef1cf52b"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtMS0xLTEtMA_51e7b540-9c91-40ee-8424-9dafa472f4c0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic3c381b5fdd1485eaf0e8d5e50944068_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtMy0xLTEtMA_5a057cce-9934-4153-b523-aa92797df326">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id1b4731457c545dbbf6e2ea53f66fb66_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTo2OWQwY2I1NjY2MDU0ZjQ0YjkwYzA1Nzc3ZDg4M2ZmNC90YWJsZXJhbmdlOjY5ZDBjYjU2NjYwNTRmNDRiOTBjMDU3NzdkODgzZmY0XzUtNS0xLTEtMA_9b0197cf-bce6-47d4-b27f-0984952efe34">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjA_9f8cec54-1651-40b7-a5ea-e93cc887b482">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to stock options follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzMtMS0xLTEtMA_8d1abcea-90c3-4a2a-933a-de5a528ad09d"
      unitRef="shares">6100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzMtMy0xLTEtMA_86998461-d065-4a4b-9e68-ce23c36eea4e"
      unitRef="usdPerShare">52.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzQtMS0xLTEtMA_f0a7a256-e828-476f-a5c4-0dc1c42451e8"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzQtMy0xLTEtMA_4d6b7597-dc40-4161-9288-3d765655ff0b"
      unitRef="usdPerShare">103.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzUtMS0xLTEtMA_eb2030fa-6df7-4238-982b-3e07916b35fe"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzUtMy0xLTEtMA_9f1625a3-10c2-4f8d-b1b3-006536481422"
      unitRef="usdPerShare">43.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzYtMS0xLTEtMA_414a3efd-4ca1-4f58-be1c-154c17564591"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzYtMy0xLTEtMA_bf4de1c8-52d5-4fdd-a914-562cae20558b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMS0xLTEtMA_19f03c5d-3625-4d5f-b0ae-99428d85ab01"
      unitRef="shares">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMy0xLTEtMA_b3b10b61-fd0c-476d-821d-3a71a06f9c67"
      unitRef="usdPerShare">62.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNS0xLTEtMA_bf81e26b-4922-4c6b-8211-2bb9f47f60f7">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNy0xLTEtMA_8505ac97-fcf8-4e50-8fec-e2f2bba1bff0"
      unitRef="usd">235400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMS0xLTEtMTMyOA_4f48ab47-afc6-4545-b2a2-5f4efc961f99"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctMy0xLTEtMTMzMQ_43bae52e-73f9-455d-af42-658a7e854a86"
      unitRef="usdPerShare">49.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNS0xLTEtMTMzNg_7bd4869f-d99d-4037-af04-134078bfa02a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozNDA2Mzg1MGI5NjA0Njk2YWE2MmEyYjc0ZmY1ODEwNC90YWJsZXJhbmdlOjM0MDYzODUwYjk2MDQ2OTZhYTYyYTJiNzRmZjU4MTA0XzctNy0xLTEtMTMzOQ_04182bbb-2e65-429d-92b1-cd1327cafd83"
      unitRef="usd">218200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MDE_c2e8863d-3c6a-4421-bcc3-e8108b2498bf"
      unitRef="usd">40200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MDU_b8d76a6f-2d78-44ce-b09e-f8592e592210"
      unitRef="usd">64300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU2MTI_25da2c8c-74fd-4f5e-9f4e-399f415a764c"
      unitRef="usd">117000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MDE_57f80bc6-1926-4ef3-a70d-13288fdb9c37"
      unitRef="usd">23500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MDU_ee3e706a-0d17-4319-a072-62c6d2101d27"
      unitRef="usd">27300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzU4MTM_b5ffafab-0e53-419c-a634-88b3f212b222"
      unitRef="usd">29500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzIxOTkwMjMyNzU2NDM_c0b97396-8530-4d85-9f6a-fa1b3ac55f28">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzgwNjE_88cd43da-b089-40b6-944a-3f43e4b07651">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to RSUs follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to PRSUs follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date &lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9b9010f4078c43eb99d30b01f597843b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzEtMS0xLTEtMTQ0Mw_49144743-2626-4bd0-99dc-e5ba87da050a"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9b9010f4078c43eb99d30b01f597843b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzEtMy0xLTEtMTQ0Mw_b87af189-d4e9-42b9-844e-3f8c04a41546"
      unitRef="usdPerShare">74.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzItMS0xLTEtMTQ0Mw_e85ef5d4-a9b5-4abf-adbb-7cfe1a1a30aa"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzItMy0xLTEtMTQ0Mw_8e708789-6b19-4f90-b7b2-7aba3d63b943"
      unitRef="usdPerShare">102.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzMtMS0xLTEtMTQ0Mw_0da44525-720c-4cb3-b250-3ae9db7d66aa"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzMtMy0xLTEtMTQ0Mw_1b712158-5449-4b44-be95-52e8c9e21666"
      unitRef="usdPerShare">67.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzQtMS0xLTEtMTQ0Mw_3350e92a-88ee-4b29-b4c3-5e7461d7dc4b"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzQtMy0xLTEtMTQ0Mw_6678926d-f97d-4227-bac0-4702682290bb"
      unitRef="usdPerShare">84.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtMS0xLTEtMTQ0Mw_9f934935-0703-4da4-97a6-20039c603653"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtMy0xLTEtMTQ0Mw_48119b3f-5888-44d3-83b0-48f9b87859c3"
      unitRef="usdPerShare">89.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtNS0xLTEtMTQ0Mw_551a1753-81f0-4872-aab1-34f1f3d110d0">P1Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ia5fcf6a1f40f4a5db1431bd2466bb505_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTpiN2ViZWRjZGEyNjE0ZmViYmMwZDU5YjJjMWM4ZWNlMC90YWJsZXJhbmdlOmI3ZWJlZGNkYTI2MTRmZWJiYzBkNTliMmMxYzhlY2UwXzUtNy0xLTEtMTQ0Mw_41d2520a-0ab9-494b-b88c-0914f7bc9086"
      unitRef="usd">147500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM2ODk_e4966ab4-29f2-4bbb-a954-88d682aa3438"
      unitRef="usd">49700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i0a5da15a23c440438a656972a3d3afb8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM2OTQ_0390b30b-82ce-4110-b2fe-e67eb9d8c2bb"
      unitRef="usd">36100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i4b17f77321ea44a2abd666cf6bbf6c24_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDM3MDM_221d712a-02bc-493a-b29c-4d11435a8693"
      unitRef="usd">35500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ice8da843469b46af91bfcfc456693d02_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3OTQ_233b7470-6410-4b61-a9e6-01d64ea92bc5">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzEtMS0xLTEtNjMxOA_abb306b7-49f3-4d8a-8838-0a7e6ed94206"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic3ba18eecfeb42c2a0c3e5dc3d1c790e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzEtMy0xLTEtNjMxOA_aa181035-60fb-450b-a29b-82bdfcb7ab31"
      unitRef="usdPerShare">59.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzItMS0xLTEtNjMxOA_c7f25dcd-3428-4f98-86db-62af8682164a"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzItMy0xLTEtNjMxOA_feda5102-8f25-4efb-947b-96e90b014532"
      unitRef="usdPerShare">102.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzMtMS0xLTEtNjMxOA_c605b36e-1052-40b3-9e46-a6a5fafc90f3"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzMtMy0xLTEtNjMxOA_defa3e0e-a350-4e1f-96a1-ca035071c6a4"
      unitRef="usdPerShare">82.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzQtMS0xLTEtNjMxOA_f14aac9c-9516-469f-a934-d130155e0b4d"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzQtMy0xLTEtNjMxOA_69cc08ff-02ca-454b-b0a4-b95ca5104ce9"
      unitRef="usdPerShare">45.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtMS0xLTEtNjMxOA_435339df-d672-4004-858b-ee14ff44f1ad"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtMy0xLTEtNjMxOA_96ee7990-2018-4a18-82c2-e11c5f1fe852"
      unitRef="usdPerShare">102.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtNS0xLTEtNjMxOA_1e5417fd-703e-456a-9882-afbef3dca72b">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90YWJsZTozZDEzY2JiY2Q5ZGU0Y2RkYWRjNzIxMjk1NzgxNjY4ZS90YWJsZXJhbmdlOjNkMTNjYmJjZDlkZTRjZGRhZGM3MjEyOTU3ODE2NjhlXzUtNy0xLTEtNjMxOA_23914e1e-7927-4bf6-8353-dbb1ceb2bd6e"
      unitRef="usd">15800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i44e7588a0725435ebb6068dce53086b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDgwMzQ_13477837-65e4-40fd-8d4f-e301abecaed2"
      unitRef="usd">17000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic8fba4e9b5d54f00abd47d2a7aa7528f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2NDc4NTM_3348e31b-8902-428c-977b-7654462f5f9c"
      unitRef="usd">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia96c81fcdad947ee865eed7f92fdd202_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE2NDkyNjc0NjE3MjE_34f6fa57-674c-4857-aec0-2be7b2d3e45b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ibc9601e80f4c434dbba6dfd65da917cf_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzE2NDkyNjc0NjE3MjE_ca840c1a-8659-43ec-aa4d-89b770c29d4d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i3c587d6dc8c6451fba9c6dbe18ec82bf_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzc4MDA_96077c8e-e0f7-4fca-8174-ec06235b60c1"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTY_b8027867-0be0-4935-ba9d-4b86f021abe5">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit from) provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21% for 2020, 2019, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit from) provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(346.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $49.8 million and $346.0 million, respectively, against our gross deferred tax asset balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $319.4&#160;million are realizable. Accordingly, we recorded a net valuation release of $296.3 million on the basis of management&#x2019;s assessment. The remaining valuation allowance of $49.8 million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had federal and state income tax net operating loss carryforwards of $518.2 million and $340.8 million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have federal and California R&amp;amp;D tax credit carryforwards of $92.1 million and $56.4 million, respectively. A portion of the federal R&amp;amp;D tax credit carryforwards expired in 2020. The remaining federal R&amp;amp;D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&amp;amp;D tax credits carry forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the future utilization of our net operating loss and R&amp;amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&amp;amp;D tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to unrecognized tax benefits follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Decrease) increase related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $3.9 million for current year tax positions, as reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had $53.9 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTc_3d755f1d-0749-4327-94dc-29a8a19efbea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(287.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit from) provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtMS0xLTEtMA_f7bffe75-7e7a-44f6-92e2-f1da48c1bd25"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtMy0xLTEtMA_36bbd02a-3418-4dda-bcd8-191b43751ce1"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzMtNS0xLTEtMA_9e4a29cb-afea-4176-88ba-5b4101eb2062"
      unitRef="usd">-100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtMS0xLTEtMA_6d7b357a-8870-4a8e-9f09-66fd828758f6"
      unitRef="usd">10100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtMy0xLTEtMA_0b9656ed-aee3-43a9-aadc-a3750b63e961"
      unitRef="usd">9500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzQtNS0xLTEtMA_93117d7f-4b8a-4783-9aaa-0c91443a57b2"
      unitRef="usd">800000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtMS0xLTEtMA_02ee7312-46a6-41ad-8180-080ec8f99275"
      unitRef="usd">10100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtMy0xLTEtMA_05627f39-54c2-45db-8ead-8b6afb3e154f"
      unitRef="usd">9500000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzUtNS0xLTEtMA_eeda28bf-af22-4382-b8ca-34b09c1ef863"
      unitRef="usd">700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctMS0xLTEtMTA0MjI_924655d2-3d73-40c9-86bc-a51941d18c37"
      unitRef="usd">-287500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctMy0xLTEtMTA0MjI_3102e637-1ee9-499b-83a9-e252c17ae29b"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzctNS0xLTEtMTA0MjI_354b7c5f-9a3a-49e0-9864-ffb587e997bb"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtMS0xLTEtMTA0MjI_bf4e2b71-b710-4b8d-9155-a030cf6090c5"
      unitRef="usd">-23200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtMy0xLTEtMTA0MjI_d1c3048a-613c-4a42-9f96-2a5bbf7482c2"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzgtNS0xLTEtMTA0MjI_089338b1-d766-4386-83cd-49c6c05ab02f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktMS0xLTEtMTA0MjI_5582e22e-61c4-401f-9454-2e1b83f1bb26"
      unitRef="usd">-310700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktMy0xLTEtMTA0MjI_cc2acea0-ebc3-478e-87bc-abecf530345e"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzktNS0xLTEtMTA0MjI_933a219d-6791-4e96-afd1-47c9bfe32747"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTEtMS0xLTEwNDIy_7baf89c4-d40d-43c1-8f81-f1c19cee412f"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTMtMS0xLTEwNDIy_34bef9eb-e1b4-4044-a1ff-f81a771c6a62"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTozYjNkM2QzYzgwZDA0YzYyYmFiNTNiMjdlOWYwYzEzMi90YWJsZXJhbmdlOjNiM2QzZDNjODBkMDRjNjJiYWI1M2IyN2U5ZjBjMTMyXzEwLTUtMS0xLTEwNDIy_0049c50b-313d-4710-9b3c-14a1c8f81e7e"
      unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTg_14b4c41c-5400-4c03-9a7d-006366bf8a4d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21% for 2020, 2019, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Benefit from) provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(300.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_76f6e3f9-4a07-4540-94c4-e9f7deda16d8"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_8c6a69d2-7f66-4b08-89d7-bf2872a59a97"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMC0xLTEtNzk1L3RleHRyZWdpb246YThmMGQ5Nzc4MjE0NGE3YWIzYTAwMjY5NGQ2OWUxMGFfMTA5OTUxMTYyNzgzMQ_9ed365e8-8dd3-451e-a5b8-b971e438471b"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMS0xLTEtMA_827e3b0b-9da1-4a88-9648-a89f615659f6"
      unitRef="usd">22400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItMy0xLTEtMA_7f4bb2f4-c676-4ccd-ab52-f3a6a1a24675"
      unitRef="usd">9800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzItNS0xLTEtMA_6c60751f-dbfa-4da2-acb0-b0969fd3d407"
      unitRef="usd">4600000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtMS0xLTEtMA_ac5889b8-161a-4a27-bae4-64648108694a"
      unitRef="usd">5500000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtMy0xLTEtMA_a2715398-3467-4417-b0c9-4942d93d8fb0"
      unitRef="usd">4000000.0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzMtNS0xLTEtMA_893b137c-522c-404e-9cd3-e5a727522086"
      unitRef="usd">400000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtMS0xLTEtMA_a2bd8c00-2d22-479d-bf43-ad6f46b45825"
      unitRef="usd">600000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtMy0xLTEtMA_752dcd77-25cf-4e23-a001-93750059633e"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzQtNS0xLTEtMA_c7c2faf0-f78d-48ec-8c5b-a748d3311358"
      unitRef="usd">400000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtMS0xLTEtMA_50343b8f-1023-491d-b439-36d83098261d"
      unitRef="usd">4900000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtMy0xLTEtMA_6eddfa12-0b4a-4d42-96fe-6785a12ca0d3"
      unitRef="usd">3700000</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzUtNS0xLTEtMA_a02cb758-7e51-41d6-b45f-a747d339caa2"
      unitRef="usd">0</nbix:IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtMS0xLTEtMA_40bbdc5d-44e3-4c48-ae39-bc74d33688c9"
      unitRef="usd">-6700000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtMy0xLTEtMA_a45a5492-ce01-439b-a723-d7e3cec021ee"
      unitRef="usd">-12800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzYtNS0xLTEtMA_bdc789df-bf60-4571-96fd-9c89b6580c4c"
      unitRef="usd">-9800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctMS0xLTEtMA_9a181445-57fa-49f3-969c-a5c0cfeae8e2"
      unitRef="usd">3700000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctMy0xLTEtMA_1293a2ac-5f35-4713-97e2-d8fdea83a456"
      unitRef="usd">3100000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzctNS0xLTEtMA_5b348e4c-b16c-448f-bed0-40423525af51"
      unitRef="usd">900000</nbix:IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtMS0xLTEtMA_5886ec70-1ea5-4d6e-a9b3-c0e3b087ac2d"
      unitRef="usd">3300000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtMy0xLTEtMA_6e766741-ed19-4c67-8002-92807773751b"
      unitRef="usd">-4100000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzgtNS0xLTEtMA_c547641d-4b3c-4e10-becb-e804ae1aadab"
      unitRef="usd">-200000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktMS0xLTEtMA_a944304d-5aa2-41ca-a3d0-24b006592986"
      unitRef="usd">1100000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktMy0xLTEtMA_ebfe540d-9894-4305-84e0-fa018a7cb89e"
      unitRef="usd">1200000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <nbix:IncomeTaxReconciliationExpirationOfTaxCredits
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzktNS0xLTEtMA_19c06344-f1c0-4618-be60-ff7441704a23"
      unitRef="usd">13900000</nbix:IncomeTaxReconciliationExpirationOfTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTEtMS0xLTA_c0c66ab8-12ae-4ec0-9efe-36d6a29ca210"
      unitRef="usd">39000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTMtMS0xLTA_f6bbfb44-e1bc-47d8-9d97-e448c1e353b2"
      unitRef="usd">10400000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEwLTUtMS0xLTA_bd204da1-e9af-417b-b2b1-78a616cfa55b"
      unitRef="usd">13500000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTEtMS0xLTA_2644deb1-d034-4297-92e2-63f163435acb"
      unitRef="usd">-296300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTMtMS0xLTA_af936aaf-c3a7-450d-b2d9-b3634afae750"
      unitRef="usd">13900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzExLTUtMS0xLTA_56124c11-c3db-44d9-9350-6fe29793737e"
      unitRef="usd">4300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTEtMS0xLTA_57ef03d7-426a-4bb9-bb1a-a567b98945a2"
      unitRef="usd">-100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTMtMS0xLTA_223f422d-506e-4328-8cdc-206037375a80"
      unitRef="usd">300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEyLTUtMS0xLTA_52f00ac2-3ef9-47a9-9aa6-d2300f965b38"
      unitRef="usd">-300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTEtMS0xLTA_4af68ecc-3ab6-41b3-a223-0d3a3e5da4ff"
      unitRef="usd">-300600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTMtMS0xLTA_86d575d8-7893-47cc-924c-a63cf27e7d22"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTphYjkzZjU5MGUwNzM0N2M3YTIzM2FkZjc1NjFhNWI3Mi90YWJsZXJhbmdlOmFiOTNmNTkwZTA3MzQ3YzdhMjMzYWRmNzU2MWE1YjcyXzEzLTUtMS0xLTA_54adbea0-94c3-4f16-be37-000b9f0fb2b8"
      unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NTk_169d40e9-55e5-4424-9f6c-f92ca17dac11">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(346.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzMtMS0xLTEtMA_a03e643d-c509-4776-b8a1-6a8d6e8467b9"
      unitRef="usd">111400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzMtMy0xLTEtMA_d8fda1dc-e3c7-4c5e-8cab-e9cc2d1f9104"
      unitRef="usd">181300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzQtMS0xLTEtMA_d1dcc055-5286-413c-92c5-54eddae2800b"
      unitRef="usd">109600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzQtMy0xLTEtMA_c59f692f-8985-45bf-9da1-474a55ca2b5d"
      unitRef="usd">71900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzUtMS0xLTEtMA_cb2b5589-06f8-49b3-bd21-840f128bdd3e"
      unitRef="usd">24700000</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzUtMy0xLTEtMA_78601701-5afd-487e-9b37-0ce453fec67f"
      unitRef="usd">28000000.0</nbix:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzYtMS0xLTEtMA_e77ccb24-c440-4b82-befc-956776b3eae9"
      unitRef="usd">29800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzYtMy0xLTEtMA_a7911d46-2f92-45b8-a0c0-23829e5cfa28"
      unitRef="usd">22900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzctMS0xLTEtMA_c17140ab-43f7-40e6-8871-e217e6ad43fd"
      unitRef="usd">25200000</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <nbix:DeferredTaxAssetsOperatingLeasesAssets
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzctMy0xLTEtMA_5368f955-3b18-4aad-a698-727c84fc8f80"
      unitRef="usd">23300000</nbix:DeferredTaxAssetsOperatingLeasesAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzgtMS0xLTEtMA_737c93fd-a3a8-4aac-be13-9f805045c747"
      unitRef="usd">86700000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzgtMy0xLTEtMA_315a30d5-1f75-404b-bd2f-32283eaaaf13"
      unitRef="usd">49300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzktMS0xLTEtMA_66296ce7-51ec-47aa-ac78-e22d4a958c82"
      unitRef="usd">23900000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzktMy0xLTEtMA_6749bb46-f31f-4bf2-945a-bbec108185fc"
      unitRef="usd">18500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEwLTEtMS0xLTA_f45475a4-358d-40fb-bbb0-81dc130fce05"
      unitRef="usd">411300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEwLTMtMS0xLTA_7a9f9932-5ab2-47f0-b84f-fceda4705d57"
      unitRef="usd">395200000</us-gaap:DeferredTaxAssetsGross>
    <nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEyLTEtMS0xLTA_684509fb-2b45-4e7d-831c-219cc4f4d94e"
      unitRef="usd">13800000</nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes>
    <nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEyLTMtMS0xLTA_40fa3f8a-7cca-4879-92aa-4573380f5a12"
      unitRef="usd">24100000</nbix:DeferredTaxLiabilitiesConvertibleSeniorNotes>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEzLTEtMS0xLTA_f64395be-5099-4982-b175-a883dcf4e4ec"
      unitRef="usd">19900000</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzEzLTMtMS0xLTA_d428f057-7b7a-4343-89a2-8c3682b73d63"
      unitRef="usd">18200000</nbix:DeferredTaxLiabilitiesOperatingLeasesLiabilities>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE0LTEtMS0xLTA_ef6247ca-15c8-4cdf-b02c-c42dd93579c6"
      unitRef="usd">8400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE0LTMtMS0xLTA_16f601a9-09fb-4ecb-a4b2-aeff82bbaf71"
      unitRef="usd">6900000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE1LTEtMS0xLTA_42710c0e-d729-425a-9733-2edd662e1632"
      unitRef="usd">42100000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE1LTMtMS0xLTA_0479fef9-3673-4cb9-ac52-f3c7fbb72984"
      unitRef="usd">49200000</us-gaap:DeferredIncomeTaxLiabilities>
    <nbix:DeferredTaxAssetsLiabilitiesGross
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE2LTEtMS0xLTA_f17fa7a8-32d1-475a-be49-1edf607e9192"
      unitRef="usd">369200000</nbix:DeferredTaxAssetsLiabilitiesGross>
    <nbix:DeferredTaxAssetsLiabilitiesGross
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE2LTMtMS0xLTA_ac89601a-6264-4ef6-a608-85986bc9a947"
      unitRef="usd">346000000.0</nbix:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE3LTEtMS0xLTA_66bdbc91-9a91-4abd-a5a9-32c447b47c22"
      unitRef="usd">49800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE3LTMtMS0xLTA_58c160e7-a534-49f0-8a4f-df4d03e19e52"
      unitRef="usd">346000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE4LTEtMS0xLTA_a97d4cf6-935f-44f5-bd03-0456c846178c"
      unitRef="usd">319400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTo2MjQ2MzBjNWZjODg0OGFhOTljZjI2YjZlZDRiNjFkOS90YWJsZXJhbmdlOjYyNDYzMGM1ZmM4ODQ4YWE5OWNmMjZiNmVkNGI2MWQ5XzE4LTMtMS0xLTA_5b22a87e-832b-4173-9632-a49fdc5254f2"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzExMDM_66bdbc91-9a91-4abd-a5a9-32c447b47c22"
      unitRef="usd">49800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzExMDk_58c160e7-a534-49f0-8a4f-df4d03e19e52"
      unitRef="usd">346000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzIxOTkwMjMyOTg4NjI_bdc6be5a-996e-43f4-962c-8d41e9b2176f"
      unitRef="usd">319400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzM2NzI_6097cfe1-d07f-4ea5-9b64-da021ebe7bf0"
      unitRef="usd">-296300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEwOTk1MTE2NzI1OTE_66bdbc91-9a91-4abd-a5a9-32c447b47c22"
      unitRef="usd">49800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iaad045d0ff0b4b949b001aa2efd85687_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzEzOTY_1f18f9f6-d7a9-45d5-ad05-749b97aee453"
      unitRef="usd">518200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i478244770d8e4c27a0658c7c1918fbe0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE0MDM_e42ccda2-5c9b-4d75-bbd7-79505294eb42"
      unitRef="usd">340800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iaad045d0ff0b4b949b001aa2efd85687_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE4MTg_2c895d0e-3ae6-49bf-a54a-5e725a3d2a36"
      unitRef="usd">92100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i478244770d8e4c27a0658c7c1918fbe0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzE4MjU_380d73db-df0c-4b32-ac4a-2ce8147aaf71"
      unitRef="usd">56400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM3NjA_5c8ef811-dba2-4db1-bb0c-bc9d93fe840e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of activity related to unrecognized tax benefits follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Decrease) increase related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration of the statute of limitations for the assessment of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItMS0xLTEtMA_32c0aa4b-14e0-4d43-b7e1-3556140cf181"
      unitRef="usd">63900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItMy0xLTEtMA_0d4a41f8-cc54-4449-8eff-e4108cf35026"
      unitRef="usd">54800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie84e64d4ffbf45999357185cd064c9c1_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzItNS0xLTEtMA_075ff4fc-6131-4329-9174-f7f2e3ccdae6"
      unitRef="usd">37400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtMS0xLTEtMA_e3f85e58-b17d-4ed8-b4b3-0c128ed9dea4"
      unitRef="usd">5700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtMy0xLTEtMA_3538bc30-b742-4eaf-add2-6507afaec7f5"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzMtNS0xLTEtMA_13f9575c-8948-432c-8080-7309ddc948db"
      unitRef="usd">6100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtMS0xLTEtMA_0b52feeb-2a06-45ca-a43c-d8b1ecc26eea"
      unitRef="usd">3900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtMy0xLTEtMA_78b0cca9-b48b-4124-9872-bb6846796838"
      unitRef="usd">9500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzQtNS0xLTEtMA_c6cee376-14de-40d1-b0d8-1fc78f752ab5"
      unitRef="usd">11700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMS0xLTEtMTAxMTQ_29bee1f6-04de-40ae-904f-69cbd417c3bb"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMy0xLTEtMTAxMTc_d7909242-a794-4e01-8345-be0514155d11"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtNS0xLTEtMTAxMjA_315cd701-8e06-4c58-ac65-8e073d29c6c4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMS0xLTEtMA_5ff759e3-e5a1-4612-900c-81a956bf2f80"
      unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtMy0xLTEtMA_da7ebe13-3456-4bd5-83ee-33b946460955"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzUtNS0xLTEtMA_306b95a0-235b-4b73-8310-d934113a7c0c"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtMS0xLTEtMA_307edb2f-3aea-4df5-987b-700141e334aa"
      unitRef="usd">60800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtMy0xLTEtMA_7f619099-4b7c-4c68-85df-84fb27f9fd8e"
      unitRef="usd">63900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0aa89f41ac1a41899038841e6f4faaa1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90YWJsZTpmNWFjMTk4NzhlNTE0ZGI1OWQzMTEwMWY3YjQzMjUyZS90YWJsZXJhbmdlOmY1YWMxOTg3OGU1MTRkYjU5ZDMxMTAxZjdiNDMyNTJlXzYtNS0xLTEtMA_21badfbf-d0c3-413a-9f91-e420411491cf"
      unitRef="usd">54800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM0Mzg_f7060e0b-3f36-4965-937a-f61f1e500d47"
      unitRef="usd">3900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzUvZnJhZzoxYTIxOGMzMTFhZjc0MzJiYjg2NGMzMzNlNTQ0NGYwOS90ZXh0cmVnaW9uOjFhMjE4YzMxMWFmNzQzMmJiODY0YzMzM2U1NDQ0ZjA5XzM1MjA_d8b4ec76-2b41-40c5-a53a-0dbe0fb7b7f7"
      unitRef="usd">53900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzQxMjM_9eedfbdb-43b0-49e0-89b1-80438175c884">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have two options to extend the term of the operating lease for our corporate headquarters for a period of ten years each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating lease cost was $10.1 million for 2020 and $8.1 million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $8.6 million for 2020 and $7.7 million for 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases had a weighted-average remaining lease term of approximately 10.3 years and 11.2 years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of 5.6% and 5.8% at December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad"&gt;Less current operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nbix:NumberOfRenewalOptions
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzIxOTkwMjMyNjYxODc_2e5c676f-39da-42a4-b632-3cc70ca5a6ad"
      unitRef="renewaloption">2</nbix:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzIxOTkwMjMyNjYxODg_f810eace-1c32-4491-ade4-cf0115e286d4">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i6da45b8c6e074d14bdc079a1f2265f01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzE2NDkyNjc0NTIxMDc_dd981b41-6ebe-46cc-9950-2b9010d61e27"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MDM_2304650b-a270-4156-9c1a-2b8cd7a9c84b"
      unitRef="usd">10100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MTA_d8399174-7b3a-4965-88d7-13f99019c1a4"
      unitRef="usd">8100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MTY_3724a067-37d4-4c3c-9762-ccf09e9a2abf"
      unitRef="usd">8600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MjI_97cf0822-837e-42dc-8d03-426307e80c72"
      unitRef="usd">7700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1Mjc_676bff7d-b46b-4a39-b927-d0f3b501bd4d">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1MzI_a82a6373-c26c-4573-b859-147f916750fb">P11Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1NDQ_fe5fcc31-7b17-437b-843f-5304d59b4483"
      unitRef="number">0.056</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie7ce5f1bbc51478e98b231f0247f59bf_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzM1Mzg_7edae265-9f80-472c-8870-1638e81efe34"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzQxMjQ_1f2258cb-f129-47f8-a80c-28871141e76c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad"&gt;Less current operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzItMS0xLTEtMA_8ceb558f-f3e2-4d82-9443-d75d7eb49d20"
      unitRef="usd">10700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzMtMS0xLTEtMA_a265c4d8-206f-4746-aacf-3f8f6e4ef6f0"
      unitRef="usd">12400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzQtMS0xLTEtMA_eeb785d2-485c-4803-9464-a546c924e8b7"
      unitRef="usd">12700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzUtMS0xLTEtMA_085e673a-14eb-4ab1-9bd3-5e6f9fa970fb"
      unitRef="usd">13100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzYtMS0xLTEtMA_675d0883-ed3d-4752-961d-2ec9e3a9299f"
      unitRef="usd">13500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzctMS0xLTEtMA_3191a454-f853-4755-8cde-245fc4c0d8b7"
      unitRef="usd">77500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzgtMS0xLTEtMA_489b261e-8c65-42eb-8f06-c668b1bd5f08"
      unitRef="usd">139900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzktMS0xLTEtMA_279b3faf-3a6a-4ba1-8350-67ef596a57af"
      unitRef="usd">35200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzEwLTEtMS0xLTA_496c9d06-d570-412b-a9a4-6360f1dcf68d"
      unitRef="usd">104700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTEtMS0xLTA_8b988c23-7f8b-410a-889b-d755943cf69b"
      unitRef="usd">10300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzEyLTEtMS0xLTA_897576b5-51d2-4181-8a68-edfee6a484ec"
      unitRef="usd">94400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced
      contextRef="i04b7ec05369244eebe79a6452649afd7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90ZXh0cmVnaW9uOmRmOTY5YzE0MjE4YTQ1Njg5ZDgzODdkNGFkYmQ0ODUyXzEwOTk1MTE2MzgxMzU_a78448d1-3cba-46da-80e2-2b99f8256deb"
      unitRef="usd">19700000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzM0OQ_e6d56cfb-de21-48e6-9208-010487a86bd5">Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $6.7 million, $4.9 million, and $1.8 million for 2020, 2019 and 2018, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzIyMA_5fce0afb-f117-433c-bbe6-67dca97f764f"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMwMg_9589f26a-ff4f-4563-ae72-40a8caac5763"
      unitRef="usd">6700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie48225642b5d487980c178811a2c13ed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMwNg_3e30597c-ede2-41a5-9956-a4b450d5602d"
      unitRef="usd">4900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5ce8ecdecf3545669ffafc8f9bc8e713_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODcvZnJhZzo1OWZjZDgwOTY5MGM0MTNjYjdjY2ZlMTY5OTViMzA0Ny90ZXh0cmVnaW9uOjU5ZmNkODA5NjkwYzQxM2NiN2NjZmUxNjk5NWIzMDQ3XzMxNA_450c4cd4-40ab-40c0-a736-04c225fdfa9a"
      unitRef="usd">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTM4_1a192c06-571a-4d6e-98d3-eba2007ad6b9">Selected Quarterly Financial Data (Unaudited)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our quarterly results follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0&#160;million, accounted for as IPR&amp;amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5&#160;million, accounted for as IPR&amp;amp;D, in the third quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1&#160;million, accounted for as IPR&amp;amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0&#160;million upfront, accounted for as IPR&amp;amp;D, to obtain outside the U.S. rights to the Friedreich&#x2019;s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2&#160;million, accounted for as IPR&amp;amp;D, in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTM5_8ad4709c-97e2-4443-98ac-8581a55bd0c1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our quarterly results follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;302.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share, diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0&#160;million, accounted for as IPR&amp;amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5&#160;million, accounted for as IPR&amp;amp;D, in the third quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1&#160;million, accounted for as IPR&amp;amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0&#160;million upfront, accounted for as IPR&amp;amp;D, to obtain outside the U.S. rights to the Friedreich&#x2019;s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2&#160;million, accounted for as IPR&amp;amp;D, in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTEtMS0xLTQyMDM_67e33c26-a279-45ce-a6ea-06ffeaf45efe"
      unitRef="usd">237100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTMtMS0xLTQyMDM_adde9ec3-d9be-499c-8f36-b54ab87d63c6"
      unitRef="usd">302400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTUtMS0xLTQyMDM_01266ca7-2082-4009-9860-591e5531b53e"
      unitRef="usd">258500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8yLTctMS0xLTQyMDM_9cf6d050-3544-48d6-b00b-911d3b853208"
      unitRef="usd">247900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTEtMS0xLTQyMDM_0dd65d69-007f-45fa-bb2f-ea53fa980fd0"
      unitRef="usd">178200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTMtMS0xLTQyMDM_d6afe626-a859-43e4-b840-32eb25f3cb90"
      unitRef="usd">225800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTUtMS0xLTQyMDM_99d7565e-49a7-4c52-8d90-02f1ea079227"
      unitRef="usd">302800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8zLTctMS0xLTQyMDM_7724d3b1-a5da-4b2b-8d29-ca0bb2447421"
      unitRef="usd">176100000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTEtMS0xLTQyMDM_674e2e86-f3fb-47fb-ac9d-3d0b5177c5f1"
      unitRef="usd">37400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTMtMS0xLTQyMDM_cb1f2be2-6a1c-45f0-99cb-ce0597a0690e"
      unitRef="usd">79600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTUtMS0xLTQyMDM_8370d6fd-9613-4a07-825e-261feae56448"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV80LTctMS0xLTQyMDM_71c6e80a-2f5c-44ac-90eb-f2c578bcbd1e"
      unitRef="usd">347900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTEtMS0xLTQyMDM_920e27c8-32e1-49ba-8de4-05834515ce0e"
      unitRef="usdPerShare">0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTMtMS0xLTQyMDM_b57f1a8f-3b18-4297-8e1e-a1207f95a3f0"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTUtMS0xLTQyMDM_0ec9963c-2a23-478c-b782-c6dc277775b5"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV81LTctMS0xLTQyMDM_fa3da188-02a9-4e68-81f5-c06e3560e0ed"
      unitRef="usdPerShare">3.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTEtMS0xLTQyMDM_7cbeac96-21e3-40ea-9ed5-518cb4d0119d"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTMtMS0xLTQyMDM_6c4aa32d-f93c-4c8f-a2f6-ec00389f52da"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTUtMS0xLTQyMDM_55a52e20-0865-423f-91ad-17f403620e6a"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV82LTctMS0xLTQyMDM_69ce4aa0-9c15-4a17-80e3-6d87d63d2a98"
      unitRef="usdPerShare">3.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTEtMS0xLTQyMDM_43258673-e8b2-4e8f-b3af-d8d77af3778f"
      unitRef="shares">92600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTMtMS0xLTQyMDM_1975686a-0ddf-4a66-88fb-6d3e5caafca8"
      unitRef="shares">93000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTUtMS0xLTQyMDM_69c788b6-899c-49a3-98ca-98209853f898"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV83LTctMS0xLTQyMDM_313e21a7-d872-4138-9090-b7efccb3b5ff"
      unitRef="shares">93500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b9ed75b122949a7b7b6a7ea13c4338a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTEtMS0xLTQyMDM_84944d59-698d-4769-a7f1-b5596bb560fc"
      unitRef="shares">97000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfcaeaa1bbd4448cbdaae3ca6a5bbb4a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTMtMS0xLTQyMDM_51ad58d5-5449-4d91-8cef-9a3fdb15d7ea"
      unitRef="shares">98200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i73305e27fb584214b81d59db4d6f5a06_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTUtMS0xLTQyMDM_6b801b12-aa4e-4e37-9172-f5abe2bd28f7"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV84LTctMS0xLTQyMDM_1010995d-d255-467d-836c-e022869a2415"
      unitRef="shares">97200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS0xLTEtMS00MjAz_f5117385-eaa7-480c-a368-a8f187021a0d"
      unitRef="usd">138400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS0zLTEtMS00MjAz_6dd0e748-e3b4-4832-903d-85075ad1756e"
      unitRef="usd">183500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS01LTEtMS00MjAz_dbccd33f-bad0-4de6-a539-4314ca998a9e"
      unitRef="usd">222100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMS03LTEtMS00MjAz_17eb7da0-918a-479e-9086-557918ec5cfc"
      unitRef="usd">244100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi0xLTEtMS00MjAz_0fd940e1-f9c1-4220-91ea-929437413798"
      unitRef="usd">239400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi0zLTEtMS00MjAz_3786aa55-2069-4df7-ae2f-213ed5a41f50"
      unitRef="usd">149100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi01LTEtMS00MjAz_8797f181-3280-467f-9a10-abc27c0b076d"
      unitRef="usd">132000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMi03LTEtMS00MjAz_dff28f64-f908-48ed-a7be-e85c41f3ed02"
      unitRef="usd">195300000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy0xLTEtMS00MjAz_b0cf41d0-ed9d-4903-8b7f-ad707dba5009"
      unitRef="usd">-102100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy0zLTEtMS00MjAz_2b54ab86-6561-4eb8-809b-2659d2373d2e"
      unitRef="usd">51300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy01LTEtMS00MjAz_def31df6-9337-4ea1-b94c-f71fffe96e22"
      unitRef="usd">53800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xMy03LTEtMS00MjAz_66c5bc66-4380-4c7e-9d62-7c51a034aa33"
      unitRef="usd">34000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC0xLTEtMS00MjAz_58e68ddc-138a-4114-ac10-22811c653668"
      unitRef="usdPerShare">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC0zLTEtMS00MjAz_ec1fbc57-9733-4cf0-a415-f744f7ff0173"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC01LTEtMS00MjAz_35302713-4e6a-4571-b8c0-e72d7ac74a41"
      unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNC03LTEtMS00MjAz_aec11b7b-9f1f-41e9-b37c-acb774e8cd05"
      unitRef="usdPerShare">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS0xLTEtMS00MjAz_b09d4fea-b22d-4b9f-b802-0da58d9699a4"
      unitRef="usdPerShare">-1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS0zLTEtMS00MjAz_6f197d71-7f7c-4228-bcd8-db81b11a1a41"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS01LTEtMS00MjAz_901dd5e9-fdc2-46bf-b424-46226c941ee8"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNS03LTEtMS00MjAz_a294bc3d-1f57-4855-996f-57238cdde560"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi0xLTEtMS00MjAz_2cef4720-a313-4b53-9e96-140e15e8f3ff"
      unitRef="shares">91100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi0zLTEtMS00MjAz_3683d772-7dde-4193-9da9-f4e42468422d"
      unitRef="shares">91400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi01LTEtMS00MjAz_bc6bb5cc-f808-44a2-901b-ed8e55c93530"
      unitRef="shares">91900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNi03LTEtMS00MjAz_150ecb71-73d8-44ee-8956-4e0319e1ce4e"
      unitRef="shares">92200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id5d9c09cff344f60ac745c98108fd74c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy0xLTEtMS00MjAz_bb4e3ee8-76c8-499e-afad-e38c9faa5355"
      unitRef="shares">91100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b568645343f41b4bd612156b22c5ec6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy0zLTEtMS00MjAz_e82425f5-a09b-4dd1-b2d0-7e1c2de2c2d3"
      unitRef="shares">94800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i46badc678aff4acbbf531e54236f3a54_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy01LTEtMS00MjAz_7dc78c40-433f-46e6-889e-77bb14162e66"
      unitRef="shares">96100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic33e64a4ff294466b361b9beb327ccb2_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGFibGU6N2I5NDNjYTk5ZGFlNDdmY2I4NjlmNWUyZDkxOWQ2OGUvdGFibGVyYW5nZTo3Yjk0M2NhOTlkYWU0N2ZjYjg2OWY1ZTJkOTE5ZDY4ZV8xNy03LTEtMS00MjAz_2db9e2e3-43eb-4493-851e-958698f2414a"
      unitRef="shares">97200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ib123ada82f724fe49861cecabdde52c1_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTQx_2fc7e9a5-7869-4db2-aee8-e030bcccb7a0"
      unitRef="usd">46000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i8d2db4ddee19489eaad07271d5031b33_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTU2_21bc42b2-dce4-4a5e-ac20-c79dbc7254d6"
      unitRef="usd">118500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ia0eb9bda630a4c7db0529ab2270d1ab6_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTcy_9d75f6ce-aed2-4cb8-8bcb-299857827122"
      unitRef="usd">113100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ibdce474493ae4a06a307c4ae63aafe45_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MTg4_3a674afe-246d-45b1-a3af-60becf8fba3c"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i80d5ad83d365407dabbf6debafe102c1_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xOTYzL2ZyYWc6ZTViOTMyYWQwYzc3NDlkNTg1MzEzOTVmZTM0M2JjZTYvdGV4dHJlZ2lvbjplNWI5MzJhZDBjNzc0OWQ1ODUzMTM5NWZlMzQzYmNlNl8yMTk5MDIzMjU4MjM4_27dc7071-4069-4bea-ab06-aa51e3b5a1bd"
      unitRef="usd">36200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765752894520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San&#160;Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,231,617,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,943,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement relating to the registrant&#8217;s annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2020 are incorporated by reference into Part III of this Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765746903864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 187.1<span></span>
</td>
<td class="nump">$ 112.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Debt securities available-for-sale (amortized cost $612.4 million at December&#160;31, 2020 and $557.3 million at December&#160;31, 2019)</a></td>
<td class="nump">613.9<span></span>
</td>
<td class="nump">558.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">157.1<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">30.1<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,016.2<span></span>
</td>
<td class="nump">831.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Debt securities available-for-sale (amortized cost $226.7 million at December&#160;31, 2020 and $299.3 million at December&#160;31, 2019)</a></td>
<td class="nump">227.1<span></span>
</td>
<td class="nump">299.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">82.8<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">319.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,734.7<span></span>
</td>
<td class="nump">1,306.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">168.7<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">408.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">186.5<span></span>
</td>
<td class="nump">565.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">317.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">94.4<span></span>
</td>
<td class="nump">86.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">608.5<span></span>
</td>
<td class="nump">669.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December&#160;31, 2020 and 2019</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,849.7<span></span>
</td>
<td class="nump">1,768.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(725.4)<span></span>
</td>
<td class="num">(1,132.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,126.2<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,734.7<span></span>
</td>
<td class="nump">$ 1,306.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748341960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">93,500,000<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">93,500,000<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 612.4<span></span>
</td>
<td class="nump">$ 557.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 226.7<span></span>
</td>
<td class="nump">$ 299.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765753340824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Income and Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,045.9<span></span>
</td>
<td class="nump">$ 788.1<span></span>
</td>
<td class="nump">$ 451.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development</a></td>
<td class="nump">275.0<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">155.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">164.5<span></span>
</td>
<td class="nump">154.3<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">433.3<span></span>
</td>
<td class="nump">354.1<span></span>
</td>
<td class="nump">248.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">882.9<span></span>
</td>
<td class="nump">715.8<span></span>
</td>
<td class="nump">414.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">163.0<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on restricted equity securities</a></td>
<td class="num">(17.7)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="num">(18.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(56.3)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before (benefit from) provision for income taxes</a></td>
<td class="nump">106.7<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">(300.6)<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">407.3<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 407.7<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in USD per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in USD per share)</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 994.1<span></span>
</td>
<td class="nump">$ 752.9<span></span>
</td>
<td class="nump">$ 409.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding the write-off for research and development assets that were acquired in a transaction other than a business combination during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747705304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 372.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,572.8<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (1,198.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on debt securities available-for sale</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock option exercises</a></td>
<td class="nump">$ 29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">480.8<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,660.4<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(1,177.7)<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on debt securities available-for sale</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">75.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock option exercises</a></td>
<td class="nump">27.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stockpurchase plan</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">636.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,768.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="num">(1,132.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">407.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on debt securities available-for sale</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes, net</a></td>
<td class="num">$ (47.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock option exercises</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stockpurchase plan</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,849.7<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="num">$ (725.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765830683112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 407.3<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">75.3<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes (including benefit from valuation allowance release)</a></td>
<td class="num">(310.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(30.5)<span></span>
</td>
<td class="num">(69.2)<span></span>
</td>
<td class="num">(25.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(10.7)<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">228.5<span></span>
</td>
<td class="nump">147.0<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(735.5)<span></span>
</td>
<td class="num">(797.2)<span></span>
</td>
<td class="num">(545.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">750.5<span></span>
</td>
<td class="nump">669.7<span></span>
</td>
<td class="nump">327.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(68.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(24.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="num">(211.1)<span></span>
</td>
<td class="num">(242.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">29.1<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Partial repurchase of convertible senior notes</a></td>
<td class="num">(186.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(157.8)<span></span>
</td>
<td class="nump">32.4<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents and restricted cash</a></td>
<td class="nump">74.8<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(112.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">259.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765744227576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Segment and Geographic Information. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single industry segment&#160;&#8211; the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December&#160;31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during 2020 or 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">three</span> to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If&#160;the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December&#160;31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;D expense as incurred. These expenses result from our independent R&amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;D expense as they are incurred.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747883048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Under the terms of the following license and collaboration agreements, we may be required to make milestone payments upon achievement of certain development and regulatory activities of up to $8.5 billion and pay royalties on future sales, if any, of commercial products resulting from these agreements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which, including certain transaction related costs, was expensed as in-process research and development, or IPR&amp;D, in the third quarter of 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda may also be entitled to receive additional payments of up to $1.9&#160;billion upon the achievement of certain event-based milestones associated with Royalty-Bearing Products, as well as receive royalties on the future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia, to license the global rights to NBI-827104 (ACT-709478), a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the exercise of the option, we paid Idorsia $45.0&#160;million upfront, which we expensed as IPR&amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2&#160;million in funding, which we recorded as a prepaid asset and is being expensed over the two-year research collaboration term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive additional payments of up to $365.0&#160;million with respect to NBI-827104 and $620.0&#160;million with respect to the development candidates. Idorsia may also be entitled to receive additional payments of up to $750.0&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the future net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 (XEN901) and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#8217;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the U.S. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the U.S.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $30.0&#160;million upfront and purchased $20.0&#160;million of Xenon&#8217;s common stock at $14.196 per share, representing approximately 1.4&#160;million shares. Pursuant to the terms of the agreement, Xenon may also be entitled to receive additional payments of up to $1.7&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Xenon was recorded at a fair value of $14.1&#160;million after considering Xenon&#8217;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $36.2&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as IPR&amp;D in the fourth quarter of 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a collaboration and license agreement with Voyager Therapeutics, Inc., or Voyager, which became effective in March 2019, to develop and commercialize four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 (VY-AADC) program for Parkinson&#8217;s disease, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $115.0&#160;million upfront and purchased $50.0&#160;million of Voyager&#8217;s common stock at $11.9625 per share, representing approximately 4.2&#160;million shares. Pursuant to the terms of the agreement, Voyager may also be entitled to receive additional payments of up to $1.7&#160;billion upon the achievement of certain event-based milestones, as well as receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies of such program.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Our equity investment in Voyager was recorded at a fair value of $54.7&#160;million after considering Voyager&#8217;s stock price on the date of closing and certain lock-up and voting provisions applicable to the acquired shares. The remaining $113.1&#160;million of the purchase price, which includes the applicable transaction costs, was expensed as in-process research and development, or IPR&amp;D, in the first quarter of 2019.</span></div>In June 2019, we entered into an amendment to the collaboration and license agreement with Voyager. Under the terms of the amendment, we paid Voyager $5.0&#160;million upfront to obtain rights outside the U.S. to the Friedreich&#8217;s ataxia program in connection with the early return of those rights to Voyager pursuant to a restructuring of Voyager&#8217;s gene therapy relationship with Sanofi Genzyme. The upfront payment was expensed as IPR&amp;D in the second quarter of 2019.<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the U.S. and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from BIAL in the first quarter of 2017. We launched ONGENTYS in the U.S. in September 2020, after receiving FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients in April 2020. FDA approval for ONGENTYS for Parkinson&#8217;s disease resulted in a $20.0&#160;million event-based payment to BIAL, which we expensed as R&amp;D in the second quarter of 2020. We further recognized R&amp;D expense of $10.0&#160;million in each 2019 and 2018 in connection with BIAL&#8217;s achievement of certain regulatory event-based milestones related to then ongoing development of ONGENTYS. Pursuant to the terms of the agreement, BIAL may also be entitled to receive additional payments of up to $75.0&#160;million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the U.S. and Canada. Further, we rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $19.8&#160;million associated with the delivery of a technology license and existing know-how and $15.0&#160;million associated with the achievement of a certain event-based milestone. We further recognized revenue of $2.7&#160;million in 2020 and $0.9&#160;million in 2019 in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#8217;s disease patients with chorea. In accordance with our continuing performance obligations, $6.7&#160;million of the $30.0&#160;million upfront payment received from MTPC is being deferred and will be recognized as revenue over the ongoing study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $70.0&#160;million upon the achievement of certain event-based milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the future net sales of any collaboration product in select territories in Asia.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie Inc., or AbbVie, to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor, or GnRH, antagonists and collectively, GnRH Compounds, for women&#8217;s and men&#8217;s health.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval for ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We recognized sales-based royalties on AbbVie net sales of ORILISSA and ORIAHNN of $19.2&#160;million in 2020, $14.3&#160;million in 2019 and $1.6&#160;million in 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0&#160;million event-based milestone, which we recognized as collaboration revenue in the second quarter of 2020. In 2019, we recognized collaboration revenue of $20.0&#160;million in connection with the FDA&#8217;s acceptance of AbbVie&#8217;s NDA submission for the approval of ORIAHNN for uterine fibroids. In 2018, we recognized collaboration revenue of $40.0&#160;million in connection with the FDA&#8217;s approval for ORILISSA for endometriosis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $75.0&#160;million associated with the delivery of a technology license and existing know-how and $165.0&#160;million associated with the achievement of certain event-based milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0&#160;million upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We are entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">On February 2, 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program. The effective date of this termination will be August 2, 2021. The termination does not apply to any other development program other than NBIb-1817 for Parkinson&#8217;s disease, and our collaboration and license agreement with Voyager will otherwise continue in effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765744242328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December&#160;31, 2020, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December&#160;31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our security portfolio consisted of 148 securities related to investments in debt securities available-for-sale, of which 30 securities were in an unrealized loss position.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position at December&#160;31, 2020 are of high credit quality (rated A or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745639192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 15.0% to 34.0% (weighted average of 24.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765744190200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;2.25%&#160;convertible senior notes due 2024, or the 2024 Notes, and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;2.25%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;5&#160;business-day period immediately after any&#160;5&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the </span></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume-weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 5.0 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;outstanding principal value and any conversion premium in any combination of cash and shares of its common stock (at our option).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2024 Notes prior to May 15, 2021. On or after May 15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;100%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes, as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At December&#160;31, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.4 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7&#160;million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3&#160;million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity component and recognized as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4&#160;million at settlement was recognized as a reduction to convertible senior notes and resulted in an $18.4&#160;million loss on extinguishment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $514.3 million and $596.8 million at December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745700984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Details</a></td>
<td class="text">Other Balance Sheet Details<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Branded Prescription Drug Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747608104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 2.5 million, 2.1 million and 0.9 million for 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745636136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2011, we adopted the 2011 Equity Incentive Plan, as amended, or the 2011 Plan. The 2011 Plan authorized 21 million shares of common stock for issuance and allowed for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSUs, performance stock awards, performance-based restricted stock units, or PRSUs, and certain other awards. During 2020, the 2011 Plan was merged into the 2020 Plan (defined below). As a result, there were no shares of common stock remaining available for future grant under the 2011 Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we adopted the 2018 Employee Stock Purchase Plan, or ESPP, pursuant to which 0.3 million shares of common stock are authorized for issuance. At December 31, 2020, 0.2&#160;million shares of common stock remain available for future grant under the 2018 ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we adopted the 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan authorized 3.3&#160;million shares of common stock for issuance and allows for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, performance stock awards, PRSUs and certain other awards. The 2011 Plan was merged into the 2020 Plan and, as a result, all remaining shares in the 2011 Plan were transferred into the 2020 Plan. At December 31, 2020, 8.2&#160;million shares of common stock remain available for future grant under the 2020 Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, stock options have a ten-year term and vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzYwODU_f346abaf-45c2-4a93-82f2-7b777236c5aa">three</span> to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, term and interest rates. The weighted-average grant-date fair values of stock options granted were $45.67, $41.74 and $43.42 for 2020, 2019 and 2018, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 years</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility of common stock is estimated based on the historical volatility of our common stock over the most recent period commensurate with the estimated expected term of our stock options.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate for periods within the contractual life of a stock option is based upon observed interest rates appropriate for the expected term of our employee stock options. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have not historically declared or paid dividends and do not intend to do so in the foreseeable future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to stock options follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during 2020, 2019 and 2018 was $40.2 million, $64.3 million and $117.0 million, respectively. Cash received from stock option exercises during 2020, 2019 and 2018 was $23.5 million, $27.3 million and $29.5 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, RSUs vest over a four-year period. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. RSUs may be subject to a deferred delivery arrangement at the election of eligible employees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to RSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs that vested during 2020, 2019 and 2018 was $49.7 million, $36.1 million and $35.5 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRSUs vest based on the achievement of certain predefined Company-specific performance criteria and expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNzIvZnJhZzowOTlmNTcwOWJhOTg0NWEyODE3MTBiNWJiODA3NmE4MS90ZXh0cmVnaW9uOjA5OWY1NzA5YmE5ODQ1YTI4MTcxMGI1YmI4MDc2YTgxXzEwOTk1MTE2MzY3ODc_5d15221a-7a45-46b5-9a36-6d279f3cbde9">four</span> to five years from the grant date. The fair value of PRSUs is estimated based on the closing sale price of our common stock on the date of grant.&#160;Expense recognition for PRSUs commences when attainment of the performance-based criteria is determined to be probable. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to PRSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized share-based compensation expense for PRSUs was $17.0 million. The total fair value of PRSUs that vested during 2020 was $13.5&#160;million. No PRSUs vested during 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85% of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of common stock on the purchase date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748403192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense for continuing operations were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2020, 2019, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(346.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, our deferred tax assets were primarily the result of federal net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. At December 31, 2020 and 2019, we recorded a valuation allowance of $49.8 million and $346.0 million, respectively, against our gross deferred tax asset balance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. At December 31, 2020, in part because we achieved three years of cumulative pretax income, management determined there is sufficient positive evidence to conclude that it is more likely than not deferred tax assets of $319.4&#160;million are realizable. Accordingly, we recorded a net valuation release of $296.3 million on the basis of management&#8217;s assessment. The remaining valuation allowance of $49.8 million consists primarily of state net operating loss and credit carryforwards for which management cannot conclude it is more likely than not to be realized. The release of the valuation allowance is reported under continuing operations as a benefit to income tax expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had federal and state income tax net operating loss carryforwards of $518.2 million and $340.8 million, respectively. The federal net operating losses will begin to expire in 2028, unless previously utilized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California net operating losses will begin to expire in 2028 unless previously utilized and the net operating losses related to other states will begin to expire in 2026.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have federal and California R&amp;D tax credit carryforwards of $92.1 million and $56.4 million, respectively. A portion of the federal R&amp;D tax credit carryforwards expired in 2020. The remaining federal R&amp;D tax credits will continue to expire beginning in 2021, unless previously utilized. The California R&amp;D tax credits carry forward indefinitely.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the future utilization of our net operating loss and R&amp;D tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. No ownership changes have occurred through December&#160;31, 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize interest or penalties related to income tax matters in income tax expense. Interest and penalties related to income tax matters were not material for 2020, 2019 or 2018.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the U.S. and various state jurisdictions. Our tax years for 2001 (federal) and 2008 (California) and forward are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&amp;D tax credits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to unrecognized tax benefits follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We excluded those deferred tax assets that are not more-likely-than-not to be sustained under the technical merits of the tax position. Such unrecognized tax benefits total $3.9 million for current year tax positions, as reflected in the table above.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had $53.9 million of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate, subject to the valuation allowance. We do not expect a significant change in our unrecognized tax benefits in the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765744197704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating leases for our office and laboratory facilities, including our corporate headquarters, with terms that expire from 2025 through 2031. We have two options to extend the term of the operating lease for our corporate headquarters for a period of ten years each. However, as we were not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease right-of-use, or ROU, asset or liability. In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost was $10.1 million for 2020 and $8.1 million for 2019. Cash paid for amounts included in the measurement of lease liabilities was $8.6 million for 2020 and $7.7 million for 2019.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases had a weighted-average remaining lease term of approximately 10.3 years and 11.2 years at December 31, 2020 and 2019, respectively, and a weighted-average discount rate of 5.6% and 5.8% at December 31, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">Less current operating lease liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765744158184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">Retirement PlanWe have a 401(k) defined contribution savings plan, or the 401(k)&#160;Plan. The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $6.7 million, $4.9 million, and $1.8 million for 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765849710536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our quarterly results follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0&#160;million, accounted for as IPR&amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5&#160;million, accounted for as IPR&amp;D, in the third quarter of 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1&#160;million, accounted for as IPR&amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0&#160;million upfront, accounted for as IPR&amp;D, to obtain outside the U.S. rights to the Friedreich&#8217;s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2&#160;million, accounted for as IPR&amp;D, in the fourth quarter of 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765753101896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_BusinessDescriptionPolicyPolicyTextBlock', window );">Business Activities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine. We also have two wholly-owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd. both of which were formed in December 2014 and are inactive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a neuroscience-focused biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Our diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, we specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc.)</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Neurocrine as well as our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Industry Segment and Geographic Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Segment and Geographic Information. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single industry segment&#160;&#8211; the discovery, development and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. We had no foreign-based operations during any of the years presented.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts in prior year periods have been reclassified to conform with the presentation adopted in the current year.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks and any allowance for doubtful accounts. We estimate the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of our customers and individual customer circumstances. To date, an allowance for doubtful accounts has not been material.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt Securities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts', window );">Allowance for Credit Losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.7 million at December&#160;31, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during 2020, 2019 or 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels in the fair value hierarchy during 2020 or 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on the first-in, first-out method. We assess the valuation of our inventory on a quarterly basis and adjust the value for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzk1MTk_8d0fcf19-f18b-4cc7-a570-ecad81280ef1">three</span> to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. Depreciation expense was $8.6 million for 2020, $7.4 million for 2019 and $4.0 million for 2018.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If&#160;the carrying amount is not recoverable, we measure the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized using a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the U.S., our product sales, net consist of sales of INGREZZA, primarily to specialty pharmacy providers and a specialty distributor, and sales of ONGENTYS, primarily to wholesale distributors. We recognize product sales, net when the customer obtains control of our product, which occurs at a point in time, typically upon delivery of our product to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, payors and other third parties. Such estimates are based on information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the reporting period), as supplemented by management&#8217;s judgement. Our process for estimating reserves established for these variable consideration components does not differ materially from historical practices. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant categories of sales discounts and allowances are as follows:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Discounts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product discounts are based on payment terms extended to our customers at the time of sale, which include incentives offered for prompt payment. We maintain a reserve for product discounts based on our historical experience, including the timing of customer payments. To date, actual product discounts have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates for mandated discounts under the Medicaid Drug Rebate Program. The liability for such rebates consists of invoices received for claims from prior quarters that remain unpaid, or for which an invoice has not been received, and estimated rebates for the current applicable reporting period. Such estimates are based on actual historical rebates by state, estimated payor mix, state and federal regulations and relevant contractual terms, as supplemented by management&#8217;s judgement. Our rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time-lag in our receiving rebate notices from each state (generally, several months or longer after a sale is recognized). Estimated rebates are recorded as a reduction of revenue in the period the related sale is recognized. To date, actual government rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The difference between the list price, or the price at which we sell our products to our customers, and the contracted price, or the price at which our customers sell our products to qualified healthcare professionals, is charged back to us by our customers. In addition to actual chargebacks received, we maintain a reserve for chargebacks based on estimated contractual discounts on product inventory levels on-hand in our distribution channel. To date, actual chargebacks have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor and Pharmacy Rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are obligated to pay rebates as a percentage of sales under payor and pharmacy contracts. We estimate these rebates based on actual historical rebates, contractual rebate percentages, sales made through the payor channel and purchases made by pharmacies. To date, actual payor and pharmacy rebates have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer financial assistance to qualified patients with prescription drug co-payments required by insurance. We accrue for copay assistance based on estimated claims and the cost per claim we expect to receive associated with inventory that remains in the distribution channel at period end. To date, actual copay assistance has not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor and Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the sales of our products, we pay distributor and other fees to certain customers that provide us with inventory management, data and distribution services, which are generally recorded as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify the associated costs in selling, general and administrative expenses. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For INGREZZA, we offer our customers product return rights primarily limited to errors in shipment and damaged product. We do not permit returns of INGREZZA for expiring or expired product. Accordingly, we have limited return risk resulting from INGREZZA product sales and therefore do not record an associated returns allowance. For ONGENTYS, we offer our customers product return rights primarily limited to errors in shipment, damaged product, and expiring or expired product, provided it is within a specified period around the product expiration date, as set forth in the associated distribution agreement. Once product is returned, it is destroyed. Where actual returns history is not available, we estimate the associated returns allowance based on benchmarking data for similar products and industry experience. We record this estimate as a reduction of revenue in the period the related sale is recognized. To date, actual product returns have not differed materially from our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaboration and licensing agreements under which we license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; development, regulatory, and/or commercial milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Each quarterly period, sales-based royalties are recorded based on estimated quarterly net sales of the associated collaboration products. Differences between actual results and estimated amounts are adjusted for in the period in which they become known, which typically follows the quarterly period in which the estimate was made. To date, actual royalties received have not differed materially from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. We have established guidelines to limit our exposure to credit risk by diversifying our investment portfolio and by placing investments with high credit quality financial </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions and maturities that maintain safety and liquidity. To date, we have not experienced any credit losses and do not believe we are exposed to any significant credit risk in relation to these financial instruments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Our two largest customers represented approximately 86% of our product revenues for both 2020 and 2019, and the significant majority of our accounts receivable balances at December&#160;31, 2020 and 2019. For 2018, our three largest customers represented approximately 93% of our product revenue and substantially all of our accounts receivable balance at December 31, 2018. To date, we have not experienced any significant losses with respect to the collection of these accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes third-party manufacturing, transportation, freight and indirect overhead costs associated with the manufacture and distribution of INGREZZA and ONGENTYS, royalty fees on net sales of ORILISSA and ORIAHNN, and adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation charges for those individuals involved in ongoing R&amp;D efforts; as well as scientific consulting fees, preclinical and clinical trial costs, R&amp;D facilities costs, laboratory supply costs and depreciation of scientific equipment. All such costs are charged to R&amp;D expense as incurred. These expenses result from our independent R&amp;D efforts, as well as efforts associated with collaborations, in-licenses and third-party funded research arrangements, including event based milestones.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Asset Acquisitions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions of an asset or group of assets that do not meet the definition of a business using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of their relative fair values. No goodwill is recognized in an asset acquisition. Intangible assets that are acquired in an asset acquisition for use in R&amp;D activities which have no alternative future use are expensed as in-process research and development, or IPR&amp;D, on the acquisition date. Future costs to develop these assets are recorded to R&amp;D expense as they are incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed when services are performed, or goods are delivered. We incurred advertising costs related to INGREZZA and ONGENTYS of $64.8 million for 2020, $40.6 million for 2019 and $20.5 million for 2018.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant stock options to purchase our common stock to eligible employees and directors and also grant certain employees restricted stock units, or RSUs, and performance-based restricted stock units, or PRSUs. Additionally, we allow employees to participate in an employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and shares to be issued under the ESPP using the Black-Scholes option-pricing model on the date of grant. Restricted stock units are valued based on the closing price of our common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xNDgvZnJhZzozYTVhN2Q5YjJhODE0ZTZiOTBlYjZiYTExY2U3ODFkZi90ZXh0cmVnaW9uOjNhNWE3ZDliMmE4MTRlNmI5MGViNmJhMTFjZTc4MWRmXzIzNTk5_9b6b4cf3-899b-4055-94dc-05632180c7d1">three</span> to four years; however, certain provisions in our equity compensation plans provide for shorter vesting periods under certain circumstances. The fair value of shares to be issued under the ESPP are recognized and amortized on a straight-line basis over the purchase period, which is generally six months. Additionally, we granted certain PRSUs that vest upon the achievement of certain predefined company-specific performance-based criteria. Expense related to these PRSUs is generally recognized ratably over the expected performance period once the predefined performance-based criteria for vesting becomes probable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax benefit (provision) is computed under the asset and liability method. Significant estimates are required in determining our income tax benefit (provision). Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by </span><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal. Prior to 2020, we recorded a valuation allowance that fully offset our deferred tax assets. On December 31, 2020, based on our evaluation of various factors, such as our achievement of a cumulative three-year income position as of December 31, 2020, as well as our consideration of forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit. Refer to Note 9 to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common and potentially dilutive shares outstanding during the period, including the potentially dilutive shares resulting from the conversion of the 2024 Notes and excluding the effect of stock options and restricted stock outstanding for periods when their effect is anti-dilutive, using the treasury stock method.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 5.0 million shares underlying the 2024 Notes at December 31, 2020, only the shares required to settle the excess of the principal portion would be considered dilutive under the treasury stock method. Further, approximately 0.2 million PRSUs were excluded from the calculation of diluted net income per share as the performance condition has not been achieved. In loss periods, basic net loss per share and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2016-13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2019-12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We plan to adopt ASU 2020-06 effective January 1, 2022 and are currently evaluating the effect ASU 2020-06 will have on our consolidated financial statements and related disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessDescriptionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Description Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessDescriptionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (a,b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745615608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at December&#160;31, 2020, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross unrealized losses and fair value available-for-sale investments in unrealized loss position</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at December&#160;31, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765834558216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments measured at fair value on recurring basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,069.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity securities, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748388088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Convertible senior notes net of discounts and deferred financing costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748980376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee related costs </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Branded Prescription Drug Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745626632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net income (loss) per share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765835267496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Compensation cost related to share based compensation</a></td>
<td class="text">The effect of share-based compensation expense on our consolidated statements of income and comprehensive income by line-item follows:<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by award-type follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized share-based compensation expense by award-type and the weighted-average period over which such expense is expected to be recognized, as applicable, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Recognition Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions for stock option grants using black-scholes option-pricing model</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected option term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary and changes in stock options outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to stock options follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary and changes in restricted stock units outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to RSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to PRSUs follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date <br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748764408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax expense for continuing operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense for continuing operations were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Provision for income taxes on earnings subject to income taxes differs from statutory federal rate</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on earnings subject to income taxes differs from the statutory federal rate due to the following: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2020, 2019, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(300.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets as of December 31, 2020 and 2019 are listed below. </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net of deferred tax assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(346.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Activity related to unrecognized tax benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity related to unrecognized tax benefits follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration of the statute of limitations for the assessment of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747608104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of minimum lease payments for operating lease liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkNjc4MzYxMjMwMTRlNGM5NTM0YjBhMzYwMDQ5M2U0L3NlYzowZDY3ODM2MTIzMDE0ZTRjOTUzNGIwYTM2MDA0OTNlNF8xODEvZnJhZzpkZjk2OWMxNDIxOGE0NTY4OWQ4Mzg3ZDRhZGJkNDg1Mi90YWJsZTpmMjgyMzhhYWViNDk0NjIzOTRhNzNhZDgwNzA4NTcxYy90YWJsZXJhbmdlOmYyODIzOGFhZWI0OTQ2MjM5NGE3M2FkODA3MDg1NzFjXzExLTAtMS0xLTMxNg_d8b1a23d-ec0a-4994-85b7-72ebf9c2e5ad">Less current operating lease liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Amounts presented in the table above exclude $19.7 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 2: Current operating lease liabilities are included in other current liabilities on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765752890984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Results of Operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our quarterly results follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0&#160;million, accounted for as IPR&amp;D, in the second quarter of 2020. In connection with the payment of the upfront fee pursuant to our collaboration with Takeda, we recorded a charge of $118.5&#160;million, accounted for as IPR&amp;D, in the third quarter of 2020.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1&#160;million, accounted for as IPR&amp;D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0&#160;million upfront, accounted for as IPR&amp;D, to obtain outside the U.S. rights to the Friedreich&#8217;s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2&#160;million, accounted for as IPR&amp;D, in the fourth quarter of 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765828537624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>subsidiary </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfIrishSubsidiaries', window );">Number of wholly owned Irish subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff', window );">Accrued interest receivables write-off threshold period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,800,000<span></span>
</td>
<td class="nump">$ 40,600,000<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares) | shares</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares) | shares</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Share based compensation arrangement by share based payment award purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest two customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue, Product and Service Benchmark | Customer Concentration Risk | Largest three customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfIrishSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Irish Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfIrishSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267859-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nbix_LargestTwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nbix_LargestTwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nbix_LargestThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nbix_LargestThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765736848888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1">42 Months Ended</th>
<th class="th" colspan="1">126 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500.0<span></span>
</td>
<td class="nump">$ 8,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
<td class="nump">154.3<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247.9<span></span>
</td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="nump">$ 302.4<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
<td class="nump">244.1<span></span>
</td>
<td class="nump">$ 222.1<span></span>
</td>
<td class="nump">$ 183.5<span></span>
</td>
<td class="nump">$ 138.4<span></span>
</td>
<td class="nump">1,045.9<span></span>
</td>
<td class="nump">788.1<span></span>
</td>
<td class="nump">451.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Incremental funding provided</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_ResearchCollaborationTerm', window );">Research collaboration term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialCommercialMilestonePayments', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement | NBI-827104</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement | Development Product Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember', window );">Xenon | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember', window );">Xenon | Collaborative Arrangement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Equity securities number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember', window );">Voyager | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investment in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember', window );">Voyager | Collaborative Arrangement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Equity securities number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember', window );">B I A L | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsReceived', window );">Upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe | Collaborative Arrangement | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember', window );">AbbVie | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember', window );">AbbVie | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember', window );">AbbVie | Collaborative Arrangement | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments made for milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payments for commercial milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential later stage milestone payments and royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments to be paid under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ResearchCollaborationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ResearchCollaborationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments received under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_NBI827104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_NBI827104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_DevelopmentProductCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_DevelopmentProductCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765835557656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 612.4<span></span>
</td>
<td class="nump">$ 557.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">613.9<span></span>
</td>
<td class="nump">558.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">299.3<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">300.7<span></span>
</td>
<td class="nump">271.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">230.9<span></span>
</td>
<td class="nump">142.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">231.0<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">226.7<span></span>
</td>
<td class="nump">299.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">227.1<span></span>
</td>
<td class="nump">299.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">144.8<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">145.2<span></span>
</td>
<td class="nump">250.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 81.9<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765847451432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745495240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Debt securities available for sale position number of positions</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available-for-sale in an unrealized loss position</a></td>
<td class="nump">30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765751600024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Fair value measurements recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">$ 1,069.5<span></span>
</td>
<td class="nump">$ 1,029.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">445.9<span></span>
</td>
<td class="nump">521.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">312.9<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">841.0<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember', window );">Total equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair value</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Total equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">841.0<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">445.9<span></span>
</td>
<td class="nump">521.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">312.9<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">841.0<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Total equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Total equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748671320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities, beginning balance</a></td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 68.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="num">(17.7)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities, ending balance</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Equity securities&#8211;biotechnology industry | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities, beginning balance</a></td>
<td class="nump">55.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">68.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="num">(17.7)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities, ending balance</a></td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745355304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - Measurement input, discount for lack of marketability<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, FV-NI, measurement input</a></td>
<td class="nump">0.150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, FV-NI, measurement input</a></td>
<td class="nump">0.340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities, FV-NI, measurement input</a></td>
<td class="nump">0.248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765746882968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,300,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance</a></td>
<td class="nump">$ 502,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TradingDaysDuringObservationPeriod', window );">Trading days during observation period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtConversionObservationPeriod', window );">Conversion observation period</a></td>
<td class="text">25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.00131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Conversion premium</a></td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance', window );">Carrying amount of the liability component upon issuance</a></td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Assumed borrowing rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of the equity component upon issuance</a></td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior note</a></td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault', window );">Events of default percentage of principal and accrued and unpaid interest due and payable upon default</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment', window );">Fair value of the liability component immediately before extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement', window );">Carrying amount of the liability component at settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514,300,000<span></span>
</td>
<td class="nump">$ 596,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the liability component at settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentAtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component upon issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtConversionObservationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtConversionObservationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Events of default percentage of principal and accrued and unpaid interest due and payable upon default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the liability component immediately before extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_TradingDaysDuringObservationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading days during observation period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_TradingDaysDuringObservationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765749063752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 381.3<span></span>
</td>
<td class="nump">$ 517.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount, net</a></td>
<td class="num">(59.4)<span></span>
</td>
<td class="num">(101.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 317.9<span></span>
</td>
<td class="nump">$ 408.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748730056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765829315672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 86.3<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(41.7)<span></span>
</td>
<td class="num">(33.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">26.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_ScientificEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765753044504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee related costs</a></td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_RevenueRelatedReservesForDiscountsAndAllowances', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued development costs</a></td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_AccruedBrandedPrescriptionDrugFee', window );">Accrued Branded Prescription Drug Fee</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 168.7<span></span>
</td>
<td class="nump">$ 141.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RevenueRelatedReservesForDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue-related reserves for discounts and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RevenueRelatedReservesForDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748989832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 187.1<span></span>
</td>
<td class="nump">$ 112.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 190.3<span></span>
</td>
<td class="nump">$ 115.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other balance sheet details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747789816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 347.9<span></span>
</td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="nump">$ 79.6<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="num">$ (102.1)<span></span>
</td>
<td class="nump">$ 407.3<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">91.4<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">98.2<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities', window );">2024 Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747593048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember', window );">Stock options restricted stock and convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from diluted per share amounts (in shares)</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748038616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>May 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of stock options granted (in USD per share)</a></td>
<td class="nump">$ 45.67<span></span>
</td>
<td class="nump">$ 41.74<span></span>
</td>
<td class="nump">$ 43.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Stock options exercised in period intrinsic value</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 64.3<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from stock option exercises</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Discounted purchase price percentage of common stock authorized for issuance</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of stock options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">$ 86.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value vested in period</a></td>
<td class="nump">$ 49.7<span></span>
</td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">99.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized expense</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of PRSUs vested</a></td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenPlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nbix_A2020EquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance (in shares)</a></td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_TwoThousandAndElevenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nbix_A2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nbix_A2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745416776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 75.3<span></span>
</td>
<td class="nump">$ 58.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">66.3<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 33.7<span></span>
</td>
<td class="nump">$ 25.8<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765829421464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="nump">$ 75,300,000<span></span>
</td>
<td class="nump">$ 58,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">47,500,000<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">44,200,000<span></span>
</td>
<td class="nump">30,500,000<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765749076216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 86.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 99.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Recognition Period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765748892728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of common stock</a></td>
<td class="nump">48.50%<span></span>
</td>
<td class="nump">54.80%<span></span>
</td>
<td class="nump">59.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747664472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding (in shares) | shares</a></td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">$ 52.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">103.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share) | $ / shares</a></td>
<td class="nump">43.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Outstanding (in USD per share) | $ / shares</a></td>
<td class="nump">62.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 49.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 235.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 218.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765749125128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share)</a></td>
<td class="nump">$ 74.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">102.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share)</a></td>
<td class="nump">67.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share)</a></td>
<td class="nump">84.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share)</a></td>
<td class="nump">$ 89.60<span></span>
</td>
<td class="nump">$ 74.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value</a></td>
<td class="nump">$ 147.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Unvested (in USD per share)</a></td>
<td class="nump">$ 59.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">102.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share)</a></td>
<td class="nump">82.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in USD per share)</a></td>
<td class="nump">45.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Unvested (in USD per share)</a></td>
<td class="nump">$ 102.90<span></span>
</td>
<td class="nump">$ 59.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, weighted average remaining contractual term (in years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, aggregate intrinsic value</a></td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nbix_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765745767688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense for Continuing Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(287.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(23.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred taxes</a></td>
<td class="num">(310.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">$ (300.6)<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765749033736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes, rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21% for 2020, 2019, 2018</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost', window );">Officer compensation</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits', window );">Expired tax attributes</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(39.0)<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(296.3)<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">$ (300.6)<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationExpirationOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation, expiration of tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationExpirationOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense branded prescription drug fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense officer compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765829440840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 111.4<span></span>
</td>
<td class="nump">$ 181.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Share-based compensation expense</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DeferredTaxAssetsOperatingLeasesAssets', window );">Operating lease assets</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">86.7<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">23.9<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">411.3<span></span>
</td>
<td class="nump">395.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="num">(13.8)<span></span>
</td>
<td class="num">(24.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(19.9)<span></span>
</td>
<td class="num">(18.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(49.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DeferredTaxAssetsLiabilitiesGross', window );">Net of deferred tax assets and liabilities</a></td>
<td class="nump">369.2<span></span>
</td>
<td class="nump">346.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(49.8)<span></span>
</td>
<td class="num">(346.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 319.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assts (liabilities) gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxAssetsOperatingLeasesAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating leases assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxAssetsOperatingLeasesAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765747111416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 49.8<span></span>
</td>
<td class="nump">$ 346.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Realizable deferred tax assets</a></td>
<td class="nump">319.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, net valuation release</a></td>
<td class="nump">296.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">53.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">518.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">92.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765835253272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 63.9<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">(Decrease) related to prior year tax positions</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements related to prior year tax positions</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of the statute of limitations for the assessment of taxes</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 60.8<span></span>
</td>
<td class="nump">$ 63.9<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765753138840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>renewalOption</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfRenewalOptions', window );">Number of renewal options | renewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Cost</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Payments</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">11 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of renewal options under the terms of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765753097288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2021</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2022</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2023</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2024</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2025</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">77.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">139.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">104.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">94.4<span></span>
</td>
<td class="nump">$ 86.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced', window );">Non-cancelable future minimum lease payments for operating leases that have not yet commenced</a></td>
<td class="nump">$ 19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cancelable future minimum lease payments for operating leases not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765829409224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum employee contribution percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, employer contribution amount</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765746751176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Quarterly Results of Operations (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 247.9<span></span>
</td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="nump">$ 302.4<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
<td class="nump">$ 244.1<span></span>
</td>
<td class="nump">$ 222.1<span></span>
</td>
<td class="nump">$ 183.5<span></span>
</td>
<td class="nump">$ 138.4<span></span>
</td>
<td class="nump">$ 1,045.9<span></span>
</td>
<td class="nump">$ 788.1<span></span>
</td>
<td class="nump">$ 451.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">176.1<span></span>
</td>
<td class="nump">302.8<span></span>
</td>
<td class="nump">225.8<span></span>
</td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">195.3<span></span>
</td>
<td class="nump">132.0<span></span>
</td>
<td class="nump">149.1<span></span>
</td>
<td class="nump">239.4<span></span>
</td>
<td class="nump">882.9<span></span>
</td>
<td class="nump">715.8<span></span>
</td>
<td class="nump">414.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 347.9<span></span>
</td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="nump">$ 79.6<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="num">$ (102.1)<span></span>
</td>
<td class="nump">$ 407.3<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in USD per share)</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in USD per share)</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">91.4<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">98.2<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139765746674424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Quarterly Results of Operations - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="nump">$ 154.3<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 118.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember', window );">Voyager | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember', window );">Xenon | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=ES\N86+I0I? 595DRQLT:U9+=NSVA?-3O/"X6Y_8*P*(W1K&:$'Q!20&L,
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M[G'-*$@W!O#]2D#IT[^8R_?]/UNN_@502P,$%     @ <()%4LKO#"0, P
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M\9KI)[']3G:&!H8O$4S9?[0ML1& D[72(M\%@X*<\O**WW:)J 7X_4\"@EU
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MH(+YV'S#I&5!W,52'5B!KNIT7-=<7 43MXJ$ V>$GG+%8'&J2[*M$0H,6M.
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M3HBX.Z'G0B2G6%5'-)8>J.^V;4C(\J=/UDBK]\2M]ZZSM=JT6RM7*V.+OK;
M%I&Q/]Y88*&_ZO0&_7/&5M$#MZ*O10HR)_3FM]P)E7Q<)YBMU@;XIR,=M$(6
MN(7,%>G 5*4(&U/;@@HBHZ^WH$)LA'G6.8_/6+$OWVM(6*6G7%5GULVOS;N3
MC^4;@\'OC_AV4[T!:=U4+V0^T6+/<XE2M@.7T+M!I2FJ=QS5A1+'\M1_*Y02
M6?GUP&C""@V ^SL!.[OZ0C^@>=/T\!]02P,$%     @ <()%4J<Q[H5I!@
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MQ]-M'*4K>K-^&CJVM4H&5C0=FQS<C@A>X<YH-/2D&WH2=-%WGLDJ$X5@3>&
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MP%-R;"9WD.E-9\@XX),N3&U0GC&'+ZQM"B!T4+HJ>,K\$!^ V ":EUWOP#S
M/?!88!MMC6 %OCUR,%P+.=KU>\:=B3)X&S&WLG 5!H\$W]NMP('X^- X_.L*
M%R6D7&R $$M#8OC'BXO+&4C.WP8'/ 7V0@,&%FZ-G+TQ'VUA%6B6'QT895O&
M1+\V?6&62Z ,1OR&\0[' L:* $P>#!?3VR(LXWF:EI #BF2 IP$@X(,.$##4
M($H<[.2+I6\W\&+;)9"= "%58 &!)+ZR*X(>E__1(D=M03#"]VR5TFV U /Y
MB4H"(30%,D"-_Y8U.EF#6/KL6P)3A=P^B+BP#>C)C\QE@-M<8(K<@/>#*,&'
M[BBVYFA$5LJJC+)$DL$QU@9D8(N;@$W9R/-\-KJA:O#,_7OEUSU(C@XIKP-8
M+.B/=[:LX5))P=-+)\5SZWN#F)'[A'\"H<%!\.5BB\*Y2DG?AR58(0C!,K7V
M3.BXG6C2JDVILQR\1[3@VK"U =7X$HCQVM1()G1*9"8'9P:E6A=K,)Z!R&L'
M#^$BUT %3%%,CJ#.T.5P\ R\!S?6NP5=+@*&JR,6"78#7.<=Z!8@-2 -0%4O
M:$*INF'S$TY=HVUCF,2!X(B3MX,'>0DT"*LN+"]L(]C%B5I*'2+8PN< 1/*A
M#Q\*Q"7>*BHT(A VY_G$[8Y%#:E)(/YM#T)X3Z1$1(GKD:8$6;\PY4?A4[CR
M\#*]6[7#HE\.=9"/A%OE(>;%FU\HA+Y V'UR'5$\H)@,7F17A0H$YP8@&GT*
MB@.^:$@ H?S5(W:BFT"SN@I?"&<OG2^'#8@,/#Y(3+ T - 9WMMM@,+5H"QA
M\L3C>9 ^)V .+7J0$"5>-4EZ^J +'S"E=70%*66A$$9"(AYA&5J!C.M</PM&
M(NKA;+$9'2Q9'-Y:H0AI<-%YMT45X2VJS5[ 05IG3MJ/5T.U9:Z-JY%FP$+S
M\\X@18U/</A,3F! QTOC? &$.@ NB46'!C@&;8:J6 '?\XW4;8<R1Q0KL6N+
MU@C9@-ZNT=N^MF2:(TMX>F&F!-R;3TQ>GU@OP\WXP8H- GAE,4ZV*VF( !(3
M[P;T!\%3MO LD)T3I&>'!7[*/MJC_;ZM0?H2D39M0]N*WAER)D8&$?4)#P#\
M 32A6"!W2V=[>@J$!Q8/VK+-;P-\A?I&'M:#+8:>*(X9&\T46-*,P+L)-H="
M@<Q2.#]=0Q]!8BPGVPK:@]DJ& NV1)!/<%4;-VSP@"HM3L#@H@^#1E%[J3FD
M.F^3VV!3$5%H2>LS 0A(Q -@[ZY;T"H_CND(UD9BG+K&G$#;1O0EV+3$\$AY
MD1GUY+@TT2.1W$R<#10]KLD@)8L8&+< #=+T0<T%2"\R4?(<&-+UQ4\$--O:
M!] ><ACJRB9E(SQT00("MB+#?.D\4@LN"W;HVA(K[1A]#6G-#HQ3,LE@?R &
M0+H%+??1DIUO&J(N4G'PULZ!)EQ8M=O"^WQB);>%1<. 4(N6"TFUOIOD+B"M
M96$=0266 I@D)#?A_14Z/H!/ K9'&&5C-11I;P0:KR*%(7A%DRP-_]O!4[ H
MR/!=@RLED@#T<#NL0*\:\/2;U=VO@[!4M82Q#88K2;<A+A!>N!&$0DY'EV-Q
M0R0UO1BR^"RZ9G2Y"5"H6=@N11Y'(58RR2B=>Q&32]!_K2?3%.UH)D>,+Q )
M(""T=;!MB*L^]8)0]N:3?>%-LD.(%')DSDB6D6=- CMG2=%#Z2.P/NZ&1B(;
MK3G5@.&@WX$OT)1@\L*&^.3H8,OQB4B-LXID8RQ%#AL-W2RU".5P:/&@!;4$
M5L3GMNQKBFT%?AK_+::_S>0]>0_" N*$3.J.]#V!_3/!R*[BV):SR</+58SL
MEYR"2!&P,)P5Z%3BGHM]XF$Q<D=Z\TY0@;@#.G" ,>>9=W&ES%H*@EC9[V[@
MKAK:ZHY6 AHSVVT-M*)F<6X=1/-X6BM-\'S;PW^JXHM')U\5&Q"/Y&KT,0*F
MH5\R2X)P,-W@[6U')%5^ X@LF(B>!C &.]9RHF_V&G[AS?BOY IFATN[3NVF
MZO/L)!9?B>5Q4GQHA(#)&[KI-,C/+7CK2'8<;U!PT1?-[!E6W#<;+<4 ANY8
M^0J,$0LGQ9OV9J@HLJG:HETNU;?%.\6;/7N*Y 7__1JN ]'T5^7I5R'\\!K@
M\\,F.)9,ZP?>V^PN!$<!+WBGWV</IN9U])=,ID(<^.=@GNU%4;$K-;AN;='F
M['?(AFF<)2S#D0:TBDQQOUUTUK,+Z9KMT'</V"C"T/DN7^#^T!P^S3&H2;C$
M#0JTM&R1.UB%H6]<8P2D^Z;X"?];G(5 R7\,+<4(O4.'%78UU:_@S=GJ 9E(
M;##R(9BKF"PP^HE*I&=WVYF%J\7 YQW.C^R 2W0@(6OCIQ<XW'96_':P1(3B
M+NLI_"'<@))$-B$W K$;OXV(GZF!50$KE3T&'SUI3/YKQL<9%NCQ]HY">83\
M >TZ,&SU-@BR%+"]XNE1P-.'PPMGD+Q=HA28)!.S:(=>M\BC?$)YH&D!4> Q
M4:B>PG)#9R5 5*K)?0@@&E:DE3PK*N!BQ(=;%I3RD=4-YX_V(6@VL9 H/I'<
M' 4!485F5N:OWX6#?7"W,7 %.DFIC>+RQGLW=I@/0R8)_TQY-H>[@B8?>CC+
MW\4B]-4<L;H/&,1K<Z7$B,F#RS^7U]-X)1!,!29ZP68L>3<M>*M [.P@XNND
M0Q+GB7$N(4/*>)ARC=8B(I_-3PRW=4GR3^CH=U(UF$\!8RDFKX9RK4MJ^%[)
M3(X<!!\Z5G-RVX-?:#+N=U&R8Q:O&VQ0XE*", /1VI1KW*'8.UO3)[[]:/W#
M"E:'YTDP=-&S+ Y8B*X?P*=,1,0V2(D%!DRCB7K\5NG^,8M%EZ8<P]>%O 0V
M'R]&21E&!R&LX[49LK JL'$937Q3[XFL"#T2M#+D$(0HVHA-#C48&L'R&@?F
MG4VD&8BG7RG<WQ;KMB;X.1Z,3A'&K!D?-;@+Y--@C+7AJ/-1?GMTG-_$C\=5
M2!J%@X\HG779!HV@E&!3,8:FC(2<;UZ+X"1OH6_+CZPGBNNV-CU)H)DPATOT
M,CX-GA"X1:1%XL.(3271@,U9R'UHZ(5(N3:P&SS/EZ[RSMM:\ZP4%DGT0(IQ
MR9,!#MG>W(0,F)D*.2.UZ.=;LT\_) LL57DD&SX%B>=\<C^88; "&WS6K<$>
MG1.,$E!W(L?0=K.D*SF9ML3 K]HZ;$Z$;-&419(8>V+F/65:;@#I^^2?>"_T
M<J6J BP7#FJ0C4S)T[[@2 V=.PKV$#_B^$<; \&\=!)4$HD[IX<XE*2$D>"K
MTR"XFN>17"@>-'?-3/Z%FE=#4K]8#13ADY$\)7(> 2++\K<!!(W%=##;_W2/
M9'>%U]FI 9^",ADHWQ9=6UN*K>E:0F 2@DCR@ $K7?0[Z3S 8NPU:H0)_=20
M(8A90[(JED./GE9E8>4JO2]<2D,JB%YU\D'S\2DD72B!+/$S31?NA\.*0CPB
MC. OO@SX;"\U#Y1H0NRB*2+@ $]NK.>,.>/8=2$D0T9BNPC,P<88O0> -.W&
ME:A3[-*)RY;%"S06.$O-=T5J"(O].E2K& LR6]=S\AYTUKPV0T,J,D<5I^)@
M$V]7 P@'_(8K%C#%<8FE(:AX$&),I&W9O<H^M_HYR_2>) Q<+:&4(ZD @/B
M>+-,&G*E9/-AN@5+.[K,*NTR'O$&"]WF%$53V@X@(<H.MD%''/X+6)K:;6EC
M>NYUC&' 9S^!OIG_1''W"X)#W+MK+/9#932OZ4L!DHS^N  :I^C%%O::: T#
M #&:EJ6A0H0KX045NL$*-(U8KANS+W(6X7C'ZZ6NTWJ.%41@*%!$Y)#(@/!V
MT"H<TEPRQ1V><+$/?(N@I7'-0W@[M,3D16#JG*,U# 1&BV@K-'.8#233C'G
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M!VS!^PH\*K=OT_;769*#)F9[2#:&YM2Q#AO0C+NJF<)9%:!FL.\=%W?'T!V
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M@AB=3[*2.%<NE99Q$F14+LFZB7P-8O6PX4,*]/D$6 4EN&-3:Y>60$^>A'"
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M?B";?IRQZ?E7I,.GA?X&]P7_]'1\G'_ ^V?C5]@07MLEO'IZ\M67][@C3O\
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MC?\HP87[%K]YW/V+!A^DG='9L$Q-\>K^Z/1XQWE@^%&9@K_,![2LS(+_!')
MF-(#N#\UI@H_:('X3S6\^"=02P,$%     @ <()%4BO1SE\>!0  C!   !@
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M5PG*%^[ -&!\,[QKHPOIRI,P?4\Y6/'_4+;L#9^U]2>273D*J.W?XUG6M=5
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M+<#O"P/EAB]T0/N*]IO_ 5!+ P04    " !P@D52$P;W%AL$  #$"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RM5FUOXS8,_BN$<1]:H'/BE[9)
MD01HVA4[8(<5;;?[,.R#(C.Q<++DD^2F_?<C92?- 6W18??!UAOYD'Q$2IIM
MK?OF:\0 3XTV?I[4(;07HY&7-3;"I[9%0RMKZQH1:.@V(]\Z%%54:O0H'X_/
M1HU0)EG,XMRM6\QL%[0R>.O =TTCW/,2M=W.DRS93=RI31UX8K28M6*#]QC^
M;&\=C49[E$HU:+RR!ARNY\EE=K$L63X*_*5PZP_ZP)&LK/W&@\_5/!FS0ZA1
M!D80U#SB%6K-0.3&]P$SV9MDQ</^#OTFQDZQK(3'*ZN_JBK4\V220(5KT>EP
M9[>_X1#/*>-)JWW\P[:7+:8)R,X'VPS*Y$&C3-^*IX&' X7)^ V%?%#(H]^]
MH>CEM0AB,7-V"XZE"8T[,=2H3<XIPYMR'QRM*M(+BS]"C0Z60@LC$>YC'EQC
M$$K[V2B0 18;R0%LV8/E;X!E.7RQ)M0>?C455C\"C,BSO7OYSKUE_B[B-<H4
MBNP$\G$^?@>OV(=;1+SBOX<+?U^N?'"4)O^\8ZC<&RJCH?+G\/HN&!?FA6^%
MQ'E"E>?1/6+R;BB?S2.:8)U"#])2!?F %=@UD ZLK:925&9S0?(2FQ7!,,5'
MRE"&:4W%XH\CX?3+IG GMI1Q 9T2!/T)LK/TC)LRS> KE1R07NNL1.\A3TO(
MTE.X44914E:PL;;R,$W'-'T.#S8(3?(OWGV"?$*+!'>>%G#KZ+1QX1F$J0"_
M=ZJE^@\G8)!^_SN0!S3"!% ->?N(C!SM3\E?:L[(_KU4-*O62KY8AV*:YE 4
M)'5EF[8C(@X6LR*=0I9SR)TS*G0.H_-K]<1]#P6%71# A/'/3TGP=R9*2-DU
MG18<3H6TJU*)>$P=E434,1R1P;/C@;#V;5K(\[*,^T%Z4[B4TG8<5RN>Q4KW
MOI MUY$=K<1*:15^2E9<#J#8M-H^(]()W4<CK8^\%A.*.C:40D@[WN$O.YDA
MB3U9=5 I/S@=G64W.*6).@ZL&--O9ZPB'&U[YGL[14[P.=.ZDUDZP8</Y1)Z
MZ50;6;UVW09NR,N<:(7R+:9LK*G7^*(D*)GB<M@2\5&BN5XFE -<,!FEP,,A
MUQ"B+N>CJDA8$#.T,Y*4^VR@S9'"UQ$]=GCW'X7&'5T49'!*1N)YW6%K'8^V
M*M2T=;RUO-=6JRI2OQH.C'AE>%H7@6]D"#;*AAC=D!->-/3K)-EO^FA];;<&
M7L/U@9J^IG9.KRE(GWXLG:[>C)*(FYS344,MU5E!N?1CQ%Q<_/7[PE,G'Z.*
M *=C F1@3J#73OW1P<W:H-O$]P-7#['17[+[V?T3Y;*_F5_$^_?-%^$VRGC0
MN";5<7I^FH#KWPS](-@VWM,K&^C6C]V:GEGH6(#6U]:&W8 -[!]NBW\!4$L#
M!!0    ( '""15*U!.\--0,  .P&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;*552VO<,!#^*X/IH87$[^PC["YDDY3VD!(2VE)*#UI[O!:1)5>2
MX_3?=R1[G2TT@=*#)<UHYM.\O>J5?C UHH6G1DBS#FIKV_,H,D6-#3.A:E'2
M3:5TPRR1>A^95B,KO5(CHC2.9U'#N PV*\^[U9N5ZJS@$F\UF*YIF/ZU1:'Z
M=9 $!\8=W]?6,:+-JF5[O$?[N;W51$432LD;E(8K"1JK=7"1G&]S)^\%OG#L
MS=$9G"<[I1X<\;%<![$S" 46UB$PVA[Q$H5P0&3&SQ$SF)YTBL?G _I[[SOY
MLF,&+Y7XRDM;KX-% "56K!/V3O4?</3GS.$52AB_0C_(9G$ 16>L:D9ELJ#A
M<MC9TQB'(X7%2PKIJ)!ZNX>'O)57S++-2JL>M),F-'?PKGIM,HY+EY1[J^F6
MDY[=?**\?Y2%:A!N4<-]S32N(DO([CXJ1I3M@)*^@)*D<*.DK0U<RQ++/P$B
M,FFR*SW8M4U?1;S"(H0L.8$T3N-7\++)S\SC92_@73,MN=R;9R_A^\7.6$UE
M\>,5_'S"SSU^_I]Q_'<4<$P^,%MB&L_LF8&"B:(3S&()1%5*4(>9<_B&3 ]Y
M (HB-CM2<I%\RR55D!#4#.8$\*G UAXAEE0^[WRX:4F6;ED<OWWJJI\7P&0)
M)1>=>_8-Y/$\S&C/YF%,6YJ$"7SUK8#E*7M$39T-I-]0!_IW#-!H,)90*!WG
ML/68RXS4EDDX@V4<IG!=5=2TH*KA(6I;,%ATFEN.Y."]5<4#J-:UM8$TS.F;
M04:*=T@9Y84SS7BA3G)K( [/Z,OIFSD'<_BD+!F2A MP]B;DP=7HT7).S.59
M.'=+_M?8'XPFY\-L01M!QWY+GW'<93+SW&PY7*9#/@WT-2]JJ"DZL$.4+A6B
M<^FJM&JFV#YGAC6JD^3&#@O6&01;(]> 0Y!ZU8GR"(Q)RT^GL/5(^BFY/R:>
M^HD<'@F?RCA<3C3->%\ )T,%N&M7!2<T?4V+?GZ*7^'?NB4ZFD -ZKV?LU2A
MSO!A&$W<:91?#!/L67SX#]PPO>>45X$5J<;A_"P /<S6@;"J]?-LIRQ-1W^L
MZ7>$V@G0?:4HNR/A'IA^<)O?4$L#!!0    ( '""15)4<Y,QT D  !L=   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;-U96W/;N!7^*QC5Z20S,D51
M%TM9QS-VXFWSD%V-G6RFT^D#1$(2:I)00-"*^NO[G0.2HFS)VG;3E[Y(O  '
MY_9]YP"\W!C[4*R4<N)[EN;%N\[*N?7;7J^(5RJ316#6*L>;A;&9=+BURUZQ
MMDHF/"E+>U$8CGN9U'GGZI*?S>S5I2E=JG,ULZ(HLTS:[8U*S>9=I]^I']SI
MY<K1@][5Y5HNU;UR7]8SB[M>(R71F<H+;7)AU>)=Y[K_]F9(XWG ;UIMBM:U
M($OFQCS0S<?D72<DA52J8D<2)/X>U7N5IB0(:GRK9'::)6EB^[J6_C/;#EOF
MLE#O3?I5)V[UKC/IB$0M9)FZ.[/YJZKL&9&\V*0%_XJ-'SL<=$1<%LYDU61H
MD.G<_\OOE1]:$R;AD0E1-2%BO?U"K.4'Z>35I34;86DTI-$%F\JSH9S.*2CW
MSN*MQCQW=;^25IW?P*Y$O#<98EU(<M=EST$ZC>G%E:0;+RDZ(JD?B4\F=ZM"
MW.:)2O8%]*!6HUM4ZW83O2CQ@XH#,>AW111&X0OR!HVM Y8W>-'6.=LZDUND
MEA/7ULI\J?CZ[]?SPEGDR3]>6&S8+#;DQ88_P+'_G23Q,1>?Y!;>Z<-'&R5D
M8M8.@]Q*\4-Q^ZW4;HMQ,<Q#\HM9*O.ND(60,!A!Z@IC=\/I;2 ^MV^%+-W*
M6/TOB(WZ2, TI94+4JD09B%BDV7TP)GX08 CA"Z*4F)!(?-$R!2@Q]1%M<P2
MSG8TS8^'NI!6=*M;N0:OQ-H;9PE.>(5UG-4QV56-VDB;''I1YMHU;['@W?T7
M7*R59>HBE?8%M-Y427%0I!<V\]+(J%A9![83!A;92EH@/I16YTM.U>Z^2\4&
M#L^474*LSIVIWD:A?_L:'(*()V).#/DF$-<(#ZD"7F%)5B&X^,G-,;];1?1+
MR\M'J5,Y3Q6[?%&ZTM9>+Q'P9\'>I=#D4 I-Q&VV3LU6*7'/*\U*&Z_@JRJ3
ML,;M_6P&7Y:6PNX$S-NL=+P283 XE2YXV,ZO=O; "TX _RJ;0^F: [J0&IV2
MZIWQNSTQ80M:GJ!EGGD"P3H"I@9 53QK -7A;1DX..V2PP@J_B< .H4/3OD7
M,O[S?Y#DD.)YITEL&-;*V\H=6.,)="CQP<EYL5#6'I1]+%4F/SI5FO6.$O+M
M=[I6WC5JL4#GP;%JU9VX/5[Y\0*7IK1XEQ<FU8GTL<(?E2566^>8Z#.")%BU
MHKX(25B]F&\%E8USC3FP@I/FK?B;DM97XWT'O8;1E6N*-]XRN'SJX7"/#@DA
MZ8JERI65J4_#!+V'INK(J5\K?B;&8R3UF1A.@Q'^!OU@*NY4@75! 30Q48^@
MM377UWK68!!<B&@43$0T1I ^&X=53CKI3/3#, CQ?S'B-4>3H"_N3TV#9SAA
MS]UVK?ZH:]J@(ZLOO-5C_S<*A@PJ,1S"K$&(IQ$YQ .)E!X%8_'G/TVB?O03
MTPXH ?+AC1#.^$-^.(R!,@<?F&7.]'-2\KZK*'J4^!MN;%5R+A^1#DM%C*%-
M(@QN*ZXO2OS44G3!ETPXP.I<B9T.G@/6ZU3'A+>NQ[<L=G%YG>!*6J:"71R^
MM.VH4":^UHI=5XK=^3%LT\PK^31B$TJX"&[;*EJ$ W,FII2]NZ=^TJ]^$L"\
M74/=--UV]UE7K. 1,)I3^3E-Q(7-V&V/H%SO'[Q=651/(H2%U%8\RK14A&@E
MR7$M>9YQ8!\Q*03HC'G >$HD4J!I%2T51)KT_":5\</Y?;PR*1$<2SI?@^]I
M "WF0YR91-'6PJUXEG<W#7D678GJDWD#CZ/D"2[N=/%POB [0<^*"HZPI&\?
M@'@%Q_K?$7YOZ\QX-"DT2ZFB/F7EX82'CH; !/ZF?/=!/^H$/:O8:I4F@@#P
M:N^WD5QYDX,Q:F)*V/170\#-7WT^E-T[G[4\X?,T4224>[5VRA*@H_%/GO1_
MAWVZ'5X/QRK(*S L>@4DVY/YOCJT9'!RT93,D+,5]20U,&D@ %)R")J0[Y;<
MH9-<5$G?R^S@L$UMSQXVHF4 S;):<1]#_D.YQS]I0I6MY*K&>E4-9B"PR\8L
MB7L00Z)A%&3Y!L0L%AI-2 .YU&#/9@]KYE;4;V YWZW4\I\898^D+'4 WH\%
M^Z[J2%":>6=8PK)4+QB*<A^^\(CW0[FF>CXOE'WT#<M./).?-<!GO99K.[@=
MD%KO8Y'YJKPS<N-:;D^WR-(8!$I.@252HP17T/&N3 Q/(;5R)F@\*$S=>4$E
M5&_EFR%NA-!>U2<V;#2=HE!66I7*BN+W67%'Y2T*[\+(6*U=@S=1XPW$)M^(
M7TKF%BQ0L_HA>J^[Q?>M:'PFGUTOEU8MR:<?\4:C-8K%;\RTOY8.^98GO#EZ
M5B-!8&,43]30*!A'XB\5 _>YKO;#03 <@EB4C34%]G48C-]0V1\$TU"\IY8Y
MQ>.ZH)\U5R\O"NH<@]K0.T7!=(+KFIG.1,0]1+4B!^'@=*(P[KDF(8AMM)O>
MIZ:7TMMQ+Z$;9S1E9S]6JK$M:6]?V3&4+,SN5(_.AJV=5U><C8>MO0R-/.OW
M+\##S0BD$24UFL5T&\!7Q8I92A,D%M9D^]BI]2A.ZA$-8.].C^CBJ1[1M#U@
M7XV[W5;(U_@OM+_?J_#<$;3K]P)@].7=TT)PH);SI ;_%9G'J>$J74B$D2JR
M.LSD^_5]MP%FH1FVI.B@BG+^3]I, &R2SAS]7@@E'88!E[)UB(6$84ZICSVI
MU4CU4E,RM;CP)*AY^1^$Y0;"###Q@6S],?#^DE.L2(5#V*;^ VTRX'+18#MD
M[/1#8"_"FJF2%;1'!.WQ13 9[Z"-QWUZ/!D&T]%+BP&4?=X$3*;!.&0"J4'9
MYUW"#I0'4@<ERXE*]DD@3F' #@ #XJ\]  Q&QP$P:QUY^?WK,4C,=D#8RVIT
MK1I;.DXU:FRJDP'L2.MC+-H1RWQ[3NMJE.V]$X;88H>*ZL>JHNZARC/"3N?C
M[/\A(4._89NVBPT1:Y60X5Y"^LR+@G"XEY 1ER#L)"].).2>X @W34;2UOM'
M;!@7]<&H3\UV!0B.9OSLI92O!+5(/A"_F%8VMH?#H5" H!&\>$X9P%'U,8X_
MKGS.B,RTZWK6[KSH&5]#;5"P+F)3(G,*E>ESF><EMUX-4B0E/?7DE$>^T84+
M_+@]5WHWU>(PN5'!5PQJL[_1I.K4BX[3.9,GHU?T]UJ_\=L :1^4JYR,M;T%
M=8]]J. LM 6V$[FM!Z''5NS8>G]O(?VD^$.B&QNHJ 6'OJ7T6A^L^-"0/LL5
M@IW@OUTU3YLO?]?^@]=NN/]L^$G:)0 H4K7 5+#[J..//NL;9];\^6MNG#,9
M7ZZ41#[0 +Q?&./J&UJ@^1YZ]6]02P,$%     @ <()%4M"L^#A""@  Y1L
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MX.%"%U+PJY""7U$*?K5+P0ZR)-?1:DT14I'7YDV;EJN-#$<-Y&A9^96Q: #
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M$.'?[;O>;F"S#_\*VP !49N%4A+=\-5B =*-J.[1"3[V5>!C7YUD0=>P:HD
MHWT!87=PJQ6M-\7/OGBR,Z1..(]^!0!9 C4U"/.BZ^$+QA9!)X*082;>Y4RB
M +:V T4 _T5N-\U9B)5>P5-R"TQ]P/Z;SI!*P8!?F-H@>V6&L["V*8#N0%0K
M'RRS0YP ^+, \&<G8?0!J ?.\Z;K':@ETU+C\V9@T():MS6"*/#K$>#B>9#)
MN7[/Z&2BH-S&VUM9P$Z#8(7?[59@@7?RH7'XZ08GI8NYV@!MEH8DTT]75]<S
M$"9_# [8#&@Z#>B&N#0RNXWY: NKFV:6VH$^N>7;Z->F+\QR"<3"E[_ANX=C
M :^)&Y@\&$ZF&$,WC>=I6@(.R-8!GH8- 6OH  !##=S5P4J^6/IV P/;+MG9
MJ4O^.ESRUR>OZ&U3@?8'XNW&KNC\N,&?++*I+4@;H%Y6R8]0V7_;Y"2G0.*A
M6$< F@)95HU_RQR=S$%,^.);@J**I7T02F$9T"X_,E^$J\]%G'!Z&!^8/SYT
M3T$S1^V\4N;*-YK('CC&VH#4:G$14-8;>9[/1@A4#9[Y]5XY[!YX?8>$T<%>
M;'7J8I^'BWU^$O;O;5D#UI)B3<M.7=]G3G%6O+*^-W@]@O/P)Q C0!-/4&Q1
MIE<IB_)A"M8CA*B9HGMF!GAF4<"J-J7@<O >[P;G/@62%P$D+TZ>YY4!G>P-
MD/RMJ9$8IR#R>3/0=2/C=7#YH _6Q1K,,V!&M8.'\""W0*U,^<PV0!-#J];!
M,S .4+=W"\)R! [.CNA$\#/ ';T#M0A8 M (X$PO^((*P8:M&H!\C6JY858$
MC($X[G;P(.J!5\"L"\L3V[CMXA0T+\ZC37=^$AI7*O4 42S,#0>9M- ^>Y:S
M(GSIPY<"NQ()#;5"HEDV71GV[8X%).F:P"ZW/6@R>Z)NXA,X'ZF;H# M3/E1
M.#M081A,8ZMV6/3+H0Y2G6Y9N2YS[],#"B%Y$-&?7$=,""Z;+#ID\+HK$/<;
MV-'H6]"^X(>&1!9J#7K$3A0\4$]=A0/"V4OGRV$#0@:/#S(6U'78Z PQZ*Z-
M I*@]&%BQ>-YD%<GL2.Q^"].WNMKN^B!\9>(N$=LSL^;X:R@+[KP!5->1XB0
M4AHJ#TA8Q+=8]E<@FSO7SX*]ARIU-MF,P)M,#J-6*%L:G'3>;5&]\A8UX%ZV
M@[3/W&T_G@U5/G-K7(V8"\:6GW<&\7I\@L-G<C0'NEX:YPL@W %NE-CFT  '
M0?6_*E; BQDOZK9#821**;'0%@T+,N>\7:.#Z]:2E8TLPM. F9)1;SXQDG]B
MG1;PPP]6S F *ZL?9(:29A.VQ"2T ;V']E.V\"P@OQ.@9X<%JLZ^VJ,IOJU!
M+!.I-&U#RXJ^-.1,#<E4U#YX /8?MB9T T1GZ6POS@']P7A!L[3Y8X"?SD#1
MD(?U8(NA)[QG]H(J/DQI1ML[M3>'K(DL3#@_74,?M\103I85L <+5" 6=.#
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MA1^#,_ MG-$/FV,.B#\_*R$H4^&!Y3^[#RF0GQ_&]/OLP=04B1:NR82;L]Z
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M9;1W@(]R2S9W6=F?VZ9*E&0Q9B..H?^KJ>8@IWS(:F6% 3.AHP?E$07LN@&
M33HZQR./Z.R6%=E?^?[)KB(3BT&%DQZ]3;9M;@'3Z49S;H BO&U(Q:I:R^J
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M"B@D-'P"XYMP&-K].-CS<UCD&F,UR^7?S*C_!A5GSQ*/5ZZ78M(42Z+##*%
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MI\=&WS-#UD"C!S]5[XWDI*)%N7$&HQ)^[O1*9;H0[)8_",OZMWR>"SLX'CI
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MR!NM2?<_\#"%*R7?@]V#DS%E[TI1K>,I+"O5.*]IZAJB>E_!E@C675I@F7I
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MM\%A&[0X" ;1\=J$+6$H@AW2#)"AF\B=%J^U)FP%UFQ/>5Y\UQ=;U8PPM8Q
M'9TTO6$PC"YF>@->Z":OA^G;8$4X:.'7$@8)ZKJ10P-@Z":PC^DG%C_#8WVV
M(&)7APRH4?!:T^L*+M,[0YK*#,W1"9J?9WI=S4="K=MU\]IM>IW<<#,^OFK(
MPG.UJZ(.:0;6R UKQWT]RRA?)'$*MO&6<E?7;P",R*6<C0QRD1NYIYV-VM@=
MHUK'I"^!I5,FI.M^B0QWD7<GW&5L=+H5=H8TE1D0(W<W[&-J5PNLE7EWR<C0
M&IV@]9FF'GM+,#Q&;AZ?,'6;LK8MU8YR;"EL:(S=-+YC^?JLG]>&IAA>RL'8
M\!.[^7G:P;B-1X1&K<;)%M;HVYL":T\=O%O>+@OK"EV]MM;G#FJJ,]3%[K;7
MP\:Z0GW@?KMU.!75U&< C4\ ^CPSXW;WVV%F;!B,W0QVFUDG-W=7U%X>2YC:
M71WW:&PPC-T8MKKY%W]Z8X-8/+Z8TPU4L1NJ'DZW(W-\?"W:82CL]!(Q9"7>
M?6Z7TW6%K@9;/^VS!76I,W0F[E[7P^G$U=]J;>W'%MTV)X;BY 3%S[,Y:;?%
M'38GAM/$S6FWS4F;OI"$K9NV):S86AW/0TGM.;(;TUTV_W]^?A.#8Q)>[!FZ
M 3!Q ]CC*7J;KF,XF 2U?\= MJ20<0T53:V&Q\2[+>YD0.3Q2YQX-\;$4)NX
M&V,? K0?4%CN]<2[92:&[N0$W<\DP,170FCX';KY[2: 3H[.V&.6%,L>&]9>
M2Q;OA+_$?)WD J1TI=*"0:0LR0^O60\'DFW+-Y5/3$J6E1\W-%Y27@2H[U>,
MR9>#XN5G];)[]A]02P,$%     @ <()%4GD(E#TI P  P0L  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULO59=;]HP%/TK5M2'5BI-',I'*T!J@[I-
M:B54VNYAVH.!"UAU8F8;Z/;K=^VD2;I"&B9M+R2.?<X]]]KWX-Y6JF>]!##D
M)1:)[GM+8U:7OJ^G2XB9/I,K2'!F+E7,# [5PM<K!6SF0+'PPR!H^S'CB3?H
MN6\C->C)M1$\@9$B>AW'3/V\!B&W?8]ZKQ_N^6)I[ =_T%NQ!8S!/*Y&"D=^
MSC+C,22:RX0HF/>]*WH9T8X%N!5/'+:Z]$YL*A,IG^W@RZSO!581")@:2\'P
ML8$(A+!,J.-'1NKE,2VP_/[*?N.2QV0F3$,DQ5<^,\N^U_7(#.9L+<R]W'Z&
M+*&6Y9M*H=TOV69K X],U]K(. .C@I@GZ9.]9(4H >CY'D"8 <*Z@&8&:+I$
M4V4NK2$S;-!3<DN478UL]L75QJ$Q&Y[8;1P;A;,<<68PA(DA8YBN%3<<-&F0
M3TIJ31X3/!2"_X(9N<4QSK!D1FX85^2)B360JPWC@DT$-+"<C3$30!R7+KAX
M\B<-&4G-W?8=#\$@@3[!B(_C(3D^.B%'%G''A< %NN<;3,^*]*=9*M=I*N'>
M5*9GI$E/21B$P0YX5!M.+]["?2QJ7MDPKVSH^,[W\)6**N=D(3>@$CS_IJ%7
MF)Y46!(<N045T9IYM*:+UJRWCZ>E_<%>;VB[/]]N$42^&(CU]XJ0YWG(\\H$
M;P$W]&')$D)#<B<3L\2PQ0G9M8$I8<L16H/9#"Y:/7^S0T0K%]$Z7,2[P[M+
M2\K;+6EI!&=TMYIVKJ9=J2;70*3"T,D"U$<E20G;)1G!;@V=7$/G< VU*M*I
M*Z6;2^E62GF0AHD/\N^^"[KO2%SD42]J1*V5<4K4J74&:%!8:E I())J)14S
M@/\G;QRQHNEHR;#I_^IT6G@9K3:SPWL]RAC+Q:7=]M[J%D9'F_^FXZ.,N%[+
MT\(&:;4/'M[T4<98H]5H882TV@G_NN^CC+B.FL((:;43UFC]**/HUCPAA0'2
M:@>L;P!1QO2! _BE^Y6]W-XQM>"))@+F" O..EA E=X7TX&1*W?EFDB#%SCW
MNL0[-BB[ .?G4IK7@;W%Y;?VP6]02P,$%     @ <()%4ND^9_,O @  PP0
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MM8A5U.]9FA^LZC_OY"^P?BO%JOB7*(_OR^-U>0Y57BU,WTIOQ_KUV,H!'J[
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MBD9-&QV6FPD$%"+P(B3 M73I1A&ZH!ESVHS?B0>16$!-$[V3&PD ./HMUT4
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M;"]W;W)K<VAE971S+W-H965T,S4N>&ULS5==;]LV%/TKA%H4+9!87_Y0.MM
M'+=8@60($J1[&/I 2]<648IT2<INAOWXD10CR[:LI$,+S ^V*-US> XO>74]
MWG+Q5>8 "GTO*),3+U=J_=[W99I#@66/KX'I)TLN"JST4*Q\N1: ,PLJJ!\%
MP= O,&'>=&SOW8KIF)>*$@:W LFR*+!XG 'EVXD7>D\W[L@J5^:&/QVO\0KN
M03VL;X4>^35+1@I@DG"&!"PGWF7X?A[&!F C/A/8RL8U,E86G'\U@T_9Q N,
M(J"0*D.!]<\&KH!2PZ1U?'.D7CVG 3:OG]@_6O/:S )+N.+T3Y*I?.(E'LI@
MB4NJ[OCV=W"&!H8OY53:;[1UL8&'TE(J7CBP5E 05OWB[VXA&H!P> (0.4!T
M".B? ,0.$+\4T'> OEV9RHI=ASE6>#H6?(N$B=9LYL(NID5K^X29O-\KH9\2
MC5/3CY@(]!G3$M -8%D*T$E5$IVC.T@Y2PDEV":(+]&';R51C^@>TE(014 ^
M03*$%6HPZ? [$R0(6Z$9ED2BMW-0F%#Y3C,_W,_1V]?OT&M$&+HAE&I^.?:5
MMF-$^:F3/JND1R>DAQ&ZX4SE$GU@&63[!+Y>AWHQHJ?%F$6=C'-(>R@.SU 4
M1$&+H*L7P\.+%OC\Y?"DPTU<IS:V?/&SJ3U#EU*"SBIF&;HF>*&SNI^_O8R9
MJ#\X$P<I_.M:3X ^*2CDEPYY_5I>W\KKGY#G=I.L=],96L"*,&9F7&"*60IM
MFZ)B'5E64]4VT\&@IY=[TZ)E4&L9=&JY+46:Z^K1N@LKZ+ Q85#/5FV+P9&D
M8=*["!J?<!\QKQ"#5LX]!\/:P;#3P8-.%Z;D;YU+RJ74)RNEI3X5YH@!%F91
M6\U5K$E#R'DXZHT.# Z/EN \C \L'<><L#2J+8U^=(, RY[9':,C/W'2BP[L
M' >=WD))K3;I5&M/V\:6OZ)92'>GZ!]TY.C-JR0*P]\6A"M(<\8I7SWJC&6Z
M[HM'#;B&#5 4=YRVBUK>Q?^Q&(3![CT4_))RX&A/)K/*N(OJ.,3SSI!]4XV7
M:_C?ZXK#=A46%Y+\0&7I9-VW$>UL1+^DN#C:YZJ+"^LN+RU!IWSM7I!A_/,K
MC.,<=9>8EJCC;3EW45WO ;_1VQ4@5K9'EBCE)5-59U/?K?OP2]M]'MR?F?[<
M]HP[FJJYO\%"'S2)*"PU9= ;:3VBZI>K@>)KVT$NN-+]J+W,]7\,$"9 /U]R
M7;_<P$Q0_VN9_@M02P,$%     @ <()%4IO SUM] @  :0<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&ULQ57+;MLP$/P50J<6<*R'[=@)9 %Y-*B!
MI@B2-CD4/=#2VB+,AT)2MO/W65**Z@:.BQZ"7"0NN3.<'4K+=*/TRI0 EFP%
MEV8:E-96IV%H\A($-7U5@<25A=*"6@SU,C25!EIXD.!A$D7'H:!,!EGJYVYT
MEJK:<B;A1A-3"T'UTSEPM9D&<? R<<N6I7438996= EW8']6-QJCL&,IF !I
MF))$PV(:G,6GYW'D #[CGL'&[(R)*V6NU,H%LV(:1$X1<,BMHZ#X6L,%<.Z8
M4,=C2QIT>SK@[OB%_<H7C\7,J8$+Q1]88<MI, E( 0M:<WNK-E^A+6CD^'+%
MC7^239L;!22OC56B!:,"P63SIMO6B!U /'P#D+2 Q.MN-O(J+ZFE6:K5AFB7
MC6QNX$OU:!3'I#N5.ZMQE2'.9E>4:7)/>0WD&JBI-:#EUI C<E84S!E'.9G)
MYOB=C9\NP5+&S6=,V4$0)JO:]DC!3*YJC!%!.,U71"U0KUXA:LXXLT]I:%&W
MVSW,6XWGC<;D#8V7D/?)(.Z1)$JBO^$AEMO5G'0U)YYO^ ;?-9-,U.( TZ!C
M&GBFP7^YAWZA%X906?C%QK@?D)>2/=9@R*]OR$-F%H3Y?4#%L%,Q/%C/E\<:
M?24&\EKCD8'ID:O[H^^S'A&O#VB?^0UYW+CO_N)U%O7C41JN]V@:=9I&ASVF
MVW]X?-PQ'7^@Q^-.Q?@]/1[O\W@PW._QI-,T.:CIP;<<* A=@\86>J#,DX[R
MY /-CJ,_72EZ3[M;]E=^)\/)*\/#G<;I+J%KJI=,&L)A@;BH/\:/7#=]O0FL
MJGPOG2N+G=D/2[P+0;L$7%\H95\"UYZ[VS5[!E!+ P04    " !P@D52 "2K
MBBT'  "B(@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R]6EUOVSH2
M_2N$<1=H@;NQ1$K^N$@"M$G3+7!S-VC:W8?%/M 2;1.51%^22IK%_O@=2HHI
M6]+(;=KM0R/;G.'A<'C.<.SS1Z6_F*T0EGS-L\)<3+;6[GZ;3DVR%3DW9VHG
M"OADK73.+;S4FZG9:<'3RBC/IC0(9M.<RV)R>5Z]=Z<OSU5I,UF(.TU,F>=<
M/[T5F7J\F(23YS<^RLW6NC>FE^<[OA'WPG[>W6EX-=U[264N"B-50;187TS>
MA+^]CP-G4(WXAQ2/IO5,W%)62GUQ+SZD%Y/ (1*92*QSP>'/@[@26>8\ 8X_
M&Z>3_9S.L/W\[/VF6CPL9L6-N%+9/V5JMQ>3Q82D8LW+S'Y4CW\3S8)BYR]1
MF:G^)X_-V&!"DM)8E3?&@""71?V7?VT"T3)@X8 !;0SHD0&=#QBPQH =&PS-
M$#4&T;%!/& 0-P;QJ3/,&H/9J0;SQF!>;58=W6IKKKGEE^=:/1+M1H,W]U#M
M;V4-.R(+EXKW5L.G$NSLY94J'H2V<I4)<B\*J33Y0UEAR%_)FS25+EUX1CX4
M==*[Y'EU+2R7F7E-?B%38K9<PVA9D,^%M.;7UANW,LO P)Q/+0!UTTV3!M3;
M&A0= '7+GTA ?R4T".>?[Z_)JU]>IWZR'G]7N+]KD9P1%CJ'-&@<#OJZQGW]
MH1[ 5W#@J\?+NV]'U./EYF0OX7+8R_O3O2QZO4PAJ?:91?>912NW;-#MRD+B
M&*M+H"Y+_O4[#" ?K,C-OQ'W;.^>5>ZC ?=W6A:)W$%R\ER5A>W+BMI#7'EP
MG/QPR18A"]R_\^E#>[=.'GG3'1F'\_APY,&"HOV"(G1![_XLI7TBB<IWJG !
M4VO@^EVIDRU0;0H?^)-JZI-:N)/:EWSU3+,6R C%&.\QQBC&WY4Q!#A ?+6R
MV)32;/,&Z;>@BSLA#!=17ZSCSC*.1KSONAI8X6R_PAFZ0GI&X[^0JX'5D+04
M[LA&2 +/]S/-?\;Y6.S=+UYZ/MXNOC67E_O)E^CD]Y9;2%E96 $D:XF&EV0G
M= (+A0*G#PONL-H6)"IAX/4N&(F+2H1(#5EKE1-I3,F+I!=1X^@@/ %=(.$)
M6ZH;HB@^;2$N6Y6Y8YWG<*) Z),OQ&J>PL$B*7\RY+\D[845=DX%'<+CN3JD
M)^,IC$A*5R!^!S;:P<:&L'FB#W&F]]A\!M64TT*WTS(1@%%N-D+W0L,G ;(_
M"P(TQ3R1ASB3'Q\]QY@U/]8%/!R&7H11EQ>'4\U3=HAS]J?VOJ6E=L]J981^
MJ.LY"*I4_;N).V9!Y1,+F6?=$*?=*Q^>$[&-T'@\BLWS=#@_%9MVL'KAU"Y"
MUE8B2*B0A?,P'-A"3^4ASN4M!'6>OW+U-E1J$)^Z*'X-)Q*MD-\V4SA2VR.<
MQV=+.@#.4WTXPO5-P0],"I1O%0BFM:";M6!R"RH UP@X#$='H%I$C=>A1VK[
M98=4XG[0U*L Q57@(*(BEV7>%[,1)Q$]BU'*H%X/**X'MUQ_$;;9W6-N^X[=
M;J8[V.V8G='%0.!:13TN%!]%*O*=Q7ALQ -PV@C34B\-%&?M*Z[UDR.T9Z)=
M$[L5))-\);/#:KJ$OZC<TYX[P&S!$+FG7A$HK@AO8-X<3L=*:;!U@ >#ASN:
MCV6<EP6*L_= Z,3Q+60\;CWE?+2D6-R\+%"<QC\)W7\P<;,Y>1)<8^Q//?M3
MG/T_"M?0JP14FJ0*%40,[@;_&9&H=R..60V21 1.NMT:0J,QS:)>,2BN&"#Z
MA>%UMR]1K@(76562 S\_;R9R;>N->?>V$$9S;)N]A%!<0MX]0*89AZ=I(AY5
M>CM?4!4IX4FBG=2XY[+8<=FZ:+C[F7M_QY^X6U.5O8W3WD7AP,:YBGG)8;A:
MO-ELM-A4%Z'C^K!US>]K2+'N121D,^R$,2\\#!<>C\J#:&2HB2Q)N-GVPNI>
M1,+%;(G!\C+#<)&XX5*3!YZ5 N-TF0.I2@"?/9&56"LMCCH3O;"[=Q0H_K%$
M9JV>%*Y'/["'<]U,=5#VS# Y8EZ.&*XBWR";4+_5]=Q@.+N]IC"D$8;3:Q3[
M/[2;KMD)_:9#@%Z?&"XT/DU[VX^SGOY*U-]_/'GH3=_0Y0QK2S O=@S7I!.[
M7U!^M@KHNTH!R=\+@?&DERZV^"E]8Z\V#"?U%_1>6/<J,M1[B;PP1+@P_*#>
M2S/+*;V7R,M#=&J?ZB6]EY%)QGLOD1>."!>.EV3PIT>%8? J$+&?D<%1ZYL"
MG+]?D,%1EZX'+M.1I^EHI,/T@Q*XV^X?@N8).L()^CM;<5&78X=;<9&GUPBG
MUUNX2.1E_K*SA$^Q7(P=)4_$$7Z'./TH73_?C+KQ/)S;<W2T_!E'*/:D&^.D
MBT"NJX;&/HP..WJ,S8^R8-KZ\MW]>N.6ZXTL#,G$&@R#LSEDD:Y_$%&_L&I7
M?1^_4M:JO'K<"IX*[0; YVL%\6U>N*_X]S]+N?P?4$L#!!0    ( '""15)\
M# @^BP(  '(&   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(V534_C
M,!"&_XH5<0 )\MFD+4HC02NT>P!55.P>5GMPDTEKX=A9VVWAWV,[(0HT9;FT
M=CSOFV=FDDEZX.)9;@$4>JDHDS-GJU1][7DRWT*%I<MK8/JDY*+"2F_%QI.U
M %Q8446]T/<3K\*$.5EJKRU%EO*=HH3!4B"YJRHL7F^!\L/,"9SW"X]DLU7F
M@I>E-=[ "M13O11ZYW4N!:F 2<(9$E#.G)O@>IZ8>!OPB\!!]M;(9++F_-EL
M?A8SQS= 0"%7Q@'KOSW,@5)CI#'^M9Y.=TLC[*_?W>]L[CJ7-98PY_0W*=1V
MYDP<5$")=U0]\L,/:/.)C5_.J;2_Z-#&^@[*=U+QJA5K@HJPYA^_M'7H"8+1
M"4'8"L+O"J)6$-E$&S*;U@(KG*6"'Y PT=K-+&QMK%IG0YCIXDH)?4JT3F5S
MSO8@%%E30"M@A OTP!7(2_2@'R%>H@61.=\Q)1%F!5I "4) @>X(PRPG;(/F
M7.K#\P4H3*B\0%?H:;5 YV<7Z P1ANX)I;I?,O64QC4W]?(6[;9!"T^@+2!W
M411<HM /_0'Y_-OR8/I1[NDB=94*NTJ%UB\ZZ;=6MAJ4RYT ].=F+970C^'?
M+\RCSCRRYJ,3YDM!=#5K3(?*U$C'5FK>RGT630(W2KU]OQK'47$P=N,NZ@/7
MJ.,:?<G5];OL^IV;?@]A-DY)#^!J](FQ"9GT0Q)W.HP8=XCQ?Q!U7XKV*;U$
M#-007'Q\YWCJ?N8;B K\P)T,$R8=8?(EH7F3<BS$JRD?K@SG$&)RW&;=P.DG
MQ..HD3\Y(O1Z$\%,XWLL-H1)1*'4.M\=ZTQ%,^&:C>*U'1)KKO3(L<NM_BB
M, 'ZO.1Z*K0;,W>ZSTSV!E!+ P04    " !P@D52*?D^@V8"  !(!@  &0
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ME_K\#,(8Z/L+SM5F8TYHU8E\_!=02P,$%     @ <()%4DK_6DGD @  .@@
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULG99=;]HP%(;_BA7MHI76
M)"1\I!4@%5"U2:N&RKI=3+LPR0&L.G%F&VC__8Z=D 42.K0;8COG/7[.&W\P
MW OYHC8 FKRF/%,C9Z-U?N=Y*MY 2I4K<LCPS4K(E&KLRK6G<@DTL:*4>X'O
M][V4LLP9#^W87(Z'8JLYRV NB=JF*95O$^!B/W(ZSF'@B:TWV@QXXV%.U[
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MQOGN2-.(I@4U$\6W]A:ON=(]P0Y+W;5!F "]7W"N#A/3&+K_0/H'4$L#!!0
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M[@C,MW09$/1;;HF*WPL(YQJ.JKQ!?B]AE.W >L.MTQ\>G(,&* -#RO!"51D
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M.DU48SF3L-3$-$)0_6\.7.VFP3#8'SRP367=09@F-=W "NR/>JEQ%_9>"B9
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M/B693Y9\H\7:=?.%T&8VN&5JIC%*:V#NET+HX\8&*.=[_Q=02P,$%     @
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MJJ=5\YO)!H#)[G&+4_!'LB2Z77E8K1A9J3K\*K\FLDN-SA>C46MHE^OW2-Z
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M:T1]C7 RJV5:M+.:=C9(J_<W-%BO$%5UBB4HJ<*P!0H)D3;*TO*\X<YT,NU
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M@@H\+WO.\D6R@^G"MDRJGLX\IJI/!ZX%U/>$,?GZHB>H.__5?U!+ P04
M" !P@D52T+!B\N4#   4#@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6R-E]]SFS@0Q_\5#=.'=J8&!#:&C.V9UIZ;RT/O,DG;>Y:Q;&LJ)%>2X]S]
M];<"BHDE:/(0\V-W^>RBW2]:7*3ZH8^4&O12<:&7P=&8TUT4Z?)(*Z)#>:("
M[NREJHB!4W6(]$E1LJN=*AXE<9Q%%6$B6"WJ:P]JM9!GPYF@#PKI<U41]>]G
MRN5E&>#@UX5'=C@:>R%:+4[D0)^H^79Z4' 6=5%VK*)",RF0HOME\ G?K7%N
M'6J+[XQ>=.\8V52V4OZP)_>[91!;(LII:6P( C_/=$TYMY& XV<;-.B>:1W[
MQ[^B_U$G#\ELB:9KR?]A.W-<!GF =G1/SMP\RLN?M$UH9N.5DNOZ/[JTMG&
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M;-'<<(M=-"B[ )^OI33/$]NG-7WY[#]02P,$%     @ <()%4DK!Q=N' @
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MM$ZD::,'DK$-1:-LA5< ?];.-ZV6 #J?LWKBK,/$W5FM$8=XJ2';O$"681E
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MM:L_CA^?16>:_C.?C?_MN7H'4$L! A0#%     @ <()%4@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !P@D52<LS2J>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !P@D52F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '""15*"
M)?SKB 8   ,:   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !P@D52';^Q_2X&  !X&0  &
M    @('+#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M<()%4LKO#"0, P  1 L  !@              ("!+Q4  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( '""15)ILJD@8 8  '4:   8
M          " @7$8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " !P@D52IS'NA6D&  #I'@  &               @($''P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ <()%4EB WR>$!P  $"
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M965T,3 N>&UL4$L! A0#%     @ <()%4DO\:'0'#P  KBT  !D
M     ("!$W,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '""15+C@,D.X@0  *P+   9              "
M@8^>  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ <()%
M4B &TFF> @  M@4  !D              ("!J*,  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " !P@D523: YEJP$   A#0  &0
M        @(%]I@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( '""15*3B#=?"RD  'R(   9              " @6"K  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ <()%4IG.)!ZC!   >P\
M !D              ("!HM0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " !P@D52PO[!U7P$  "##@  &0              @(%\V0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '""15(]8-#:
MF0(  )T%   9              " @2_>  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ <()%4@K&'1M[!   N0L  !D
M ("!_^   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !P
M@D52J8F 90(#  !"!@  &0              @(&QY0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( '""15(^17]\\P4  +,0   9
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M970R.2YX;6Q02P$"% ,4    " !P@D52&L'KVI8)  !J.P  &0
M    @(%0 P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M '""15*WH^0@HP4  /@>   9              " @1T- 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ <()%4GD(E#TI P  P0L  !D
M             ("!]Q(! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " !P@D52Z3YG\R\"  ##!   &0              @(%7%@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( '""15)W/(=AR@@
M ,9.   9              " @;T8 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ <()%4I9\0/*D P  P0P  !D              ("!
MOB$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !P@D52
MF\#/6WT"  !I!P  &0              @(&9)0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( '""15( )*N*+0<  *(B   9
M      " @4TH 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ <()%4GP,"#Z+ @  <@8  !D              ("!L2\! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !P@D52*?D^@V8"  !(!@
M&0              @(%S,@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( '""15(,F#D,*@,  )T+   9              " @1 U 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ <()%4DK_6DGD
M @  .@@  !D              ("!<3@! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " !P@D52,UF:NV$"   3!@  &0
M@(&,.P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( '""
M15(V/[09?04  'L9   9              " @20^ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ <()%4D_\>>Z_ @  TP8  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( '""15*4YFOA' ,  )T)   9
M  " @356 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M<()%4L8UY^H !   U@X  !D              ("!B%D! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " !P@D52BJ/1>/,$  "+%@  &0
M            @(&_70$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( '""15*5+4/S* ,  'X*   9              " @>EB 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ <()%4AO]6X%V!
M!1   !D              ("!2&8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " !P@D52T+!B\N4#   4#@  &0              @('U
M:@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( '""15+H
MI!;$U ,  ,\,   9              " @1%O 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ <()%4J$6!_UM P  G@H  !D
M     ("!'',! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '""15*:OX_3E0,   (/   9              "
M@2Z& 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ <()%
M4@T/7^F& @  $A    T              ( !^HD! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !P@D52EXJ[',     3 @  "P              @ &KC $
M7W)E;',O+G)E;'-02P$"% ,4    " !P@D52#L1%$\D$  "B*   #P
M        @ &4C0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ <()%4O5)
MDLP! @  7B0  !H              ( !BI(! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ <()%4M9,P)+@ 0  XR,  !,
M     ( !PY0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $4 10#:$@
&U)8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>281</ContextCount>
  <ElementCount>434</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome</Role>
      <ShortName>Consolidated Statements Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Other Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetails</Role>
      <ShortName>Other Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2139109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2146110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2150111 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Other Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables</Role>
      <ShortName>Other Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OtherBalanceSheetDetails</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetIncomePerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ShareBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Leases (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTable</Role>
      <ShortName>Leases (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails</Role>
      <ShortName>Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails</Role>
      <ShortName>Other Balance Sheet Details - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Other Balance Sheet Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Activity Related to Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails</Role>
      <ShortName>Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Summary of Quarterly Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails</Role>
      <ShortName>Summary of Quarterly Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nbix-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails</Role>
      <ShortName>Summary of Quarterly Results of Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="nbix-20201231.htm">nbix-20201231.htm</File>
    <File>nbix-20201231.xsd</File>
    <File>nbix-20201231_cal.xml</File>
    <File>nbix-20201231_def.xml</File>
    <File>nbix-20201231_lab.xml</File>
    <File>nbix-20201231_pre.xml</File>
    <File>nbix-20201231exhibit211.htm</File>
    <File>nbix-20201231exhibit231.htm</File>
    <File>nbix-20201231exhibit311.htm</File>
    <File>nbix-20201231exhibit312.htm</File>
    <File>nbix-20201231exhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20201231_g1.jpg</File>
    <File>nbix-20201231_g2.jpg</File>
    <File>nbix-20201231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 281,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 564,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 13
   },
   "keyCustom": 39,
   "keyStandard": 395,
   "memberCustom": 25,
   "memberStandard": 40,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Fair Value Measurements",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Convertible Senior Notes",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Other Balance Sheet Details",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetails",
     "shortName": "Other Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Net Income Per Share",
     "role": "http://www.neurocrine.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Share-Based Compensation",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139109 - Disclosure - Income Taxes",
     "role": "http://www.neurocrine.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146110 - Disclosure - Leases",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150111 - Disclosure - Retirement Plan",
     "role": "http://www.neurocrine.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Debt Securities (Tables)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Other Balance Sheet Details (Tables)",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables",
     "shortName": "Other Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.neurocrine.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Leases (Table)",
     "role": "http://www.neurocrine.com/role/LeasesTable",
     "shortName": "Leases (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "nbix:PotentialMilestonePayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i257e90a486974747899becd428e20bbc_I20200731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:UpfrontPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "idce3e91b366c406685df930cadf32f38_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gain (Loss) Positions and Estimated Fair Value for Available-For-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "idce3e91b366c406685df930cadf32f38_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i37972e19ce3448d8addd2bec549432ab_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Debt securities in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i37972e19ce3448d8addd2bec549432ab_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Debt Securities - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails",
     "shortName": "Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "iad7d8c26c43040ac8423eb140604d3d1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "iad7d8c26c43040ac8423eb140604d3d1_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Equity Securities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i05c117b96dea48f4ac63a4022bae19d6_I20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i83c603ce0ef14a36b7c219ff93558f30_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i83c603ce0ef14a36b7c219ff93558f30_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Convertible Senior Notes - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
     "shortName": "Convertible Senior Notes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i4275d4edccb744bf87c8dce992b293b1_I20170502",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails",
     "shortName": "Convertible Senior Notes, Net of Discounts and Deferred Financing Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Other Balance Sheet Details - Inventories (Details)",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails",
     "shortName": "Other Balance Sheet Details - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements Income and Comprehensive Income",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
     "shortName": "Consolidated Statements Income and Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details)",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails",
     "shortName": "Other Balance Sheet Details - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Other Balance Sheet Details - Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Other Balance Sheet Details - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "role": "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ib9f0bb09b01845ce9c7ec4ef22aa86a7_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "role": "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails",
     "shortName": "Net Income Per Share - Schedule of Anti-Dilutive Shares Excluded from Diluted Per Share Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id1037f7d26e440b1a850a872e881c1ff_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Related to Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i965516f5121d4176b5ae292b90be804a_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense by Award-type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ibdaaf1063b5640c096eab926298a36b4_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails",
     "shortName": "Share-Based Compensation - Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ib20438b56ac9433bb1bffb44583e9870_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i3a23b0e35de74dc0b44113bd6d8a068e_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i3a23b0e35de74dc0b44113bd6d8a068e_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation - Summary of Activity Related to Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i9b9010f4078c43eb99d30b01f597843b_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "role": "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
     "shortName": "Share-Based Compensation - Summary and Changes in Restricted Stock Units Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id346ae866f214a02b30d9c12a084f7ef_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense for Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails",
     "shortName": "Income Taxes - Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie7ce5f1bbc51478e98b231f0247f59bf_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "role": "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie84e64d4ffbf45999357185cd064c9c1_I20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewaloption",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "renewaloption",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449430 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "role": "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments Under Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "i04b7ec05369244eebe79a6452649afd7_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Retirement Plan - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Summary of Quarterly Results of Operations (Details)",
     "role": "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails",
     "shortName": "Summary of Quarterly Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "ie215d2c9f17d4c709f20026fb2fad01e_D20201001-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Summary of Quarterly Results of Operations - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails",
     "shortName": "Summary of Quarterly Results of Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.neurocrine.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Debt Securities",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20201231.htm",
      "contextRef": "id7971ee3765548c5bbbfd7f27e9eca1e_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_A2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Equity Incentive Plan",
        "label": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan"
       }
      }
     },
     "localname": "A2020EquityIncentivePlanMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A225ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Convertible Senior Notes.",
        "label": "2.25% Convertible Senior Notes [Member]",
        "terseLabel": "2.25% Convertible Senior Notes"
       }
      }
     },
     "localname": "A225ConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AbbvieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement.",
        "label": "Abbvie Inc [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbvieIncMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AccruedBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Branded Prescription Drug Fee",
        "label": "Accrued Branded Prescription Drug Fee",
        "terseLabel": "Accrued Branded Prescription Drug Fee"
       }
      }
     },
     "localname": "AccruedBrandedPrescriptionDrugFee",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_BIALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to BIAL, an entity with which Neurocrine has a license agreement.",
        "label": "B I A L [Member]",
        "terseLabel": "B I A L"
       }
      }
     },
     "localname": "BIALMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BusinessDescriptionPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Description Policy [Text Block]",
        "label": "Business Description Policy [Policy Text Block]",
        "terseLabel": "Business Activities"
       }
      }
     },
     "localname": "BusinessDescriptionPolicyPolicyTextBlock",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentAtSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the liability component at settlement.",
        "label": "Carrying Amount Of Liability Component At Settlement",
        "terseLabel": "Carrying amount of the liability component at settlement"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentAtSettlement",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentUponIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability component upon issuance.",
        "label": "Carrying Amount Of Liability Component Upon Issuance",
        "terseLabel": "Carrying amount of the liability component upon issuance"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentUponIssuance",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CostOfSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs relating to expenses directly or indirectly attributed to the goods or services sold, which may include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, unallocated production overheads and abnormal amounts of production costs of inventories.",
        "label": "Cost Of Sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtConversionObservationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.",
        "label": "Debt Conversion Observation Period",
        "terseLabel": "Conversion observation period"
       }
      }
     },
     "localname": "DebtConversionObservationPeriod",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Conversion premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Debt securities available for sale position number of positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs capitalized.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assts (liabilities) gross.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Net of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxAssetsOperatingLeasesAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating leases assets.",
        "label": "Deferred Tax Assets Operating Leases Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeasesAssets",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxLiabilitiesConvertibleSeniorNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities convertible senior notes.",
        "label": "Deferred Tax Liabilities Convertible Senior Notes",
        "negatedTerseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleSeniorNotes",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DeferredTaxLiabilitiesOperatingLeasesLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases liabilities.",
        "label": "Deferred Tax Liabilities Operating Leases Liabilities",
        "negatedTerseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeasesLiabilities",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DevelopmentProductCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Product Candidates",
        "label": "Development Product Candidates [Member]",
        "terseLabel": "Development Product Candidates"
       }
      }
     },
     "localname": "DevelopmentProductCandidatesMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Events of default percentage of principal and accrued and unpaid interest due and payable upon default.",
        "label": "Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default",
        "terseLabel": "Events of default percentage of principal and accrued and unpaid interest due and payable upon default"
       }
      }
     },
     "localname": "EventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the liability component immediately before extinguishment.",
        "label": "Fair Value Of Liability Component Immediately Before Extinguishment",
        "terseLabel": "Fair value of the liability component immediately before extinguishment"
       }
      }
     },
     "localname": "FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd",
        "label": "Idorsia Pharmaceuticals Ltd [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncomeTaxReconciliationExpirationOfTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation, expiration of tax credits.",
        "label": "Income Tax Reconciliation Expiration Of Tax Credits",
        "terseLabel": "Expired tax attributes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationExpirationOfTaxCredits",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense branded prescription drug fee.",
        "label": "Income Tax Reconciliation Nondeductible Expense Branded Prescription Drug Fee",
        "terseLabel": "Branded prescription drug fee"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseBrandedPrescriptionDrugFee",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense officer compensation cost.",
        "label": "Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost",
        "terseLabel": "Officer compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities",
        "terseLabel": "2024 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LargestThreeCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Largest Three Customers",
        "label": "Largest Three Customers [Member]",
        "terseLabel": "Largest three customers"
       }
      }
     },
     "localname": "LargestThreeCustomersMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_LargestTwoCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Largest Two Customers",
        "label": "Largest Two Customers [Member]",
        "terseLabel": "Largest two customers"
       }
      }
     },
     "localname": "LargestTwoCustomersMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made for milestones under a collaboration agreement.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Mitsubishi Tanabe Pharma Corporation.",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NBI827104Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NBI-827104",
        "label": "NBI-827104 [Member]",
        "terseLabel": "NBI-827104"
       }
      }
     },
     "localname": "NBI827104Member",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cancelable future minimum lease payments for operating leases not yet commenced.",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced",
        "terseLabel": "Non-cancelable future minimum lease payments for operating leases that have not yet commenced"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NumberOfIrishSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Irish Subsidiaries",
        "label": "Number Of Irish Subsidiaries",
        "terseLabel": "Number of wholly owned Irish subsidiaries"
       }
      }
     },
     "localname": "NumberOfIrishSubsidiaries",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of renewal options under the terms of the lease.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Accounting Policies [Table]",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_OtherBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other balance sheet details.",
        "label": "Other Balance Sheet Details [Abstract]",
        "terseLabel": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "localname": "OtherBalanceSheetDetailsAbstract",
     "nsuri": "http://www.neurocrine.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nbix_PatentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent term",
        "terseLabel": "Patent term"
       }
      }
     },
     "localname": "PatentTerm",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_PerformanceBasedRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units which are awarded to employees after certain performance targets are met.",
        "label": "Performance Based Restricted Stock Unit [Member]",
        "terseLabel": "PRSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_PotentialCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential payments for commercial milestones under a collaboration agreement.",
        "label": "Potential Commercial Milestone Payments",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential later stage milestone payments and royalties.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments to be paid under a license agreement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding the write-off for research and development assets that were acquired in a transaction other than a business combination during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Research And Development Asset Acquired Other Than Through Business Combination Written Off",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_ResearchCollaborationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration Term",
        "label": "Research Collaboration Term",
        "terseLabel": "Research collaboration term"
       }
      }
     },
     "localname": "ResearchCollaborationTerm",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_RevenueRelatedReservesForDiscountsAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue-related reserves for discounts and allowances.",
        "label": "Revenue Related Reserves For Discounts And Allowances",
        "terseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "RevenueRelatedReservesForDiscountsAndAllowances",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_ScientificEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific equipment.",
        "label": "Scientific Equipment [Member]",
        "terseLabel": "Scientific equipment"
       }
      }
     },
     "localname": "ScientificEquipmentMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024.",
        "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]",
        "terseLabel": "2.25% Convertible senior notes due 2024"
       }
      }
     },
     "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period",
        "terseLabel": "Share based compensation arrangement by share based payment award purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_StockOptionsRestrictedStockAndConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options, restricted stock and convertible senior notes.",
        "label": "Stock Options Restricted Stock And Convertible Senior Notes [Member]",
        "terseLabel": "Stock options restricted stock and convertible senior notes"
       }
      }
     },
     "localname": "StockOptionsRestrictedStockAndConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_TotalEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total equity securities.",
        "label": "Total Equity Securities [Member]",
        "terseLabel": "Total equity securities"
       }
      }
     },
     "localname": "TotalEquitySecuritiesMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_TradingDaysDuringObservationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading days during observation period.",
        "label": "Trading Days During Observation Period",
        "terseLabel": "Trading days during observation period"
       }
      }
     },
     "localname": "TradingDaysDuringObservationPeriod",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_TwoThousandAndElevenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Eleven Plan [Member].",
        "label": "Two Thousand And Eleven Plan [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "localname": "TwoThousandAndElevenPlanMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_UpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made under a collaboration agreement.",
        "label": "Upfront Payments Made",
        "terseLabel": "Upfront payments made"
       }
      }
     },
     "localname": "UpfrontPaymentsMade",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_UpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments received under a collaboration agreement.",
        "label": "Upfront Payments Received",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "UpfrontPaymentsReceived",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_VoyagerTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voyager therapeutics.",
        "label": "Voyager Therapeutics [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc",
        "label": "Xenon Pharmaceuticals Inc [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20201231",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r113",
      "r120",
      "r219",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative-effect adjustment to equity due to adoption of ASU 2016-02"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r113",
      "r120",
      "r219",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r113",
      "r120",
      "r219",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r183",
      "r287",
      "r291",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r504",
      "r561",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r504",
      "r561",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r183",
      "r287",
      "r291",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r181",
      "r287",
      "r290",
      "r505",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r181",
      "r287",
      "r290",
      "r505",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r294",
      "r314",
      "r315",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r504",
      "r561",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r294",
      "r314",
      "r315",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r504",
      "r561",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r479",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r401",
      "r402",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r254"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r61",
      "r62",
      "r63",
      "r549",
      "r572",
      "r576"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r64",
      "r110",
      "r111",
      "r112",
      "r423",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "negatedTerseLabel": "Equity component of repurchased convertible senior notes, net",
        "verboseLabel": "Equity component of repurchased convertible senior notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r317",
      "r319",
      "r363",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r319",
      "r349",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r80",
      "r95",
      "r450"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r77",
      "r95",
      "r452"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares excluded from diluted per share amounts (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r164",
      "r173",
      "r179",
      "r215",
      "r420",
      "r424",
      "r441",
      "r523",
      "r546"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r57",
      "r106",
      "r215",
      "r420",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r194",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "verboseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r192",
      "r195",
      "r228",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r320",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r104",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r109",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r38",
      "r97"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r90",
      "r97",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r90",
      "r442"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.5 million and 92.3 million at December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r74",
      "r531",
      "r555"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r183",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r183",
      "r439",
      "r440",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r183",
      "r439",
      "r440",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r148",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r153",
      "r154",
      "r183",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r183",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r276",
      "r277",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r20",
      "r526",
      "r547"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r295",
      "r310",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r397",
      "r405"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r397",
      "r405",
      "r407"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r397",
      "r405"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r151",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued to settle notes at initial conversion rate (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r19",
      "r20",
      "r524",
      "r526",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying amount of the equity component upon issuance"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r50",
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining discount amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r451",
      "r453"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r49",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r108",
      "r270",
      "r272",
      "r273",
      "r274",
      "r450",
      "r451",
      "r453",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r450",
      "r453"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Debt discount, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff",
        "terseLabel": "Accrued interest receivables write-off threshold period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r196",
      "r228",
      "r237",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r208",
      "r235",
      "r240"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r208",
      "r235"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Longer, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r208",
      "r235",
      "r240"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r208",
      "r235"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r204",
      "r231",
      "r240"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r205",
      "r232"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r203",
      "r234",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross unrealized losses and fair value available-for-sale investments in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r206",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available-for-sale in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r398",
      "r405"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior note"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r43",
      "r452"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesNetofDiscountsandDeferredFinancingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r107",
      "r398",
      "r405",
      "r406",
      "r407"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r388",
      "r525",
      "r543"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes (including benefit from valuation allowance release)"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r398",
      "r405"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "nbix_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Realizable deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r394",
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "verboseLabel": "Research and development tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, maximum employee contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r95",
      "r252"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r128",
      "r133",
      "r134",
      "r135",
      "r139",
      "r140",
      "r532",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share, basic (in USD per share)",
        "verboseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r133",
      "r134",
      "r135",
      "r139",
      "r140",
      "r532",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share, diluted (in USD per share)",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r376",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income taxes, rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Expense",
        "verboseLabel": "Unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-Average Recognition Period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r115",
      "r123",
      "r125",
      "r145",
      "r219",
      "r269",
      "r275",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Equity securities, FV-NI, measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRestricted": {
     "auth_ref": [
      "r487"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Restricted",
        "periodEndLabel": "Equity securities, ending balance",
        "periodStartLabel": "Equity securities, beginning balance",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity securities fair value amount"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRestricted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r214",
      "r557"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Unrealized loss on restricted equity securities",
        "verboseLabel": "Unrealized loss included in earnings"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r13",
      "r18",
      "r212",
      "r545",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Investment in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of equity securities measured at fair value on recurring basis using significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r310",
      "r427",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r426",
      "r427",
      "r430",
      "r431",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r295",
      "r297",
      "r302",
      "r310",
      "r427",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r295",
      "r297",
      "r302",
      "r310",
      "r427",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r310",
      "r427",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r310",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value measurements recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r104",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r234",
      "r236",
      "r239",
      "r240",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r245",
      "r247",
      "r249",
      "r250",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r95",
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of convertible senior notes",
        "terseLabel": "Loss on extinguishment of convertible senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r251",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r164",
      "r172",
      "r175",
      "r178",
      "r180",
      "r520",
      "r529",
      "r534",
      "r558"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before (benefit from) provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r377",
      "r386",
      "r393",
      "r403",
      "r409",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r124",
      "r125",
      "r163",
      "r375",
      "r404",
      "r410",
      "r559"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit from) provision for income taxes",
        "totalLabel": "(Benefit from) provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/IncomeTaxesComponentsofIncomeTaxExpenseforContinuingOperationsDetails",
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r104",
      "r371",
      "r372",
      "r386",
      "r387",
      "r392",
      "r399",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r370",
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income taxes at 21% for 2020, 2019, 2018"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesProvisionforIncomeTaxesonEarningsSubjecttoIncomeTaxesDiffersfromStatutoryFederalRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r92",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current operating assets after deduction of current operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r135"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r162",
      "r449",
      "r452",
      "r533"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r89",
      "r91",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r243"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r54"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r55",
      "r104",
      "r142",
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r243"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r33",
      "r243"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r579",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Equity securities number of shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r521",
      "r539",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of minimum lease payments for operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year ending December 31, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r106",
      "r174",
      "r215",
      "r421",
      "r424",
      "r425",
      "r441"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r106",
      "r215",
      "r441",
      "r527",
      "r551"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r106",
      "r215",
      "r421",
      "r424",
      "r425",
      "r441"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r46"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Debt securities available-for-sale (amortized cost $612.4 million at December\u00a031, 2020 and $557.3 million at December\u00a031, 2019)"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Debt securities available-for-sale (amortized cost $226.7 million at December\u00a031, 2020 and $299.3 million at December\u00a031, 2019)"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on debt securities available-for sale"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "terseLabel": "Measurement input, discount for lack of marketability"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90",
      "r93",
      "r96"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r65",
      "r67",
      "r73",
      "r96",
      "r106",
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r132",
      "r164",
      "r172",
      "r175",
      "r178",
      "r180",
      "r215",
      "r441",
      "r530",
      "r554"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r164",
      "r172",
      "r175",
      "r178",
      "r180"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r460",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Less current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesSummaryofFutureMinimumLeasePaymentsUnderOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r457",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forward, net"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on debt securities available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r47"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r83",
      "r193"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Purchases of equity securities",
        "terseLabel": "Purchases"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofEquitySecuritiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r296",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r320",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at December\u00a031, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Incremental funding provided"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from issuance"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r81",
      "r82",
      "r193"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r253"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r255",
      "r552"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r104",
      "r255",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r187",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r304",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r304",
      "r468",
      "r470",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Partial repurchase of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Aggregate repurchase price paid in cash"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r104",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r12",
      "r97",
      "r103",
      "r522",
      "r548"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r16",
      "r97",
      "r103",
      "r597"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r275",
      "r360",
      "r550",
      "r571",
      "r576"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r115",
      "r123",
      "r125",
      "r219",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402",
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r171",
      "r176",
      "r177",
      "r181",
      "r182",
      "r183",
      "r286",
      "r287",
      "r505"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r462",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue, Product and Service Benchmark"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofAntiDilutiveSharesExcludedfromDilutedPerShareAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized cost, gross unrealized gain (loss) positions and estimated fair value for available-for-sale debt securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r199",
      "r200",
      "r207",
      "r208",
      "r209",
      "r211",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of income tax expense for continuing operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r51",
      "r108",
      "r270",
      "r272",
      "r273",
      "r274",
      "r450",
      "r451",
      "r453",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Convertible senior notes net of discounts and deferred financing costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Provision for income taxes on earnings subject to income taxes differs from statutory federal rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r319",
      "r348",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r319",
      "r348",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Compensation cost related to share based compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetailsPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Quarterly Results of Operations"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r320",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary and changes in restricted stock units outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r326",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary and changes in stock options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions for stock option grants using black-scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r385",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Activity related to unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Industry Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationCompensationCostRelatedtoShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance, Unvested (in shares)",
        "periodStartLabel": "Beginning Balance, Unvested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance, Unvested (in USD per share)",
        "periodStartLabel": "Beginning Balance, Unvested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Unvested, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Total fair value of PRSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Stock options exercised in period intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair values of stock options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r328",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance, Outstanding (in shares)",
        "periodStartLabel": "Beginning Balance, Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance, Outstanding (in USD per share)",
        "periodStartLabel": "Beginning Balance, Outstanding (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r318",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpenseDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationScheduleofSharebasedCompensationExpensebyAwardtypeDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails",
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r104",
      "r320",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Unvested, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryandChangesinRestrictedStockUnitsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Total intrinsic value vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r343",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationWeightedAverageAssumptionsforStockOptionGrantsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Discounted purchase price percentage of common stock authorized for issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r110",
      "r111",
      "r112",
      "r115",
      "r123",
      "r125",
      "r145",
      "r219",
      "r269",
      "r275",
      "r357",
      "r358",
      "r359",
      "r401",
      "r402",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r145",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r269",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock for employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r269",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock for vested restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r269",
      "r275",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock for stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ShareBasedCompensationSummaryofActivityRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r269",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock for employee stockpurchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r269",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r106",
      "r188",
      "r215",
      "r441"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OtherBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r295",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainLossPositionsandEstimatedFairValueforAvailableForSaleDebtSecuritiesDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleDebtsecuritiesinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r369",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "(Decrease) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Expiration of the statute of limitations for the assessment of taxes"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Deferred tax assets, net valuation release"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r135"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConsolidatedStatementsIncomeandComprehensiveIncome",
      "http://www.neurocrine.com/role/NetIncomePerShareScheduleofNetIncomeLossPerShareDetails",
      "http://www.neurocrine.com/role/SummaryofQuarterlyResultsofOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a,b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r604": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r605": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r606": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r607": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r608": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r609": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0000914475-21-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-21-000020-xbrl.zip
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MSU?TSM&:)G^![[0VB 1$DC3Y D?TF7R#G=8>27J-GE-(WIHH;2>E\3%+92
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MW@R_!]A?5C9Z2@L=M9#:EZHPDH@)&D=N!M<.(2?,.5XX&GK"3)?0J21T;GI
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M<)US!<CFX\',DG'> F"FDT.9&2:I510*0DG9-)"Y\R7KK0( GB?&^7A&T[P
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MY3G++8RF2C19<LZBP>"80A&@K O)SLDL3;*Z L:Z>D1SB>!I(EA&)B5G(ME
MGK7+ )JHIU R,;3"53RRN6"@69+.6Q"<R<F/T7 E2A94%)YKI2U&EPSJ-"XC
M,M\(KA[I7(SA-"\(CHES'K61Y."KY+(77@2G(5HL&:D5"%<M-SAZJ.B0RDH:
MI31(H:QB$'1TF,EZ:X-*NOF'2F4(YQ*W4\2MCBKPI"VWW"EN,F 4@46T/#F
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MZ%6OTX$A/;RS:#,:\P)8TGC:I*BD#T9QJ9W2/I -=<QZY^S89+HE8)> _27
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M\U3*#]$=]Q.<E6=B][:!_W;D0JV-':M*COQ?L>5K\F, 9)BBK'M K"L6H.Y
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M)-\-VIOMO(^M\#YP. Z_'43(\3<FL"XLS]9KQRV$_DK?X,4\//HF#OB3;^R
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M'QPM/L-BNOTXVL<C5?:'*MNUHF6--:09V>@AN8ECD\>_TD=ZA,GF60U9W.3
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MNA!A1+,X[$ 0,7>>?->D8^,OM49=^!6.!0R\[\2ZH67TA4]-XCE=(?J'"QY
M:54<@[\LRDNEP@6M9UH5N?Q$KQ8N7,5=%DII+"24Z4)T*#HZJ_X=>+WK!?[Z
M6([5:-XC%"TF0?P.P"((O!>,YZ+-D( &9]A2Z<&3X7'X,_)JL3359'R6.J=@
MY5P(AW,K"&D!9;(]$I-?:-!L,X[C/2G77W8:8SB00'02=D(\UYS')LSPYA[3
MI7&*&CTK8/9XT#6[$ 7BF%KRIFS&G*;)TSDR*?#_86]8SF-?[0 G2&,99HKK
M-5E*$MLU=GTI*&=>4I@NVB5(0J;NQ"QZQJ@"DUM05MJ[3&*E:IVIX<3MQJ3C
M$)NJ9^]>#EH@^;&!A/362BWH2\B4,<PRS'K6T#J3G?9QN<!G(+#=YW7N<F/A
MZ!CNHH/L#I+6S=SW(JEJ)H$OC1DN9MI"&9FJ^]V#FFU49Z$@5CQDGNE%9;ZW
M_WA.\H>\P>7W:<Y[SE]ZCFX'W&!>#)2Z6'A=OK<O^KPNZ?\G]OGZYSW^TW=U
MLOJW)WM/1D=K_[J_-UK[MYN>^HS&\_3X3H_]CD<LHZ;I8R7_\\'A V_B<,G4
M]P>+S]'(%I/)_%%%U;,F?_Y-Y)4_YR-QYLZ"SGN;IW3:N51M<:(=K*3<UU-+
MJPTC.%7;_M!1EBZM5%%2Y8&@5)LY?3QC!81&:9688)I3+  8JJ59'1C&M;-[
M@!EWEQP5[615&0N\9,BBI1!6F>Y3)1"4>$P9+]3&Z(*6@&>F.VSJ55A2<'8[
M7LJAW/,;]WX?.__@3L>D]=%_L=ORK5T7]"Q=J!NA!XVL,5)FX862/GD3URT9
M'G[)\/KP1I%6S=C&)5UNU3/'4Z#6<8=@V'ID-N((!N$$I"JXYQ"NX>XX_[['
M^5_J//\$R5<.I-AD*.&0@<65LR?5M;IZ3OQO/N=]5FA<*9)PR2%11/BFWK_O
M@I"LH8FJ'BF8<R:LKR;2UI7=0?5<D._8&-M@G^"CSI?AG!FG6Z4GNVK,RU)#
M&=Q]U/:NAET;L5W+?^MNK4LJM_R)%@1N'I, 6FF2 A#&T'H8:/_%IZAJ*JDW
M*#LM5VK8_F1R2RMIU_54REXGDX9;0%A$)[(91:JN7)?.(ZYH*I5C8(!/DE:?
MOK,)3'9B/3"43RF*FNCU=:.NQP>2F+0G+PID@@:=/[ZJ9XC/GQ;S.1J^&'7;
M7V*D%W)HW\K*8S[R#"GC[&R,UC/QLKHJ+%]$YJH_R2$@V3TKLJ2R=1K=7>)+
MP+@Z7A I#Q>;2&"W21%5Q5[4556M35V%,C(D 4,( E0NVH KUE,;[$"2G*5S
MZ,J-]ZC?<RX?]T#2)B34V^)MOL@,(SV2+_9^V9_L7C#O$>O%XBR=^,3OI*8G
M#O)"K@UHIP_OBY]L'UXK BW4$A,+BPU1%\!E?,S0/\'-'UA0Y3RM;"V7?ST]
MFD.9 4-!"Q,9^N5-Q3$N$W8'/:=EF92I)&,Y=O S/O7:<):,1W_^\N?7)P.W
M$C,.#EP6 KU"T;*THETM:B=G@E$#W-U3*XQXW"+7N=Y?*(GB$%I6R@WG>!MN
M7]Y9 (&D8B@^JB*#JM+/0QZ,?88=)>-;\7AZ^Q:<]S5EG.=&4G$3$H**&W[U
MSR8 LASL[Q^&^  )1NKM_Q7WPW6\#_L!%5H";'LD"5E(<'#F3>5:4HC8=ZHG
MK,\5Z2Z[U;(0I)0]5Q7'1P0GS=6-*M@)*6L[IE3H(\B@)CW%86<[=SH(BV+A
MH0>QE%Q;HX.L;!L>:C<7XM>Q>EWSK #PU_)C*YY->R[^#+*&1:0*HN4:$2O:
M-S'%&-2CLN>?C?$M-QP9Q4 X"@#L83"CY(C;=[TJYO(HL&FXD?,N:*-ZI)E:
MO0'#X>.!C5AR<2("$%1?P))+RW)(B>N8"X_]%>Z\* QQ;_[UL5O#ZA&JVN+'
M.T*4C8\PVLBJ/;5Q3E_IZ^' ?.Z9,42Q1JT#730U#XP/ QY>R3FYZWLD*V S
MTH(PX$]<-N0E5H,@5PRET>3V[XI2"<PK^YL\^0YGQ^<M3'C-N0A>CG<#A):-
MPEAPN>D4XFBGK8$USF!D\-\5M2!I%)XN=XJWE<YU03[7]AP<-;TX"!ZX]*I4
M<'3H^D"5\$Z2"I;8E+41TI*N^K%T(-3;Z4_>P(;'R7(V"O>;F3G?4U&8@[:S
M=3TS"HPU2RVF@<^5"@&%M7VT\ K&CE/_7&.#(;>DE1-&P:%H 4UB?1V4 (^Q
MJP[\4/<B-LTZ!@JJ;/B+RB3AIJ6#X"1 )7F%84*?F]TX9OFYZA@]X1H->A'$
MP<+)]>R5Y KA#7#FC88ZP^];E#AW3!6L&VN&'3K"H2..=^B(&Y8G0)>1&:99
M*OXGUS\R2Y'@G<!R4OF*_%91B@KL0+\[U]JS (CM-0"+B@,^+QBSN3T26.34
M%';-JNPAUX$\724AL=1V5VD%5W=B7?^]Z*3OUU("2#,SF:(DF60!NHP+M.LV
MYQ,[A YTIG0Y+'LY(N6^PG:!"JJ!2]XZGCD$>?%>%PAPL$L:?BAGPJE6,S8'
MQK;&3@UZ\0>N\4+?5]-+2YH?B@G&X$ZSD;;V:ROU(%<7AW13@UB1:X]:*8M.
MY_M 1@A0G,:>6]!W8B9IM3$@A!N/V0M5P;RNXBX$NL5KJMIFIRU6D)D]VAH!
M"LZ57RN4IN,_A)??[Q0_$GNEV]L]ZDW.^*:T]HJN\@9HFY3&"A1-L?GQQ-(^
M9(49Y'9&DQ[BD+:OUY3&%I&SQ=GBB@I70&TCQRYE [JVC6T;MS6^X]Y 1-@-
M81;>,IJOP@XBTJ.F:HVXO1*\ B[VUCOYS3_/)VQD6@]# 5F!L<2[)^ZTMDAV
M]MXJ,G]%9+:O/U/KQ?G2<IY9LAM%1(75FZOG-#R9*P$WV:O.#H,W6F^&^+=D
M[=92-\C987:/-5 6>W-8^Z,;_3@=LK5_"\)(&N.H)&!5NV;T+@41=#(6M"(B
M(RC ,G4K5\)5$H8+D;,5USR\Y#::;%W4P"AWBP-'/8A8VG"\>Q]THB93L%7:
MV;KSIKWH%>@&^<RW_6#F:>QW!OQ>(-^D9"88+F1]$KC#+8[,PH@.JNCG:FI5
MD(M&3\@40650*R+*+)]J=?L(M5MLAI*.0>H]%ZKO;F9!WB4E5W[4+&*]$%]W
MF,16:/\N<F&S*HS0^H+_T/&75;6'9"$QU;%LDO>L.+9C/Q0$NS9?OO#12:<>
M'R8:J_)9.]1<\<G@^G%[)L1J">-Z-AS55A&#H,1?[)JZC(.OD3,7ET#S5_8R
MQ(T2;!D;+PDP^:)VLAAT;G \6P\GUXH<)KO9&OX/I: FCO_>30= -059&3J$
MEC%? Y\Q'X;@2$H,M!6>"P:CUUC8#\LK0V<UK$9GI16FH^R\Y($K3 T<@-$*
M+,N?8>]/JR(U#.BP0<DEHQ+PL?'@,) 3Y[& ;NGNH1%%6LTK5_Y\Q]"6K1";
M<'MB5QBHL-<VQM$FA,5TGJ:N7+-]9MI!#11B:"VMG$"[-ZT+ZY/,DLO4W$*8
M&L+I\-^QV2&.RO;L$4F.SO:R/D*7&$G9SM"_P&62W)5PY]Y&W 2 P#F1UKEO
MJT]]W H8V1YU+4L>=$E7[&+8,[=BVODXBZW<$:F\\9+I%R-"GF.]K"4LSAV:
M/A3UEL/$HOAMMKK%11RH\/""F75TI_0%3BET"@CD;+9?G31:1,XI=8!96W2K
M[L/<48,#\?HP&8S\TYH+BHMMTY'SWC(!%(_%,[/@&^P4&L^)G"NDEFXALU]K
M#3+,Q Z/:!^$0W)J$Z'4<?-(;=[29:EM1"X.%OFCNW%:H8S'!$/T\4W,7(PS
MW4N.*C)8MS1T);AZ7:J)A6*U7!3\6<;L*JQZ"]3KF>?3KJ44HPQ)AM%(THM'
M)A_21)$Q['GWL(=+G,2>6/8R71J0<T'Y$CS44B\GQN[W4& &0<22SWS2.;=D
M7??]C4^+%&GW_GV@U:>3=C:Z"MBR>>0Z/%4C-EM3<Q>D%'BG.#=%4_FRRMRB
MT<,#JHQ&CC&J\'%[.JF9%$W#70QG'CVL+:,(,O+#\&^/U,^I0_0*Z_B#YTZ)
M](7<+#)*/\OW!./0,(Y3!0_AF,[57=*]9T)[&DF9!QZ_W4QH>/90C! KLPI&
M^+\9T^)J\<HC&_N1&QC.2--\/M/ITI$<(=<SY4[20X7"8#0F::U-]4AN\[I3
MDYE8JK5EL*(2D9[-@MWS8JJ;\PWXO_2(K3E@CF#?22+-T3B>+)+IZ95EI!ZG
M1>WJXZW7R'5K?.($2<"#7'L\ W='3Z/KAO!66AC09$]P&)?2&.'MB3.!7'(I
M#PTGZTZ@D GN;5+&U\*SH,GE(.SH:87C24E?T)=KIP339F>6Q@DPX-D0R*;L
M$\TZ\1U<1CV]@SY\G[9\>.L]+@>R\G7-[.W:.AW,Z T#P'\6!I[H] WH<;GT
MOPI[]Q2+5#I(N'WDREN]_-WUY?>*\RK)I9S[$TOL$9=14NJZGFMV<"_Z999F
M$JA[=1KV1"#-45P+B 'C==-U@Y3$CX^Q(A$E"*Z+%O%9APJ;OB.$T2R!5)\/
MQ\NA5>VDM.=CU-Y*(=2M%MBWEV%Z\JUGF.Y96/=>^EXPJNNE[WNQ\>:01Z>%
M,V X6A@:U'O>W]Q#M(ZD?0,",:'!);<56M:"G(O 50Z$4-S[ 84^L>-*8I/T
MN=JW!_O[ UJ7@'BCTU8%[OD4XL-^F</5X7>M^<?R!<BMJLB%/N$S@JP!+YH0
M"(<AJ-"-88]HQ9(NIE/ND\?J7&F*%2IIXQ":R7$/=3UV6H]_OV;);3!4 0:0
M=!++5TMN)9B__E$NADCK?F6$'2Y.KKAGH:+2D1\K:Z.V9U.VU&BY8OV%;NV7
M50E^%<^@-^;&X>NB=+JIOU>1N !V53M]< )8&*_7NOL0@.+HY%['5?! 1:;*
M8%C!A8UP8FEP,V1F#-\&:$V/)&VLY(U2>\O;"3+-P-YG_BX^*[A$4(0*\&->
MI-;*<2+"0A+Y<\JKX^,QMEV4L]V#%76MD%#2JXS2D[2<-'.D\IG6Q<9ZTJF"
M=-58L"N8F#G]@R-F%9M\@0EG8Y$9EU=@-<N]Z*5V(EE9D'"GPTY$L@V#H%L6
MN(V*:]JH<J!Y"&9G;#N2S(0CBYBD4_:2ZM8JIJ9J+]U=UZPHNR]8MTLW/059
M:WZ,&UP876\)F7 U!&XWSHK)I^#A$MW0OIXMLMUNTR;>QZ#QF%#C5ETG_-83
MV'_Z@B54,7H-]V!@\\+7XBJR=&8PE#L\HB)0UY8G,FJ\'0Z%ST&M.R'F<UH)
M[+N/,:/W%+Z6X*+D!=?)&SU7U=I81=Z:L+)_N,#1'>63ON6&EE^:I=!0$X/.
M,R5\]:NP^7KA)^ N%;;<"FBNV$P,C>?,&;D?MIRDPZ_-O6Z0S]/#\7/.XNNB
M[O9 DRB5./VZQ%DP$M<7KM6?SQYK*>E%8)%[8R):W<FF:CI@JN!I,:Y 2@R2
M1K&NA!)4(]Q9.C60>?O/GJ-6"KT5+4WAK"SL24T,YP\D,1Z\TA8CR^DA@\OE
M$&$V^.:>F(N+G<G<>YJ\J89+51#Z7FZ(QG"+'<OTAH\)%P*=5_#9"G[=-]V;
M#BQNG,NQIHHJG9($P2<&P=*Z\E&RM^@7:34S/1$C9TW]@RRT=,K="2!S8BT\
M79W.1MR >[H[YTC=.,J0#T%T8Q,F<^-U?LGZ+X0)*:&?=H=@ !]:AK(A[ZU!
M6P$5I'KH@%W%3' M#!FN1=HJW3X])[C<_2#:5I!(H@M"4"HDLY^,6?!WY5QS
M;$IY<0;N^)$Z6V36Q6@SZ3,##MTZ^U?ZRKQPB43/L<,TD4R6$_11"2P&EQ/L
MIN,D'_';LG ^(=K)LZVL/=/HK\NE07+8HCVMVM2]&2AEH",BMY5:JS$Z85;%
M=0U:"[3HU#'XEAELC"TKL34^W4B\0,)LMAL5'QMQ_^^,%-6L=QQ07K2S_.U\
M9\5FFS4@;+,>-?PZ#BJZJ9C/.,"F'7VP:?Q.PEBS<'?#$ZRD_GLP!?#*5T$
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MI*^;(T30LZ"Q_\J-'K4G2.RE3&#1&K %V'E\B31R[8S1:0-78Q23O5H,7>=
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MX$M"9QA)Z-KU>9$U!FM4.T]<-R4\"2JA)/S=FH#GP7?;]->&7G1PI!H9W[Q
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M)&:^'=MMAH;S_B.R'EW?7FKV9LUTB4H&'E?_U0;Y^1FMEJ"H-:V,D>=B2 ;
M3OU*]T9<P4OM?P[+=VS-ZGY4UL9N[_9@-9]NG5H3LB4%NF5V>@V<5-XL5_0J
MG8^GO[JF-TGF@ .1X2R$>MS71M]AB8+PQ.X!_XLN(7(B3)=8K("7R2:O+\Y>
M/O<M%RM.^?J#,HY\LRJQZ+_ K<P@B*+FC]-J;)F0?/+S9E6T*XHH/[<#SU2B
MYV<_9^@0(/NM$>Z,9<DXO5[(;.?*>VFR;D9TB\_F(M$T;=!$ $$T?)@7$;VX
MM&QQ/J[A%2XD"+.-+XMJ5(PO?0"KRC7C,M_]K.0) ]JZJJD3"EX!ED&1F4[H
M>?,;=^(X:G'/.*NOI TH$>,U;-D8G#;WBPMH1-.H(CR,?AUP.-F8B-6-I!H6
MD;[])2[S%ZNR*LC?_<SG4N#-B"R[@_&-IK27_&&A3RZ2G;X1,3W,@DUU#M>Z
M/#$%"6>XT!-V=O%*(X(]BT8T" ']E6@U8&JT[!02Y.?6D@0[KA=/,,E&G+2Z
M*NK-NBD94T976Y=L=-?Y$D!,<N#L)SHWFVF^I!.+<58M_U."#80FT_PW_E!%
M]Z"#X!*_)B>6GAQ?:#[@*_8%"N3H-G*M*B?309/+J&FR<SF_0B$9\5E>U_FT
MG)=-E)UM"P=[KYO45W!S9W13"(N5[<EITQ=YB]\O>%)8@1JSRJ$7IXQ75V0V
MR-F]XEUX<?[ZV=G)\Q<OI WZQ<GYQ3\N?HR4\-X5%YY!-GH\Y(.GQ53(BG$P
MO%6SZH-3\ 7NY(O95?E;L[JBE_S<Y].[JV+W=IZ\_NGER>-'WWW[[)MOPC*H
M&97/YX=W;CK_1K=M\\CHGT;P\/;H-W/@?KL<J&%UKKR32/NB7+7(%+@8/YLL
MJK[YP <$_YHGHZ%/T0ZCH6'W%;_'/99EU],^*]&\L?]<NH]E&5B4I&I?+O-K
MFB9V\K))VU0]$VK/<<Z^??/=LV<_?//M(^7FF)?]4I(3M/W(+,4N5N=]-B>)
MUL;==_'MT_<EGHUH4SG]K"FLCSH8R8.;T9) _98+>'VK_T0MEW=&F8/6W[?_
MC]QH*%]P[X,V*5K_'L?I1\,HOCUD&,7//5UB<DZC3"OS2]PGM'9>2(=R\9D3
M'/\H!'K +"3@IN->J7R)8ANW\CS[YEMKIB[0'TQ_"'"ZIZ%16TDL;ZZ:)>T0
M6NCZG0"O1$C#[\T16+71MO72&G 8RL#Q$AM1OKU1K&@7OO+P(M7FE' 4VK&P
M%A\6,FJ;KA-*[\P+2@U0$!'*D"F^HG !NH*CF-\B*''!(VJ5M8$)+'LP;PLO
MT#\44EL51AL:^LUNFO:]X7^5<VU1%1^,!< JEU-6H6#L%_-XTA6?2QPGHWL#
M2A4:F\<_/$:9/\Z(/@D/VF$X87>E56D2G ]SUSC\6'P_;=4QJ2ME4*H=-Q._
M?H3"H&) _P_%^23K)(LE@E]V(68PF_IL.+U56K88F2=9,VB1Z6MPCA^Q%Q%[
M\>2(O=@S/+)2*R5=HJB,O9%T(<_R53YC*X'5SUH"+7;'Z(<2'Q7</MQ&4">L
M.9J:7 ^A](=@.#[B##WO*] ;?O;830\"P[9<P3^9B7^B/0S*;VI4IR"/+*X%
MZ"5Q2\_\.M&V3Y@CM4D#=3T6.SV_VM! 'R_Q4Z,)R^=(7:,6E;!Z,#%_D)L9
M?6!3S$98QL6&RSIH3\+:2J=EIL99#BB<^G6^U.0[ QU@%8O)3XSJOP PC=<K
M]PM0:/4/.A?1L=9)IQ?S9T_:O$9#X6MYW6=VGFN#!BW>#<PS;H835^Z83_Z*
M;/^O:(&C^_/5)^>\2Q;"D"\2A-(]"D8FO-5O(NTT\N50.<33AX>U\B)F,#SW
MEQBKF?\Y>5%?ZO+,)N]0O24'+Q9H_B-?KGZD44 _SN=W5EEUL;@V.F1:C!I8
MV0ZL.#M-VT($63K1O1"PK7@;<\]FF:_%' J<!5!\]4^[]V7%Y"Q%=-/_$:1#
M9!<$'P76.=2!.*@GLQY!]$TM:IBIGP V['_U:-6XJ6D_7I6K+"F-Q8P[OZMR
M+\?78(:+VEK$E400>95)VTS[P($DEU(*)EQ)938EE#V14%+W&?9HPCU&UJ*2
M,I8K#RJ34MZ"UG"M%&#H;PM/A 8>IM;E1!-:(LT&*5!/94-UZ*4(&4W+C>YO
ML9CH@*FM%3&?RW"E(%SKEK-1\[$Z")'7?:D-?KO)C6\*9UJ-2I\6>C#*K"I7
MB-IAWE\6\0]%V$:"3Q!1JPW'#1(UP77]$BW%\Q+'!2U4L04O>2%T*,A^3F/P
MJA>M1Q>(X61L&D>T. _/KI_D0$G==D'@+TM)L@H/M;T8[77V^OT%&&5=5<9S
MGJND8VA4B(')NHB!B?NZ=+++#3QSJ^T]V!30>2%FA XO'F3+Y(481+LDNTC+
M']/X+/BW,F:_7!_$75K8*B*C A*Q?/FNJ*Z%Y9/59WDWLT/0A/ZGSHB&)2)A
M+AIQPZ)4(J9$2.^6)6)S18S1B'Y\3NJ[QX><DSIO6H[X*4Q\&5&\A[#;;SM1
MX0\U*'UILGIFKX)MY)L?Z]A>^<,/3XR/?/"%YQ33WB@A/-AU?OCA.\G]*)M"
MVI3/>@':/L1*AMI@_/C)]\\>35Y4='N*_9K)VX(9TB]HA)Z7Q663^<?ZX<GC
MIX_D#NNB*E97S,.N'C-9A*^>??OLZ\EWC[\_^9[6TD%8X%LCFS,1\GQ;K,!I
M0AN(O.FE\"0_?G3RW]GD?V@:UI#-WO6A_\DL(AS_R+.3_]9"#!FL0.+4ZD<7
M);L_GJSI0AK@.[W!TZ]R08@^_O:K^=?6UDH?ZD5];?+B@U*.*Z73XQ^>?N/Y
MFC/! P;@[Z(MT!U WR(?SNS(33$E,P.R_@<^;>YY+-[<W)RB5,"E@^*4CI+/
M>1IB8+NFJ05HDG<-^XL;XUS" "._(DAIF^5T!I0CV,TA"L<VCZ#X@3E'X?_B
MQ7EVV-/3%;/3R^;Z<\[+$)HW:R OK-Y(LLT3/KLX*]E@8V02T]RTS+8D'+SD
M(9_Z8X>\D9X]')DG:2K6/ETXR5FRLTK5F3$'/;/N E6I\L9]#6XP^EOZY&I7
M)FR:/OY\_^:0S_>7Z\),Z]E#.;Y/;EWK.Y1B62CW+Z*.?O#'&^?+1+]:"+_B
MJNT*J=!2; GIWT3O71K+A.06FA2S=2]9?/3',)F/2&4R.*>5IA)UBYNN,/4'
M\5#H'DR.?E(US7M!R]%WY 2\T7H8]B""B%V+/1[&"H7GV]R(! ]+7^C=.0+F
MA!A$9EZ**I">E7$4^'4[?27.VL[( &>)K\_I@X(1Z.C#Q3N#",B"==\FS'&K
MA+HS4Y;GMB F?73-9G)/WN/*[T8W%N4Z>MQ>L%W&$Q^A0/."U4*6-LB9:YV-
M>B$A0-%G9H301UN%[P_9*EST-!3D#G]1.U!;[FW5U7,GV,R'DR/(2I?@4A>O
MI*'9=Y@6FR;$TN#4>"#XQW Z=L _/FN78.VT7C(;W:YK9B6&4U!7?GMH??N_
M[KYB?EQQKJJ^/*F*Q?J_GO)O4.XK:\XW_=?)XV>?;56! >Z[S]C EH[-XV^X
MW0Z+W<O9J9*=)HP6?84\GS4BLE9=%)&,C4$JCY&V+GLV"8BM%1OQIPW-<YL&
MUW&2?Z])IG-U" NQAJ]Y@[E/P 8S, .'KEZFPI-/Z5^2B4<R"Q+Q*==%4&\"
M$' =*:@R\P+XM^B-XZR0$T8$]4-_7!$/N2+^FC 0C:D#BA2-*A;%"=Y!3*NG
M6V=I"4]?,) ,IJO\YY;XX("A('%JY?O>LN@*,1Q@!57'3AU8$UQ#%>NHYAWQ
M)D^_#+S)<3/?=S._\4Y3B&GR.4H: Y4\]$C@YRYJJ@5>,>S78E7*#[ZHN8/?
M'=1*ET  0JE0E5IA3<3=DUJ)4_BL-EML3GL/$!"@^.8M^A?O;4"(6; .?9]K
MT^9(N4\FG,+I(G_+2.B5R1U"5.P"-?\AI(+EUV.W2,#//%CQ3OXZYB,E *-L
M<O[VC7O(=/3@%RMR--1<[>K'0_(!]]5/3C3(U]+W^+F=YWC+^0=ND@2:?EY<
M:J(R97J+P>4F<8W@@XN;[/H%]_K97\QJN&>R^D#7QQMO"[IU/Y=&4R@:PBO1
MCA9F^Q7)5-G?4G\0PV."961/A113J:#T.T!_LV?,K+\[YST+O UL^Y4[C:^>
M,N:)IR2HE1&RNE/.VT7U42/C8?9@@+L8.Q->]ZJIYE80>?OBXMV;MR].'F,0
MN ^$B79HX[Q\F3%F;=XL&4J6R66FS0EWV!?MQKQ&R,7-FYZ"SY,IW8!^6O;5
MNCP1?RD=8PS#ZY]>3FF)/OZ>=\<VG85UL4>B_)A+%#S$U KO$"*G6.>YC;B4
M?GR2AU^QF7)'>R#:>O7V)<7*-03SI!)DK*+RB)+H*&F=KCOAE0[OP/RKH;/=
M6&C]Y0>]A;4D'7'\(*.$LU$QUW/P]_ZEF+:B>F@J;#>(N03<][_-ACFB(\*C
M!>.8X]J-HSG.#A*&4[!#\D*14AA*7'HI?W6KUQ@Q4W9?58GCB?41V1Q!]ED<
M9JWZ+-^;3[E.!95[;;,;LH3Z3$]8(8[>_R[$H>+$;=  ()RZO(6A#AR:O.Q9
M3"Y)GV/K&8K  /SE'WE?XG+Z>^0CW.[!PQIJXB?2)1;#D$&&EYG58P326I@R
MP9EUG,X'M@["@JB,PPFW$HK:"P!+:8_VM:6"K24SV'M30YE#8G$[<Z,.D+!Y
MS(\3^K 3&CT%!-5U,PB6N?UEJN$R"JP^T9=*<- ^WD[NWY[;CQ[L=9,F<E'<
M%1"<$3-KS0QA>ZLN<&E(:HJ24>VNE:E3@B=FF,E&XN[T!"K9DPQB'*D3GCE
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MQ^CKP=.+/#I3.BUKT[VIRN#.)>71M>B<7TT6W"3K4./JGOM21O$!1=U> .W
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M87=Z,B"ZO$E0-0L69LA!#W "$,[2:M@\+U#ED _+*<DNIIGN/E$*UJ[>!>]
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M;@H4DRS0Q4H.VR$4@:P?7:WA@&(LR4E(:5CF4:&D?-ITPCS>MV,6&H:$'J!
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M+B=YJ45*WGXWJ;=,H9QZW)I$1UCO_]9!^]$+RPFYVS:%^T!/VM)Y,KGLZ0X
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MW-+J6>R]\)_%U6\=I8"2./Q9/W=#C<PG$X1(9P./6*861VHU9%;JR^[(J?"
M8% 9Z"W'(^ZEH\;+@X[_DAS&9MX)GA"^.6Q,*W;<ZFCD+G)>3;*]FM?T<<(U
M'=GL2QRQTP\\7=QE":$5BMZJ@F+Z(E:69U7>=87QW='Y!/,L=)A?@&5^'K=_
MQYER]=ZD(L8<*[MRW1RB.7/! (4&101&Y#9U.%RO#\-YNXWO#&'?H&L!9V[1
M,HA/PG(]JJ4KQM<GS2NPP#6I3!CSF>?2LBU,0]R0,6C+IBO9H^8J.KGD\TWW
MGG=VF6>3GC&(-7=U3=NFG-.G*'K02(7NLVR8;YP7(:#]S)3"+NHDG]/\T7^O
M-O0**_H[7VN%P&DG1#6;_(6<+OHBQ<6NY2__P-^-O%]UT;?!XQ)IAWDSXX<\
ML=)!J,(@#V$O/@21>@R?+1B%2MS!V9*X1]H4D%6)3&MVI3$(2N2G3O".F;*Z
M(1:ZQ<U&^9ZS@C4@"E^*Z=T9P'Q1QO@?G,"@O;C2D" AKAO;0#?%)&E(>5=<
MYZQ5Z'WIER'B,!3";MCXV=\OWKUX_B8H,HW<E..)L_Z2A5Z?/'K\O:Q[LP-C
M55;EC@YK4XJ7< 2V+RY +MEHVTQ]0TKOG=M-;1TG0 ,_*<)UOLT$Q.?[7K%9
M+$[H2P7M'$M/_5^R.+^QK?IJ33:-_B8_?AU*VRW9J*BKJ?;@F@*!!HW-ZW+5
M;697#1^@DCB0<.BKXO3RE*U<\QO%?W3!3#*G5PTO&=ICC$"EN_W6S,O\MV*%
M%_@J/.#7<A_:ACU]OE]" ^\^R)FCQW3?3?JR'AYM8U27DR('^,EM3MLDM.M.
MMG%XH^?KX$;;YV59+XIVC72=K 0NM;::3&]F6'RK?LJ-MN.;I^PD8O49 T3Z
M7=]>:L9BS?#,6K([\7R_VK#0!UFJ9FDI:]IGLJQ/N0$D1\K+J!PXMVB2'@,@
M?3 -93V.TQ"S!90H[\68S@R$A^'A3R>_Y$P$X&\2&CIVF@#.66^6*WH53TD_
M^>J:WB29 V1F![- '^=AJ#9?.WID#&IX8O> _T67D+PHS1. -==LF5]?G+U\
MWCE/A/V9Q%+$D2?/C.][K/''&O_C+Z/&?[2V_ZY+%/I1V%[N\?;C[H\5+U 6
M8W,E)OC\S:MWKM_M--Y#S7?<X0%3S=E9NAJGF3KS_,MVS!&XF\^25[0>:^5H
M<LUZ\3!03::ODD?7;KLQH_GUCA$*'3\&SW4GE+UXFHD1%^:7$VX5Y',%AET,
M.?\*I?_\LN&>+?K5J[,W)S_Y]L%@TCJT_S!8H$O9W[>MN!\F.S;]*3&F2>+>
M_>C_/."./!-?Y?SLYVQR19^E1:!)HEE#K@@7*PLY%_-6>^&4HI@I4.?D;>.S
MN50\:29X$;9MH<W-?-S2-N(EA^O1"<0<(J@]SC8B_E!5_%^)6)4DET-=WC%G
MY^]^YL;6HM+EQF#6TXM3:?M/7(^ 5L!.;GXK:M>=&3G0068GKW0R!0@Z0FAV
M;>V/BX=H2--H*CR-2\BH#R,9$H-:ZH0<U_T#KOLW8+"Y9I:Y2Q/U&DQ!-&D]
M6JBYB[ J*/!3=A$'N$D-;_!0G65?E_3TY6_\6><& AMP=O$JX&!VKBO1*Q)"
M-B"%@TR!)'=#B6UR3@%S4U<;\8KUXK%J%5H@61BIJ#?KAC-MO,?6);NPZWR9
M,=2 3@K[B9S!9IHO ?[AKG+ZI\2NB'2G^6_\H8KN06[U)7Y-IR4].;[0?,!7
M[ MK6O>M7JO*R;S0A,_IWPPAX%<H%/.3UW4^+><E]\.^&SG]ZR8]]MW< 7^]
M4#%=9<8LHE !*Y*#.8@GI2IT5CF2YPK&ZHI,"YVJ5[Q1+\Y?/SL[>?[B!9[I
MQ8N3\XM_7/S( #CIB?%G/J/H"AA&'O+!TV(J9,7$_GI:8"O#.!_W^@/N]7<H
M4>W8ZUXC(*R1 #CW<60WNRI_:U97-*=E?IL-"#F=0;8(@37]9EXPDK]CZ$B(
M8[VC-J-=LFJ1E7+YI&RRJ/KF Q\P_&O.D#;T*=I^-%R<*<#O<8]EV?6T">E&
M@S[M[7/M/F9G8&[\(Z_*97Y-4\?Q=#9I*=9D1.L<!_7;-]\]>_;#-]\^DB.Q
MF9?]4A)A:"0_MYV2!/K-24QIWFN+WSY]Q_UV:&>K5F:TT<DJ-YH'P_XI\W7+
M/T>?L1FY40I(S.Y_5B?%G-_C1#[XJB*#7G*3J\"0U9N1&I7,1)@X_Q< EITL
M NU*;0(ZHF,><*/-<B <':OI<;0?4BQY!_NP4]1SIR&YVDUM_FP$R!VGZ-/H
M6<=^FN.(/^"(#]L\!  ZI'$_SL8G@NOY/%?FE4<%W4(!^A3(73\A1U#>0V\1
M.)2HQ>8SU84Z?*^0N[,;I#DB8<0 B6[]2A$P)@&8-@.QZ\U=AB##Y/QL[#3D
M&$!X8LA^M+U(PXL,?")9/]:@#2Z=DMXX;W?<^2 &]_Y=&#%?I%PS@[PUN7M!
M5PR8,M_7XF0^V\[K9&:Q J;MYKMY :SC1E6O7)L0L\(,^0R-XX2,2*NY3)&7
M+EN#(Z)+1Z@:K5Z0C4ZJ1\Z5S(.G6R8@VH+LL?4G21\5\)]E]V5@-S&M&HRN
M\FX]Z1GL$3BOT"DR-P4SZP'1SV1[9CO0+:D4%,AB::NR;BF:[C3(WC7PV_JB
M._3,T*^"MQAO6T[7:X*&\;*R?;MJ N:R$8&;=.WS,DTOYDSGY 6MI6E5=MQ_
M(8B6.O=\H7OVC?:D&0>6;^':7N+:E3-*0JLT2<+K%2E*"GLTP9JE6_:<UK,U
M\V;"[Z#BQ3OZ?]S?8QD)4)/U8 DLA$1]X@X;+\:R:/;)MX09\0%,@"L"!V6\
MNJ/DI=KXC;: M7# [%BJ.YOJ3!)YH*I7),OO#H_'N=XCDB8@:9Y\&4B:SS0\
M7AI[V#>7JE%%6SEFQU(N8DM. Y";\-BX]+X6T?_:-//)J\1:_0K&UUGAOWHZ
MX9SJGET5KPS!:"/AA4ITB4\L^;U52VRY,O#+X!$%K:N$L:D1_>C!"0TH[0XV
MA+JY41(BSV PK%E,!I.U@_#'<0LR\5[HG^Y#B\C].=EH>I&_T7J#L%!]P%?E
M!N3DK8LNT87%N;CFOD$I9TJB3I+5 +5@1FFX2V')JG<9=D /A5FQ4Y<9P]2P
M8@:Z/9CU^IAF?<@TZ_C,0,RHGK&^+/<H.@4C$&JA:1V8*SHKEH4[F;/)O_H<
M/?FF5$O+WWX5B"*UCL?3/Y!-ZJZ:EFL1N ^^!SZKD'$<T'\$;NF15PA&P1W%
MRZ)8IZYBQTSOX*T QX?0/U>;=$MZ^Y 2K?V+*1'5^[HJ KW%_)@*>D@9%;)A
M,SC(VZMVZD/Q:1%YSB.<(=9YTJ^7@;&(3/1Z^VK"F=:03>35%,/\1<F+F6E]
MJWPF1M9?F-9(.7O/_G1M_ Y8C0PO1&#);,)5=5PQ#]EKO<=.&.^\1/70H>##
M<FZDI/Q'H9VQ<WSD2M!04%:1V"'!49<764_"*0UK*?Q9HW&NC5G,U.0<LY@/
M+?[(286!:Y)27AB7/I]3S9S\7PH0ZYJ.QQG 3P!]L\NEE/WD>F81T/F<+_]"
MA.9@'<X&PA&QE\)3/1<L8@!AT7*FGJTX5/#@9G]]]:O[XCB]I#JN+</2&VCC
M\MHL6$#94E:2]]!,A9!SV<%]7>SQRZVK<_A< @,;/D.\V\'GLMAWM1!&<A1P
M3,"&BM& QGA9Q&V^+]22'FZDK_3W"\@G\;MFG%+,:U8XJI746@1FMM.;F5%J
M*\XC 7(,F) LW:#L8ZPCZGIO'0VV1C76(CZ9YEUY&!/T[^270UZ)7M0R>?'L
M]^LY1)#*,-ATQB#0%3Z\1'[)!%QI).GT7@9N)7QNXV=MXE2-,F6M,A$;'?7;
M2*?WJ$"-W>4@YNQ6QJ'!-MDA6&'G99?D+V\+.8?:)P/2.N,#5-/6)8<R"^B2
M,9;5XW/-N;2V;/$BD7<P5R(NACC_^C*TU+,K6'97A<_W^TI#$BV4:/65&N:<
M<XN5^UY  :KP?2T.9@$LH&Q4EUO1LLBN(=T?S?G@S9J(D\^(?$U,ODIU@E]Y
M4Q;57!CRD_'=C@+YTR-AH)LUK:8SFG&M6R%C?YM\J[6U;>J/&^V;\$V(X^-&
MY[$)K,YQBXFROF1;!Y><LYSFEI-ZCL.;O3, NI$1:>H3G.A)YDOKSVVOC4\(
M.8":HQ5_LLSG0L?!VE1"0)%SDX88$^%\WBOK$Y-,P;]$6<#NYP8QPY&D8F#B
M@&R+_^"XWVLC@^D;,IMJYCU)3W,JCK9 X+\;-;"X4/A:7(K:;:NE.[SDH,QO
M:T9RYS9A?GEF5L28^K0] GT7ISOJMGBZ>MV'W]]"#_)\DJ5#6&"-9;AFFICC
M%&?&3797H([4<H3X;S'N5*\C-Y'9!>HCOAMPJ!O+IJP,P]46$HZ.)U3E_7"L
M\67A'=O^VEM.BZ4*7)@S@$4W:=*:R8XPS-7YDHI'-QIN_;XYJFPT2;7--+O_
M60:I)I=+&K[8'7-(F>O25L6?+5=/W+M8!7?NW>&X<[>)1<9-4LJF<(:#J_8H
MOBV0R DKL]=SR?M#:HL"]SPC.W!5XZ,%%W">>!;YDA<0_#ZKD;*S4<O-) .Y
MX6X8II_2QQ)_$0!^CFT4KZ'%6L5JNXK M %#\)*92!2*O0UI< Z'U,MO]3Z4
M14%@*K0ZWN>7DA)3O<30F;/#+4B]WCR\W;:4TBC_]:PJ<E']R:6P3\<039T>
MMU9_,,!XMT.+BS93W2W,-R\P?4T\SK>*[FQT T+$NBG4.P\9XPU_V$]8)^RU
M5F7'B9-\0"1 DL/#U(3N-+^;T+6\S1OMI3@ T3=1M9#L3F,^?RH=R[VAW/OT
M6.[=6^Y] /=E(>=XW!O!$'<CEC@<0EL.@[?%'$PWA8AQ^GVV8W>%/-.>?74S
MP.TT*];7 ]'Q?AM>=K^[\W=0(?E'R&EPDEAR7NM8(XM]2-8J$]R@R,?77N:U
M^H+& :^.IJ3.HG;=+F4:=:#F-,Z7B.FY]9Y5<-GGA$^3!9D 8"^7%+:STD/F
M$O-R!XU%<.V#F(K;X',Q(OM]9@ ;[?SM&^8PVC_R(2XI73"B6[I7)V%P^U;$
M A,!W( GX_9F(#$D\(=?HSX6IE&#_$0[>BVZ2PK-C,R#Z$8+H:4?F?2)/@;;
MN46\:_>[!]BSQ3B(-Y\D$X!].;>1-MA+!U<T$6$R50@,DU-"X2?4#M$J9#,L
MV>M!I/QAMFL@>)'9XFD7PCU=(B*MAM1 ,>L]^'&X&%;\6*F#3)-8C.PO<=X"
M.D92H5.%  *(HB41Z0K.JPU(J180S#J=_$6E!/1*>&3SO&3@FVFEG8]FI;?,
M\BZIM!36&<'>$L+M7D;\J'B2P(N%<T7<*GJ.JW*E&R/T05H,5V@$ETVZ9HG7
MBK%;TI2I(NEW> AF$^W6VYV*NO$D2,&*&BA7^IR^.7H'803OG];7NE0 D(8B
M52Z*=AQG5Y6*O$O4D<J@WL85?U,81 HQS-ET^K_EEP&X_K>&AE;T95.5'Y*N
M/H-% /TB#E'R]7S:]&."N2P:RR@\59GP7T&-L[C$QDAM#>U9MC(:<*M9RDS1
MSB22P<FWI:N3?BA+Y$46=!:T+B7M3$,V""==V96]T\G[NKE!"5=709J_,R^3
M;.!"E/8T,^GL5$3B#=)Z=L5W5]R$/' GWQ?%2M(>M(6+JZ92?F(>1B98P;##
MP*[S=0\C:O,7T(#F^VH!>E[P_:.^CMP?=P+2+EX<.*RJN3$ WKSL9E6# A@$
M$>)<*CI/<M8P8GI5/GV[\"+]UJ-OKYABL<#T.I'#N"(UPQA?%B?/#L75,649
MICBYR:47)"D.N'WO-WVY#CEDN)5!\T68E?^SL4Y\X7@M9F67.+F26PK[#QG_
MJQS.T)0%BB1.L$'Q6;V[Q!TAZX_E&N1H#L)&W=^@[\!5^$UDWBTW"B0ZOBKN
MY7/X0V(K:)KOF',IMRL50A;S,.YQP&J2F@8Z0-<GL=DP"4/5KQ2-ST.9D[NJ
MMJ7Z=?M[I[2\XD>*[4TL3D;W%2E'(RU!IB"*I[H#V2XI(RM@*S4P08A)\I(A
MS%<!YBT1L81S P%YATIN.G%:7_0'WJ]73)WZ\G_'A=NZOKTNR+J*L#GKQM?L
M@"E08U1<W;]?&#WR=7U1[F9 $ZEPH<CT[H* 6UBU07"]:BGT$7[KFZWM%;+#
MMRQBMM"E4)@,3[T=1-^*X*U'Q.E"0!=3J" ,:7,M7P%_Y UWO[YJ4-;5)=0-
M4?%)\C<+VS2+:>\L:0'.4M%P]13P,0;;Y9>%?F)-IAS7(3^C">$*,Q*W<S[-
M%#&5S*P=N6Z<BP^L@V2Y>S-J.YH"K*R5S(+QEM%%EV77V>IW"VW4'"7N&9X\
MND0>8!9Y9:)EW4*4W=ZW$6W%,'"TL] B1#RGK>48[JFZ5LI/>LMX8>=7N13Y
MNAF'<AL3;6'"3\XPU>*[!7 .KI[;E/E-GZK)\W48RF<*D$IIJ!5GE:><;? (
M$OCMZU41Q.B.19OHVQ_%ECX]P4DXINW <L)BPWE+C7FFDF8!]*6_#T9;*?AY
MA<S;_$:LM[<9QBVN]\1ZXKHT'6?M1F\_EZ4?10NY)>=(>_.0JV(AU'0WN2C6
M5L7:D#D<A6&A# S=<3H>=),N^HZ&.J*HD<70DCFGRV#!?4JT4;! %)2-Q*3^
M<PN@ZZ8;D(#A2QWGS\I&6WNOFUF L=@.#+USYBGOGOP_7CGVFR^C''O<A!])
MZ3(Q2E^@G]>FJF$5X!SUEA7KJ8NOSYU1K5"=?)!_Q1;]8P/+)YJSLA9"?K6,
M-B]B7$!F7EX+GFK60CFK8JN:5U\&:P_7MIJ9A"FBQZA9"PDCU*-'[69?(BUS
M*LZB!1,RL:;&+ >$A,[HV+#/ %^G?PI [$,8N'MFXL:8+I3?0@-@$!?%!MP.
MY5063M#JJ$L8O2^8(+0N8X'Q&DH4G<6:W>1*!&DXV)&*<4R-]UM5T3[E\[!D
ML;1?&@IR%("ZFQ=H.TL1Y;B#MW$0,WD7D416,PBM+LB$6US"<J4K[FPM&,T=
M4,8.+(S<ELPF$SG04EXL!E! OZM614/>E69+:?R+N35'8*OXDFN#?(BH!*7M
M&!$P\S#S-OE+WW(DS4Q<F:U>R^/*NN:?MI8S#T DLY0##4V@._DP;YKV?4KG
MD$&PX5*[),+%\*-K;$_YZL@V(<^\ YH)7H89-S[,Y* 54"P&$0#^+;Q[OI92
M?WQA]RPCC<>32YHG*^I'XC/)2B2JU]GP(?D6VK$P4\5.(\SN:X8C=[%A@SLF
MM.=M7&1;4 DV2HF=$1@L;<)RWG.*Z=\:T3!JD(-'!]^L9U1G:[X-Q_A555B8
M7X$^0,-XUB'D-"*$SR_;YF9]99Q3*1=J62_:O%NWO;0Y&3*"/J1"AF;!^+I<
M9;/$ C!28M?:50,],@:S;].%./1^BM/PLH(UIYER"X@$1X"Z'(_WLE<>E 8L
M'3L6NE9N-XZ3;+AQ[2/"]^'OR@.MQ=*06*9'D6[W^343VVE+![Z#.4RA1YFF
MQ@Q7(0E&OBXJ#X97$LW$<'[W7^IA'%-##KUH/:9WT;Q'XI_5D9%.I+="\;&"
M-P-L5<Z62F:<-GX?BSI#7\GST(7:(W^6455%>Q #O)_R6XL>NG>#"BY6T,A)
M8R^[LU;,8RN,Z+I!I&Q,>[)%7;8%/@JU?^CH254=/\_+_+)N(,7C!#&P7^A&
M_RQFH<X%>:$!3X4<O3=7BD.2 ]G>)\GJ!_C5VG\QIMC#(/#%4,#HBN*]4XH0
M)KXM,J1FO)#JVUW8(4>92U%Z7&=;BCJUY4 +*(S-I \NOIYQ8?KBG3@R1GQT
M+<I+!=HAY#[9_KWR,?-KU<T[;9\8._#M(*.6!QI@WCVVP7;OKX/?7O<OZUNJ
MS,!O>I(5J3PYSA@0.#I:3LF,N[YZX^&;%XL<M"NU#S:VX39RD.H32';ONFPJ
MJ42Z;CO9"?%S-^;5 NX"T\@OI314_+M;'YYN-45)<R8F8<5!3+YD_J*#F,B[
MQ!))$&&C,S(MPDWKYI?#/C]"5M<,UUAO5DHK9J52@1B94-^61Y'%0JTK>;H9
MMZ5A>-^16F+\\'"&)4,%2"OFV2YV4[1*TQC6V_A"<ZMPURJ2\1&Z2OUH7%1Z
M>AAW=7!;H[E%<3.$-FXL!R "M&6PT>#%#0%T_U31E\I$PP,,H 8%,QQ;?*[Q
M#@; 9=Q8]YWO^JRLHP,AA87H@RG19FQ&=XSLVF+L>26Y0+?%W-]PQS_GCQ4\
MLO6%@7,<9$K, MU*A]<)^LT-7R/-J'%DI2<^?D&>+T0+>#!TO6G56/O'0\IH
M$6 8W.,"7'0OD0ES&FQL(L*;B\\\R2,(4T> KD#'M[3AH.6O#0%*A!NFO+/Z
M]'H!GA2-797B"&$'/B?,-H/Q+),-8E8UY@?25N:133$M9KPC'%3"S./DE_)]
MP?,[O,O0&NO>"U.G2Y&'CP)!U$]#$+-N0#X0(-&C><#B0RE4 \GR4/ZW_8T_
MR TPVC[]*H)+X,4172)B++OWXG&F*PO/)7WZ7F%-]A)#6QH14=.&A+6"Z!D!
MT0B169F>4X-3*O9"";Y1NPZGTD%<MEKM+C[P"/1*,[PUVGXV@W5='L21=D_?
MY(WVC4S)[PHHRJJ,G,EJO"VHI-.]NYHLV"1H<*DM]S@2 OHR4]I*(WIGGDJ9
M[CT++R:@%V19ZIDH#2G8S<"$= +)ACHLI.=M+=ROZ# **+2NH2'XT[>/OS_]
M]C_^S^/O'OU(]ZSPCI>7C$%?^TQE;,!^<OKDVS_SB "8Q0.O664R9IQ0)I^:
M;_/XVXQN]>2;@!3F'R:O^3,P7Z_I$,6^HM\_PO.@4 I@(C?OJ=X[EP'*:VG0
MKXO+9BV=R6A(SC4N$UR46N]C\3<4?[_],HJ_GVEX#,&O9V1<GE)E(9=L!N3I
MGQX__>[TR7UVR.!R L9SWW$7IZ]+C>Q/CY]]=_I#>A?N6",[=SHY6T^>%S/9
M+D\?9[IE_O3TV>/3IY./>B9A2F27KU^C4XX.F)!\Q1DI/ %YP&VG]MF:P)3H
M3"TE^OF+N:9.DB]8\]-URG@?=!)G1DP_<^FTKI@)D9#-U3 DS\9ML4@*C%CO
MZ>8(Z?O$16^5;C$'YKJO.!?CBKF&]*19:I:J3TK#V7?K=N-0YD=(UP-.$APK
MFR(W.<HGXJQ V.G'^7A0B!T#JR--GLEU&P5,9'E'(L9U"@>_&*DA9Q+A4[77
MI5)<>N.<<-8K#:9O"%_(90>>MN1IE6/_N!H^U>Y<5!09QQW*79T\'XKYRA&^
M)TAH?UX>I^DA^8E+"@MLSX(HI>C6(>T2\AG=NIF]#PY-Y"[C#Y9=U^,SW&+:
MQ039<HE"+GU1<T&(OCK=^*EO=X3Q/32,K\KAZO;H\L\G@6O>=_0S@>3\FHPT
M$T=)@.K8 9"#X+1^Q;YQA7SH)8>U7-3J!83%KO(44'?7*ZZ<JH>?;'@S+)QQ
MJE/K< GUQX(5PA*9*Y=33K@BR1.!-^*^C'.)\XJMM*-);4?.+4E%Q#2VBWZL
M*6YG=*-M4J+<33'((.$:3EI$._8Q*!3N%9'A>VK$M/]^2D@A[QL#F5AM"8TR
M")VNBUI@)'P=29(-';F5#/P@>,IYE(VG%_TM[SFON9$4>LPRRDW],]]>XXF/
M)4VCNZZ=C 28%6G>D!"M8]LVBLNA]F.3FJ]'_1C-WO),]&V=Q7XNW7=)I3FY
M/1+AZ-A;,D^"\D+F&ZS!4GK$#V+OW;_V*Z03#/%$_Q(=&PPDU,T@57&E!Y1U
M[-A+(L,LMX5V12%.H.'J=@K4C8)S#V+X]IJNB[(.3C+#\1)>"6Q/SE*F68RU
M'\V8U-CEC>]*Z=P()4$.)& /"%C!@"^V=W 0_O3H]/O)U#(^J?,@4PL\G=Z)
MFZ7P6'<=]&\^9YF;X7M WRFCDC18)YS$=^FPGAB#<("6\ ^_YBU]NFOJT VH
M8!O_Y2>/%/23MVLZJ8PY8_>#O7G[\I>7%Q?R8$4];Y8%F>6&.93HLG_K*Z3;
MG\5'>OOR[.?7KT65ALN&->?.IFU3SO$-R<_S8_S<W!1@0[*%QWMKPV":J:+:
M1S@U'$G #A3-Z>0% TJMA!EU'@%;%2)27VCV.H>N['L':CT4ZMH$5 P+CN*Z
M00>&M_((DIW\$/<Q-J'D%RV<?VLY;/U6CCO'4]C#$-(IWK-7#D#7%Y,SW'E2
M?%$^]PYUA7%[<(QR/]E,W,W&'B?D(676&"*Z\S 8IXHY3LA#YH$,0&8H_L)3
MFA5;!U]QG*3/498Z,:@2.RHS85%GT)!-1$)AYA',QWEYR'E9*DM FIQ1@?5N
MTZV9.&:[B>>8]7S@B;GB_>'FQ!@W,M>EET$;K5/Z9^O[BJJP!Q_Z4[1P6RHD
MYN BVV!@G-'LT:;(6XT3D-_<@J4%ZZ- /]@?Z__VMB;;&890: -M*L-D6MSC
MM&?X,3@JI;!N)-?@=.IBT&-P"NU?<CW5Z,JK>+-Q'A'Y# &C:D,F_VLN414R
M1738<:9[7G2SMIP*R^1U3!<)&6HA@/R8%_:,QM8!Y3J^96%I'CA]/CPQ,%I)
MXF6T%=R +H,0,CS&6IF_Y '2%!='Y>%YCF"S #;[[@@VVS,\M_,3# L'G(=:
M1#ZVL.J!*E?#=(>K"N[*,I)5D"AR[5D!@S:L-1Z$O?[(3+?T E>Q,*/DYW"W
M-</DF/@=07,1] 9]FD@&?-\E@E79H7:%T@@Z_*V4+RW*J93,*"3Y"P4<[\]Q
M<YCZ 3V(]++/OOD6Q943* $$N8+3R9G36!/T8 2_W'EV8\ZP"$VAWI<94;!/
MU0BR";@UY9XU'2M6L=.JBJ.8%P\(O27:<:V$C8.F<^T[+&M3(#.M%K#R#,@U
MAB%CRL\<*SB%];TSUP)NHVWP6-H@F4D/61H$I))5N"XH+]6>FB+24@P9(VP\
MA6E[L0FL#EDT6.*KKXM+'*UNU >B%&B4XAJAB$$P-32\C+:O00NA'.#:UJFS
M'&N9\<%N'[B=%+J'OZ?>1*\MUH6]^H55-UWQ=SQY.NB]W5<UD.6N99!1,F^L
M+^E1S*SK*;,>/?<HLI1\(5P7: %KAR,*1?/(_: =U+L$=OG98S/<T+.T#24Z
M&$HPXME?H^2BK0JW@>.I4)7OI0-A^W"@G1>D-9S]L=7-Y["XY/+NW"J6>?+R
M;%>!7TS/Z>1=(^./L65#Q@IU2>4C%F.^F++$EQ@"Z^+=Q7SDEO Q1?2@J;N1
MP\2?4?E\R0+/X%4.06/"]VNG_'&>'I*V5=B>@M*],%PE;$ PM=Y3.Z;Q'MR&
M;:/HTOV2,?:$ QB;)<=*EHC&N%RL*8H?OO\TGOGA-V::]<[ :^N<6T6;-D4Z
MN ,@;3:2,8-H#^M;V!T"4:&C<,I2K9MQ!_6R846\80[ /65"_H9/#^6EHE,Q
MR.F) WT0,W7_V'Y;XF)6Y>4R0BBUY!EB"XG0;EKR]V0.(;?;M$%!!\(ZQ:7T
ME#*U/P4PQ=K: LL65;Q B$@'QT&,W/ZXNP,Q'3(Y#%8.H-2$,2XT64GS+5XO
M97)C$B))+0<*?QV%.?3-8-W3:S(344KMYGCG8H@V5$OSVB#^#R[^K\-4YY<Y
MD],!?\W$=A)?,U!3J*>]U/R.A:)4I&&1L&Y  /B)Y(1<TAI= $?>7CJ#)>-0
M2X'UP)O,W6MJ\DNY5NH->_2Z8,/#EQ#6$Q:>M%=7A"W>*(%TC2&N%L;(/?+E
M;%+%&YNBM*%E?9^1:D/7JHD,&0_IOXYA':@^#F%WW-.N_%3,\KY+[+HKA?!T
M7/,TN+P),D\6P4KQ0P7#I$E#4JI"ELJ%LB] JX[/FG_U%'47+5ACK/:1%KZV
M1@=[)M2%YD%Z(>\D^8(F!PF>F9DC%)"V!G,K][U]?H$'=\7"ZC,I=%G:*%Q6
M*3M<AV^@[-#:5"=T.*%D%*5.9V0,FZ7TM*$YNQL<SN:N>B)43Q3I4Q23*N]K
M5GM=I%D6!8!FD[;9"*&S0H/[M>$1 G&@ZNO$6[Q"'R"-PJ_,*?-<>(B@DH,L
M2TKU.@IC"-2O,G0EO<^ZJ4=D_XJ:W+DJI-!L$62[F2B3=8)TBXPL -'Y6E5$
M@]AI$I!E(SJYUBF0A=F%LZ4-;2'6)D_MPT2((O!$9=?V*Y4CS6&PI_#;3J#W
MQBP5_"RL4%=VM$951T+4\HPOE?,YQ;*<X4_%JHP_Z)%G?2W )=C]W/F6*6&J
M\D#Q:)R_^=^7ST\>_Q N3D<;"(*W.CC%T,JQRY3N3'!4S(5?C?Y7,RL1:CNR
MIHUBR.AGDPKJCKG"/4SF$(1Z9J<PP$:-)^<!#12?9_*4DJW7TL3V%N5TKUF1
M RQ0RQHIXG&IQ$?NT1KW!G+^IT.^'WSLBW.:8?9@Y*AQFW?!!T(CDB9MM2*G
M]7Z+!F!C.4^JK4?CB5\R6?8^L>?>L;J)QKJ^EV1\\6*B^E5V@4F%9T;*"4:Y
MM#@6NF.A^_MCH7O/\"AEAU QLIRT<J8!*P./_MU5$8):M7G;AL2)3'?I:B2/
MI%3X#:B5:8T7HQM6-W\#O(:KBYM1H+<V><GH_GGW#6[WX7AO]W1JSYT6%AV1
M57[3.276J(S*)PTT> I?? 9]FP73YADYQFA'>Q<(/+1>70\*<P&+LX-1J_EB
MZ]M\&3*U#2\D^(89..^"GV#CSG*&Y'6@>:7MJR)J(1NC'5)'.;AO@N!I4>="
M0[M&MD?6ZZU0@42'=F2X PE_%CO2_[WGA!.T8H+VN?$.T#^6S5PY)=M=RVO
MEEFQ%F*EE6U]=UJ\0E>F430G<-;ENM)Z_SMZ\/->O8&_-=-N<C9;!\(Q_BM^
MMJLM>1R]@V0L"8I9^_M%&(I8/^_+.8[7H WWTL"H;]5-NE!:C5B\XZN87&:
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MA9F@PUNFAP^4F"'-A5VD94,&M:C(U8#-E.\H5Y530FI D>4+*ASF<LM3G-*
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MZQK&;-S,A;D<L!2@)^OYF5]DSEVAIXAO:X/@DZ+![7D:[(3L+'[F0"6!4DV
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M N#3H[VM\T ZUU1'<U]0;#'>OMJ\H[B.XKX@Q'BP?>UO1W$=Q7U!P&=_] B
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MT!0RGX1[1=\W1VTM-7AOEOD@>L%L(#OH.G+1!T;_,#+F_S/2Q3W_T:!OOYF
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ML";#CY!0A$]1*K7)/Y)LO5JN3Q_TFL*/D/G5I@$J!.6G<T+YE/06S/1 XB^
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MK^V9'ISBL6)^R/A&@P,"\U=J&X?-_17X& T--G$*%T-=B/?8)&1AZ3"*6HQ
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M5O#7WZ!V7]-A;S#9O6UCI:^W2RUO!-;=E^Z^B(?TX."VC>^ZV]+=EN_LMDS
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M1WY&H\GVA;[=&7UC171_:QB:KWA&CT77M)DE.I'D<:J<F'+>:49W<0V[C7W
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M,,C9GGF@VUY$N:86.(5TH8"!?&X'Q.#5]P;(;>HL!CD<SI[@B?@&C<'.JF-
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M1_G5<R/:-5Y,$13WU3"Q^0P>(D4?IPFE-F*^Y)E*T)-.#.[>J?FM[Q"RS4C
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MHR6UU6!4)Y6M53M34AO2"Y55LPW']HM.ZW8#1$T3Y,(?LO"PG"!)V.=#0 %
M-)08G3)LDX[T&13<"U<#[$GYC)OBR#7%5:^]J2LB:6(BZ(Y0X/W%-VT,WDD
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M+O_=,DJHF2BGNC2+G_9GC7%63!E2;V)<B!]@A8V?K+APPY&P4_$>Y^0]ONY
MO:<X&IJ\H\&+8QZ2_C5\\6P].Y<SC239>'C(=1^Z/*$RB[RBH4?60194'&3\
M0\_+&^QO[IK*;<]-@\M\+4&X  FEO)7R,]/%7/*/\ :'38E2FO[US+F$Z"E&
MOCE=C;K2SE0F'4Y];GTNNU19ITU/LBO6^T?YZ9@!E3(1Z@[PU[RN4YTI+RM>
M]:@V*HYM2I34NDC9C1U"2SJ],W*<C8T9G3.TNX&-1?F\BMSI'DI/X)^^[BE@
M]46:P$ +S)VCTI%?^V=]Z1B*]3+<8EA1Y8UFN9*\&*M\G1G=7U(G=FIV[R@?
M&LPZ"^DRF@[D5 L"7->4Q8A0T6?E")=WF+Z(WQ$^_?37)#+&;_[,>_K^^.C=
MRV<]]ZSE[N2<1IAH(*TT]C"ETJ&5C(0=?F;#)>]Y4VHMB\526424YZD<%;@(
M. L5!YSH;QSS-W;P#^<9Z_F9OU"7:?9)]T"?KO0\X;@+1:F&9TN\"QDM-COW
MD^@O(3C9FX^@IX2@GO!;>8ZT_12(=NS-]/#/F'ZYO3#);[$SU#0K_6S%R5M2
ME8=I@T#E.=5P>65"^::S"%<I8@(S356:/#PY=Q2FIFLV#NG0T9F0W.W6='_Y
MW4=GOWJG:1^YU-[.8-1Z,7U$#<F#DN@K2J@0S!MJ*_A:ME^YQY+&RVQWH8HY
MI],Z?! 9L"X0HFQ>%*?_]!,D>H_N,/+VT*;H^@Z%-%!'[OVZQ,EY3V'?G[D;
MW_-^X>\\_0C7)/ .)J-GZS(4[F,2<HKZ@[L\+_T\8I$FZF+K:>TCE8HU:@\^
MI:J3.$?V&DVC6'+3F^0$S,3GSNI][QWW:'??XLH!89O(--.J/ET?KG%&1I!0
MFW 4D-R0'&?J>TL6@"YI@U4%$S%VEQ&>)/"X%#>K]J"?JO^?O6]M:BO'VOTK
M+LY;;_5493&Z7])SJ*(#G:%/8SH)Z4SXDM*5F!B;L4T2^/5'VK:Q24R"L0T;
MH^E) AAO2UIZ'JV+UEI5LO'8:)N5$CQ&U@T'<Z5ZQ."SZC&= - V7R8&DSD[
M2V.M;D_VSMM7Z;G'Y^WK!]>;ZPD$NU]'M_*GSK'Q(ZLYU4B523R5N[<'/R6M
MVRLSU60:AQ^[_>E7QPF6XZO^9VTS7("D(F;];[BV^:.RL+JV2A_.F27=87/X
MJF7],,>RRE+Z\C%4*2'7U=]O,!![0R7C2FW.*S_^E6=7SQ@Q9-+U<S)D+VL6
MYWZ(A:O)CS(51J,=:J%=%WR5.%79!_T,CPIUK?ZG_HT?.UZGV?S_PR$]FUZP
M;X>0UW6(7#_<[GG]JZ%L-MZ<)RU]ZI>OIA.^FIP_TSE^EK%I&H.<=6(S%3YK
MA"JSWV60'2<1#I/GPU4R;)5D.I4\-M+X9TWKVE)6>O)D #GG9)@..C9IOU/R
M&^?]4<;]5.I15D1;IU5^S*GQ(>N6$QY[EC7:+R$GW_>__8BL!&=3:F1AF6EK
M:?;@$R)L:(\RFD;%&T:326N:5RFMW-16M5='R93A]_A.Q!>9O5Q:B^T*E?MF
MD-.\&X_A7*S,E6KL0T8YK<9>Y2:?=UK#Q/,DTNZ7?+B9\<LFH:4Z>WK=(1U5
MF58Y_VEHQ0Z?]8.M,B*WM.>N?5)5Y>+:.77MY;%N5CW=7=E&P\/!#)XW<FV5
MH8HU9)HA1JIJ&M, K#X\L]X5[8R>/)L>T^-S9G^K\[G;_CRB^NJT;%5V=SJM
MVNW0.:ZXH7\^2>+K]D:%7;XV3L[]\51&XF164Y":+8FKE#C3'E1%0JI:(]G,
MFX+,6,&XC=IL/H5.!KM)#-IMAR%3?AGJ%^ESGF5^F!K?B MF#VZX,X;0KJSC
MJ_H7WXULYOLS\#O3='9=4EDLPU()K<%8KB6';1+YH#='/FH3P\#R$>348+$I
ME%IZ3HW"FQB3^B35W%^=MLD.OGV>'AJ&E:JLZZ%2,)79W O6#"O%M,='0:*=
MK'LW^B9I/K-2<+XA!CK<><M:WVN_.OL3Q<R/['6_+"BSE>9!W2BPV27E=D(_
M<?O9]$$VU'_FZ#0_U[0?PMQ#8VUI;!;WD\;<;_C>^7&E:(R4@<%%X^RCZ9T:
M-[9E)R\D+AOT6O:\BAN.+(#*BKX62'EV%3:I2GB-XCO#\$CVF%6+;9?@,>L%
MUTT6PF4%J<^A<SZ"7 6F*JK;?/EZ]^AHNRJ[D*,9XP&-JK0EDR2!+Q_Z$V/B
MRK$QL3C2DT:%%*[5%LLK5U50JTH"')NS,<"?Y:.^JL$U-AB&I7&^HX+\^G'/
MG/8;OXR6['NVF*S=[FA ?A:G9,UG4L<GV^LC"[[2'4=UQZ[5-&NW3.7RR6*>
MI7I=CRINWGPO:U&*FOT8R6[QG,<!NLJB&BNAU[;5#$&.[(E*X\[B&FO="0=3
MKMUVVN_M_(3SSJCX6G;=C97[)/H9&[HJ&#<L"#6TL4<(/DVV;%)4A[4?LM>@
M/ZRSE93@M(CG;=-[-O6X:H#3!LYX0L\J[(T/M)&#(E?+NJ***_K(/)O]8YTT
MAUFARB',1]40\RRO/;55%<@*;G!E8(T,ELI<FH&R&;Z\Z68S,V 9>EDISK!.
MAD2:5G"F?R7!$=<\&Q='S'6\+LY&(&]??/-K,SV)HW$-2\F-:P!.'K5"L"V,
M2S83E^NE#_P[&83O0F/;^U'L<*(1Y+V<W5L5IM=./7@7*I_@:,8_BS#WAR'F
M&50SHI'AG8$A/XQAL314+Y%M)F?Z3V<V)H.A4O -PG.Q'N.JR$LZ0\TUEDTR
M=J.@P;V?I1BMSV&:;[=EM_4/-+:9)^N5"C=QZ,[RD3_+K)PV0E6!JG*+7W,G
M#P.S::K'K9&G^EDUG/'KTR[KZ?-V$B8>%6_-6V;J?>/BR9UAT,U?VTOY%Z8.
ME\G6FMRP&,>Y*I=[@NA%58'R3=;<X[ 4[56-9M,;P?NFL58J1JOG(2L %Z-+
M%OV9GSAU_%]A<0C#/-!Y@7BMNN?WXYU:@A\=V=>5FV\Y;+PXDZ!)%8VL+KB,
M)C=U4$]]3LA%]2Z&4<PJ^#,:U<<TNVYOZ!:<DMF,[3D:Z94"^&S,M:,"RR-#
M8Z3/3T(_547M?KX^5Y5WNQC-H57]_@^$.-JZP]CP,!QY18YC#:3=[GZIM/RA
M+[LJ(3:\%3;TBW_SMJE/N)'$;E_=_(%<CO_L_[.QV^OT!\.;0O]K3L]^;;Q/
MJMAQX\\__ZI]P&-\-[1B,S^^J?C=/L\$EVWA5I8NUIH\8"WB6\YL9G'@VH]Z
MYKVSXN"_<O"SI:0VY&(*=0L+//HZ:/6=SK5B:+]M_[F=9M-X\^_=W5N70</X
M$<1L)-N4:/EUT##:Y/INH: ?OR96,UB!;G[Y#@&F!XT:J5M9,;/[UUS-2=]F
M3D. /LRL9@>^IC7Z^Z@GMYHISAGM^R5[6X<-([*]^#4G,&35O='/"5B5M?:/
M6SB*YFD]5.]=D$VY94WX%K[+=5HXK.>!S8P^5RZ$&.=M_'X_W;QFSWD[&=*#
M[YJ\SS/9I>VCGZWF(L^8?Y!SRSY6_ZNG[&<?@B]&%^Y,M0>>WVD3?#/K.\EH
MU<]8$HRKAG-BD_":2S6G#%YE<.9 X6?3OI9U^]-N?=]/?]U:-LZ88:V;+OZK
M]?5YI]OYO3?L^]4X[[0&KW.9B/.^WZBB)FGPU0]:B%D9'.)4:,)8"#9(;03C
M1#!MHI<?]K*"D$Q]O-'PP;5.3;O_?S> ;S0ZYC3D)\*Q,6?/\S[:[OC\S^YD
M$VT/7IA>+SN!_\[M"Q*(T@*E=XF-H2?!T[\O[$[W\Y_D]>?W=/_<G^Q^/GJI
M3PY.?OO4/'%L__+]U_V3_2_[AZ_;S9?[O'FXC]Z?_/8Q_?S+_LXKOD_>HC]I
ML_W^LOOE:.<]/=C9)_N'>Y?[.[OHZ/#UR<'AV\OFR[TO[P_3SW>VT<%AL]W\
M77W=O]S^?-3YX^/1Y5GKX-W;_,Q/^R>[%\V3MZAY>71RL/,V_=UL[9.CTZ.3
MM_S]N[TOS99&[]_]T3\Z//MT=)*>]_(MVW^WE\:XBYHGNU\.=OY(S_CCT\'+
MM^3HY!,_.OST]>#%Z#W_^>.C/?7M@]/7IWGL1X?'7]^?'%_N'[Y*X]UF^Z>O
M+M(?=G1X='IPV&X?'.ZR_UR^&NR_05__/-P=[&]_"-8&;Q@!RQ0"1F4 K0T"
M&UF(@BC, ]G8PDINXG_]\[K\;[!?[D)H*^LV^^/#NY#/6I)/D"[PB*UU'#.I
M@E8V$4U$A,G(M8V9?+ NY/- Y'-Q13[1"VFE5*"("\"LL& U(D"92>)B,6 G
M$OE@LDEK1#[WK91/>3='CX#\^\\QFU(#6U4&Y'/0*VPB^9/KL]?Z-#7,9].J
MNO]![/8@W\9L_&).\[V/RZIH2'_0^)\Y,.U=H$%C2X5P# FAN(^:(F=\I"12
M=;-"D:.G9I >\77PO'-^ZKN#T>O?PGU[/.+?N[TW:;QY1I.,SNWQV%^DH5>9
MPP7Y<R'_[6#_Q0CYEP[_25^WP[]?7QR]\V>6,'%4K<<V/GJW1PY>OB+-EW^<
M')VFSS],:_?N]T_[Z<_!3O/3T<N_X_[A^S3W/=*\?(7V#X^_'+SZH+ (1A(!
M.!B;F(1S4#P&0#P$9HE%297)O9+()ON.22:=7B?7$8;L<JUJRCR[U6&)+59"
M4JR9-U%'13!+/[6(1H?US2=0V:UKOELOFE\^&*D53AI)4K6U \:]!,U1 $.X
MT82(0"W;V.)<SCCW?K9;L?['C$L9TT<5F>^HFJGX/F;U<%FVZ;!I9H;@!'<C
M;U8!V[Q@FUBDGG@6&>,0/9+ 9-('C:(!?.38<\(YDR93.=W4BRJ%LQ6SE5JD
MMW4S/G60+LN&*R!=(D@GEIN3.B =/3"ET@E&8K+<HO- 0A8*QU9'G4\PM4EJ
M!-*GY8/?'B=^]9*:T/J<,7!C=.5'='-;9]ACIIMEZ03C-7]]M>3-,"A\<Q>^
M>3^M%'#+50P4@R VD8ZC%C3Q%&Q@V@O$E5)\8POSM713%Y0N62DH*%TF2B=:
M@?<L*)MT >Z0 &:5 L,L3W@UW%*D&,E>&$S$IJ@12I?DSWTD6L%>YW/:Y=U>
M*]Q\X>:I&Q_+T@;&:WV1Z*7PRER\XJ9/?QLHT2(:H,PG7L'(@0J.@^ >(V$)
MT\QN;!&UB6ID;!2/0#T/_P+*14 Y.>Q%TK^YQ!J8EBC]I048X@3$( *S%L<@
M63KL9_FPBP?@?M!U4-45===N6!87P(H/_6K1AS>:BTEQ%Y8YGC[Z41 1Z\"!
M<YVH1J2CWQ*#<HC7"A\1-B@9_A05NW^-H;FLH[] <W%H3A0 A)T1G"!0^<X6
M0\&"2?L3E.<Q8HI)S%%LO);&?IU/_<-NKA.VA%-_-/5;YU:M'>_<726X_36>
MPD9W9J-/TXH"]80:(CUX00.P2 Q8'SF@X+!20B5*PHF-GJ%$2,N*2<Z3=?A8
M? A/%^U+BRX42"\"Z2D%P^ HK"9@,67 0M(M-/,2, ^8<!(DDV)C2U&\-+_?
MR@%]W\F\-]T=5T_HZKAS.IWCPA.9MA&FT@:EI3$<4TZXYKY<':\[*^Q^^?-P
M>W38[[/FA49'__F(W.G?'?-.GQ^<')T<O4RC/'W+FB<?/QWLO&[M7^ZQYL[V
MY<'.J\M\Z?;HW2O:O/QTF9Y%FCN?TOP<:N[LLOV=3Q^X"I020B&B?)<INJ0Y
M!&[ <6)B<-0Q(3>V"!&;\E[NCA//)$<(,X69YEP)36VTP>DH*3*AW!U_PMOU
MQ'U VFFI% %EN0=F7 0=E$J')(K)/O%.,96VJ];W?GG\*;BB5GEYO-GMN*(U
MWA%PNR/ )4M0:X2DC6!MY2C6!M)YKR =_5X1'Z7F(?-YN2NVSD!=Y07R M0%
M@+I_!50GL?6:*P@R:F!,4E"2:C!6,(N2E8=H')YDWRM>Q8.\0IB]SE]#-\)Y
M/RS!@;S6/+.TL/%9Z%4EQJNNRY4$#N+;?JB\285FYJ.9K]?T@1 D\I%!)#'I
M PCE7!7D02M! U48">TVMA395#6ZJ%)NC]53'2@P72Y,)]H IL$X;2PH2A@P
M:@,8011HQZGCB@3/Z<:69.MXGZS.RD N?3.XF/+/EAMD*U8%ABL^,3=^_]QL
MO0ZY?T9NC%-(9CZ2N9C6!0R21AKK(42$@1$;05EKP&:_&:'&$)),#KJ$M-7B
M&J@M3I>E"Q2<+AFG$V6 ,A,,"A@$S152I!8)HLR \=2E_SNLB,SYY8O7@"B>
M@7E0]E>OFQ3@JOV0K\JZGN6F1<\:G7!S'[RG;GHL2RT8K_U?;=,9;'?\[GCY
M2R++W&1S.:T46!.%UQX#00$!,R2"%C%I!I@%BY0(R/"-+<86O\A:' 2U1>FR
ME(*"TJ6B="I:0'DN^T@ !YQ4 A4X:&X5I"^8=1H)PG5"*:Y56:@GX!_8"3'T
MJO:,YFO),;L?56"\YGL=UST-A^;K\,YIH9BY*09-%(%/=/]P_P.CB#$J"42%
M(S#A#2@I'$B%':54,9QO@U&L9U02+2Z"=0'JW;6!Z4MXEZ'7]:;_L<!WA?#=
MGX+O^P\:^Z U,L"8S7?&2:X>B0-(3(2B6C/&?.Z\I@@FO]8(P$_ =S!QC55=
M88J_8,5*PF2]9S<R*+>8EJ T;'\(*/V'DR$2-%+)+F$,%$U: [>&),8QPB"7
M%(9:%<(LSH.ZJ L%LO>N*&Q_T%HD;'H'.,JDXT<5P29N!>^(8Y8[E5ZN&V2?
M@"=A6*ZFW>T<PR#T3HLSX=X+UA1^N2N_X&F5@+A(#78,HK<$F*N,$(J "BFB
MX$*DDV(I_%(\"+5%YVH]" 6SR\'LM$[@G>4FP96@ (P)"38#UWJDB!<J:L>+
MX^ !"]K,U@;NG-&_SLT=YYO[NC#NO57K*3P['\^2:=TH(B^,PP$0"2R7\=.@
MJ51 $4,8.>Y(B+E.CZ1L\;2ON8#PP,Z4PF2%R9:J.Q8F6P6336F,0A@D0P3E
MJO)$"B4KST@(* 2LK$M"0YG)*!*K+U"T3%UR/(KQ]B453RW;0+S%,Z9F2].4
M?/?<ML-W]9@6^80'&N5:*>UR)MW]V3*VU1X5=.KXQIM!UWWZV&VGI>I75I3\
MM3&\0'^C@V\9D8F'?,83<-F.JMPUVA-I/[^3/)>(QY4]XVDUBKEJ'W=F+G+Y
MBPK%QKG>>?#3\EXD&+*>VNI:ZJ3+[I#WUW!7;7?\]G!/31T8I7;F7;33O6M5
MD'+B@A?<0!".Y.(J"A3Q#G@0U%-GC:"Y%Y=02[.R'Y$M73BH/E-[P/Y_A8-6
MP4$3"YE%*96,!B+)<5##DH7,B05* ^%"6R:"3!S$\#K6='@D:MZ+;J<:3=;P
M^J'3ZO8:G>Z@5'E8<9CAIL#NE#AR5=;"0G=BH6_J/UEC"(H0%%7 L B@B4-
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MPWBJF[.+#C%AP5+M@#DGP$9*(4DP2ARC,V)YQ0++A;K:HG:UZ7D%M<M [21
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M93:V).$S".@?Q26Q!HB]N])PA=A;.R<*F%< YBGGA)6&<D.!"FJ!(8S <LL
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M7"6YHZYX?7B[I:!T<91.; [#)-?I/Q"2!&!<:M 1>9"&>$\183SK$GIQDZ,
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M1< Y4=&%<,Q190 [@I**[C28H"T$%CDR%GOG8U+19Z0Z%G"N"SB7KJ$7<"X
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M1)'LHCP_HC0%>M838O!!XJA5U9QA(QY,5(!$TB2I 8B95?/:-O(9\Q7?W(/
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MQOEL2CDD#X =KJ@C#*>GNT?8C%>;'1M0OKBBTFUGP8(&B0QP:A-EFV=@RPG
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M!,[0<=YV/8H!=-52)(AIZ^RTCIA5%><K&R)LK;:>X4.W+*XOJ2;;*<AY5_9
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M6F:,/OG"%D+G8U#!V?J>,8UL:SS@/G9(U+T]E[K9N,R[HBLONK[B_*IAA[;
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M[;.-[1S]/Y:87;&:<J\='52C;]_G?N-24JB?J(K>-S,:]%YQRK,W#]/UDCG
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MW=>&]>F9C'LUL74-Q"F2#MLBV6TOWPH7=F*;KQK$>BTM[:.?^WIC(]\!K(/
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M78CF:QN/N5N<VCM.P-(BEF%0 WAV']8K?LCM>-W3QQO1QY[Z>,@5ZMW9U--
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MU BEW=[^)H[PQ&"[%=@;]FMVVO9A+Q]@A77:#+L;X]'V:T@:O;U7OV2TU/M
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M[W>RO]C9'<>Z?<.SL4X9VK1< $+R6D'D01G.P2N$3T+;9U>-B+^5S$'YHP"
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MVMS.U\>.4:ZS0U4X9J4A20BQEBTQH0CG:\YT.U\7!;EI>KX6A=GER$ +P<!
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M%URP^F*\LT_NY>-=/-[4*V,C:7ZS^VYB0_TEC/JC][N#2/C\JP[U]>[> 0V
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M'NR0]6WW"LC_@JO=:F5X7AU?^ME5[Y@<4>M-LI& RH&IY31ZI".@EB;PY%W
MC! ':$C4@L;CHU9-Y7)GBW5\W(W'A31TP7XTSFRS9HN'?"44]V->#Q.+W;V_
M;E[\W=R+)_;Z'^%2/_7AK_ ^=G.''J"'*\3 GET>=B[J'XX,9@I,MT%*<V#;
M%">D\PB/9+C%-J7<V!48V :=%XA_E6OL)W"V5^)L.^-L+0!7 7/(UVOP5J9(
M^1\E!J\7-*5HDE2P$'#( .\:[0!O@7D$T>K& EZF?[L[^@+@4J-_DMG36?3]
M[,]-'[^DAN-_UZSW8!3RF0I1R#T4;2TU?L#9NUF"*X%]!0);OP#WT% NN%,2
M''\-U $[BURD 1'@F9AZ(GV>N'V3P)X!W[V(MKM>.[,799?+V&K8-IC\9K-@
MZ;8+I+I;$.@KBTA$(;-[G>\3 2EX,\>0K#\9'M%=M9R"W\Y^M[2I<[()!BW+
M?'FR6ODU<'F*KP$+!W3M^!A#KPQ)%1Y*KS?(634CCV7B8$6K4'L&O_D!XM:/
M<$/WL<S*VX"%ET!3**=)6.$%L9PD J8!<*'(C"LD&CW:1+\?WM=?<%L39"WK
MPANVTI]Q_?@(7 T-KH5"4F56S"E'3A",\IA*Q;$$%XN"G<9T@6,\LM. L0EP
M!%8G#. 3$$D@<BT0G=QNL9#E+#H=@/BB<>S0\^M=*87+X=.-N<ZPJ\9:_[].
M,\1N;X$JM$";AL9I]J,,_^V+6A\N)).7;&-*$Y+]LT*M7&ZA&WL%!N0/KOX=
MX*B-5BN&1JE=9]WH8Y'J-@$5ZR/#UX9O#,!JE49LW W8-[I^T.KULQ;WYMOO
M+G[(#![(<'< Y3W&WY@<;3R6IO,W1/2++<0OC:O<Z.<__?1ST1M"Y><0!H5H
MYZ7.<-(.MEO[[\!VLUK\DC6@6)_AMWH#0/'9K_VZ7FN4@M6T0!NZ\:S3S9Y0
MSQ;-G!LE!G<&W4*Y.OFNP:LO8D @8\T(/[J%6,PBL-66@J?HP8<4G'MF"%62
M846H$=8:=0L"WTHN)I#VX 18Q@GHST'7YH>W;2_&V<CXS2'OMXR\ANG$A#3(
M<DD1MPKH1>(",<L @77R2<O<3?.:K<)^^20S2O1JOYR?Q"*Z5E+BO,XY$)?#
MCK^.I Y<:I#W3KB=@:Z"H/PYOH,)F2%O6&AVX'H/CQ3C*?) $78I(A[ <NO@
M(B*>.I$4CRD/NF772<V$8-2F)"B62=1#&U1 T,3G5P'KA>9H#O$:O1JX5;9?
M&"/;?HC#\TB9H_>7N+'GLY\^96Q]GT'WH-LX/LY7]W:=H1VX#W_DE,<\&(8<
MC0GQY"BRQ.12::N<T$DIS',ETX*]LG+]AR)4\J1,#4=6K5VZ->!*-!N^((03
MDO?[3\)85H>RB T]P5A@2>YI#2+6X$M9RF5TW!'OJ+3>)QD\5E;36-&&IU/$
M_0-_9&-(1C.-J&(!%)%$L  I(&HU-B1XGC0!C^T: S#R+E!&]2$AF$3UTI,#
M'OL*I*+B"+,2L@L2\NT<CGFQ=PGW<;IS!)HO O8:)0(RPA6-R&@"+%-;I2VP
M!6GP]=*R@"Y,"LXO&= G-HF'[Q<[U>4\F?R%$9J7</^+!<\V)A#"JWRIZ8CK
MK_DH]]_I"932E+27U =."+' KKT*0E-'58S\A@CIK7&DMH/K>#_:>BBW=_;;
M?UY9LAP^?<-2MW.Y=WIXQ(UD1E,.M,"*C$M $'ANGPV>#-7.$BU%,9@;7T=.
M%VSN%/)QE^2 H4$=6CV5-^//.KU&_L)OHPR,\6R@?TWOBPXY!![_Q+I>ISGH
M7_^3N1$,+\0L-)YY.A-_GW3'PUN.(W) R;^A N!_L\WS;$O_/<VH@$Y-/L#9
M>R_O</-_7???FXO.NG!'^]8=ZID=;2]!2Z4-GGC+%=<V4?BW<P1>64_533O:
M"TG@"RW,1 PPQV@*BKO HYI'SR*)J)D#@ _UG99GBPO@JS?:C=:@->D?#<UM
MZ2%U_@/>XL=AO.H38&#Q]IOVF/#>Z><CH0QC4FAD9-2(DV*VG.4(EB8)RUAT
MWJQMF@4)9U,.TUFWD\/J(X&Y5W1P%'N?<+K*3<BASU5$(G]&;VMUW"VV@5E^
M$H.S86REX_,$O3C<5,O;RHW4B+D<J0N+FE<G?L\9@>O#Y+DR=M>*W>,ROF?+
M18??VF8SO]$;N!S>[S>*3<7BS5(4;#$E\G?XSMWW5E9Z6;^OT*J6<?]&*O*6
M\D.?V?C)H-^-(;;.^L46&?"91O/1.S]E0NGHJ/#%?ES]C;/]=B&WA6?YMP5V
MT)W;OKK#T^GYDQ@&3="423-ZYPVRD^'NW<Q>7:-[S6[=ZC_6SQE1QL@^OL7S
M!HAC?A:%VW:R,&MJP;V#K<@W'W_X_-0G3$:1#+R>I=P/FK9(;;:YW&6X,#G+
MH7>2LWV_ V=N1327&5\:J"L:5)Y]BMDL3(9]4(K A#,'#];_%@9=D),I0C,1
M+-@NHF#[Y<#2K%+O"P[VYAC++LN,A2FG@6EC)+2TP%B20,YR 03&,1VX%<&G
MR<V%46+K+7L+XU!CK3-^TE=!!*"[K0Y(3QID^Q5BSW<;[MKHP$;M+Y C4+Z3
M6='.>5[7R>ZD]H\TP]O>R7HIN;V%[*DPMO".:[2O)N?F'Q6GNOYWZQE&\IN=
M J17'TAV^WG')E]QSEIK]XO[.^LT&_XB9RL B>@W)SED]DRZG<'QR=3#*;]6
MIM*5P1]8BCBB)8TV@,/W7/06S\H^M@6#:4\@4O%HXW\'L);#'(E<+$DGXP*9
M]1:)H? ^^;VXSA";L)C=*X=J^)L2D,J#C[Z>6X66 G)%K6<.G+\R7MA98<@7
MN &B6#N.;0"VYOH8TIX^)[F*5"T_/GIY?&3AJ4OO.%)62<1%),B*&,%3$PE<
M-N$BE?>;RE"M[NJL;@+EU#0Y%(AVN6L;&#18$<0X#F#G<%(A71>3G$]W:[3'
MB+%^)X :H5KA_(T!,L/M* 9N>Z5;G\&RFW]00<EK%+;3XR/GM* N$*0<98C+
MI)$+B2,J7<@%/3QZ>9VPK2\*U91%>!/LZ3G(\GFG&\!L3TE!WHH;+WS%EB?7
M_@/<S^>C2**FBB<DG:>(&PEKKW,;'9*PI,HHH\W:)A5Y]VR6/2\BQ<4FV0P1
M;H_K#>:$I%&B2&_0&G&;8($HSG^Q9&;#K\^$%F-*T1?T?39>"*2U$<J2UI=P
MV"KYNPE[]K>/CY2+F%IG$9,4(QZCS<U'(E)46R,4=BSD6@4Q)WN%@S;"GE)F
M;O3BBS*9?[YLO5]?Y/J4TGD3!2\%SP]:@V%5]/#+Y:D7_>1&[W%]+-"3X8F+
M4F)'ORL/GJ^ZK  JJZAS/GH1AG6Q?QYC^R:U^:6Q$3?6Y_3BQ\2A?RT>8V6]
M7YT& 8)O[QXE)CW+80^)29[]P2)8;QM0XD%X'[4/_%KKO5%;>1__H&@WT,C>
M^)P4I[FJ.="G8?R4;1!%2/F/:SSC!Z5K5++_8K+_X;QPC;3B0%@8"DP)Q -0
M5IOSA +#6 K- MB0^Z5K3&!Q;@;Q/6<%%Q631<'EG.B-=BW+@]VCD R,_J<L
MB<]3(CF1>#:6H&*'^RTGFGV <WK 3&8U%@H(APF(8R^029B@&'2,CB7 5& =
M2FR8Z_KLCO<.%K*)K?ZP3\I"X%J?=*GGJ[(RK-T0W2W;HDS(W?7=>\JCS":<
M1:V(T@;4A0'9E29E#P!CZAP3*H:R50>@[]W&;][:8V L?4.1S&._1E):*$1O
MM]<;Q$#><$UC[@OTC=0/=NC>]N$/N(\C(F12S@CD9 2[CDUN\B0(F/ED&'<Q
M19)R6Y9YE!N5-PZ%:,[S*FQGL=?FLN?E3H<%XC:<#LIA;$4X.7>[*7?T:V[0
M+W^0:W3@1^4W<PNX3I%S.RP>#P63'+3/;"-<%9*7I[\!1V?%OQO/X'<Y-ZUL
MIQ%;C=([G(+:YRM&9W,NW:T@6USR6TXD^D#JEY^/I _*<281I2)',:U%#G %
M18LY/'NAD^1KFYPN:*4Q3"6:J#DM"A GLX;NP-V6:G'G2G.*0T_GC+U!@TH*
M@\JQ-H11%$S.UA;.(*LT1RY&K%UN)RISUQ2V0>>SQNY@4$<[]GNV%^Q_:^^:
M'0=8\BDV,W+5BPYB^2M;(!K-87<>.6K/4SK'_9Q08/LYZ:60GS#:1_M>]K88
MEGC/H=$KV 0M'TV!U*6+LR"QHJ , -;'G2+/*@V*?@I7O3Z&.YM%TY&+$8"/
M,'W<$608;3GK]'J-8<,V.&$:=(L2SJ%356AGAFI0G"+BL5'[/$HA*W:PSV8N
M$][][P".WRO7ZD9J-+):Q06>#;JYR<-5<Q.XS-9TE?O5[GNQ^SE^3(4H#!/.
M9NO>NR-;"?:G:.Y4/CP7B^MLY&XL<+YB-WB<#=(9]',JVZA<8.A>E"&847[*
ME.DKC5INI%%\<MM6?:/?FU:(7Z:VZG]=?3']$HL<ADP@<AY8;,T^^*LF Q,M
M/LA&;3(':_*38FG*K(CB:&FXSSU*+CRSW44"=%NI^AVJ/!;ATPG\S.50W*BD
M_9X=-1_95*2J&EUF=Y&B*"1RH8@/2'%G$5>1(BU]1"HYZIE6FN1RY855HR.I
MFZ.Z\&:1J%%N5TQU0+A>7);<?J:J8GRX8)#ZZ<Z12HPPHQ52.$_HL5X@ZZE!
MS">K<'"">[^P^T'M_HT/VA>K+1=5'>.\C.Q=^B,CN8$'#/37ICP\,Q-AS0F(
MC _&!N%"7-SK8%(,%M4M7C4[*+?=K_+LUZ?J%6?3BUU,.4WQB@B7T<Z""7?R
M]F@6P*$K/D[1+MWVB93M$L,* C;,=1OOV_[2^/4A_OA3R^S'JZLOC-NDR9N)
MLG\L2,3$'(FW:/A8]N0"!W_-"8, XQ(".09/3@>.J$@X"NRMR'V*R8+@^FSU
MS^*:R DNYF*6UN[PT:_7SIH# ,;&2)9NB"E-E9B$4)0^PIDF/LXIFA>@%IWU
M(G@5?TQIRFPE EQ0K==H?\O'2X.L6;V1<H0%NTRKS[9WB_*.HJU6=OF*F[)9
M)7(([B2/;UBOW<9TUR=C@QZPWS:*M/WR<??&WN7BOF)#;ZD&:UKZ2X,NG+D7
M;V+J\T4-DS\L$6B4:%L!SFL'G-ELI*TC[;FEL"K(QF@09X$A[0U#/B2EX7\>
MS.J2P =DLG#I1](UPI\;4.<Z-)E7KDFI+0%FMWT%5"4Z%?DC1/X^_$_+?HOH
M'#1JT>&*[ZC?A_^YDX^::_4F?.IKJI?.2X.>X72LX9-]]];'_?P7E6,6+LP0
M!X!6=&I%1*YXN-.E2F6[VQ(_VK%4U:(_;5%*?-.]WZG#_ILMHB<K7D3_F*+X
ME\TYF0D)YHC/L'H"8*$8%I$+R1S(0'&[O3*FV+7M;Z,6SR#MQ1RJ##ZCTI%^
M9[+.-=>FNGX,[6'1?)%?'7_D[:]>3BH;Y"E8.3!8*OJBHRUL&EU8R&M^D,\[
MOH')*UA]5O,E%FLQ&8?M1: /PPY ?CQ=I(CQ-493188/);_,G?H[[6)3<\XF
MK ]SVB\*_N)&H>BB"S><#TXQ9"NCRJ")'/D)9"PFE<"]MLLN<CG.F$I8S,\^
MPC<[K88?6Q7?&6V2CJ_XZC+G)ZX4;1:*R'*XX50EKA8;(U<GFH#L7@.6QV9<
M;D\V)Y\XB^V/'<8<@![V4Y[9S;7=[D4FS5/38:ZYC149?U#LXOXYO/!ACE7Z
MS^B2_QQ=<=ZSV!W>]!O.2_"7>1A)!!U11@(;TXDC+G5"CC"+@I/$FBB9P^ 4
M,JDWV"U#$;+P3B2\#HIM7?L"7'YN&M7U#>;+6MM1RO;;Y>O^<G_[\(AAI:T6
M&M%8U-KFP32>YU0J'?,+&ZQ9VUPT'F/(T2UH52LG.W>ZW;+5<[>@R!E89E%Z
MA7#C]BR[&4R!^RDGG%UAREO&$5R_]$=4!1PPI0@P R1&:'@EK44)7D86I8LX
MYRISLV"^_;AI^U6"T"A-?L+X=H9=*\X+'RGO"!=N4DZLOVKR7OAL<S/-%EFM
MJW$"8/6GOSW3?R"?K@NFO3L<&381E,HN)"JXPEDCNS7#K? <Z<U#38=M"9K%
ML(+>28Q7IO=JA$$8J@>\/Z<?N2ZAZ%A;E-[8\8RU44/<ZRG%)/&Y2H %?QFD
M.<]*ZWP?MF1_@>*MQ;IV *OYYA3G&]X[\$?:\9@GR"')#1A@RRVRF$?DL4\A
M"<<%#VN;O9S=@/*8C;ERF:P)"V2WM+_3-533?+$5^R>=< TZ@\"4&_IHV ZL
MD,)F)]MT</?[5RW2BI! *POW4/:'0<2R$'UXV"98AF*Z7[G_<,MLVVYLV48Q
M1V34'OQ[$808=6^\BR:,TDG&4I\5>3JE^R;QUT9*105+1 JNI7 N.1PME9@R
M%:Q=./5N@?CG);NSG?DXNO'MX1UNE5<_45A&WIR:'/_(\4.*78R!8^145A,J
M!+*&4<2P9@E;*RG5P%,W^)Q^Y!5X)1YPL]GQ!> 7>WZ=;%/Z73CFD!UE=[)W
M3;KLRE&I%+L &G\UVMG0_9FO_%VWT^N]8:)T_&/O<O=(>Y:<C2#(QA#$59[Z
M2G% *8+O!5"=[6LF2AOJ%G^KB'Z6H9(I3K$P(/Z@J,E43Z5&=SPVMN!+.?M\
M3CAMO]]MN$&_[)D^>]XQ/ ]K*H?0#%^\,DW#43Q7)&58YW5E_ZZQ=\-J]3M=
MT)RQRU?3COW\-*]"U_,6<9@1-MP;&X7LR^^M/K[,1#Y#9Y2<4FP-Y(245.AJ
M#OYT<O9A!))0#DZ"1V\+ 2DK O(R ;*65G[4<&O<0*<LS&Z'8=+GI%R.QNU.
MQ$:'$;WQM[J3.RRY&^%X>F\YE&D\0>QJ5V1T&[V:'\ :P2._&-4WY N*R>8Y
MPS=/S9O<>"X";F7P;[AU,G>T]9?=I"Q"73O%1>VG[?*2%N])ML-6N>\%KSX7
MNUZC ,CV(,)[[\N)5SDH-CS.6PZ$' LX_Q$81ZVD",BQ7'AK@8YKC17*$R&#
M#8:G/&;O7IN5[7#C_F.G/8N]!8&U@RS-_88OPM(N%G.JPS#S>#BK;/6A9W<\
M#7#(\L_C]/S+4:Q_?92W#W?;CL>=?J,T<6-8[Y5J/-++ZQ,5IC,3[D./@/-'
MZG *-GF.?;182$5,C(P3EUC*] C4DS"\I$C3Q_%6=36K=Z9B[O-%,3) 4Q&-
M%DAIHA'7U"-#-$5) (P:++AQN6D2DPNB2Z5&C@KG;IS;NZA<TT[^9BYEY9Y!
M3!D5%UF,&&'<@!])!8>[<<+S%&20PP+-*Z_R,3+V<=35KK 0;WJLY(Q 7?HC
MDL"[Q]PAB:5 /#) >$DM8E2Y8!+FC.=T%"TWS"T"-=PKW*AE!Z[<IYS(+!ON
M*<YPFMDP8Q'>@R4"\ILIUZ#1.\D+MU';ZA5Y4KU,.#)HCMALO%]7C^<0NX*1
M_&4;W7^R<[!HWVUWG+CZ1Y&WNC-UMY5\#N5S/Y<(8Z:Q 82+X)$C3@#U-+,&
M^<"L$X(ERF11I+# 39R6SZ&XW8!A-[AI4TUU[Q987Y">/"O5!W<^V,R>(K#R
MB1JRX0[C53@P-RS/N_:IV3D'V+;-BUYC2!<FHN?#B=?WK.))/!AB I-*,RZY
MT:"NA"FK&)/2)[.8$_";[7Y]/&AAMWTV>-/$>TH%X/J^'3FLA7?8HA0P1]QP
M@\!?8DAS1JW3SDOB<\2/S6O OT;;'N=V*E_B*DUBG"114,7L[IW8[SE=?BH1
M+G/8H<,YT9MIA6W^UE6=?^^@LW6U4_6^\/K^++>I9G8N]]/,^.E/ ]?+99OM
M_L31*G >2>;!X1%-DH%L:N1S;U984XU<) I9P <)KKPR4:]M"KD@96(:FR>[
M?,T#XABR\XYB(Q0!F:*HMM7H#R-_M_M!H]+>NP/N!,D8FH9NM!ZDILRAO&K-
M-Q=%@S/EG=+C=A'4LR5W*;9FLP7IW+!U.FQD,<HYFB;DX^M<0<V[8\[15O_3
ME>&J=&FD2Y?@V5D@W,($I 55H$O,(ZT [[UD46M8$R5S.)S0\<[.=9[=%#D8
M;=M?*XR3R7'#M,[VE<*4E'NXX=]^;J'K-8[;\.H>N/\N!S__T^GU8F^_/4VK
M*^=O2N;VMG,A5#0I* ="EAM%I2B18S@APS'7Q@'Q\"X[?[>*7+-3S@*9(;C3
M ;D;-IF#,HK$R)04@FLOG'-P78FJ:**W)"[<9)[I5#(<05(N\YA;]@[@+'\T
M._[;FUOPG%=Q?*1R0B,G 1G)P,/7C&3F2) BP@8O,?CXH L1U.(LI_UW!W$R
M&?YE=V?6\VY4N9=2>BV]X5R!<E-UM%-3;,X4W34*@E"T;1K:S-1I-HL,O-_F
MHL.;_UMNAEW52'2!.2"XT:8]Z\7?1B]^AW.?->W%;XUV<;G%CWXO(!.09%@B
MT>^<C:L)-G!94=#OPI\P.O[PXXWBHW_WP_QGBF\H3*[]&&]<_]E-AR5X0QC]
MH,/>_)E\FHN5^/J/)P_[[^+YEL\8%BNO;I'S>E424LR$^HV>_:B1T:BLR8*6
MV34LMP>6O36@;Q/[XFZ'FV@C$1W>^M5=F56_*[7PKD:Y335&UJ?N[>%+ER=\
M/?,M%@?\+;/SAK_#3?\"5&EH%WN_7KNBXYL=X@X@R&]PK[4B8[(VNNY7M=S9
M-"_KAG&^W;4W\^"(N8]^..N_'7?!'@8TO$+O8TSIIKM^/L4Q=T*\JXWY68FY
M[1[OO.RX]@H>P_\\W>U/WG81P5NE^[Z'(XFY4]%CP:2AG,?HHC)6<D$E-Q;<
MA&'(>4$/UYMBSC_1!O/AE[][7P\ZX!7LG>YO?[C(?_8N=W#]X!A>?P-7;X?6
MO_Q]NO_N\\7AZ=[X-__W]XEKA2;<5^.0UOG>]F[^P^H''W[LP^M]N*_ZP>&/
MPU:=?SWXNU&G14E[O_X)__C/P4Z_OG64*UREPP(QJRGB%'-DE,BC#CPGRGAB
M*%G;9)I<&P)\,OG/G]Y3#VXR-K=![JS!>O!]O&4,^SD!+"H?12+.>4&XTM%H
M!V"5<L%A$L85>33$5 #V? !V<05@P4F!C<%(41H1)]PAXY- TE,>%4]@=O(6
M!EE4[+=D %L*>MV;.:;B?Z^).6Y?$_VYUO6@][O]A9B[<OCSRXLPJ/EBAKU8
MX<_]\*<^2:"LT8FFP) *42/N34"P(A(%33UW-C<1\6N;?$$+_+G8PCU5_$G)
MT<PIK_7FW[QJ+H\;5*JY%-4<4X,4,+4B>D0"3^#;F(2L2!Q9!HX-U5%C8=<V
M%R5&OHAJOH&842; 5UM!Q=[0@VS^@AO_^8#E::(FG]M7Q6JCTMP*8NX%,1\F
MK3]G-C%-"2)"Y-2^D(=;!X$B,]S@()C2 #'"+-B OSO&+-;SEXR-5%KZM*&!
M2DN7H*5C(N C=2IXA10-N1\Z%\CHF%#T0D8)Z\23SE5P9&-^\LN+J.D;" (
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M.Z.1<-$AGA*PJ& Q<IAIIVRDGINU3:H?3Z-6IGJJ*B^MP'$UP7'I=+8"QP>
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MU%O$=;3)D4!%P&N;ABW-_*T02Z\T^ F=[$J#GU2#)YSPD#@!ASO[WQAQ*X'
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MO% 2<:L3TE0R9%BP.6CL$RT5?UE;ERLV\/3U=3Q8U(K[815/\UU/9D=L/*J
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M^%PY.T.*-7)V1HSKP<X.U\X%ZD*> \1Y\!8S(Y(,QL _C;6EZE5(OR*J]XV
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MQ+@K *T ]*X NO1QJ16 /@V CIW9W _.1X<1<=(B'F) FB6!*+-&D^!A/0%
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M.:AZY!3<"JI6'ZKVQJR*<)<T51S6,B7$(W-(>\:15]PGZB4V26:H>OQP\#<
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M$:N5@/,DP!G;I_,A8<$UPD$GQ+,ZA3/:((T9==K9B),J :<$G+<>\Y6 \Q3
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MK]C)+MX,UXIBK?RGNV'@^@S?V!&^%5 A>S$@&%,A<TF32*5#W-#<SP5^ R
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M@&@*92A==U5<]T5V DK7G8OKCK%]8CR6C'.4B,>(2Z*![4MPW:2R8AE0?LK
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M]5CL05@R0@F/M.$ZQQ[P&]88*89-"![^&%QN['>[*/_UG/H-;+9]GA)2%*7
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M.]V2-;TF(.TUAS74,6S_]/#6S>+488E.,Z'3Z3@Z464<2S;KM4N+N+.YUZ?
M2*J8A)%6* N1&A-W'FPO6=,+LJ:Q@[,E<7I-G+H#H4HDF@F)MB\*%"K0"(B2
MD=X$8$9!%"H%U"%K+$>229Q(\$GJXC 6+\N0%LGYQK\SGUM#]9_HN!Y";+XO
MS?]^\\]F/S!_N+^CK,U)+&4! 41E?0;#D19.(05!0S*>1I&UP@IJ.M2B?<@*
M47+6UU@+/JR(BM++^\1H2=#.:.TI0RII!TL">(6&<#H7I@K#&2P)QDV>SRW9
MZ4MXV4@D;!:*^L#EN.S<\?SC4V+X@S!\A<3P7AC&+R=@W"BAI!-(D%PM1S1!
MVDJ-8D@Q2LLUCWYMP_"GE^W.W5/FV,3C3LT3]OQ-.ZX=[\X#@--/E/9UP=]7
M-@?R7N?MV,D'^:;U.!CV^UB41@%]A>)6\T,6BV_D^_Q8G(FM]H_$3@@Y?6RU
M;XB2PY/OQ^Z'@=YI6'K_G\^9^*.?U:N]0ZLTYSH0Q+R#.$4&H&4XTBR&:9*F
M0H:8:9FY3^JIE2KP=^2O)^<7)Y8+:>.;YY4+">U"(#N+VU[&[K5 ;7A%I<TG
M.1M]7_GP:VI5R,Z.:^VU"B'>(2D;?V>K[ZC@=07*%0*\;M"YMW,<8W=:FX,)
MC?@GM3U0B]_V@#Q[VX,OL=F!D=MLAIT\3U]:G6X[=NM]7<1AYY(LQ=%H9;7$
MQ5%=\,,>)63G^\%)Y@<9-ZJ?JKBZ6SO9/PDG^_2@486_[>S^5:]>;>+:Y<T>
M)7OBX*R6^8&HG9Q>[&=E!5JKUVCMY.!L[R?\3=2^YWOYRG*_GIVOAU$&(7V"
M,"]2@KB.$AF*-8(AYEI9+5T0-]L.\$2"TY8$#LN(CMS"+#%!L_U(RG6Z*=+P
M[7KX*U_ %^YOC+" :F73E==^.0K7C0YLA6/R]]-_Y*Y<15^M?+%VW?6*BW7L
M#X =6.YA: I![HP@_0_T"5D>L_7*[O5?BT&LU/LPG=\\:*Y2B*(U&I7_]@ #
MTV7&LGAVWFA=QM@7SP*(.\MRV3]:#2 8MGTY<2.=+*D]^D#O/*N5SR:B\T2]
MT*(;PJ0S;_5'[,/8?>:GK]J?>=W:;,*,-,9?['R)[>W!,RR@Q,Y+N_CGR^KF
MH4@^8INRKDHAI,0\<@[\7*K@K5%)29YRF^@IHCI@42ZOAAU8P\!<&G6PG[[V
M>K:[S]_^1/6S\U8'_G36GY'URF#TVS=LJU [653MV3NL+&L:?[O6V%\@5OKB
M*\5%]>C0"&T2E1:EQ!/B0C)DHX(0$UOMK?40=3(PHWMXZ+N%59PM#>!7!E [
M.F2186&41S%DY0)B19;EE\ARQP4&&H%I6-O@]S0S>S>S[+#P44</LY:8 ).3
M)B6;O$[&>1T58841Z*$13&T;6QK!O(S@9VWS$&;:<Y_EI[%UN:4=1E8QB3#W
MX*TI)&LLA*-3)-IN:5"_*Z39AAIM^I9&VZU0Z!9/?&!<9#(P/9Q>3E/@?=,:
MR&9Q-) 7-JZESQ[7?NUWEFI<?JPW;=/7;>-SLX]M8$T+$\7N[E_]FQY<[G_W
M\@!09V>W"K]_!63QK+;5.*WM'I'JU?85(-+9 7QGE?YQ<K"[_R-\^HN'__NC
M<4 ;/]S)>0-01U2O -VV?C^I77F\\_TKV=G:NZKNPKU^!U2[^GJU?P;?V="7
MU=U34=WZG+MA<W@='-X20SV62"AB$0\R(J,#0]%9&&-E@W2W6NEQ3IF31"KF
M#7?.:@[D)D!$AZ52CLN;,>V?<=!_]GI:*M?S4MFR75OY^U[3]D+FR_]X1"O
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M] W'@H/)F,+T[-*B!*(A'4 ,LX!<R[$>3W+ &)A$L.$8B<DCT0!A@*[ %.3
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ML(O/H1,^-8>I *]X-I@B/M<8Q!X*)J"A&* \*;[+T9D*\"@I&M@\8C<:3G+
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M*64;E7U0?7^*;3P2IY"\W>'9HTL/DFS-@:3.Z@-)=W^TJ#J 9LT[U0$TG3V
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MOHE"KB,D=VU[E"^%ZS#3083U"[B_:GJ5@U3(Z+Y(2(BT3*091%DXD>^ UL'
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M^C_G5#I2>"6C^W BQ81)Q5F0G:$T@I%D@R\'.$^U$H_ZIT?[GX&3I$F.P/R
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MKD@ONS@/+Q=M,]M *^ V>M!NQ[9RH6VA,O?;0*5JGO\[4(_,PRIT)98W;\@
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MJOY9-SO+6R[>N03HD'+@K4]O609\]W3:55C/<CEU]VHR^W;P-;#;']I6<#>
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MJ BV9%R:. SB2UM)'1@D$4R319,[D0TI.SXB7?94337&O(&^![@!W,; OUC
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M$)"J^X-^73W>TK>+)]1W[8H%OTUPD#'__%,___WGOK=>!"FSLPET<0[HFY0
M9;8\RLQ[*U%M+Y?!>'C6SW7#>0%G=2W]>(HX&>\FIW4/ZTAN&V%=DF/,4@J#
MQH.6.J#R *4X [1.\QRDZ6V$NC.YOH<1[?&G..DGV&!EWT+(-Y_<5N)WC&)9
M_ 82!ZE0F*1ETL%'CS%:[73RFLOUXK_YCCJ<BP&=#=.-5Y[5;7QXN>Z<0<2S
MV:>]Z9A]!OC2^SBAQU?CBB2 ;^C+<2\8:W/RF<E0S2-0@44-G@5O%%KAC;9Z
MY:HU6[$*C.-LV5J\X9>JHU_P;#*^^&2F-<;%PA+XU_50YKK:?7 G7Z%/'Y_A
MZ^'H(YSA*XR3CYBF(](YCD_.AZ-)_W\QOQR.)R]@W!_W$ 0F3:,6P9/)YTMB
M49)YZ+W(Z#D(85.+H6\+]*9@KFA\,KH0T6+_V7&#JE9UISR9# ^HF3D]:( _
M_S0<91S]_6>^+Y/>D[)Q-,+\<3),?]($?#>:223_)YQ-\3V./I[2I.QIG:,7
MIK!L/(G$@68Q6,X4+;#)!QU<+BWXLQF\1\^:!EJXS171+5=FD,8GT\GI<%0I
MW5-9Q)R#8DD+2]YG40R 7*,H#0BE'2?#ICU'EF$],6[L)?7;G) M./%F/)X2
MLBAH!2M:,Z5])+86RR!G1VH4T>LBE7=-]ISUD)XD%W:0]FT>J!8\>#>=U+.:
M>OS5 ZT"[6::"<,=TYQ&330%%G2*J0B,036QO>[!]209L:O<;]-"[TN+E\/S
M\^%@'3;#A0_!,V^1*)MM9A&#9"))S45V1A73@A-W@7KTA.A,XK?98#IGPV+M
MXEP3+%J["!TP;5Q@ 04P1%XD@,H<^$&(\$2VB2[D?%O]MG/U7S-CR%S)P4G#
MDA"&Z2#( ](@&"].FR#)"\KB(!1X0I9C5_*^3077(176>CO.!\DA%Q94J==4
MEBP:[STK0@+ZX(M7H3$EGJS#V;7\;U/$[TN1RQ%_JL<I/2,"$D,#\T$0FD@#
MA< +63/)H'*)HV[B7=Z$T:'BKUWS-5?W'K)<=8[PT_S2YF_I;#C&_/>?)Z,I
M7GTX'$SPV^37L]D+__[S&#_7+_:EPYO!5QQ/9F.@OW'RK3_N:1-ML&3-9!7)
MFC$J,N^\8PA"QI1*"K')GG$;2H>TN..F]0Z:[*#78:?R;7#<=!/12QKIY[IY
MS:[O?YLMEQLA["W=_K9CPBJ(7>X4Z^ZS;_-B7V7>R8W.-'$<SC@>1<[5\O%.
MTB2)-$FR19HS05I.H+UK<A)Q+*[<B"5X"%391@$-*/*13.#))QR=7T$=7R S
MTAJI,LM&TA8KLZ7=561FH[.N6"\):Q,;8RVDPQN:72MPV1+I1OH=WH35^_;>
MV^'@\VI411<EC*3M5"5RE*1$%HL6!"T&G@!RR/&^"_R[7_%D=-RA)-?.^W__
M94E*9"#_V4W0QJ4Q-7XSH%] &&1RD[Z,\+0NI5]Q_NF^ 1P;OJ7S8(Y=1K<4
MV"%<QA@21B-1.\Y#Y$4D V"EE6BAM\/[.@_RB Z+-T8PGR*Q+$-FGLM"JT@0
MW()P >%Q!'E\P*\XF.+X)(XG(TB3GK(!74F2>7"Y#JTP&JEFLB0'@HN48FXQ
MM&4@#^+T8QL]+V]">TFV01#& L]K&C=-H1FD?_8GIR^GXPG-D=&OW]+9M)[?
MGXS'2/_D3_"MYX7FF7O/(@HD(XU[%JS63" J50JMIMPU),,V6 _/E_T4O)HM
MS;33P,9]]P5'M)L//O_Z[0LMM]<$88N4WFK'."3/M.610;2:9>F+=EH6;II<
MRJ]%].@7DVYDW2$)9F98#3![5VH$VKAG<M)>6K*DN;1,>P7,ET!@0O&*)^0<
MU$8F[+6''EYM'<EYV(&0NE;6!QPC/>WT9)!?T6)S-OQ2Z;D8Y^7ZLOJWZJHS
M.4G_,^V/,+^;G.+HTRD,/IV.AM//IR^F8^+X>$R65^P/9O;]/T?]"5EU[TKI
MD7*+-D:RXH&L\N(<"[$X9@5ZK\D=T\L!6VMX<1S\3X*"CT#U#:+&.A]/Y! +
M>2,,.*?]UD9:RF,VS"5E$7U4G#<RC7]P>K7-=$0%-PAO^XAG]*//_\ !2>N,
M1G62STDU55(3<F87LNNA-$7;E!B&3"C!&^9%I&]35-$X)X1O$M&T&;RG0JX&
MRF@0^G9K[#U?:L"=2,R6E*M34,.WR3/0*8#6U@@#38XF;B%Y*D383\0- MPN
M <U/M]X.Q^->\35<0GLFN"Y,.YX8&&V9LUBL,YAD:7+?M ++T_&U=I1O U/F
M]^%@>!/5@HR7#,_16DXN/R'BQ,DH# -'*G/96(O>NNB;1#?>B^S1TZ%;V3<P
M&]X,)CC"\84]W_-.<(/*,#F+NO-<,;!*,>60J,JMUUFVN7N^@>/PBN]84[<N
MG7<7<X/3MU_)P)U\O\KZ>_WU]_X?@Q'"60V]_ ?):[9PY6#KE1CM4*D TY)S
M%JSQS!LG4RPBDW_6@@R;P7MJ'&F@E :[2<4QKD!P_&[PZ[<JBFE_?%J7S'>E
MYI+VE""7O2HV0:@GV<6P*&1F 0H(GH(Q;:)B[T7VU C3K2HZW%QFYT97U^OS
MD9,7-'.H?\=)KP@>E+>)"2E"-7TY\^ =*QRTJ"$\46UVWGO'2YZ*MCL59@,O
M<NVH>P H"A9!2**F3<[S&J6%S"HI=,A%>FQRD[,6T5.A1+>B;^!E7CD_%W>2
M_<&40"Z\H^%@_ ++<+0(L?@$WW!,Z]<(Z/W] 8R^SPQO&EV-U"9QG\W&-[>@
M>LIG@"+(8]9(WI1RDD$QF:$0PD8E389&T9'-QO3HW9R'HN\&R]LEY,74>H$#
MTL^DQYU04D7%4M21:12.15V01;!!II(LF"96SAH\3X1"^\FYP4I&&^RUDQS/
M32*^04U:J*503&*@G&?&>6Z=U=JT";^]@>+1JWIWF39(^9R942OB_JX\K_\[
M/*LWG!<.V+O!M6HYH_Z8?O2*OAU\?H^C_C#3X-Z5&F #,7E4F?9T2/4^*&OF
M(Q3FG,TUD+0DW<1Y;C6@1T^[!Z'I-IFJRT.ZA&9)5@F%9%P&R[10F46O"LO%
M2N#!",UC"Q+>@>G1\Z@K>3?(2/T51@/BY_@B0[86\$H]&8/5BO H52ML!"Y9
M--*1OTC.@<EH%38)Q%R)YM&K?W\9WU9\Z%KQK_IGTPEFVEQ]4(B)N3H\;30G
MPTE*5C*0SZEUD+K)S<X:/$].^;O(><5Y_M[QV?_$6G0;\\E7<K@^X^_3*I5W
MY59]E3E9N;,6C8VL)#*LM16$5GE-SI7T*?NLO&T2!+(5RD?/E78Z6<&@O:^$
MUJ!=$/QVH1XCH1#/:U4W)+/=@&#!^.J@JRB*TUF*)J$B6^)\JBSJ1"\K>+3W
M_=!2PK_UTD0GD"65) U=%!:0 TM.VZ*U@LQ7U^%^*D4Q]M']'K(\=E&,\6C2
M>S\:YFF:O!M]Q-'7?IJG;LM4LL-0_?M @_ .6>#>,!DPZ +6E[")14+/OT8&
M^FZ9".L /)!"&%OI<MBA3#N,)KB&9WPRR M$XU>S=7(C4%M4OMA&X;?1'+;(
M13>*NJWUCJ1\. H(KD,1@N58J[E);<DILH&^Y3FA]JCX)E<U#U'U:VI6'%+S
M6PBW2:GE&;!%YKS29+PFVMM4BF1K%%][]9#5$4"HDG41134Y&+^!XG"V7H>:
MN54M=5>Q=EUPXN7PC#X:SN_O%AFF%Z47LA?9RLRBKKFJ.D4&'( 8C='SJ(4N
MFU6<6/^.QZS++L5WW#(3PS(KP'<Z/*-7C^<!:C>1[5->8N73&Y:5N'\T2^4D
MN,TFY5QDT*AYR*!=1+"J2$PE%%Q33F+E>SHO(\%-3CYPQ3*@9UKDQ"+2(IF3
M2&!D#EDWJ2W7?1F)VTYLB#%D5([95"+3)'$6R7VEN4(N$P?RG6*;+*4'>7RP
MC:9O5S/:1[8-*DG<GAH]8VDIE<K6+A&$(V%=8PTR*5P)+D;C3)NB5FM6G\>L
M[OVDV\!.O'G9KV(*Y-L:1B9O386IQ96<+DSD['/]@T.;D, '%T"QCY9WEVF#
M@/#?8/0G3NJAQM5M^8JP=5NX=-Y*AK$DII7.S'L:>>:!UVI-,H4F87N;P7OT
ME&B@A0;91B?YOZ>+DFN?AB<YSV0,9^^AG]\,7L*7_@3.9CM6;5LZJ\9%_O;"
M@J;5;-R?X,(^GX=@?, T_#S7U*PR= ^C(9.<!F1-K6J#(C*?)#*/&6MFC>>F
M21>HU@-[]/Q\4)IO$"9ZDM)P6L->/W^LAA:,\OB/+]4O^+6Z%.,^3<RW_?&D
MEXI+-::;E2+)G]3D6<9B##.\@$PN9MJ;FQ!T,WR/GV<-]- @K'23Z3"WW^I4
M& YF*3WD;7[%T:2.8=:T;QK'-#=JU8JKI_6$32FG$.I!(YGW-0P)-"*KN3[%
M\A!$;%*%OMF('C\E'X2N&X3.SIR->>.6ZW&1<Y?S(C;JYF+>$PH41^Y8TH$S
M;7PD[S/1" "#R>BQB$8=3K?&^NB)UUH_#6)9[X9<?_CNRRR?Y-=O.$I]0M^3
M 9U$T,QZ\H%T*9P!+XH96MX1/5BA&IV#;0OUB1-J;^TT:=&R$O',9%P-6-A8
M?%#U9(R3AX0YD#<M:@WH0BZ3M3JF0])I/=*GRJ:.=-,@R/9.^O]Z_N5L^!WG
MR-]/1^F4UM;W9S 8DZUIC?,^D--->[7F'FF;%H8Y4TR- <H^-7%*=\3[5(G5
MJ9Y:!/'>-2'6PNY)J;.4)9#CFVOE>B\9!().LT,'K6E:M#'X=T+[5+G5H8Y:
M!/?>O@52(AMR$9!H7JN(9')]HS*1"2\Y"J=CJ]O#NV_8.KE/ IJO*))@M04$
M29NV"? $):0(1L?BP#5)S;WO/FGO8-JB'0B(GAFM)-,!"@M2R%G?"^F4PN14
MFX$]D&#:_6;NSK(\=C#MK2$L'1>,YTV1/"IG@F)*V1I64AMFTG;&7*PU)K,'
MX=OVE5B%ZH&$VVZE[77$V5OJS2IY76):1"UM JIEU[F5J([3:*Y#[:VLU]6%
MZ _&"TQ>VT@J\]HXVAG)BXJ1 \T*(8,"0$AM,D$/QX=[FLD=F@[;2+P!#:YU
MT5T$'YI(=A^0N8<ETTHH8NV9RR5S D$;)95NLTO<0G)X5Z ##:UO4KR#>!M$
M5ZVY7EB RT75*W[)$) S'36R(+AA(6>'R1CG3!/[\4Y43X$'W8F]P1IPDM+T
M?'I68U37E<"X (HJI "<@:A5P\AE)1%XQ6S*7,=8HO--DO4V1O@DN-)$'4U:
M8$QHK)@O<MX7J!(75ME4F)*B%C#'7,L-:C*ET160WDEHU,AB%9RGP(@.!-UA
MK%;-AW@Y9VAM55 *ILG\D.M=.<G#V9G\S%A2Q>0<#6=6^53[$2D6%$9FI; Y
MUB/YLLDQRT;979L >L2N9A.9=[@D;()O,1$V0=AUVN=FT Z? ]J]2K?@RQ[Z
MZ#A!=$.D*2!PA<"*LD!F$JVC@%XP!TD$Z5!QLXGU\> 9<T?JZ$,@S#9J.#!1
MKF*?+AMR@Y4D#%:"J^6V>&$QA\"2MI(;'WU*G143V!;<83,86RAWF\UI'\VL
M]8,/E./X$L:GK\^&?XUO MHOM?'JH4TS&M=@7TIDM"YI$X7*/$N=10CD=289
M@U3!>.[XVD3&E:/85N[O1I]AL&C>#H/\<7I^#J/OP_*Q_WG0+_T$@\E5V.Y[
M@I'ZN),N=GM1)_KI8(Q+.M/6)QF$4Q R?:U (TU7K9/6.A>PO;U'>Q ]'ER?
M#T"O&^F7EY3)O7>*_$:MK >I2-6T>4,0(5NWFWZ/IN>K([ W@S(<G<_^]JOJ
MV9X=3O=W@C@>'S:7S1)'/)*I5Y*30GF-W 6,WNC:&5!'Q&)VX\B=</:H&'$=
MS,DEF'=W@WE[>;F/.B$M<KK&L->.K\8R7UMI6J6\08,E+'<;6E-58C\<>Q7-
MN"C/]F;4'Y_6H/U^[L.('M\+2MC <V#<)LZTEL"B#<"4BXF46TI:KI>W9G1K
M7W$X@_/0VKY16*,;$3>X>[D =MD"\.,\ZJ.6.+<N6!V9D+6BHPAD=?N$#*67
MRG"OHFY2A7DMHJ=/E6Z5TB(O?@'L WX9CA:)NPMDT61,"2S#7)O#82X,4O74
MR.ZS3OL<;9LN VLA/3^^[*F6!M<QLS2PJWKT7VFWKO!>#T<?X0Q)'J,IYHNN
M*9^(%^,:BCAWU&N;:AR6TN,Z1PZ<1",@TA))KG] QUGVWBLC1$39)/VJ"_#/
MAX0'5W7#QJ(?,&'_:X7_<CH:T43J*8.6).!9*(467M26 6I@&I!LVZR2XTU;
MC-Y"]'R(U8U2&J3/;\7X2XIKF5U!E9D+4&MFI\RB48'%) QXE"6WJ?:P$]KG
MP[+VRFR0D?]^5%OI3;[7?(T)":Q>\W^I&_\?8RS3L[?]@CWKC'("$Z.%M0JE
MFHS:>Y:C+"Y$(UQNDFJS ;;GPZZN%=4@,?X5?AEAZL\SJI&&J"0B<U8ATZD&
M?DG+6?312<=KMY@FF3;703P?=NPL^B:-F0:)>+DH =H?_TD66OT /J/H&5KL
M?"W]R6WV\XXAP4)B$+.$FA:68I/.+'>!>CXTZ4PU#7+63_*L\D=M-W;1SC6
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M[/#F1S?J'CX07;5H?%.CVR^/$CT(5#X4!A+)%!,06.#.L&1B\-QD#FV:'-U
M\9QLE-W%WZ#\PKW9$>,[<R-GPQCD6E_BVD3;9$Q-SU0:#.HX9M$>7-DV#>90
MBFYQ5M-B;&BX\RD$%JU1Y$@F9$'&PJPB%U62%>+4<7*]'PQY[['B'CAWM]%O
MU\8?V0JS8L*#-(?\ <E<Z:=90?EA^O,/TL["5(C6Z\C)2'&^D-A(3LQ'R$PG
M910'$?QR?<LU9MW&KSS">='1U3MLKIO.P\7_FPS2Q67=O!\G&;?H+!26N(Y,
M.U>8M](P)W@R/DKKP707,[[\^N=@P'4@^ XK)U4T\^/5&Y@6]-\$5-<)66O1
M'#X]:U\U#5O)N./$G_7@P$074\PL)F.9SC8PR*2O["T1/\:LXB;U'A^BXN_(
MZ#J(WK<1;=>6PUL8?:Z%;/\:7HYRL1O1RV4,3K)<?.V<*@E52;5=4<%,]E;=
MCC:R%-:^XK#)01W)?]BY\#K<RF^@(J7@,BZE(1I9!%$VTE"- ^9%!A9\0<]]
MJ2E36REUQ4N>C%KW%>#:N=IQ;ZVW_51+I,& [-TS8L-P'F9U\IGPSTO(WP"T
M60^8^Q_:24^7+;$O]6A15A:KO98B:DUVN8\"HM*"9S1:%]_;:A2=R[WKOCS[
MO? P^MJYWT[00@)7B0>?M84 6)SQ.26T,04N[]=E@]XZ5_&1EV_\BM<]27(3
M?A\.TIH?7PM4N%;XPX&Q!F5DUD;)=(F\ULJE/Q""$: "EDT\JQT"DKL;Q'['
M%4/2_*0/9[_USVBA'0YPX82/>UD6G3T)0P1TM+XJR0"$9:KH8+(S2NO-ZL>M
M?\<QHFN/Q)Z;!Q'=2+UK<^6/+R2PP>0"RV^0L<=E]L4AX?$2:P=+26,4JL8&
M2X/&&5'$1BQ8\?#GJOY]Y=S@G/W]"+] /R]*O)(T9A6Q3L9C)$X6R,4D0!J9
M)1/:&V0>1&2N@"H0R91KTZKB+E#/D#N=ZZK##/<9KS\@V02C='K#*/B$H_,>
MYS8YZ02QNR2F%1$;;*J-R2SY!E"B=&:C563M*YXA'SJ4>8?Y@C<WN)?#<W+9
MTLJM#H7(18%FP2H"6(,ZHPB2*51U$93)PF9Q+9N\[;GRHW---,CEF)=CO.J5
M\L_^Y'0XG7Q R/VS[^0V$)W[@UGS%.B/_A/.IGAR7L_^>T$(B;S&!2.0M61#
M82$YSHJ$[#S8J$.;8.Q=$3]#&AY6RPWB?&<7E.]'Y//VC/=0^VBR&(NOQ<2
MIDRH19FE318Q%VP2^GT%X1D3:$<]- BM>C.K#EM'^>ZO >87<%;OE.<5E7O!
M9Y<]N6Q>S!936YCW*;+H,M<\.Q';M$>Z"]0S9DUGNFK0&F=Y27S]]??^55!"
MCVO'DPIDO"-73,L4"*<DG"D5[6,1+C4IQG$WK&?,I0[UU:!CSH4K0%)YA5_Q
M;#CK!S;S"T\2(1]AOJQS_>ET-)Q^/GTQ'9-@QF,R#B/MO554M1,=F8SO2ND5
M&A"JZ!AP%:JH0DWS*\PD@]H4*+Q-_'#7 WG&C#TJ)SIL_C/S998=EUZ$$'F.
MFF6PF6D3# ,E-'-!Q.205O"PV1WJ\I.?(6/VEW"7G7"N^#NKH?6:Y/5R6*M6
MI$GU&R[N@G_]ELZFN3_X7!E-_^1/\*T7DBP^"<6DK^Z"RY(%Q0WCQ20K9 Y%
M-=DV=\#Z#'EV*,VVZ(FS"NC;/L3^&9D%BP%]P#3\/.C_+]D#1JKD2T*F7&V5
M#H0Y&EHK,4G#@W625LLVMXO;P'S&'&RHSQ9-<NZ$VRLENVAR9#*56F8Y%!:%
MJDNU00ZR'O'Y@[/M![DZT%;G'666+B#G?=")X!"#5-DEYDSB3 >N6=1!D^:M
M51*B![M9NY@U+WB&;.A,WBM(L//!^]U!"#-X7R;C'G!"Y(UA2LH*SQ86K U,
M>. Z1RF]=?M%@%R\ZKD2HUL=K*#(SH??<WA0X<UN$YW1RB?MF=)6,:V!' $?
M9"V?K(BJ0>OE\O;KN'#YS&>K]-VDND*[^^<(IU/,TUK3IP/1S--OO"9/405@
M-F1-A!6<>4,>8RZF.(RB<-ODT*C[H;3N7/9@6/E V'#L+F=7GND9S=#\'D:3
M[]='].+[]9_,,E# >AX=!V9";10<9:(-W&7&:70\:N$MY!9DWQSBH;/W'@J7
M;ITV--%I@TB\ZW@NTB<V0-2RZ,)M2,<IF=!*B7=P90\-'(8;&+U(J4B6:75G
MVM)\B,:Y>BX6O#4&50J/F1/W5"(X'B6V$7S7J8*?X$_,\/X41N>0<#KIIUE\
MUQ<8?'_;/^\3TD6.%'I>0HJ!!1?)OE0E$,C@&9"7:8+01N3-/+A-WWAXFWY?
MU0Q;R[7K*/TW>3@:]Y=0CM].+K"I$B4W7#'K::^<M;KSVCJF,GD;4LN"N%G$
M_CTO>MRJ[E**74_O_\+!<+"$[,T@711$#9"<BH7YF#W3]1JV9MHQ+!FS""5I
ME3;2[YVO>=S:[4Z"7<?(_^?P.WRN]^TX@B\S:!?YK%(Z$. 3;;:9!DM.'(,,
MEJ7L?5'>"@-Z([VN?<7CUFDWDNLZTOW%FY.W%S""!>\!F8::Y0S<,I^\9 :U
M%,Z)O&E&]]4S'[?&=I1-AQ'FBZ"&R7@:^^/3_B<8T,_FZ\++X>C+(EWBHE*
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M40";C.5'7.0N<9%;L:1EI-DN*G[H<9%<8K'.%R:=KPEDBK/H2F2B!M>GXC1
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M?M-FG/T=0G[]5_T61R:[D$A(K$A;';6@&7@C6$PF!8U&*M=F#-]>Y TP"7I
M--Z)O/:OPJ9]S/N1W;?I4BI+$3Q#C+4QL)<LU'8HY-DGDIR(R-M,DF[!S:F2
MB\\)O,/#XERRCM<C2#XL:277Q[W=\+GROR*HLKKW-!YKKX=,_%BA&"UH 8JX
MX=CDL'J IN%OEP8#S*R-XAJ$1':0MKE]W8>XE@DM#U(W3&9*;[K<#R-'*.+D
M:%&Q!$P\, ?U,I:'S,!*7^M:G?,9BH,F<Q(&0,DC*2##@*2+_%MD(^&$/KKZ
M"TYQ#I,7T_PB?R9A+Y:U,]T7W%B9WYI 6XFB6*]9\GE3L1:4UO7B0D2%*:-K
M,OBP$Y6G=QMZU/"V'=5,/6V&+R,]\!.1^0J_X&3V9Y7&AL9O.2G:(NID:2$E
M(C'FS&*1D7%3BD2M(_ F)L\>M/U,N.E;%</>&OX8W'=_->Z&K_AU%62LM/9^
M<7@X"0WO#GN2R];U(1@/ JSP 93.)7KN+/EZTD'Q(@?<<7UX.#'G=8.8B7M9
MTYTX;9NT[( SC\77!0+1UD9DNLG=PV7>($H-S@@5& H)3/M2Q^@YI)VJ!%>D
MMQS#\PWB:=!XX UB%Q5>S UBH1=)%2WCJHYW!$/\<#KF!%GLW%J,#MLTVG^^
M0>P'O,/#XEQN$&^7)A2GA3#%,J]#G?T3(WFB4%BD8[OF57F-Z@G4Q T&B@?K
MX[HHYU)*B_;AZ;D^KGM]7">LG*+&Z!!%7PJ(97'()7B6=7!DXR3-?,'(A G*
M"9U FC;SD2\&O)WJX\X.NUWTV[H^[E;Q#'J15)(D&NF(L%0""Y$7ECQB!NZ5
M"DW\HY^]U*F3PO<N=>JBK387J \4S0AM58 D6*8_3.<0&7A.;EMP1AL4V;2Q
M_)Y"J=,Q<.I/:WVWP=F_G*84YP")MB1JY" 2^H,)FAFMDA+)>U.V*C*?2YT.
M!DY#W31HNG%?93$77H/7CHF<R6.2PM:4\<(XN**B!I"IR5;T\]9^]W:>':"A
MG152YQ3<&2JB<SYAG'UB-S(A:&DB;1=&VZB]Y]E);Y0&)[4\,G9SG@$;'Q#J
MZ'3:+] P';)B$ "91U-[8?%D<Y.1B6<6L&G7ZUX%3T(D&7CN/=-:UUYCT3$C
MC,M180C6#";@RYB#,"3F3S<4H0M06C8<Z9NQM0I>S^:;']7?$R,'VF+!P.@T
M);M,1<^B(.9U]F!09B\X7-2RN)?-Y[5RII!J<?7:)+SB0O:H;6!19V2:DQ4:
MR2QAU2HA_T5'U>CN]3D4V\\B&!X6YQF*A8#)<5.8QMHLV4B2*3>6%>0B&Y]5
M5DUZ#_W$H=A.H'@P%-M%.9<2Q=J'I^=0;/=0;">LG"*<=8BB+P7$QD.QUG&F
M8HY,1V%92#$S8CD9.I>\#\^AV/U#L6>'W2[Z/6DH5D?O>+T-#;98IF7(E3#-
MA$($+6R)=I_V(L^AV&,4OG<HMHNV3AZ*]4&C*S(Q%STPG6H+I:@D4\F2_Y9"
M1-_$]7\*H=ACX-2?UH8M>/D[CJ\^U0N%+SB'*WRQ6%Q_7@]2++/YC;7R%Y+T
M<G&]&$^O?IE ^@<9Y?30Q?K#.GB./OCK+..D]^A),PH;QEE.(]6MB PZFS3(
MG!"#CN!#0.N-%SE&XS2('8NH&:T#S9W]<1/!P>ELBF!@H-;DU^]TD,P*E;(T
M2:32)'9\/.F##>W]/BKU!@S>CQ?_>#W'.I(;Y[3MO8<ECHS+)2AK:8>K"?=(
M/G3P5M%62GM? BZB;E.?VYJS,SS;^D5Z;Z-XFV"E1=E/GPS6^'0]]?\VF]!C
M)N/EUQ6+(A<1"@*ST9,"HLXLBI1J;R3NH^!&Y?,:5[T_;\\+8F"\#''=<@B+
MK\9?QID,DA6#*6NOI NL]H0D!=C$0LR%F6!546AU#.=U]N[+V?-R&!0K#=(.
M[T]$VF/N]D,,?L3Y9S$R22N,)C")EC@S6K,H@V<*LR\&0_;YO*:R/\K2TX3_
M\.CHL;?\W;C:X;<KZUB:SW58E2\L%8ZU&PRP:$/-RPF@>8X!H0W,G^)4]F.P
M/(C&SS.D[I+1T2K/0G:^+CZRP(*@Q2=11;#!9-FF(>UYA=1/"H0'P^A=%'(I
M$<A]>'H.HW</HW?"RBE"D8<H^E) + O7.FO#T(I,"QLM"P(4RRZ@RK'>+S>)
M9EX.>#N%T<\.NUWT>](PNLO&FQ(CL[9.'G<J,Q^$9=D"H/(JJ_ <1F^M\+W#
MZ%VTM?.6]S1U8->?/\/\ZZR\2,OQEWHE]WW^Q ^N%OV7@75Z;<LJL,/YWPHY
MZEB'%2M0TA8M8@C1.<DYU&E/ 7<7@1TJB5[U#]/\\E-=1XOQ]+YP_N_7R\62
M?FD\O6J%A0-(:(^+8^6RA1%7HHG22>F%HEU' (IB'(8<:W9-" ]CY !B!H\[
MEY*<2Q"8]S[50GS#/&AD45G/E>(U.^2L[KZ'CSO_^K_7M V\F9*"KU?'VN_+
M3SC_2)K?; ;?*U_>SR:3U[-Y_4<C A38ZG(:+@73Y&HRVGD4*]%FZY20(35)
MCCHMFV=H=?2[!GJ+.+1'T3F%I_?G]K?KE846M8H6R$+3FM?6B!A8)&N/.255
M1AG JF'RH?OB\()6R@F@>OI5=0#.SBFX_2BCZQ2X-]-U,=$H<Y\LF;R,>R0^
MLP,&L79/B3FY@HJ#:M(.X%0,/B^G09;3$2AK%1UOPN??5OKXSB=Z:7PRFH%0
MA6EA+8L%#:/_?)(ZQ)#;]%$^$8//JVF0U70$REK$W)OQ25HH.+[):E(0$\K(
MLM>*U1Y-S)-"F$'@P2H!R=K+6E!W>'Q>4X.LJ>.P=G=9Z?-=5MNV+8F\Y(2<
M>5E/8ZCE0LHC"TDIE4 $UZ8?W4 ^U%FJ8JMB964OO8(E?L^XNKF").G%8"ZL
M6&>9]B1:KW5B/'%,(=L$<&%FQ4%RN*"=\F(ND9KA\**<XOW%,7*:*VWI(#.Z
MMH:16K)@"F<0,NB4L@=U7D5#/3)_00OP'%; &:[F3O"]J"5\^\;A<4%$[XH+
MSK$L:D%7Y+0O<Y*&X")YDUTR]L*,H(X2>%[,Y[F86P+Y@N_6'A>$<B+6\G$6
MG8':!% R$"8SY;@N+H48^86MZ(X2>%[1Y[FB6P+Y$N_WKN>X>%P*(I9DI-(,
MI91,JSIC,5O-G!6<=CE?)/#+6LY=V']>R^>YEIM!^#)O%!^7@31"9"43T\'Z
M.I=;,X@RLZ MN!BUR="D1ND<F#]?!;[(>;6=P.35>%$+V"J@7T3Z?4C+49#.
MV9@DBS$2;D5 %@.=1ZY.4H\QE 3GU0GB.'XO:*\]]WO%_G!U4:[*C0S>K4WA
M/59 T,]?SJ8K(5S#I%9.+T9DW!D)GA:!])J$46ACU":PC!C1*0-<-YD3<592
MN*"E=TKLGVR]M@9NJRO$^+@P8G<%7EW-\8H.\#?$\7BZ&*?5*?[]O!_Q%%*2
MWC+KL) M@X$%S@VST0'46YAL2K,E.PC+S^MS[_5Y_I!L<:3V5H0/T;OL,#&I
M?21G@>O:2$JS%(K/"H)RL8V[_P3[;QQE.PZB\?/LOR$Y;1&!#D$1HV(ZQ<*"
MTH'IP@/*J%,638I[?[+^&YV \&#_C2X*N9C6!7OP]-Q_HWO_C4Y8.4D/@P,4
M?2D@YFA#"2DSK,W)M;"9@>"1EKA(202CT3V/L=B__\;98;>+?AM@]N%.]@!D
M>7/AF"J>9)0X9U%DS[R1)7%0*?LF*5M/8?Y )\5WFC_016L]EK1V'#>>I0'A
MR(K.J(E_5T,\N&K^J814P=F0M\(;SZ/@#P9.0]V<:H+%FRE]BQ_A7WA0)XZ;
M_[R7+AH[Z=D>E1V<"=R+A$)I189Y+*0W2VXC9&EE'NV@[ CYK)R#8Z6T>4C?
MLKJ/MNV>(484%[0-0H+VY%FC2?7J-)N8O9-B]""51\BM+M+9M"[+6?G^X\U,
M<EHY]3YW/+T>3Z]^)V]OM92/Z1/4SXO[UD]?,MC2:;'%1*,AFEAH@^)1 8 N
M IU))K@XZET:1^#@W7SV95R-2WK;C1_/IK_"O%[L+SY<Q__!M%S.;GSZ:EP*
MSA?U$/BPA.4U'9)?7R-MB#"I?:[[ 4I+ROI&TLFD>*<M5;*1OCBOHS;"^.BX
M Q.BBSZ2[3,ZO3Q[VI->(;UWCID^>+%8X++![K/S%2WWF?WXVE*SK5VEC.$H
M,SEP,H2<(>IBC.(E>@>[=I1].#Q"7S]B)6^F*VNK_J4?/3WXZ+[ULS\?6WI1
M(CO4,G/4I!=.5J3$X$+,407/I1KM^Y(CO) ;K_AQ=\^3<E86SGST9-0BV<W!
M.$XVKO+>"S*JD]W+X;COZ<?ZX7=06:-5:V]A,IG]L]KL(X'!6*?K(+G@F)9%
M,.\+,F4<0N*TYY4F'4?VH.UTKE4_^MUVJ/L6?X-.47=(_ V7HQ(L1MH#60F"
M,PTUB&F49#Z#LX7[''V35)C[B/GI,-!5P VNY^["<)O*=7_$-],7GV?7T^7(
MQF+ %,]$$9$\=Z-85"JR+'TN2(Z[%:$%(+H2>NE@::J8!ND&&U=I>O5VMEB\
MA/G\:UEGBR]&20C+D7-F1<W?2 J9+THSY9+P')7FODG^P&Z2+AT</0F[087*
MG3V.OGE)?Q\O;Y'Y'A=([_TT*BX*-% [E?-0.Y (%F5M&^T*<%E086J2@]Z1
MSDL'3$NU-"B/^&,ZQS2[FH[_;T7R+S@EB=?*RS1'6&"E\WI2\?^:Y/;RFCB;
M+M<E7/3;[V:+E6X6(TPQ2,43<YY.5.UR8:#J_&UON/;.A!*:-'#MA_Q+Q]P
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M>]&JTO>[S3E(06W?LWQW"N7%,!:!1P1@,G)1>JM>3!8/JOO(P</%+O;Q;>Q
M!'("9'@&7MCK0E'"GE5\*3XBW['_O:K&FG"-/PW;/\>^V""GHU(Q+LA=/B*4
MU5B9Z-KX@-?\[2&"% /?=LNRUJ=QRK!V6M]&WIO37NVB]F+/\'&1L?'Y="!8
M(Y=#_J%ON(3>WC)N).$D ;ZY9;;.4!^@[YATOV5.4-04@GEZ'(A&M6_Q+=;4
M1^J-.3QS==UE$O!LH/8_0O 1@$ 5#*R].[WKA@3B24..K#<-_0R6\?@%&AEH
M9]8PFIL J7O";);H^H2F/K*IOP#'MVEVG89F/KVJX]WL^^;>=Z,71E(BOG"J
MH\@O<Y+P8'F!YU#SY'Y?<^-KRR W2_PBYI1H"Z(_?#=0QCV&-]HL'-!]QD1!
M]IC,VIO,-WFUZH'-\ZJO'F;TEIVV=/4@?APC 8A-Q>A?-!& ]5:(KOY7K,B\
M+SJRDTJ_$S7E-P_Q0*W/F3[<>^.Y5N591;Z]*&A^W94_]85LZ=<[S5;06OT>
M>(4(+EZ$U=N<  Q6'7%Y0-I!?K;H@R[#U7H747<)(0)0=W-GLN[$I5_\_F],
MY7WL=5N6\LI")7YY6YD*LR4$+@9$#Q^/)0"JBRUFJ%/.<OB$JOW%5>DC,!OV
M#;:_]:PTF.=<<CKC_FGMGYF3SG<P-JRU#SU6I5+'Z_AB7,1Q]?/TB5^8&9[D
M;'"$SXSW.4>1_\>+I?SO"7$E/L@8GRG4/@D:<>&M3@ RA+SV/L.7=0;/"4!F
M^^4]Q2+^(8P=S%CL7.28'RZS+=:8'.9U8@>8(:K<SN0BCTUCS<U;>L]E^1BV
MS61>7<=_=;G^02S ./U:P&>$U*/J!I-U]\#(<W7OH$6]H@4"P#!!=?7/(]DB
M#R.>GCM'46?W6TD=P(8G,C+GMJJS/%6U$:N,1/'**??OG'27BBQ:7"98L)>?
M'^80^6N%NR+A]K[W(GX2 '<OT%"C)?[7'-_@!^<!6>@Q].5'2?$?96>?.;4+
MUKUN1S[(8^Y"C!9RQH9J:+MNIIU=VERKG--2==/"A<A"<Q5##5?#Z=C>;89=
M!;>OD0F66U$.3M/T:P2@+"YU1IYR+"^.S9:[$<+A]C3@-!B'7#$X$]GV%SK.
M2/ 1Q(C7QP_'1Z <A>4H6SCV$9F5<M3(=D/UZN3<::Z<N/KM"%XD -=1>-UK
M2D(4UR_8.NJ2\XA/5<^:?Y;6&]9/6W:1&Q&+ ;^ZK$I"Q?>VA>1 OVH2RU_8
M7#M-.=%C>G2;IG>\;F)3KSZG7M/"B7Y$F$0PJO:-PEZT,;P#X9]V&YMMUS(5
MWR6P/FZC/T8 ! OE:$Z"RBX$.J>/U3'R7V0008V7TG@'#^ZA!.4_462)WOXH
M^R>%BZ5%+S]&77R%T:Y@%W'Y'EKS'7:V% M7Q3J5($O5['Y)5""I&C\S>JBF
M)C\W]O=/FT"(7(3:V'.@TX-+.6>J=4SNM:<%Q%'O@\5QA52@8X7:$0G2.HS%
MEY61)^F)0B<,CAM-IZ X;\K+%:;9P#,.[E0V"4\*"=J.VSC>F?>,W5193J+L
M7/S![*,O6T&F.Q:GPCV;%%+S_JQB><]?_FX%U@JSU*%GRO'6BFNXSR;A ;IP
M]?%O%3D2HO$9_?'!_MN#01&*T31WO_J!I0_L0U# (4W(1Z&9[3.[XD(ZT^E\
MKD_K;/!0]B9HC^VE4P4S;%S:Z;&/U,-C$M_;MOP8_+I43J$TIDJL](Y#YVC'
M.4MC@8I4=6IE/71?SFAQO*N/=:$ZCI\3@]HJ+YV&DALY,<@23ZRW]&<@:"^B
M=X5+F[G=DZ#S/1Y<#8VM@>1._/'=.WV>B/;TR?3V.?(1LU'[M03(:-2>2NE7
M\B7[O2MK/#-)3>CI^2)W,J3T2;!&KC !J.P-^K5_O#W+C:];#7^2)LG3:E[;
M2,U@IY.BWSQL_.><:Y +Y=JODQ7"'_G'[S_[6Z__D_"_Z+C1/T$Q ;@!%<5Z
M/6L:656*$7B=I/=J\_%AJ5DGF+Y85J8$;C;]>@XJG91[:KMM-O..J;_7)[U7
M[T/94@D8":;$J<DE]9 .3"O'&AD+3W+8.-\K;*N;=K<P#>V8HD\K(!9W-,X]
MTM]\A#PL43UH(<;&(-O@9,[AFMH)OZL#9][[QJB\ TCJQ'M X7HO(0:*^>M3
M:9'VGH]KZAN#R:>ED'!/H0E].?:095DKS#UDZTFU*\B\;N1()O-;\?:X4]P1
M.!H7KC7H(V9EV-5DEA4J,VVBL3#W2&B7@V) +&PAT"OB\\L*MD&4KKJ1MCI(
MI:DEVF"IRG?-W/0[?_P=']UN]]#%T8C04I7O!E;C4[,X@7K+2Q;O'?.,9<G+
M#</<T"<=%1.G47U7PMLTH=([,=S[TW[@_J>*WXQKY;FF>M#;ETFKBNFL[S3)
M#:;%)ZD^6?4F-*],G)Z7C]R\;N5$^YN^/BQLL;%G8:SD;1:,='C/1092;?",
M2X1Z8+IEZ#8U#9NCB6Y0AQ"_G,[3(8ZJI%$7 =VTP6I?]IGW/&1^HNJE;743
MPZ:*8>83O 3 <O$' F9N8;&X14--OI*$WV1(/WEC^^6JSP>Y<@7ZU4N+Y GE
MJ*BJ&%)L&D_ABECJ?W8QA_IFVX]@XU7=MITX]A3X5(UM_?Y\(;'**!DZ+949
M;3O$O- 1^\CX4W:3I JVT\*E9-(J*3XZ?]T)<MM([O"MWA//ZV<I^*P(/4:E
MHY;PDE)9*W!@AQCEM[<'82FV'!%@;1,V]_BB1:@F!<QN5,2N(^;#+[,()GWG
MF#K* .U-: W:OE,-Q B5E%8S,-DP_"K0LGT23)_H_7R5UU(E29X*TX<(9WUE
M9/D^Z%Q^>1J<&)D8Z &*<ZY:AA QF\5VA77PEQ;=Y3R\765I G,?YHA955/G
MT1D1[W&;%,XD??K[]GQ*[%!@53GE1L'&1^6RTC5SQ2.S$!=W-V0_NX$U.V5E
M59G1%[U#13?ZH;LWK\RT6\DE1\1-6,$9*^/1HW,Y3E!O\RO!$6(U-W:L#'Q_
M*J!V!W]O,XX<LF0BK-N?#NX>7?53^UP=UCW8<761S-B;#!SPT8<-6V51 M4[
M,YE+R+>LD51IGMX9#*"-M&%9AUD1@'L^-03 5 >^?C6N:L2<%V>U.F-B.[SZ
M4"^?,VV+PQJ_K1+F(GOS)=:M<ZO41,5>Z&LU[46J" =MU-.VY0";B* [R_I7
M%KEJ*H:X&H9=*/T]' 5=:^(#\)I)HVY +7YW."GMS#Q6<W1.DJJF-?2 ;]U1
MQ+.(8JT@--_@$VV7BA2)P]:&ADIV=$A1T?U-.C]%CZO9V9,3OXI5[($(-<<<
ME5M\CYY;M-\_D6*6PQB":<RJ-6]L1%Z#R-OR6]1.30KBX7HG6ZJM3B.662$Q
M?_?8_U_VV"0=.++%<!X%;/A2G0L4*\05L\YI*P.H!L)\MZ6*JUHJ1_;D!4Q>
MOXB=ZK-D?A^V8A31D@8U6M@+.BQQ6N2)Y!C9%MKC5/LQ6+S.],E@7PE.,]1
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M<W]$N49[]J(B7QS3#0_HC72-^]!>5'0\V))^6..283(39DQ.)_9K+RQ,+R'
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MTKHI%[SL;0G6F<?3]V"3XI1'$+RZ@1@5*&,%1 [44W=.\@]3I?^3J4)S"$#
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MRWE+AZC^ $>O+0A=:8P.>_GJHSEH-^+>Z+8H[<$Y<!]J?8H%G HC6S&;UUG
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MIP^B=W /+U]OM+^\&P]]5,5_8<)R\*\WUCUII&_D9*;'@E>!E)+BF^Q&P)8
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M:-#&K+OJDEZ75SB+Q-ZHB3>6/WCO-0MH?!;+W,.:LB/_.U37X5^HM0<U+&#
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MA//7<9=U2&W?Y "0-QRR5R\O+K_>O*UZ5U0G,/W3MIW9G3 "["VT)FB-!;"
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M0^<O4]EL[BXOFB&FLJA.E9^A9Y6C1L4V]H[LZS%Y0UB G$.++8W[-FJI#&:
M:I)E ?/KJ<S&&E3G5:XE<;I(*L78=MR9 */\B?+,ZVB02OQ3?AJGL]"@9_DX
M++5]8;>SHQ>6, ,@=8-3*1[4^D_!'69;<O6#[IL;JO<5#_48M'Z]9'3__E-]
M?1,SE%45E< "#MUA)-JV](M VS9X1M=)TQ7ZU@^G#^T]_CL1G<'QT7+PERZT
M_ASXX[0&M81]=N),V<9+8P_"NZK: 1T8Z+:5)*=88EVYK!Y';M&#2VOGL8OP
M_WEURR"T'+3N"VU"\0:O$IBUQN54HS;#!ZUV:I9B#HF2-UX)_)P\O,\!T_*
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MU6H7:UB.^XR&9'$/E9SV2T/WVU(=F$IL\.#MP (:)5'43"@!1LUE1M?#6 #
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MQV%-J,1JP_;O\N=S79TM\UQNGT[?O/FS_#M'"L?'1>FY4]EI^UT$S+'@L/9
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MU62F_5XF<CRNS8QW4*9'PMPI>XUSU>5<:A[N!NBI/.N8GUCH21J&2V7'A2"
M_55O.VIW)K5GDBRB4@-<DB*/?D$VR?G>UBR BY@0E?:J)AX^IE+TOGU#A&A,
M?09M=7"ACE?$TJ-?)#R8MO>Y[.@*6W1@T_#=36[8?DA"BOPF*;'KF"[W_M?U
MN@S.[.RU\ 0%*%^!UQD,V!OWZI85>[ZK?G5)C:L)X'<W\\^ 3*;62"X/S'V
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MFCYNI[,S/JH[GO+'I7(1$+O(G--]9D4^=C-Q'3R+PL@3KV3C9(G4PT0[5)@
M23V5]U>N>'/R)U$('N#4#FF+R;R8JY$_/M;&;7:=69TU.%]K>"$I5&.BT\U=
MO<*W%UL^$D9Y:F1;:I.HG9ZEE77N$;/[U73[O[(/2GJU9]] +X%ML<Q42W)(
M/OG1\T$9F);F2S^;I4227#RGX>+S'W>-N!82SKUG.8-^74K<BDU/6B]4@%24
M)V[8)YK XRY7\W$*HCF(CS;$Z "1#_-X"B.4#EC]Q)%L>:G-6=.R]W= T_R=
MN1WVV;E?L:$-F_@A"O,\MGV3F>33Y[II8E8R)%FX7>3;_2_?W[?++#V5L^^\
M1B3;>ME,X*,DW5'J,VOVX@G;&9 FV3+YS*V,G,C?GX7>7^!N$IRI1]*83HV,
M$+891;H./A9>K]L!4G^\S3X)T8<>0SA8_72^UDZY.KKF$HI_Y*!]]>[17BXB
M9Y/ NVH'O93+6%IH9"TD E2E[H>Y1HZ<QY%(":F"PYN1DP&E=VX&U*4_5BS>
M!\S7%$G3+FTCCJ$;E+G)L48;\0/FD.\"7PMK6:GY?^B V=1:^X1"ZIN=R(J"
M=@<7'P>')169\7/IBECIRX=*TMLF+UA=DA?[#G;D%)5>VBM<#PG[;E.QE0VK
M6O(>;<)/EC71 >SU>HR!VZ[KVU=LJR07)T_*8,\$Z0 7Q\?ZQY^5U@=HCWW[
MS#C(#+\FUP1NQ=@428QE9J&L?F<GA]O?N ;0B8X78E%W/H_X5W\Q#.PW2,\]
MPO5>7;6X>' WN?U>Y:+SS)O@#FV%B':4N2&TJ@*';G4(XHFLC'#ZK6%^.4:-
MD>5<Z."7K3?HU1</S1]QED/VI=._O]N)*QZ^F\WU1M?^45V]E\B2%P>6RCZ)
M*W0]1[LR? VO6.ZBUAOU^X9OQ<&HO^)KN_FH2ZL"-TL#X?<.- VW")&+3SM8
MAQYL :*36?L2EZAL<\ @/%N]V&7CRQ/*91D_]*5AU]J:+BC/BU@H77$GR<H>
MOXUH2,E@G30V:2O&77[!(:@*$/TL#P!P%=E&\JK)*CO<S_T:]_NI?Z;009W#
MWHN6?1U5"_CO?Z\9_3>#47SG.@XR!P&63A91ZMSW+'2H;T-I@@=GZ[F_IW.\
MT_O2Q)B#SLD/WJG"F2"OELT8?B\? HJG7H,6R8.0?QM,!>[JFOWU!DDE?8AI
MP3JHSZV=BH4F1>TJ1<GY*\^:JW@+43YU?)T.(E,.2,LMT4AT&O2C@1KSNG55
M;"4!Y^W?%Y6I@W;+&8I(S45Q<.OAAFKKWT?!B=LM$8)F>FK?#:<%%)/\ "+C
MM: ^BH$>5&)D)&I>W/(I4V7"P#W-@>M'@[M*8*9=V\75=:V3Y2'S,E*"Q*U'
M>] %'S;3T5 ,+]RDK0MGVO?)[;IYE+SAD^\^0ESF9)[Y\MZ(UQ+77PW&0(S$
MI] T>1?J>NX@[0[9BW*F*'4XBCBEIK[V &Q,('$E7EL*M3F$$H'NCP.9.00,
MA%?^#62C.<A851-/T?+ 5H7X->UNOC1XT.QL%4W)S*F0AN-9N-S^?$<6Y=40
ML"%IC]R9/CB83BTQS['<J*H\Y*8#4G7SD8(&8GV9*4OL#TD)!P;4@P>I.I_1
MVW<D8ZL6?Q,O%%*$J"\&G2T&Q \X^(T'=B47%C6H^;%#RHS4)P.3;'"PH8.W
MM_H/WX_ 3-^X?K,,N70.4"0KTNL$(H]X%)C0]%BRAA:T&+?\U6WZ$4UY_ZW:
M**W.^#GJC[YI=/T#]FAN?K@H[IS!^A7UAZQ3MSLMC5X7C;Y27W\;/5?CDP<^
M>D1EB#%]@.EQP-$N':E \RN1.ZN,E#!J7F9[D&M^89K/@[_O&A2[73_Y6I3+
M.\IQ$);&2_\,*SQ+B#]Q:*A/L)SHVJV*KYE!3(VLVJ%IUMVHBH.%&=&=A"^*
MC+";!O7)D%M11GRJO+Y<"7OHK$*[S?*WLER"XP[6-A=5.YLS;*OY2 "F(Z0!
M8PNJBB.BCDI<C<X"CT]^_  B4T)7L9_P7#,KON<''RI<$KCK5A<?^1ITGO"$
M681Z*47Y%^M,+<P\\^T[XGWW>D\L41PZ%=VK>37GQ(%7V%LS@0XXT^][;T51
ME6*,D">>S$]DI;ODU<J.VBE/U3)L_'ES_U!7U08N0HHC7H\\N%@@+J->@OVQ
M&8I_%=S\7OE+C2G%6J3"D.Q"O-YL=I'8DY)<RQ'X.^?HA?VVY V-5 VIO7?%
M<J;[#.%G\(D$.L#&X0N&OX[LG4OV5QL0+R^TUE1Q%BH)?BH<\7R&_PW L>;&
M//C.,G>1EV/7NIXA?"^_[NY;AYF1L1F7/[FOW1:[-HKFK8\.E>;?#+WKWY^L
MHV3=M8,Q]XH!-"[F&44RFITIXMF;/_R\3P<PCZ_OD?W.E=;KP^"DDM274J^#
M/^-Q=[D%&49JD$'*#VIW>C=:/9 ^@EH^G+&>-HH%SF_3U5^U' H_C?'10,N>
M1&&NDPU:4]F&#@IAJA7##K-#/!.R]= ',BKL=E'WJ!F+44)66:EG(^3=LD,=
M#ITU-6%89"]1-$N^XL7WWX&:A]&8JD%[?,*<%W_49@1Q;6OEF=!Q7");E++W
M@U?>U,RD?;1Y'T(EBXS2]-<=<# ?NF?-'0GG>X!RL%#P[RC@MR2 _ ZFE6%B
M6.95->X+ET+[!=T.]5\QH1QAR]OC6W/;!&@[F@TA%S.G45X3'O6I5."9:(@@
M\HGQ+9?(:N@+5#Y!RM46PI3)K?(V:[!VW4'EQ)(C(/^BA?%WJTW70NO!;:7T
M%LP-LH_USFO501EO7B.$]0/!L5[AR*.S,4U.$E.7.3ZYM'K=BQ&2*H]YD&'+
M+"W5"' 3&OT#XD N["@RT@%FE73 \0.O\9.R>B?/7V1)3>))>!1[[<+?LH?O
M%W^'2RS,4_ZL'@ B#R"2;FOF.<W:>Q$'JPV;B^]?M(O>;]%+UOLM9C,*@R[]
M36I!5D3AT"PSG;:U<6WY0M:PRI0ST6=(SD^KAC4X) /H -NH(,Q=K%^7THNY
MYC4/P[E(TGB"-]OGN@1G_P/!0E.R.9&Q.961V!!7\3?(,F>MD"FINVZ,\S1Q
MSOMM,=KZ-S+TN2F.:G@2$YH\!IL44SD'=.'\[R,_VEV[R_%]X6K7F5G*B)N
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MQG!Z176TASJ,ISSV_L'8KV]*?QDYENF $FH8L(GKO4O%M5W"CV. JB,= $
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M=?)SZMV1N,*"IZC$\X) 9? X(\-)&N;@Z/F?]Q9_-*7Y8KQ'UQE;>\>6F^D
MGGKS1\&(9X4P+>>.$O5S#]):F5A"?^4>RK0B<548/F2?P5LZ -M/!^QPI-D(
M'M*NSD7R$_XTZ"9GK/4:8<P:KNU"4_"O]_0SC$]$Z( @!ZH<'? KJX8.0*;3
M 7-W\<0MR2!!FD7B\@DMB@X(SHG/GD:VO#@UV$NH?Y/J'/6(R.CG!@[&2 PJ
M*F0\M<)@?UJHC+L,AVP .D4FL!;*'-3'@\IL9* &L>V[_P9)QWRQC<<&*"GH
M'8OZU;AI"FJ"C#]K0C&X319:J\&ZI]4^UL<E'@V'B_J2_MQI4K1>->O7C2;C
M^79<Y0(+%959UK[*C&K;>%3%]".:0^]D^;[Y3]VJ=J*H[+VX3:=3$FCV&B@B
MV.3*E+$F?Q'Z-'YL)75L,#Z\"*U@Q+F3,XG@5IY[K-P.(_A-=]OT>U;!(1P&
MTY5QI\2E/_2A6T=ZK'-'[%)4NK&)"#J]GV;5VXB\*AFJ?(7\Z#5P2:8MX8Q+
MG=#])UQL:Q=E=J,V']GBF9&?>H-F'ODI%=O./'VYV==1\ [9)1M9NTT6 ;<$
MC"KSV9H!:V*O3_ M&<Y;:'*]?]P[.\[1YSN#9SIP",9><?7& U<3C+-J,J!;
MH;QRW=V+SZN= <M^T2,[9G_+PL93MWB8)?_FF>?5/37M]XTQ]@U*0%R-E Q#
M57F$(70+21'@9R8AXE,IG=_.UWZA WS*@)E0.L#/'Z&]PU\5C)":Y6=^A8)4
M#J6QO>6UN6PG+?W]C<7CR3:G[;=15#8Z@"!103QLP@@-*ZIGO;7QJLR%EP0[
M_);J$HS0^'OQ+U?-\6:!P^3@K$.HX@=/PC8O_$6SG?[>BZB.U(%^YI[/BP.J
M.MWO8NX_SM>-JM+8*%>Z.(I3)+$O"A&T1:4<8#FKY.2$8/!LLI='4#UWGNVA
M[\.&&DS)X%)=M&6E#F]'=,*-]\OGHHI$'<BW[TQ@% 5(6(IN@4@[=H)Y[C0J
M18B8G\2F_?7\?.ORAF')P@R_6]Q,'>H_./2B%-_/*XEYT"[M$"=;P4"AG7I?
MH3YTN:5T8XG,PA6>[O+.F*^G CYZ7>\Q9%SCC5?2W+H%'5"Z\W#GP/(NI5*C
MM0[:L0<93Z)!ZEI!!WMY=,"*G3&H,HB::H"#'!\,@O<QMJ,G*-_KY#J5DS*$
M*MI6F7=HH]PH>RA1Z:FWM:&I@NP 7[A+=)2Q]6;K+)#O/^YNA=?+$-YJMG!Z
M6:7 @DHJ/=M3.(8&/GUX8I(N:7]@VCTI[L4O6G'7:G\BL:JT<MU;"5A&NXGL
M")H#4QA-D2N5Z$ Z8#;9"3ON*ZP\6#S>]KNDS4F$XU$$V 82B>545/ DO!4D
M^&:F=^?\,Y+P2&ILBI-I_C*#?%Y[=/0I,F!H[=BRZ>W&[2 #1[A_EYVW0<+?
MNL#;+,6WI^Z9!%UVBGD^+_3Y^5)Q56FFL/@XP?OZ]\6XE3FAFC6Y\=M)_3/'
M('9:-[BL*(SR%)[=&B_?5NB3*9N8>^]IM]7RU!:OPO?]1NKZJ7\GNSOX.U_:
ML:I';O?2 :QFGFB$)#F7<IL*&Z8:S4*!O7-1++9J3Z\-7$CVU*;\T55#/?A^
MP[PDW&.-\2UP\_4.'=!6-FD"=R&(M_I+$Y;JRGZT/1$41'QAA0R-[,5I*-LZ
M]QV65(>WL^D8=.^PODF$VHI.V*8<B".;-,3UVPGH+YMQ8?<>H;FLUIY$J/K(
M$"5ISWO]D!NL,#H@;:1>D,;$. ME)1\VTCB"<!/\I#*G\QLQ6E>^7] /9V<0
MDO >Q5+Y!K?*40'*K*4-?IHF=3X2,W?-XU[4W@\_F^%^8_0>:LNB?GS7,"\Z
M7BLHXF I/J@561I%3?4(1VX>T@'/\K#EG.ES41,@4@$R4+9VX=@@:/.#B<HU
MJ=U1UL!XM2=/W*>_24]RC/GV0"]3C0CXB?96XY%LPO0+W'/4IJ_>06N9$*2F
MM-KBOHOA*2%%X4#!8":DS3ERX6PAT[Q926VTQ$MW1Z7VA!OA0KFB(G\8WE5N
M6"ZM1[\U,!O5VLS./7AQ&C\1;3K+) V5.I-$_,]NWSY4\5("T9)@E3M7Y\!N
MMO;:J/Z.^%( APDB-$4]RP6JCFP"/X>.8R$BGR6WL/LWS81WGK7A!9 V#D$3
M\7% G)$K$)AV[_ 6_+W1%M/]#X;^ 5;+?**I*3 ,69. Y8,+DD C^]U*;+HE
M.Y:\Y8&=A=/V3]P9G-&FLS%77AYE0N(=3)+'5BVDN"UP\S#58;?K;S82URW_
M8 1M_P=[[P'49-2UBT9%45 0!.E$*=)!D-YB P1$!&G2(B+204!Z2!2D2%6J
MU$B3#M([H2,@(ET(+:&70$() 5)N_/Y[_W/^_SMM[LR=.>?.-YEW,K/GG;S[
MW6NM9SW/WCM[L8'JM#!6]J@@99.$CC:@S\=O<8G2N8SJX/M682.;V<X';'IC
MF)H8]9G>7ZSU-74Q-F$"[$8:[( @0,7/X?=>1'?"&?>BBG#R=6M+RTW);\XE
M0Y*O$YSBDL[0V-P3(.D%:9^J$%\2^I<J>/L+_/8[)% 8)I?E)+>A#]]7GPZP
M^DKS?[*(<XK\[5-C7J6X_Y-E3K'WP]*VHY:^O]61S\XT6OT*!9 8ZP0_)%&I
M7XYY#6@Q%[;WE,Q# 4S=^EO:H[9%##O<DXRH_Y:+?MZB4J2%.FII]!Y/F_YP
M_O'C,PO1GDY'F!7L0H^Z F[XO1L$A"(]>%Y?&_-A[[E%313'_KWC"&X/<Q$I
M9UIH>/:36BG,8X'&I"2!^CW[22SL1PJ0%-)'CJJ@8F/:PIZ2WQ&Y08O*4*\$
M]5UI*4')ONOM=/_^80_W:U>*_62U[2[I'93+KZ2]30R71[Z)Q>?F='E==J9?
ML*BY?U]  /-C+7(UQ/H7C'_MMMQ-[GJNZX>0NOV)+. B/#C-O0\^,X8&A1U:
MW=_5JXM[.N'6/1GHFVQ1]172'@U9VZN 4G'V-4'V\-]#VC*\%Q8"9&Z[ (&T
M$+*Q4]KI5F.'E_(:D^<G^55R^W^.]#,3?Y9.OS#]II7OK(!QQZWU,)5]>X\-
MV_F%B^WR4(OIZN6:K2JN@'YKLA.-KRZ0$ _2Y&?Z\C)7I]S*2A123#XPAEO,
MGO)WM'&$=V1=&Y7E\G^5=45^4N712@K7M,']8(]>OXJ0%ODA')!,IU0(1H:F
M(?5:O80,65TQW;04 / <;B@H$PV/N.;'MHB9BFS1<!-W+Y-=J+$T3[$L/05-
M!%^BV5D*=EX!$X04@MT.R\"],.;#N]:!_6D#E[Z\:*Z^9.^>?4L]Z-Y!>0!T
MVUYA';+Z'*+.QA%3>.C\V;]1S?48[F6Z-HRA4D0AB470"<J5:I@9Q+V297=D
M+MX7)]3]41;,X7=_KO:*Q:.X_JQ>/IH*]I=; OZG/R^!I"S?#NMDJ"8Z.7F^
MP02\E<9YVPVD.>TZUP1Y@=DI@ Y-LJ@SF7D$<@>5R7D2I'P%_"MMQ_DYG3;?
MMPFF9:^:E'X>7&S2T :LM@)S]N25N0Y1O*5Q$O4TWEH[;_;=$\#E_G=G-O5_
MTJJ55)#JV^@()>BC=RV"Z""NQUG[ST>_@EQ&4>#YT,_&&<5[9B7"7%J*:ELZ
M;TF9C_;_''AN(TX5I'/%G>/$W&8*RFK<Z^IJ?[V6(MRJ332_U#).=/4["4:F
M%ERUJ$A!N#VBR?B<M5I%S4>I;TCP'MA5-.W-&[66)%X#"W4@*1?A .99Q_DY
M/R;8RBIW:> =#YU/G[^(X+9);6DO+HOU:,:6 ?\PHMRCVKC]FON6ND]X=I(%
MS?@BT>CKC]9>Q5OUL,=]\630>BGV7.E4233Z$&=<"9_^4^P?:C:@GY(DQ$6T
M^MP'4:.&9R(U/$]A%$!>O.D(O&Z-F)[R$5H)6W_9)HN#1ZD:+,*17CV<?2$U
M/E.UIX&GN5>"[^YSL'1V/N:#='\0]SLH3T'[]DC%4I$V+#:+#LC@?M#L:&_2
M@+215;)3I8V_R\K"O:;FE*_7V!G$K/DGNBW?Q9J1;8CUXGVV9EU7'_6/I-"W
M6U:V>-N:RM;ZV,U?JZN;(E^3? 4BNL_F^=*8,N$LR)>Z4',OYIUX+TZL_79#
MOOU88$4^0:K=+PDZX%VN$YMH85K49R8/PZDCB7\2XI#6%^WB:KYHT?OM8?S*
M@N#='S^>>G2LN?I9K6%@N%G'N'SX!U_L5M5-HR9.NQ$ !>"G40T_W6*-]I]=
M$74O6GJ:K%PGWR8D49QH.8\1*\<'YBS\97#HOH_>8L/7_.B[3<? &OE=J^;T
MWZ0$SIN5]#7L&7F\1V;-4;G]'U/RD\$^!)X!00&,_A&;I !L$--KW; KF,,%
M5L+ A:I)N7RF'GNQ"\F*>\\S?ZS_U)_;E/[%>*X=]ATJ1AZ$UPA%>,_1=DS-
MS++MZ5\V[+&3^,DFOZ\C\)17NFOE6FP+KU)9T+2.1]RS/YY=Z$KV;75.@Y8E
M+J=X5W?W5 P,^TS_6)#,0@%\IRJ,$2FKA0C8<B<&M*U#'9A1OY)56&P:&,.(
MV^^4#XB+4&63^!;CZMV$U*FNXUOR,%2H\9=Y<2[ZD_)!18GW,-W6-6@/?AX8
MI]<8Y H1='1Z>QA]W&D7?+N_OGSQ'CN^=,;@ ]_"L\&R)XJ6MQ@^%+ )CT\.
MJ3CYZV\SYR->+W 5!_]TVWD'> 4_L*O(H*I \/2P-BE;51OM+ $V:AN=TO]H
MIUDUG2R(O3?[K:V9]+Z%L9P@AI*OMD&K<>YK-:8;^5^?/[D>DWKYT9U@Y5><
MV.:*,/AUQ"M@5$!=ZR*<RG_@5Q:2+9%WI\X^TG6[Q%?P*[J 4!E7YI"_JZ>Q
MB5?3\4/@6X*XU8PY$QQ[YIXC@WS4[H^1+Y4L;JG\D*2-K)UTR+2\L.?1,7PD
MM@[\2 &<)0KB0CI-FA@_EIIOBFF<G=R3G_8X=YZ^D3W@_8\;(;U:9]L<QV!.
M4G'6RA-O3ZW84'J_DEP%UH4:&JN_E \MR//>C6P)6&UUQB<0*G @5-E1^"VL
M0L@MG#Q<UC-31[%,H.$MI"#Y:U\\*$Z(QH39V#(^L?90'<9Z>>8;7Z+8I/68
M-=C?<=\"7."UO$L5@E76U:?2?WJ6*F@)53NZ](&A<=#';#X]L2R[]\\%OV$\
MM^Z\ YL>0PLN]+@'M['B-+/K,4=UV_67OP+V-/B[=]^WS]H*G7N?1D"@P[N!
M,0NUK^'V*'IPN,+,]2_[I0G5R$%NM\$Q2%6H\;ERY:E9V 4H3T$G+)3,@TT;
MJ&Y+=ZUZ;LMNFO2EY4,@V^N^6N/7I+1GT*/UM_;>HJKGA6WM.%ZR9$VZ)\^Y
MKI'<?!(---[ Z?YGQ3KN^=NZ%R)KV)YJ>=![:[/<+K]F3E IF$M.>-(0R*9Z
M[+[?1^;?EULW,AG?,LK'JG G81.E12=L8<.[JM=,"*X5CH)Q?X9F;<GFYIG'
M1/6C#<OQ[RW,+)\Y%:R+NVB@K(?G35K'7.4$D+[.5P9.]-C=UZP3[W!(Q2JH
M!]0SCB77V+M;Z:<Z5/B,JU\G0$\%7:U'XG 6/[36/4$Z:[O02]W3\FFY!3E#
M5]W'F8@E=8HG,@L/^HKB7Z*P^5):9!_5;S42D'O%9DO;)S'C_".W7H#$IXR]
ML;X6X;=$7-UH7<N-R+DGDWI377 F\S6?5/XXLTSP,><"T@ ^HT7?L23<O*<=
M #[@<<7Q=_NT7-'.XXW7C#GYG#8:LG2AF7'!0ANQ$!&WW-D8%7=E<[)QOV;P
M1U_)W7:H7[',0VS=--/G5O87(]L.^MO9)'<.+2TE*0MR078?KI@(*QTK2X>C
M7@.73)XM>84>'WC;DH=^@? Z^W2BO PAIZ#4XJ'*RIF"1<2/0SL"DF$D\];=
M0/0;&-[\H,=U@+%P"-(,?JI!+E,/;BEUI7OK[\]:X;6Q![&#@&OPHZUE(_YX
M]>=8!#$+W[QJ[YMX"L-RJD(3*0"DJC(A!=752.J#OU$/AW"0I(^IP@]XA3QK
MDH#H9\CGC"O?>D!-PGV_3=U/+8DJK;CZ+F30@\?O=]P/GL?T); /MHA+WQJ9
MC18+8ID:U<QS7,)ZW]K.5*QHE3O.,"P0_2)NQ%<^CCQ-@WW>\>XCVMJ!/[3=
MF9<!5>Y0 "#!RA-TRSX*@;%:' KL2A:K<(+_F1GW*/65GNU=X6GO\'YSL6/K
MU\7A)<MPS)E330=>46Q,WP<(C^S,:GZ)C$5-';;!R+ ]R?*=57IH._OR?I98
M=]>*7P,Z]](SIR$KI*Y0*UXM\CCYNIGC$[EK33ZFD_@99#+,WO@SS&Z!E>VT
M5.XL?.<8 +OM=+1-39P"P^9_:U-15>V7DC)LW/O7!*]3A7F'J;OT*Z.2:TWG
M"';Q"IX(+'<H!?!NZB-T@ +@;I' +G0%A$6AN:*B:!O;G+_L$,/BN=E'?.(;
M7WBV?5GVLN[1$'>];/NUL4)VHMG)WVCVC??WXN:5&E[2@?I@1>+.'2','./G
M+CY&60I@5G'M@*_5U)Q4V,:UP>F2HHT^/RY WRA1=O-SWJ>3RX74W-:BX1^^
M/?QU$W85*NP7A4XN<IJ<K*[Y/"WV]K572,W1Q9#7@<EXN8[WV::7M)BL6RR?
MA40VU<XV\S3,C..,'0QR!6_EY6'*X@4))52>]I'*TP[KJ:DE84(?*29-0**6
M$V!]Y<>*)[K7=W]'POI*UB'\I_I^C-V<Z>FN-RSN\VXD8JRJ!H!?U\Z,9_CP
M-2W,5+3+$!\37+]MS3!3  [ZWU[OW:3]^;KNLU&COC4KU_J5 "-1S4P(J_8&
MVX6*U1W$L^$R6L-8F0RY^'B?O9&L8PT_A4X*8*:YXV0JK-0&=SV?%%76Q=SS
MIEZZ,=;DW/F)=G[:<H:+P]#:\5GHZ +#4FMM=?U46+:OE\P];I,WCXY?W[A<
M^?3KJ]C#?3F963NE!F7#L7[DKGHD1]CU/)8)C8HTQ869.^BUB!K8-0?H.:PM
M"6XU$2R;XL?U227QH:$G2SQ[<M\Y]L)2V*O!&,,Y01PX[I!D>/A]E)3E>95W
MD4,A82KD_4&Y/3ZYOH7@BZON!#&I_S@RU_$W&*J.YY5W'5RGUUR0#$A23]IZ
M2AZC "ZOC"VUN%_3HOM.TXG?]R_V^%UXWP__XZC"F_0ZECED$)67TC+:O-HV
M-%WK%A[95F'!^MPV']MZS<>D[K1L.$-=DL@_TL8,,<1*?(M3PW3.6VK(CH)U
MJI1LE*-7C&%) 0J8$0J KR ,M(77)[%9^^-"T,GI.&=T08CW%89)K&-:T+)\
MV!Y:(DH\S,X]9>S][\53TVSR''!/U,^6C'A%M;3WU@-DD/.YP[C8T=8CU?Y
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MXT KY(Z\68"HY28=:;O<:X$)M PGP,D=OG\!O1UANWMY0UV<H%W^W%G9M;S
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M$<P*0FA]_9;\V1 1&7P)XR)>F5*(FIJ(Y_O<HL0KKW\< E44B^6U(I-)JUB
MH?G?LG12=_#L0#>G]V6XJ@CSD-:QU0:7W-Q=^J9]1(6Q[V%DTZ4_]-:RVKT9
M$Z@89J?.?T5 X%[PWNX^@K:%8J7\98@I:X59=8^VVLP+X(&:'YYN>TX<^\5R
MH?N>6OGV.#79IP$P!5'4'YKNM9L"]3=?L! V:0#8;S9--%U&N#S2;3%H7&^!
M!'GEQMLB/),SOFI0BQNOO%3.G W3LWC9H^DLE"./U@X6[OY+0..H+_V7P<'@
MJ2I?A2 7,(LR;&[OP%U)-)VI"V6X7AVYMK[GX/#V8\3[S0_;6MJ>,W9FHTE-
M2:<CP\"8#O+PE@$7()O$;+MN6(SN<'G9\#C"K_^$!>NXX$/5C:?2;0/OS)KL
M<Z>I'E?ZUT[E-[(<CB89%W6LGSG1.H7.1V)[+\B5%F'W9K&MO].80]L8Z:K+
MQ;^VNC_QO)ZB=\+,0K08C7Z7_&!_??;R7D,:-/ _NVYY39EO890V=8F!.-.,
M6;"*8XZUDX&*N=WCKND?86OO O-(3#6KQ?J6 -QMLY;A+1_&^$?7)BOMN"]H
M%[/BU_0ZS1U;G=A=:9^>E5 >^^Q;SA]+_V>#O9,_L(]@ );W5!,2U 0*?5U>
MUQ!GY?@T!V+',I5Q,=2 ^7SP84 @TU^S[^T"%=DDA5PY>G[7&<.E.)QQ(9W^
M 9)O,"U;FVRF!"/.7 UF!]R(42IAOZSB*[:_ EB34:"DVLKE;!^E/&>-T/\H
M:TL1_])W8VYO@L'\^_'3BGAE;(ISQMNL,$]-'+*G)96!\19'!&\CH49FWG)]
MM?'%;L:@[W!Z&36.PQ@HJ;IX^79;%WUHQ-. -I9-#I7J$JG_\YF%1<R\4VO*
M1/@LU*)V?E*PPP#6"J.U2;M64X:\P5G6;G;.TH$WHCH1+W1"Q.)OW%FE,V[U
M_"/YF5("/@*F+REV59L0N=?='6R_SRLD165=S.YTH+S+DV]A(1FCQ!K;^10I
MOFU$4&"*CLT)BM^9@:S"KZ,]@O6^QPKL/?D?GSN4.6JJ&#[=7_>V]C:9%1G8
M31K6P*YB0C:%0OE8WF'D2X4PA@G6.O-]\2F)YD9Q8?S<S1[:[ RZHZ?@4J86
MV,W-JKO+L*!J'3K_CA]5GA"$T 9\:N;,L:O8]]T?LKZ9%$P4URJ9'Y(<M*@%
MU4#OAR215<A\</ =I%'M>>]BM3HARM>_6K_;><M-L-UV=Y_<H_#$[1+.'7-H
M,L;-76EHRT]L9".JFFL\=?8S*B.EX(WI^PZF1KF/WJ#>-'--<OEL%K4?&BJZ
M0'?85OL9D(&*,]P@OI;-N)%RGK-JM]!U/C=->3T<ZG$96C%_&PI*;I\C&"^N
MG'TR-<?UP\X>:,^H1Q,S3JY*[&]&_&>"Z_.7>1A MPMX$KE+>,%DTT2.-1?N
M^(;[4+0U1S>P;+L)%2V:M8]@;C)5D62U"WM0]+;W<Y39X^#'9*C1V?BQDQ'#
MDY03GZ+Q_!7'V]1;-3E V4EC.^_<\TH\V$]ZXM\H\6XD VBETN,*@&\GE;T"
M*)N5Y"'_Y:+(P7['=?AI KJ.+K^^NP(,_>!*)+T"L+Q1R(:Q>M%< <[8T>"E
M='P\RU8DEGT>%:YKT#B.HR[<<C^/TSEQ--D,=L";N97*O]:0+^IPBDPCS9-^
M1UY:$5N_?@6@A3XN'T#:/,7"^,Y%HIV7[GGKC77I6 0,K2E.">M&431^C)?A
MIE\CVG>5CK^>*;NEM;%+ZT%\5',ZY8&R,;2\P+OAC_:8G^74W6P19694E.^0
MU8<]%"Z4\CXYJJC]E=SO!Z+<U"F:UG?DYH&0%/H1*;&X]LN&A?F1FC/-K %'
MI2C\YTMD<]W:5FI>Z(XIPSF;<,6G9Y^:5C0NBT&6L/M0@BO -TT\^<6LQN&%
MX:XO["2NM&F>JW.ZVLPZ\C@\9?WGIK'";]A$O2HFO14+M5MN]-I^-<1KMUH;
M,C:K,[OT19'+D7N80_M5P>[GFF?JIP=RKB"T!N0,#CXEOP),&XQ@>2Y4H8*8
M].9+KL7Y-IV0=KVBA2&VB(-)5&H7!P<%=X%A-V<PA5"$*?&Z4]1MW?1MFL[5
MD0)-NZIY0>6]<4O(B%.7Y]H3?U>:=GZC_'J%Y 0^'1G;"W(<.V8LV3?M#C;4
M%99G>.8-#SD?5@\A[>WXP: <N$:\ -W^TR_VI$FI":NVY*T67,UX(_1-PFE;
MJ8EPC.'+,()LLV#*&B-YS=,O$S=^[8DQC$^?PW;2%Z2<+]3 6"7,/2UT[TA-
MA6')_:V6O2$23SO6-^K?PFL J#<S5)H#A"6\EQ&^=',XJ<N\!I6_,ID,.@LW
MZB1[8A[K:]-F5]_C5@T+'U3V7*SZ(W.+5;/5=%;<%;YK=*9]9E8TCB/;'N,_
MD[35:=7P<%5]J^/\K82J(5'!K@1[-%U^&81G\&"2*[L"^,=CJ"]$=>N[V6-]
M[#[8NQ5 %'''%HFV_&=XHP"CS-.%)BG?]B$/LI8K /J'![UV(LJ$ZF!L26^"
M-;;97EVQYJ'"02_MV?>R@ET-.$E&BE?D+G!Q_@LC,[:TH'MY/XB1=1BJ0.(@
M^S3=CB%&QB9-HXP;ME$&N&.W<IO%)<R#-60:"\84+I"U]-^<\7@UWJ%[OA8H
M&5-:/2YTD>RO%?W2XU6HN?KU_8N?J]1*V:;1%'TR)<8X)WL7*W1;3N+AKI^0
M7"E;'S@Y79:*L_BL:F/!/<G;HU*-KM(26!:T@@EV?6ET2,C_0CA.PFQ$6.E!
MA8[C0T\I48GW_B]E/I(]EA6XU+2\H(>2C$B^G"(M:>.Z2'4TBZ'(E47H-?YQ
M(:C[_DVBK-Z0A9;^K9>NW[42)\/F+$4^L#EE(H7*4 <FM8C-G=AV^U4-4=TO
M94&5M@7>UJB/\F]^H:$KC5P$3UXLCG_&\UJ=PX-]!5!+8/)P)\I M;)PU9FD
M]*E;SVK:8L4(1^.["<^^FX^@O3''\-T<H&%"MQSE-#(MW0T>&?N!0U*(4X48
MWLMC_N)9^WAU/6+><./X(M$//S!?/E9X <+ZM8]MG?. E4=,+<M&6-0XLI]1
M]RJ$.E-R&GM'R7(02<3[]"^>[@@O=H,"T1[)2Y"0X@JF"L-6![0\9B(WO0$=
MVRF>4CM+%UTITK1Z5B/LC2=6O0((;>.70!>VQE6!%PK01Y<9#4 XUGF),J%*
M_%N3H='D5M!)U=*26&O#KQFNZ(>6/=H\3VII-:0_B0IA/+IJ.(5-?2 ]2Y5E
M/LB2FOV<A%4/Z#@P(!_BRF<!?YKE5E)XT)BP-V?)Y'-!C"5J3Z.N:< Z+D^Z
MWOMC9D9-,3L];R#XC;W3X@MENY)5)^1[07J-TS7/W+C^"$%MX$?LWUQ2!;3'
M=.15ON]%9QHRAU<II+,\>X!V$DQY1AA$M$N_/[$N,PIE*YR#/L4&%ECKU(W_
MJ*,1?NR<,_>:H(!G A5@1H(2%536@A#JQ1KMXRC66PX\8"@FBEU7%9J,<:%\
M'I<S?3_)J >G-_5:P] F;'W#?NIJ8I2;%@]S A :PO]7P%9?U7C,0A[32A[1
M,A!/9@;WKNG"Q,<?[6;BO"9X0:9,7^?N!DRK8>!MDY\JV\-ZYBRR+.%%0<9^
M9;*<]3?:9_:8X^U3B:+P0TQE.H5H>?)B:W>-[3F*F%>13H-V26V)3X2^W_*[
MPTGP$V#(7&!^RTL7Q4>,[_-:;XND,/'(6M(-8<'<VZ+@.7K"P:K'ILOY\=6G
MZ175>DI[9L[/=V_6I7HO)S;;B9ZXCS4Q;:;QUV'8$[-F#3:WBR9FNKFZ*Z=F
M5;X#Y3LF'BP0W$D56<M-8*%]J[66L@X+%A,J.H>OV 8UF\=G&,3%BQOE'PBK
MOS!VB6FJWL9[I=]6EP.>L*\N_LO%E'D0^FT)>:?W A/E1N1CU^'C.WOJ;WVU
MDR3?>UL\=-Q20_A P+2P9M&*,],AJ*>7S(%%6A]0JOI)C]KFD_')RC,+^SC'
MT8<'N.A+TE:!N+*0^\;IB^R0W\\R0S#]<.)GF9__@7_7.43XB/!:'EX\OJ9>
MFRM V0\$;)<.</X?I?#\EZ/!]J0::\?7UN]G@$*DJ$K#<\NV$J)+=*R:YWZ:
MQIA: QY-(+QY@)5T91D:PJ9U[B\<]3P^;JB1:5H_;3K$2(><)Y[\ODS<PY$B
M3+##K2(6$!(318OZZB]*XM BIXY;V6\\"1RR=Q?L^KNUS^?H*=2 2MJY1[#
M:-QDY.^Q[M*'K>,ZMGNV=0?7@U87*?DO\RV/]R?9C8:AHA<R6$WUT>-[QGQJ
M@;N^=K,[W21*R4IQ]F[,)#& SJV7Q<B3/8Q.Z-(5(#1);NUKD9ZMF^.&0\LI
MG>N0D7PQ+^]=C3^*1"3P1PX*".BJG(/*7=J/"9SG.;:,#8(<K7P)X.[LG%[?
M>C;([WUI IQ\%58%8]J*YVHH3\#WM2@1#+QL-N-@5:,06/?34M3C8'Y8T[7.
MLLL73L?WFRDB_3W&I!YS?ZS=6PITHV+6@+(FYKZYEJV[KL^6/CKDR\&J(BL
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MT_\55"%7@@KW.E6BDTPR^]5NX=\PR.Q"0,)XFPRD?"*.?:'4]_8-WJ]M-?[
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M<]@5H$XO[/K_?RO1Z'M@OPX/ZG/:X;*I],A-36JJ/IHYU4R;M6UN>F@]3X7
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MWD$1^C%[52@';?P;TS.TM9A@18]A+(H_=?O, S3!JJ1*'["EA!J=VX560MF
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M3MTXT'!IPIL!0=/1U-[RE/*D?!%.&E9@"8H6!?E@9,X9&8JS6)\:9&LFENY
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MC6C0G+OW5=J#3:DW<BXO$3R*QZD%&/R^4U)M]@'WP*OG.Q =[%K*OJ0J7#0
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M?OE5?U  %GHUS%2NKU[$+>^H)7ZWZ^,4I]X/I=0\I A:@>Z,+5I!JPJ7P,;
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M@/)&^,G9*K(A0S4VX']E,U,=1A"$*KJ;FQ!;71YOEU3=]N(MU\0RO8Z%#4G
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M_[!KD#/B2N:>53WB7KOKJN>&O9&LV3E5.2M<IM1IR[+U&!HABVO7-1XO,1&
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MOI2Y <Y.,U5IW/&EMXM30>=]%R6NB<57SR(W: 5.T^2ISWU]FJ$4E".8J&C
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M$EV*\T:7CK@]V"M5Z]#A*;@J?H:ROXJ^E/M'A;S_DCXA/?L9%-T.UD8_2DG
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MUBB++31:7,",'EM?U:@9-R /65GY;69B1U_UJD^Z'YPBA"]D%E+53 Q;( $
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M6B87#BMSBB?<#4Z[*G&I1J:*[H7U[9I=:3\_<OL# %^L-5;BBQ8=O#,B)7'
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MNC/S,XDI_ONI3?L,A;Y \1<C2/PHX4P.8P:<'SBNBFMLFJT>R)15W=HA]W_
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MW*HR[\G\F&%*NHOH0YRGY%Z_>'D $V;X:\^&:T^1A1^3ROFU>OAZT7!BU.1
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M:'-4GI?.VF$K@F\N\"]:2Z4LY1?Y>TA/#V.>'C>0"NE1Z*CM<;?W//;XZDV
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M;JM83;T@NG5I"RW&T%^?  SLIC#>D:Q#]^X^1(Z6V(*8)\D#,\0 <6I76]V
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M.I)-YK=C#1X[4W7\*<.4]G="S;ESQ,Z9Q]AK]CE4ILS<L8U9O $-$';D6.
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M%*O+U,-3W[OE6?7X?A]4-;Q?(7+3U-"B^.Q;0/\+1CH(^.=S<NGGSR!;=:I
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MV\>+"_UY4U!)2IW+$F5TP"4KL#8ZRP_W^TC<7C#O""%&.111,MOI2 AQ0B>
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MN%A^]W+64!T1<#05<Q>+K"6/$#E&?VBPC5 S?@;;7?OTK"T+\ G6FWJ.(GD
M(( YM PC)GA?OUY<5U?C=^ED!>M*D4I<\\/4SL=)3J\*9+I"=;\/<?D"<DZQ
M-"!" "/+O9"(>]3KX7O*8X])^-?&@PC5&)6?OTH>WN,JDIJ),_3&KK(0*YK
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M,/PT/WH%<#\8#Z;)X8I]P ^8H(C$X?M4_W7E;B;()*-CM!Q2MU/[76OQ X\
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M>AIY^+J]ZX5#C2LK+R7&VOD)A'LZ()F@\X*V9[)/9NV4&$A&M9?Z706$F86
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M..W&%\IM CCTMW$ TI7@C.8S**!$R-=T>QFF;9PR6[OQ2-L OO%+S\$V_GC
M*]V+JB]Y5@Q(PH!A*\8U84,O2=3@GY/@38K'<B(\..E7?I;%8 6@7OS:9WN/
M7"[A]1C/B.J"/ 7%[P1G4/W_T"N-*#8D(.W<AAE(:]+E8< O_)7<A#>\,ZP?
MA]H]1*]RR_86TF:"T(A:@9+UQ81UO6# -M:@*=:P4OLZ0D;.DC\7)<LNTY&T
M2-[A5VB+1>2T.WK$'RDH0;U]_O;GNV<)JEML BPDTZ253JJ!#AYV""F)B&2
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M42]!<5N>]EN+S-AE:/_.3&E.XI[KD5JMB^4U$C5C/72!->\779ZHR!!&T8P
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MA:E_4%H!H[\%6T%1W#CQZ^*SR:09Q4TMQWCRT4W(W/,V>B.*ZF<:3^8$KGR
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MB_IN0YP"Z3Y <?)C51]DII*BZ=O<+4]\VRL5N3DQ0,%/Z6: L)>CR^H9H N
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M8XN@ >""W$E.ZGX %4;VZ5$.D?G0LY*38"K+SL @VN_7U&6$M+="STV)4<
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MW6J/IFB0:P-)JNM+\*RZ3X$SVD(>G@O"&I6V6M S,@2W2M $$V:^P)#.TQH
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MDAF!<TC!1;V5(M8T@'%%D9QN1R][9K4L*1$F.&6$IS5B[\K^2)^:.3I 5F:
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MW\8&[L30\:.AQ%P7X@\16)-S&+ !,8/N0O0J7PTL7;!U"LXYI?QB-4EMQI+
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M7>\V%9>7N/G$">J)FAU;Y(W'<K.!R-P$.,9C"<G#3@:"^?,#ZRVX)RRI0-2
M/*2PLB,Q6/G%:OP_SL__W0+"/\O._^CU\WX76+Z*F,\484]#G+1ZR(DK,?VM
M6V)I423?4T/11Z[*=V12$N^3]+W-@G3XO5,^+_3*VO3>Y=&W\7TROX1(N25\
MEY"@E//UN0.F[^V>V0D/"YE+J/0<TS,386:JH6\F2Q HH[-: X1XU+!4JZ"-
M:@,;X&ACPHWY.\(Z)-X4!W$IT$U]]+K'O*W9P$N$=N'1@>GO\W2]'QZKW.:P
M%=<  Q28,L5J+(X9%$4258DO. %>;5YI6;2'503:&*Q42 2_29FP@4\7X3C
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M*I,(.L?:(Y.^M[4>@4K$%4SY./:XO$;YT%HV\+#'JG@!R 1"_D@*#P"_6[3
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M"2C*=)V"U)"Q(=OO29.;>M(IJ8+T/MNQ1IGNM/>1TLE]^H^D,5X6^V;6N:J
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M$J[W,<V7; R^)/>=;=D5A>RY^Z*K+S?R4-Z>VS;*A?XP-D8O5#R8'255!NA
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M]D:KRN+2?J)-^*''^#9K@Z"F9)W3=K'D?HIS/\YI^KG68M/Z,X8L62Z,ID]
M'OXP5)$ZV;T=ERW@(*JT&$68N)=RE/?I846WE_(*A6\<"];*L4%,T(6:LIY2
MEZ+H6O[9P/71"N*UT+QE_DG-!E@4GBO/LC;I#=+9ZC7;KLRK]/)-Y_EV_.?5
M/4IKT-*=EI7I,%WA_BW$0>O"8K)*LQD3Y(1T-UJI?J3K'JES+.P:12X.U/;-
M@.^=LJ/("GJ)/GEI\2VRL96;(&'6:&'R=GFL?JB(@?=4&]D7/T*+F7HP%U\.
M31$5G8M:5B2BQ5 Z W6@B>#N8 B,WRV@O 0]ZY1F-[A0_:(NVTNI]/G]4>CR
M)O[C!=#L.?6Y?M1=$J(5%@GG45>)KL8VF:1#C(8+2VW!> 9_R<!-_-C49+E_
M7Z?;'O^)N1<V\TLQ]N*M7-^*A'V7%CW"NH)?]<)3&!K]NJ)U&!& .Y-F6PY\
MHN0<CM7&C7/M0RPHSYZNMH<D53Q>W8Q+^N61'93O^O@^[5W=AMD:.[1FP4.\
M>.W-D& .53I]YV=^2WKGK1OZW@)_\TS_;]>V)_7^O9#97U;DV\E3;[@\FD(B
MC >E;G;:GS>4A88YL"6NO63!X%[!-5\S\[XUWZ\:1#Q%L+*T4N](?,4E\.Z*
M)>>C=M5HT?!?4Y(^@4S0%4 A:ALK$=RC]3/45WKLI$?^4M/\7M[%MUN.#)7<
M[2W!1DAXL,(^#&#P;RIS1M?.6%ZE?2CGXK]TC3\4]ZZGUY;C_TEH[DYG%>9S
M 0WSTQFJ[_//_ZX@X)[J*I,%.SY2;E4_.+?[<4"@29BQ-]@>.'BGU^8+(:SH
MYIWB4$0ORW^4Q$5J9)&%%.?-YEQ)[5*X!U]>WM@^'TGC#K*]T]K(!(%&4-K?
MF\/BSW0L!C5WQJ@5Q=75/Y:HJU+O'TZ_>6>C&@KK(#VJ)R2=H\$L6&WM$$!@
MM24'AO%]^DO/4YRK>Q [C*\]WS5@/=Q)4PL2@8+F?$VGI"@:'<)(R[V<,*VU
M]\X2;+%T1PTN,D LL D$N/!0835LI.Y1,BQ.]P2 -7RF_\%TEGY/7?V+XR-R
M.^3GRY^QKSO89<S?5%XG6 6__1?3G_^UZ= _P:]<<RJ+&68(#OG UI3T#!A]
M7U([J89&V+;:LDTIA\V[B1P.>36/R@^+L,4I6D>!R$S0**L+V9-V5C>]B 5Z
ML&':#2(3Q -DN/O[PGF0N%N:.\-<^YS.2BD+&HP,8CD\U['[(VYQK;(\KB2:
MG$< TY0Q!\=^8$FI0&,]UOFKR?0:9+\;;G0XP2/N\D:&:>PKS.O*PG,.>AD*
MTPWH9[J2 !<)U\C82\KWX_UA?5))@/VG_<D^U1HCZ;B)O3U2-2_>GCAY*3?G
MX'GK?_DXDJV'H8XZQ@2%]1)L;/D9_' 1)/_JSJ= >M9,@255:\.TN"W#K+VX
MA'=34[#U9(1WLPV@0@IOG-X3+ R@Z^T$XX@Z7/IAF4\FNQQ3#?Q<I>/'GUC-
M^3T2V+\_PMQ\CZ'[G\?;(ZQ +1L3Q*57GXI]#B5(D3F>U4W.HYMF\</3]P<\
M*,8)P<L>!16/NV,;.DH.;_?0]@!LA/71X8:*.@B)_K,XKR[KTX2[5D81D:O?
M+RC'KLOPM7;?O8OW<Z(W<A>=KMTNT<SN_<_M=_G/D9T[.(R:T&!IK]=>SZJ*
M]C&.DU];AW&+*[;Z OWE'WSE<S\_3#&K3WV;\-6R:1I,&)0.3).S<4^>CZ^;
MQ<+M[\CLA/JF:1[+EWD!)CY#<&P4OFI7G<^[Y]87:'MDJXPM:&PTL3&@:BG[
MKU*ZEZ9$ATZS^F?>G[1O<ZO/II]C@A1/B[WUW"Z?^JV1R_MGC5Q!-J2E]2)#
M^J]2N-=^-/=C-TH$672I8(B44=%#,RH#T_:C23GB>*UU^AY?UI=$FD)A3+;Q
MQPU<)3[A74(%'"_V;XJV"J+:$D78W9!E., I!YB9BE2;0Y/H+6P[N6NV;$C5
MIB-,4%/T;QG;<U#\.\1^9#CCB1:6L:?]M^I4]6D?-[0B-2[ N$C&!S:#Y45_
M9[OUIY\"J<]A;,!OI5F6+P*]_RW)^B'&5@S7P9A]$Q!6,VS V$]6H7.-%3'V
M_)8"'9"K#Y9=9,A/VOQ%#]:M*CXF9Y!AN7.D<\!T)];'8P;R>_E?U5^T9B]/
M@VDW6"1=8*KHKT*I RG>HM?S?F.ANLR9:GG6$/G(""OX-T%8W+\"SY3/>?\>
M>/ZC\&IO5TWTB 7#<$<5FUD-_D=9TABD<-/SF7IMG=S7@WJOZIJ59][/'/'X
M=@:L.^"M3%A51$M17X?_G]42_N\#^O_PKVO_]M=]"[:-?[G>CXV'4E2E3[7T
M=4KMOWPQH6D+%##L\8XF0(ZK.I/[8]/* '9F.GA.I0[<A0:Y3S%$:#S]*/;>
MZ<G*@;(79U]A)O&!JY*X-<G@I#>Y+2>V2/[7Y 1ED)6M-?3SJ6@.%/L4&PEE
ML0-"N]AJCBFC1^^#. 'PL/I$K[Y_=]7YDNV#:O;A'\6NC[(&[)61?\V5_V8M
MM*7^/P@%_3DE^'_F]0_*[</Z_[#O[F_<1%/P69:+3\&@7-\A63V!<1*]EW:Y
MMV"N./JF1N;/L9^](ZHV$Y>N3-4\O[B/QW\QBK*L0#AW<>HH:MAK!CV6RA J
M0T1.L?5;7"R=&@,\765BT/[F\V.PX:@Y&@<K^M_NKSTSS:=6@&CVJY,G[6!\
MQM%KK@CV<<J@?=*<9N[LO-EKSNL<'88!U+U1TRN"?*4/OO()QF_*)I)J**])
M0<^T#%+(]O@ 1IK;4T7W[L#&#:Y&$9$;BH8G+.^>3J[OL1X#G*EG@51HU&,<
M'T,!Z(.((TNNE27T&);VK^Y/3L^6#N4K]?KIY"KB:%+\C5.DZ*W+)]^%_E%X
M^W[,*WMZ:K T398L]-6+9$\4>OT.L+>N2S3#XAG2?;'S7PNZPL]\K8U8;LOW
M'WFD:EYK2#U+NP\,NTN&D&V(GG&HPQM9RV)RS[;"RQ)OZM_%RSLG&"B*'G6\
M]4AQ.4">?C]P*9ABR2650/X]Q7T890QX?T)";/K[T&"X=5!LP3!&Z<(>43#I
M"T_VE3E!]MI$BC<]91OS7%>VF@S'T*RG>;1M$$[5LK$YW4(]GUV]Z$ULC  <
MNR'C.$==<$1F2:Q5BS+G#WSK2YH;H.1%MFR&'-J.#KIVGFV&Y;25BZ7/7(:O
MR<]K">R#O*35+Z;.E&%&<:T,-O)BI+8)R;UU2%?T"UEIW,VZZ+GOVJFID;)9
M^Z[*L*3!3.>6VX>>NB]I*619>UG8[,>D>VBK4&\8^K+=0:X0)CXK?DI0_UYX
MT;'G*$0S-&:XE_?GQG"PYNS">+_NP+*"G*9.GUW$WJ@3^2W_.<:J+]B \@(:
MWM.X /=<H,:"W:'L>C(E=\3]]7@$D:,<9C:R-] <S_=)YD!>^>5%,2_OQ"^&
MCKEN0UH2,<-CL?-U6,<#DS+= WE'7'2L7CV!BA'?T]_I"EV:EP929H )7XOA
M@HNL(#0)F"9'SU;$!)\#XFQMFK7R4[@JTP(/O"HHR*7<GOW&,3"7,3>,'1[J
M:],9'\RH,VPS)W)TNUWO[Z)_8X*>1P$L/Z!_O@$'0$N9H-F7Z$9]E#P3E)D^
M,TV#C*')';33F>6,^M^JS*(IOQHL&4%9.^<98HH$&%U@G9WE(AG]3%"<Y0T"
M3@P(;'F\#@W?7E.U#=/=2O68\SN(NQGC!0]1SR.@A=SM.(?6MF/9;M7T;IMX
MORI<S7:9@]^('Y"<(1FR9Z*@XH%)ZIOZ>A%RZ.",C*MT:CY$&$EMU 65/EUI
M8ASKH^EXG-_U,LVU,WSP14.US"0^,>ZA8CT3=!\V5@X;$\</5\,C#IU&#AN8
MNV-E+LG,<82EW_(Y2BL$U<M<:9G)FD99S<"XD1M#7 A^9* Q6; 6O*!_.,]1
ML,-@I&6>3QXT&Q.UZ_;23C(OV\ICY%>U;_+QJ+R+Z]/;Y^" J\JSZ2VSWWHP
MH34(AC+F'P^PG.AS'X#%3RZW-DP#1TO_M.2N40MU@M6,]C/K-!YK-+D:1X&O
M!^]#EZ']R*QRSQ, %H[I:^*AP/EREA?\\<^'EF& ,RP,LG45)<'BW5PPAJ8A
M3?4C'O-+5O<P$]2P_^/OM8#T%.KTDS^,_F'T#Z/_8&&%JP5="L/7?)54"R4:
MALFBRRZ,VP\5M-<G&6E#+RB^^^<QZQLZ"QO=(7@48L0;2>/X4[BQM[:]/RQR
M'SI>-^3=.IY"5=G!L4)@-\8ZT0/=:(2290WO- *$)C&.)OO\XP%?N7\^7X9H
M/\&0S@_A0,\\98%F+.OER-B9@:S!)VE76 '#^SI^=*\I"<,XO(8#JJ'_\#WQ
M'XOW,D&'EDA9C$A,*(YTT?7/JX__,/B'P3\,_F'P#X-_&/S#X!\&_UL,XA%C
M<@0X34[>BPGBDL)G&%*\#1>8( ^;M<F%3^/I=*^Q:L@_\K7;2E1=FA(3]&R)
M]4:P01JV,;I=M8M6%6UK:@?%B^=GSZX;_K<SJEY&)WV]'CJ&JP'BF: _+/YA
M\0^+_Y=9] T#K_&3"E >O@^#I9'7+PSQODVDNDV[WI-*4,45'J"M_*O(+ R\
M2B65 E/+;*S 3';_Y]@F](A%C9[H$7Z,2B&(EO,WZ&6*_>^9KX&.HK\"'%3+
M'30?] ^+?UC\P^+_;18_E_:P:,F=8.5A642DI,!MA^<CTN'6%0>;.-HXT&?;
M_ATD^1#<@^-R(#^NXD)ID*+UCF@T2VD)?C*7UKTB"1>M_P-*_K#XA\7_WUG\
M7 K_#26ZTN1#160I?*3 EPOVCX<*ZE&7]S1,?^/V@9*^80]"?[P"SC-!^X2P
M-$]6@=$=PH,Z:;( C$5)5 1N7I R^%YPY6H39_T&T+[PMY/%#_Y[6-4?L\5_
M&/S#X/^%!H< ;R*W2C.;S4!ID,&P>?]/%>TVS_P%J_OQJ#+QI)<O#"Z*2CXO
M01/2=070O:=)?HP#2E!@TI5V_KM/SR$FR&-IS"#=-=N5LE-W1Z/\^LG3!G76
MZ;E1(#;I-WLFALQU8G%^@;LC0]ARW+H20C$]3.#&G<4+EO5,$,F"VXT(!M/.
M]@D9"%586@[?-!RI-3KXCK9O?3>52L3I,$$S^4S0IC$3]%.1"2KW79E7 ,;\
M-FFO9Q=^CB@D;]!Z=]?U!2R7Y!9"_I+)FJ,/3;I&=ULQH>?23KM[4H\/%!1Y
M*'/L9 GU7>6@[QR$X'%P=W(/90\3E%A!DJ/CF*"E_<W!+98-SIWT7"@!GJ;+
M!!U#KW[Y:SZRS?"^_WBMGZ7\##Q:\@#PCK(.Z*$<"4R0$#W<>8P)^EQV185%
MU1[WJ'8\'J^QGSW[;:A5[X*$[?_.D,W"XA='T-L[""8HR^)WDI6_7T0*\KGU
M+]*'_4^^!/]6'\ ]\^^S5?U. F[)10XD@FE')455;=8\KOUX59!4=="K,WYB
MSZ]X<Y&J=GW><[E>CY+;G)O@,0$JC?4>"TI!N;Q)7YYM<-Q?ZS5<6;,#$\%C
M?LW#_?QW3V[E>&_D/XRTD9S? ,_L]R^C#PP/GYFX8[P)4Q3VES[G9#^0:.4]
M_/TFWNSI3M+H9E)QDA-]V,%/-;@7RS/\,>(T$^1IP031/'.-J$8H [N,XTQ0
MNSB"H7GGT*"QV^HM>?1Q:CR>+(A+IZ^NS]$_U,DH>Q%AM/CRWRS: C862G3;
M(JLPKE@S0>3<S=?5J=ER>M8G=2!S\$=GD%'3WQB4 &ULF6'S_F_:,";H)17.
M4#=WH.?5*:C !)B@^=_Z4+&6KTVG<KJ'RFX'0-OJYAS(ZDP0J[:M79P[(FKE
M#;((LG/XMR\WOPD;VR&.;9&=&68>4&#0W[8U($MSJ\!"+'Q#I4JDUD**$0S]
MFE&DLA9)]C>45&ZE-[)\+M!MEDCI IJ^:M]CU=\)9:C:F6A.YN_FZ8>Q @/=
MX8F8J=\9>: R.R7#"_32NC-%,)%9!N$QG.:4:TKU0+G>F6U!,D&5MBE,D&C1
MD<I<88D5\[!&)JBG;$=*.*:)]4=[T"K%'^H)B8U^@V1=C[P%J^PG(ZH/ZB&K
M+!.T:U3,.GM!XJ9?_E+-4!YG.!.$]:+&)[;<1R^NUE$"4;B*\%;U;]I>&.JS
M$58S1GV46ULG3WIC)-#SQUD5Q5B&L]K'=*KTMK8FC8J9B,G0%/QSWJW)]W1<
ML([\;"MZU_ SJPZ!:8 U"C#H+5WTO.2?2O;T!RW'%2TC$;O;D"K1H$#!?\MV
MI1O&8DNLYMEA@O06&3=6H4 SA,0:,9),T \4$]2APSI-D:*,G(_;K%I_829"
M5T:*=JDJ-$XFZ/66"DV3"6K%_8) -S"L9FU1^,*89(*.#%\/[)V-L=6^+Y1(
ME6U-VO?B])S])_49GQO_)S9._-/YH+;U(6:-Z)X<>IONU_^="0Q[B<6DT+1
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M*P^[O972LTO+21%UO0KC;9&*JFL)@E$7FB/N$L+W67[#E4":>O8%?X,>@;K
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M@WX:-'/LYX;:FO*@4@%AHGG<P65OH=7K. Z9R&5WZRC0/)1@!D@Q^'& *8[
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M=+DB+;1GM092CAG>G2&LEW?1 9;DGOH=M'O#".,X/;$P; *&6QQ+<GCOE '
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M:MO_MZ;#HE>>A;?[7 BLFU48;:=YF_H>U!8T/-7!_W/Z^96]?U?+\>_<]^^
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M4VUIA&B/@,^11EH/YSJE@JN/%G&T6GJKL9G;W'BH-!R=\O*HWJU#!TH6JF/
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M;I^C)G5/SS[@O7M$"6T^N7'81II;#CH'?0XMAS:OGV!"U^NX-<//XU=WHN5
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M0?#0- W*&0;(-QE _PR).E>2IO'FWQY$]V^H0_L/Y4+XCW[^3C#E[QB\DJM
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M$.V84MY(9D,[7"3R<*/, HX8C0/2+#_75C% MZ+6OS'GJ)RB-+RK-@*3(TQ
MDJP]-X@X:>]?-.Y-YS[T(>17.<9>W<-("-/_(P7TM^^J-\0VYBNG\Z0$NP:S
MM:@L'[!EB=M?M64D'OLLD>/3S.S!DVIF9"@1O-I*D0!8[A)1+Q#' >B]?ICO
M%24+\:%M?3TGSOI[-^[S;?.U37[*Y^O1F\\$%VS=99EG:8*,0F;"H[)I>8WG
MJ>:]JRL:Y^";39;A83XV+(:-%1LVCI7']HUT160V.Q^_W>_9=,OQN]1\'\89
M-R+=+"Q#2Z!S RHSV.>-@P3#O4/MG:?0L8W\4<0@4BQ_OORMZ)KVLXWN&/O0
M.*A;KZ;P^1G(L]J_I'HY'70>L'\7'-\'.[XL@$#ET(K0"A/-J@<W\U^C4UU1
M<H!@[;/+!(P#=G3&X@?2CDU^^E>+NR"*?<FLUJDTURV)G'Q77Y'#9M(FZ+L(
MO^CD[.U"]JY]HJ(ATDO'SAW8/$#G3R9G,4!AT+WT*DP$%/W*M(E86G47 _0R
MCE:/:"=#52E:'10-7(4_QHV&2YOU&-_8@=-H@2QM):/@-LP)Q+D@=J" "+U3
M3<K+)6*;27!+)-OR;JIE]P=7TKOJF&;)I+A"NLG@N-JKI<P<1_M'7+#JA4SV
M*(PS S1:0FC\0$J8 ;=#A80@^&14/2Q;.3ISL=:F):"$S DJ%1L^9]:1<9_G
MJ9'<]Z<:CA.1-2+^#% 4 HP8@8 ;3TT&'0%2\%#V=KL/R[=2T:V^ QX6)]*.
M$_"6ZAJ'=5WU6Y[SY?A?_R#F5>J:O&4:!0+,9N17PDGL>$R;82B8!\%FY4I7
M86KJBD^#'D,V219/L>IW4LQ?5%%F/C<USU6H/(F'=MYW20SIK.L\G?\<:8<6
MHO>!N364J=> S3P&J*FZ@C29V!C-$D:%O+_FZW_ZI*&]FG%PCG_I<3:-(SWW
M4_CS/%X_>X[1=LED[X:.J=*/]LXT6!'ROP:BC@*;A'"4CY6ZR_?B9808*8AS
M"A[ KO&#EM6:PU&F7^D8U,;$ 3 _"&Q"RX0XXB(0O,!WHO>,;M-[#-X>GH"G
MQS2"!Q21W.[[I;N=!@Z_N)GPYCY%7WQRYKM,,>^3MB:5*[J4/969"]Z8AD:<
M;:?H!MVB9=*E%J\B7]3K$<;/;35 FL9LL^0UOKK%1&AWOCRW\::\W!&>(^77
M<>OLV5,KQ_ZQ@@&;#!!J#/5J"Q.*D$G#OXJC5<_,E;DH!L(JOL+*_(_$&-9Z
MS8+%+J;9$^FF6$+)WKU?)&!".1[$!\"(,\T9_/6 US0#Q 5=K+KWU:]H*0-<
MG4&@!SE93.9Q7IZ:_>/LDY,GHS?>'YB'HG!E\BU"X"\,$+B1CWJ.Z-BPWEPB
MI)4+)&N75]26EX;K#XEB*JV6%?4<3G3*7)#]\M#HW(N'YX8ET3\^_KX],[:)
MAT72F7YU(M/DG6_3^YE??@3/2(*0,4WD7"/6#C;OWX\@)3^=7-XH-I]_YD)[
M3><!T'@D5:X$T*O KF"!FXT2RXBS?0Q0GTCR*@^OL&&"RMIHU=H(3MHN[,K^
MQF=9SR#J02P4<) U,7REA*AJ1F2:.U6=U(]7&QN<185OGY==>^1[KL1S3F%,
M7^2BB>N#$8XA3=[ \Q?CQ:,72E[4#K>O1^ X5BK7A>%00T![VD:Y@W"8F-M8
MZE& 6QKNLM^83_5YEF4EI9AF)/G*\.(E2F\(*O-<)GN$!AM@2'[#1!RA10:(
M1>TB<;B) >*HB+Y2G*Q#FJ>*:=VI*H\BS)GI#L@X&"M4P$1O+7NV\(W>XT_7
M%S;^@BS]U8H]@NA@@ Y4(MEIZ&:<D,:I[B);<P!I%#\UUVX415ZS5\\I$^4V
M36)[+N2PSZ\L@5_$''/]?29[+!)_ ,!33)DZ*[\CZ7]E[F>'$4)P%N-*DE)C
MM$>AI3OOV%0)Z^=G*02^J"/#JLDNDH'[ZFL"D;?^/>.K :(QO1I'3"1]'Q.\
M5.F31.P($L_<A5ZTTSD-MR@6&E_)ZRHKZ"?&<^L3F*5?'MCNJLI'=(&@AX ^
M:9R@DX_'/9\" ^E%\-"688&J4))SRUAW>GVM(N_33RU)W1R;\FR5^>LBYP7?
MP0=#1,+V-R[M62SMQ9ZDT\B5T4SF;")2:.@B^--?=RM="351[H$+4QNN,Y^?
MQT7[WRX''2PX_:S $?15<G696-W"  GLU:D\#:A\K74FMT<JR7^BQ7>N<ER;
M\_<C;V"PTE+'Q3S][=X^>*)9LC>/: 8(;PJ@Z8++=!X(V9EZ#TTL9#X2IO=3
M;D"9CBJM8'Y'PW1=@6;67><Y-8KE"N('K C(H_0A< 4TIM)&8:51D.1,%46/
M5&-<(NF#9"N6J)F?IG)I-L]V!KW?QKQR7_C+5;+QX;W%H$C_3K]"A(7Z8%=1
MG&Y0.XIX\IA(:-?&^NHL,L/T/M_-B8WFRU]^/K<VS25UDLN'9?L-?S#]? ]P
M4VUBUX^6U.$(-6]GI+U3GC:GGB(/1=SW:%W$^.,E;E)I8^7>#?]!C%VZD>&H
M89/M\5ZJ!2V99-\\-J!Q!<IM?:A.GP$Z5;PCEKHZ);39@I7.^K;@<.1U$N>C
M<S269N0I!'-U<JD93"]0':=CP=/#X17^\3,MU3RU@\7Y?H3]9X(_C>F(ILAF
M*DBE:&'22@=TSTFU-F8RU]]5C!,#%($6J#] *!ECIY]D?Q& ;#5DFZ1:D$ZL
MR[=\6OB5Q*LO9NN<1GYY7N9.[.%N]*4*;Q@^OLX#2=8@%8=.X\*B7<G(4T#9
M^HPCJ@7'_SW_6]*0LG97V/I*M *+BXBPY7OQ7(252T_K;O\7"&O012*&S@D!
M=!1_&W!E ?KD$GJ1LY,<38EM],'5.XW7/:06O.2;/K:TP$2QL>7I\-@@7Z]I
M5"24U5<U$!8%/N%45]];T:W'4>CK4FQ_<ZU(7#8D5LSKI>Y$IN>#6SR<K>YX
MN4H2A:#2$B@;V)[!VT_G@/,:E-4\KS\/*[1R^[5;N<E'_3R7?N9<4D>LQ$#D
M3$+7[<:M!]E[,SW-/N:'A[:5O!KSK)P.AI&? $A"0\"R4Z(]Z:62BX=(9:6*
ML(/?4;>5X1\[-^=]]!6CYXX>L<CVB ]@@%K8#U#U "LBZDO&0>)Z,Y*5_L/V
M:'\0Q!%/,VY.K?BTZ'=IPC+GH?3J+UG9NB]!&0_.SXEE6$G73);_9AERT!$_
MPFU<.7A52#S\V1;R"%!.0.3G8G.IRKWR[UQ\T@+5-?5#?38B]*^JE3VZ7OK^
M[DD)_''H+40O[@A"; $MH*9"FI_>>DH7)3FEY,F'^98<<C/6@ITHSU'Z_D>$
M''C_T3Y=W.>T@R+;([V&VX>X]FV8-8/#(+P:RHA>2\DV<,Q5<4RSC<H7XJ0%
MH/^%S$O>C<'*#M9$K:TMK5W0DCX_]K[NSCVX0<PPMP8+]1 )QR1>TZE7DYO2
MH=<IDJ@\(C;"9ZL/,7Q@+C!%WO+@9I(6;Y<$*AT0_"S* GZP=_&>H@Y8W2="
MOLB'90@.K2):BUSH_/V*E&7818<-YZBARS\-OMVJXK_9$7_BLIA9YC],YO^J
MX!W3._A3[ ;3WPC*IVB[8AU) G-/P;(_.6[G+]1!4LT&$V?18 2XD[#.EO?.
MGB/9J-_O<JR.I3EJZMZ2SCYPQ.G4Y::!^TL%VY=+WTS>,I =RO\V_/OFY",;
MG\+ XNVM7@U3'>U)!QL?I=\YKMA\6F;C4'^Y#=F #?A6NVZU]^!W^BO;O=(T
MP[?ON/+]+C13Q?P7]4F?&W-Q<7]Q_XK<&\/*/#6V?6[,QK%QW3-U^I-ZY=.8
M$]@9=CZ7 .X*#]FV_.!#;UVRQ2KBI=CGS0?)\]13,/+3>I)DK!G!L]2-Y))Z
MT:%?K?6,C0VWE$VPZ05#R)0H)?]T3>&-QP..1C80A6J6\"2I>E?=8GJZ87_
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M/G^EES;H [K^\913^KE5+PU0+(+D'!7LDF\[NZ$<W%7<A#P4AU4EI9C,,SQ
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MQ1GT5/M?BRA/5>'E4#:8\K(^\2@JTA$]KINKBHM(36ZL9XTK-W@GQU7%XVO
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MOL<%)PPUI\D&QUXHC#5\D^"QY3F)ZFYH$/IV+5'8GXWQL/54+&#O*&"I*HK
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M]71^?'1;1;D,C^4B[-"*&.]MPV1X;US2SVK%R5XXOSEM^^;D@\TT)B?I)0V
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MML/;J53Q<Q.CQ24>CJ2RVN8E^=\J]W8STVFV1DB0Z#3/D2)A8E4=O,O)(<>
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ML_N"X$DL^T$QH@WZXH8=Z[@TH3%YN;,Y:\W<\^)GRQ6P1%;[&,O7B-TM(2Y
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M(N<+W(2"2QF4V W:PQ_<IA\YUX<A055E20=4QV, -ZSAH'-A7_VR;X90\S$
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M[(6!4OE3BE?VZ_L495_[ -'62 QUMRV_>@XJB39BCCZM#G.3'%\DUD YZCD
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MH,.F;ME?-MZ*>Z_?3!A+1?C0/;UO#8F7K!BV/5#6EOPBT9WM<,W3<K@F8AN
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MQT,^_>L5H6,,/&]?"F"BUP<X_&>3WR'V=#F&I#F'\<+@,(;=:_ 0'O[S)![
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M5P87:T=.[3:LE=>**JV=-LXF8C7;FG[9U^\I(7C$>]BL'_7<;RG;Z_\O'UT
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MMR#S.A+P%LUQ&]_Z;R2:-8ZN56V[,0"G@TJ/MT^_T/TBU"VJ<J 5"$!%8*I
M,=3;%,L)>@^8[:>-O+I)):&2'-_=<K*IG&(RXL9=+-!<PGO$PC72[OF1Q-.O
M8M8\.QZRUP_9*U$T8$-9QXB(+B2(_@DBT)5*/8G@47"['TC39CW04IUO=U6J
MINE:VNON.9"".7=?&8M9.&?+P,6]_"8707OIX^"-@ ;FH(^:A-,_VP8]!=7P
M4+/*4 S@7@V" 51:@?X"_.\DXH843WAOJ5\.?1JUU3"+TI)=Q4_UXS#AH'8T
MN'(@[(Z;F<UH?JW-UYJ=EH]'[B?SL4KE/;5@8;_H&1 ,/:$X#B?EI$NE:0N>
M.?@V>+<K(1-T\\%'[6Z4+O9]$N$HA'(CZ=S"Y#=G.^O3NXCO T/%8BD$P3#-
M:?W(O)#=L1-YUMJSN3+GDVAOA#:[C/2KINV:2N5S,S:B?B+&W>E&J>W,8<6,
M_7/5^>$=!^A?45L&#&"CUH$!]!0/,F-%XPDS'*;#/3Z A^FTYL#ESBD0%XKA
M "FO)$-]\K,PM;SOD^>GG." 7:N"M >W?6XT5#E8'ZC3E\RM'MI!Y/G%SJN'
MU^%YO&+41#3:O^02ZB*ZE3I-D_)D3---HLS<:B;UI9YNZ4WPF^C ;L 3G^GP
MWV3YGP+1A[=IH;ZY,X Z.'T:_;EZ*Y7*-T5_P)Q4PAG VF<@2.J?PYG"'D*?
MA9>[=Z F!UIY77934(5^7EWT0R&!&$X_U-6DO%G$R4\5F;PMTJ>4Z]D7^RHR
ME_I1<V_ U>[=,RHVA*75NY1;9.UA-"2Q]6G#0+"F1>XA-]4UJ7LW),KV]4>,
ML'P +HB<KK-,G&I1@1XEC[R'ZC:0RPD.\_9I#] M//2.,:ALV?=2K9KL\E[-
M#Y\2]<ZZN2N+1)H?%MOOE?Q=3Y6B">N=U1B$7L+&QS( D283!Z]Y_ 'JA5H"
M.NRLJYA&:<JSHU%@K<R=+VBK@Q_?#\N>>&17F"/UD=V1<M,OI]-WE@<QY]2.
MUB,6Q)9(5XS<3JIP5BO3;(PUA0:-O[7J>TZO,.-WP"?(+8,K$&T&X FD$2VQ
M&LZI4##7>$!XRBC1L"$-O6;2;O'\XU"R5+K.824VQ\A=JQAG3+G5&C[;K]&>
M6/:, >R5_5#90A3[7O=5$L16\N"XU8E3O-^:?&\YF%[6:^2JSTCQ?;#%A9I@
M=IJ\$:;;>4%0#V4 CUP3B4(K\$DK.OBKIO1C @9&0%30PKWTW-F3).)YSQSK
MMBG^<$R<:QXTX0B?RX!4I7;$1\(K+.O?3_BQSPO&RU%E<>[A5@$QM6H1V\\Z
MU0?]2V[?<.0ZK'\WF&7\4_4@[/,1= J$< LUJ4)YPJN%#M6\H);RF?HT>WA&
MJ(!RO)6=]M9U!BI ,)N'-<_+\_0@JGHZ#44Z Q!A"_Y;\HH=Y]G2GV8X/R6>
MU5T;=HU<R/(033A1[G/U<#WO^O$78'ZPTP%C<_)*+NPK:#]4SR'';\1H,'^P
M6G54SCY0WM7 ]W"T?XJZGE[<'<DX"VF0<L4'B8?L$5#Y,-(VG2N<J$SO.-G7
M/U<:6Y-ME3W=Z^$D>:F96NVI5;P:M0D.!E6^0;8Q %X_U'QX9-/%='QL$[RH
M*W"^U%-6L?)J/_=E$==;)Q2^:1R/<;OY957_P8-S0( C(#!O7? ,[J[O<R'-
M.SZ.OC]LJ,#+E;]%\%6:A-S3H@OUQ^[PV4_I # H]$HUT2H<[AH+PY!B1]V@
M.H7P=D6GC'B>UD>XQ1;CY,JA*ZP_KFV5@M>0(8@MJ14060E"R"$Q2Y0XBF8
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M V C,8 T%!W+#)F\+H+T373X@;\C+ 3(VG,&(%V,9 #CI05,ACC:@[Y+N<,
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MA/_RQ0GZYV:4>J=G*BZN&[<,Z?C[?7*$^OA:%C?"/>U27^WX"A'C GMNK]U
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M4&: OE?R:XLL=3\9-P>?DC B^P3A>/:0W=LG6R+G8R_<@"@O7:7<*Z0/Q_*
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MN&T".0GO,('-6*L+(U=WE@HI7Z"R4+AYXIYXLCLD/MU86X*&V.. A^?876(
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M=4FCQ#+8-;*HK1PJ^(:+<_%2UZE/P+W1,ZKKS"SH^>JVF@+;KG<38IP!:&(
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MKIA4(":$)EIF*7>;&B^$S]S$\^/O?]B-4@"B\!;RH?1KY(ZV-PEFHSDQ=QB
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MX*EZG1ZG]=MOGZ),-%PAL!A(V-9YDQZE*NKY^>9GL;0@0I5AS2[%<M=EF7[
M\1Q"(/1%\ LP )^!.+Y8[RG:^C[D4$JVUU,SQ-VK>&7<IQH]=-@#[A]M6_U!
MBG/;>PSLU:_@ ]4,87#^MNJPKV [Q.1.FX4=ZEAC4]'^%>@[*/EP2O$$LH29
M'9XJ&]%K_ZSTR^O.V/^>IY.[Z9Z0,3EKZN/=^37PM@8#0#RRHRQ/C70OK&.?
MUN7E=XZ)?..]H^)(6OCK "FB)JT&L>+9 /<U^8VYTGB:/NHKW+)AT([@515/
M[N4?_"F?I#=J&]LKJ6R'JCTI\/:NN!NT75,!G5:P4>W,KLOVX<MU/=V9=VM.
M\2&DOOZJD-MT/MQ;#6[6K_KM.6$I*7^F6VY[Y.:PE1<//#8Q,WLDGD<6GP.%
M\I\G)V:OH=@\@AM'TW=B=2NU-5)*H*\UKK-:",CXGGE-8'<;7@/_F*6F@H*8
M;KC/ #QZ)S[2T6O0-)QL\OBVEY\*/W*(9AU-+"_=/-DK[6G77FZ/7^L=1&'E
M+NF_XZ*OQRS"GZ9EO*$(T(> _&B!$8P=*$PW9R)^1N+U5]T;B+HS#Q_P:[JX
MW0TG08+!):@FYV KRRG^\Y<:=J'@=R,_4S_L&39%^?RYO^ [FM\/B7_E7HCE
M/*LN]0@AX3],=MPOHY;,Z5ZJIH2Z8/1R+%_>*E!_P,YS/\FRB,-7NTO?\>?#
MAU'W;P09\0'. $3MTNMCM_W_A\>M]0C2-UHA59K ^\2)0VN[ L@]I9YL"?;2
M'^-L+;/^MLE;X'?6D9642RO94+W4+8S5#3+W!/'\:KDH&*8\],,&=^;,5G(:
M=PJP@3:82 '1.WA];;(Q%U55WPW!U-U!$T[EE(X=U9Z%Y=ZO*5L)U5=YIQNW
MAM\<Z/ >#WX>;)\);-;=,$1D^C5B/!D Y5_0V%N]KMN=4-]?^0-%3GAUN'[>
MA H_1=4"/+Y%TB-"VE"<S-)Z2,O.3-O4[N >M]L/9 =[VB>0!5@NO^+[V7[/
MZO)J=7KTR1$^:\.'SW+#__'D<&A5O+/7_:VQDZ5.\6<S#?%';5[:>ZO^P+.$
M&0@6JJG-X:.CLY-2D;(XW$G7?K/FU27"#,D__[F-5,5(2#R*$_J!9)=T<WA4
M0?*,8.YA6B"QV.+=799X_&)HVW"4DNN,04RD28&3H*&U:)VZY1?'0=63,)DR
M(G]$[IK9^L7PI0L5Y3\7$+YJFV<!JNUEN[KCRQU*\>-R\I4_'@QI2^UW]-\&
MWQ:?\)"\U(>=D*L,R\F^7OGQAF^*I_!42NRF([EN16#WXT\7JE2I%6>/M0F/
ML6-:UD5W,9= _0'7?8N<FSR;59MY,Z,FAQ(HT?PURI.'DN?+=0O@FKV74"$5
MEB K%#9FXNZTFG1DQZ4+$IHNK,\T!<9&M?%]'U151BN[/5\GP83)6Y?9D?LG
M=)?#]YQ#Z2) #H\<HDI(<'IMO(^QXM*QZU:WLGX>^X'CZ*H/;$5<I"+F5/I5
MB]_BG0^L7RDS\XF___S!Z!#!-FQ&EMR,W2VQD ]LP>6.W\\6JM!UF'Z4M:$2
M=U*\O7=&K&@P0N?PZZM;S[T@1NWE6<+]-YV4+#&_UV/QSBT00&XU<31,?:A+
M9N'N.NO*I3=]R^$1S\@4/)K#/%4>O__1^N%5P;AC6BC+B&ZXX*7M!._//3&*
M?YWKHR@X8#+:3V!A23.*%H[:>:+AI'=W6T<G^JHJ\;M6)H8@A#)TKQ\Q3)"Z
M=#II>YBV_J=>DVC2824R?95>)^A21:V;H&](_W'MYLB3^]7/%(@Q+IL/L*9R
M'[M<R@F[">,Y)YM]*\X74V<*=_*'"\PLA@4G=TZ+I#?$WDK_G^TZ_C_?R)WE
M/Z/M9Z/]7R]1.D!XZ,=@K@3PQN<<F%(C,>0#3![O!'E(U$C-!B6ZI_N7&"+L
M-4*0M?F%5$"N4>*# !43$JB&?),8BT=CMR:X\<@PV6ECRA.R.T>P\Y;$R=MG
M)#.1SF!-D_!'ET\V6?]ZI?#V$X<)T;E--WB&9607P0[MZS S3LR#!NPYR:HH
M;>]Q^1V,X02E8VL?K+V_MQ4^G63G]-TO(LQ885[_U^;8:5;!&-_3!RSTTQ?Q
MP-,3\!%(F7"DD[*\]84B3Z+% \^\-KL(Y?Y0WM/;1VK>CU4?2W'B*^(@2SBW
M L^1G4F6_70^J*-^T@ D+$UU@"KLY_IN\>K;S3,Q.BQ>9W\<.*V6WOKS%.#'
M +P'VSE_8 !XY*H(RUA,^"55M&_EABM/0^J8M>O1'\9)W /0P'/9C_:O"1[U
MX<DALLVAL)B@2Z\O85IU><?M;TU/1?A=]P1M265?^WQ>.K(>_5YGZ!B..Y(%
M F)66G-/.[ M9GRK"<A//>+(GXP@8.<NQ-V)EABTF132DEPNY5LY\_E<9.K)
M>W<-9\_4&_D10^AL;,0+HY;N*B$MNB'Q2I 0IX5%R4W/(\=[V[I8!C3T7THH
MBKSW^,:1I\PSCSI!?418X <1>,/6*_QO+_P(INA6/[>V,19;^]P?]\'8(*#P
MY+5SZ@ZCG4  S-P'!R*+@]H1[Y6>%-8"P^HOYT![W_*&%J%_FYM9/ K\9E\_
MY UN?<8_O-? !"BKF_GP(<S%MW)WD]F<QZK:]_6:[W9<[3&Y,VGSK)7UXKN/
M9Y!% !CQ7U);'9'#<J@11!^]1"^:1[-;0D\CR.KK#,!OV+VN;5C1!SI:8.G8
MY_7L<@8 ;P[5I8<O(1D .!,M3@/F_Q1CZ3Q5'QF /\5V3"C;U"5D_&W\[:QJ
M^#KX;W_X]_%_G"%J*ZT&O+ "TV/&*^3P@3.$24?-$HB72':8/=EZ'A3&])SR
MU$-X38[N-RBT_D7YZP_+5IJH.8V3N;,SSX]#F2AB1 @Q(R<S ,>/#]'/0D_0
MK^KLF YY=&MK5Y\_0*A$E=ASN.3*7U )X(8484XU7B0[XD:QEMQXYX^2U(:[
M#P8S*JI^'LF<4+6_#&S=J!G;MQ'"'#NT)O=%$BC8'DQ(J<-F&OC2=WF1NL>I
MERQ*W70]5@WU O[,7PIE !Y4#R+7"!T!4RIQ.#&%5ZY\%A+)NJ8&06+OZ#KZ
MC\5K#<"GZ:)4>2*HF2GQ)T:Q''SF/F;Q(;F=]AZ NZ9Y^%$5HX0S.;4_5-8V
M^\:<Z4\=6YC+3&$ LD9Y5E"$9R"RD-%?_]]\J*HD%41\EYBQ-CN^YI@WL?KI
MYW7,.#W_@>#+Q"N@GW"-KGR/R;X/9'/Z*6_F/  &E>]RA*#F;>+PTT+#F9QC
MV#GS[=!LC5?-DM_>8+D@,:K["HH\AT" _XUZ6:)YH O8K-?NI3LKG]*0@_9X
MIY&>:U) :LW<XI;FY^YI!Y*W-JHU^B8>=!$FT_S2<:G<Q33<\Z5Q?F[V^KQ.
MH6#&>;3@U$'Z2'Q_^:YJF*"(1"N 57#D3A'Q,GXS$+71QV\W8NY+0QL&*R-F
MGXBW#M)/W9VS]+J/.H=YV\L-!=<;E=7^=0=DTOCQY  "]PE\_'H':7E#EX2"
ME)H6*C( C8&CJQ''/[=9F38Z$YKI?L#>V57Y@&K@?J-8G,F(K(LGXE27!>;#
M\"JF KR^D6&[@>(M-^F E%H<, "'(G+N9NB--8JL_?B%&5!=HT!%]F>%/AK5
MB.>W/83P&#DNH\.R@>*980"NPD?A\^#]%:Y:2W'ZJ5'*U3\+<A4=(:\%&J;V
MW6T)GW_FO+N<4U< HAX'[?"6'BK@5,42XX4@TZ:^K@@R;STTNX@Y\6)D>:>X
M 67@G'CEU3.?U+A0';W"N\5N%/IIAU%]6@(6?/Q-XN1FXEXT8NOCQ^4==)$L
M:OPRZ>WOGTY"D*/WL)EAW[*9(;YF@S#[4PCG@K(^B?@Y"!?Z<V&%]E,RD77A
M.-#B9QY5P1;TO.* @^9,$#]"W\(:%33NE<2&S.2USPK,R5#LX"-6-YFB!D2"
M=LE/NZ9;3<W/BAG"OR!:6OZJ2>1<!J UHUGXZ?0@_6;\CWD&X*@IO6(?2!5W
M/L4 ]%OT,P!;4RB\YM_'I$8N(+9%S7<&\A71:HE_PDN-J#9@X9\9U\',]HI,
MD5U@DDSST=""*,C<]4%O)L6&M3YC6C_RA?X%@3U''Z0+,K_4+"GD[.4MC@WS
M233MC*1_!S,!3+8@=DUD$91]8;+>WX;T'_,"5(7[_)\@15BZ$%OD+09@6ZH9
M]Z.A(?I"4E6.O")1*I6I'CO*O'>H#XCQ<][6"1<.;QF@]I.,^Q8MA>*8OQLG
MW[0/&59^.G>W_:K)QK/V$ *G[1ZZ"/-/LM(OF%J*X4S9@2!&T*=Z-I,U4F'/
M(;%\#E-SR8,!V U]>(!Y3/N(L'&29P=_6*Y_V5^\YXA<B/Y&-QI8 9?QKA]D
M6*\C6'<O=#SP?%'&S(B]PQL(0E&], .@[J[) &#<$$' OXU=^V[WB%$],YGA
MODRW[9BO5R>RR&!&RMX^&;6URH!XRV%8?I6CCY(%[@/LX&<'"@-H_?8YZOS@
MK3B> LN0?[)Z%C%?LK>$W1>(?(4Z4K"]I25*9R6=Y+IK\O+?7 ##K_P7*4;D
MRVU@+OA1QYG3!..$O^XVKV-L*G<&5"A2WS\WVE_\[W>;_WKY!A_, #A #IG>
M=V#.I-;YX4/O?].^257\\EA/<6#68VG[NE74ZUJY,5H5UID?BFE9C\XVBGOV
M7<D]=[7*6.ZFE+W&.7L%HX"*;[56^Z.O,=+@?_%9?Q"E.>MYQ"U\54<#:WNC
M' $X5MX-JO#/7J;HCSQ-WK")@ILNVBC:Z#6I^(MO(<G&,]P,0'I-!@,P6P-N
M^?NXEGC%Y.N<B,Z7##8MV764D?.2*EKUT @:U/J<7URL%>^2GW8C946KG<?P
MBX-Z<W659>; N]&G$ _2?]_Q[X0''XHG@6F46*K(_S@47])=<O_'P0'_]C=X
M_T\MB;#\*V82/7$<Q\;-M?S\B+$/@OF>U9=V734Z?R9>D "XLO0QV>N^TTTO
M-Z,=X :(\M)A(JT<?I+^R^K=]\+I;I)CD7&3LTA'($_-5?/BUW_J<<M+9I!R
M\ ;/'!().<>Q/D\16P7E/K=\_**1>$;LA7G%G\7G/UY5 =L$7E2I-1\T!M(2
M$2\Y@L!E]."J,JK9;S15R_/DI>B\Q4?W;6//*P+R668!E;==6Y _L&_(3P(^
MNOI\\<EO>*F]_84"DL+X8V0Z;!43+KY:CE\P6,"V311?A]_*FK%<+)WV<.[!
MO$&,[6N15:[ E8A;<7G08A=(CS#,ZW)M/O=^YO)2+,'JMOG4VC^9^669,UC>
MQ#E+V$.T\/[-<:DPH&OLZQHOM??1',?/FH(:&HMU"_PAW8X"_X[EJ48:_I]F
MJ2T/9$"M5[V0DGRKO]+R.G$K^6?5YTH.@P,@7"SA;Q%O!0?*=9= 5\EB<M9B
MY3[^F08C5]:2E+MS;@][JU?K2.L[:I;\8X/YOYTXK#ZP M6]_IZK_CX&_--,
M\NS_F?DO;L8@G6R-]UG@?$"TUO*V#C(*OJ^+#]?_\I)7]*[@Y10GGA4O3!D\
MPP>8[#PWZ9;YFK<TSIT!\#]B7(2PJ98TV5!B "+[KUM!NJK8/M!W[K N0N*(
MPE%T'I?,5&4O1ZVAR9A8SQSX5/F7"6?*R-W<Q>K5P_:STS,11.7\G!^#GE?U
M79VR39^Z7E^YPLGK_/,TB5T&"RF;#1%D<RTTG7F,V1Y8)3P!G\. 5LP-8 \)
MQBA[$I@-FG"O4F]?/N$D&'<RXV"4"2.MK^=5!?:AVD%$N7120;AKBSX#P+5<
MGP/4ON.!L,4ST8F_WN2+_S(# -C>X,9!6I]:<T@E7/UB2]YZP\8 1$=6K5BJ
MH-=I^-2SG#[SB$N%]M/6HJ=I\HJ*U""M(G*(Z<AVSGS[9_N+#$"\US-EIG;Y
M8.V]9M$V^K[^KK]T=0.Y-ZM7P'_E)E<9L+6?7N!_#9IC,:F$72Q/VR5X6&I-
MEA4\G[F])6+I]5NET>@!V6-JUN<N_.0*L_+>H*%@/.T)F5)92@BN)AO%O>GK
M$V"<G*8I+7//&"* A5^IK+QWJ\AE\2=_L]>'PQ'>?Q+XEE!0!BIDIU63)ZV;
M,W$4XLQKY2FW'>X:5)]B^?EV+U'+;:"<=U]?\SOUPA#5=FZL&&8YEVKU_+KU
MPKAY_D<DLG[2$.#:=&R97-" 1OT+&?KW#$A-B%8-*5? A#DN06$C:5Q?"O/Z
MLP+#@Q34;_(5FQ&>[GVI,9%-]C(IF0V>8PU)_X9;.*R2A.#\LC'IXV2D>LWO
MO>,])L^^O%/D_^@7&* :MR-5DS$#19C4]'L>FY0K;Y??5=A4"5WP=\S^MPO$
M'H2%RMU3?\FT%C@Q:XX=74PH(_'WQ61Z+.M.&I(S,A/$&M*W-L<)2\^_R/";
MK!^8K?FM[/][J@4&H9SQGU?S_Y^9_SO-_/UN9 ?B;WZ_CQI#8FM-0EX3;]M;
MB9<//URS>>VH_N+ZY#+NRN&F @/@\:\=T8+@8P#L^X(;CY##<JDGR6'%XW8F
M2N@ H &!_CW?2N+<JCYO=;BCH>T1Y:%3;!_//(_7O__^(RH!\Q(11.<@)&PD
MX)%<\,Y]-F#0'D?@G1B8=7G_TFR69B'?'.4V-;,]H5#[KL:MKN2Q#TN56_4P
M-?PT6YOOPT/6,-FOH+?%UJ(J%3TOXS[P*0/15NG?"8B/RG(X#C93J'CSA++Q
M):L$^ZL542F*D^<??3=\'6.*<],23-,23@(<"--/ZQ%9F\R &W(4F97#T2B/
M9*UUN!A;\I]WGGS]1=]OY8<)GFE*Y^J2OW)6G2D?"89;@?SBY&F*U#@4C;>*
M.1RIP8%X5F9N]9=30*E[QRND!*.5;7UN=0OD1VZ*?'O]&?*D_Q[P(GWF<#0
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M1O@=4RGZWFU-6^Y;"5^H>.IN-K*X4Q%EMK12UER=B (^21,KXCG,82<CFJ\
MSY=:U$:=:!P2;7MZ^&MJ:UG(9:3ME2NP-1D!_LU,HH<[*?^1?1O^;^II(=X'
M%X-WHX[100<)JJ($CUNSG2FKM<Z;4C*TN2[IZPP 3,Z7AZ<_N.V5BZ?18V[7
M!(]UU_E2Z@E;M=]M U&/5&.TT!WHQ&W5"LH%^F_(,<^+RD\I\M2G:2LR-85/
MYB:\6=)+2V[U(DF5%$D[*#?]]%4B!"]5W7B9?$!@ )[]J$<>0>^.30PL V>D
MI=F$_(V^^+) #(UMPZF\>.!5>Z=T:#?6RRPU ]'--NGYB67UMJK!YBW'F8(T
MW(XO!T<J_F5HH/&[SL<S_H+U257N^%F65VX^M5.*D6D7M]87IA_KTJ?C2S >
MDY:<:((Y:;<?+M 4V(PY5TY[0UK<7=O=WOSDW76UV)6VJ5F#-HJ83WA?KW=I
M@KS6;)VMW"=I:[2_< *"E2.@6OO(PJ" "L5)<[+:7#*:8R;#.7A@<<+1!?NY
M8F=)LP^&^5%\#Z9+JP*_B;E&#OG>.>=TXBS[8OL[ZY-W([X<#$[VLM(FJ C5
M0VFH3-L8LFCQO/%E[EJ/3$(%4UC4KE3HZ.^XPG.<0)P*Z!"3LKDK DP +<?X
MZ8[HP:F\Z"EX- /04DN^.>^<W (7NN .G@J2NLL C"K"G7^&MX\B;$%\IN]B
MU1LK,&K]WC[ZP.9&"-6W\1G9A.(+.T<.6APC!Q_JGIEM/!)B]'*!F]XSO]A1
MMWYH\MN*EYPZ5R0U(HXY0ZXUJ?1@/]O9^KN4)';6A'^ND?4R7C-:^91!@L#<
M1>. B6AKW8D<Y\/0' =D52VRNJL:%:P0'E*!5>CU]%C,WXN8[,_4+()JMM*O
MO*J="?)\>Z3]X,9=COY:8-.(IZ]Q!$7+\5-N8*LO>\4$9S"4K[W5+_ 3XG$_
M _ Q@H0@=EPJ_E+KQ$2$R_=?*NY- [L0.*,V!H!3N^TL[V!XM54AKJKH0U*K
M^CZ\K4)?U'E+!6FRJB#&S%J%L1N2X*M(P?0&LWV2[^^*4/;] &6;F';X:H^Q
M$9@@NW)P:5&N+V"64U:YSLYF4YH!D)2 ]/116;?@<7M7%.<Q019/3<:>]7Q_
M7/DKU>]W$J+;(5\4(U+#9]PM/60T)5579()S^V*P*5DL*>3HE\LO>AX?HRZF
M.73I#;SJ5$OF>=QF6EY18M.@FOIYH[_M,_59WCA%T22+D^"$V<F*O.,S!6XA
M%!G-\'N"*;M3LU.1_(7P0.'P/RUX5[X)8L9]*?WX3@0$^0!YJ^?6<^.ST$*+
M(=%FRRJ:PS]Z/3E27Y'[<(@ ?J[8-KC<T!V6N++2T$"YJ:^4T ;*ZUV6&,?%
M/C:RS!P#L$&<+YEWYK=XF@F]W>)6V7]?IZEF2>0(4#DDX[$&*XZK&':#S$$4
M)M43PZG.M&\@X0@UF]Z@@"5P>?O9AZX@4]R><_T4+D:;HW@W2N#);X]N?^Z'
M@W,5Y15AKRHKJR+%--Z_$&'YAB[,@YQJ*9^6N&O0IG)395ZW%NGC[0]FV0E7
M>-+=JM3?.I\AINCF'22993;Y.,?.4V\-8V- L V@2A,H6*]&+@(<R1.-LDM^
M&7#]H$0X_I6/A(]PD8-Q8RP.>,GQJQ(D&"1H,/#@E"&8(-1$<\P90-A"KLS@
M*T37UQ.J?;Q_4,]S'H[BJ5ISF!"8G*+RK/QW';_JVL]QNF W*0,$^=3A"*\$
M>CU#ET,K-^MU3*G6VX2'T2?"]^+^=61-^->1D[I(NZ& D(/52\?-NPN1XJXH
M9VC39_(,8N-\ME-GQ^7L&0!^UY""T4W->-.5I/@\T.=L^YTI\/ZUT!KJ^^)8
M+;(X$6B,90=,7J??K;F@##^V21//;:1E6E=$K#?R$F#/TFE8Y6H6.N ]0FEI
MSSD:P5EAD>^P8A="EKS&=IA2M:9->W6H[@JD1FR_%3)G)9483=M/UD8=BX'K
M3^;Z74E'=N@S%=[IJB4/)>?U86@8"<E)+IXYII=P@7@!N#_(T[%HC,&?HZ%@
MPK_*YJXC;NP]\'B]3!O3!#ZP@N0Y^OXJ$TXN6!V5?YI6Q5W& ,@8V3$ H49S
M< 2:D^CDR=N@?%7A9<RV$:_L;($)!_I%'N)$P%ZL&Y7#C $(ZB/485F</RIS
M-(QF!AP+ 1.DS'=X/A? ^^G2]5WV9IZI26F1AC_GB<+ +)]%GC^+*$WP*8(I
MLG".X-9NO&; ;9QE#S82=0-3 8E+Y!4IT^XXKW!M^JF: I@6<:GJ<RXTFU#@
M^2AS>X@9X@9'2RXFCM65"*;$Z K%A-.\17^6/@D.^=%]J_S/@P/[EEL0#WU-
ME'[1X^*=6.?>*?$JLBL1WH=?BA)*9OW8."@[R)NV,/M6<NS,6P6 WY[P2'6X
M>,\<_0S^EW)GFD&:GJ?+YF.=TYZBTQU&WCK/8K76;#8\4HOCRK%SXB\=_![K
M]/6#>_:09 >.P\\,P'8. S"1R]3DWQB /" #((:@Y=>GA5-1])O.3:C#\XC%
M=G$&("%U=M('1:52!>CJ16Z'?0;#FYY7P;H409D>2\GZWCGEG?<NMV4&PPO4
M>2CMO.S:QX-R0K+@INKJEC5W;[[QT:K1&G=8F/2K'%_LK-&J/*^G[G%25&^:
M3TGZF,<U7/AC4=FD,A:-OK89\4$B"<@UBXWNGU$ ?B_2!D>"N=ZZ7"=:K+-2
M20]C&8#[!A;#/#N*R&,$&V<$>K':=Y3N*[O,)$7U9"QW: ZA%ZWQ:W60%$P.
M<D(J%KX#KU54RC +_F>S>$3Y2.E7^F]"16%CXY,-X Z[E;4ZC-]ZUY]@+8NI
M[+0K8*HY.1!-7L1T)=CQ*]8!N8Q>\NVC@F:/.2"V^0E'WM*VXD4QN]=$P7@9
M6IJG,YE*R!EW'Z6QV("W^N46=DT"&0"N\28^R '/*^FOJC-87N,[N\ON<O2Q
M-G"4AE4)A,#Q7(EC?9KY.1UII9):#$!.H@%P?_>OAW(&^'=Y#, U4.ASX6^4
MU[<9  F36#U-JEKTK2;$SX)(:<+&QK2R[FP?WQ2XW&6'3" >6/+G>%)N3\7-
M9I-;1(]0TLWO8W*MGWNCRA*B-[:=BG</.E[$EJ*H/O=HCL$50Z!U<\^X]=\H
MTTQQ:H%^WQP(*>$B287DOO PJ;5E(;QBQHEAXZ<#9TH5U\L28P8 1588I$Q?
MO$4Z>$(7DU*-P2S9S<"XR8FV,; [KR%;#UPOPS^4'1H;+;^G.KZ,]<:KJ /H
MH)(:X%>^H@AP-(1;\M9ER//W](M%UN#<9PBSX7):9KW]V>,S"3E/5!Z^RZ0_
M10X@-\"9O\RIL!/F$=IT?Z,B+0SU4A(&=R51EO1E?C66B@2G32P-4^L*O*,P
M=3?.(<S>^!8"RUMZTHP+<.6>*D^\87!U<!%S%MD"<?2"]C(F>IWQ+?D11"0O
M7 +/B4!KF#S_LR]0;-SS>WB&&=U!5'C[K6K6>U1S*$2AW"<Z*,,*&O*\LE]V
MMV=4YIBN6EHFY4B,?Y O1P='<#S\RH 'S?E^5>L=0E'1#*O@A^V?_GW74!;_
MC;WWCFKJZ]:%-Z(B(E*D(T2E21.E2XL-$!%0 >E$1;H0.@%"@M)K% 04%%!
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MY*WH(XUFI,9K*UQ'IGY7_A9#[I#3VM;G(<(F"P;Z91NNM;HQ9E^PCVE'*J1
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M&5P@T/O$5*X:!8/=7_BVH/^W+1%CM.3GD-2T]PEV^5!([%$0 WH !::O]L$
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M*7X7E6:X)IOEBV#+HB8WO9\5146R7-F/NG1)G99\V)_F)VE$/%UJQ%=_A(S
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MPYI* NC1!'-E'2:$,JOR<'VDF!K+W#V(0A MH67,>J\I,".;P8$=F(<:^:_
M)M.E5N$*K)6XTC6VJ5#F6J:LM!I^H!4!6A.'0?*7 .DTCKZ7(..&VE^"U5XT
M_D4/ZQ%-=?=M<?>P6)8DYWH7/A=?17,,T%1D99CR4&*UY8W34%%?'$,L600Q
M$W$2A)Z,$Z/*F 9C38W@ L_W:S^313#,&31/LYACC ;F*B4H6$E:ER1I9*T1
M.]].UAHZB[ @=Q".U6FL"R4Y J6K !LS=$[&RYQYQ'CA+V:Z;$6S&-[2LROW
MLLBS:EGH0BCOLN_Z;^7J_66I0 0AF' I(4H\G>,H/9@*$>$H2).48ZNFW$>'
MFAJ/KB6M7VW9RFK9HOLXL&:6H1NX!J;4;:168@[1F_LL&DY;<Q\?;=S.W&>U
MWFO,??X.^_)&;]7&MGJ^YEP]K-25X\5-<5LLOF9*B5D0$\8)0Q#[+-!=F 1,
M0\$@CQ6!1/ID%1D=-IP;:&HDT<@*6F&O0"VN@A2L!#:O?'02W]-LX1*U@;FB
M/V!619%,T+B@.-+)QX]6),E$R6ZQ)*/KIY8\_9<Z,^=]WCC>9\S#4<R18A:*
M=565,%7V".=0RC0)? ^1D/)5K[V[$0XW+>4W6HG;+?ON1J"QSV(NZN,TZ^R8
MT5^ @4](AYC//\SIJ6&J:0.!SN28S %KSVF;Q.&KK>Q_C(/9GC,R7M;GD?$O
M+ !6>SY7#L^9'Q%*2!I!$J8I1$QBF"(90H^C.*$>26AHE;%Q>)BI&<4KN7J6
M_]J&T(SO+P=F8';>.QHY"U+_,F ',1BD$MCV2"]3#.R@MD?K@1V^NM^B;VJ+
MW9'OGX46.IMG-3FM?_SVNR8L\4KD0F;5=?5.J&>3N;:\EVHJGS?W*SMOAE$4
M)C1-( WC"**$Q)"*1)FW7I*D49+ZA%G%ZSF5;FH4TPJ[JHU=D>^Z054% O]_
M *EVD_K%O5)_^KC^,[6C(K<3:\9@+S9=0V_XZ\Q*G:_;5C]4(@(M(]A65,_>
M:E;72NW><P6N'W6$A3O2' 1VEUSK5L!1*7H0;'>9?9A!^GT0/HN*Z-RTMZ30
M-<7*:\:6CSK+77"=M<:R:N;'2' O\13!4PX1\4-(HR2"*8EP'#(9)I%5DZ/S
M0TZ-NCL2 MZ(:,?.!BB;4:Y;[ ;FT96P8"4M^+&+9"NPPZJRYNBXI#N#44?E
M,',4=HG)XDX7>\[/NG31C?RU%'4"W8PB$:5>&L DQABB,. 0Q[$'$YY*A@GF
M06I4'LAHM*EQ3"T>7$BX+ 4@/3)63V/;9T]Z 6)C;TW7Z"EA02WM4)O4(Z ,
MMU?='? %MZQ'=#^]<SUV4]^B)+3:>,A^52_)HJBR_U8$E95U)/-,^!S%7LI@
M@E(*D="-OL*(PX#ZE"(F4H]$J^,6,QXY.V:/(Y*!V:0N,L5;\2R:?9G#;$8H
M;J ;J[X'K3H'";H8ZEI<L)+79=T.0VC<5N4X-^C(-3<,,=BOJ&%Z8S^:^479
M0:4NP2_*F_SM=TUFRZQ\T(,U599F' F/"Y% *<(4HA@G$#/LP33E?D@]%$@A
M;8R5LR-.S6#1LH)%#L26K+NUS?HWE#X_!01Y,2*409:R!")?!) &C.HJ)BA*
MU.Y4,MGC8-W-3(Q_(O[R$V+V37#ZI@_\3="RMLU/-+1O]Z!UVQG)&!J7WX3S
M@X[Z33#&8/>;8'[CL!EMG]0"O/LFYE_%QT5>/90S(G3/%1'#(,*:I^H H)A#
MP0,_)M)+/6&4V7&I(%/[@M395**I0/]&L#K:$X2^/OX(_&%2W?;FQHRRQD!\
M8":S37BK)^<F?X%,MV,@OD2RVYXLD\QW.X98WY2WH\_KF:NQJD7>U,GZ6->T
M%?PF_ZQ+E19*DE>DS,I?\P4M1?%55Z5YGS\MJ^WCD3LEU"N%SN^S-/$5F+J>
MJ'81HD!-+Z%JFN,$X2A.N(Q"*SYU+-_4:';GT%(9+:()FNN4''YL==9'FE+W
M6_BJ\= F3['" % -0EN<N,SN\TQF3)>&6G9P 9D&QC;EQ/'[8<;I+SCK U/]
MIF'&%6@K_ZVTTS.ZU@_4"FH_1V<":QUW#[J;>E] *PMJ;5UFR PS#T[3:AR+
M.&XNSC#X[B7P##3,A7%.HM3FS$R&(DIBI&96Z"9EE"8P#3&"5 8D#&B0,&)U
MAKWS_*E1_FM2/H G)5@=6=2-..H95=3":,:L%X S,#-N8G/4-T_+-D!4SK;2
M@\35M$.\3&3,MGY'8UMV+ALY1Z<-F+Y1MDA%ZAWFIV6=PYI$?N('&,.(^QY$
M/$:0Q)1#RCU&8N&'*/!'[%9X3$Z;-?.BK0<[DK] )L[1:?9H& =^',&@WB*0
MQ(,T]1,H$Q1Z))24)&RT'H+N)GG\AH 3G5^S#]&+SMC GS('N5/K[*B.GE>@
MT70""5+G)F$2F5!'A?QCI#R=P]A9;M/9@8;UR=?UF]3:F['4CT,A8XCC!$&D
MF]$1FA 8AVHC0 (I:&P58V8KP-1V"J=\\&@8'_QZ+MSZWOL@/$6?N]9A?*?[
M+GHOX6Q?RS!))_LN0GV=ZWO/Z<=\J_XP7T3Q-6/B,#&OVX36'%S>+9K.8NO?
MOUZ4U:=%]3=1NV'N<QU!,TMD+%D4AC )D(0H$BG$7/J0)RG!21)@7Z#95U'0
MA2E)#B:KS5KO2CS<DO\U+];2 =$D<MC1Z' 3Z\N()RQ((4/Z\"1(":1"(.AA
MIKZ)(F:A9W5N,HEI'>,CN36I;Z<UJ68?T4E,U8@[HO5.9V.9=OJ-KS9 6B'=
M8Q<\B^;(H]')?<K>X/"[_%P/)^RHW_7!,=\U (8?L$?167T2<)WSCXM</'\D
MQ>^B>K=4_VP*^F&9) E+,?1CD4"$<01I$L<PX9Z'.)+<XX%QR=E3(TV-T.OS
M$5WY[U%+"QYK<8%4\MKT8SZ)[6E>=HK8P+Q:@Z7+SM:"@D92H$7M4WSV)&@6
MI6==@3=2X=G7RZ(0.7O6!_ /=?'9$GP3\[G^+Q>/^B=</"W*K%(_SZH'0$G^
M>ZFKS,DL)SG+ZLH!9955R]9I5Y?XU&^L+G54J5]J7@&UBW915% MH\?F]8;M
MZYUM"LM<U>>"XCM1E*6VHVSQ^"B*>HPGHC8P5_7HHOB7$A"FN5;[@M5-A7A2
M>#P0G:%V7PC1/NM^H6SKO/[>;D)*U%-UR+&.$=$]['7#[$:_1O)%7:3I(;M_
MF#^#>?9?RXQW;G95@=?D)3E9?_?D \:KOFNBQU;M7:,;[#XG95'-/I*_+XK7
MR[):J/>EO/Z>E;- !$($?J"#L=0W)$D3F#*>0I_%+ @XPJEGU(7P\.,G]^%H
MA0._:>D,>>\(<J>_$)?C,?1GP1 *XQ5[6N,3%JZZL6/=JG_M6K9'GCS*^CVM
MU6K1GKFJGXNH^>94==E,108?%/+SO?(2LS#&U(MPK'9.A$!$10I3*AA$@1^*
MA/AQ'%J5RS8:=6KKNI;6;DMOAJ[9]MPY9H.O_5K>MA2N_I[7(M=%;UJAP8^M
MV [K.UC!Y')+;#;PJ-M;*RQVMZIV-U\0N],]\)O%'L;<IPF441!#1 B'!/DA
ME&$2$(;C(/!8S]B;[CA3CYVA36S%A>$4V\@*R6(:)]#W0@%1K#B<\%2[[*5/
MI.+W5*:]PETNPW6T<)4!(+6(,.D+TAC^T.WH#L=1'8<4=QZ5L37(^%$5AW0\
M&!5Q\,)^U'FK,!2*H14Q+=CO=53U#'F>]&5"((F(U$F$"<0D09 RG_@(Q2DQ
MVV>=&&-J1ME:1%!J&:_ /WD_>9X/GDB;G_*O(/K):Q<\(,OJ85%H?^F_@GRQ
M^FE6EDO1M/I9=$+92+6.=OCG?_1C[U_;D >OOE(78;3CCT,S9L8@%\[#P!RR
MF8(OS12T:27O:UC=T<D)%%P2RJ%A1J64$WKNDLJI2WN&#-1I7U_67K9W7S]E
M;9Z&=M[5Z1@S%*0^]T("0XH11"SV(-'=DUB8QE[ HH1CJYJN)H-.C7C>[N;'
M78%W?X&?WE^M\N1J7V>=ZF9Y#&PR X8GNHYQ'9A(6DB_[$/:$;I)/G-X[&J!
MD=,35)-QQST,M4!B[US3YMX+T[7J)L3/FU3.D,<R$3* @2\X1*G:V%"""12>
MH#3 )$6I537Z8P--C8&ZB4H]4[9VH32C%1< #4PE&VRNFA[BS^"W]K^#)*B>
M@V20%*_=L5XFU^N(QD>3OHY=WR-PX;;(<I8]D7D3BW.3OZZ+&)79(J]+E(=!
MH$B $^@EGMH/Q6$(4UV:V(M]70& ^SXW"N0V&6QJ[+ 6%Y!:7GVHS-82@\+8
MEVV$]&GB<(W?X!N:%72-J. F!QMAZXKM#J&SB&=P".%((0T&;Z&K<WQ#<$X>
MY9][QGBG^8;:;!WHF]YS85WF]@2@G"4^)2R,,$Q202!"?@1)@F+=Y(,+1;O"
MI^FLTM%K9H;7W@A6G+H>9[BWN8[$ XMUID8;N]VW"/,:R""-P@BQ !*UG8=(
MJH\5\1,)_4"JUY/$:9!PNVCZBZ <)PI^*##-;-B+ !KX^[-)!7I[#I/^A:IW
M]1ZD./5ZD)<I2+VKX]$BU'L7]@RF6#P^+O+:%W=+BINB/COEM5ON5A3U"<",
MQ6D<$6V)*N-4]T[3WGK*()9^+$)$(XZM$BP,QIR::=J(O'+8KSWU]<G<KU_>
M #4KC6O>\H#.!'XS=G ,ZL!\T>+9>M^5P#HDM!&Y\<7KAI9-DK?#. MSB)Q&
M61@,.VZ,A3D.>Q$6%K?VM-ET!.TJP3 3Y2>E4Q/6,<-2\#3$*90>#R'B*(0T
MCM0_2<RE3&./,:.X_O-#38U^FMZO\T5^WP1 SS="6]H>Q]$U-$*<8#:T-5+#
MU9&R3I)JY71HF)S%PJF%<GRT<4V5LUKOV2SG[^C;-:,Y2EP[ZIHB;9]$-9-Q
MZGN<2DA3H;9W2/V!(\QAB#U!B&0Q\:S.^XX/-36N6$FJ"Z/UZKAS E4SCG"#
MU< <L8:IT]BPD5.1A<L^.^?1<-L)X^AH([? .*?U?N^+LW?T8XDF44179MP<
M]K61HK,X0%'B<00C&6I_4.!#$HH0,HY03'RA=CY6X4<GQIH>3]!N8A,@7TDV
MUY)#N2A@2>9J=[-I%,-T3O$_Q7[P$P*/V7S>]@D]$6WT3U&4_!2>N]C'ECNF
M4[-I1D^.YFA@?MI(N15=\-JU$6. ADM^.C7<J 1EH/<N0YG<TC=0X*MZR*)X
M_NNB^/U]?ELLF"@U]=W(ST+7E17E+(U)Z@4LAEY*&40",[7[\1GD08Q\SBG&
M ;.+&3@[YM0H2TNJ4T&?&EEM(PC.8VQ&((Z1&YA(UM)>@15^K<2UH:-36%=2
MNPPN,(;(;9S!^6%'#CDPQF$_^L#\UGZL<\W_OBRK.MOY;G'->:8/5LE<%^UZ
MG[\F3UE%YK5+A^Z6>_BL2^V76;4J"G%;YT6TI1WT!6UP=Q3&C(<<)D)(15E1
M!-/$0U!96!&/ I*&=INPH06>&M]U2[^P;C',7A68!I]N,_:<TB0.3+W7M^]?
M7QTN5=HMX*-V/(4NJU97+ZB+]W1T<L?)8P'ODM 'EWG4K\%8,[#[*1EMW!X!
M<4V]5/U-R\4W,F\+JLXBQ%$D?/75J)L@)EQ].OP$P9AY/%$F;^"GYC5\#H\Q
M-;9OI-3V6-'("1:-H!:16T?0/,W,CC :F$Q;>&ZTN=K <^,*'HMXMLMA&BF,
M[>Y!@/S8&P66N5J>H%+7Z/.DNHZ-_L=<?X9<1;>=ANID4-N16\>+93LM^U8(
MVYE++W0(:*\[BR+,D/X^2E_7,Q,,IDRD,(I20HC/_4!:%7?N/GQJ)+B2S?ID
M<PNQ..*)EY 81MC3;MTP@IBG$L9I@J47^"+@D4V87V_$1HOPRYS@9NG_F-:)
M3L?1X?0 YY"Z@S@M1C^D.:3943=$_X.8FB;O"J)3E-^0Y_+-4O?-NFD:9FFV
M;*S*&>4L%#B,82JI@,CW"<0QHI#2@"">\I@$1EE1AN--C?I:B0%7(@->RPP6
M&Z%!4WS"PMHQ@-S ,'0+Y, <L,)02PL:<4%'7G [ (86UJ-;+,>R)(W>2U=6
MHSE$)RU(@\>,9TV:Z[1E65K<UL_*_"P4MR_%.R7MZT5>%815?\VJAU6QMK??
MV7RI)= G\>I__(Y\GV$?RU (#DF],=>U.NJ_41&DBK$#Y,6IC3':0X:I$7>K
M@J7AU0=\D8B8LB""*?=2B"A#, T2#)F0<>"EB<0QM<NZ&!C^,?,RBM&FP<Q,
M'AC:@;^DK?1 4QE8R=_4\%UI< 76.H"5$CJ.RIWI?0&$+BWT/F*,:LA?@-.N
MO7_)HWH5<B^*9_VX)O]/KEO+:"_T(E?6S:_J/[HNCZZ$-@MC)/V4,QB26'U]
MO(A"'(8"4NZ'$A/LT]3HZ]-C[*E]=5;2K]-46Q?>2HGZQ+#6 BS5?^N245H/
MJZ+F5I-CL)D8#O*!Z7"-]BJ_6FZZ78&U\$!+#]X/CK150?FA$!_1D<UZONON
M"J[W ?%,"7:K1XY9E+V/KCMEVGL]HM\F9MVAO5.\YUTA_FNI^Q*\63R2+)]Q
M/_"8H @BGU"(TH@KNSF,E-W,>,HP\;!G56_'8,RI?2ZZ]:C6HMJ9RB9(FYG&
MCO$;F/L/0@=^:^1T6)'' A67UJW)L*-:LQ8X[%JO-K?V#9K[JAN E)L4[%G$
M(X\DR(,QCB*(DMHE0BF4)"6<(3\D/K<+<]L=8FIDTI&P;RS:'HIFS'$9-@,3
M11>6<_WT>H1O'=/<;<#5WB@CAT@=TW(_J.GHE1=4=K\M,F5?8S^.9,@\&(D0
MJQ6M_D8Q#V', BDP\K&76L7:;QX]M95<2P:>M&@7%S/H "B%)T24$!C$6)>,
M( QBCWLPD33U8TYP(&,[1V4_",?Q/[:]PQH4U=Z$=:I%N$35C"+[(34P-3;O
M62V5XVKM6YHZ+]/>/'W\^NQ;6ATLS+Y]10_76YV6_:II,?#E08CJC:A(-B^O
M:5F[_68XC$,OQ8H 0ZYV33*4D*@_(1<T3%-"@Q";.]O.C38U8FQJ"+0"@UIB
MT(H,?EL);=,A\"S<!NXSER .O.#'Q\_"*>82QY'<8 V>JXX@98TG;Z1VY>4R
M1>6D7^OL0\;S9)GJL^6[,KZI;[TM]5Q]K%)'UV?E[[>BT#\@]\*?D=B3C"IC
MDZ0>@HBJ/U+%N-!C@@AMB@K?LM#6\<&FQK=;LH)""7NE3:967-NJ6B= -C.B
M7$$W]+'$%FJ?:]1NSZ/6HW36>3C<ULPZ,=[(Q;+.:[Y?)<O@G@LVJ7MI.IUT
MLE?/FTO:;+.Z)[?:(V=%-VS-\Y ?R)1"3AF#*)525\AA,,4$XS )4H:LO%;.
M))L@,]7,OR3S.EM"[_":K9U5?H[[&;38#HX]+V/L)MN4RJY6W;Q*0)\/IUYJ
MW73HRDJ[<T&A_;:E+A%WOJMU(MSXFV*7F![<4SL=H&]-,UJ]7[<T;\IA5QF=
MBZW*V-G"GZ5Q$B'"$T@B]0>2/(9IXJ<013+D3-(P)%8$;CSR! FZ4YT]6]B6
M.S,%W(QO!X%Q8#ZM:T%MA+X"';&O=AH)G,"W1VTT2ZS<EDHS'7SDRFF6F.P7
M4K-]0$]35-=^U4-\R'+Q7OVUG"&4I)SZ,91UL 7C#&+!)$R542E\KN;!LSLW
MV1MB:MRSEA#\IF4$M9"&;JT30!J:=A?!,[2-9H>,O95U5'FGYM+^*./:/4>U
MW#-@CE_9LZ\B*71CYW)5V/D5*3-VG?,WV7Q9";[VNWK,P[%:X3#D:KVC,"80
M!W$(_1BQE$=>F@;2JK6BV;A38P)=2RMK:HFNC_K^;-E'T1!Q,W88 ,>!*6,E
M\:;X^Q6HI:X+2K9RFYP>V+=4M,/*:5=%PZ'';:QHA\=>;T7+VWOWKGA2CRMT
M)\<GS7P?Z_*B,TPH#PE)88@\O3$B5&V1=!V E+(T1C22TK/L5W%HG*D1T$I,
M(%9R6O>B. BGJ</\8I &]Y6W^*Q%!+\U0CHDDC,P..XK<7"HL7M)G-+W0/^(
MDY>[\)G<B>)Q1D(1$!D$T"=)#%$02HB5):)[UD0!%VG,[2*X]H>8VO+7,EWB
M^:AAZ^/BL 5C;%_&26 N=%ET=1_.-U&/\H).B*Z6I[T-6U?V="NP!\&7<W$C
M7R_FZA<+[=/[*CJ>V%)9$KJ'Q)%?WZF_E<JZT$<S=[I:\RPD"*4ACB'F?J #
MF1)(6!) -7Z /<93RJT, O<B3HU,MO3:.E71EGCWWTU<2O5 =,/1[DV_U8K9
MND+<3[ZA*^5%IW1PRV?PV;1WWPP&N%/WCWLIQW4?#8;RGOMIN)'LOB-<9+.W
M>955SW]9S)=Y18KG=]E<<>8L):&R"(D/X\C'$#&A;$+!*0Q#YB'IAY)'PN0S
M<'2$J;%X(R182PD:,<TH^3B.IQG5"3I#.YHL@3%FM[/*;\BI7+%3*=A/]XNO
M/ZM[&V)2?]GEH^//'85.SJJU8H/S%_;LX;-)YWN?JQWDG7I,FW$:T"2(0Z*,
M.TQT'!/'.FB20D%]+-.$(2^R*C)_?*BI+>]N7FHM*M"RGD],M478S()R@]O
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M_E6459L"V H/2 7DNB\P4!NG8J4,H%J;GLGLIG-DZ#8<$/FA_8;KE/:KEK3
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M/S6#28L%1&V5@C>"U><5(/2O@'I=@\OS4$_-A!G!#8COP#1W-$]U+?X5J!:
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MR?(/B[*\R3=GI==%5JI?O5'_S.\;>3^)ZD;>D>^SB'B>"%@*DS14NQ-.U;>
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MU(I\!XYJQFSEOC-G/DPV-3;]\8\K5#ZYR'KL47G)%9%#CG*^_[;D@6_T9Y/
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MQ\>2FX+*;5+P3@U#L-\KV>8?#6B#9CD1MO[Z(/ &7KGVI-Y;KOJ-8X,<%P\
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MM'PO:DOM:*4;RVXF\8;0\.1Q" [X45GI@2ZL4.A@"/U\BQWTWPZ9H;N#4<C
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MWVG/:IN[UM[)IY7D>7F\JG^>R_*>RD+</BY7Z_P_R]^?W6F<)53S=T82&+,
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MJZ8VU^WV9H2Y^EEL_0/TJ,BC(3FZ )M=><>Y*>_X5/OF\XZN[1C;37BCC]S
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MIPBB!#-()*$0DU3$@4A0&&<N_+3?_-08R%@'C'EN+'2 F1W/]$=B8";9@C!
M\'+::9]$<-##J*_Z:>\.7^8SGW)[787,9^_UHFC]\D\YG_^_B^7/Q3=)B^5"
MBK(:U6H6<Q$%F>10*;.AHU<RD 69@"3E@0BR ".%;=[<BSU-[26NC 7&6O@O
M8RYH[ 65P78O]V6$N]]SK[@-_,KWA\R: :SAV)%!T;!!(?G?[I?/_Z;;J(A
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M9EC&(0E2J]0ZJ]ZF%MLUQI;5I@"OS;T!\XN%3GH@;4>>WO ;F!7WH7N[A6Z
M&C%6D'@5).GL<%S!$1O?CP1%K![JNS)\KUN[UXSU]]7RIVY_^?A$%R\S(KD0
M&6&01I$IZ)[JM2$E$J991+(HX &.'0NZG^QG:@Q2KWD:6T%E+*BM=5T;GH;6
M=G5X-6#CK ]=L>JQ.NQ$XNKUX>G61UXA=KIXO$;L_GC/,R>3,%66@1?O-BM3
M%:,,7<I\@O+?#O(/Q$RF&9913"%#$8$HH_JGB"N-<B0R&862!FYI:JX63(T^
MC.U4C[@Y)^'+Q\?E A1E&IK1-RY:"6G;?#37XR?G,;(\C1H2^:$/ITI<*^-!
M9?TVE:LN*EI]I/9AF_3E4;"B-WY>#ZN<C1CW[*HO1D='6;T;ZGNRU3XP:YTZ
M?]>C5SPLYT+_SI0=-MG=WU=4:)/>T9<BG.$442D1@3**D(ZB,@99%F(84<)E
M0!**>.AV#-;3DJD1Y=9>39-;@_<I<UV9#X2VW_58K>]XV9[!C3 *@Q_8[9W=
MWX"6&S=@-SPM3T#M"GC7-2(]#OFN1-/OB6!?8T8^/KP2L^.SQFL;[$NM55+.
MN0H.,54BIGH9F@H:0T14 '' 8D@9IR@-.,TX<:F3<:$_)YH<H5Y&F=F[RUSJ
M41KC$L"VC.<-ML%YK<9JG)H9EL#XI:CN+D<F(BO_C^G&[K$>V>O; O)?U':/
MS*R/EPM-;!\?'Z7(Z5K.7WZ7>DTFW_\RF_6;O'@PO#=#BD8X% )R%280A:80
M6DQ3R%$D"&(D20.KXD=76S*U>,WX4MV2,DO;]8/<[:F;J*WR">0[IP KO=+K
MW+9;#EG=5XUC-ZN-.CH#\UTY,*4?IM#PUA.P=06T? &5,^#]JPR*0Q+^6(,S
M4GJ^I[?'5^5A'^AVIOA?U<%XR?\^<-B[%N"EP;[E_/0TL*#SK_)9+C;RFUP]
MYUQ^_/JMO@&3\#AD&3&UAHVR;TA,N0W,H$P82R@1<2"== \N]#>Y^4MJ*.G<
MM:Q<-Z9VL;-'I :>2QI+06TJJ&T%;[2UOUV^FM6CXIP5-'XKSW5W.7(%.BO_
MCRO1V3W6CTG*JZ9&.:$4[>"48,ZB!!+),4192"&F*8,QX9D,@RAF@5-]X+W6
MI\82I7' 6.=&%/N0V=%";R &)H$=!MYU2DZZ[//EWN]@U%?YI&^'+^[I#XVL
M0V+*.*Q?6A> 2IV:[P]T41^;?#:[?\5:BG_*_/Y!_WG[K.?.>_EWW?3ZG0Y@
MMF%.2T)NIK D*DXPY&%*(&*:+2@2",:"*QY%818@IW(-$_-O:E35V YKXT%I
M/3#F@]V:<"1)DX&^4I9'U].R>D)4[D$HI<)H[Y)G2]9J*Z.R1>H&-%B!SB^F
MGEM842:U^;PB.LUOPB246 9R\:\AVC+L^'K3=QG8S+X5Y>03S46]07^[$*51
MMT4AU\4L25&D*(\AX:4L=F!TRI""":88TX!F:1RY59$[W]G49N"/"[XJAU,O
MF-5F49Z,EP7M14=BD3O$=I.@+^ &GI%J,[<G<D:7H9I/*E-]EH.[#(C?$G =
M_8U<]NVRY\>EWBR>Z7$8=[=<ZQ<DIW/-A(\F&8O._\CGFL*6"UDS7S&CH>0A
MY1%,,LHARK($$H8HY!%#)#*_1%9")M8]3HU)MC:7"5"5T>"QL1H\U68[G--8
MX6YQ2.8;S:'I90ODSEZP-;B);;T#Z7"PY1O0D0ZP=L V7\8RH_G4U[4 >B[4
MA$[UOVY%;_6:@]ZOI/1YBN4"9>=IE55#XYU*N?BU=_KD]& O7< J:>,[_57-
M#,T95RZ+OZ^6A0X'J6(BTO&?PJ9HI(89,A5'D 0LI9D4),213;:677=32];Z
M7*M.M;*U "TM+^.<^<Y\)W&[2Z!;T+A7* ?F\&T"E\G<JJP%+7-!::]7 )W$
M 3T".9HVX/[W4>/YIO5=_ W<&\-]L;(U0A<T B^U,J9$H*5'!PJ!MD]-;?O_
M'^4.PYZV['9;819G$B.$*61)$ICC0 5Q&FB:CX, 901)@9A;@>#7<<3E/1VG
M_G"5ZJOV,H7NOG[[LP#5EL]4MO([OQZOO6/O:\C_RVS,5X"TQ<TM#H<FM/%N
M,Z!_C?WU3D_^BVRCVXS6>+OE5M:XUSC[@_[*'S>/=0X8BE-$F*0PD;)4Q9(0
M1S*"(9<IPADF862EH7?4\M0VJ6KC[$N1[>/4/3-<Y?W 9%W;Y3'][:RWUU8(
MVV]TM$)@)WUIU_LZ_8%^@>^'1KWYJ^0R?S:"P[?S^?*GN7;_8;EZJV/N?/U)
M!]BRN%O.<_ZB?_GGPNQ%25[>:+M]+#6A9UF8Q$'&%$PS1B!*:09QI@A,XCB-
M9*P4R:QJ&/@V;&HO_M:)<LNO<@-4?KC%I-Y&SB[*?(WQ&)B*MBZ!G4\WH&.
M;D#E6ODO>\Z!VCOPH_[$(*+=OL? 9ZCGS;91@S??B!Z&8][;[YF$_+A<K?/_
M+&/!+VIKU%LCV#^+! ^CA!/(9*"9FP8ZYDHIA9$0J;G-0)E=S&73V>38N&5K
MM=O,UB!O9&=Z%#3H1-J.:7WA-S!['D)722 TT+WMA,X]U]D"$Z^ISUW]C9L)
M;>'Y46*TS3.]\Y>JG=A2&:9<2A:WF_7#<F4T/&<!3J-$* 2)S*2. A6%-!(A
MY#3.4I+*.%#4,8.IH[NIL<G6VDISY084I<& ;BT&;_)%_=OSU^;[ &]'+?[@
M'#KU8(ODMPK)RE:P,]9K;I,%*)ZSF[IZ'#N_R<+[$QE.-D]=<1C#+N]A,><]
MK-O[^U4I6+Y?WF^;"#H3G'(6Q0C2-#7WLQ2&!.,4ID0%))8D0\I)8>KU7)D:
M-_ZY36FGC>4>*L:^SK?$X5QF\F/_7^9L9@O*8<'9UGT*SV<TKSJXWL]I7L>;
M\<]J7G743I[7O*Y%_2;IKW)-\X44[^EJH=<636E0FHH J32 &1491 $+(,D2
M"M.8AXR%21BD3MO I[N9VN1VR_GF<5/5)'DG5<YS2QF8"VC:33378S3P)- 8
M"!H+!Q _Z ;!)UF>Z6E4(NOV]I!D+GRZ1_+J_Y&+Y>).$].C'O'-.N=T7GQ<
M\/IKBS'* L0I%%Q$$(4XABQ-(X@3'F&3TTH#JWM,E[N:&A&4QCJD4W;CV/WZ
M^T5G8 HH[00'AAI5P3XEJKM1<TA ]8;>2,FG9U'TE&YJA4=GJFEW"^.EF5IY
MLI=B:O>$OUW3+YMUL:;E1<<9CB22F N8$($@DDH3)I$)Q(CA3 0\Y<))^?]"
M?U-CS7/[ILN=R7XW3MO8]]\Y[8GH*VV=MJP==N_T!"Q#;YZVNWSUW=,3_MML
MGYYZK$=D5HE-%WH:JA/U?BZ;>5&:N^5I"!$2&"+%$TBC@$,6*RZE3$AD5X.H
MNYNI<<O.T&W%P9]+AUCC/)X6T9D7E ;FBY, ]8G*.KYY]A&9%\1&BL;<OEIN
MD=A%'#JCL/-/CQ>!7?1@+_JZ_&D?5RR_/$ES?W9Q_ZDL+UEK0BB"&4VC"%(B
M.$1,"8BI9! %2L8\0(0H*U$^ASZGQI);(\&\K-A*N_4C>D-MP9G^ 1R80$]=
ML=SA61E]29"C-Z#7W+:\&MA7NG)I %[N?V&+^O>#W;OLQ,KM\N7IIE[Q!F:G
M;]W7,+L?[9F2WMPJJ5J[78C69<\_=#\;;<&7Q5?)-RM3KDI_X//2%!*N_OH[
M+?*RS/O'M7PL9C$.DPR%IN1)3"&B40JIR *8Q()D <IHG#EE-WJU;FK3P.XV
MVTW#9.:N??O">.,BT%'/ULGR4VTW0>DG^&$\!:6KEI'D,%\"NS7^JPWMP!/4
MJXRJ>W+[$.A[S7#W:N"X:>Y#8'N4ZSY()_WFD,]R_986#W>U@-SO+W\6YN[B
MQ_+LV_3-U_ES:=@,A6D6QT1!PC,=\PL>0::4GB\8%E%,S&%5X%(3R[YK)_8?
M27&%:].WNGLF,>?-IBAO//^F_ZL] '3K@ANI.XR*'6,/@_7 =&Q@-E:#NS;,
M?S8P;XT'MY=A=F99=\1\4JA#[Z/RHSLJA^37HX61E4J:M" A<O,#G;_+"SY?
M&E8N&O7@&49)(D.40,E( %%BHN5$(LV--%."2LEB.8KLN(VU4XN>CT3$O\I'
MFIN,"U/WLS1Y0^<Z[E*55.?9C,61Q$FLOA%V1#R9<1Z8NSVDL^X25K<^@Y;3
MTY+R=AF>20B'6!G\U] '<<'>FPR(4Z<]9S#^(,5F+K^HBU86Y\S\;F[2SH@0
M(E-(0HZH#MVS)(",IPRR1 0BX0QEJ5N1#%^636UF:APS]S1M**SHY##PHW32
M<4?'W[!;3DFO,9A#3S_CCJ/[/.,;<Z]SBC?CQIT_?&-Z-%=X[Z#'4>U764C]
MQ,/;MLKQ=[EZG#$>1SQF 0Q);,YD@PA2$<:0I&G"$Y3&DMJGK9SM9FJ,W1AZ
M(/NLN[;4C+J JL5!K!>L!B;$+4Q[1H+OOF!R.%[U M=()ZI]8',[0+V(1N>9
MZ?FGQSLFO>C!WLGHY4\/M-USEI)WU?$6XDZ/_F?]?7BW-!L2LUBI6* X@#(,
M(XAP3" A#$.LD$J58BEB5G79AS1R:H3<MYCE( /H:5-FX&$9F/O;I34KX\;<
M,;D"NU$W2OK8.:W]D2N0=MX6N::OOI7&S0F!Z<>T_I:NY;T1T2@-:XJ-DS2C
M-!(P#G *$9,!Q(Q3J+(@9B'2G$VM*OK8=SDU\MU9['CB:(&N'9?ZQ6Q@9FS!
M-0 UVD/AM]+XQ5Y'+C9NB\)QO7'K)WNJ_7%>B@9J_BH%!YOZ8YRO-K*=E/%V
MLUII,V:<2I60,(,B#525 $W"A,(D(SA3@D4L2IP4 !T-F!K=-/:;\DS&@?*T
M;EEJCM#*!_?R,[T'QXZ?AH1\Z#BN0?NNA79=QK!&NV7_#:@]\"@NV!,[KX*#
MKC:,*T+8$Z$C8<*^[?0CPK?+U9-9BDNC3?G-))K5N6CEQ"]QQA$...2I-)=N
M P&Q$#'D+ A1*@,LJ5.N0V=O4Z.XK;&5Y&FQ-=>-S;H1MJ,N;[@-S%,[R$JI
MTYVE ZB96&'BDW^Z.QR5;*Q\/V06NX?<:$3(?/9]1<V-W&\OCVPYURNQ &&]
M&(,DCCE$/-:!DJ049E&&-9W0,$%6ZD9'+4^-'FKC0&6='2<<P]7]_E\%PL#O
MNJ7_UN_U65]W[W#1O,2:B_]VOWS^-_U,]?[J'PY?V^/V1GE%S[K1O([G/_ Z
MV8[O?YG*G84)-@Z*O-?_(N]6.9>SC"<)3HUN<81BB$0D(24H@DD:QPE+PX"S
M=,R\1TN[IT8;+;-+P8X_O[T#3SJ.+X4[''4[QAIZ3WOIXP_HP!3H,]6QY?T-
M:/P'39IL@P H(9A.UJ/CF$TI_]'6]&GM]/L=#]\YD:[=]\B"*>5@ZNZ^RF*M
MVUO7(C%ZK5QI))1E0;[)1;Y<?5ZNMVLM% 2,\0A!I@@URM7ZG0QE!F4:2!S&
M/ JEU2'!E79,;48J;0;+RA6PVOI2*4V56TU\YXY>!QM_P,(XY)! <L6X=4\_
M(X[&T--)B7?M!=BY4:E4 >T(:'D"*E= Z4L?,9HK1L0AYV><D1DI*6CO5;EQ
M>U=\Z2Y<#VAG7M$5S8^7>'0]!GN921Z:FUI-[994VL%,O+UQU;IP9;*PBEF(
M5,3-"H_+,(2(AC&D$940"ZK2)%4BPU8B/Y/T;FJS[J[8P\\FV*=UL+_:WHGC
MK3MQ)J^U7#&^2+IR57B<U%"\>M'N@;\^TU]U6M:+:.%T8DUZ^NIFB=8$%JA#
M?@DFL8P=Q,&_QF)WR+$=KUKX-4;V"S<:<?L[N2IM-A58RP*L,R83&04D@7&2
M(KTTYJ:H. ZA3,)4R3!1F7)25S[;T]2F8:,T\7'!EX_2"%16G.DVM9X'U6Z:
M\P+5P%/.MBC%%B/P8Y#RO1?!\$F]YSL;E08O^GQ(29<?Z$</Q\DE6XD#&E"2
M1H%>&@1$0(1H"@D6$JHDE#C&FB4BI\.?\UU-C2!J\]K9;/_N1A =L-HQA!^P
M!J:(4_EG@P@U7$;#)T=T]#8J25SV^I E+)[H&44H92IO/\MJWOQ.?WVE:QVS
M&$]TAU5\M/X@=8MT_FU-UQL]H"]['YYE!%&<2KT\X9+H>$.$D#$6PR +PBA,
MPAC';O'&]39-C7AJ8T%>12=K^LN\629_QS$^\3!<EI',N(,P=,S3>-/$AT:[
MV-@(]CVZ 70-FL':>G7XT(T)G;C7G%R/<'N-JCR8-6[\Y0_'HTC-8]/NB7GO
M%VN] OWV(.=SLW:EBY=9(%2:L1C#5)HJ%UPA2)DI.T8YYBP.HIA99^<=-S\U
M"JTL!*6)H+;1/E'O!'S=/'@]*$-3F@L>3HE[Y]V^(GOO1*.CI?"==ZB=Q]?Q
MJ=<3]C;/UW?K^<,B__\VLJWUG489I0F'@7[C(4IT"(89"F'"4I%@D7&1.=UC
M&MK@J5'*3BBZ$80N]]4_+IXVM6;TUANP<^>55;X[OQ%VL=V4QGE@EAQRB%]%
M\ML&]ZFI@'?:_)<3!K<9@2&TPJWZO7*F:KTCQ=:8ILHM5XRDF,,L(!*BE(0Z
MTB0(2JI8QKGD$79:YMMT.LD9X[FDD\>6U6 [4CWG@R[<'3G=$YJC\?)-JP"#
M_XME+K ,0IM=_;X.]5D@<9:^;)[MD0=\R]AS+EL%M;E(-)\0F*%,092Q#-*$
M,4B12E/$&:&1E=#IJ<:G1BG:O'_DEMN )\'JYH=K(1B8!RK+^A;&/H3"(97U
M"DA&RD_]N%#+U6,5FJ[DG)ITG?425-\7@]C?;G0 "V2U#_ S7S^ GP\Y?P"?
MY6:UY"L3P3Y0'>0>:"K2^Y4LWV!?2:QGH.S,3#U\9KQTTS/6[N60GOM,S\10
M>6_@_BJ?EBM3&^%N.<_Y2_7_78(!U9Z(3 =52@H!$<U"2%BH(%.14JF*)0Z=
M"G=9]3HU,ORX$)MBO7H!M?7E"NWO<GF_HD_ZNPU:[X1CSJ35&-B%6MZ1'9AC
M&RRW!M^ RECPH_YSD/0/)YB\9N%9=3QN=IP+%D=9:TX/]RT@];,6*S$=K)8+
M_2.OXKS3KTI&>29(%$,9)!0B%D:0)0'3B\.4\!0G04"<\LM=#9@:<^EH6-LZ
M?P&W8OE4)H!KYOI8%$;.9^<8V/?,M9R4XQC9T=F0R _,;-KT\^".PW)]T?-;
M9LK1AI&+3?5#Z+CD5,]V^AZVWFV8;O##?$G7,\%9&B0XA#@6"41(48@QE3 -
M:!0&21A2&;F=M;9:GQJ7U4>+E86@--'UI+6-G>U!:T]$QCEGM0*CQS'K":>O
M/F5MMSGR(>L)=X[/6$]]J%_8TMJ/*H]T3/4>PQ FV:+>$T@3H7B$,10BTNNJ
MF"<0!RC3BRN*F4092KG5FVO?Y=1>Y\;"'OEF%OC:!1E^41OXE3\Z*;P!6PS+
MI#'_^]3V^/@,'"QZ'354L$?A,#AP>++G)LY:MV2:_Z(^Y NZX#F=WRV+LFK8
M-@5<I2(5$4H@X4Q'"8PB2 (E89Q$<1JE29!PMST<BTZGQC9;FTW1IJW5H#';
M)HV\_P!8;N!XAG7H_9OK$77?O'& R.O>C4V_XV[=."!QM'/C\NPY7FH/ZB?]
MT__^;\UO]/_,C>#__=_^?U!+ P04    " !P@D52ZG]%2QRA  #,> < %0
M &YB:7@M,C R,#$R,S%?<')E+GAM;.R]:7>;.9(F^KU_1=Z:KS<JL2]]NGN.
M;*=K?,:9]K&=73WW"P^6@,5)BG23E-/N7W\#U"Y1,D6^T O53"U>))F(Y4$@
M HCE7_[[MY/93U]QN9HNYO_Z%_Y7]I>?<)X6>3K__*]_^?W3:W!_^>__]D__
M]"__#\!_O/CP]J=7BW1Z@O/U3R^7&-:8?_ISNC[^Z>\95W_\5):+DY_^OEC^
M,?T: /YM\X]>+KY\7TX_'Z]_$DSPV]]=_G-,7JEB+"03$BAC+81H(_!2T(L0
M@@OV__W\S\GIZ .+(*/EH(+PX"-G$&212CAD.OO-A\ZF\S_^N?X2PPI_(N;F
MJ\U?__4OQ^OUEW_^^><___SSK]_B<O;7Q?+SSX(Q^?/%3__E_,>_W?GY/^7F
MI[GW_N?-=R]_=#7=]H/TL?SG__CU[<=TC"<!IO/5.LQ376 U_>?5YHMO%RFL
M-S+_(5T_W?L3]6]P\6-0OP1<@.1__;;*?_FW?_KIIS-Q+!<S_(#EI_K[[Q_>
MW%ARCJ?+15I.Y_C7M#CYN?[(SR\7!(CWX7,E>/,!Z^]?\%__LIJ>?)E=?NUX
MB>5?_S*/TV^TL&!<G"W[WZ[^\<]7%'Q9XHI L^'X+7WA_#/J:OM2@]_6.,]X
MQN?%.K-%NO%#LRKEQ?+B7\Y"Q-GFJY.,T\GFDX_B:KT,:3W)+.@@! <6'4',
M) L>O8685$FEJ/K?F\Q7PE=$^48I*TQ__;SX^C-]\,]5(/4/&\D X^<J^6]W
M%CV3T7[47^S$3_2S$Z.<"BY)0%D0E+<!HF8%;(I%:LFECFP XJ^O>9/VZQH^
M6J:?%LN,2S(H%XN&9;JC[9M@/O^)G[^$)7T0I./I+%_\ZVI9AM#;>C& _,Z4
M0^3^Y2?BNN!RB?GMF6[N96[#V9K,+&Y^<@B]'\WGIV'V ;\LENL)!L=EX&1&
M/<<J! Z!NPC*"IN]LH5Q'%#_U]?>"0>B?QSL+<].\/ >E]-%_F6>7]&Y/$F&
M\&P,G09,,B+;1&) (;"2G%#1L8)A0$#<6'PG1,C^$;&_1$>&Q,O39974Z^DJ
MA=G_PK"\X"%&P7DRY"O81+"6*8(W5D V4JL82I+!#G'&W;/^3L!0_0)C$+EV
M8BX^+<-\-:VR/S=Y 7EA5GO@/M<C,&=P.3LPP9>HC56AQ"%=B%OK[X0-W2\V
M!I'KR-CX9;Z>KK^_GL[PM].3B,L)CRABB 9TL1I42AXBEPYR"3Z5: 5790!,
MW%YW)RR8?K%PD!R[P, '_#RM0IBO?PLG."F,69Z)?>NDI_ [,"!_F=QC@\XD
MQIU+?# <W%Q[)RS8WK%P@#R[P,.;>5HLR9QM!/^1Y(\O%Z?S]?+[RT4FUTB[
MZ#/YR+%X\I%1.0B>16 L191.*U?,8/!XD)2=T.)Z1\MPTNX"/)_"MS>9Q#<M
MT[-+KW.K*#U3ENM,;A+I6B%M )>T@.*DXUEFU&((;_1!(G8"C.\=,$-(N NH
M'.5,*EB=__9V.D<^89J7R@?%7"41$SI M,8!<T9R*8,N)@\&DRT$[';1Q7K'
MR*&B[0D?+^F/[Y:?%G_.)\HAUSYX$"H5.DI1@<_U%<&)J CU!K,>&AU7R^^&
MC8YO08<0:T_(V)R6[Y;OEXNOTWG"B70QU(<D8"&2YRT=0J1?P0D?HS.H, ]W
MQFRG83>,='Q#.IB >P+*^\5J'6;_W_3+QJ<J7$D;B@4=0KWO918<UPI$S#8:
MY-[)P<^8&Q3L!I*.+TT'$N[8-Z>5AR6&#=U<L\R<-12K<P7*$P=.) 0II94Q
MLA*L'  4U]?<#08]7Y'N*\"1%5_?XV?OCQ?SBRL;Z[-3G'QE:9T I3,)0#H&
MF7EI4"LNXQ!77[?7W0T '=^#'B3(D4'P$=/ID@#,1?PT7<_(<GGE1 F.^"?L
M*F\].)7)27:,"63:YCA$3L#M=7<#0<<7H <)<F00?%J&FOWT\?M)7,PFG/$H
ME<_ @R<_6&,D] 8.0ENG>?9:^"',P(U%=U-_QW>>^XNP$P/PR[=T'.:?<7-9
M:R77L00)F=?<D& *A$3TD]U***TG[ [Q,+9M[=V0T/%]YL$"[2)D^#O.9O]S
M3F'Q1PPK.MGRF]7J].QZK>8$2I)%H*/-.Q*(CX3Q9,C704$.SA#'PX-$[ :1
M[F\PAQ!Q%UCY]\7LE!2PW#S_+5>3XI)WO":MVN))+&@@\"R!:^T([::$/$1F
MUM;%=TO-ZO[F\A"1=H&)\[R1LX2 >C"2$DY7$ZO0,BL9!%]3RQ1+9 <U!W29
M8=99E#3<I<-V&G9#2/?WEP,(N N@O)G3IY$XIE_Q55B'<[8FZ'5V6F<PMK[X
M)4<1M8X(M LPHDLL\C3@^^HV&G8#2O>7F ,(N N@;"SAR[#&SXOE]XDT3MA0
M''!'&E6E'I)!(AAD4N<LM=-#9']O67HW6'1_;;F_.+M P\>3,)N].%U-Y[A:
M38(54G,R<R9E1E:OD-6SPD$@)J)QCD4VW(O8C:5W0T/'MY>'BK,+-/QR@LO/
M= C^;;GX<WW\<G'R)<R_3VPN(I08 6--04,A(18M ),)JC##M!SN(6PK";NA
MH^.KS:'$.S)*WJ2R/#K-4_J)H_4:5V<Z>#T+GR>**1-9O:8O3E6L:W!!D8)%
M-BD$Q\P@ >W]%.R&D8YO/@<2;A>&Y.,Q!>47 $^21VLC RZ2KM?X&H(,%@1:
MB\QRFP9,!;Z^\FZ0Z/@V]$!A=@&%]Z=Q-DVO9XNPGF@D1\A9@K"UH9HZ0K0G
M1),#;3G9NAC2$,^B=Q;>#0@=7X8>)LHN<$  /JDIJ8OTQ\=C$MOJW>FZ%C?7
MZ_Y)EDAXYAY\CB27;!QX'3)$%3EY28@A^L& \1 ENR&E^SO1P82]-W2(E[@8
ML.AH=979C/G%]P^5%IPG_(3?UB_HA_^8:&8$YJAJ>8PERUAO?A5Z0&-+LLQI
M&8:X$]N9H-UJ&3N^0FTC^I&-T1%QE"M7&\?*YJPPY$#.=B;1,/K%6R177 6?
M4 ;IKTZ% S!S8]'=<-'QQ>G^(NRD@/&J"O,U?64UL4Q(IXASGX,$19XV!*T#
M:%X<0T\,#A+@WK/\;GCH^'YT"+%VA8RSZNTS)K237OL@0&,D)IAGX(7,X*P)
M22FNC1ZB0.E> G9#1\?7I,.(M@\7EMA8AMF;><9O_Q._3Y!%KU.@<Z[D6#/=
M WCN(R26<XG">FX&]%IO+KX;+KJ_,#U$I(-AXE]^OB/$M_2%0]H@S5>+V31O
M'*8PJQV<*(C']>HFZ;NV1;KOPP9KD[03M0>V33I=P><0ODPV50#5(+PKKZ=S
M6FQ*5F%Q5O=^"2H3373,D"T0Y%4JPS3X*,BKM%9K;U+:6C5\L;%*6,6-RL_7
M/-M=.%NO+KYR>YL]AKA][<C%&D>K%<GVDE7+K"!P"PA<&E"RB/J 2!O )I&=
M$ESD+7<BA[-ZDXQQ6C(UP\2%H1E YB.>/#>I/W]QOC*\Q<E"0@&9;:ZFTD$T
MGH-5RC$;D^:XY>EV*.#<HF9<_!RBWJU(.436'0#F95@='\US_>V7_SR=?@VS
M&L8?K5^&Y?+[=/[YW\/L%"?9&25<B)"="* RN>:N8.VGZ /7:&/V32S/3M3U
M *B#4+!HK9(.</9K6/Z!ZQ!G>)ZM.\4+H4V88\DX07(JNC:J<+9Z<B0Q)TPQ
M6$HQ6]J('8ZN!V@:I]]<.TP-)?X.D'244NU3L?J "6ES$$N_X?J"%X-"D90B
MR:B6 4BO(*).$$4L$JW*-FU)A!W@I'N J'$ZU;7#TF *Z !,;^9?B>K%\CNQ
M,$FN*"^D!"X=F52KD-Q&5A/TK&=9>=H+34*)ZT2,T[VN'5CV%G 'X'BW/L;E
M#9%,,O,\2+*51LL$2@D# :4 ZXH,V=O$U98DV<,A<I>4<5K9M0/*@<+N "XW
MB2=^M4--FE1%DG_F:ZY6D%""9L$6(Y79<AL\<,PU3H^[AD?/WB+>'Q^+=9@U
M<X%_6\S3.3?:$-79)RC"RAJ*%G R1^ IA4R.&*/@]*F\X"NR>G"$!XG6!Y1^
M![;FW1>LC=OFG]]B6.&'.OO@7?E]A1N!37(R&77Q8*0A)RR'VB[%%M E<93&
MNR":.#(/4M6#&SP(DH:3?0= JC<,Z^]76^+UU]^F'Y"D-$UKS&2L<[*H/#!5
MFVL(3]RXNBUR=%%DCL8UN?AYF*P>G.1!H#2@]#O TOOE@K;&^OO[6:B=[G/E
M[DN]JZ^^O_(E114U\)J(J@R9VE@*10%<V!2MX[G-X\5#1/7@0P^"H\$DWP&*
M7ITO6U/)3O!3^'8FI\I)MEX%LJ\@:AZSXL[60UI 3F@Y.B.C:^)3WT]2#P[V
M( @:2.H=X.?*?FZ_2+_F]!'URFGMB"DD@:&-$"6%$EHR;8TN"F43/VEW$L=I
M3-T 7XVTT@'>KEU<7&,"<\'B-)W54410!>GHCMF#M\$;;ARB:1+-;:5FG(;5
M+5SO@V7= 6#.Z)^(G+Q(V8 Q7E"@D!7XE,G*YJ %UP5C:/@H/TY+ZF:O\(^2
M9@=W06^G(4YG&Y^?;.&F^N)X,2.AK\Y"@DO12*NBR2Q <;:VM709/$I)HO%"
MR92%*TTNG'<E<-S[H>;90$WTU($-NL;7[?O96G>NM$GDY"6RIHS.8,<"AX@A
M.H]6L38A__TDC9O@T08"]^/L$'UT@*R+U^'WX7N];"61T5>6IT3''18G+!E$
M5CB0=:;(PM19J\)F*(*YP.N]J]I233'<:_T.-':#O8-@<<\+_M ZZ@!^+Q?S
MK[A<3XFM5Q@OTQ*P3KYAY!3$I+"VAPS@O#6@G0MT/EBI;9.\D.WDC'MH-@+5
M )+O #^;"&/+-B!:-9)PP-:A.$KQ!)[5ND7-=6TPFIEIXJW?0\^XCRF-$#2$
M[#N T!8.M&0H2"P0*$@!Q36"YSH KT.\G2]2I=9>_&. T^SII!%P#I1X!_'@
M+>-Y[7+#9*N5373@EIA!>5.[-_@$64?D@3-G;!/HW$M1-X=7.V]\&&UT8(IN
M/E5?R.[[-88R2TS88B@:KHWSC4X0@BBT8TR()5F%<DMAXM"I ELHZ^:$:P>S
M8;73 ]QN'>#7[VB1QZBBA)1LO=G7FLR[$9""#PFU-:B:/-W=3U(W)V%#@ VC
MCPZ0=8V)26$N.:M==0=KK\0DP1N&$%"QHF/1MOF5Z+B) T]](_4HB7?@3#T@
M$1.%,2)K,)%94$)Z<C"] BZ#E5EIC;%)&'?@!7JS#((G@=) ^NC #+V_6'?#
MTEDA'BW# @O5!^2NLE# .]HFC@NOE,XBMTE*V4++V*79PZCY3F[383+O #;7
M>JR=T5^'T7&LKU'"D4&-9%"CDPI\'5$B/"8O&UU'WB1D[->[)H Y2-H=H.4H
MY\T#9IB]#]/\9OXR?)G2T7B-K8DO*!)7 K#4@26RMN1S/(/0/I#[9E@J6Z8%
M#?!P\D/2Q@W;&B%J8(WT@+&43D].9[6/RR9(J#UCEWB,\]7T*Y[E +Y=K&KZ
MW[OR*7R;\)"X*!2(!H,9E#,2G%<16"%[ZXMROFQI]S[(2]UCZ!PWIFN%OH:Z
MZ@"*'W =IG/,OX3E?#K_O+K&[BLLTS0EYY/$9Q6WD).ES15+@<A,!%VB3MY*
M9K>-WQXB3_-'I(T;"#8"W, :Z0!C=P4U4<9RYHNL4X))0"4)B($98")'9VV4
MW#3)/;A+RK@18",,'2CQ#FX1?A0:TY'OO*2XN+:J]+75@0<7$(&A,]8QQ8-L
MTK;D1X2-FS/^U)=3A^MF,*P]77/ ]QM5'.-ZFL+L)A\'=@J\^<FMVP8^P,=3
M]A!,B1?O4YT9G,EC$A$A)CK<D$<;>&2ZR$:W@NU["%ZN\:FF>DTT]S4CA[:#
MYYP.[N @^-IN-R2-TB;6Z!WF)AEC7U0-C(F[A]_>,N_ 6:HM6U;K#?GT+XZ^
M35<3I:/QQCO(,D906D9PUI$P A<QI9)\;-89YR8IG2!G#\5N:8QS@)2[P\GY
M8+OI?VV4\2N>1%Q.+(L\9Z$AN4V8$$E V6#-F1"&$7/.;AGU-#1NMI$V+HX.
M5?Z#6#I8$QU@Z^/Q8KG^A,N3*]96%YQH871M_IUUS>P2V=0)FIF"%&ML,4X0
M;TU.L'M)Z@E+ARO_]EDVC"9&Q%3U?B=O%_//V[DHJDBN!=EO6<=D"4$'?5&<
M6(F>I1"RS_%'[O3#2XS[RM(('P-*M0=[<W&P4VB#;^B/JXG7QN1$4:GP@= =
MZNV'HA/>.RW1<*>5:7)VW25E[%>ZP7R> Z7< 4Z.OH;IK,KA]6+Y,9REAUZU
M;SDZJ9/!_POSR\5J_2*LZ%BGXQN3(M:XKS,/7*FM,*T%1X82:X(S-TV2E1Y+
M:"=^]9[ N/UBTE)+H\XYVYX4\3XLWRTW,LR;%^_WN-S,<ILHE:/CNM )[4B(
M-BB(WC"00OGDO/(V;YFG.71NRGWD=6+7AL%< XUT8.]N<G4V(/#H='U</0C,
M$YEYS+7O8E+<@#)%TCG )&T>';A4EF7[!+E/M\D:.P>A(:X.TD"G>'JS6IT2
M)Y&3K2U*@52. N":]1YRM@0!'ITJ0KHVA2[WDS1V-D%S'.TA^4XQ='UH:5#2
MTYFM@.OZ;,E(2K0E GB58BH<HY=-'/<?T#5VJD!S-.VK@PX@]> 0W*!KQ:!W
MX S&.@0WUV=P 3P)Q7BV6K;)?3IX^'##G(%!P328]'M$TKF-94P1&V1CB9L
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MM4^A=0YLK"G=V07NVG8AV$95)X#:0]WW(>=@V7< I%L\G#?WP.24B:1CI^J
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MY>(D3N<;#5U<V B;F<ZT8PPOO&:^8.WE[\$DPXPL(<0V-VGWD[0;JI[;N\-
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M=-F!>:_W"F=5)BMB][S>I-XD7!2S;)A>O5FM3K'N3H<LJ1(AE.J%DS@A:.%
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M:\H5![YD!R7RC#$DP5*3Y]U6#(V;Q]P(L_<_S(V(AN=B-#<E"0.8SO//:6)
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M^5A"^W_.W1,SBR=48/\ 3>GTY'16$X^V)"F]J$E(6-L%1&:,#X2JK+( Y6.
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MWOY! YW1.U YT'%\N=+5T)TKT#%T0E(<#=+5)PHI/7A->E<Y\=J1T*G;)\U
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MSH<$GE-D%JV*SO[?^?1-@#/H?/I':''L@_><D5\7<_S^:UC^@>O7I_37\_N
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MG;O_S47M87T?E[CXOM;992)ZPCS%1Z)N*,N>D?AR 5]J',X*=R2_R!^NVMV
MJ>>_:RO\^)/!S\#"'1LK53ZW)O5G7H11/ JN09>ZU,Y)1I O'D2RF(+EFHSO
MUB_%3WS1=LE7=C(P&5*N/;OD]Z[CZ9Q/3"*OK:"!PE.LPTL$>*T$&,NDB RS
MCD=X$GJ"PNV0=L)Y_J&T<QJP6U_/?!*CXI+.%.A8A_0P3397&0XID=5%QY*5
M1VA^>8+"[6!WPGG_H;33">QN>;ABK*Z$N>;UTU<2^O+7Y?(",Y^@\U$)[^F^
MK[WYRNDZ<;< #U'+& -]09/Y1+N1N1T 3^IUH*&>>O#+GCU;>#Z].)\$GJ,-
M/$%.-H$R(9*[:<BS4%R$NA0F9;>UB[;==VZ'I9/(^[>4=@>F;'T"+D/8&#S/
M4F@H$C4HB19\U!:8B-%RKW3B3<;*W)*P'6Q.*BF_IWP[?(_\B!G/OZVN+^V[
M"9('2;CZ-_$<\X0N=5FR]H#U,E=%>A)A;?;0,AOE99%MEK,<2OAV.#SA5'MC
M78Y].;X.B\6/.JKM,B=<K@>Z_7@]/_\VGQ&K_Z3_JM=^F-'!-$HD*:,"44,=
M)6T=I<D"2"5*T+*PZ,)6%^1NW[L=RDXG%=]0ZAU<E)N+F"[3?%=YF]IVE+U/
MD%@]',P+H,^J<]")2^^"-J;9;+;GR=L.<B>1K&^HE^[0=M?A?'#(/G_%RQF1
M-X=LHE/TRE,P;5E=T"""@B#1@?9"2:DSZGSD#-NS-&^'RY-X!#BV!KL#ZV=<
MG$^$<R+[+("%LGX.0XA"9HC&:,>D*5(=P0Q64K8KISV)AX.!Y-T=8NX<CH]8
M.VKJ^]E5URV=$OK-_]UY&N$3%C5YI;7B0]9YMXXIXE,I.AZH/3=))G'<^IUM
MJ-X.AR_C66%P+78!V<NO?3>=5??U]7RY6OYC45<K>V=XD-5&>T[6VG)1V[_(
MTXA&)QT,!H%MX+B!HNV@=F)/"4-(?^RX].UW$LBRCKXLX>)L]7C8/<NO4EI<
M8*8__7/V+4SSM5/[Y@+I9Q_"C]HZ5F.IJ\^96.U\<HHB<N4\J(@(06D&*1L3
M.',6<;L MA&!VP'R))X6NM%C%R;Q?D[IV\4B?0U+.J6WG62&6^\+D^ L)\=$
M"V+.U"UCNMI_0^XLFO9W]:.T;8?*DWBD:*61#D!&3(0?Y]?G+:XF,E!DI,G"
MUUH$4+FV1G,1@1L1T6992( M$/60D.W@<U*/%0?)>NS+]6:/QV.9QU_/SS%/
MPPK/?OR"9;[ MW^NR#^]F"Z_GJ\C[HP\,H9 1T/6<BOZDU(,(E-2!W2)^[+5
M#7H(%=LAZB2>'8ZKD0[,U'WA_;2B16C"22X"N*H-U:$N7<:LH%@>A)-UU -K
M?PWNM7A'G,0+1 ,]=("J5_E_+I:KR_GX\]O9ZA_6SN3K\&VZ"F</DH?ORX,^
MV$\7<8G_>T&_NO-I$YF"=%IE,NJZSC&+%'T[)B!:QU7BT<<V3[/-.-H.RR?U
MM-&']D<M1=CR8?'5ZA.N5F?K@S[AW*)/I@#YLKY.YV/@R(F!8#GQ'4+*:KL1
MPKM][W8 /(DWC-92[\"R_B-,9\O?YLLE+M_/[KL>5[YOY"D0;9R<7:5 <<M)
M<-&#D$DKKG3PK(F%?):R[:8XG-2+QK#:V!U>_A)>,_Q2YY%\;C;;Z,H?GH3D
M-"95M]L$^D=Q",';0EZ)1AULBOC01+49;71%SW:(.N&WB?TD?VK+A?[ U;Q<
M/[G4*>WWL^9TJ-9Y\\'7#>WXO4T7$!TB@[8KB8SE!FT,8!@!684:T ;)P6IM
M+(M6^-2L"Z#U2J([Z44OC;*F]C6:$NKVK@PQ>@WD5&I&7F=P[ @O_SU-;3L0
M"UL/;=M%\IW4%__\J$?G=U)$BBY:!LG5)C17]YL;)R!Y1TPA9YDU2I8\2L_X
M ]D&1]#A<C_4QVK@7OUS%B[+##!?7P"3HG1.,EC(JK+$O0%G]7J>G$!&?#%V
MA.>G1R@;?Q1;4[-TJ"ZZ@-?#@7*1Z4)>*$*4D:RL3PD<,04R4 2"/*9\N[1^
M2##M,\6OZ;/EP- Y1,[[^^CS53AKZ:._7WW%Q2_AK)K83U\15P?XW1L_:R!?
M>CM:#_2/UUFE3=]T R3G,<M$ML'H4%=W4(SO='84I:E"&!,FV>T&B3_W30=W
MSEU\^W:9^PIG][[FYG#<V6G++ J%48.VKKX[4!0;2HR00C3,$*Y9HPW#.Q Y
MXM3]05'Q4PM>*T7UFQ_8),_]]Y\_\XF-[5"#'>A;XDX:ETGGD&*H76^Z0&04
M75F;Z,;368:P75U <VMTLU?[UUFM3ILO?KR^6-2#MY;=+<"E*49I@K77J8[V
M=A0E"FU!:J=<"4Y+U22XVI; KJW0#FC8O/A\0 5U\)#R83'_1L[;CP\DMM6K
M6:X/DM\N^Q*N.=*AJ)@+V6TZ$J#JNDK'N 57ARH8^IUM,QOV>=)&W"G2%&P#
M*Z4#F-T>GU?I,K=[53][6V=[_4 YQ>6#(V6,X%EI#UJD6E=K+ 3+,@1,TA;'
MO#>^K<W;G>AQ$@3'M(.-%3EV/>*GB_/SL/CQOGS$-)\E8FBMO??E=5A^K?]?
M#^7W<%8+,HCWCTC"G:85YOJ[!WS3?<!3CA*XK7QK'2%RAV",$NAX*CGFK=R0
M 8D:)PW1#J"C*NWT0HEK+X8.:8/$QB.?WCC$>(Z?HX0;V:F8ZA(QKWD!986!
MJ)6%8NDWGKZ=1=]%N''CPWX,__D]$ BGX:R^(=2#4T=9XG(BM%:8!0)#8T Y
MQR%(J<"FQ$)"SS5O<ND^3UK/(<8N"'AXM0ZLE Z\OAN._C5?_/O7V7K;R_(A
M2Z5H+-* "]*"0B5JH7@@TR^(1YN+;(RSS;3U'%X, K2!U-(3TMY-9],EN:C_
MF,_S Y:*+"9+H<CGU!I4B %"\!D('UXDXR66)AN=MJ"MYVAA$*0-I):>D+9^
M<D=G>9:95,Z(=J<XU,W#0/(*WGG'O6_RI'B7B)X=^4&PLZN@3^]-\3K?$^ZD
M>AIXY4]]36/W?&L.!RKBVYA!NX$F+R4G%Q)X5OMHO9/@(K? 33":*Z,8;W)T
MGZ5LN%3;YC3B>GFM]ED[P0H(#'5YK4S@D#,0M4$O1>9T;E+%O"V!XY;^#8N@
MS6FT 974P>VXD9M??GRFCWCUYW0YX<X;JS-=!;;N]"'3#DYH 6B+RAQ9$*Y)
M4=<6M(T+N3:@V/9M84\-]0RZRM#5DG?+D?[#$N3"B:7,+'F9+$(600H6>58/
M7X);/V+=T-:IG=L7#UN_9>VGG [P]AN&)=;U=K^>?UO,OZ]K4Y:_XWG$Q40K
MKZ2HTW6-H+@YAP#>.0VH2BA!\9C;;#U_@J9.\;6O_N=ME#'Z>U.:$N73,DTW
M$KKB0AHK95U&YE(-HDRM*$ *HHSU06O)!=KT7$CP]%>,6R+?"B$#BK4#HU/;
M=B_HXQZR@<2#-2F!""A A75G92D@R3B'6)+7KHD7OX&><0OC6QN;(930 9;>
M72QFTU6M_Y[E=],_ZY^6-YS$ZC]:B-$AJ)09.$.G0O"0='39.]$D+-Y,TKCU
M\JT1-9 J.@#51DG]=ML1'*,T,4NHNUM)4+'4\4"ZELKIX%%'WJ9X\7G2QKT!
MQPW\]M-/SXB['"U*PM#"2 D8ZCXH+ RB5P58B4&AB4G8)AV[3Y/5J3>^)PBV
MQ=CN&ND 7Z]2NCB_.*L-:6^0B$B7U43TYS-<*VR6[TU&WL3\)%GNDC,")*,3
M2YPBV70ZP$(8@<QHDWV3D?Y#,=!I?# ,9D?1<A<-DAM96;^XL10I/HYT0EWM
M)J9+QTMO0%IE<I):Q38M3T\1U6EPT=AV[JJ-TWO_?%!*'!XK)6[P'KK+US9^
M']U; D>I:_04W"0M$ICZ\*ZXIY@D, G&*^;H+@_)J>>4<)2ZQK<$A_D/)%"N
M[?D=X5TUZTP*]QI=4I!"C=54+A"+SR"LHF.D2U&LB5/X+&4]5S7NHO^'9FU8
ME8R=I?V(WW%V<<W,=0W3N_GB9F91=1?.SN;_J<)<3B19:L6Y@1"2!;+52';;
MZ2H^I;6-,3V,03:<G!V_N.?2Q7W0U%SX8P/KRMQ7IHB(KZ_JY*OO>#9?>P!O
M__R&LR5>'Y@L WT_TW7+.X):#X/G+ .+*C(>O7!2;P6J';ZTYPK%O0'52NB=
M@.F71:BNP0=2%KDAZWVA;Q877]XA3ICS5EL1(7/)R%%-!0(G1]61DRFS<SYF
MM@N$-G]5S^6)AP)G( 'WD>IXT,RW%M[/3NCU<6 ^,@PF G=.UCW9#D)!#XKE
M%(0T);;9FK0KH5O!;_ M#^W=JJ8*ZQ*0FUE+0C&MB+4<UN.P11U\9@,(GR77
M5N6,30K[=Z!Q*Q@.OAIB#!@.HZ;3RV'<[SB=/]9Q&AYVG#;(:1Q"1N,<QV 2
M.DK.HV236:8#@=+6MI02P#-7F^[J,A-G?=@R<FN=\ZABHG/WL+MY=3T _G)P
M<O+!,(T"@B=;IJ+F$*R+H)%+GYE'9&V&WVU#7<^YCUUP\%.YR."JZ>!FOG]
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M6C*6#^KKZ]2@IVH5?9'"<^TA*UD+[^OHR!(I).$\.AEY$?I9K_M &GH$Z+Y
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MZW8/H^J01JT]!.L4"!M<E"*FT&:LS^"<=)Z5'1B*0YV$07#1R\&(SPL@/A3
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M N6- \6\@A!%!J],L#$JG4-?LR2/G2<XY0S^"S  C:#\XK/_3P^:\,):$Y.
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M8#R)Q,.TU _HGA;<)*NH(\L9DHOU388K<!XM>*,-"ZJ$DIM<!%M1-VXL/A8
M!]18/S#<D!R;,)8Y'2L!D?M:;&NJ!RY)7H:.EF=9(F\2=#]-UKBQ]5C &T)'
M^R-NO@IG@R#N.G&PF_RBLDDX;R$K5=_4;8)8GZJX=L$F9;-43>[@O:CM-TEY
MB"O87G$=V,,'3&X\<YS'F#W!105'7.D(@5D&,@>CO,F%JR8#-+8C;^0]1^UQ
M\C0RAU!:1U"\)\!-O(7B"_/> UI#;D>,"J*G(VZ<SCG)6'ANL]ML!R+'-8OC
MP7)P!78$SDWL^%282B6")#<'E*A-F\D(D)'"-.EY2;9)&OP9NL;U',>#X!!J
MZL!WW,1&-";:: U8)^CP6$,B8BP".=?,",5R=$W0UB7*6OE_0PA_, RU?"[Y
ML)A_GR[I$\M\<>?'\]G;L*@E\,M/%_%_,*U6\SN_?3,MQ,ZRJJ.>ZPL"\H^K
M<UY?\(=Y3VE)V? /+D>3XQ%>9"SGP3BOP7)FR5!F\AT=>9':2U,G%)%];N)?
M-7R1V:;4Y-7=-,=:%_?^\H1SQK@CESJ%>O919 AU*F,I)29+UX?!)G'0 +3W
M^UZS"]8>&NEC*[4#5_26^'M<;KBNGF/>,<\-%P94J-544@@*$K4!EW*0B=QP
M+9I4<0[*1;\)J$.P/9ZB^T7YX[$E+B=,2)]%TI!#(<^>N0+11 \R:)$DLB)B
M6Y=X.SK[=94;('409?6+Q3_FU0F[H.LGGN'585QWH4V$QX".&_!9U1L%$S@;
M&3AF D4<WHK4M@UI2T+[+85K@,9AU#7V4M@=F/ME$>H//Y!:*6A9=T6^65Q\
M>8?D\B0>>(D14A$:5*D;<%U6D*U'SZ3+UJCGXK3AR!EW9,W0,!Q)3:=E)Q_O
M57X]7ZXF:"5#04ZXD ;)42&FO>$)K(B!2R>UQB8K8P>A?BLHFU.!\GB*/2$S
M^[Z4:<+%3^R6G(P2NH"-6M=E8P5"L!)84BXPY81B?&@;NX&6K5!I3P658RBH
M7^OZ^FL=E?#K[.TLU)7CU^&>E:@HJO. HLA:'NC!E>"!D>.=(_G8WAS3BCY.
MY5:X=*>"R_:*ZM0JTCF;7G80O"_TR]=$U72UG)20==)H05NAZN;Q0 YV'1-"
M_TKFWAE3V"$&\/&OW0I3_E0PU5CL_9JU6X8^D@:)PJ\39SS/="R@CH>K81KQ
M9)@'Q:SW')DNMFV7R',4;I=B9Z>"O;8:ZF)SW#.F^J>FSSI"Z%*A9V?S_X19
MPHDRRDN,Y-6R;.L8H5KDRAW$H)A3(E07=X2+=@O2MX/KR3T)'5FG_9K0=7+K
M5?Z?B^5J/2%K$GUP"I,$7<?(*I,EA,@2Z!R*$<%R],>$ZD/ZML/C2WG&.4@[
M/8'N07F,\*BSRPBL9JIJEQ*$PBUD9XHLTNHLVHZDVJ<V^'1?7 Z0_DD4)]WM
M8O[)= _?M;WQ*]KV9V_'V1'J?H+/F)(W@#(FNOD(CDZK M+I3*Y<,,FVO2*&
MK_OY2;;_6,R7M],KHW>11\Y!.V3$L0K@0C;@+<84HL'B5 N.GR:KWVJ=71"R
MJ3QW %5T< /^Q,W5((79E]^(J]=AL?A1+@=N+"?>)>D#*@@Z"(J,; (O68:2
MB2^5A"NJ:;_"%C3VT44S!#2>0]U >NH1@C=!^3VV;@)T;\@94,J"".L)F(Y#
M9#+5VGH46KO(7),!$SO2V4?GS#&@.*"^QDX._\3;Z_!M2HYBG4-TS="K67Z#
MW_%L_JW&/!,O:B>P9R"R1V(//3A5%'!'3FL)3JB'CQ0;,L2[?W<?G3$#0NP8
M.NC4XEW_["H6NOO01\Q>#\":A. ]2S+0Z:FVG>4$,08#)EL54RY%V":EKON3
M/&Y]UI'M8 ,M=F<2;ST/#$M<7OYP$C %$WT!441MU*V%$9(9*$+4!T!=///[
MF<%'OV_<<JNCF;[#9=VCN?O'?)[_,ST[HR/Q*VEM]J46.ESQIDK,7HD(F%@D
MYS4I<%(*X-R1T\"M3.$X!NX)(L<MD#JF21M*4SVB\+)NUG$D+S0*0%V[*W4A
M4YP3DCW6*<B0DU--'F0?)V?<(J>CQJ\[2[]'#*T%-$$?#>=D@*.M"QJ-U!"=
M\<"<*]F19^I,DX3CX^2,6Y!T5.NTL_0[Z(>_P\6=V<NWJ4DI6,K*U#69=+<;
M55=S^0!9%RFM*2$HVQA+CY#5;W/:0*G<0U71D9=^AY77=5'48EU'^@EGT_GB
MC_D*EQ-CE2K><BA<VSHQ68+'.@R Y^)0\A#0[NJK/_NMW:1F#U;U!H]]6+D?
M6EKTN26N'H0E=WXSR2D(7L?$1TN7N>*&>'0LU(UD/ OELD!] +8V?W,W^=8C
MX&L@^8^/L:?%=^DC)J=31NL@(J^CW2G:#4D$D"4R:[G2D36I G^"IFX2KT-A
M;6@]](>L&Q_B[F%A*;)<-P<%2RZIXN1&U*8TL!3'*HO<&-4TV? 84=WD2UMA
MZV!-' RN@WWYQY-U=_BYC$PD<XS^DH>@!3%E<P(7681L#-%D@J*#LU].].%7
M]=N2OX]_WD"\?05^&XMVBU)<>$,>HB7P*^-2W>YH@)E4G)4D+'><;-2>E=:C
M]-D/6LUSH%+ZN_@>.S]_8)5:3"$3%)*SGDZ/+A"]*9"\ETY:+"(UV03Y#%W]
M]M$/"K,#E'$2):^WV[9_K:/DSM>?/DRIZY,?/7R)Z_:<'*&TM3BR13(6$(X5
M4"(&<#DKX)R1=RZ4=K;);/\&I:WWNP*OML]-$BM18DC *4X%A73(O.82LO<8
M+=.<F;B5R_3PD_LM1MU%IX^W5.XCO Y>4V[H?W6Q^CI?3%<_7OTY74Y,KJ-S
M*<0,6'L_,Q8(QG.2!W=<E.!E;KNB^!XYX^!F /UN:K;87]A=0N;-_#Q,9Q/D
MZ )'"X6M.]#K' 0M*2IPB-D'F^B0'0<TEP1U8FX.4/:S^-E#\ET@B#Z++O./
M^!UG%_@)%]^G"7_]^.EW/(^XF)A8HE:\SNN6=<!+1 C*))"2Q,6D0"L;S9)\
MDJ[>\+2/\G]"U'":Z !8]P8%_K\7B^DR3U-5T!4[.F9I:H&#2HJB2*GJ2 .N
MP*9L7#!T[ZLV2V:?IJN3E]TA@36D)L9^U[WC U ,@[^N\+PF2Z4UHC!PT642
MCLGD!U@&&:5SCAM?DMG52;[Y]'$ ,9S#,XS8.C HVZ2F.'IMK!(@DZ_MMX6#
M<P5!:DMB8U'%<IS&OWTG,[3&T9[:WR-+N(LJ>D1734,5;S!JAE!\7?D>T).,
MI*!X-%A3F,O1Z:/ :=M$8',[U @_NPJ[ \#\#/F'7%U/)WEU/K^8K:K_IH,N
M#GCAL>8T)40I(V3A<D%KO.%-XOA="1WG[:P-T)HJJ9^WC2>:7Q/GAB%C8'@4
MY.%1Z."*5"!MXHZA5*S-"]J!/<F#/YRUP== @N_ G.W:Q5ILY*CK#D)=AX%A
MX! %)_G9$I@H*#$U78XV9-?QX,]G1[HU!U31W@C\CHLX'PB#_YPM,,V_S&IG
M*_%VW1Y(@ERLZ_J(LXNS>MK>D:2O-@I_P,5T7O_VA_ER_2ZUG&"*7DB6P#IR
M'Y3-%"M+3X)VFBEGM2^^24/\,.2/TTS5!K$C*+0#4[J!Z\]?P^I?\XNS_.OY
MMY!6-UN./E\-C568N8C$EBOKT<7D"5-P'X%SI3D:&81NTC6S'[GC=&8=%:9#
M*FPP6+8L4OAT<7X>%C_FY57E<[KZ\1'/JJ.ZFF^0T# %#'M_[?#%#<-(X B%
M#T)$@HA04%SAH&+PX'BV4+).J%%HH4YMIM<&"4]89M%86T"CSI<]D8%<%\"0
ME-#(0L(F+U ;Z.GDY>E 3&QI G<2_MXV[MOZRO^T"HM5RPOX#3[F=GR@[UX\
MXG1$EJ+#8H#X#)<;!'TV]*?@@U0R9YZ;Y/Z&(+Z31ZSC8+2=6OM)\.SD2&]B
MW6AA4I09C!42E$3R7 QI(?H28LF2,SRF@[D3\?T6]#= =#NU]AL=[1H3%J^#
MU\P"4SJ"2CY"-*4 LS[GE$Q]TQX=S(<%^:,T#QP-SL.HME] /WXM?<+5Z@S7
MP\'_-5U]I;]/O[@N]JB-7\GPQ.O"&"8L,:^X@"@D PHF!4.5B/\F%<V#<M%O
MT\+1_(]!%=V](_+Q<C\7G=Y[0O@M?*NKNEY]^W8V3;6"Y7*/,?WHM^GY]!(1
MRPFB92R0)&(6"511&H(J$GBTA>(/69@_)N0/X:7?58$-@'\TI7>Q5F93A!Q,
MT$HH S50OF(DTVV57,XFLVR#;+(;X9#TQ"AK 5ND)W81_H'IB;>SW#(->SFY
M8I],ZM7_<J!DZ&-T#)3/O)K9>(,'4EE**D#AO("RT=:%X0%"(F@D)Z.3319J
MWR?C4+/P&RZ7B \&D'PFB?U"?^O?$\YL-#P0D]H+4,%(<,(X8(P5+85 -$W>
M(I\F:]P<Y@$X>&@7!I1^OR\T5URMN_;VM@]WFOZ&,A*/4-3&4D1O9?#1 />!
M@=*>P)&3@F30H0IDXWV36I/VEN*Z[?G'[^0BU7+_M4QO 1R-X(PY!100Y]H+
MF>LL/PXN(K<LI:!2D^JM/6CMRJ;L@IAM;,J0>NK=T S=JK[%IPYJEH[>H/X
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M41HV:@Q"3L9+YF;<O=COOC[9UOF3C$<1^*&N1 S+7J/%QUNF$6+=JU/+W[1
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M^$^7YON ]N_S^XD7'![[W_04LH'#5M\:RG3QSE2ON)6=BR??(RHIKW4_A$\
MG=P]'E(LS&E_0E:L(7;ULW@+RK^/=?I?4$L#!!0    ( '""15+)]\Z:P@<
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M%Q>&-S&4*,>(.,^H'LB@<M11=_!*27#T6^>5ID&?^XN8)A)\08FD 2PREES
MQX!F7T#3UJMZ/%T)=C&78)NV!1^Y^,(N24&73$;TJ)33,8K?'2/?I#/CP>JH
M$[!+8,&["O-MXC?,IC\CEN]8S48SI(229D#J=7/FV/Y?%BIIX/*")Y.KB+ZK
MQ"S1YE3MWWIKI[*]9(&<MRS3_+UR8YVD5U(C$;M(6KFV2 TY8EN3?1YQT=HS
M\[^VHF@AB5FT:KWV6$PS&-$E3'A,DM?5#"VL952PL%B8L7\H[HB;YS^7:VU0
M3L026FIGV4HE]VK.9DQ"S>X8:G6)Z"XN(BX0FN0I<J+H#?U]M"45CP[ N1=
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M,#(P,3(S,2YH=&U02P$"% ,4    " !P@D52:Y9.EW83   EQ   $0
M        @ %2>0, ;F)I>"TR,#(P,3(S,2YX<V102P$"% ,4    " !P@D52
M2'3=FB,H   6J $ %0              @ 'WC , ;F)I>"TR,#(P,3(S,5]C
M86PN>&UL4$L! A0#%     @ <()%4K8!'1:>:0  J)\$ !4
M ( !3;4# &YB:7@M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( '""15*A
MW\F&[*P! )@. @ 4              "  1X?! !N8FEX+3(P,C Q,C,Q7V<Q
M+FIP9U!+ 0(4 Q0    ( '""15**T0_*\(<" /M@ P 4              "
M 3S,!0!N8FEX+3(P,C Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( '""15)<"7?Q
M4>L  &I: 0 4              "  5Y4" !N8FEX+3(P,C Q,C,Q7V<S+FIP
M9U!+ 0(4 Q0    ( '""15*U.$C8[! ! %TQ"P 5              "  >$_
M"0!N8FEX+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !P@D52ZG]%2QRA
M  #,> < %0              @ $ 40H ;F)I>"TR,#(P,3(S,5]P<F4N>&UL
M4$L! A0#%     @ <()%4JR[5!'9 @  $ P  !L              ( !3_(*
M &YB:7@M,C R,#$R,S%E>&AI8FET,C$Q+FAT;5!+ 0(4 Q0    ( '""15(F
M^K_[400  &<1   ;              "  6'U"@!N8FEX+3(P,C Q,C,Q97AH
M:6)I=#(S,2YH=&U02P$"% ,4    " !P@D52UY1^IQ0(  #J)0  &P
M        @ 'K^0H ;F)I>"TR,#(P,3(S,65X:&EB:70S,3$N:'1M4$L! A0#
M%     @ <()%4LGWSIK"!P  728  !L              ( !. (+ &YB:7@M
M,C R,#$R,S%E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( '""15+5N7RVD04
M "$M   :              "  3,*"P!N8FEX+3(P,C Q,C,Q97AH:6)I=#,R
:+FAT;5!+!08     #@ . +P#  #\#PL    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
